id	sid	tid	token	lemma	pos
admet-337	1	1	doi	doi	NOUN
admet-337	1	2	:	:	PUNCT
admet-337	1	3	10.5599	10.5599	NUM
admet-337	1	4	/	/	SYM
admet-337	1	5	admet.4.3.337	admet.4.3.337	NUM
admet-337	1	6	186	186	NUM
admet-337	1	7	admet	admet	PROPN
admet-337	1	8	&	&	CCONJ
admet-337	1	9	dmpk	dmpk	PROPN
admet-337	1	10	4(3	4(3	NUM
admet-337	1	11	)	)	PUNCT
admet-337	1	12	(	(	PUNCT
admet-337	1	13	2016	2016	NUM
admet-337	1	14	)	)	PUNCT
admet-337	1	15	186	186	NUM
admet-337	1	16	-	-	SYM
admet-337	1	17	211	211	NUM
admet-337	1	18	;	;	PUNCT
admet-337	1	19	doi	doi	NOUN
admet-337	1	20	:	:	PUNCT
admet-337	1	21	10.5599	10.5599	NUM
admet-337	1	22	/	/	SYM
admet-337	1	23	admet.4.3.337	admet.4.3.337	CCONJ
admet-337	1	24	open	open	ADJ
admet-337	1	25	access	access	NOUN
admet-337	1	26	:	:	PUNCT
admet-337	1	27	issn	issn	PROPN
admet-337	1	28	:	:	PUNCT
admet-337	1	29	1848	1848	NUM
admet-337	1	30	-	-	SYM
admet-337	1	31	7718	7718	NUM
admet-337	1	32	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-337	1	33	review	review	NOUN
admet-337	1	34	tyrosine	tyrosine	NOUN
admet-337	1	35	kinase	kinase	PROPN
admet-337	1	36	inhibitors	inhibitor	NOUN
admet-337	1	37	for	for	ADP
admet-337	1	38	egfrand	egfrand	ADJ
admet-337	1	39	alk	alk	PROPN
admet-337	1	40	-	-	PUNCT
admet-337	1	41	mutated	mutate	VERB
admet-337	1	42	non	non	ADJ
admet-337	1	43	-	-	ADJ
admet-337	1	44	small	small	ADJ
admet-337	1	45	cell	cell	NOUN
admet-337	1	46	lung	lung	NOUN
admet-337	1	47	cancer	cancer	NOUN
admet-337	1	48	jonathan	jonathan	PROPN
admet-337	1	49	r.thompson1	r.thompson1	PROPN
admet-337	1	50	,	,	PUNCT
admet-337	1	51	smitha	smitha	PROPN
admet-337	1	52	p.	p.	NOUN
admet-337	1	53	menon2	menon2	PROPN
admet-337	1	54	and	and	CCONJ
admet-337	1	55	grace	grace	NOUN
admet-337	1	56	k.	k.	PROPN
admet-337	2	1	dy3	dy3	PROPN
admet-337	2	2	*	*	PROPN
admet-337	2	3	1	1	NUM
admet-337	2	4	mazie	mazie	PROPN
admet-337	2	5	froedtert	froedtert	PROPN
admet-337	2	6	willms	willm	NOUN
admet-337	2	7	&	&	CCONJ
admet-337	2	8	sue	sue	VERB
admet-337	2	9	froedtert	froedtert	NOUN
admet-337	2	10	cancer	cancer	NOUN
admet-337	2	11	fellow	fellow	NOUN
admet-337	2	12	at	at	ADP
admet-337	2	13	froedtert	froedtert	NOUN
admet-337	2	14	hospital	hospital	NOUN
admet-337	2	15	,	,	PUNCT
admet-337	2	16	division	division	NOUN
admet-337	2	17	of	of	ADP
admet-337	2	18	hematology	hematology	NOUN
admet-337	2	19	and	and	CCONJ
admet-337	2	20	oncology	oncology	NOUN
admet-337	2	21	,	,	PUNCT
admet-337	2	22	medical	medical	ADJ
admet-337	2	23	college	college	PROPN
admet-337	2	24	of	of	ADP
admet-337	2	25	wisconsin	wisconsin	PROPN
admet-337	2	26	,	,	PUNCT
admet-337	2	27	milwaukee	milwaukee	PROPN
admet-337	2	28	,	,	PUNCT
admet-337	2	29	wi	wi	PROPN
admet-337	2	30	2	2	NUM
admet-337	2	31	division	division	NOUN
admet-337	2	32	of	of	ADP
admet-337	2	33	hematology	hematology	NOUN
admet-337	2	34	and	and	CCONJ
admet-337	2	35	oncology	oncology	NOUN
admet-337	2	36	,	,	PUNCT
admet-337	2	37	medical	medical	ADJ
admet-337	2	38	college	college	PROPN
admet-337	2	39	of	of	ADP
admet-337	2	40	wisconsin	wisconsin	PROPN
admet-337	2	41	,	,	PUNCT
admet-337	2	42	milwaukee	milwaukee	PROPN
admet-337	2	43	,	,	PUNCT
admet-337	2	44	wi	wi	PROPN
admet-337	2	45	3	3	NUM
admet-337	2	46	department	department	NOUN
admet-337	2	47	of	of	ADP
admet-337	2	48	medicine	medicine	NOUN
admet-337	2	49	,	,	PUNCT
admet-337	2	50	roswell	roswell	PROPN
admet-337	2	51	park	park	PROPN
admet-337	2	52	cancer	cancer	PROPN
admet-337	2	53	institute	institute	PROPN
admet-337	2	54	,	,	PUNCT
admet-337	2	55	buffalo	buffalo	PROPN
admet-337	2	56	,	,	PUNCT
admet-337	2	57	ny	ny	PROPN
admet-337	2	58	*	*	PUNCT
admet-337	2	59	corresponding	correspond	VERB
admet-337	2	60	author	author	NOUN
admet-337	2	61	.	.	PUNCT
admet-337	3	1	e	e	X
admet-337	3	2	-	-	NOUN
admet-337	3	3	mail	mail	NOUN
admet-337	3	4	:	:	PUNCT
admet-337	3	5	grace.dy@roswellpark.org	grace.dy@roswellpark.org	PROPN
admet-337	3	6	.	.	PUNCT
admet-337	3	7	received	receive	VERB
admet-337	3	8	:	:	PUNCT
admet-337	3	9	august	august	PROPN
admet-337	3	10	15	15	NUM
admet-337	3	11	,	,	PUNCT
admet-337	3	12	2016	2016	NUM
admet-337	3	13	;	;	PUNCT
admet-337	3	14	revised	revise	VERB
admet-337	3	15	:	:	PUNCT
admet-337	3	16	september	september	PROPN
admet-337	3	17	11	11	NUM
admet-337	3	18	,	,	PUNCT
admet-337	3	19	2016	2016	NUM
admet-337	3	20	;	;	PUNCT
admet-337	3	21	published	publish	VERB
admet-337	3	22	:	:	PUNCT
admet-337	3	23	september	september	PROPN
admet-337	3	24	30	30	NUM
admet-337	3	25	,	,	PUNCT
admet-337	3	26	2016	2016	NUM
admet-337	3	27	abstract	abstract	ADJ
admet-337	3	28	discovery	discovery	NOUN
admet-337	3	29	of	of	ADP
admet-337	3	30	the	the	DET
admet-337	3	31	epidermal	epidermal	ADJ
admet-337	3	32	growth	growth	NOUN
admet-337	3	33	receptor	receptor	NOUN
admet-337	3	34	(	(	PUNCT
admet-337	3	35	egfr	egfr	X
admet-337	3	36	)	)	PUNCT
admet-337	3	37	activating	activate	VERB
admet-337	3	38	mutations	mutation	NOUN
admet-337	3	39	and	and	CCONJ
admet-337	3	40	anaplastic	anaplastic	ADJ
admet-337	3	41	lymphoma	lymphoma	NOUN
admet-337	3	42	kinase	kinase	PROPN
admet-337	3	43	(	(	PUNCT
admet-337	3	44	alk	alk	PROPN
admet-337	3	45	)	)	PUNCT
admet-337	3	46	rearrangements	rearrangement	NOUN
admet-337	3	47	has	have	AUX
admet-337	3	48	expanded	expand	VERB
admet-337	3	49	the	the	DET
admet-337	3	50	therapeutic	therapeutic	ADJ
admet-337	3	51	landscape	landscape	NOUN
admet-337	3	52	in	in	ADP
admet-337	3	53	non	non	ADJ
admet-337	3	54	-	-	ADJ
admet-337	3	55	small	small	ADJ
admet-337	3	56	cell	cell	NOUN
admet-337	3	57	lung	lung	NOUN
admet-337	3	58	cancer	cancer	NOUN
admet-337	3	59	(	(	PUNCT
admet-337	3	60	nsclc	nsclc	NOUN
admet-337	3	61	)	)	PUNCT
admet-337	3	62	.	.	PUNCT
admet-337	4	1	survival	survival	NOUN
admet-337	4	2	outcomes	outcome	NOUN
admet-337	4	3	for	for	ADP
admet-337	4	4	patients	patient	NOUN
admet-337	4	5	with	with	ADP
admet-337	4	6	these	these	DET
admet-337	4	7	mutations	mutation	NOUN
admet-337	4	8	have	have	AUX
admet-337	4	9	improved	improve	VERB
admet-337	4	10	dramatically	dramatically	ADV
admet-337	4	11	with	with	ADP
admet-337	4	12	egfr	egfr	NOUN
admet-337	4	13	and	and	CCONJ
admet-337	4	14	alk	alk	VERB
admet-337	4	15	tyrosine	tyrosine	PROPN
admet-337	4	16	kinase	kinase	PROPN
admet-337	4	17	inhibitors	inhibitor	NOUN
admet-337	4	18	(	(	PUNCT
admet-337	4	19	tkis	tkis	NOUN
admet-337	4	20	)	)	PUNCT
admet-337	4	21	.	.	PUNCT
admet-337	5	1	multiple	multiple	ADJ
admet-337	5	2	generations	generation	NOUN
admet-337	5	3	of	of	ADP
admet-337	5	4	egfr	egfr	NOUN
admet-337	5	5	and	and	CCONJ
admet-337	5	6	alk	alk	VERB
admet-337	5	7	tkis	tkis	PROPN
admet-337	5	8	have	have	AUX
admet-337	5	9	been	be	AUX
admet-337	5	10	rapidly	rapidly	ADV
admet-337	5	11	developed	develop	VERB
admet-337	5	12	,	,	PUNCT
admet-337	5	13	and	and	CCONJ
admet-337	5	14	patients	patient	NOUN
admet-337	5	15	and	and	CCONJ
admet-337	5	16	clinicians	clinician	NOUN
admet-337	5	17	now	now	ADV
admet-337	5	18	have	have	VERB
admet-337	5	19	several	several	ADJ
admet-337	5	20	options	option	NOUN
admet-337	5	21	for	for	ADP
admet-337	5	22	firstand	firstand	NOUN
admet-337	5	23	second	second	ADJ
admet-337	5	24	-	-	PUNCT
admet-337	5	25	line	line	NOUN
admet-337	5	26	treatments	treatment	NOUN
admet-337	5	27	.	.	PUNCT
admet-337	6	1	while	while	SCONJ
admet-337	6	2	these	these	DET
admet-337	6	3	small	small	ADJ
admet-337	6	4	molecule	molecule	NOUN
admet-337	6	5	tkis	tkis	NOUN
admet-337	6	6	have	have	VERB
admet-337	6	7	some	some	DET
admet-337	6	8	similarities	similarity	NOUN
admet-337	6	9	in	in	ADP
admet-337	6	10	therapeutic	therapeutic	ADJ
admet-337	6	11	and	and	CCONJ
admet-337	6	12	pharmacologic	pharmacologic	ADJ
admet-337	6	13	profiles	profile	NOUN
admet-337	6	14	,	,	PUNCT
admet-337	6	15	the	the	DET
admet-337	6	16	differences	difference	NOUN
admet-337	6	17	can	can	AUX
admet-337	6	18	be	be	AUX
admet-337	6	19	clinically	clinically	ADV
admet-337	6	20	substantial	substantial	ADJ
admet-337	6	21	,	,	PUNCT
admet-337	6	22	allowing	allow	VERB
admet-337	6	23	tailored	tailor	VERB
admet-337	6	24	treatment	treatment	NOUN
admet-337	6	25	for	for	ADP
admet-337	6	26	each	each	DET
admet-337	6	27	unique	unique	ADJ
admet-337	6	28	patient	patient	NOUN
admet-337	6	29	.	.	PUNCT
admet-337	7	1	this	this	DET
admet-337	7	2	review	review	NOUN
admet-337	7	3	details	detail	VERB
admet-337	7	4	the	the	DET
admet-337	7	5	clinical	clinical	ADJ
admet-337	7	6	efficacy	efficacy	NOUN
admet-337	7	7	,	,	PUNCT
admet-337	7	8	pharmacology	pharmacology	NOUN
admet-337	7	9	,	,	PUNCT
admet-337	7	10	safety	safety	NOUN
admet-337	7	11	profiles	profile	NOUN
admet-337	7	12	,	,	PUNCT
admet-337	7	13	cns	cns	NOUN
admet-337	7	14	penetration	penetration	NOUN
admet-337	7	15	,	,	PUNCT
admet-337	7	16	and	and	CCONJ
admet-337	7	17	mechanisms	mechanism	NOUN
admet-337	7	18	of	of	ADP
admet-337	7	19	resistance	resistance	NOUN
admet-337	7	20	of	of	ADP
admet-337	7	21	the	the	DET
admet-337	7	22	four	four	NUM
admet-337	7	23	egfr	egfr	ADJ
admet-337	7	24	tkis	tkis	NOUN
admet-337	7	25	and	and	CCONJ
admet-337	7	26	three	three	NUM
admet-337	7	27	alk	alk	NOUN
admet-337	7	28	tkis	tkis	PROPN
admet-337	7	29	that	that	PRON
admet-337	7	30	are	be	AUX
admet-337	7	31	currently	currently	ADV
admet-337	7	32	approved	approve	VERB
admet-337	7	33	by	by	ADP
admet-337	7	34	the	the	DET
admet-337	7	35	united	united	PROPN
admet-337	7	36	states	states	PROPN
admet-337	7	37	food	food	PROPN
admet-337	7	38	and	and	CCONJ
admet-337	7	39	drug	drug	PROPN
admet-337	7	40	administration	administration	NOUN
admet-337	7	41	(	(	PUNCT
admet-337	7	42	us	us	PROPN
admet-337	7	43	fda	fda	PROPN
admet-337	7	44	)	)	PUNCT
admet-337	7	45	.	.	PUNCT
admet-337	8	1	keywords	keyword	VERB
admet-337	8	2	epidermal	epidermal	ADJ
admet-337	8	3	growth	growth	NOUN
admet-337	8	4	factor	factor	NOUN
admet-337	8	5	receptor	receptor	NOUN
admet-337	8	6	;	;	PUNCT
admet-337	8	7	anaplastic	anaplastic	ADJ
admet-337	8	8	lymphoma	lymphoma	NOUN
admet-337	8	9	kinase	kinase	NOUN
admet-337	8	10	;	;	PUNCT
admet-337	8	11	targeted	target	VERB
admet-337	8	12	therapy	therapy	NOUN
admet-337	8	13	introduction	introduction	NOUN
admet-337	8	14	lung	lung	NOUN
admet-337	8	15	cancer	cancer	NOUN
admet-337	8	16	is	be	AUX
admet-337	8	17	the	the	DET
admet-337	8	18	leading	lead	VERB
admet-337	8	19	cause	cause	NOUN
admet-337	8	20	of	of	ADP
admet-337	8	21	cancer	cancer	NOUN
admet-337	8	22	mortality	mortality	NOUN
admet-337	8	23	worldwide	worldwide	ADV
admet-337	8	24	,	,	PUNCT
admet-337	8	25	leading	lead	VERB
admet-337	8	26	to	to	ADP
admet-337	8	27	1.6	1.6	NUM
admet-337	8	28	million	million	NUM
admet-337	8	29	deaths	death	NOUN
admet-337	8	30	annually	annually	ADV
admet-337	8	31	[	[	X
admet-337	8	32	1	1	NUM
admet-337	8	33	]	]	PUNCT
admet-337	8	34	.	.	PUNCT
admet-337	9	1	non	non	ADJ
admet-337	9	2	-	-	ADJ
admet-337	9	3	small	small	ADJ
admet-337	9	4	cell	cell	NOUN
admet-337	9	5	lung	lung	NOUN
admet-337	9	6	cancer	cancer	NOUN
admet-337	9	7	(	(	PUNCT
admet-337	9	8	nsclc	nsclc	NOUN
admet-337	9	9	)	)	PUNCT
admet-337	9	10	is	be	AUX
admet-337	9	11	a	a	DET
admet-337	9	12	heterogeneous	heterogeneous	ADJ
admet-337	9	13	disease	disease	NOUN
admet-337	9	14	that	that	PRON
admet-337	9	15	accounts	account	VERB
admet-337	9	16	for	for	ADP
admet-337	9	17	85	85	NUM
admet-337	9	18	%	%	NOUN
admet-337	9	19	of	of	ADP
admet-337	9	20	all	all	DET
admet-337	9	21	lung	lung	NOUN
admet-337	9	22	cancer	cancer	NOUN
admet-337	9	23	diagnoses	diagnosis	NOUN
admet-337	9	24	[	[	X
admet-337	9	25	2	2	NUM
admet-337	9	26	]	]	PUNCT
admet-337	9	27	.	.	PUNCT
admet-337	10	1	most	most	ADJ
admet-337	10	2	patients	patient	NOUN
admet-337	10	3	are	be	AUX
admet-337	10	4	diagnosed	diagnose	VERB
admet-337	10	5	at	at	ADP
admet-337	10	6	an	an	DET
admet-337	10	7	advanced	advanced	ADJ
admet-337	10	8	stage	stage	NOUN
admet-337	10	9	,	,	PUNCT
admet-337	10	10	where	where	SCONJ
admet-337	10	11	5	5	NUM
admet-337	10	12	-	-	PUNCT
admet-337	10	13	year	year	NOUN
admet-337	10	14	survival	survival	NOUN
admet-337	10	15	is	be	AUX
admet-337	10	16	less	less	ADJ
admet-337	10	17	than	than	ADP
admet-337	10	18	5	5	NUM
admet-337	10	19	%	%	NOUN
admet-337	10	20	[	[	X
admet-337	10	21	3	3	NUM
admet-337	10	22	]	]	PUNCT
admet-337	10	23	.	.	PUNCT
admet-337	11	1	within	within	ADP
admet-337	11	2	the	the	DET
admet-337	11	3	past	past	ADJ
admet-337	11	4	decade	decade	NOUN
admet-337	11	5	,	,	PUNCT
admet-337	11	6	numerous	numerous	ADJ
admet-337	11	7	somatic	somatic	ADJ
admet-337	11	8	molecular	molecular	ADJ
admet-337	11	9	mutations	mutation	NOUN
admet-337	11	10	have	have	AUX
admet-337	11	11	been	be	AUX
admet-337	11	12	discovered	discover	VERB
admet-337	11	13	that	that	SCONJ
admet-337	11	14	drive	drive	VERB
admet-337	11	15	oncogenesis	oncogenesis	NOUN
admet-337	11	16	in	in	ADP
admet-337	11	17	nsclc	nsclc	NOUN
admet-337	11	18	.	.	PUNCT
admet-337	12	1	protein	protein	NOUN
admet-337	12	2	kinase	kinase	VERB
admet-337	12	3	inhibitors	inhibitor	NOUN
admet-337	12	4	that	that	PRON
admet-337	12	5	target	target	VERB
admet-337	12	6	these	these	DET
admet-337	12	7	mutations	mutation	NOUN
admet-337	12	8	improve	improve	VERB
admet-337	12	9	response	response	NOUN
admet-337	12	10	rates	rate	NOUN
admet-337	12	11	and	and	CCONJ
admet-337	12	12	survival	survival	NOUN
admet-337	12	13	compared	compare	VERB
admet-337	12	14	to	to	ADP
admet-337	12	15	standard	standard	ADJ
admet-337	12	16	systemic	systemic	ADJ
admet-337	12	17	chemotherapy	chemotherapy	NOUN
admet-337	12	18	.	.	PUNCT
admet-337	13	1	the	the	DET
admet-337	13	2	most	most	ADV
admet-337	13	3	common	common	ADJ
admet-337	13	4	clinically	clinically	ADV
admet-337	13	5	relevant	relevant	ADJ
admet-337	13	6	“	"	PUNCT
admet-337	13	7	driver	driver	NOUN
admet-337	13	8	”	"	PUNCT
admet-337	13	9	mutations	mutation	NOUN
admet-337	13	10	encountered	encounter	VERB
admet-337	13	11	are	be	AUX
admet-337	13	12	the	the	DET
admet-337	13	13	epidermal	epidermal	ADJ
admet-337	13	14	growth	growth	NOUN
admet-337	13	15	factor	factor	NOUN
admet-337	13	16	receptor	receptor	NOUN
admet-337	13	17	(	(	PUNCT
admet-337	13	18	egfr	egfr	X
admet-337	13	19	)	)	PUNCT
admet-337	13	20	activating	activate	VERB
admet-337	13	21	mutations	mutation	NOUN
admet-337	13	22	,	,	PUNCT
admet-337	13	23	which	which	PRON
admet-337	13	24	are	be	AUX
admet-337	13	25	present	present	ADJ
admet-337	13	26	in	in	ADP
admet-337	13	27	30	30	NUM
admet-337	13	28	-	-	SYM
admet-337	13	29	40	40	NUM
admet-337	13	30	%	%	NOUN
admet-337	13	31	of	of	ADP
admet-337	13	32	asian	asian	ADJ
admet-337	13	33	nsclc	nsclc	NOUN
admet-337	13	34	patients	patient	NOUN
admet-337	13	35	and	and	CCONJ
admet-337	13	36	10	10	NUM
admet-337	13	37	%	%	NOUN
admet-337	13	38	of	of	ADP
admet-337	13	39	caucasian	caucasian	ADJ
admet-337	13	40	patients	patient	NOUN
admet-337	13	41	with	with	ADP
admet-337	13	42	nsclc	nsclc	NOUN
admet-337	13	43	[	[	X
admet-337	13	44	4,5	4,5	NUM
admet-337	13	45	]	]	PUNCT
admet-337	13	46	.	.	PUNCT
admet-337	14	1	rearrangements	rearrangement	NOUN
admet-337	14	2	in	in	ADP
admet-337	14	3	the	the	DET
admet-337	14	4	anaplastic	anaplastic	ADJ
admet-337	14	5	lymphoma	lymphoma	NOUN
admet-337	14	6	kinase	kinase	PROPN
admet-337	14	7	(	(	PUNCT
admet-337	14	8	alk	alk	PROPN
admet-337	14	9	)	)	PUNCT
admet-337	14	10	gene	gene	NOUN
admet-337	14	11	lead	lead	NOUN
admet-337	14	12	to	to	ADP
admet-337	14	13	fusion	fusion	NOUN
admet-337	14	14	proteins	protein	NOUN
admet-337	14	15	,	,	PUNCT
admet-337	14	16	which	which	PRON
admet-337	14	17	drive	drive	VERB
admet-337	14	18	cellular	cellular	ADJ
admet-337	14	19	proliferation	proliferation	NOUN
admet-337	14	20	.	.	PUNCT
admet-337	15	1	the	the	DET
admet-337	15	2	alk	alk	PROPN
admet-337	15	3	gene	gene	NOUN
admet-337	15	4	rearrangement	rearrangement	NOUN
admet-337	15	5	occurs	occur	VERB
admet-337	15	6	in	in	ADP
admet-337	15	7	3	3	NUM
admet-337	15	8	to	to	PART
admet-337	15	9	7	7	NUM
admet-337	15	10	%	%	NOUN
admet-337	15	11	of	of	ADP
admet-337	15	12	all	all	DET
admet-337	15	13	nsclc	nsclc	NOUN
admet-337	15	14	patients	patient	NOUN
admet-337	15	15	[	[	X
admet-337	15	16	6	6	NUM
admet-337	15	17	]	]	PUNCT
admet-337	15	18	.	.	PUNCT
admet-337	16	1	egfr	egfr	PROPN
admet-337	16	2	activating	activate	VERB
admet-337	16	3	mutations	mutation	NOUN
admet-337	16	4	and	and	CCONJ
admet-337	16	5	alk	alk	VERB
admet-337	16	6	gene	gene	NOUN
admet-337	16	7	rearrangements	rearrangement	NOUN
admet-337	16	8	create	create	VERB
admet-337	16	9	constitutively	constitutively	ADV
admet-337	16	10	active	active	ADJ
admet-337	16	11	protein	protein	NOUN
admet-337	16	12	kinases	kinase	NOUN
admet-337	16	13	for	for	ADP
admet-337	16	14	which	which	PRON
admet-337	16	15	there	there	PRON
admet-337	16	16	are	be	VERB
admet-337	16	17	multiple	multiple	ADJ
admet-337	16	18	highly	highly	ADV
admet-337	16	19	active	active	ADJ
admet-337	16	20	tyrosine	tyrosine	NOUN
admet-337	16	21	kinase	kinase	PROPN
admet-337	16	22	inhibitors	inhibitor	NOUN
admet-337	16	23	(	(	PUNCT
admet-337	16	24	tkis	tkis	NOUN
admet-337	16	25	)	)	PUNCT
admet-337	16	26	available	available	ADJ
admet-337	16	27	for	for	ADP
admet-337	16	28	treatment	treatment	NOUN
admet-337	16	29	.	.	PUNCT
admet-337	17	1	these	these	DET
admet-337	17	2	tkis	tkis	PROPN
admet-337	17	3	have	have	AUX
admet-337	17	4	dramatically	dramatically	ADV
admet-337	17	5	impacted	impact	VERB
admet-337	17	6	clinical	clinical	ADJ
admet-337	17	7	outcomes	outcome	NOUN
admet-337	17	8	for	for	ADP
admet-337	17	9	patients	patient	NOUN
admet-337	17	10	with	with	ADP
admet-337	17	11	nsclc	nsclc	NOUN
admet-337	17	12	who	who	PRON
admet-337	17	13	previously	previously	ADV
admet-337	17	14	carried	carry	VERB
admet-337	17	15	poor	poor	ADJ
admet-337	17	16	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-337	17	17	mailto:grace.dy@roswellpark.org	mailto:grace.dy@roswellpark.org	NUM
admet-337	17	18	admet	admet	X
admet-337	17	19	&	&	CCONJ
admet-337	17	20	dmpk	dmpk	PROPN
admet-337	17	21	4(3	4(3	NUM
admet-337	17	22	)	)	PUNCT
admet-337	17	23	(	(	PUNCT
admet-337	17	24	2016	2016	NUM
admet-337	17	25	)	)	PUNCT
admet-337	17	26	186	186	NUM
admet-337	17	27	-	-	SYM
admet-337	17	28	211	211	NUM
admet-337	17	29	tki	tki	NOUN
admet-337	17	30	for	for	ADP
admet-337	17	31	egfrand	egfrand	ADJ
admet-337	17	32	alk	alk	PROPN
admet-337	17	33	-	-	PUNCT
admet-337	17	34	mutated	mutate	VERB
admet-337	17	35	cell	cell	NOUN
admet-337	17	36	cancer	cancer	NOUN
admet-337	17	37	doi	doi	NOUN
admet-337	17	38	:	:	PUNCT
admet-337	17	39	10.5599	10.5599	NUM
admet-337	17	40	/	/	SYM
admet-337	17	41	admet.4.3.337	admet.4.3.337	CCONJ
admet-337	17	42	187	187	NUM
admet-337	17	43	prognoses	prognosis	NOUN
admet-337	17	44	.	.	PUNCT
admet-337	18	1	the	the	DET
admet-337	18	2	standard	standard	ADJ
admet-337	18	3	overall	overall	ADJ
admet-337	18	4	survival	survival	NOUN
admet-337	18	5	for	for	ADP
admet-337	18	6	all	all	DET
admet-337	18	7	patients	patient	NOUN
admet-337	18	8	with	with	ADP
admet-337	18	9	advanced	advanced	ADJ
admet-337	18	10	nsclc	nsclc	NOUN
admet-337	18	11	ranges	range	VERB
admet-337	18	12	from	from	ADP
admet-337	18	13	4	4	NUM
admet-337	18	14	to	to	PART
admet-337	18	15	12	12	NUM
admet-337	18	16	months	month	NOUN
admet-337	19	1	[	[	X
admet-337	19	2	7	7	NUM
admet-337	19	3	-	-	SYM
admet-337	19	4	10	10	NUM
admet-337	19	5	]	]	PUNCT
admet-337	19	6	,	,	PUNCT
admet-337	19	7	but	but	CCONJ
admet-337	19	8	median	median	ADJ
admet-337	19	9	overall	overall	ADJ
admet-337	19	10	survival	survival	NOUN
admet-337	19	11	in	in	ADP
admet-337	19	12	patients	patient	NOUN
admet-337	19	13	with	with	ADP
admet-337	19	14	egfror	egfror	PROPN
admet-337	19	15	alk	alk	PROPN
admet-337	19	16	-	-	PUNCT
admet-337	19	17	mutated	mutate	VERB
admet-337	19	18	nsclc	nsclc	NOUN
admet-337	19	19	now	now	ADV
admet-337	19	20	approaches	approach	VERB
admet-337	19	21	3	3	NUM
admet-337	19	22	to	to	PART
admet-337	19	23	4	4	NUM
admet-337	19	24	years	year	NOUN
admet-337	19	25	or	or	CCONJ
admet-337	19	26	more	more	ADJ
admet-337	19	27	[	[	X
admet-337	19	28	11	11	NUM
admet-337	19	29	-	-	SYM
admet-337	19	30	15	15	NUM
admet-337	19	31	]	]	PUNCT
admet-337	19	32	.	.	PUNCT
admet-337	20	1	currently	currently	ADV
admet-337	20	2	,	,	PUNCT
admet-337	20	3	there	there	PRON
admet-337	20	4	are	be	VERB
admet-337	20	5	four	four	NUM
admet-337	20	6	egfr	egfr	ADJ
admet-337	20	7	tkis	tkis	NOUN
admet-337	20	8	and	and	CCONJ
admet-337	20	9	three	three	NUM
admet-337	20	10	alk	alk	NOUN
admet-337	20	11	tkis	tkis	PROPN
admet-337	20	12	that	that	PRON
admet-337	20	13	are	be	AUX
admet-337	20	14	widely	widely	ADV
admet-337	20	15	approved	approve	VERB
admet-337	20	16	for	for	ADP
admet-337	20	17	clinical	clinical	ADJ
admet-337	20	18	use	use	NOUN
admet-337	20	19	.	.	PUNCT
admet-337	21	1	the	the	DET
admet-337	21	2	first	first	ADJ
admet-337	21	3	-	-	PUNCT
admet-337	21	4	generation	generation	NOUN
admet-337	21	5	egfr	egfr	NOUN
admet-337	21	6	tkis	tkis	NOUN
admet-337	21	7	,	,	PUNCT
admet-337	21	8	gefitinib	gefitinib	NOUN
admet-337	21	9	and	and	CCONJ
admet-337	21	10	erlotinib	erlotinib	NOUN
admet-337	21	11	,	,	PUNCT
admet-337	21	12	reversibly	reversibly	ADV
admet-337	21	13	inhibit	inhibit	VERB
admet-337	21	14	the	the	DET
admet-337	21	15	intracellular	intracellular	ADJ
admet-337	21	16	catalytic	catalytic	ADJ
admet-337	21	17	domain	domain	NOUN
admet-337	21	18	of	of	ADP
admet-337	21	19	the	the	DET
admet-337	21	20	egfr	egfr	PROPN
admet-337	21	21	tyrosine	tyrosine	PROPN
admet-337	21	22	kinase	kinase	PROPN
admet-337	21	23	.	.	PUNCT
admet-337	22	1	afatinib	afatinib	PROPN
admet-337	22	2	is	be	AUX
admet-337	22	3	a	a	DET
admet-337	22	4	second	second	ADJ
admet-337	22	5	-	-	PUNCT
admet-337	22	6	generation	generation	NOUN
admet-337	22	7	egfr	egfr	NOUN
admet-337	22	8	tki	tki	NOUN
admet-337	22	9	that	that	PRON
admet-337	22	10	irreversibly	irreversibly	ADV
admet-337	22	11	inhibits	inhibit	VERB
admet-337	22	12	the	the	DET
admet-337	22	13	egfr	egfr	ADJ
admet-337	22	14	tyrosine	tyrosine	PROPN
admet-337	22	15	kinase	kinase	PROPN
admet-337	22	16	domain	domain	PROPN
admet-337	22	17	.	.	PUNCT
admet-337	23	1	osimertinib	osimertinib	NOUN
admet-337	23	2	is	be	AUX
admet-337	23	3	a	a	DET
admet-337	23	4	third	third	ADJ
admet-337	23	5	-	-	PUNCT
admet-337	23	6	generation	generation	NOUN
admet-337	23	7	egfr	egfr	NOUN
admet-337	23	8	tki	tki	PROPN
admet-337	23	9	specifically	specifically	ADV
admet-337	23	10	designed	design	VERB
admet-337	23	11	to	to	PART
admet-337	23	12	inhibit	inhibit	VERB
admet-337	23	13	t790m	t790m	NOUN
admet-337	23	14	-	-	PUNCT
admet-337	23	15	mutated	mutate	VERB
admet-337	23	16	egfr	egfr	NOUN
admet-337	23	17	as	as	ADV
admet-337	23	18	well	well	ADV
admet-337	23	19	as	as	ADP
admet-337	23	20	other	other	ADJ
admet-337	23	21	egfr	egfr	NOUN
admet-337	23	22	activating	activate	VERB
admet-337	23	23	mutations	mutation	NOUN
admet-337	23	24	.	.	PUNCT
admet-337	24	1	crizotinib	crizotinib	PROPN
admet-337	24	2	was	be	AUX
admet-337	24	3	the	the	DET
admet-337	24	4	first	first	ADJ
admet-337	24	5	tki	tki	NOUN
admet-337	24	6	to	to	PART
admet-337	24	7	show	show	VERB
admet-337	24	8	activity	activity	NOUN
admet-337	24	9	in	in	ADP
admet-337	24	10	alk	alk	NOUN
admet-337	24	11	-	-	PUNCT
admet-337	24	12	positive	positive	ADJ
admet-337	24	13	nsclc	nsclc	NOUN
admet-337	24	14	,	,	PUNCT
admet-337	24	15	however	however	ADV
admet-337	24	16	,	,	PUNCT
admet-337	24	17	it	it	PRON
admet-337	24	18	is	be	AUX
admet-337	24	19	more	more	ADV
admet-337	24	20	potent	potent	ADJ
admet-337	24	21	at	at	ADP
admet-337	24	22	inhibiting	inhibit	VERB
admet-337	24	23	met	meet	VERB
admet-337	24	24	than	than	ADP
admet-337	24	25	alk	alk	PROPN
admet-337	24	26	.	.	PUNCT
admet-337	24	27	ceritinib	ceritinib	PROPN
admet-337	24	28	and	and	CCONJ
admet-337	24	29	alectinib	alectinib	NOUN
admet-337	24	30	are	be	AUX
admet-337	24	31	tkis	tkis	NOUN
admet-337	24	32	that	that	PRON
admet-337	24	33	are	be	AUX
admet-337	24	34	more	more	ADV
admet-337	24	35	potent	potent	ADJ
admet-337	24	36	and	and	CCONJ
admet-337	24	37	specific	specific	ADJ
admet-337	24	38	for	for	ADP
admet-337	24	39	the	the	DET
admet-337	24	40	alk	alk	PROPN
admet-337	24	41	tyrosine	tyrosine	PROPN
admet-337	24	42	kinase	kinase	PROPN
admet-337	24	43	.	.	PUNCT
admet-337	25	1	in	in	ADP
admet-337	25	2	this	this	DET
admet-337	25	3	article	article	NOUN
admet-337	25	4	,	,	PUNCT
admet-337	25	5	the	the	DET
admet-337	25	6	relevant	relevant	ADJ
admet-337	25	7	egfr	egfr	NOUN
admet-337	25	8	and	and	CCONJ
admet-337	25	9	alk	alk	VERB
admet-337	25	10	mutations	mutation	NOUN
admet-337	25	11	and	and	CCONJ
admet-337	25	12	the	the	DET
admet-337	25	13	tkis	tkis	NOUN
admet-337	25	14	which	which	PRON
admet-337	25	15	inhibit	inhibit	VERB
admet-337	25	16	these	these	DET
admet-337	25	17	mutated	mutate	VERB
admet-337	25	18	proteins	protein	NOUN
admet-337	25	19	will	will	AUX
admet-337	25	20	be	be	AUX
admet-337	25	21	reviewed	review	VERB
admet-337	25	22	.	.	PUNCT
admet-337	26	1	the	the	DET
admet-337	26	2	clinical	clinical	ADJ
admet-337	26	3	efficacy	efficacy	NOUN
admet-337	26	4	,	,	PUNCT
admet-337	26	5	safety	safety	NOUN
admet-337	26	6	,	,	PUNCT
admet-337	26	7	and	and	CCONJ
admet-337	26	8	pharmacology	pharmacology	NOUN
admet-337	26	9	of	of	ADP
admet-337	26	10	these	these	DET
admet-337	26	11	tkis	tkis	NOUN
admet-337	26	12	will	will	AUX
admet-337	26	13	be	be	AUX
admet-337	26	14	detailed	detail	VERB
admet-337	26	15	in	in	ADP
admet-337	26	16	order	order	NOUN
admet-337	26	17	to	to	PART
admet-337	26	18	promote	promote	VERB
admet-337	26	19	understanding	understanding	NOUN
admet-337	26	20	of	of	ADP
admet-337	26	21	this	this	DET
admet-337	26	22	promising	promising	ADJ
admet-337	26	23	and	and	CCONJ
admet-337	26	24	rapidly	rapidly	ADV
admet-337	26	25	evolving	evolve	VERB
admet-337	26	26	field	field	NOUN
admet-337	26	27	.	.	PUNCT
admet-337	27	1	egfr	egfr	PROPN
admet-337	27	2	tyrosine	tyrosine	PROPN
admet-337	27	3	kinase	kinase	PROPN
admet-337	27	4	inhibitors	inhibitor	NOUN
admet-337	27	5	egfr	egfr	VERB
admet-337	27	6	protein	protein	NOUN
admet-337	27	7	and	and	CCONJ
admet-337	27	8	activating	activate	VERB
admet-337	27	9	mutations	mutation	NOUN
admet-337	27	10	egfr	egfr	ADV
admet-337	27	11	is	be	AUX
admet-337	27	12	a	a	DET
admet-337	27	13	tyrosine	tyrosine	NOUN
admet-337	27	14	kinase	kinase	NOUN
admet-337	27	15	receptor	receptor	NOUN
admet-337	27	16	of	of	ADP
admet-337	27	17	the	the	DET
admet-337	27	18	erbb	erbb	PROPN
admet-337	27	19	receptor	receptor	NOUN
admet-337	27	20	family	family	NOUN
admet-337	27	21	.	.	PUNCT
admet-337	28	1	it	it	PRON
admet-337	28	2	is	be	AUX
admet-337	28	3	composed	compose	VERB
admet-337	28	4	of	of	ADP
admet-337	28	5	an	an	DET
admet-337	28	6	extracellular	extracellular	ADJ
admet-337	28	7	domain	domain	NOUN
admet-337	28	8	(	(	PUNCT
admet-337	28	9	n	n	CCONJ
admet-337	28	10	-	-	PUNCT
admet-337	28	11	terminus	terminus	NOUN
admet-337	28	12	)	)	PUNCT
admet-337	28	13	that	that	PRON
admet-337	28	14	binds	bind	VERB
admet-337	28	15	ligands	ligand	NOUN
admet-337	28	16	including	include	VERB
admet-337	28	17	egf	egf	PROPN
admet-337	28	18	and	and	CCONJ
admet-337	28	19	tgf	tgf	PROPN
admet-337	28	20	-	-	PUNCT
admet-337	28	21	α	α	PROPN
admet-337	28	22	,	,	PUNCT
admet-337	28	23	a	a	DET
admet-337	28	24	transmembrane	transmembrane	ADJ
admet-337	28	25	domain	domain	NOUN
admet-337	28	26	,	,	PUNCT
admet-337	28	27	and	and	CCONJ
admet-337	28	28	an	an	DET
admet-337	28	29	intracellular	intracellular	ADJ
admet-337	28	30	domain	domain	NOUN
admet-337	28	31	(	(	PUNCT
admet-337	28	32	c	c	NOUN
admet-337	28	33	-	-	PUNCT
admet-337	28	34	terminus	terminus	NOUN
admet-337	28	35	)	)	PUNCT
admet-337	28	36	that	that	PRON
admet-337	28	37	is	be	AUX
admet-337	28	38	responsible	responsible	ADJ
admet-337	28	39	for	for	ADP
admet-337	28	40	intracellular	intracellular	NOUN
admet-337	28	41	signaling	signal	VERB
admet-337	28	42	through	through	ADP
admet-337	28	43	tyrosine	tyrosine	NOUN
admet-337	28	44	kinase	kinase	PROPN
admet-337	28	45	activity	activity	NOUN
admet-337	29	1	[	[	X
admet-337	29	2	16,17	16,17	NUM
admet-337	29	3	]	]	PUNCT
admet-337	29	4	.	.	PUNCT
admet-337	30	1	upon	upon	SCONJ
admet-337	30	2	binding	bind	VERB
admet-337	30	3	to	to	ADP
admet-337	30	4	its	its	PRON
admet-337	30	5	ligand	ligand	NOUN
admet-337	30	6	on	on	ADP
admet-337	30	7	the	the	DET
admet-337	30	8	extracellular	extracellular	ADJ
admet-337	30	9	domain	domain	NOUN
admet-337	30	10	,	,	PUNCT
admet-337	30	11	the	the	DET
admet-337	30	12	receptor	receptor	NOUN
admet-337	30	13	dimerizes	dimerizes	NOUN
admet-337	30	14	,	,	PUNCT
admet-337	30	15	leading	lead	VERB
admet-337	30	16	to	to	ADP
admet-337	30	17	autophosphorylation	autophosphorylation	NOUN
admet-337	30	18	of	of	ADP
admet-337	30	19	the	the	DET
admet-337	30	20	intracellular	intracellular	ADJ
admet-337	30	21	tyrosine	tyrosine	NOUN
admet-337	30	22	-	-	PUNCT
admet-337	30	23	kinase	kinase	NOUN
admet-337	30	24	domain	domain	NOUN
admet-337	30	25	.	.	PUNCT
admet-337	31	1	autophosphorylation	autophosphorylation	NOUN
admet-337	31	2	of	of	ADP
admet-337	31	3	the	the	DET
admet-337	31	4	intracellular	intracellular	ADJ
admet-337	31	5	domain	domain	NOUN
admet-337	31	6	is	be	AUX
admet-337	31	7	followed	follow	VERB
admet-337	31	8	by	by	ADP
admet-337	31	9	binding	bind	VERB
admet-337	31	10	of	of	ADP
admet-337	31	11	adaptor	adaptor	NOUN
admet-337	31	12	proteins	protein	NOUN
admet-337	31	13	and	and	CCONJ
admet-337	31	14	signaling	signal	VERB
admet-337	31	15	through	through	ADP
admet-337	31	16	down	down	ADJ
admet-337	31	17	-	-	PUNCT
admet-337	31	18	stream	stream	NOUN
admet-337	31	19	pathways	pathway	NOUN
admet-337	31	20	.	.	PUNCT
admet-337	32	1	these	these	DET
admet-337	32	2	pathways	pathway	NOUN
admet-337	32	3	include	include	VERB
admet-337	32	4	the	the	DET
admet-337	32	5	ras	ras	PROPN
admet-337	32	6	/	/	SYM
admet-337	32	7	raf	raf	PROPN
admet-337	32	8	/	/	SYM
admet-337	32	9	mek	mek	PROPN
admet-337	32	10	/	/	SYM
admet-337	32	11	erk	erk	PROPN
admet-337	32	12	,	,	PUNCT
admet-337	32	13	phosphoinositide	phosphoinositide	NOUN
admet-337	32	14	3	3	NUM
admet-337	32	15	-	-	PUNCT
admet-337	32	16	kinase	kinase	NOUN
admet-337	32	17	(	(	PUNCT
admet-337	32	18	pi3k)/protein	pi3k)/protein	PROPN
admet-337	32	19	kinase	kinase	PROPN
admet-337	32	20	b	b	PROPN
admet-337	32	21	(	(	PUNCT
admet-337	32	22	akt	akt	PROPN
admet-337	32	23	)	)	PUNCT
admet-337	32	24	,	,	PUNCT
admet-337	32	25	and	and	CCONJ
admet-337	32	26	janus	janus	PROPN
admet-337	32	27	kinase	kinase	PROPN
admet-337	32	28	(	(	PUNCT
admet-337	32	29	jak)/signal	jak)/signal	ADJ
admet-337	32	30	transducer	transducer	NOUN
admet-337	32	31	and	and	CCONJ
admet-337	32	32	activator	activator	NOUN
admet-337	32	33	of	of	ADP
admet-337	32	34	transcription	transcription	NOUN
admet-337	32	35	(	(	PUNCT
admet-337	32	36	stat	stat	NOUN
admet-337	32	37	)	)	PUNCT
admet-337	32	38	pathways	pathway	NOUN
admet-337	32	39	,	,	PUNCT
admet-337	32	40	which	which	PRON
admet-337	32	41	contribute	contribute	VERB
admet-337	32	42	to	to	ADP
admet-337	32	43	cell	cell	NOUN
admet-337	32	44	migration	migration	NOUN
admet-337	32	45	,	,	PUNCT
admet-337	32	46	survival	survival	NOUN
admet-337	32	47	,	,	PUNCT
admet-337	32	48	and	and	CCONJ
admet-337	32	49	proliferation	proliferation	NOUN
admet-337	32	50	[	[	X
admet-337	32	51	18,19	18,19	NUM
admet-337	32	52	]	]	PUNCT
admet-337	32	53	.	.	PUNCT
admet-337	33	1	activating	activate	VERB
admet-337	33	2	mutations	mutation	NOUN
admet-337	33	3	in	in	ADP
admet-337	33	4	the	the	DET
admet-337	33	5	egfr	egfr	ADJ
admet-337	33	6	gene	gene	NOUN
admet-337	33	7	were	be	AUX
admet-337	33	8	originally	originally	ADV
admet-337	33	9	reported	report	VERB
admet-337	33	10	in	in	ADP
admet-337	33	11	2004	2004	NUM
admet-337	33	12	,	,	PUNCT
admet-337	33	13	and	and	CCONJ
admet-337	33	14	were	be	AUX
admet-337	33	15	associated	associate	VERB
admet-337	33	16	with	with	ADP
admet-337	33	17	female	female	ADJ
admet-337	33	18	sex	sex	NOUN
admet-337	33	19	,	,	PUNCT
admet-337	33	20	asian	asian	ADJ
admet-337	33	21	descent	descent	NOUN
admet-337	33	22	,	,	PUNCT
admet-337	33	23	absence	absence	NOUN
admet-337	33	24	of	of	ADP
admet-337	33	25	tobacco	tobacco	NOUN
admet-337	33	26	exposure	exposure	NOUN
admet-337	33	27	and	and	CCONJ
admet-337	33	28	adenocarcinoma	adenocarcinoma	NOUN
admet-337	33	29	histology	histology	NOUN
admet-337	34	1	[	[	X
admet-337	34	2	4,20,21	4,20,21	NUM
admet-337	34	3	]	]	PUNCT
admet-337	34	4	.	.	PUNCT
admet-337	35	1	the	the	DET
admet-337	35	2	egfr	egfr	ADJ
admet-337	35	3	gene	gene	NOUN
admet-337	35	4	exists	exist	VERB
admet-337	35	5	on	on	ADP
admet-337	35	6	chromosome	chromosome	NOUN
admet-337	35	7	7	7	NUM
admet-337	35	8	,	,	PUNCT
admet-337	35	9	and	and	CCONJ
admet-337	35	10	activating	activate	VERB
admet-337	35	11	mutations	mutation	NOUN
admet-337	35	12	are	be	AUX
admet-337	35	13	predominantly	predominantly	ADV
admet-337	35	14	located	locate	VERB
admet-337	35	15	on	on	ADP
admet-337	35	16	exons	exon	NOUN
admet-337	35	17	18	18	NUM
admet-337	35	18	to	to	PART
admet-337	35	19	22	22	NUM
admet-337	35	20	.	.	PUNCT
admet-337	36	1	at	at	ADP
admet-337	36	2	diagnosis	diagnosis	NOUN
admet-337	36	3	,	,	PUNCT
admet-337	36	4	90	90	NUM
admet-337	36	5	%	%	NOUN
admet-337	36	6	of	of	ADP
admet-337	36	7	patients	patient	NOUN
admet-337	36	8	with	with	ADP
admet-337	36	9	an	an	DET
admet-337	36	10	activating	activate	VERB
admet-337	36	11	egfr	egfr	ADJ
admet-337	36	12	mutation	mutation	NOUN
admet-337	36	13	will	will	AUX
admet-337	36	14	have	have	VERB
admet-337	36	15	either	either	CCONJ
admet-337	36	16	an	an	DET
admet-337	36	17	in	in	ADP
admet-337	36	18	-	-	PUNCT
admet-337	36	19	frame	frame	NOUN
admet-337	36	20	deletion	deletion	NOUN
admet-337	36	21	in	in	ADP
admet-337	36	22	exon	exon	PROPN
admet-337	36	23	19	19	NUM
admet-337	36	24	or	or	CCONJ
admet-337	36	25	a	a	DET
admet-337	36	26	l858r	l858r	NOUN
admet-337	36	27	missense	missense	NOUN
admet-337	36	28	mutation	mutation	NOUN
admet-337	36	29	on	on	ADP
admet-337	36	30	exon	exon	PROPN
admet-337	36	31	21	21	NUM
admet-337	36	32	.	.	PUNCT
admet-337	37	1	these	these	DET
admet-337	37	2	mutations	mutation	NOUN
admet-337	37	3	all	all	DET
admet-337	37	4	cause	cause	VERB
admet-337	37	5	prolonged	prolonged	ADJ
admet-337	37	6	,	,	PUNCT
admet-337	37	7	ligand	ligand	NOUN
admet-337	37	8	-	-	PUNCT
admet-337	37	9	independent	independent	ADJ
admet-337	37	10	signaling	signaling	NOUN
admet-337	37	11	of	of	ADP
admet-337	37	12	the	the	DET
admet-337	37	13	egfr	egfr	NOUN
admet-337	37	14	[	[	X
admet-337	37	15	22	22	NUM
admet-337	37	16	]	]	PUNCT
admet-337	37	17	.	.	PUNCT
admet-337	38	1	due	due	ADP
admet-337	38	2	to	to	ADP
admet-337	38	3	the	the	DET
admet-337	38	4	dependence	dependence	NOUN
admet-337	38	5	on	on	ADP
admet-337	38	6	the	the	DET
admet-337	38	7	constitutively	constitutively	ADV
admet-337	38	8	activated	activate	VERB
admet-337	38	9	egfr	egfr	NOUN
admet-337	38	10	,	,	PUNCT
admet-337	38	11	these	these	DET
admet-337	38	12	malignant	malignant	ADJ
admet-337	38	13	clones	clone	NOUN
admet-337	38	14	are	be	AUX
admet-337	38	15	particularly	particularly	ADV
admet-337	38	16	susceptible	susceptible	ADJ
admet-337	38	17	to	to	ADP
admet-337	38	18	egfr	egfr	PROPN
admet-337	38	19	tkis	tkis	PROPN
admet-337	38	20	.	.	PUNCT
admet-337	39	1	the	the	DET
admet-337	39	2	receptor	receptor	NOUN
admet-337	39	3	targets	target	NOUN
admet-337	39	4	,	,	PUNCT
admet-337	39	5	clinical	clinical	ADJ
admet-337	39	6	indications	indication	NOUN
admet-337	39	7	,	,	PUNCT
admet-337	39	8	pharmacokinetics	pharmacokinetic	NOUN
admet-337	39	9	,	,	PUNCT
admet-337	39	10	pharmacodynamics	pharmacodynamic	NOUN
admet-337	39	11	and	and	CCONJ
admet-337	39	12	cns	cns	NOUN
admet-337	39	13	penetration	penetration	NOUN
admet-337	39	14	of	of	ADP
admet-337	39	15	the	the	DET
admet-337	39	16	fda	fda	PROPN
admet-337	39	17	approved	approve	VERB
admet-337	39	18	egfr	egfr	NOUN
admet-337	39	19	tkis	tkis	PROPN
admet-337	39	20	are	be	AUX
admet-337	39	21	summarized	summarize	VERB
admet-337	39	22	in	in	ADP
admet-337	39	23	table	table	NOUN
admet-337	39	24	1	1	NUM
admet-337	39	25	.	.	PUNCT
admet-337	40	1	erlotinib	erlotinib	PROPN
admet-337	40	2	clinical	clinical	ADJ
admet-337	40	3	efficacy	efficacy	NOUN
admet-337	40	4	prior	prior	ADV
admet-337	40	5	to	to	ADP
admet-337	40	6	the	the	DET
admet-337	40	7	widespread	widespread	ADJ
admet-337	40	8	knowledge	knowledge	NOUN
admet-337	40	9	of	of	ADP
admet-337	40	10	egfr	egfr	NOUN
admet-337	40	11	activating	activate	VERB
admet-337	40	12	mutations	mutation	NOUN
admet-337	40	13	as	as	ADP
admet-337	40	14	predictive	predictive	ADJ
admet-337	40	15	biomarker	biomarker	NOUN
admet-337	40	16	of	of	ADP
admet-337	40	17	treatment	treatment	NOUN
admet-337	40	18	sensitivity	sensitivity	NOUN
admet-337	40	19	to	to	PART
admet-337	40	20	egfr	egfr	VERB
admet-337	40	21	tkis	tkis	NOUN
admet-337	40	22	,	,	PUNCT
admet-337	40	23	erlotinib	erlotinib	PROPN
admet-337	40	24	gained	gain	VERB
admet-337	40	25	fda	fda	PROPN
admet-337	40	26	approval	approval	NOUN
admet-337	40	27	in	in	ADP
admet-337	40	28	november	november	PROPN
admet-337	40	29	2004	2004	NUM
admet-337	40	30	for	for	ADP
admet-337	40	31	treatment	treatment	NOUN
admet-337	40	32	of	of	ADP
admet-337	40	33	advanced	advanced	ADJ
admet-337	40	34	nsclc	nsclc	NOUN
admet-337	40	35	,	,	PUNCT
admet-337	40	36	regardless	regardless	ADV
admet-337	40	37	of	of	ADP
admet-337	40	38	tumor	tumor	NOUN
admet-337	40	39	mutation	mutation	NOUN
admet-337	40	40	status	status	NOUN
admet-337	40	41	,	,	PUNCT
admet-337	40	42	after	after	ADP
admet-337	40	43	failure	failure	NOUN
admet-337	40	44	of	of	ADP
admet-337	40	45	firstor	firstor	NOUN
admet-337	40	46	second	second	ADJ
admet-337	40	47	-	-	PUNCT
admet-337	40	48	line	line	NOUN
admet-337	40	49	chemotherapy	chemotherapy	NOUN
admet-337	40	50	.	.	PUNCT
admet-337	41	1	in	in	ADP
admet-337	41	2	a	a	DET
admet-337	41	3	phase	phase	NOUN
admet-337	41	4	iii	iii	NOUN
admet-337	41	5	,	,	PUNCT
admet-337	41	6	placebo	placebo	NOUN
admet-337	41	7	-	-	PUNCT
admet-337	41	8	controlled	control	VERB
admet-337	41	9	randomized	randomized	ADJ
admet-337	41	10	study	study	NOUN
admet-337	41	11	,	,	PUNCT
admet-337	41	12	erlotinib	erlotinib	NOUN
admet-337	41	13	provided	provide	VERB
admet-337	41	14	advantages	advantage	NOUN
admet-337	41	15	in	in	ADP
admet-337	41	16	progression	progression	NOUN
admet-337	41	17	-	-	PUNCT
admet-337	41	18	free	free	ADJ
admet-337	41	19	survival	survival	NOUN
admet-337	41	20	(	(	PUNCT
admet-337	41	21	pfs	pfs	PROPN
admet-337	41	22	)	)	PUNCT
admet-337	41	23	(	(	PUNCT
admet-337	41	24	2.2	2.2	NUM
admet-337	41	25	months	month	NOUN
admet-337	41	26	vs	vs	ADP
admet-337	41	27	1.8	1.8	NUM
admet-337	41	28	months	month	NOUN
admet-337	41	29	,	,	PUNCT
admet-337	41	30	hazard	hazard	NOUN
admet-337	41	31	ratio	ratio	NOUN
admet-337	41	32	,	,	PUNCT
admet-337	41	33	0.61;p<0.001	0.61;p<0.001	PROPN
admet-337	41	34	)	)	PUNCT
admet-337	41	35	and	and	CCONJ
admet-337	41	36	overall	overall	ADJ
admet-337	41	37	survival	survival	NOUN
admet-337	41	38	(	(	PUNCT
admet-337	41	39	os	os	NOUN
admet-337	41	40	)	)	PUNCT
admet-337	41	41	(	(	PUNCT
admet-337	41	42	6.7	6.7	NUM
admet-337	41	43	months	month	NOUN
admet-337	41	44	vs	vs	ADP
admet-337	41	45	4.7	4.7	NUM
admet-337	41	46	months	month	NOUN
admet-337	41	47	,	,	PUNCT
admet-337	41	48	hazard	hazard	NOUN
admet-337	41	49	ratio	ratio	NOUN
admet-337	41	50	,	,	PUNCT
admet-337	41	51	0.71	0.71	NUM
admet-337	41	52	;	;	PUNCT
admet-337	41	53	p<0.001	p<0.001	X
admet-337	41	54	)	)	PUNCT
admet-337	41	55	compared	compare	VERB
admet-337	41	56	to	to	ADP
admet-337	41	57	placebo	placebo	NOUN
admet-337	41	58	[	[	X
admet-337	41	59	25	25	NUM
admet-337	41	60	]	]	PUNCT
admet-337	41	61	.	.	PUNCT
admet-337	42	1	erlotinib	erlotinib	PROPN
admet-337	42	2	was	be	AUX
admet-337	42	3	next	next	ADJ
admet-337	42	4	fda	fda	PROPN
admet-337	42	5	-	-	PUNCT
admet-337	42	6	approved	approve	VERB
admet-337	42	7	for	for	ADP
admet-337	42	8	maintenance	maintenance	NOUN
admet-337	42	9	treatment	treatment	NOUN
admet-337	42	10	of	of	ADP
admet-337	42	11	nsclc	nsclc	NOUN
admet-337	42	12	in	in	ADP
admet-337	42	13	april	april	PROPN
admet-337	42	14	2010	2010	NUM
admet-337	42	15	for	for	ADP
admet-337	42	16	patients	patient	NOUN
admet-337	42	17	whose	whose	DET
admet-337	42	18	disease	disease	NOUN
admet-337	42	19	had	have	AUX
admet-337	42	20	not	not	PART
admet-337	42	21	progressed	progress	VERB
admet-337	42	22	after	after	ADP
admet-337	42	23	four	four	NUM
admet-337	42	24	cycles	cycle	NOUN
admet-337	42	25	of	of	ADP
admet-337	42	26	platinum	platinum	NOUN
admet-337	42	27	-	-	PUNCT
admet-337	42	28	based	base	VERB
admet-337	42	29	chemotherapy	chemotherapy	NOUN
admet-337	42	30	based	base	VERB
admet-337	42	31	on	on	ADP
admet-337	42	32	the	the	DET
admet-337	42	33	saturn	saturn	NOUN
admet-337	42	34	trial	trial	NOUN
admet-337	42	35	.	.	PUNCT
admet-337	43	1	the	the	DET
admet-337	43	2	randomized	randomized	ADJ
admet-337	43	3	,	,	PUNCT
admet-337	43	4	double	double	ADJ
admet-337	43	5	-	-	PUNCT
admet-337	43	6	blind	blind	ADJ
admet-337	43	7	,	,	PUNCT
admet-337	43	8	grace	grace	NOUN
admet-337	43	9	dy	dy	NOUN
admet-337	43	10	et	et	PROPN
admet-337	43	11	al	al	PROPN
admet-337	43	12	.	.	PROPN
admet-337	43	13	admet	admet	PROPN
admet-337	43	14	&	&	CCONJ
admet-337	43	15	dmpk	dmpk	PROPN
admet-337	43	16	4(3	4(3	NUM
admet-337	43	17	)	)	PUNCT
admet-337	43	18	(	(	PUNCT
admet-337	43	19	2016	2016	NUM
admet-337	43	20	)	)	PUNCT
admet-337	43	21	186	186	NUM
admet-337	43	22	-	-	SYM
admet-337	43	23	211	211	NUM
admet-337	43	24	188	188	NUM
admet-337	43	25	placebo	placebo	NOUN
admet-337	43	26	-	-	PUNCT
admet-337	43	27	controlled	control	VERB
admet-337	43	28	study	study	NOUN
admet-337	43	29	of	of	ADP
admet-337	43	30	889	889	NUM
admet-337	43	31	patients	patient	NOUN
admet-337	43	32	with	with	ADP
admet-337	43	33	stage	stage	NOUN
admet-337	43	34	iiib	iiib	NOUN
admet-337	43	35	/	/	SYM
admet-337	43	36	iv	iv	NUM
admet-337	43	37	nsclc	nsclc	NOUN
admet-337	43	38	who	who	PRON
admet-337	43	39	received	receive	VERB
admet-337	43	40	erlotinib	erlotinib	NOUN
admet-337	43	41	or	or	CCONJ
admet-337	43	42	placebo	placebo	NOUN
admet-337	43	43	after	after	ADP
admet-337	43	44	receiving	receive	VERB
admet-337	43	45	first	first	ADJ
admet-337	43	46	-	-	PUNCT
admet-337	43	47	line	line	NOUN
admet-337	43	48	platinum	platinum	NOUN
admet-337	43	49	-	-	PUNCT
admet-337	43	50	based	base	VERB
admet-337	43	51	chemotherapy	chemotherapy	NOUN
admet-337	43	52	demonstrated	demonstrate	VERB
admet-337	43	53	improvements	improvement	NOUN
admet-337	43	54	in	in	ADP
admet-337	43	55	pfs	pfs	PROPN
admet-337	43	56	(	(	PUNCT
admet-337	43	57	12.3	12.3	NUM
admet-337	43	58	weeks	week	NOUN
admet-337	43	59	vs	vs	ADP
admet-337	43	60	11.1	11.1	NUM
admet-337	43	61	weeks	week	NOUN
admet-337	43	62	,	,	PUNCT
admet-337	43	63	hr	hr	NOUN
admet-337	43	64	0.71	0.71	NUM
admet-337	43	65	;	;	PUNCT
admet-337	43	66	p<0.001	p<0.001	X
admet-337	43	67	)	)	PUNCT
admet-337	43	68	as	as	ADV
admet-337	43	69	well	well	ADV
admet-337	43	70	as	as	ADP
admet-337	43	71	os	os	NOUN
admet-337	43	72	(	(	PUNCT
admet-337	43	73	12	12	NUM
admet-337	43	74	months	month	NOUN
admet-337	43	75	vs	vs	ADP
admet-337	43	76	11.1	11.1	NUM
admet-337	43	77	months	month	NOUN
admet-337	43	78	,	,	PUNCT
admet-337	43	79	hr	hr	NOUN
admet-337	43	80	0.81	0.81	NUM
admet-337	43	81	;	;	PUNCT
admet-337	43	82	p=0.0088	p=0.0088	X
admet-337	43	83	)	)	PUNCT
admet-337	43	84	for	for	ADP
admet-337	43	85	erlotinib	erlotinib	NOUN
admet-337	43	86	maintenance	maintenance	NOUN
admet-337	43	87	.	.	PUNCT
admet-337	44	1	patients	patient	NOUN
admet-337	44	2	with	with	ADP
admet-337	44	3	activating	activate	VERB
admet-337	44	4	mutations	mutation	NOUN
admet-337	44	5	of	of	ADP
admet-337	44	6	egfr	egfr	NOUN
admet-337	44	7	experienced	experience	VERB
admet-337	44	8	more	more	ADV
admet-337	44	9	dramatic	dramatic	ADJ
admet-337	44	10	pfs	pfs	NOUN
admet-337	44	11	and	and	CCONJ
admet-337	44	12	os	os	NOUN
admet-337	44	13	benefits	benefit	NOUN
admet-337	44	14	[	[	X
admet-337	44	15	26	26	NUM
admet-337	44	16	]	]	PUNCT
admet-337	44	17	.	.	PUNCT
admet-337	45	1	table	table	NOUN
admet-337	45	2	1	1	NUM
admet-337	45	3	.	.	X
admet-337	45	4	egfr	egfr	PROPN
admet-337	45	5	tki	tki	PROPN
admet-337	45	6	characteristics	characteristic	NOUN
admet-337	45	7	egfr	egfr	VERB
admet-337	45	8	tki	tki	PROPN
admet-337	45	9	name	name	NOUN
admet-337	45	10	erlotinib	erlotinib	PROPN
admet-337	45	11	gefitinib	gefitinib	NOUN
admet-337	45	12	afatinib	afatinib	NOUN
admet-337	45	13	osimertinib	osimertinib	VERB
admet-337	45	14	primary	primary	ADJ
admet-337	45	15	targets	target	NOUN
admet-337	45	16	wild	wild	ADJ
admet-337	45	17	type	type	NOUN
admet-337	45	18	egfr	egfr	ADJ
admet-337	45	19	deletion	deletion	NOUN
admet-337	45	20	19	19	NUM
admet-337	45	21	l858r	l858r	NOUN
admet-337	45	22	wild	wild	ADJ
admet-337	45	23	type	type	NOUN
admet-337	45	24	egfr	egfr	ADJ
admet-337	45	25	deletion	deletion	NOUN
admet-337	45	26	19	19	NUM
admet-337	45	27	l858r	l858r	NOUN
admet-337	45	28	wild	wild	ADJ
admet-337	45	29	type	type	NOUN
admet-337	45	30	egfr	egfr	ADJ
admet-337	45	31	deletion	deletion	NOUN
admet-337	45	32	19	19	NUM
admet-337	45	33	l858r	l858r	NOUN
admet-337	45	34	t790	t790	NUM
admet-337	45	35	m	m	PROPN
admet-337	45	36	her2/3/4	her2/3/4	NOUN
admet-337	45	37	deletion	deletion	NOUN
admet-337	45	38	19	19	NUM
admet-337	45	39	l858r	l858r	NOUN
admet-337	45	40	t790	t790	NUM
admet-337	45	41	m	m	NOUN
admet-337	45	42	type	type	NOUN
admet-337	45	43	of	of	ADP
admet-337	45	44	inhibition	inhibition	NOUN
admet-337	45	45	reversible	reversible	ADJ
admet-337	45	46	reversible	reversible	ADJ
admet-337	45	47	irreversible	irreversible	ADJ
admet-337	45	48	irreversible	irreversible	ADJ
admet-337	45	49	clinical	clinical	ADJ
admet-337	45	50	approval	approval	NOUN
admet-337	45	51	first	first	ADJ
admet-337	45	52	-	-	PUNCT
admet-337	45	53	line	line	NOUN
admet-337	45	54	treatment	treatment	NOUN
admet-337	45	55	of	of	ADP
admet-337	45	56	advanced	advanced	ADJ
admet-337	45	57	egfrmutated	egfrmutate	VERB
admet-337	45	58	nsclc	nsclc	NOUN
admet-337	45	59	first	first	ADJ
admet-337	45	60	-	-	PUNCT
admet-337	45	61	line	line	NOUN
admet-337	45	62	treatment	treatment	NOUN
admet-337	45	63	of	of	ADP
admet-337	45	64	advanced	advanced	ADJ
admet-337	45	65	egfrmutated	egfrmutate	VERB
admet-337	45	66	nsclc	nsclc	NOUN
admet-337	45	67	first	first	ADJ
admet-337	45	68	-	-	PUNCT
admet-337	45	69	line	line	NOUN
admet-337	45	70	treatment	treatment	NOUN
admet-337	45	71	of	of	ADP
admet-337	45	72	advanced	advanced	ADJ
admet-337	45	73	egfrmutated	egfrmutate	VERB
admet-337	45	74	nsclc	nsclc	NOUN
admet-337	45	75	second	second	ADJ
admet-337	45	76	-	-	PUNCT
admet-337	45	77	line	line	NOUN
admet-337	45	78	treatment	treatment	NOUN
admet-337	45	79	of	of	ADP
admet-337	45	80	advanced	advanced	ADJ
admet-337	45	81	egfrmutated	egfrmutate	VERB
admet-337	45	82	nsclc	nsclc	NOUN
admet-337	45	83	egfr	egfr	NOUN
admet-337	45	84	mutation	mutation	NOUN
admet-337	45	85	ic50	ic50	PROPN
admet-337	45	86	(	(	PUNCT
admet-337	45	87	in	in	ADP
admet-337	45	88	vitro)[23	vitro)[23	PROPN
admet-337	45	89	]	]	X
admet-337	45	90	23	23	NUM
admet-337	45	91	nm	nm	NOUN
admet-337	45	92	(	(	PUNCT
admet-337	45	93	del	del	PROPN
admet-337	45	94	19	19	NUM
admet-337	45	95	)	)	PUNCT
admet-337	45	96	39	39	NUM
admet-337	45	97	nm	nm	NOUN
admet-337	45	98	(	(	PUNCT
admet-337	45	99	l858r	l858r	NOUN
admet-337	45	100	)	)	PUNCT
admet-337	45	101	30	30	NUM
admet-337	45	102	(	(	PUNCT
admet-337	45	103	del	del	PROPN
admet-337	45	104	19	19	NUM
admet-337	45	105	)	)	PUNCT
admet-337	45	106	100	100	NUM
admet-337	45	107	nm	nm	NOUN
admet-337	45	108	(	(	PUNCT
admet-337	45	109	l858r	l858r	NOUN
admet-337	45	110	)	)	PUNCT
admet-337	45	111	0.2	0.2	NUM
admet-337	45	112	nm	nm	NOUN
admet-337	45	113	(	(	PUNCT
admet-337	45	114	del19	del19	PROPN
admet-337	45	115	)	)	PUNCT
admet-337	45	116	0.2	0.2	NUM
admet-337	45	117	nm	nm	NOUN
admet-337	45	118	(	(	PUNCT
admet-337	45	119	l858r	l858r	NOUN
admet-337	45	120	)	)	PUNCT
admet-337	45	121	9	9	NUM
admet-337	45	122	nm	nm	NOUN
admet-337	45	123	(	(	PUNCT
admet-337	45	124	del	del	PROPN
admet-337	45	125	19	19	NUM
admet-337	45	126	)	)	PUNCT
admet-337	45	127	12	12	NUM
admet-337	45	128	nm	nm	NOUN
admet-337	45	129	(	(	PUNCT
admet-337	45	130	l858r	l858r	NOUN
admet-337	45	131	)	)	PUNCT
admet-337	45	132	t790	t790	NUM
admet-337	45	133	m	m	NOUN
admet-337	45	134	ic50	ic50	NOUN
admet-337	45	135	(	(	PUNCT
admet-337	45	136	in	in	ADP
admet-337	45	137	vitro	vitro	X
admet-337	45	138	)	)	PUNCT
admet-337	46	1	[	[	X
admet-337	46	2	22,24	22,24	X
admet-337	46	3	]	]	X
admet-337	46	4	1600	1600	NUM
admet-337	46	5	nm	nm	NOUN
admet-337	46	6	(	(	PUNCT
admet-337	46	7	del	del	PROPN
admet-337	46	8	19	19	NUM
admet-337	46	9	)	)	PUNCT
admet-337	46	10	>	>	SYM
admet-337	46	11	10000	10000	NUM
admet-337	46	12	nm	nm	NOUN
admet-337	46	13	(	(	PUNCT
admet-337	46	14	l858r	l858r	NOUN
admet-337	46	15	)	)	PUNCT
admet-337	46	16	>	>	PUNCT
admet-337	46	17	5000	5000	NUM
admet-337	46	18	nm	nm	NOUN
admet-337	46	19	141	141	NUM
admet-337	46	20	nm	nm	NOUN
admet-337	46	21	(	(	PUNCT
admet-337	46	22	del	del	PROPN
admet-337	46	23	19	19	NUM
admet-337	46	24	)	)	PUNCT
admet-337	46	25	196	196	NUM
admet-337	46	26	nm	nm	NOUN
admet-337	46	27	(	(	PUNCT
admet-337	46	28	l858r	l858r	NOUN
admet-337	46	29	)	)	PUNCT
admet-337	46	30	3	3	NUM
admet-337	46	31	nm	nm	NOUN
admet-337	46	32	(	(	PUNCT
admet-337	46	33	del	del	PROPN
admet-337	46	34	19	19	NUM
admet-337	46	35	)	)	PUNCT
admet-337	46	36	13	13	NUM
admet-337	46	37	nm	nm	NOUN
admet-337	46	38	(	(	PUNCT
admet-337	46	39	l858r	l858r	NOUN
admet-337	46	40	)	)	PUNCT
admet-337	46	41	drug	drug	NOUN
admet-337	46	42	interactions	interaction	NOUN
admet-337	46	43	proton	proton	NOUN
admet-337	46	44	pump	pump	NOUN
admet-337	46	45	inhibitors	inhibitor	NOUN
admet-337	46	46	h2	h2	NOUN
admet-337	46	47	antagonists	antagonist	NOUN
admet-337	46	48	cyp3a4	cyp3a4	VERB
admet-337	46	49	inducers	inducer	NOUN
admet-337	46	50	/	/	SYM
admet-337	46	51	inhibitors	inhibitor	NOUN
admet-337	46	52	proton	proton	NOUN
admet-337	46	53	pump	pump	NOUN
admet-337	46	54	inhibitors	inhibitor	NOUN
admet-337	46	55	h2	h2	NOUN
admet-337	46	56	antagonists	antagonist	NOUN
admet-337	46	57	cyp3a4	cyp3a4	PROPN
admet-337	46	58	&	&	CCONJ
admet-337	46	59	cyp2d6	cyp2d6	NOUN
admet-337	46	60	inducers	inducer	NOUN
admet-337	46	61	/	/	SYM
admet-337	46	62	inhibitors	inhibitor	NOUN
admet-337	46	63	p	p	NOUN
admet-337	46	64	-	-	PUNCT
admet-337	46	65	gp	gp	NOUN
admet-337	46	66	inducers	inducer	NOUN
admet-337	46	67	/	/	SYM
admet-337	46	68	inhibitors	inhibitor	NOUN
admet-337	46	69	cyp3a4	cyp3a4	VERB
admet-337	46	70	inducers	inducer	NOUN
admet-337	46	71	/	/	SYM
admet-337	46	72	inhibitors	inhibitor	NOUN
admet-337	46	73	p	p	NOUN
admet-337	46	74	-	-	PUNCT
admet-337	46	75	gp	gp	NOUN
admet-337	46	76	inducers	inducer	NOUN
admet-337	46	77	/	/	SYM
admet-337	46	78	inhibitors	inhibitor	NOUN
admet-337	46	79	food	food	NOUN
admet-337	46	80	interactions	interaction	NOUN
admet-337	46	81	food	food	NOUN
admet-337	46	82	increases	increase	VERB
admet-337	46	83	bioavailability	bioavailability	NOUN
admet-337	46	84	.	.	PUNCT
admet-337	47	1	take	take	VERB
admet-337	47	2	on	on	ADP
admet-337	47	3	empty	empty	ADJ
admet-337	47	4	stomach	stomach	NOUN
admet-337	47	5	.	.	PUNCT
admet-337	48	1	none	none	NOUN
admet-337	48	2	high	high	ADJ
admet-337	48	3	-	-	PUNCT
admet-337	48	4	fat	fat	NOUN
admet-337	48	5	meals	meal	NOUN
admet-337	48	6	decrease	decrease	VERB
admet-337	48	7	bioavailability	bioavailability	NOUN
admet-337	48	8	.	.	PUNCT
admet-337	49	1	take	take	VERB
admet-337	49	2	on	on	ADP
admet-337	49	3	empty	empty	ADJ
admet-337	49	4	stomach	stomach	NOUN
admet-337	49	5	.	.	PUNCT
admet-337	50	1	none	none	NOUN
admet-337	50	2	metabolism	metabolism	NOUN
admet-337	50	3	liver	liver	NOUN
admet-337	50	4	cyp3a4	cyp3a4	PROPN
admet-337	50	5	liver	liver	NOUN
admet-337	50	6	cyp3a4	cyp3a4	PROPN
admet-337	50	7	cyp2d6	cyp2d6	NOUN
admet-337	50	8	non	non	ADJ
admet-337	50	9	-	-	ADJ
admet-337	50	10	enzyme	enzyme	ADJ
admet-337	50	11	catalyzed	catalyze	VERB
admet-337	50	12	michael	michael	PROPN
admet-337	50	13	adduct	adduct	VERB
admet-337	50	14	formation	formation	NOUN
admet-337	50	15	to	to	ADP
admet-337	50	16	electron	electron	NOUN
admet-337	50	17	-	-	PUNCT
admet-337	50	18	rich	rich	ADJ
admet-337	50	19	small	small	ADJ
admet-337	50	20	molecules	molecule	NOUN
admet-337	50	21	and	and	CCONJ
admet-337	50	22	proteins	protein	NOUN
admet-337	50	23	liver	liver	NOUN
admet-337	50	24	cyp3a4	cyp3a4	NOUN
admet-337	50	25	method	method	NOUN
admet-337	50	26	of	of	ADP
admet-337	50	27	elimination	elimination	NOUN
admet-337	50	28	83	83	NUM
admet-337	50	29	%	%	NOUN
admet-337	50	30	feces	fece	NOUN
admet-337	50	31	(	(	PUNCT
admet-337	50	32	1	1	NUM
admet-337	50	33	%	%	NOUN
admet-337	50	34	unchanged	unchanged	ADJ
admet-337	50	35	drug	drug	NOUN
admet-337	50	36	)	)	PUNCT
admet-337	50	37	8	8	NUM
admet-337	50	38	%	%	NOUN
admet-337	50	39	urine	urine	NOUN
admet-337	50	40	86	86	NUM
admet-337	50	41	%	%	NOUN
admet-337	50	42	feces	fece	NOUN
admet-337	50	43	4	4	NUM
admet-337	50	44	%	%	NOUN
admet-337	50	45	urine	urine	NOUN
admet-337	50	46	85	85	NUM
admet-337	50	47	%	%	NOUN
admet-337	50	48	feces	fece	NOUN
admet-337	50	49	(	(	PUNCT
admet-337	50	50	89	89	NUM
admet-337	50	51	%	%	NOUN
admet-337	50	52	unchanged	unchanged	ADJ
admet-337	50	53	)	)	PUNCT
admet-337	50	54	4	4	NUM
admet-337	50	55	%	%	NOUN
admet-337	50	56	urine	urine	NOUN
admet-337	50	57	68	68	NUM
admet-337	50	58	%	%	NOUN
admet-337	50	59	feces	fece	NOUN
admet-337	50	60	(	(	PUNCT
admet-337	50	61	2	2	NUM
admet-337	50	62	%	%	NOUN
admet-337	50	63	unchanged	unchanged	ADJ
admet-337	50	64	)	)	PUNCT
admet-337	50	65	14	14	NUM
admet-337	50	66	%	%	NOUN
admet-337	50	67	urine	urine	NOUN
admet-337	50	68	cns	cns	NOUN
admet-337	50	69	penetration	penetration	NOUN
admet-337	50	70	~5	~5	NOUN
admet-337	50	71	%	%	NOUN
admet-337	50	72	cns	cns	NOUN
admet-337	50	73	response	response	NOUN
admet-337	50	74	achieved	achieve	VERB
admet-337	50	75	in	in	ADP
admet-337	50	76	patients	patient	NOUN
admet-337	50	77	refractory	refractory	NOUN
admet-337	50	78	to	to	ADP
admet-337	50	79	gefitinib	gefitinib	NOUN
admet-337	50	80	.	.	PUNCT
admet-337	51	1	~1	~1	ADJ
admet-337	51	2	%	%	VERB
admet-337	51	3	csf	csf	ADJ
admet-337	51	4	concentration	concentration	NOUN
admet-337	51	5	of	of	ADP
admet-337	51	6	1	1	NUM
admet-337	51	7	nm	nm	NOUN
admet-337	51	8	in	in	ADP
admet-337	51	9	single	single	ADJ
admet-337	51	10	case	case	NOUN
admet-337	51	11	report	report	VERB
admet-337	51	12	0.2	0.2	NUM
admet-337	51	13	-	-	SYM
admet-337	51	14	1	1	NUM
admet-337	51	15	%	%	NOUN
admet-337	51	16	in	in	ADP
admet-337	51	17	case	case	NOUN
admet-337	51	18	reports	report	NOUN
admet-337	51	19	.	.	PUNCT
admet-337	52	1	higher	high	ADJ
admet-337	52	2	clinical	clinical	ADJ
admet-337	52	3	response	response	NOUN
admet-337	52	4	witnessed	witness	VERB
admet-337	52	5	than	than	ADP
admet-337	52	6	first	first	ADJ
admet-337	52	7	generation	generation	NOUN
admet-337	52	8	tkis	tkis	PROPN
admet-337	52	9	.	.	PUNCT
admet-337	53	1	abbreviations	abbreviation	NOUN
admet-337	53	2	.	.	PUNCT
admet-337	54	1	ic50	ic50	NOUN
admet-337	54	2	:	:	PUNCT
admet-337	54	3	concentration	concentration	NOUN
admet-337	54	4	at	at	ADP
admet-337	54	5	which	which	PRON
admet-337	54	6	drug	drug	NOUN
admet-337	54	7	inhibits	inhibit	VERB
admet-337	54	8	50	50	NUM
admet-337	54	9	%	%	NOUN
admet-337	54	10	of	of	ADP
admet-337	54	11	receptor	receptor	NOUN
admet-337	54	12	’s	’s	PART
admet-337	54	13	activity	activity	NOUN
admet-337	54	14	;	;	PUNCT
admet-337	54	15	nm	nm	ADJ
admet-337	54	16	:	:	PUNCT
admet-337	54	17	nanomolar	nanomolar	ADJ
admet-337	54	18	;	;	PUNCT
admet-337	54	19	cyp	cyp	ADJ
admet-337	54	20	:	:	PUNCT
admet-337	54	21	cytochrome	cytochrome	NOUN
admet-337	54	22	p450	p450	NUM
admet-337	54	23	;	;	PUNCT
admet-337	54	24	p	p	X
admet-337	54	25	-	-	PUNCT
admet-337	54	26	gp	gp	NOUN
admet-337	54	27	:	:	PUNCT
admet-337	54	28	p	p	X
admet-337	54	29	-	-	PUNCT
admet-337	54	30	glycoprotein	glycoprotein	NOUN
admet-337	54	31	as	as	ADP
admet-337	54	32	knowledge	knowledge	NOUN
admet-337	54	33	of	of	ADP
admet-337	54	34	the	the	DET
admet-337	54	35	egfr	egfr	NOUN
admet-337	54	36	activating	activate	VERB
admet-337	54	37	mutations	mutation	NOUN
admet-337	54	38	developed	develop	VERB
admet-337	54	39	,	,	PUNCT
admet-337	54	40	development	development	NOUN
admet-337	54	41	of	of	ADP
admet-337	54	42	companion	companion	NOUN
admet-337	54	43	diagnostic	diagnostic	ADJ
admet-337	54	44	assays	assay	NOUN
admet-337	54	45	for	for	ADP
admet-337	54	46	a	a	DET
admet-337	54	47	predictive	predictive	ADJ
admet-337	54	48	biomarker	biomarker	NOUN
admet-337	54	49	of	of	ADP
admet-337	54	50	treatment	treatment	NOUN
admet-337	54	51	sensitivity	sensitivity	NOUN
admet-337	54	52	utilized	utilize	VERB
admet-337	54	53	in	in	ADP
admet-337	54	54	registrational	registrational	ADJ
admet-337	54	55	studies	study	NOUN
admet-337	54	56	facilitated	facilitate	VERB
admet-337	54	57	fdaapproval	fdaapproval	NOUN
admet-337	54	58	of	of	ADP
admet-337	54	59	this	this	DET
admet-337	54	60	agent	agent	NOUN
admet-337	54	61	for	for	ADP
admet-337	54	62	first	first	ADJ
admet-337	54	63	-	-	PUNCT
admet-337	54	64	line	line	NOUN
admet-337	54	65	treatment	treatment	NOUN
admet-337	54	66	of	of	ADP
admet-337	54	67	patients	patient	NOUN
admet-337	54	68	with	with	ADP
admet-337	54	69	metastatic	metastatic	ADJ
admet-337	54	70	nsclc	nsclc	NOUN
admet-337	54	71	whose	whose	DET
admet-337	54	72	tumors	tumor	NOUN
admet-337	54	73	harbor	harbor	VERB
admet-337	54	74	egfr	egfr	PROPN
admet-337	54	75	exon	exon	VERB
admet-337	54	76	19	19	NUM
admet-337	54	77	deletions	deletion	NOUN
admet-337	54	78	or	or	CCONJ
admet-337	54	79	the	the	DET
admet-337	54	80	l858r	l858r	NOUN
admet-337	54	81	mutation	mutation	NOUN
admet-337	54	82	in	in	ADP
admet-337	54	83	may	may	PROPN
admet-337	54	84	2013	2013	NUM
admet-337	54	85	.	.	PUNCT
admet-337	55	1	eurtac	eurtac	ADJ
admet-337	55	2	,	,	PUNCT
admet-337	55	3	the	the	DET
admet-337	55	4	open	open	ADJ
admet-337	55	5	-	-	PUNCT
admet-337	55	6	label	label	NOUN
admet-337	55	7	,	,	PUNCT
admet-337	55	8	randomized	randomize	VERB
admet-337	55	9	phase	phase	NOUN
admet-337	55	10	3	3	NUM
admet-337	55	11	trial	trial	NOUN
admet-337	55	12	demonstrated	demonstrate	VERB
admet-337	55	13	improvement	improvement	NOUN
admet-337	55	14	in	in	ADP
admet-337	55	15	pfs	pfs	PROPN
admet-337	55	16	(	(	PUNCT
admet-337	55	17	9.7	9.7	NUM
admet-337	55	18	months	month	NOUN
admet-337	55	19	vs	vs	ADP
admet-337	55	20	5.2	5.2	NUM
admet-337	55	21	months	month	NOUN
admet-337	55	22	,	,	PUNCT
admet-337	55	23	hr	hr	NOUN
admet-337	55	24	0.37	0.37	NUM
admet-337	55	25	;	;	PUNCT
admet-337	55	26	p<0.001	p<0.001	X
admet-337	55	27	)	)	PUNCT
admet-337	55	28	for	for	ADP
admet-337	55	29	erlotinib	erlotinib	NOUN
admet-337	55	30	compared	compare	VERB
admet-337	55	31	admet	admet	PROPN
admet-337	55	32	&	&	CCONJ
admet-337	55	33	dmpk	dmpk	PROPN
admet-337	55	34	4(3	4(3	NUM
admet-337	55	35	)	)	PUNCT
admet-337	55	36	(	(	PUNCT
admet-337	55	37	2016	2016	NUM
admet-337	55	38	)	)	PUNCT
admet-337	55	39	186	186	NUM
admet-337	55	40	-	-	SYM
admet-337	55	41	211	211	NUM
admet-337	55	42	tki	tki	NOUN
admet-337	55	43	for	for	ADP
admet-337	55	44	egfrand	egfrand	ADJ
admet-337	55	45	alk	alk	PROPN
admet-337	55	46	-	-	PUNCT
admet-337	55	47	mutated	mutate	VERB
admet-337	55	48	cell	cell	NOUN
admet-337	55	49	cancer	cancer	NOUN
admet-337	55	50	doi	doi	NOUN
admet-337	55	51	:	:	PUNCT
admet-337	55	52	10.5599	10.5599	NUM
admet-337	55	53	/	/	SYM
admet-337	55	54	admet.4.3.337	admet.4.3.337	NUM
admet-337	55	55	189	189	NUM
admet-337	55	56	with	with	ADP
admet-337	55	57	standard	standard	ADJ
admet-337	55	58	first	first	ADJ
admet-337	55	59	-	-	PUNCT
admet-337	55	60	line	line	NOUN
admet-337	55	61	chemotherapy	chemotherapy	NOUN
admet-337	55	62	.	.	PUNCT
admet-337	56	1	a	a	DET
admet-337	56	2	benefit	benefit	NOUN
admet-337	56	3	in	in	ADP
admet-337	56	4	os	os	NOUN
admet-337	56	5	was	be	AUX
admet-337	56	6	not	not	PART
admet-337	56	7	demonstrated	demonstrate	VERB
admet-337	56	8	,	,	PUNCT
admet-337	56	9	but	but	CCONJ
admet-337	56	10	most	most	ADJ
admet-337	56	11	patients	patient	NOUN
admet-337	56	12	in	in	ADP
admet-337	56	13	the	the	DET
admet-337	56	14	chemotherapy	chemotherapy	NOUN
admet-337	56	15	group	group	NOUN
admet-337	56	16	crossed	cross	VERB
admet-337	56	17	over	over	ADP
admet-337	56	18	to	to	PART
admet-337	56	19	receive	receive	VERB
admet-337	56	20	erlotinib	erlotinib	NOUN
admet-337	56	21	upon	upon	SCONJ
admet-337	56	22	disease	disease	NOUN
admet-337	56	23	progression	progression	NOUN
admet-337	56	24	[	[	X
admet-337	56	25	27	27	NUM
admet-337	56	26	]	]	PUNCT
admet-337	56	27	.	.	PUNCT
admet-337	57	1	multiple	multiple	ADJ
admet-337	57	2	subsequent	subsequent	ADJ
admet-337	57	3	phase	phase	NOUN
admet-337	57	4	iii	iii	NUM
admet-337	57	5	trials	trial	NOUN
admet-337	57	6	have	have	AUX
admet-337	57	7	shown	show	VERB
admet-337	57	8	that	that	SCONJ
admet-337	57	9	erlotinib	erlotinib	NOUN
admet-337	57	10	improves	improve	VERB
admet-337	57	11	pfs	pf	VERB
admet-337	57	12	compared	compare	VERB
admet-337	57	13	to	to	ADP
admet-337	57	14	conventional	conventional	ADJ
admet-337	57	15	platinum	platinum	NOUN
admet-337	57	16	-	-	PUNCT
admet-337	57	17	based	base	VERB
admet-337	57	18	chemotherapy	chemotherapy	NOUN
admet-337	57	19	in	in	ADP
admet-337	57	20	first	first	ADJ
admet-337	57	21	-	-	PUNCT
admet-337	57	22	line	line	NOUN
admet-337	57	23	treatment	treatment	NOUN
admet-337	57	24	of	of	ADP
admet-337	57	25	nsclc	nsclc	NOUN
admet-337	57	26	[	[	X
admet-337	57	27	28,29	28,29	NUM
admet-337	57	28	]	]	X
admet-337	57	29	.	.	PUNCT
admet-337	58	1	clinical	clinical	ADJ
admet-337	58	2	safety	safety	NOUN
admet-337	58	3	skin	skin	NOUN
admet-337	58	4	rash	rash	NOUN
admet-337	58	5	is	be	AUX
admet-337	58	6	the	the	DET
admet-337	58	7	most	most	ADV
admet-337	58	8	common	common	ADJ
admet-337	58	9	toxicity	toxicity	NOUN
admet-337	58	10	encountered	encounter	VERB
admet-337	58	11	with	with	ADP
admet-337	58	12	erlotinib	erlotinib	NOUN
admet-337	58	13	use	use	NOUN
admet-337	58	14	.	.	PUNCT
admet-337	59	1	all	all	DET
admet-337	59	2	-	-	PUNCT
admet-337	59	3	grade	grade	NOUN
admet-337	59	4	rash	rash	NOUN
admet-337	59	5	occurs	occur	VERB
admet-337	59	6	in	in	ADP
admet-337	59	7	61	61	NUM
admet-337	59	8	to	to	PART
admet-337	59	9	80	80	NUM
admet-337	59	10	%	%	NOUN
admet-337	59	11	and	and	CCONJ
admet-337	59	12	grade	grade	NOUN
admet-337	59	13	3	3	NUM
admet-337	59	14	or	or	CCONJ
admet-337	59	15	4	4	NUM
admet-337	59	16	rash	rash	NOUN
admet-337	59	17	occurs	occur	VERB
admet-337	59	18	in	in	ADP
admet-337	59	19	2	2	NUM
admet-337	59	20	to	to	PART
admet-337	59	21	13	13	NUM
admet-337	59	22	%	%	NOUN
admet-337	59	23	of	of	ADP
admet-337	59	24	patients	patient	NOUN
admet-337	59	25	.	.	PUNCT
admet-337	60	1	the	the	DET
admet-337	60	2	classic	classic	ADJ
admet-337	60	3	erlotinib	erlotinib	NOUN
admet-337	60	4	(	(	PUNCT
admet-337	60	5	or	or	CCONJ
admet-337	60	6	any	any	DET
admet-337	60	7	egfr	egfr	ADJ
admet-337	60	8	-	-	PUNCT
admet-337	60	9	inhibitor	inhibitor	NOUN
admet-337	60	10	)	)	PUNCT
admet-337	60	11	rash	rash	NOUN
admet-337	60	12	is	be	AUX
admet-337	60	13	an	an	DET
admet-337	60	14	acneiform	acneiform	ADJ
admet-337	60	15	rash	rash	NOUN
admet-337	60	16	that	that	PRON
admet-337	60	17	occurs	occur	VERB
admet-337	60	18	on	on	ADP
admet-337	60	19	the	the	DET
admet-337	60	20	scalp	scalp	NOUN
admet-337	60	21	,	,	PUNCT
admet-337	60	22	cheeks	cheek	NOUN
admet-337	60	23	,	,	PUNCT
admet-337	60	24	nose	nose	NOUN
admet-337	60	25	,	,	PUNCT
admet-337	60	26	perioral	perioral	ADJ
admet-337	60	27	area	area	NOUN
admet-337	60	28	,	,	PUNCT
admet-337	60	29	and	and	CCONJ
admet-337	60	30	upper	upper	ADJ
admet-337	60	31	trunk	trunk	NOUN
admet-337	60	32	.	.	PUNCT
admet-337	61	1	the	the	DET
admet-337	61	2	rash	rash	NOUN
admet-337	61	3	typically	typically	ADV
admet-337	61	4	manifests	manifest	VERB
admet-337	61	5	within	within	ADP
admet-337	61	6	the	the	DET
admet-337	61	7	first	first	ADJ
admet-337	61	8	2	2	NUM
admet-337	61	9	weeks	week	NOUN
admet-337	61	10	of	of	ADP
admet-337	61	11	treatment	treatment	NOUN
admet-337	61	12	but	but	CCONJ
admet-337	61	13	can	can	AUX
admet-337	61	14	occur	occur	VERB
admet-337	61	15	as	as	ADV
admet-337	61	16	late	late	ADJ
admet-337	61	17	as	as	ADP
admet-337	61	18	2	2	NUM
admet-337	61	19	months	month	NOUN
admet-337	61	20	after	after	ADP
admet-337	61	21	starting	start	VERB
admet-337	61	22	therapy	therapy	NOUN
admet-337	61	23	[	[	X
admet-337	61	24	30	30	NUM
admet-337	61	25	]	]	PUNCT
admet-337	61	26	.	.	PUNCT
admet-337	62	1	less	less	ADV
admet-337	62	2	commonly	commonly	ADV
admet-337	62	3	,	,	PUNCT
admet-337	62	4	bullous	bullous	ADJ
admet-337	62	5	eruptions	eruption	NOUN
admet-337	62	6	can	can	AUX
admet-337	62	7	occur	occur	VERB
admet-337	62	8	.	.	PUNCT
admet-337	63	1	toxic	toxic	ADJ
admet-337	63	2	epidermal	epidermal	ADJ
admet-337	63	3	necrolysis	necrolysis	NOUN
admet-337	63	4	(	(	PUNCT
admet-337	63	5	ten	ten	NUM
admet-337	63	6	)	)	PUNCT
admet-337	63	7	and	and	CCONJ
admet-337	63	8	stevensjohnson	stevensjohnson	PROPN
admet-337	63	9	syndrome(sjs	syndrome(sjs	PROPN
admet-337	63	10	)	)	PUNCT
admet-337	63	11	have	have	AUX
admet-337	63	12	developed	develop	VERB
admet-337	63	13	in	in	ADP
admet-337	63	14	patients	patient	NOUN
admet-337	63	15	taking	take	VERB
admet-337	63	16	erlotinib	erlotinib	NOUN
admet-337	63	17	.	.	PUNCT
admet-337	64	1	diarrhea	diarrhea	NOUN
admet-337	64	2	is	be	AUX
admet-337	64	3	another	another	DET
admet-337	64	4	common	common	ADJ
admet-337	64	5	adverse	adverse	ADJ
admet-337	64	6	event	event	NOUN
admet-337	64	7	caused	cause	VERB
admet-337	64	8	by	by	ADP
admet-337	64	9	erlotinib	erlotinib	NOUN
admet-337	64	10	.	.	PUNCT
admet-337	65	1	any	any	DET
admet-337	65	2	grade	grade	NOUN
admet-337	65	3	diarrhea	diarrhea	NOUN
admet-337	65	4	occurs	occur	VERB
admet-337	65	5	in	in	ADP
admet-337	65	6	21	21	NUM
admet-337	65	7	to	to	PART
admet-337	65	8	57	57	NUM
admet-337	65	9	%	%	NOUN
admet-337	65	10	and	and	CCONJ
admet-337	65	11	grade	grade	NOUN
admet-337	65	12	3	3	NUM
admet-337	65	13	or	or	CCONJ
admet-337	65	14	4	4	NUM
admet-337	65	15	diarrhea	diarrhea	NOUN
admet-337	65	16	occurs	occur	VERB
admet-337	65	17	in	in	ADP
admet-337	65	18	1	1	NUM
admet-337	65	19	-	-	SYM
admet-337	65	20	6	6	NUM
admet-337	65	21	%	%	NOUN
admet-337	65	22	.	.	PUNCT
admet-337	66	1	rarely	rarely	ADV
admet-337	66	2	(	(	PUNCT
admet-337	66	3	<	<	X
admet-337	66	4	5	5	NUM
admet-337	66	5	%	%	NOUN
admet-337	66	6	)	)	PUNCT
admet-337	66	7	,	,	PUNCT
admet-337	66	8	patients	patient	NOUN
admet-337	66	9	can	can	AUX
admet-337	66	10	develop	develop	VERB
admet-337	66	11	cerebrovascular	cerebrovascular	ADJ
admet-337	66	12	events	event	NOUN
admet-337	66	13	,	,	PUNCT
admet-337	66	14	gastrointestinal	gastrointestinal	ADJ
admet-337	66	15	perforation	perforation	NOUN
admet-337	66	16	,	,	PUNCT
admet-337	66	17	fatal	fatal	ADJ
admet-337	66	18	pneumonitis	pneumonitis	NOUN
admet-337	66	19	,	,	PUNCT
admet-337	66	20	liver	liver	NOUN
admet-337	66	21	/	/	SYM
admet-337	66	22	renal	renal	ADJ
admet-337	66	23	failure	failure	NOUN
admet-337	66	24	,	,	PUNCT
admet-337	66	25	or	or	CCONJ
admet-337	66	26	corneal	corneal	ADJ
admet-337	66	27	perforation	perforation	NOUN
admet-337	66	28	.	.	PUNCT
admet-337	67	1	patients	patient	NOUN
admet-337	67	2	on	on	ADP
admet-337	67	3	warfarin	warfarin	NOUN
admet-337	67	4	should	should	AUX
admet-337	67	5	have	have	VERB
admet-337	67	6	inr	inr	PROPN
admet-337	67	7	monitored	monitor	VERB
admet-337	67	8	closely	closely	ADV
admet-337	67	9	as	as	SCONJ
admet-337	67	10	fatal	fatal	ADJ
admet-337	67	11	hemorrhage	hemorrhage	NOUN
admet-337	67	12	has	have	AUX
admet-337	67	13	occurred	occur	VERB
admet-337	67	14	in	in	ADP
admet-337	67	15	patients	patient	NOUN
admet-337	67	16	on	on	ADP
admet-337	67	17	both	both	CCONJ
admet-337	67	18	erlotinib	erlotinib	NOUN
admet-337	67	19	and	and	CCONJ
admet-337	67	20	warfarin	warfarin	NOUN
admet-337	67	21	.	.	PUNCT
admet-337	68	1	dose	dose	NOUN
admet-337	68	2	reduction	reduction	NOUN
admet-337	68	3	is	be	AUX
admet-337	68	4	necessary	necessary	ADJ
admet-337	68	5	in	in	ADP
admet-337	68	6	19	19	NUM
admet-337	68	7	to	to	PART
admet-337	68	8	21	21	NUM
admet-337	68	9	%	%	NOUN
admet-337	68	10	of	of	ADP
admet-337	68	11	patients	patient	NOUN
admet-337	68	12	(	(	PUNCT
admet-337	68	13	7	7	NUM
admet-337	68	14	-	-	SYM
admet-337	68	15	12	12	NUM
admet-337	68	16	%	%	NOUN
admet-337	68	17	rash	rash	NOUN
admet-337	68	18	,	,	PUNCT
admet-337	68	19	5	5	NUM
admet-337	68	20	-	-	SYM
admet-337	68	21	7	7	NUM
admet-337	68	22	%	%	NOUN
admet-337	68	23	diarrhea	diarrhea	NOUN
admet-337	68	24	)	)	PUNCT
admet-337	68	25	,	,	PUNCT
admet-337	68	26	and	and	CCONJ
admet-337	68	27	treatment	treatment	NOUN
admet-337	68	28	interruption	interruption	NOUN
admet-337	68	29	occurs	occur	VERB
admet-337	68	30	in	in	ADP
admet-337	68	31	27	27	NUM
admet-337	68	32	%	%	NOUN
admet-337	68	33	(	(	PUNCT
admet-337	68	34	14	14	NUM
admet-337	68	35	%	%	NOUN
admet-337	68	36	rash	rash	NOUN
admet-337	68	37	,	,	PUNCT
admet-337	68	38	6	6	NUM
admet-337	68	39	%	%	NOUN
admet-337	68	40	diarrhea	diarrhea	NOUN
admet-337	68	41	)	)	PUNCT
admet-337	68	42	.	.	PUNCT
admet-337	69	1	treatment	treatment	NOUN
admet-337	69	2	discontinuation	discontinuation	NOUN
admet-337	69	3	is	be	AUX
admet-337	69	4	rarely	rarely	ADV
admet-337	69	5	necessary	necessary	ADJ
admet-337	69	6	,	,	PUNCT
admet-337	69	7	occurring	occur	VERB
admet-337	69	8	in	in	ADP
admet-337	69	9	only	only	ADV
admet-337	69	10	3	3	NUM
admet-337	69	11	to	to	PART
admet-337	69	12	6	6	NUM
admet-337	69	13	%	%	NOUN
admet-337	69	14	of	of	ADP
admet-337	69	15	patients	patient	NOUN
admet-337	69	16	[	[	X
admet-337	69	17	11,25,27,28	11,25,27,28	NUM
admet-337	69	18	]	]	PUNCT
admet-337	69	19	.	.	PUNCT
admet-337	70	1	pharmacology	pharmacology	NOUN
admet-337	70	2	erlotinib	erlotinib	PROPN
admet-337	70	3	hydrochloride	hydrochloride	NOUN
admet-337	70	4	,	,	PUNCT
admet-337	70	5	6	6	NUM
admet-337	70	6	,	,	PUNCT
admet-337	70	7	7	7	NUM
admet-337	70	8	-	-	PUNCT
admet-337	70	9	bis(2	bis(2	NOUN
admet-337	70	10	-	-	PUNCT
admet-337	70	11	methoxyethoxy)-n-(3	methoxyethoxy)-n-(3	NOUN
admet-337	70	12	-	-	PUNCT
admet-337	70	13	ethynyl	ethynyl	NOUN
admet-337	70	14	-	-	PUNCT
admet-337	70	15	phenyl	phenyl	NOUN
admet-337	70	16	)	)	PUNCT
admet-337	70	17	quinazolin-4	quinazolin-4	NOUN
admet-337	70	18	-	-	NOUN
admet-337	70	19	amine	amine	ADJ
admet-337	70	20	[	[	X
admet-337	70	21	cp-358774	cp-358774	NOUN
admet-337	70	22	,	,	PUNCT
admet-337	70	23	osi	osi	PROPN
admet-337	70	24	-	-	PUNCT
admet-337	70	25	t774	t774	PROPN
admet-337	70	26	,	,	PUNCT
admet-337	70	27	tarceva	tarceva	PROPN
admet-337	70	28	,	,	PUNCT
admet-337	70	29	(	(	PUNCT
admet-337	70	30	genentech	genentech	NOUN
admet-337	70	31	)	)	PUNCT
admet-337	70	32	]	]	PUNCT
admet-337	70	33	reversibly	reversibly	ADV
admet-337	70	34	inhibits	inhibit	VERB
admet-337	70	35	the	the	DET
admet-337	70	36	egfr	egfr	ADJ
admet-337	70	37	tyrosine	tyrosine	PROPN
admet-337	70	38	kinase	kinase	PROPN
admet-337	70	39	at	at	ADP
admet-337	70	40	the	the	DET
admet-337	70	41	atp	atp	NOUN
admet-337	70	42	binding	bind	VERB
admet-337	70	43	domain	domain	NOUN
admet-337	70	44	with	with	ADP
admet-337	70	45	high	high	ADJ
admet-337	70	46	selectivity	selectivity	NOUN
admet-337	70	47	and	and	CCONJ
admet-337	70	48	potency	potency	NOUN
admet-337	70	49	.	.	PUNCT
admet-337	71	1	erlotinib	erlotinib	PROPN
admet-337	71	2	inhibits	inhibit	VERB
admet-337	71	3	purified	purified	ADJ
admet-337	71	4	egfr	egfr	ADJ
admet-337	71	5	kinase	kinase	PROPN
admet-337	71	6	with	with	ADP
admet-337	71	7	an	an	DET
admet-337	71	8	ic50	ic50	PROPN
admet-337	71	9	of	of	ADP
admet-337	71	10	2	2	NUM
admet-337	71	11	nanomolar	nanomolar	ADJ
admet-337	71	12	(	(	PUNCT
admet-337	71	13	nm	nm	NOUN
admet-337	71	14	)	)	PUNCT
admet-337	71	15	and	and	CCONJ
admet-337	71	16	inhibits	inhibit	VERB
admet-337	71	17	egfr	egfr	ADJ
admet-337	71	18	autophosphorylation	autophosphorylation	NOUN
admet-337	71	19	with	with	ADP
admet-337	71	20	an	an	DET
admet-337	71	21	ic50	ic50	PROPN
admet-337	71	22	of	of	ADP
admet-337	71	23	20	20	NUM
admet-337	71	24	nm	nm	NOUN
admet-337	71	25	in	in	ADP
admet-337	71	26	intact	intact	ADJ
admet-337	71	27	tumor	tumor	NOUN
admet-337	71	28	cells	cell	NOUN
admet-337	71	29	.	.	PUNCT
admet-337	72	1	erlotinib	erlotinib	NOUN
admet-337	72	2	binds	bind	VERB
admet-337	72	3	more	more	ADV
admet-337	72	4	strongly	strongly	ADV
admet-337	72	5	to	to	PART
admet-337	72	6	egfr	egfr	VERB
admet-337	72	7	harboring	harboring	NOUN
admet-337	72	8	l858r	l858r	PROPN
admet-337	72	9	or	or	CCONJ
admet-337	72	10	del	del	PROPN
admet-337	72	11	19	19	NUM
admet-337	72	12	than	than	SCONJ
admet-337	72	13	it	it	PRON
admet-337	72	14	does	do	VERB
admet-337	72	15	to	to	ADP
admet-337	72	16	wild	wild	ADJ
admet-337	72	17	-	-	PUNCT
admet-337	72	18	type	type	NOUN
admet-337	72	19	egfr	egfr	NOUN
admet-337	72	20	[	[	X
admet-337	72	21	31	31	NUM
admet-337	72	22	]	]	PUNCT
admet-337	72	23	,	,	PUNCT
admet-337	72	24	but	but	CCONJ
admet-337	72	25	it	it	PRON
admet-337	72	26	binds	bind	VERB
admet-337	72	27	to	to	ADP
admet-337	72	28	several	several	ADJ
admet-337	72	29	offtarget	offtarget	NOUN
admet-337	72	30	kinases	kinase	NOUN
admet-337	72	31	,	,	PUNCT
admet-337	72	32	including	include	VERB
admet-337	72	33	cyclin	cyclin	PROPN
admet-337	72	34	g	g	PROPN
admet-337	72	35	-	-	PUNCT
admet-337	72	36	associated	associate	VERB
admet-337	72	37	kinase	kinase	NOUN
admet-337	72	38	(	(	PUNCT
admet-337	72	39	gak	gak	PROPN
admet-337	72	40	)	)	PUNCT
admet-337	72	41	,	,	PUNCT
admet-337	72	42	ste20	ste20	ADJ
admet-337	72	43	-	-	PUNCT
admet-337	72	44	like	like	ADJ
admet-337	72	45	kinase	kinase	NOUN
admet-337	72	46	(	(	PUNCT
admet-337	72	47	slk	slk	PROPN
admet-337	72	48	)	)	PUNCT
admet-337	72	49	and	and	CCONJ
admet-337	72	50	serine	serine	NOUN
admet-337	72	51	/	/	SYM
admet-337	72	52	threonine	threonine	ADJ
admet-337	72	53	kinase	kinase	NOUN
admet-337	72	54	10	10	NUM
admet-337	72	55	(	(	PUNCT
admet-337	72	56	stk10	stk10	PROPN
admet-337	72	57	)	)	PUNCT
admet-337	72	58	.	.	PUNCT
admet-337	73	1	the	the	DET
admet-337	73	2	inhibition	inhibition	NOUN
admet-337	73	3	of	of	ADP
admet-337	73	4	stk10	stk10	NOUN
admet-337	73	5	enhances	enhance	VERB
admet-337	73	6	lymphocyte	lymphocyte	ADJ
admet-337	73	7	migration	migration	NOUN
admet-337	73	8	and	and	CCONJ
admet-337	73	9	cytokine	cytokine	NOUN
admet-337	73	10	release	release	NOUN
admet-337	73	11	,	,	PUNCT
admet-337	73	12	which	which	PRON
admet-337	73	13	contributes	contribute	VERB
admet-337	73	14	to	to	ADP
admet-337	73	15	the	the	DET
admet-337	73	16	dermatologic	dermatologic	ADJ
admet-337	73	17	toxicity	toxicity	NOUN
admet-337	73	18	of	of	ADP
admet-337	73	19	the	the	DET
admet-337	73	20	medication	medication	NOUN
admet-337	73	21	[	[	X
admet-337	73	22	32	32	NUM
admet-337	73	23	]	]	PUNCT
admet-337	73	24	.	.	PUNCT
admet-337	74	1	erlotinib	erlotinib	PROPN
admet-337	74	2	carries	carry	VERB
admet-337	74	3	a	a	DET
admet-337	74	4	recommended	recommend	VERB
admet-337	74	5	oral	oral	NOUN
admet-337	74	6	starting	starting	NOUN
admet-337	74	7	dose	dose	NOUN
admet-337	74	8	of	of	ADP
admet-337	74	9	150	150	NUM
admet-337	74	10	mg	mg	NOUN
admet-337	74	11	daily	daily	ADV
admet-337	74	12	.	.	PUNCT
admet-337	75	1	the	the	DET
admet-337	75	2	drug	drug	NOUN
admet-337	75	3	reaches	reach	VERB
admet-337	75	4	peak	peak	NOUN
admet-337	75	5	plasma	plasma	NOUN
admet-337	75	6	levels	level	NOUN
admet-337	75	7	approximately	approximately	ADV
admet-337	75	8	4	4	NUM
admet-337	75	9	hours	hour	NOUN
admet-337	75	10	after	after	ADP
admet-337	75	11	administration	administration	NOUN
admet-337	75	12	,	,	PUNCT
admet-337	75	13	and	and	CCONJ
admet-337	75	14	the	the	DET
admet-337	75	15	volume	volume	NOUN
admet-337	75	16	of	of	ADP
admet-337	75	17	distribution	distribution	NOUN
admet-337	75	18	is	be	AUX
admet-337	75	19	232	232	NUM
admet-337	75	20	l	l	NOUN
admet-337	76	1	[	[	X
admet-337	76	2	33	33	NUM
admet-337	76	3	]	]	PUNCT
admet-337	76	4	.	.	PUNCT
admet-337	77	1	bioavailability	bioavailability	NOUN
admet-337	77	2	of	of	ADP
admet-337	77	3	erlotinib	erlotinib	NOUN
admet-337	77	4	is	be	AUX
admet-337	77	5	60	60	NUM
admet-337	77	6	%	%	NOUN
admet-337	77	7	but	but	CCONJ
admet-337	77	8	increases	increase	NOUN
admet-337	77	9	to	to	ADP
admet-337	77	10	nearly	nearly	ADV
admet-337	77	11	100	100	NUM
admet-337	77	12	%	%	NOUN
admet-337	77	13	if	if	SCONJ
admet-337	77	14	administered	administer	VERB
admet-337	77	15	with	with	ADP
admet-337	77	16	food	food	NOUN
admet-337	77	17	[	[	X
admet-337	77	18	34	34	NUM
admet-337	77	19	]	]	PUNCT
admet-337	77	20	.	.	PUNCT
admet-337	78	1	the	the	DET
admet-337	78	2	effect	effect	NOUN
admet-337	78	3	of	of	ADP
admet-337	78	4	food	food	NOUN
admet-337	78	5	on	on	ADP
admet-337	78	6	erlotinib	erlotinib	NOUN
admet-337	78	7	absorption	absorption	NOUN
admet-337	78	8	appears	appear	VERB
admet-337	78	9	to	to	PART
admet-337	78	10	have	have	VERB
admet-337	78	11	inter	inter	ADJ
admet-337	78	12	-	-	ADJ
admet-337	78	13	and	and	CCONJ
admet-337	78	14	intra	intra	ADJ
admet-337	78	15	-	-	ADJ
admet-337	78	16	individual	individual	ADJ
admet-337	78	17	variability	variability	NOUN
admet-337	78	18	,	,	PUNCT
admet-337	78	19	and	and	CCONJ
admet-337	78	20	erlotinib	erlotinib	NOUN
admet-337	78	21	is	be	AUX
admet-337	78	22	to	to	PART
admet-337	78	23	be	be	AUX
admet-337	78	24	taken	take	VERB
admet-337	78	25	at	at	ADV
admet-337	78	26	least	least	ADV
admet-337	78	27	1	1	NUM
admet-337	78	28	hour	hour	NOUN
admet-337	78	29	prior	prior	ADV
admet-337	78	30	to	to	ADP
admet-337	78	31	or	or	CCONJ
admet-337	78	32	at	at	ADV
admet-337	78	33	least	least	ADV
admet-337	78	34	2	2	NUM
admet-337	78	35	hours	hour	NOUN
admet-337	78	36	after	after	ADP
admet-337	78	37	eating	eat	VERB
admet-337	78	38	[	[	X
admet-337	78	39	35	35	NUM
admet-337	78	40	]	]	PUNCT
admet-337	78	41	.	.	PUNCT
admet-337	79	1	erlotinib	erlotinib	PROPN
admet-337	79	2	has	have	VERB
admet-337	79	3	multiple	multiple	ADJ
admet-337	79	4	drug	drug	NOUN
admet-337	79	5	interactions	interaction	NOUN
admet-337	79	6	,	,	PUNCT
admet-337	79	7	and	and	CCONJ
admet-337	79	8	van	van	PROPN
admet-337	79	9	leeuwen	leeuwen	PROPN
admet-337	79	10	et	et	PROPN
admet-337	79	11	al	al	PROPN
admet-337	79	12	.	.	PROPN
admet-337	79	13	have	have	AUX
admet-337	79	14	previously	previously	ADV
admet-337	79	15	reviewed	review	VERB
admet-337	79	16	common	common	ADJ
admet-337	79	17	tki	tki	X
admet-337	79	18	drug	drug	NOUN
admet-337	79	19	-	-	PUNCT
admet-337	79	20	drug	drug	NOUN
admet-337	79	21	interactions	interaction	NOUN
admet-337	79	22	in	in	ADP
admet-337	79	23	detail	detail	NOUN
admet-337	79	24	[	[	X
admet-337	79	25	170	170	NUM
admet-337	79	26	]	]	PUNCT
admet-337	79	27	.	.	PUNCT
admet-337	80	1	gastric	gastric	ADJ
admet-337	80	2	ph	ph	PROPN
admet-337	80	3	is	be	AUX
admet-337	80	4	a	a	DET
admet-337	80	5	significant	significant	ADJ
admet-337	80	6	determinant	determinant	ADJ
admet-337	80	7	in	in	ADP
admet-337	80	8	erlotinib	erlotinib	NOUN
admet-337	80	9	absorption	absorption	NOUN
admet-337	80	10	.	.	PUNCT
admet-337	81	1	as	as	ADP
admet-337	81	2	a	a	DET
admet-337	81	3	weak	weak	ADJ
admet-337	81	4	base	base	NOUN
admet-337	81	5	,	,	PUNCT
admet-337	81	6	the	the	DET
admet-337	81	7	drug	drug	NOUN
admet-337	81	8	can	can	AUX
admet-337	81	9	exist	exist	VERB
admet-337	81	10	in	in	ADP
admet-337	81	11	either	either	CCONJ
admet-337	81	12	ionized	ionized	ADJ
admet-337	81	13	or	or	CCONJ
admet-337	81	14	non	non	ADJ
admet-337	81	15	-	-	ADJ
admet-337	81	16	ionized	ionized	ADJ
admet-337	81	17	forms	form	NOUN
admet-337	81	18	.	.	PUNCT
admet-337	82	1	at	at	ADP
admet-337	82	2	an	an	DET
admet-337	82	3	elevated	elevated	ADJ
admet-337	82	4	ph	ph	VERB
admet-337	82	5	,	,	PUNCT
admet-337	82	6	the	the	DET
admet-337	82	7	drug	drug	NOUN
admet-337	82	8	shifts	shift	NOUN
admet-337	82	9	to	to	ADP
admet-337	82	10	its	its	PRON
admet-337	82	11	less	less	ADV
admet-337	82	12	-	-	PUNCT
admet-337	82	13	soluble	soluble	ADJ
admet-337	82	14	,	,	PUNCT
admet-337	82	15	non	non	ADJ
admet-337	82	16	-	-	ADJ
admet-337	82	17	ionized	ionized	ADJ
admet-337	82	18	form	form	NOUN
admet-337	82	19	,	,	PUNCT
admet-337	82	20	and	and	CCONJ
admet-337	82	21	drug	drug	NOUN
admet-337	82	22	absorption	absorption	NOUN
admet-337	82	23	decreases	decrease	VERB
admet-337	82	24	.	.	PUNCT
admet-337	83	1	therefore	therefore	ADV
admet-337	83	2	,	,	PUNCT
admet-337	83	3	proton	proton	NOUN
admet-337	83	4	pump	pump	NOUN
admet-337	83	5	inhibitors	inhibitor	NOUN
admet-337	83	6	and	and	CCONJ
admet-337	83	7	other	other	ADJ
admet-337	83	8	drugs	drug	NOUN
admet-337	83	9	that	that	PRON
admet-337	83	10	increase	increase	VERB
admet-337	83	11	gastric	gastric	ADJ
admet-337	83	12	ph	ph	NOUN
admet-337	83	13	lead	lead	NOUN
admet-337	83	14	to	to	PART
admet-337	83	15	significantly	significantly	ADV
admet-337	83	16	decreased	decrease	VERB
admet-337	83	17	serum	serum	NOUN
admet-337	83	18	levels	level	NOUN
admet-337	83	19	of	of	ADP
admet-337	83	20	erlotinib	erlotinib	NOUN
admet-337	83	21	and	and	CCONJ
admet-337	83	22	can	can	AUX
admet-337	83	23	decrease	decrease	VERB
admet-337	83	24	erlotinib	erlotinib	NOUN
admet-337	83	25	auc	auc	NOUN
admet-337	83	26	by	by	ADP
admet-337	83	27	46	46	NUM
admet-337	83	28	%	%	NOUN
admet-337	83	29	and	and	CCONJ
admet-337	83	30	maximum	maximum	ADJ
admet-337	83	31	erlotinib	erlotinib	NOUN
admet-337	83	32	serum	serum	NOUN
admet-337	83	33	concentration	concentration	NOUN
admet-337	83	34	by	by	ADP
admet-337	83	35	61	61	NUM
admet-337	83	36	%	%	NOUN
admet-337	83	37	.	.	PUNCT
admet-337	84	1	interestingly	interestingly	ADV
admet-337	84	2	,	,	PUNCT
admet-337	84	3	this	this	PRON
admet-337	84	4	can	can	AUX
admet-337	84	5	be	be	AUX
admet-337	84	6	overcome	overcome	VERB
admet-337	84	7	by	by	ADP
admet-337	84	8	administering	administer	VERB
admet-337	84	9	erlotinib	erlotinib	NOUN
admet-337	84	10	with	with	ADP
admet-337	84	11	acidic	acidic	ADJ
admet-337	84	12	beverages	beverage	NOUN
admet-337	84	13	like	like	ADP
admet-337	84	14	cola	cola	PROPN
admet-337	85	1	[	[	X
admet-337	85	2	36	36	NUM
admet-337	85	3	]	]	PUNCT
admet-337	85	4	.	.	PUNCT
admet-337	86	1	upon	upon	SCONJ
admet-337	86	2	absorption	absorption	NOUN
admet-337	86	3	,	,	PUNCT
admet-337	86	4	erlotinib	erlotinib	NOUN
admet-337	86	5	is	be	AUX
admet-337	86	6	heavily	heavily	ADV
admet-337	86	7	protein	protein	NOUN
admet-337	86	8	-	-	PUNCT
admet-337	86	9	bound	bind	VERB
admet-337	86	10	(	(	PUNCT
admet-337	86	11	93	93	NUM
admet-337	86	12	-	-	SYM
admet-337	86	13	95	95	NUM
admet-337	86	14	%	%	NOUN
admet-337	86	15	)	)	PUNCT
admet-337	86	16	to	to	ADP
admet-337	86	17	albumin	albumin	NOUN
admet-337	86	18	and	and	CCONJ
admet-337	86	19	α-1	α-1	NOUN
admet-337	86	20	acid	acid	NOUN
admet-337	86	21	glycoprotein	glycoprotein	NOUN
admet-337	86	22	,	,	PUNCT
admet-337	86	23	and	and	CCONJ
admet-337	86	24	its	its	PRON
admet-337	86	25	median	median	ADJ
admet-337	86	26	half	half	ADJ
admet-337	86	27	-	-	PUNCT
admet-337	86	28	life	life	NOUN
admet-337	86	29	is	be	AUX
admet-337	86	30	36	36	NUM
admet-337	86	31	hours	hour	NOUN
admet-337	87	1	[	[	X
admet-337	87	2	37	37	NUM
admet-337	87	3	]	]	PUNCT
admet-337	87	4	.	.	PUNCT
admet-337	88	1	there	there	PRON
admet-337	88	2	is	be	VERB
admet-337	88	3	no	no	DET
admet-337	88	4	significant	significant	ADJ
admet-337	88	5	association	association	NOUN
admet-337	88	6	with	with	ADP
admet-337	88	7	drug	drug	NOUN
admet-337	88	8	clearance	clearance	NOUN
admet-337	88	9	and	and	CCONJ
admet-337	88	10	gender	gender	NOUN
admet-337	88	11	,	,	PUNCT
admet-337	88	12	weight	weight	NOUN
admet-337	88	13	,	,	PUNCT
admet-337	88	14	or	or	CCONJ
admet-337	88	15	age	age	NOUN
admet-337	88	16	[	[	X
admet-337	88	17	33	33	NUM
admet-337	88	18	]	]	PUNCT
admet-337	88	19	.	.	PUNCT
admet-337	89	1	erlotinib	erlotinib	NOUN
admet-337	89	2	is	be	AUX
admet-337	89	3	primarily	primarily	ADV
admet-337	89	4	metabolized	metabolize	VERB
admet-337	89	5	to	to	ADP
admet-337	89	6	its	its	PRON
admet-337	89	7	active	active	ADJ
admet-337	89	8	metabolite	metabolite	NOUN
admet-337	89	9	,	,	PUNCT
admet-337	89	10	desmethyl	desmethyl	NOUN
admet-337	89	11	erlotinib	erlotinib	PROPN
admet-337	89	12	,	,	PUNCT
admet-337	89	13	in	in	ADP
admet-337	89	14	the	the	DET
admet-337	89	15	liver	liver	NOUN
admet-337	89	16	through	through	ADP
admet-337	89	17	cyp3a4	cyp3a4	NOUN
admet-337	89	18	and	and	CCONJ
admet-337	89	19	to	to	ADP
admet-337	89	20	a	a	DET
admet-337	89	21	lesser	less	ADJ
admet-337	89	22	degree	degree	NOUN
admet-337	89	23	by	by	ADP
admet-337	89	24	cyp1a2	cyp1a2	ADJ
admet-337	89	25	and	and	CCONJ
admet-337	89	26	extrahepatic	extrahepatic	ADJ
admet-337	89	27	cyp1a1	cyp1a1	NOUN
admet-337	89	28	.	.	PUNCT
admet-337	90	1	therefore	therefore	ADV
admet-337	90	2	,	,	PUNCT
admet-337	90	3	induction	induction	NOUN
admet-337	90	4	and	and	CCONJ
admet-337	90	5	grace	grace	NOUN
admet-337	90	6	dy	dy	NOUN
admet-337	90	7	et	et	PROPN
admet-337	90	8	al	al	PROPN
admet-337	90	9	.	.	PROPN
admet-337	90	10	admet	admet	PROPN
admet-337	90	11	&	&	CCONJ
admet-337	90	12	dmpk	dmpk	PROPN
admet-337	90	13	4(3	4(3	NUM
admet-337	90	14	)	)	PUNCT
admet-337	90	15	(	(	PUNCT
admet-337	90	16	2016	2016	NUM
admet-337	90	17	)	)	PUNCT
admet-337	90	18	186	186	NUM
admet-337	90	19	-	-	SYM
admet-337	90	20	211	211	NUM
admet-337	90	21	190	190	NUM
admet-337	90	22	inhibition	inhibition	NOUN
admet-337	90	23	of	of	ADP
admet-337	90	24	cyp3a4	cyp3a4	NOUN
admet-337	90	25	activity	activity	NOUN
admet-337	90	26	through	through	ADP
admet-337	90	27	medications	medication	NOUN
admet-337	90	28	like	like	ADP
admet-337	90	29	rifampin	rifampin	NOUN
admet-337	90	30	and	and	CCONJ
admet-337	90	31	ketoconazole	ketoconazole	NOUN
admet-337	90	32	,	,	PUNCT
admet-337	90	33	respectively	respectively	ADV
admet-337	90	34	,	,	PUNCT
admet-337	90	35	impacts	impact	VERB
admet-337	90	36	serum	serum	NOUN
admet-337	90	37	erlotinib	erlotinib	NOUN
admet-337	90	38	concentrations	concentration	NOUN
admet-337	90	39	.	.	PUNCT
admet-337	91	1	tobacco	tobacco	NOUN
admet-337	91	2	is	be	AUX
admet-337	91	3	a	a	DET
admet-337	91	4	well	well	ADV
admet-337	91	5	-	-	PUNCT
admet-337	91	6	known	know	VERB
admet-337	91	7	cyp	cyp	ADJ
admet-337	91	8	inducer	inducer	NOUN
admet-337	91	9	and	and	CCONJ
admet-337	91	10	increases	increase	VERB
admet-337	91	11	erlotinib	erlotinib	NOUN
admet-337	91	12	clearance	clearance	NOUN
admet-337	91	13	by	by	ADP
admet-337	91	14	24	24	NUM
admet-337	91	15	%	%	NOUN
admet-337	91	16	[	[	X
admet-337	91	17	37	37	NUM
admet-337	91	18	]	]	PUNCT
admet-337	91	19	.	.	PUNCT
admet-337	92	1	serum	serum	PROPN
admet-337	92	2	erlotinib	erlotinib	PROPN
admet-337	92	3	levels	level	NOUN
admet-337	92	4	have	have	AUX
admet-337	92	5	been	be	AUX
admet-337	92	6	successfully	successfully	ADV
admet-337	92	7	monitored	monitor	VERB
admet-337	92	8	in	in	ADP
admet-337	92	9	patients	patient	NOUN
admet-337	92	10	who	who	PRON
admet-337	92	11	are	be	AUX
admet-337	92	12	on	on	ADP
admet-337	92	13	concomitant	concomitant	ADJ
admet-337	92	14	medications	medication	NOUN
admet-337	92	15	that	that	PRON
admet-337	92	16	interact	interact	VERB
admet-337	92	17	with	with	ADP
admet-337	92	18	cyp3a4	cyp3a4	NOUN
admet-337	92	19	,	,	PUNCT
admet-337	92	20	and	and	CCONJ
admet-337	92	21	levels	level	NOUN
admet-337	92	22	correlate	correlate	VERB
admet-337	92	23	with	with	ADP
admet-337	92	24	disease	disease	NOUN
admet-337	92	25	response	response	NOUN
admet-337	93	1	[	[	X
admet-337	93	2	38	38	NUM
admet-337	93	3	]	]	PUNCT
admet-337	93	4	.	.	PUNCT
admet-337	94	1	caution	caution	NOUN
admet-337	94	2	is	be	AUX
admet-337	94	3	recommended	recommend	VERB
admet-337	94	4	when	when	SCONJ
admet-337	94	5	erlotinib	erlotinib	NOUN
admet-337	94	6	is	be	AUX
admet-337	94	7	used	use	VERB
admet-337	94	8	in	in	ADP
admet-337	94	9	patients	patient	NOUN
admet-337	94	10	with	with	ADP
admet-337	94	11	hepatic	hepatic	ADJ
admet-337	94	12	failure	failure	NOUN
admet-337	94	13	;	;	PUNCT
admet-337	94	14	however	however	ADV
admet-337	94	15	,	,	PUNCT
admet-337	94	16	pk	pk	NOUN
admet-337	94	17	and	and	CCONJ
admet-337	94	18	safety	safety	NOUN
admet-337	94	19	profiles	profile	NOUN
admet-337	94	20	are	be	AUX
admet-337	94	21	similar	similar	ADJ
admet-337	94	22	between	between	ADP
admet-337	94	23	patients	patient	NOUN
admet-337	94	24	with	with	ADP
admet-337	94	25	liver	liver	NOUN
admet-337	94	26	impairment	impairment	NOUN
admet-337	94	27	and	and	CCONJ
admet-337	94	28	normal	normal	ADJ
admet-337	94	29	liver	liver	NOUN
admet-337	94	30	function	function	NOUN
admet-337	94	31	[	[	X
admet-337	94	32	39	39	NUM
admet-337	94	33	]	]	PUNCT
admet-337	94	34	.	.	PUNCT
admet-337	95	1	erlotinib	erlotinib	PROPN
admet-337	95	2	is	be	AUX
admet-337	95	3	a	a	DET
admet-337	95	4	substrate	substrate	NOUN
admet-337	95	5	for	for	ADP
admet-337	95	6	pglycoprotein	pglycoprotein	ADJ
admet-337	95	7	(	(	PUNCT
admet-337	95	8	p	p	NOUN
admet-337	95	9	-	-	PUNCT
admet-337	95	10	gp	gp	NOUN
admet-337	95	11	/	/	SYM
admet-337	95	12	abcb1	abcb1	NOUN
admet-337	95	13	)	)	PUNCT
admet-337	95	14	and	and	CCONJ
admet-337	95	15	breast	breast	NOUN
admet-337	95	16	cancer	cancer	NOUN
admet-337	95	17	resistance	resistance	NOUN
admet-337	95	18	protein	protein	NOUN
admet-337	95	19	(	(	PUNCT
admet-337	95	20	brcp	brcp	PROPN
admet-337	95	21	/	/	SYM
admet-337	95	22	abcg2	abcg2	NOUN
admet-337	95	23	)	)	PUNCT
admet-337	95	24	.	.	PUNCT
admet-337	96	1	p	p	X
admet-337	96	2	-	-	PUNCT
admet-337	96	3	gp	gp	NOUN
admet-337	96	4	and	and	CCONJ
admet-337	96	5	brcp	brcp	NOUN
admet-337	96	6	are	be	AUX
admet-337	96	7	efflux	efflux	NOUN
admet-337	96	8	transporters	transporter	NOUN
admet-337	96	9	that	that	PRON
admet-337	96	10	negatively	negatively	ADV
admet-337	96	11	regulate	regulate	VERB
admet-337	96	12	intestinal	intestinal	ADJ
admet-337	96	13	absorption	absorption	NOUN
admet-337	96	14	of	of	ADP
admet-337	96	15	erlotinib	erlotinib	NOUN
admet-337	96	16	[	[	X
admet-337	96	17	40	40	NUM
admet-337	96	18	]	]	PUNCT
admet-337	96	19	.	.	PUNCT
admet-337	97	1	in	in	ADP
admet-337	97	2	patients	patient	NOUN
admet-337	97	3	with	with	ADP
admet-337	97	4	genotypes	genotype	NOUN
admet-337	97	5	that	that	PRON
admet-337	97	6	produce	produce	VERB
admet-337	97	7	low	low	ADJ
admet-337	97	8	p	p	NOUN
admet-337	97	9	-	-	PUNCT
admet-337	97	10	gp	gp	NOUN
admet-337	97	11	or	or	CCONJ
admet-337	97	12	brcp	brcp	VERB
admet-337	97	13	expression	expression	NOUN
admet-337	97	14	,	,	PUNCT
admet-337	97	15	higher	high	ADJ
admet-337	97	16	trough	trough	NOUN
admet-337	97	17	concentrations	concentration	NOUN
admet-337	97	18	of	of	ADP
admet-337	97	19	erlotinib	erlotinib	NOUN
admet-337	97	20	and	and	CCONJ
admet-337	97	21	higher	high	ADJ
admet-337	97	22	rates	rate	NOUN
admet-337	97	23	of	of	ADP
admet-337	97	24	clinical	clinical	ADJ
admet-337	97	25	toxicity	toxicity	NOUN
admet-337	97	26	exist	exist	VERB
admet-337	97	27	[	[	X
admet-337	97	28	41,42	41,42	NOUN
admet-337	97	29	]	]	PUNCT
admet-337	97	30	.	.	PUNCT
admet-337	98	1	after	after	SCONJ
admet-337	98	2	metabolism	metabolism	NOUN
admet-337	98	3	to	to	PART
admet-337	98	4	desmethyl	desmethyl	VERB
admet-337	98	5	erlotinib	erlotinib	PROPN
admet-337	98	6	,	,	PUNCT
admet-337	98	7	oxidation	oxidation	NOUN
admet-337	98	8	and	and	CCONJ
admet-337	98	9	glucuronidation	glucuronidation	NOUN
admet-337	98	10	occur	occur	VERB
admet-337	98	11	[	[	X
admet-337	98	12	43	43	NUM
admet-337	98	13	]	]	PUNCT
admet-337	98	14	.	.	PUNCT
admet-337	99	1	erlotinib	erlotinib	NOUN
admet-337	99	2	and	and	CCONJ
admet-337	99	3	its	its	PRON
admet-337	99	4	metabolites	metabolite	NOUN
admet-337	99	5	are	be	AUX
admet-337	99	6	eliminated	eliminate	VERB
admet-337	99	7	predominantly	predominantly	ADV
admet-337	99	8	in	in	ADP
admet-337	99	9	the	the	DET
admet-337	99	10	feces	fece	NOUN
admet-337	99	11	(	(	PUNCT
admet-337	99	12	83	83	NUM
admet-337	99	13	%	%	NOUN
admet-337	99	14	)	)	PUNCT
admet-337	99	15	and	and	CCONJ
admet-337	99	16	less	less	ADJ
admet-337	99	17	than	than	ADP
admet-337	99	18	2	2	NUM
admet-337	99	19	%	%	NOUN
admet-337	99	20	of	of	ADP
admet-337	99	21	the	the	DET
admet-337	99	22	recovered	recover	VERB
admet-337	99	23	drug	drug	NOUN
admet-337	99	24	is	be	AUX
admet-337	99	25	unchanged	unchanged	ADJ
admet-337	99	26	,	,	PUNCT
admet-337	99	27	indicating	indicate	VERB
admet-337	99	28	extensive	extensive	ADJ
admet-337	99	29	metabolism	metabolism	NOUN
admet-337	99	30	prior	prior	ADV
admet-337	99	31	to	to	ADP
admet-337	99	32	excretion	excretion	NOUN
admet-337	99	33	[	[	X
admet-337	99	34	44	44	NUM
admet-337	99	35	]	]	PUNCT
admet-337	99	36	.	.	PUNCT
admet-337	100	1	given	give	VERB
admet-337	100	2	the	the	DET
admet-337	100	3	limited	limited	ADJ
admet-337	100	4	role	role	NOUN
admet-337	100	5	of	of	ADP
admet-337	100	6	renal	renal	ADJ
admet-337	100	7	metabolism	metabolism	NOUN
admet-337	100	8	and	and	CCONJ
admet-337	100	9	excretion	excretion	NOUN
admet-337	100	10	of	of	ADP
admet-337	100	11	erlotinib	erlotinib	PROPN
admet-337	100	12	,	,	PUNCT
admet-337	100	13	it	it	PRON
admet-337	100	14	can	can	AUX
admet-337	100	15	be	be	AUX
admet-337	100	16	safely	safely	ADV
admet-337	100	17	administered	administer	VERB
admet-337	100	18	in	in	ADP
admet-337	100	19	patients	patient	NOUN
admet-337	100	20	who	who	PRON
admet-337	100	21	have	have	VERB
admet-337	100	22	chronic	chronic	ADJ
admet-337	100	23	renal	renal	ADJ
admet-337	100	24	failure	failure	NOUN
admet-337	100	25	and	and	CCONJ
admet-337	100	26	who	who	PRON
admet-337	100	27	are	be	AUX
admet-337	100	28	undergoing	undergo	VERB
admet-337	100	29	hemodialysis	hemodialysis	NOUN
admet-337	100	30	[	[	X
admet-337	100	31	45	45	NUM
admet-337	100	32	]	]	PUNCT
admet-337	100	33	.	.	PUNCT
admet-337	101	1	cns	cns	PROPN
admet-337	101	2	penetration	penetration	NOUN
admet-337	101	3	central	central	ADJ
admet-337	101	4	nervous	nervous	ADJ
admet-337	101	5	system	system	NOUN
admet-337	101	6	(	(	PUNCT
admet-337	101	7	cns	cns	NOUN
admet-337	101	8	)	)	PUNCT
admet-337	101	9	metastases	metastasis	NOUN
admet-337	101	10	occur	occur	VERB
admet-337	101	11	commonly	commonly	ADV
admet-337	101	12	in	in	ADP
admet-337	101	13	nsclc	nsclc	NOUN
admet-337	101	14	.	.	PUNCT
admet-337	102	1	erlotinib	erlotinib	NOUN
admet-337	102	2	crosses	cross	VERB
admet-337	102	3	the	the	DET
admet-337	102	4	blood	blood	NOUN
admet-337	102	5	-	-	PUNCT
admet-337	102	6	brainbarrier	brainbarrier	NOUN
admet-337	102	7	(	(	PUNCT
admet-337	102	8	bbb	bbb	NOUN
admet-337	102	9	)	)	PUNCT
admet-337	102	10	to	to	ADP
admet-337	102	11	a	a	DET
admet-337	102	12	low	low	ADJ
admet-337	102	13	degree	degree	NOUN
admet-337	102	14	.	.	PUNCT
admet-337	103	1	the	the	DET
admet-337	103	2	efflux	efflux	ADJ
admet-337	103	3	transporter	transporter	NOUN
admet-337	103	4	proteins	protein	NOUN
admet-337	103	5	p	p	NOUN
admet-337	103	6	-	-	PUNCT
admet-337	103	7	gp	gp	NOUN
admet-337	103	8	and	and	CCONJ
admet-337	103	9	brcp	brcp	NOUN
admet-337	103	10	are	be	AUX
admet-337	103	11	expressed	express	VERB
admet-337	103	12	on	on	ADP
admet-337	103	13	the	the	DET
admet-337	103	14	bbb	bbb	NOUN
admet-337	103	15	and	and	CCONJ
admet-337	103	16	decrease	decrease	VERB
admet-337	103	17	cns	cns	NOUN
admet-337	103	18	accumulation	accumulation	NOUN
admet-337	103	19	of	of	ADP
admet-337	103	20	the	the	DET
admet-337	103	21	erlotinib	erlotinib	NOUN
admet-337	103	22	.	.	PUNCT
admet-337	104	1	the	the	DET
admet-337	104	2	brcp	brcp	VERB
admet-337	104	3	421a	421a	PROPN
admet-337	104	4	polymorphism	polymorphism	NOUN
admet-337	104	5	leads	lead	VERB
admet-337	104	6	to	to	ADP
admet-337	104	7	decreased	decrease	VERB
admet-337	104	8	efflux	efflux	NOUN
admet-337	104	9	of	of	ADP
admet-337	104	10	erlotinib	erlotinib	NOUN
admet-337	104	11	and	and	CCONJ
admet-337	104	12	higher	high	ADJ
admet-337	104	13	cns	cns	NOUN
admet-337	104	14	penetration	penetration	NOUN
admet-337	104	15	[	[	X
admet-337	104	16	42	42	NUM
admet-337	104	17	]	]	PUNCT
admet-337	104	18	.	.	PUNCT
admet-337	105	1	in	in	ADP
admet-337	105	2	a	a	DET
admet-337	105	3	small	small	ADJ
admet-337	105	4	study	study	NOUN
admet-337	105	5	of	of	ADP
admet-337	105	6	nsclc	nsclc	NOUN
admet-337	105	7	patients	patient	NOUN
admet-337	105	8	with	with	ADP
admet-337	105	9	brain	brain	NOUN
admet-337	105	10	metastases	metastasis	NOUN
admet-337	105	11	who	who	PRON
admet-337	105	12	received	receive	VERB
admet-337	105	13	erlotinib	erlotinib	NOUN
admet-337	105	14	,	,	PUNCT
admet-337	105	15	the	the	DET
admet-337	105	16	mean	mean	ADJ
admet-337	105	17	csf	csf	ADJ
admet-337	105	18	concentration	concentration	NOUN
admet-337	105	19	of	of	ADP
admet-337	105	20	erlotinib	erlotinib	NOUN
admet-337	105	21	was	be	AUX
admet-337	105	22	54	54	NUM
admet-337	105	23	ng	ng	NOUN
admet-337	105	24	/	/	SYM
admet-337	105	25	ml	ml	PROPN
admet-337	105	26	.	.	PUNCT
admet-337	106	1	the	the	DET
admet-337	106	2	mean	mean	ADJ
admet-337	106	3	csf	csf	ADJ
admet-337	106	4	penetration	penetration	NOUN
admet-337	106	5	rate	rate	NOUN
admet-337	106	6	of	of	ADP
admet-337	106	7	erlotinib	erlotinib	NOUN
admet-337	106	8	was	be	AUX
admet-337	106	9	5.1	5.1	NUM
admet-337	106	10	%	%	NOUN
admet-337	106	11	.	.	PUNCT
admet-337	107	1	even	even	ADV
admet-337	107	2	at	at	ADP
admet-337	107	3	these	these	DET
admet-337	107	4	concentrations	concentration	NOUN
admet-337	107	5	,	,	PUNCT
admet-337	107	6	however	however	ADV
admet-337	107	7	,	,	PUNCT
admet-337	107	8	disease	disease	NOUN
admet-337	107	9	response	response	NOUN
admet-337	107	10	in	in	ADP
admet-337	107	11	the	the	DET
admet-337	107	12	cns	cns	NOUN
admet-337	107	13	was	be	AUX
admet-337	107	14	witnessed	witness	VERB
admet-337	107	15	[	[	X
admet-337	107	16	46	46	NUM
admet-337	107	17	]	]	PUNCT
admet-337	107	18	.	.	PUNCT
admet-337	108	1	in	in	ADP
admet-337	108	2	a	a	DET
admet-337	108	3	case	case	NOUN
admet-337	108	4	series	series	NOUN
admet-337	108	5	of	of	ADP
admet-337	108	6	23	23	NUM
admet-337	108	7	korean	korean	ADJ
admet-337	108	8	patients	patient	NOUN
admet-337	108	9	with	with	ADP
admet-337	108	10	untreated	untreated	ADJ
admet-337	108	11	brain	brain	NOUN
admet-337	108	12	metastases	metastasis	NOUN
admet-337	108	13	who	who	PRON
admet-337	108	14	were	be	AUX
admet-337	108	15	treated	treat	VERB
admet-337	108	16	with	with	ADP
admet-337	108	17	erlotinib	erlotinib	NOUN
admet-337	108	18	150	150	NUM
admet-337	108	19	mg	mg	NOUN
admet-337	108	20	daily	daily	ADV
admet-337	108	21	or	or	CCONJ
admet-337	108	22	gefitinib	gefitinib	NOUN
admet-337	108	23	250	250	NUM
admet-337	108	24	mg	mg	NOUN
admet-337	108	25	daily	daily	ADV
admet-337	108	26	,	,	PUNCT
admet-337	108	27	intracranial	intracranial	ADJ
admet-337	108	28	disease	disease	NOUN
admet-337	108	29	response	response	NOUN
admet-337	108	30	was	be	AUX
admet-337	108	31	achieved	achieve	VERB
admet-337	108	32	in	in	ADP
admet-337	108	33	69.6	69.6	NUM
admet-337	108	34	%	%	NOUN
admet-337	108	35	and	and	CCONJ
admet-337	108	36	intracranial	intracranial	ADJ
admet-337	108	37	disease	disease	NOUN
admet-337	108	38	control	control	NOUN
admet-337	108	39	was	be	AUX
admet-337	108	40	witnessed	witness	VERB
admet-337	108	41	in	in	ADP
admet-337	108	42	82.6	82.6	NUM
admet-337	108	43	%	%	NOUN
admet-337	108	44	of	of	ADP
admet-337	108	45	patients	patient	NOUN
admet-337	108	46	[	[	X
admet-337	108	47	47	47	NUM
admet-337	108	48	]	]	PUNCT
admet-337	108	49	.	.	PUNCT
admet-337	109	1	high	high	ADJ
admet-337	109	2	dose	dose	ADJ
admet-337	109	3	erlotinib	erlotinib	NOUN
admet-337	109	4	given	give	VERB
admet-337	109	5	at	at	ADP
admet-337	109	6	600	600	NUM
admet-337	109	7	mg	mg	NOUN
admet-337	109	8	every	every	DET
admet-337	109	9	4	4	NUM
admet-337	109	10	days	day	NOUN
admet-337	109	11	or	or	CCONJ
admet-337	109	12	300	300	NUM
admet-337	109	13	mg	mg	NOUN
admet-337	110	1	every	every	DET
admet-337	110	2	other	other	ADJ
admet-337	110	3	day	day	NOUN
admet-337	110	4	has	have	AUX
admet-337	110	5	demonstrated	demonstrate	VERB
admet-337	110	6	efficacy	efficacy	NOUN
admet-337	110	7	in	in	ADP
admet-337	110	8	controlling	control	VERB
admet-337	110	9	cns	cns	NOUN
admet-337	110	10	metastases	metastasis	NOUN
admet-337	110	11	with	with	ADP
admet-337	110	12	tolerable	tolerable	ADJ
admet-337	110	13	side	side	NOUN
admet-337	110	14	effects	effect	NOUN
admet-337	110	15	in	in	ADP
admet-337	110	16	2	2	NUM
admet-337	110	17	case	case	NOUN
admet-337	110	18	reports	report	VERB
admet-337	110	19	[	[	X
admet-337	110	20	46,48,49	46,48,49	X
admet-337	110	21	]	]	PUNCT
admet-337	110	22	.	.	PUNCT
admet-337	111	1	pulsatile	pulsatile	VERB
admet-337	111	2	dosing	dose	VERB
admet-337	111	3	of	of	ADP
admet-337	111	4	erlotinib	erlotinib	NOUN
admet-337	111	5	has	have	AUX
admet-337	111	6	also	also	ADV
admet-337	111	7	been	be	AUX
admet-337	111	8	investigated	investigate	VERB
admet-337	111	9	.	.	PUNCT
admet-337	112	1	in	in	ADP
admet-337	112	2	a	a	DET
admet-337	112	3	retrospective	retrospective	ADJ
admet-337	112	4	analysis	analysis	NOUN
admet-337	112	5	of	of	ADP
admet-337	112	6	9	9	NUM
admet-337	112	7	patients	patient	NOUN
admet-337	112	8	with	with	ADP
admet-337	112	9	egfr	egfr	ADJ
admet-337	112	10	-	-	PUNCT
admet-337	112	11	mutated	mutate	VERB
admet-337	112	12	nsclc	nsclc	NOUN
admet-337	112	13	and	and	CCONJ
admet-337	112	14	brain	brain	NOUN
admet-337	112	15	metastases	metastasis	NOUN
admet-337	112	16	,	,	PUNCT
admet-337	112	17	a	a	DET
admet-337	112	18	median	median	ADJ
admet-337	112	19	erlotinib	erlotinib	NOUN
admet-337	112	20	dose	dose	NOUN
admet-337	112	21	of	of	ADP
admet-337	112	22	1500	1500	NUM
admet-337	112	23	mg	mg	PROPN
admet-337	112	24	weekly	weekly	NOUN
admet-337	112	25	was	be	AUX
admet-337	112	26	utilized	utilize	VERB
admet-337	112	27	.	.	PUNCT
admet-337	113	1	partial	partial	ADJ
admet-337	113	2	cns	cns	NOUN
admet-337	113	3	response	response	NOUN
admet-337	113	4	was	be	AUX
admet-337	113	5	witnessed	witness	VERB
admet-337	113	6	in	in	ADP
admet-337	113	7	67	67	NUM
admet-337	113	8	%	%	NOUN
admet-337	113	9	of	of	ADP
admet-337	113	10	patients	patient	NOUN
admet-337	113	11	with	with	ADP
admet-337	113	12	a	a	DET
admet-337	113	13	median	median	ADJ
admet-337	113	14	time	time	NOUN
admet-337	113	15	to	to	ADP
admet-337	113	16	cns	cns	NOUN
admet-337	113	17	progression	progression	NOUN
admet-337	113	18	of	of	ADP
admet-337	113	19	2.7	2.7	NUM
admet-337	113	20	months	month	NOUN
admet-337	113	21	and	and	CCONJ
admet-337	113	22	median	median	ADJ
admet-337	113	23	os	os	NOUN
admet-337	113	24	of	of	ADP
admet-337	113	25	12	12	NUM
admet-337	113	26	months	month	NOUN
admet-337	113	27	[	[	X
admet-337	113	28	50	50	NUM
admet-337	113	29	]	]	PUNCT
admet-337	113	30	.	.	PUNCT
admet-337	114	1	mechanisms	mechanism	NOUN
admet-337	114	2	of	of	ADP
admet-337	114	3	resistance	resistance	NOUN
admet-337	114	4	the	the	DET
admet-337	114	5	most	most	ADV
admet-337	114	6	common	common	ADJ
admet-337	114	7	mechanism	mechanism	NOUN
admet-337	114	8	of	of	ADP
admet-337	114	9	resistance	resistance	NOUN
admet-337	114	10	to	to	ADP
admet-337	114	11	erlotinib	erlotinib	PROPN
admet-337	114	12	is	be	AUX
admet-337	114	13	a	a	DET
admet-337	114	14	secondary	secondary	ADJ
admet-337	114	15	mutation	mutation	NOUN
admet-337	114	16	in	in	ADP
admet-337	114	17	the	the	DET
admet-337	114	18	egfr	egfr	ADJ
admet-337	114	19	gene	gene	NOUN
admet-337	114	20	at	at	ADP
admet-337	114	21	exon	exon	PROPN
admet-337	114	22	20	20	NUM
admet-337	114	23	that	that	PRON
admet-337	114	24	leads	lead	VERB
admet-337	114	25	to	to	ADP
admet-337	114	26	substitution	substitution	NOUN
admet-337	114	27	of	of	ADP
admet-337	114	28	methionine	methionine	NOUN
admet-337	114	29	for	for	ADP
admet-337	114	30	threonine	threonine	NOUN
admet-337	114	31	at	at	ADP
admet-337	114	32	position	position	NOUN
admet-337	114	33	790	790	NUM
admet-337	114	34	(	(	PUNCT
admet-337	114	35	t790	t790	NUM
admet-337	114	36	m	m	X
admet-337	114	37	)	)	PUNCT
admet-337	114	38	causing	cause	VERB
admet-337	114	39	a	a	DET
admet-337	114	40	mutation	mutation	NOUN
admet-337	114	41	in	in	ADP
admet-337	114	42	the	the	DET
admet-337	114	43	egfr	egfr	ADJ
admet-337	114	44	kinase	kinase	PROPN
admet-337	114	45	domain	domain	NOUN
admet-337	114	46	.	.	PUNCT
admet-337	115	1	t790	t790	NUM
admet-337	115	2	m	m	NOUN
admet-337	115	3	occurs	occur	VERB
admet-337	115	4	as	as	ADP
admet-337	115	5	the	the	DET
admet-337	115	6	method	method	NOUN
admet-337	115	7	of	of	ADP
admet-337	115	8	erlotinib	erlotinib	PROPN
admet-337	115	9	resistance	resistance	NOUN
admet-337	115	10	in	in	ADP
admet-337	115	11	approximately	approximately	ADV
admet-337	115	12	50	50	NUM
admet-337	115	13	%	%	NOUN
admet-337	115	14	of	of	ADP
admet-337	115	15	patients	patient	NOUN
admet-337	115	16	upon	upon	SCONJ
admet-337	115	17	disease	disease	NOUN
admet-337	115	18	progression	progression	NOUN
admet-337	115	19	[	[	X
admet-337	115	20	51,52	51,52	NUM
admet-337	115	21	]	]	PUNCT
admet-337	115	22	.	.	PUNCT
admet-337	116	1	erlotinib	erlotinib	PROPN
admet-337	116	2	forms	form	VERB
admet-337	116	3	an	an	DET
admet-337	116	4	important	important	ADJ
admet-337	116	5	hydrogen	hydrogen	NOUN
admet-337	116	6	bond	bond	NOUN
admet-337	116	7	with	with	ADP
admet-337	116	8	the	the	DET
admet-337	116	9	threonine	threonine	ADJ
admet-337	116	10	residue	residue	NOUN
admet-337	116	11	at	at	ADP
admet-337	116	12	position	position	NOUN
admet-337	116	13	790	790	NUM
admet-337	116	14	,	,	PUNCT
admet-337	116	15	which	which	PRON
admet-337	116	16	is	be	AUX
admet-337	116	17	positioned	position	VERB
admet-337	116	18	in	in	ADP
admet-337	116	19	the	the	DET
admet-337	116	20	hydrophobic	hydrophobic	NOUN
admet-337	116	21	atp	atp	NOUN
admet-337	116	22	-	-	PUNCT
admet-337	116	23	binding	bind	VERB
admet-337	116	24	pocket	pocket	NOUN
admet-337	116	25	of	of	ADP
admet-337	116	26	the	the	DET
admet-337	116	27	catalytic	catalytic	ADJ
admet-337	116	28	region	region	NOUN
admet-337	117	1	[	[	X
admet-337	117	2	53	53	NUM
admet-337	117	3	]	]	PUNCT
admet-337	117	4	.	.	PUNCT
admet-337	118	1	erlotinib	erlotinib	NOUN
admet-337	118	2	-	-	PUNCT
admet-337	118	3	resistance	resistance	NOUN
admet-337	118	4	with	with	ADP
admet-337	118	5	t790m	t790m	PROPN
admet-337	118	6	-	-	PUNCT
admet-337	118	7	mutated	mutate	VERB
admet-337	118	8	egfr	egfr	NOUN
admet-337	118	9	is	be	AUX
admet-337	118	10	driven	drive	VERB
admet-337	118	11	by	by	ADP
admet-337	118	12	increased	increase	VERB
admet-337	118	13	binding	bind	VERB
admet-337	118	14	affinity	affinity	NOUN
admet-337	118	15	for	for	ADP
admet-337	118	16	atp	atp	PROPN
admet-337	118	17	at	at	ADP
admet-337	118	18	the	the	DET
admet-337	118	19	atp	atp	NOUN
admet-337	118	20	binding	bind	VERB
admet-337	118	21	pocket	pocket	NOUN
admet-337	118	22	.	.	PUNCT
admet-337	119	1	the	the	DET
admet-337	119	2	l858r	l858r	NOUN
admet-337	119	3	mutation	mutation	NOUN
admet-337	119	4	reduces	reduce	VERB
admet-337	119	5	egfr	egfr	ADJ
admet-337	119	6	affinity	affinity	NOUN
admet-337	119	7	for	for	ADP
admet-337	119	8	atp	atp	PROPN
admet-337	119	9	,	,	PUNCT
admet-337	119	10	thereby	thereby	ADV
admet-337	119	11	increasing	increase	VERB
admet-337	119	12	susceptibility	susceptibility	NOUN
admet-337	119	13	to	to	PART
admet-337	119	14	erlotinib	erlotinib	VERB
admet-337	119	15	inhibition	inhibition	NOUN
admet-337	119	16	,	,	PUNCT
admet-337	119	17	but	but	CCONJ
admet-337	119	18	the	the	DET
admet-337	119	19	t790	t790	NUM
admet-337	119	20	m	m	NOUN
admet-337	119	21	mutation	mutation	NOUN
admet-337	119	22	restores	restore	VERB
admet-337	119	23	egfr	egfr	ADJ
admet-337	119	24	atp	atp	PROPN
admet-337	119	25	affinity	affinity	NOUN
admet-337	119	26	to	to	ADP
admet-337	119	27	near	near	ADP
admet-337	119	28	wild	wild	ADJ
admet-337	119	29	-	-	PUNCT
admet-337	119	30	type	type	NOUN
admet-337	119	31	levels	level	NOUN
admet-337	119	32	(	(	PUNCT
admet-337	119	33	km[atp	km[atp	PROPN
admet-337	119	34	]	]	X
admet-337	119	35	:	:	PUNCT
admet-337	119	36	l858r	l858r	NOUN
admet-337	119	37	148	148	NUM
admet-337	119	38	µm	µm	NOUN
admet-337	119	39	,	,	PUNCT
admet-337	119	40	t790	t790	NUM
admet-337	119	41	m	m	NOUN
admet-337	119	42	5.9	5.9	NUM
admet-337	119	43	µm	µm	NOUN
admet-337	119	44	,	,	PUNCT
admet-337	119	45	wt	wt	NOUN
admet-337	119	46	egfr	egfr	NOUN
admet-337	119	47	5.2	5.2	NUM
admet-337	119	48	µm	µm	NOUN
admet-337	119	49	)	)	PUNCT
admet-337	119	50	,	,	PUNCT
admet-337	119	51	and	and	CCONJ
admet-337	119	52	decreases	decrease	VERB
admet-337	119	53	the	the	DET
admet-337	119	54	competitive	competitive	ADJ
admet-337	119	55	advantage	advantage	NOUN
admet-337	119	56	of	of	ADP
admet-337	119	57	the	the	DET
admet-337	119	58	atp	atp	NOUN
admet-337	119	59	competitive	competitive	ADJ
admet-337	119	60	inhibitor	inhibitor	NOUN
admet-337	119	61	erlotinib	erlotinib	PROPN
admet-337	119	62	.	.	PUNCT
admet-337	120	1	irreversible	irreversible	ADJ
admet-337	120	2	inhibitors	inhibitor	NOUN
admet-337	120	3	of	of	ADP
admet-337	120	4	the	the	DET
admet-337	120	5	egfr	egfr	ADJ
admet-337	120	6	atp	atp	PROPN
admet-337	120	7	binding	bind	VERB
admet-337	120	8	domain	domain	NOUN
admet-337	120	9	,	,	PUNCT
admet-337	120	10	such	such	ADJ
admet-337	120	11	as	as	ADP
admet-337	120	12	afatinib	afatinib	NOUN
admet-337	120	13	,	,	PUNCT
admet-337	120	14	can	can	AUX
admet-337	120	15	overcome	overcome	VERB
admet-337	120	16	resistance	resistance	NOUN
admet-337	120	17	to	to	ADP
admet-337	120	18	t790	t790	NUM
admet-337	120	19	m	m	VERB
admet-337	120	20	in	in	ADP
admet-337	120	21	vitro	vitro	NOUN
admet-337	120	22	because	because	SCONJ
admet-337	120	23	they	they	PRON
admet-337	120	24	are	be	AUX
admet-337	120	25	not	not	PART
admet-337	120	26	in	in	ADP
admet-337	120	27	competitive	competitive	ADJ
admet-337	120	28	equilibrium	equilibrium	NOUN
admet-337	120	29	with	with	ADP
admet-337	120	30	atp	atp	PROPN
admet-337	121	1	[	[	X
admet-337	121	2	51	51	NUM
admet-337	121	3	]	]	PUNCT
admet-337	121	4	.	.	PUNCT
admet-337	122	1	met	meet	VERB
admet-337	122	2	amplification	amplification	NOUN
admet-337	122	3	(	(	PUNCT
admet-337	122	4	see	see	VERB
admet-337	122	5	gefitinib	gefitinib	NOUN
admet-337	122	6	-	-	PUNCT
admet-337	122	7	resistance	resistance	NOUN
admet-337	122	8	below	below	ADP
admet-337	122	9	)	)	PUNCT
admet-337	122	10	,	,	PUNCT
admet-337	122	11	small	small	ADJ
admet-337	122	12	cell	cell	NOUN
admet-337	122	13	transformation	transformation	NOUN
admet-337	122	14	and	and	CCONJ
admet-337	122	15	her2	her2	VERB
admet-337	122	16	amplification	amplification	NOUN
admet-337	122	17	have	have	AUX
admet-337	122	18	all	all	DET
admet-337	122	19	admet	admet	NOUN
admet-337	122	20	&	&	CCONJ
admet-337	122	21	dmpk	dmpk	PROPN
admet-337	122	22	4(3	4(3	NUM
admet-337	122	23	)	)	PUNCT
admet-337	122	24	(	(	PUNCT
admet-337	122	25	2016	2016	NUM
admet-337	122	26	)	)	PUNCT
admet-337	122	27	186	186	NUM
admet-337	122	28	-	-	SYM
admet-337	122	29	211	211	NUM
admet-337	122	30	tki	tki	NOUN
admet-337	122	31	for	for	ADP
admet-337	122	32	egfrand	egfrand	ADJ
admet-337	122	33	alk	alk	PROPN
admet-337	122	34	-	-	PUNCT
admet-337	122	35	mutated	mutate	VERB
admet-337	122	36	cell	cell	NOUN
admet-337	122	37	cancer	cancer	NOUN
admet-337	122	38	doi	doi	NOUN
admet-337	122	39	:	:	PUNCT
admet-337	122	40	10.5599	10.5599	NUM
admet-337	122	41	/	/	SYM
admet-337	122	42	admet.4.3.337	admet.4.3.337	CCONJ
admet-337	122	43	191	191	NUM
admet-337	122	44	been	be	AUX
admet-337	122	45	less	less	ADV
admet-337	122	46	commonly	commonly	ADV
admet-337	122	47	observed	observe	VERB
admet-337	122	48	as	as	ADP
admet-337	122	49	causes	cause	NOUN
admet-337	122	50	for	for	ADP
admet-337	122	51	erlotinib	erlotinib	NOUN
admet-337	122	52	resistance	resistance	NOUN
admet-337	122	53	[	[	X
admet-337	122	54	54	54	NUM
admet-337	122	55	]	]	PUNCT
admet-337	122	56	.	.	PUNCT
admet-337	123	1	a	a	DET
admet-337	123	2	case	case	NOUN
admet-337	123	3	report	report	NOUN
admet-337	123	4	of	of	ADP
admet-337	123	5	a	a	DET
admet-337	123	6	patient	patient	NOUN
admet-337	123	7	with	with	ADP
admet-337	123	8	egfrmutated	egfrmutated	ADJ
admet-337	123	9	nsclc	nsclc	NOUN
admet-337	123	10	on	on	ADP
admet-337	123	11	erlotinib	erlotinib	PROPN
admet-337	123	12	,	,	PUNCT
admet-337	123	13	who	who	PRON
admet-337	123	14	developed	develop	VERB
admet-337	123	15	met	meet	VERB
admet-337	123	16	amplification	amplification	NOUN
admet-337	123	17	as	as	ADP
admet-337	123	18	a	a	DET
admet-337	123	19	resistance	resistance	NOUN
admet-337	123	20	mechanism	mechanism	NOUN
admet-337	123	21	,	,	PUNCT
admet-337	123	22	showed	show	VERB
admet-337	123	23	tumor	tumor	NOUN
admet-337	123	24	response	response	NOUN
admet-337	123	25	with	with	ADP
admet-337	123	26	the	the	DET
admet-337	123	27	addition	addition	NOUN
admet-337	123	28	of	of	ADP
admet-337	123	29	crizotinib	crizotinib	NOUN
admet-337	123	30	[	[	X
admet-337	123	31	55	55	NUM
admet-337	123	32	]	]	PUNCT
admet-337	123	33	.	.	PUNCT
admet-337	124	1	gefitinib	gefitinib	NOUN
admet-337	124	2	clinical	clinical	ADJ
admet-337	124	3	efficacy	efficacy	NOUN
admet-337	124	4	gefitinib	gefitinib	NOUN
admet-337	124	5	was	be	AUX
admet-337	124	6	the	the	DET
admet-337	124	7	first	first	ADJ
admet-337	124	8	egfr	egfr	NOUN
admet-337	124	9	tki	tki	NOUN
admet-337	124	10	to	to	PART
admet-337	124	11	reach	reach	VERB
admet-337	124	12	the	the	DET
admet-337	124	13	market	market	NOUN
admet-337	124	14	,	,	PUNCT
admet-337	124	15	and	and	CCONJ
admet-337	124	16	originally	originally	ADV
admet-337	124	17	received	receive	VERB
admet-337	124	18	accelerated	accelerate	VERB
admet-337	124	19	approval	approval	NOUN
admet-337	124	20	by	by	ADP
admet-337	124	21	the	the	DET
admet-337	124	22	fda	fda	PROPN
admet-337	124	23	for	for	ADP
admet-337	124	24	marketing	marketing	NOUN
admet-337	124	25	in	in	ADP
admet-337	124	26	may	may	PROPN
admet-337	124	27	2003	2003	NUM
admet-337	124	28	for	for	ADP
admet-337	124	29	patients	patient	NOUN
admet-337	124	30	with	with	ADP
admet-337	124	31	nsclc	nsclc	NOUN
admet-337	124	32	who	who	PRON
admet-337	124	33	were	be	AUX
admet-337	124	34	refractory	refractory	NOUN
admet-337	124	35	to	to	PART
admet-337	124	36	platinumand	platinumand	VERB
admet-337	124	37	docetaxelbased	docetaxelbase	VERB
admet-337	124	38	chemotherapy	chemotherapy	NOUN
admet-337	125	1	[	[	X
admet-337	125	2	56	56	NUM
admet-337	125	3	]	]	PUNCT
admet-337	125	4	.	.	PUNCT
admet-337	126	1	the	the	DET
admet-337	126	2	approval	approval	NOUN
admet-337	126	3	was	be	AUX
admet-337	126	4	based	base	VERB
admet-337	126	5	on	on	ADP
admet-337	126	6	a	a	DET
admet-337	126	7	randomized	randomized	ADJ
admet-337	126	8	,	,	PUNCT
admet-337	126	9	double	double	ADJ
admet-337	126	10	-	-	PUNCT
admet-337	126	11	blind	blind	ADJ
admet-337	126	12	,	,	PUNCT
admet-337	126	13	phase	phase	NOUN
admet-337	126	14	ii	ii	NOUN
admet-337	126	15	trial	trial	NOUN
admet-337	126	16	of	of	ADP
admet-337	126	17	216	216	NUM
admet-337	126	18	patients	patient	NOUN
admet-337	126	19	comparing	compare	VERB
admet-337	126	20	gefitinib	gefitinib	NOUN
admet-337	126	21	250	250	NUM
admet-337	126	22	mg	mg	NUM
admet-337	126	23	/	/	SYM
admet-337	126	24	day	day	NOUN
admet-337	126	25	with	with	ADP
admet-337	126	26	gefitinib	gefitinib	NOUN
admet-337	126	27	500	500	NUM
admet-337	126	28	mg	mg	NUM
admet-337	126	29	/	/	SYM
admet-337	126	30	day	day	NOUN
admet-337	126	31	.	.	PUNCT
admet-337	127	1	the	the	DET
admet-337	127	2	overall	overall	ADJ
admet-337	127	3	response	response	NOUN
admet-337	127	4	was	be	AUX
admet-337	127	5	12	12	NUM
admet-337	127	6	%	%	NOUN
admet-337	127	7	in	in	ADP
admet-337	127	8	the	the	DET
admet-337	127	9	250	250	NUM
admet-337	127	10	mg	mg	NOUN
admet-337	127	11	dose	dose	NOUN
admet-337	127	12	and	and	CCONJ
admet-337	127	13	9	9	NUM
admet-337	127	14	%	%	NOUN
admet-337	127	15	in	in	ADP
admet-337	127	16	the	the	DET
admet-337	127	17	500	500	NUM
admet-337	127	18	mg	mg	NOUN
admet-337	127	19	dose	dose	VERB
admet-337	127	20	with	with	ADP
admet-337	127	21	a	a	DET
admet-337	127	22	1	1	NUM
admet-337	127	23	year	year	NOUN
admet-337	127	24	os	os	NOUN
admet-337	127	25	of	of	ADP
admet-337	127	26	25	25	NUM
admet-337	127	27	%	%	NOUN
admet-337	127	28	[	[	X
admet-337	127	29	57	57	NUM
admet-337	127	30	]	]	PUNCT
admet-337	127	31	.	.	PUNCT
admet-337	128	1	however	however	ADV
admet-337	128	2	,	,	PUNCT
admet-337	128	3	a	a	DET
admet-337	128	4	survival	survival	NOUN
admet-337	128	5	benefit	benefit	NOUN
admet-337	128	6	in	in	ADP
admet-337	128	7	this	this	DET
admet-337	128	8	patient	patient	ADJ
admet-337	128	9	population	population	NOUN
admet-337	128	10	was	be	AUX
admet-337	128	11	unable	unable	ADJ
admet-337	128	12	to	to	PART
admet-337	128	13	be	be	AUX
admet-337	128	14	demonstrated	demonstrate	VERB
admet-337	128	15	and	and	CCONJ
admet-337	128	16	astrazeneca	astrazeneca	PROPN
admet-337	128	17	suspended	suspend	VERB
admet-337	128	18	promotion	promotion	NOUN
admet-337	128	19	of	of	ADP
admet-337	128	20	gefitinib	gefitinib	NOUN
admet-337	128	21	.	.	PUNCT
admet-337	129	1	access	access	NOUN
admet-337	129	2	to	to	ADP
admet-337	129	3	the	the	DET
admet-337	129	4	drug	drug	NOUN
admet-337	129	5	was	be	AUX
admet-337	129	6	limited	limit	VERB
admet-337	129	7	to	to	ADP
admet-337	129	8	patients	patient	NOUN
admet-337	129	9	who	who	PRON
admet-337	129	10	were	be	AUX
admet-337	129	11	previously	previously	ADV
admet-337	129	12	responding	respond	VERB
admet-337	129	13	to	to	ADP
admet-337	129	14	gefitinib	gefitinib	NOUN
admet-337	129	15	.	.	PUNCT
admet-337	130	1	in	in	ADP
admet-337	130	2	september	september	PROPN
admet-337	130	3	2011	2011	NUM
admet-337	130	4	,	,	PUNCT
admet-337	130	5	per	per	ADP
admet-337	130	6	fda	fda	PROPN
admet-337	130	7	request	request	NOUN
admet-337	130	8	,	,	PUNCT
admet-337	130	9	astrazeneca	astrazeneca	PROPN
admet-337	130	10	voluntarily	voluntarily	ADV
admet-337	130	11	withdrew	withdraw	VERB
admet-337	130	12	gefitinib	gefitinib	NOUN
admet-337	130	13	from	from	ADP
admet-337	130	14	the	the	DET
admet-337	130	15	us	us	PROPN
admet-337	130	16	market	market	NOUN
admet-337	130	17	due	due	ADP
admet-337	130	18	to	to	ADP
admet-337	130	19	failure	failure	NOUN
admet-337	130	20	to	to	PART
admet-337	130	21	demonstrate	demonstrate	VERB
admet-337	130	22	a	a	DET
admet-337	130	23	survival	survival	NOUN
admet-337	130	24	benefit	benefit	NOUN
admet-337	130	25	for	for	ADP
admet-337	130	26	the	the	DET
admet-337	130	27	drug	drug	NOUN
admet-337	130	28	.	.	PUNCT
admet-337	131	1	while	while	SCONJ
admet-337	131	2	gefitinib	gefitinib	NOUN
admet-337	131	3	did	do	AUX
admet-337	131	4	not	not	PART
admet-337	131	5	appear	appear	VERB
admet-337	131	6	to	to	PART
admet-337	131	7	have	have	VERB
admet-337	131	8	meaningful	meaningful	ADJ
admet-337	131	9	activity	activity	NOUN
admet-337	131	10	in	in	ADP
admet-337	131	11	an	an	DET
admet-337	131	12	unselected	unselected	ADJ
admet-337	131	13	nsclc	nsclc	NOUN
admet-337	131	14	patient	patient	NOUN
admet-337	131	15	population	population	NOUN
admet-337	131	16	,	,	PUNCT
admet-337	131	17	multiple	multiple	ADJ
admet-337	131	18	subsequent	subsequent	ADJ
admet-337	131	19	large	large	ADJ
admet-337	131	20	phase	phase	NOUN
admet-337	131	21	iii	iii	NUM
admet-337	131	22	studies	study	NOUN
admet-337	131	23	performed	perform	VERB
admet-337	131	24	in	in	ADP
admet-337	131	25	asian	asian	ADJ
admet-337	131	26	populations	population	NOUN
admet-337	131	27	consistently	consistently	ADV
admet-337	131	28	demonstrated	demonstrate	VERB
admet-337	131	29	clinical	clinical	ADJ
admet-337	131	30	benefit	benefit	NOUN
admet-337	131	31	for	for	ADP
admet-337	131	32	first	first	ADJ
admet-337	131	33	-	-	PUNCT
admet-337	131	34	line	line	NOUN
admet-337	131	35	gefitinib	gefitinib	NOUN
admet-337	131	36	for	for	ADP
admet-337	131	37	patients	patient	NOUN
admet-337	131	38	with	with	ADP
admet-337	131	39	exon	exon	PROPN
admet-337	131	40	19	19	NUM
admet-337	131	41	and	and	CCONJ
admet-337	131	42	l858r	l858r	NOUN
admet-337	131	43	mutations	mutation	NOUN
admet-337	131	44	.	.	PUNCT
admet-337	132	1	in	in	ADP
admet-337	132	2	these	these	DET
admet-337	132	3	studies	study	NOUN
admet-337	132	4	,	,	PUNCT
admet-337	132	5	gefitinib	gefitinib	NOUN
admet-337	132	6	improved	improve	VERB
admet-337	132	7	pfs	pf	VERB
admet-337	132	8	by	by	ADP
admet-337	132	9	3	3	NUM
admet-337	132	10	to	to	PART
admet-337	132	11	5	5	NUM
admet-337	132	12	months	month	NOUN
admet-337	132	13	compared	compare	VERB
admet-337	132	14	with	with	ADP
admet-337	132	15	conventional	conventional	ADJ
admet-337	132	16	platinum	platinum	NOUN
admet-337	132	17	-	-	PUNCT
admet-337	132	18	based	base	VERB
admet-337	132	19	chemotherapy	chemotherapy	NOUN
admet-337	133	1	[	[	X
admet-337	133	2	5861	5861	NUM
admet-337	133	3	]	]	PUNCT
admet-337	133	4	.	.	PUNCT
admet-337	134	1	given	give	VERB
admet-337	134	2	this	this	DET
admet-337	134	3	data	datum	NOUN
admet-337	134	4	,	,	PUNCT
admet-337	134	5	gefitinib	gefitinib	NOUN
admet-337	134	6	attained	attain	VERB
admet-337	134	7	widespread	widespread	ADJ
admet-337	134	8	approval	approval	NOUN
admet-337	134	9	outside	outside	ADP
admet-337	134	10	of	of	ADP
admet-337	134	11	the	the	DET
admet-337	134	12	united	united	PROPN
admet-337	134	13	states	states	PROPN
admet-337	134	14	.	.	PUNCT
admet-337	135	1	in	in	ADP
admet-337	135	2	july	july	PROPN
admet-337	135	3	2015	2015	NUM
admet-337	135	4	,	,	PUNCT
admet-337	135	5	the	the	DET
admet-337	135	6	fda	fda	PROPN
admet-337	135	7	once	once	ADV
admet-337	135	8	again	again	ADV
admet-337	135	9	approved	approve	VERB
admet-337	135	10	gefitinib	gefitinib	NOUN
admet-337	135	11	under	under	ADP
admet-337	135	12	orphan	orphan	NOUN
admet-337	135	13	product	product	NOUN
admet-337	135	14	designation	designation	NOUN
admet-337	135	15	for	for	ADP
admet-337	135	16	first	first	ADJ
admet-337	135	17	-	-	PUNCT
admet-337	135	18	line	line	NOUN
admet-337	135	19	treatment	treatment	NOUN
admet-337	135	20	of	of	ADP
admet-337	135	21	patients	patient	NOUN
admet-337	135	22	with	with	ADP
admet-337	135	23	advanced	advanced	ADJ
admet-337	135	24	nsclc	nsclc	NOUN
admet-337	135	25	with	with	ADP
admet-337	135	26	the	the	DET
admet-337	135	27	exon	exon	ADJ
admet-337	135	28	19	19	NUM
admet-337	135	29	or	or	CCONJ
admet-337	135	30	l858r	l858r	NOUN
admet-337	135	31	egfr	egfr	NOUN
admet-337	135	32	-	-	PUNCT
admet-337	135	33	activating	activate	VERB
admet-337	135	34	mutations	mutation	NOUN
admet-337	135	35	.	.	PUNCT
admet-337	136	1	the	the	DET
admet-337	136	2	approval	approval	NOUN
admet-337	136	3	was	be	AUX
admet-337	136	4	based	base	VERB
admet-337	136	5	on	on	ADP
admet-337	136	6	a	a	DET
admet-337	136	7	phase	phase	NOUN
admet-337	136	8	iv	iv	NUM
admet-337	136	9	study	study	NOUN
admet-337	136	10	of	of	ADP
admet-337	136	11	gefitinib	gefitinib	NOUN
admet-337	136	12	for	for	ADP
admet-337	136	13	first	first	ADJ
admet-337	136	14	-	-	PUNCT
admet-337	136	15	line	line	NOUN
admet-337	136	16	treatment	treatment	NOUN
admet-337	136	17	of	of	ADP
admet-337	136	18	caucasian	caucasian	ADJ
admet-337	136	19	patients	patient	NOUN
admet-337	136	20	with	with	ADP
admet-337	136	21	exon	exon	PROPN
admet-337	136	22	19	19	NUM
admet-337	136	23	or	or	CCONJ
admet-337	136	24	l858r	l858r	NOUN
admet-337	136	25	egfr	egfr	ADJ
admet-337	136	26	mutations	mutation	NOUN
admet-337	136	27	.	.	PUNCT
admet-337	137	1	in	in	ADP
admet-337	137	2	the	the	DET
admet-337	137	3	106	106	NUM
admet-337	137	4	patients	patient	NOUN
admet-337	137	5	in	in	ADP
admet-337	137	6	this	this	DET
admet-337	137	7	study	study	NOUN
admet-337	137	8	,	,	PUNCT
admet-337	137	9	the	the	DET
admet-337	137	10	overall	overall	ADJ
admet-337	137	11	response	response	NOUN
admet-337	137	12	rate	rate	NOUN
admet-337	137	13	was	be	AUX
admet-337	137	14	69.8	69.8	NUM
admet-337	137	15	%	%	NOUN
admet-337	137	16	with	with	ADP
admet-337	137	17	a	a	DET
admet-337	137	18	median	median	ADJ
admet-337	137	19	pfs	pf	NOUN
admet-337	137	20	of	of	ADP
admet-337	137	21	9.7	9.7	NUM
admet-337	137	22	months	month	NOUN
admet-337	137	23	and	and	CCONJ
admet-337	137	24	median	median	ADJ
admet-337	137	25	os	os	NOUN
admet-337	137	26	of	of	ADP
admet-337	137	27	19.2	19.2	NUM
admet-337	137	28	months	month	NOUN
admet-337	137	29	[	[	X
admet-337	137	30	5	5	NUM
admet-337	137	31	]	]	PUNCT
admet-337	137	32	.	.	PUNCT
admet-337	138	1	clinical	clinical	ADJ
admet-337	138	2	safety	safety	NOUN
admet-337	138	3	gefitinib	gefitinib	NOUN
admet-337	138	4	causes	cause	VERB
admet-337	138	5	less	less	ADJ
admet-337	138	6	dose	dose	NOUN
admet-337	138	7	-	-	PUNCT
admet-337	138	8	dependent	dependent	ADJ
admet-337	138	9	dermatologic	dermatologic	ADJ
admet-337	138	10	toxicity	toxicity	NOUN
admet-337	138	11	than	than	ADP
admet-337	138	12	erlotinib	erlotinib	NOUN
admet-337	138	13	.	.	PUNCT
admet-337	139	1	this	this	PRON
admet-337	139	2	is	be	AUX
admet-337	139	3	likely	likely	ADJ
admet-337	139	4	due	due	ADP
admet-337	139	5	to	to	ADP
admet-337	139	6	the	the	DET
admet-337	139	7	comparatively	comparatively	ADV
admet-337	139	8	lower	low	ADJ
admet-337	139	9	standard	standard	ADJ
admet-337	139	10	therapeutic	therapeutic	ADJ
admet-337	139	11	dose	dose	NOUN
admet-337	139	12	of	of	ADP
admet-337	139	13	gefitinib	gefitinib	NOUN
admet-337	139	14	commonly	commonly	ADV
admet-337	139	15	administered	administer	VERB
admet-337	139	16	to	to	ADP
admet-337	139	17	patients	patient	NOUN
admet-337	139	18	compared	compare	VERB
admet-337	139	19	to	to	ADP
admet-337	139	20	other	other	ADJ
admet-337	139	21	egfr	egfr	ADJ
admet-337	139	22	tkis	tkis	PROPN
admet-337	139	23	.	.	PUNCT
admet-337	140	1	the	the	DET
admet-337	140	2	approved	approve	VERB
admet-337	140	3	clinical	clinical	ADJ
admet-337	140	4	dose	dose	NOUN
admet-337	140	5	of	of	ADP
admet-337	140	6	gefitinib	gefitinib	NOUN
admet-337	140	7	(	(	PUNCT
admet-337	140	8	250	250	NUM
admet-337	140	9	mg	mg	NOUN
admet-337	140	10	daily	daily	ADV
admet-337	140	11	)	)	PUNCT
admet-337	140	12	is	be	AUX
admet-337	140	13	only	only	ADV
admet-337	140	14	33	33	NUM
admet-337	140	15	%	%	NOUN
admet-337	140	16	of	of	ADP
admet-337	140	17	the	the	DET
admet-337	140	18	maximum	maximum	ADJ
admet-337	140	19	tolerated	tolerate	VERB
admet-337	140	20	dose	dose	NOUN
admet-337	140	21	,	,	PUNCT
admet-337	140	22	whereas	whereas	SCONJ
admet-337	140	23	erlotinib	erlotinib	NOUN
admet-337	140	24	is	be	AUX
admet-337	140	25	clinically	clinically	ADV
admet-337	140	26	dosed	dose	VERB
admet-337	140	27	at	at	ADP
admet-337	140	28	its	its	PRON
admet-337	140	29	maximum	maximum	ADJ
admet-337	140	30	tolerated	tolerate	VERB
admet-337	140	31	dose	dose	NOUN
admet-337	140	32	of	of	ADP
admet-337	140	33	150	150	NUM
admet-337	140	34	mg	mg	NOUN
admet-337	140	35	daily	daily	ADV
admet-337	140	36	.	.	PUNCT
admet-337	141	1	there	there	PRON
admet-337	141	2	does	do	AUX
admet-337	141	3	not	not	PART
admet-337	141	4	appear	appear	VERB
admet-337	141	5	to	to	PART
admet-337	141	6	be	be	AUX
admet-337	141	7	a	a	DET
admet-337	141	8	difference	difference	NOUN
admet-337	141	9	in	in	ADP
admet-337	141	10	pfs	pfs	PROPN
admet-337	141	11	or	or	CCONJ
admet-337	141	12	os	os	NOUN
admet-337	141	13	for	for	ADP
admet-337	141	14	lower	low	ADJ
admet-337	141	15	dose	dose	NOUN
admet-337	141	16	gefitinib	gefitinib	NOUN
admet-337	141	17	(	(	PUNCT
admet-337	141	18	250	250	NUM
admet-337	141	19	mg	mg	NOUN
admet-337	141	20	daily	daily	ADV
admet-337	141	21	)	)	PUNCT
admet-337	141	22	vs	vs	ADP
admet-337	141	23	higher	high	ADJ
admet-337	141	24	dose	dose	NOUN
admet-337	141	25	gefitinib	gefitinib	NOUN
admet-337	141	26	(	(	PUNCT
admet-337	141	27	500	500	NUM
admet-337	141	28	mg	mg	NOUN
admet-337	141	29	daily	daily	ADV
admet-337	141	30	)	)	PUNCT
admet-337	142	1	[	[	X
admet-337	142	2	62].for	62].for	ADP
admet-337	142	3	gefitinib	gefitinib	NOUN
admet-337	142	4	,	,	PUNCT
admet-337	142	5	all	all	DET
admet-337	142	6	-	-	PUNCT
admet-337	142	7	grade	grade	NOUN
admet-337	142	8	rash	rash	NOUN
admet-337	142	9	ranges	range	VERB
admet-337	142	10	from	from	ADP
admet-337	142	11	44	44	NUM
admet-337	142	12	to	to	PART
admet-337	142	13	77	77	NUM
admet-337	142	14	%	%	NOUN
admet-337	142	15	but	but	CCONJ
admet-337	142	16	grade	grade	NOUN
admet-337	142	17	3	3	NUM
admet-337	142	18	to	to	PART
admet-337	142	19	5	5	NUM
admet-337	142	20	rash	rash	NOUN
admet-337	142	21	is	be	AUX
admet-337	142	22	very	very	ADV
admet-337	142	23	rare	rare	ADJ
admet-337	142	24	(	(	PUNCT
admet-337	142	25	<	<	X
admet-337	142	26	5	5	NUM
admet-337	142	27	%	%	NOUN
admet-337	142	28	)	)	PUNCT
admet-337	142	29	with	with	ADP
admet-337	142	30	gefitinib	gefitinib	NOUN
admet-337	142	31	.	.	PUNCT
admet-337	143	1	skin	skin	NOUN
admet-337	143	2	rash	rash	NOUN
admet-337	143	3	on	on	ADP
admet-337	143	4	gefitinib	gefitinib	NOUN
admet-337	143	5	manifests	manifest	NOUN
admet-337	143	6	similarly	similarly	ADV
admet-337	143	7	compared	compare	VERB
admet-337	143	8	to	to	ADP
admet-337	143	9	erlotinib	erlotinib	NOUN
admet-337	143	10	,	,	PUNCT
admet-337	143	11	and	and	CCONJ
admet-337	143	12	ten	ten	NUM
admet-337	143	13	and	and	CCONJ
admet-337	143	14	sjs	sjs	PROPN
admet-337	143	15	have	have	AUX
admet-337	143	16	occurred	occur	VERB
admet-337	143	17	in	in	ADP
admet-337	143	18	patients	patient	NOUN
admet-337	143	19	on	on	ADP
admet-337	143	20	gefitinib	gefitinib	NOUN
admet-337	143	21	as	as	ADV
admet-337	143	22	well	well	ADV
admet-337	143	23	.	.	PUNCT
admet-337	144	1	like	like	ADP
admet-337	144	2	erlotinib	erlotinib	NOUN
admet-337	144	3	,	,	PUNCT
admet-337	144	4	diarrhea	diarrhea	NOUN
admet-337	144	5	with	with	ADP
admet-337	144	6	gefitinib	gefitinib	NOUN
admet-337	144	7	is	be	AUX
admet-337	144	8	relatively	relatively	ADV
admet-337	144	9	frequent	frequent	ADJ
admet-337	144	10	but	but	CCONJ
admet-337	144	11	not	not	PART
admet-337	144	12	typically	typically	ADV
admet-337	144	13	severe	severe	ADJ
admet-337	144	14	(	(	PUNCT
admet-337	144	15	all	all	DET
admet-337	144	16	-	-	PUNCT
admet-337	144	17	grade	grade	NOUN
admet-337	144	18	:	:	PUNCT
admet-337	144	19	32	32	NUM
admet-337	144	20	-	-	SYM
admet-337	144	21	47	47	NUM
admet-337	144	22	%	%	NOUN
admet-337	144	23	,	,	PUNCT
admet-337	144	24	grade	grade	NOUN
admet-337	144	25	3	3	NUM
admet-337	144	26	-	-	SYM
admet-337	144	27	5	5	NUM
admet-337	144	28	:	:	SYM
admet-337	144	29	1	1	NUM
admet-337	144	30	-	-	SYM
admet-337	144	31	4	4	NUM
admet-337	144	32	%	%	NOUN
admet-337	144	33	)	)	PUNCT
admet-337	144	34	.	.	PUNCT
admet-337	145	1	grade	grade	NOUN
admet-337	145	2	3	3	NUM
admet-337	145	3	or	or	CCONJ
admet-337	145	4	4	4	NUM
admet-337	145	5	transaminitis	transaminitis	NOUN
admet-337	145	6	occurs	occur	VERB
admet-337	145	7	in	in	ADP
admet-337	145	8	up	up	ADP
admet-337	145	9	to	to	PART
admet-337	145	10	11	11	NUM
admet-337	145	11	%	%	NOUN
admet-337	145	12	of	of	ADP
admet-337	145	13	patients	patient	NOUN
admet-337	145	14	.	.	PUNCT
admet-337	146	1	rare	rare	ADJ
admet-337	146	2	fatal	fatal	ADJ
admet-337	146	3	hepatotoxicity	hepatotoxicity	NOUN
admet-337	146	4	and	and	CCONJ
admet-337	146	5	interstitial	interstitial	ADJ
admet-337	146	6	pneumonitis	pneumonitis	NOUN
admet-337	146	7	have	have	AUX
admet-337	146	8	occurred	occur	VERB
admet-337	146	9	with	with	ADP
admet-337	146	10	gefitinib	gefitinib	NOUN
admet-337	146	11	[	[	X
admet-337	146	12	59,60,63,64	59,60,63,64	NUM
admet-337	146	13	]	]	PUNCT
admet-337	146	14	.	.	PUNCT
admet-337	147	1	pharmacology	pharmacology	NOUN
admet-337	147	2	gefitinib	gefitinib	NOUN
admet-337	147	3	,	,	PUNCT
admet-337	147	4	4	4	NUM
admet-337	147	5	-	-	PUNCT
admet-337	147	6	quinazolinamine	quinazolinamine	NOUN
admet-337	147	7	,	,	PUNCT
admet-337	147	8	n-(3	n-(3	PROPN
admet-337	147	9	-	-	PUNCT
admet-337	147	10	chloro-4	chloro-4	ADP
admet-337	147	11	-	-	PUNCT
admet-337	147	12	flurophenyl)-7	flurophenyl)-7	NOUN
admet-337	147	13	-	-	PUNCT
admet-337	147	14	methoxy-6-[3-(4	methoxy-6-[3-(4	NOUN
admet-337	147	15	-	-	PUNCT
admet-337	147	16	morpholinyl)propoxy	morpholinyl)propoxy	NOUN
admet-337	147	17	]	]	PUNCT
admet-337	148	1	[	[	X
admet-337	148	2	zd1839	zd1839	NOUN
admet-337	148	3	,	,	PUNCT
admet-337	148	4	iressa	iressa	ADJ
admet-337	148	5	(	(	PUNCT
admet-337	148	6	astrazenaca	astrazenaca	NOUN
admet-337	148	7	)	)	PUNCT
admet-337	148	8	]	]	PUNCT
admet-337	148	9	reversibly	reversibly	ADV
admet-337	148	10	inhibits	inhibit	VERB
admet-337	148	11	egfr	egfr	NOUN
admet-337	148	12	by	by	ADP
admet-337	148	13	competing	compete	VERB
admet-337	148	14	with	with	ADP
admet-337	148	15	atp	atp	PROPN
admet-337	148	16	at	at	ADP
admet-337	148	17	the	the	DET
admet-337	148	18	tyrosine	tyrosine	PROPN
admet-337	148	19	kinase	kinase	PROPN
admet-337	148	20	domain	domain	PROPN
admet-337	148	21	.	.	PUNCT
admet-337	149	1	the	the	DET
admet-337	149	2	recommended	recommend	VERB
admet-337	149	3	starting	starting	NOUN
admet-337	149	4	dose	dose	NOUN
admet-337	149	5	is	be	AUX
admet-337	149	6	250	250	NUM
admet-337	149	7	mg	mg	ADV
admet-337	149	8	orally	orally	ADV
admet-337	149	9	daily	daily	ADV
admet-337	149	10	.	.	PUNCT
admet-337	150	1	gefitinib	gefitinib	NOUN
admet-337	150	2	has	have	VERB
admet-337	150	3	an	an	DET
admet-337	150	4	ic50	ic50	PROPN
admet-337	150	5	of	of	ADP
admet-337	150	6	0.03	0.03	NUM
admet-337	150	7	-	-	SYM
admet-337	150	8	0.1	0.1	NUM
admet-337	150	9	µm	µm	NOUN
admet-337	150	10	for	for	ADP
admet-337	150	11	egf	egf	PROPN
admet-337	150	12	,	,	PUNCT
admet-337	150	13	but	but	CCONJ
admet-337	150	14	demonstrates	demonstrate	VERB
admet-337	150	15	similar	similar	ADJ
admet-337	150	16	ic50	ic50	PROPN
admet-337	150	17	values	value	NOUN
admet-337	150	18	for	for	ADP
admet-337	150	19	other	other	ADJ
admet-337	150	20	growth	growth	NOUN
admet-337	150	21	factors	factor	NOUN
admet-337	150	22	,	,	PUNCT
admet-337	150	23	including	include	VERB
admet-337	150	24	pdgf	pdgf	PROPN
admet-337	150	25	and	and	CCONJ
admet-337	150	26	igf	igf	PROPN
admet-337	151	1	[	[	X
admet-337	151	2	56	56	NUM
admet-337	151	3	]	]	PUNCT
admet-337	151	4	.	.	PUNCT
admet-337	152	1	maximum	maximum	ADJ
admet-337	152	2	plasma	plasma	NOUN
admet-337	152	3	grace	grace	NOUN
admet-337	152	4	dy	dy	NOUN
admet-337	152	5	et	et	PROPN
admet-337	152	6	al	al	PROPN
admet-337	152	7	.	.	PROPN
admet-337	152	8	admet	admet	PROPN
admet-337	152	9	&	&	CCONJ
admet-337	152	10	dmpk	dmpk	PROPN
admet-337	152	11	4(3	4(3	NUM
admet-337	152	12	)	)	PUNCT
admet-337	152	13	(	(	PUNCT
admet-337	152	14	2016	2016	NUM
admet-337	152	15	)	)	PUNCT
admet-337	152	16	186	186	NUM
admet-337	152	17	-	-	SYM
admet-337	152	18	211	211	NUM
admet-337	152	19	192	192	NUM
admet-337	152	20	levels	level	NOUN
admet-337	152	21	are	be	AUX
admet-337	152	22	achieved	achieve	VERB
admet-337	152	23	between	between	ADP
admet-337	152	24	3	3	NUM
admet-337	152	25	and	and	CCONJ
admet-337	152	26	7	7	NUM
admet-337	152	27	hours	hour	NOUN
admet-337	152	28	after	after	ADP
admet-337	152	29	administering	administer	VERB
admet-337	152	30	gefitinib	gefitinib	NOUN
admet-337	152	31	with	with	ADP
admet-337	152	32	oral	oral	ADJ
admet-337	152	33	bioavailability	bioavailability	NOUN
admet-337	152	34	of	of	ADP
admet-337	152	35	approximately	approximately	ADV
admet-337	152	36	60	60	NUM
admet-337	152	37	%	%	NOUN
admet-337	153	1	[	[	X
admet-337	153	2	65,66	65,66	NOUN
admet-337	153	3	]	]	X
admet-337	153	4	.	.	PUNCT
admet-337	154	1	unlike	unlike	ADP
admet-337	154	2	erlotinib	erlotinib	NOUN
admet-337	154	3	,	,	PUNCT
admet-337	154	4	absorption	absorption	NOUN
admet-337	154	5	of	of	ADP
admet-337	154	6	gefitinib	gefitinib	NOUN
admet-337	154	7	is	be	AUX
admet-337	154	8	not	not	PART
admet-337	154	9	impacted	impact	VERB
admet-337	154	10	by	by	ADP
admet-337	154	11	food	food	NOUN
admet-337	154	12	[	[	X
admet-337	154	13	66	66	NUM
admet-337	154	14	]	]	PUNCT
admet-337	154	15	.	.	PUNCT
admet-337	155	1	however	however	ADV
admet-337	155	2	,	,	PUNCT
admet-337	155	3	the	the	DET
admet-337	155	4	drug	drug	NOUN
admet-337	155	5	has	have	AUX
admet-337	155	6	significantly	significantly	ADV
admet-337	155	7	decreased	decrease	VERB
admet-337	155	8	solubility	solubility	NOUN
admet-337	155	9	and	and	CCONJ
admet-337	155	10	absorption	absorption	NOUN
admet-337	155	11	at	at	ADP
admet-337	155	12	higher	high	ADJ
admet-337	155	13	gastric	gastric	ADJ
admet-337	155	14	ph	ph	VERB
admet-337	155	15	,	,	PUNCT
admet-337	155	16	therefore	therefore	ADV
admet-337	155	17	,	,	PUNCT
admet-337	155	18	use	use	NOUN
admet-337	155	19	of	of	ADP
admet-337	155	20	proton	proton	NOUN
admet-337	155	21	pump	pump	NOUN
admet-337	155	22	inhibitors	inhibitor	NOUN
admet-337	155	23	and	and	CCONJ
admet-337	155	24	h2	h2	NOUN
admet-337	155	25	-	-	PUNCT
admet-337	155	26	receptor	receptor	NOUN
admet-337	155	27	antagonists	antagonist	NOUN
admet-337	155	28	should	should	AUX
admet-337	155	29	be	be	AUX
admet-337	155	30	avoided	avoid	VERB
admet-337	155	31	when	when	SCONJ
admet-337	155	32	possible	possible	ADJ
admet-337	155	33	.	.	PUNCT
admet-337	156	1	upon	upon	SCONJ
admet-337	156	2	absorption	absorption	NOUN
admet-337	156	3	,	,	PUNCT
admet-337	156	4	gefitinib	gefitinib	NOUN
admet-337	156	5	is	be	AUX
admet-337	156	6	90	90	NUM
admet-337	156	7	%	%	NOUN
admet-337	156	8	protein	protein	NOUN
admet-337	156	9	bound	bind	VERB
admet-337	156	10	to	to	ADP
admet-337	156	11	alpha1	alpha1	NOUN
admet-337	156	12	-	-	PUNCT
admet-337	156	13	acid	acid	NOUN
admet-337	156	14	glycoprotein	glycoprotein	NOUN
admet-337	156	15	and	and	CCONJ
admet-337	156	16	albumin	albumin	NOUN
admet-337	156	17	and	and	CCONJ
admet-337	156	18	the	the	DET
admet-337	156	19	volume	volume	NOUN
admet-337	156	20	of	of	ADP
admet-337	156	21	distribution	distribution	NOUN
admet-337	156	22	is	be	AUX
admet-337	156	23	about	about	ADV
admet-337	156	24	1700	1700	NUM
admet-337	156	25	l	l	NOUN
admet-337	157	1	[	[	X
admet-337	157	2	67	67	NUM
admet-337	157	3	]	]	PUNCT
admet-337	157	4	.	.	PUNCT
admet-337	158	1	gefitinib	gefitinib	NOUN
admet-337	158	2	is	be	AUX
admet-337	158	3	metabolized	metabolize	VERB
admet-337	158	4	predominantly	predominantly	ADV
admet-337	158	5	in	in	ADP
admet-337	158	6	the	the	DET
admet-337	158	7	liver	liver	NOUN
admet-337	158	8	by	by	ADP
admet-337	158	9	cyp3a4	cyp3a4	NOUN
admet-337	158	10	and	and	CCONJ
admet-337	158	11	cyp2d6	cyp2d6	NOUN
admet-337	158	12	and	and	CCONJ
admet-337	158	13	to	to	ADP
admet-337	158	14	a	a	DET
admet-337	158	15	lesser	less	ADJ
admet-337	158	16	degree	degree	NOUN
admet-337	158	17	by	by	ADP
admet-337	158	18	cyp3a5	cyp3a5	NOUN
admet-337	158	19	.	.	PUNCT
admet-337	159	1	therefore	therefore	ADV
admet-337	159	2	,	,	PUNCT
admet-337	159	3	gefitinib	gefitinib	NOUN
admet-337	159	4	interacts	interact	VERB
admet-337	159	5	with	with	ADP
admet-337	159	6	similar	similar	ADJ
admet-337	159	7	cyp3a4	cyp3a4	NOUN
admet-337	159	8	inducers	inducer	NOUN
admet-337	159	9	and	and	CCONJ
admet-337	159	10	inhibitors	inhibitor	NOUN
admet-337	159	11	as	as	ADP
admet-337	159	12	erlotinib	erlotinib	NOUN
admet-337	159	13	as	as	ADV
admet-337	159	14	well	well	ADV
admet-337	159	15	as	as	ADP
admet-337	159	16	cyp2d6	cyp2d6	NOUN
admet-337	159	17	inhibitors	inhibitor	NOUN
admet-337	159	18	/	/	SYM
admet-337	159	19	inducers	inducer	NOUN
admet-337	159	20	[	[	X
admet-337	159	21	68	68	NUM
admet-337	159	22	]	]	PUNCT
admet-337	159	23	.	.	PUNCT
admet-337	160	1	although	although	SCONJ
admet-337	160	2	there	there	PRON
admet-337	160	3	is	be	VERB
admet-337	160	4	no	no	DET
admet-337	160	5	specific	specific	ADJ
admet-337	160	6	dose	dose	NOUN
admet-337	160	7	adjustment	adjustment	NOUN
admet-337	160	8	recommended	recommend	VERB
admet-337	160	9	for	for	ADP
admet-337	160	10	patients	patient	NOUN
admet-337	160	11	with	with	ADP
admet-337	160	12	hepatic	hepatic	ADJ
admet-337	160	13	impairment	impairment	NOUN
admet-337	160	14	,	,	PUNCT
admet-337	160	15	caution	caution	NOUN
admet-337	160	16	is	be	AUX
admet-337	160	17	recommended	recommend	VERB
admet-337	160	18	,	,	PUNCT
admet-337	160	19	as	as	SCONJ
admet-337	160	20	serum	serum	NOUN
admet-337	160	21	gefitinib	gefitinib	NOUN
admet-337	160	22	levels	level	NOUN
admet-337	160	23	increase	increase	VERB
admet-337	160	24	in	in	ADP
admet-337	160	25	this	this	DET
admet-337	160	26	setting	setting	NOUN
admet-337	160	27	.	.	PUNCT
admet-337	161	1	the	the	DET
admet-337	161	2	primary	primary	ADJ
admet-337	161	3	metabolite	metabolite	NOUN
admet-337	161	4	of	of	ADP
admet-337	161	5	gefitinib	gefitinib	NOUN
admet-337	161	6	,	,	PUNCT
admet-337	161	7	o	o	ADJ
admet-337	161	8	-	-	PUNCT
admet-337	161	9	desmethyl	desmethyl	NOUN
admet-337	161	10	gefitinib	gefitinib	NOUN
admet-337	161	11	,	,	PUNCT
admet-337	161	12	is	be	AUX
admet-337	161	13	inactive	inactive	ADJ
admet-337	161	14	[	[	X
admet-337	161	15	69	69	NUM
admet-337	161	16	]	]	PUNCT
admet-337	161	17	.	.	PUNCT
admet-337	162	1	only	only	ADV
admet-337	162	2	4	4	NUM
admet-337	162	3	%	%	NOUN
admet-337	162	4	of	of	ADP
admet-337	162	5	the	the	DET
admet-337	162	6	drug	drug	NOUN
admet-337	162	7	is	be	AUX
admet-337	162	8	renally	renally	ADV
admet-337	162	9	excreted	excrete	VERB
admet-337	162	10	,	,	PUNCT
admet-337	162	11	and	and	CCONJ
admet-337	162	12	no	no	DET
admet-337	162	13	dose	dose	NOUN
admet-337	162	14	-	-	PUNCT
admet-337	162	15	adjustments	adjustment	NOUN
admet-337	162	16	are	be	AUX
admet-337	162	17	recommended	recommend	VERB
admet-337	162	18	for	for	ADP
admet-337	162	19	patients	patient	NOUN
admet-337	162	20	with	with	ADP
admet-337	162	21	renal	renal	ADJ
admet-337	162	22	failure	failure	NOUN
admet-337	162	23	.	.	PUNCT
admet-337	163	1	cns	cns	NOUN
admet-337	163	2	penetration	penetration	NOUN
admet-337	163	3	gefitinib	gefitinib	NOUN
admet-337	163	4	does	do	AUX
admet-337	163	5	not	not	PART
admet-337	163	6	penetrate	penetrate	VERB
admet-337	163	7	the	the	DET
admet-337	163	8	bbb	bbb	PROPN
admet-337	163	9	well	well	ADV
admet-337	163	10	.	.	PUNCT
admet-337	164	1	in	in	ADP
admet-337	164	2	a	a	DET
admet-337	164	3	study	study	NOUN
admet-337	164	4	of	of	ADP
admet-337	164	5	8	8	NUM
admet-337	164	6	patients	patient	NOUN
admet-337	164	7	with	with	ADP
admet-337	164	8	egfr	egfr	NOUN
admet-337	164	9	activating	activate	VERB
admet-337	164	10	mutations	mutation	NOUN
admet-337	164	11	with	with	ADP
admet-337	164	12	cns	cns	NOUN
admet-337	164	13	metastases	metastasis	NOUN
admet-337	164	14	,	,	PUNCT
admet-337	164	15	the	the	DET
admet-337	164	16	csf	csf	ADJ
admet-337	164	17	gefitinib	gefitinib	NOUN
admet-337	164	18	concentration	concentration	NOUN
admet-337	164	19	was	be	AUX
admet-337	164	20	3.7+/1.9	3.7+/1.9	NUM
admet-337	164	21	ng	ng	PROPN
admet-337	164	22	/	/	SYM
admet-337	164	23	ml	ml	PROPN
admet-337	164	24	and	and	CCONJ
admet-337	164	25	the	the	DET
admet-337	164	26	csf	csf	ADJ
admet-337	164	27	penetration	penetration	NOUN
admet-337	164	28	of	of	ADP
admet-337	164	29	the	the	DET
admet-337	164	30	drug	drug	NOUN
admet-337	164	31	was	be	AUX
admet-337	164	32	1.13+/-0.36	1.13+/-0.36	NUM
admet-337	164	33	%	%	NOUN
admet-337	164	34	.	.	PUNCT
admet-337	165	1	despite	despite	SCONJ
admet-337	165	2	only	only	ADV
admet-337	165	3	1	1	NUM
admet-337	165	4	%	%	NOUN
admet-337	165	5	of	of	ADP
admet-337	165	6	the	the	DET
admet-337	165	7	drug	drug	NOUN
admet-337	165	8	penetrating	penetrate	VERB
admet-337	165	9	into	into	ADP
admet-337	165	10	the	the	DET
admet-337	165	11	csf	csf	NOUN
admet-337	165	12	,	,	PUNCT
admet-337	165	13	a	a	DET
admet-337	165	14	partial	partial	ADJ
admet-337	165	15	response	response	NOUN
admet-337	165	16	in	in	ADP
admet-337	165	17	cns	cns	NOUN
admet-337	165	18	metastases	metastasis	NOUN
admet-337	165	19	was	be	AUX
admet-337	165	20	demonstrated	demonstrate	VERB
admet-337	165	21	in	in	ADP
admet-337	165	22	one	one	NUM
admet-337	165	23	patient	patient	NOUN
admet-337	165	24	.	.	PUNCT
admet-337	166	1	erlotinib	erlotinib	NOUN
admet-337	166	2	does	do	AUX
admet-337	166	3	have	have	VERB
admet-337	166	4	superior	superior	ADJ
admet-337	166	5	cns	cns	NOUN
admet-337	166	6	penetration	penetration	NOUN
admet-337	166	7	to	to	ADP
admet-337	166	8	gefitinib	gefitinib	NOUN
admet-337	166	9	,	,	PUNCT
admet-337	166	10	and	and	CCONJ
admet-337	166	11	erlotinib	erlotinib	NOUN
admet-337	166	12	has	have	AUX
admet-337	166	13	successfully	successfully	ADV
admet-337	166	14	induced	induce	VERB
admet-337	166	15	cns	cns	NOUN
admet-337	166	16	response	response	NOUN
admet-337	166	17	to	to	ADP
admet-337	166	18	previously	previously	ADV
admet-337	166	19	gefitinib	gefitinib	NOUN
admet-337	166	20	-	-	PUNCT
admet-337	166	21	refractory	refractory	ADJ
admet-337	166	22	cns	cns	NOUN
admet-337	166	23	metastases	metastasis	NOUN
admet-337	166	24	[	[	X
admet-337	166	25	70	70	NUM
admet-337	166	26	]	]	PUNCT
admet-337	166	27	.	.	PUNCT
admet-337	167	1	high	high	ADJ
admet-337	167	2	-	-	PUNCT
admet-337	167	3	dose	dose	NOUN
admet-337	167	4	gefitinib	gefitinib	NOUN
admet-337	167	5	has	have	AUX
admet-337	167	6	been	be	AUX
admet-337	167	7	attempted	attempt	VERB
admet-337	167	8	in	in	ADP
admet-337	167	9	order	order	NOUN
admet-337	167	10	to	to	PART
admet-337	167	11	improve	improve	VERB
admet-337	167	12	control	control	NOUN
admet-337	167	13	of	of	ADP
admet-337	167	14	cns	cns	NOUN
admet-337	167	15	disease	disease	NOUN
admet-337	167	16	.	.	PUNCT
admet-337	168	1	in	in	ADP
admet-337	168	2	a	a	DET
admet-337	168	3	case	case	NOUN
admet-337	168	4	report	report	NOUN
admet-337	168	5	,	,	PUNCT
admet-337	168	6	gefitinib	gefitinib	NOUN
admet-337	168	7	was	be	AUX
admet-337	168	8	increased	increase	VERB
admet-337	168	9	to	to	ADP
admet-337	168	10	1000	1000	NUM
admet-337	168	11	mg	mg	NOUN
admet-337	168	12	daily	daily	ADV
admet-337	168	13	.	.	PUNCT
admet-337	169	1	this	this	PRON
admet-337	169	2	resulted	result	VERB
admet-337	169	3	in	in	ADP
admet-337	169	4	higher	high	ADJ
admet-337	169	5	csf	csf	ADJ
admet-337	169	6	concentration	concentration	NOUN
admet-337	169	7	of	of	ADP
admet-337	169	8	the	the	DET
admet-337	169	9	drug	drug	NOUN
admet-337	169	10	as	as	ADV
admet-337	169	11	well	well	ADV
admet-337	169	12	as	as	ADP
admet-337	169	13	radiographic	radiographic	ADJ
admet-337	169	14	and	and	CCONJ
admet-337	169	15	symptomatic	symptomatic	ADJ
admet-337	169	16	response	response	NOUN
admet-337	169	17	in	in	ADP
admet-337	169	18	the	the	DET
admet-337	169	19	patient	patient	NOUN
admet-337	169	20	.	.	PUNCT
admet-337	170	1	however	however	ADV
admet-337	170	2	,	,	PUNCT
admet-337	170	3	transaminitis	transaminitis	NOUN
admet-337	170	4	and	and	CCONJ
admet-337	170	5	somnolence	somnolence	NOUN
admet-337	170	6	developed	develop	VERB
admet-337	170	7	due	due	ADP
admet-337	170	8	to	to	ADP
admet-337	170	9	the	the	DET
admet-337	170	10	high	high	ADJ
admet-337	170	11	dose	dose	NOUN
admet-337	170	12	of	of	ADP
admet-337	170	13	the	the	DET
admet-337	170	14	drug	drug	NOUN
admet-337	170	15	.	.	PUNCT
admet-337	171	1	of	of	ADP
admet-337	171	2	note	note	NOUN
admet-337	171	3	,	,	PUNCT
admet-337	171	4	at	at	ADP
admet-337	171	5	autopsy	autopsy	ADJ
admet-337	171	6	,	,	PUNCT
admet-337	171	7	the	the	DET
admet-337	171	8	patient	patient	NOUN
admet-337	171	9	’s	’s	PART
admet-337	171	10	extracranial	extracranial	ADJ
admet-337	171	11	tumors	tumor	NOUN
admet-337	171	12	all	all	PRON
admet-337	171	13	harbored	harbor	VERB
admet-337	171	14	t790	t790	NUM
admet-337	171	15	m	m	NOUN
admet-337	171	16	mutation	mutation	NOUN
admet-337	171	17	,	,	PUNCT
admet-337	171	18	but	but	CCONJ
admet-337	171	19	the	the	DET
admet-337	171	20	brain	brain	NOUN
admet-337	171	21	metastases	metastasis	NOUN
admet-337	171	22	did	do	AUX
admet-337	171	23	not	not	PART
admet-337	171	24	carry	carry	VERB
admet-337	171	25	this	this	DET
admet-337	171	26	mutation	mutation	NOUN
admet-337	171	27	[	[	X
admet-337	171	28	71	71	NUM
admet-337	171	29	]	]	PUNCT
admet-337	171	30	.	.	PUNCT
admet-337	172	1	mechanism	mechanism	NOUN
admet-337	172	2	of	of	ADP
admet-337	172	3	resistance	resistance	NOUN
admet-337	172	4	like	like	ADP
admet-337	172	5	erlotinib	erlotinib	NOUN
admet-337	172	6	,	,	PUNCT
admet-337	172	7	the	the	DET
admet-337	172	8	main	main	ADJ
admet-337	172	9	mechanism	mechanism	NOUN
admet-337	172	10	egfr	egfr	NOUN
admet-337	172	11	of	of	ADP
admet-337	172	12	resistance	resistance	NOUN
admet-337	172	13	to	to	ADP
admet-337	172	14	gefitinib	gefitinib	NOUN
admet-337	172	15	is	be	AUX
admet-337	172	16	through	through	ADP
admet-337	172	17	the	the	DET
admet-337	172	18	secondary	secondary	ADJ
admet-337	172	19	t790	t790	NUM
admet-337	172	20	m	m	NOUN
admet-337	172	21	mutation	mutation	NOUN
admet-337	172	22	at	at	ADP
admet-337	172	23	the	the	DET
admet-337	172	24	intracellular	intracellular	ADJ
admet-337	172	25	catalytic	catalytic	ADJ
admet-337	172	26	domain	domain	NOUN
admet-337	172	27	[	[	X
admet-337	172	28	52,72	52,72	NOUN
admet-337	172	29	]	]	X
admet-337	172	30	.	.	PUNCT
admet-337	173	1	in	in	ADP
admet-337	173	2	a	a	DET
admet-337	173	3	small	small	ADJ
admet-337	173	4	series	series	NOUN
admet-337	173	5	of	of	ADP
admet-337	173	6	18	18	NUM
admet-337	173	7	patients	patient	NOUN
admet-337	173	8	,	,	PUNCT
admet-337	173	9	4	4	NUM
admet-337	173	10	(	(	PUNCT
admet-337	173	11	22	22	NUM
admet-337	173	12	%	%	NOUN
admet-337	173	13	)	)	PUNCT
admet-337	173	14	developed	develop	VERB
admet-337	173	15	gefitinib	gefitinib	NOUN
admet-337	173	16	resistance	resistance	NOUN
admet-337	173	17	through	through	ADP
admet-337	173	18	met	meet	VERB
admet-337	173	19	amplification	amplification	NOUN
admet-337	173	20	.	.	PUNCT
admet-337	174	1	this	this	PRON
admet-337	174	2	leads	lead	VERB
admet-337	174	3	to	to	ADP
admet-337	174	4	erbb3	erbb3	PROPN
admet-337	174	5	(	(	PUNCT
admet-337	174	6	her3)-dependent	her3)-dependent	PROPN
admet-337	174	7	pi3k	pi3k	PROPN
admet-337	174	8	/	/	SYM
admet-337	174	9	akt	akt	PROPN
admet-337	174	10	activation	activation	NOUN
admet-337	174	11	,	,	PUNCT
admet-337	174	12	which	which	PRON
admet-337	174	13	bypasses	bypass	VERB
admet-337	174	14	the	the	DET
admet-337	174	15	need	need	NOUN
admet-337	174	16	for	for	ADP
admet-337	174	17	signaling	signal	VERB
admet-337	174	18	through	through	ADP
admet-337	174	19	the	the	DET
admet-337	174	20	inhibited	inhibited	ADJ
admet-337	174	21	egfr	egfr	NOUN
admet-337	174	22	.	.	PUNCT
admet-337	175	1	the	the	DET
admet-337	175	2	t790	t790	NUM
admet-337	175	3	m	m	NOUN
admet-337	175	4	mutation	mutation	NOUN
admet-337	175	5	was	be	AUX
admet-337	175	6	present	present	ADJ
admet-337	175	7	in	in	ADP
admet-337	175	8	about	about	ADV
admet-337	175	9	half	half	NOUN
admet-337	175	10	of	of	ADP
admet-337	175	11	the	the	DET
admet-337	175	12	samples	sample	NOUN
admet-337	175	13	in	in	ADP
admet-337	175	14	which	which	PRON
admet-337	175	15	met	meet	VERB
admet-337	175	16	amplification	amplification	NOUN
admet-337	175	17	occurred	occur	VERB
admet-337	175	18	[	[	X
admet-337	175	19	54,73	54,73	NUM
admet-337	175	20	]	]	PUNCT
admet-337	175	21	.	.	PUNCT
admet-337	176	1	afatinib	afatinib	PROPN
admet-337	176	2	clinical	clinical	ADJ
admet-337	176	3	efficacy	efficacy	PROPN
admet-337	176	4	afatinib	afatinib	NOUN
admet-337	176	5	was	be	AUX
admet-337	176	6	the	the	DET
admet-337	176	7	first	first	ADJ
admet-337	176	8	irreversible	irreversible	ADJ
admet-337	176	9	egfr	egfr	NOUN
admet-337	176	10	tki	tki	PROPN
admet-337	176	11	available	available	ADJ
admet-337	176	12	on	on	ADP
admet-337	176	13	the	the	DET
admet-337	176	14	market	market	NOUN
admet-337	176	15	.	.	PUNCT
admet-337	177	1	the	the	DET
admet-337	177	2	drug	drug	NOUN
admet-337	177	3	was	be	AUX
admet-337	177	4	first	first	ADV
admet-337	177	5	fda	fda	PROPN
admet-337	177	6	approved	approve	VERB
admet-337	177	7	on	on	ADP
admet-337	177	8	july	july	PROPN
admet-337	177	9	2013	2013	NUM
admet-337	177	10	for	for	ADP
admet-337	177	11	first	first	ADJ
admet-337	177	12	-	-	PUNCT
admet-337	177	13	line	line	NOUN
admet-337	177	14	treatment	treatment	NOUN
admet-337	177	15	of	of	ADP
admet-337	177	16	patients	patient	NOUN
admet-337	177	17	with	with	ADP
admet-337	177	18	metastatic	metastatic	ADJ
admet-337	177	19	nsclc	nsclc	NOUN
admet-337	177	20	whose	whose	DET
admet-337	177	21	tumors	tumor	NOUN
admet-337	177	22	harbor	harbor	VERB
admet-337	177	23	exon	exon	PROPN
admet-337	177	24	19	19	NUM
admet-337	177	25	or	or	CCONJ
admet-337	177	26	l858r	l858r	NOUN
admet-337	177	27	activating	activate	VERB
admet-337	177	28	egfr	egfr	ADJ
admet-337	177	29	mutations	mutation	NOUN
admet-337	177	30	.	.	PUNCT
admet-337	178	1	the	the	DET
admet-337	178	2	approval	approval	NOUN
admet-337	178	3	was	be	AUX
admet-337	178	4	based	base	VERB
admet-337	178	5	on	on	ADP
admet-337	178	6	results	result	NOUN
admet-337	178	7	from	from	ADP
admet-337	178	8	the	the	DET
admet-337	178	9	lux	lux	NOUN
admet-337	178	10	-	-	PUNCT
admet-337	178	11	lung	lung	NOUN
admet-337	178	12	3	3	NUM
admet-337	178	13	trial	trial	NOUN
admet-337	178	14	,	,	PUNCT
admet-337	178	15	a	a	DET
admet-337	178	16	randomized	randomized	ADJ
admet-337	178	17	phase	phase	NOUN
admet-337	178	18	iii	iii	NUM
admet-337	178	19	study	study	NOUN
admet-337	178	20	comparing	compare	VERB
admet-337	178	21	afatinib	afatinib	NOUN
admet-337	178	22	with	with	ADP
admet-337	178	23	cisplatin	cisplatin	NOUN
admet-337	178	24	plus	plus	CCONJ
admet-337	178	25	pemetrexed	pemetrexe	VERB
admet-337	178	26	in	in	ADP
admet-337	178	27	patients	patient	NOUN
admet-337	178	28	with	with	ADP
admet-337	178	29	metastatic	metastatic	ADJ
admet-337	178	30	egfr	egfr	ADV
admet-337	178	31	-	-	PUNCT
admet-337	178	32	mutated	mutate	VERB
admet-337	178	33	nsclc	nsclc	NOUN
admet-337	178	34	.	.	PUNCT
admet-337	179	1	a	a	DET
admet-337	179	2	total	total	NOUN
admet-337	179	3	of	of	ADP
admet-337	179	4	345	345	NUM
admet-337	179	5	patients	patient	NOUN
admet-337	179	6	were	be	AUX
admet-337	179	7	randomized	randomize	VERB
admet-337	179	8	in	in	ADP
admet-337	179	9	this	this	DET
admet-337	179	10	trial	trial	NOUN
admet-337	179	11	.	.	PUNCT
admet-337	180	1	overall	overall	ADJ
admet-337	180	2	response	response	NOUN
admet-337	180	3	rate	rate	NOUN
admet-337	180	4	was	be	AUX
admet-337	180	5	significantly	significantly	ADV
admet-337	180	6	higher	high	ADJ
admet-337	180	7	in	in	ADP
admet-337	180	8	patients	patient	NOUN
admet-337	180	9	receiving	receive	VERB
admet-337	180	10	afatinib	afatinib	NOUN
admet-337	180	11	(	(	PUNCT
admet-337	180	12	56	56	NUM
admet-337	180	13	%	%	NOUN
admet-337	180	14	vs	vs	ADP
admet-337	180	15	23	23	NUM
admet-337	180	16	%	%	NOUN
admet-337	180	17	;	;	PUNCT
admet-337	180	18	p=.001	p=.001	PROPN
admet-337	180	19	)	)	PUNCT
admet-337	180	20	.	.	PUNCT
admet-337	181	1	median	median	PROPN
admet-337	181	2	pfs	pfs	PROPN
admet-337	181	3	was	be	AUX
admet-337	181	4	13.6	13.6	NUM
admet-337	181	5	months	month	NOUN
admet-337	181	6	with	with	ADP
admet-337	181	7	afatinib	afatinib	NOUN
admet-337	181	8	and	and	CCONJ
admet-337	181	9	6.9	6.9	NUM
admet-337	181	10	months	month	NOUN
admet-337	181	11	with	with	ADP
admet-337	181	12	chemotherapy	chemotherapy	NOUN
admet-337	181	13	(	(	PUNCT
admet-337	181	14	hr	hr	NOUN
admet-337	181	15	0.47	0.47	NUM
admet-337	181	16	;	;	PUNCT
admet-337	181	17	95	95	NUM
admet-337	181	18	%	%	NOUN
admet-337	181	19	ci	ci	NOUN
admet-337	181	20	,	,	PUNCT
admet-337	181	21	0.34	0.34	NUM
admet-337	181	22	to	to	PART
admet-337	181	23	0.65	0.65	NUM
admet-337	181	24	;	;	PUNCT
admet-337	181	25	p=.001	p=.001	NOUN
admet-337	181	26	)	)	PUNCT
admet-337	181	27	.	.	PUNCT
admet-337	182	1	both	both	PRON
admet-337	182	2	asian	asian	ADJ
admet-337	182	3	and	and	CCONJ
admet-337	182	4	non	non	ADJ
admet-337	182	5	-	-	ADJ
admet-337	182	6	asian	asian	ADJ
admet-337	182	7	patients	patient	NOUN
admet-337	182	8	were	be	AUX
admet-337	182	9	enrolled	enrol	VERB
admet-337	182	10	in	in	ADP
admet-337	182	11	the	the	DET
admet-337	182	12	study	study	NOUN
admet-337	182	13	,	,	PUNCT
admet-337	182	14	but	but	CCONJ
admet-337	182	15	the	the	DET
admet-337	182	16	study	study	NOUN
admet-337	182	17	was	be	AUX
admet-337	182	18	underpowered	underpowered	ADJ
admet-337	182	19	to	to	PART
admet-337	182	20	detect	detect	VERB
admet-337	182	21	a	a	DET
admet-337	182	22	pfs	pfs	ADJ
admet-337	182	23	difference	difference	NOUN
admet-337	182	24	in	in	ADP
admet-337	182	25	non	non	ADJ
admet-337	182	26	-	-	ADJ
admet-337	182	27	asian	asian	ADJ
admet-337	182	28	patients	patient	NOUN
admet-337	183	1	[	[	X
admet-337	183	2	74	74	NUM
admet-337	183	3	]	]	PUNCT
admet-337	183	4	.	.	PUNCT
admet-337	184	1	similarly	similarly	ADV
admet-337	184	2	,	,	PUNCT
admet-337	184	3	the	the	DET
admet-337	184	4	lux	lux	NOUN
admet-337	184	5	-	-	PUNCT
admet-337	184	6	lung	lung	NOUN
admet-337	184	7	6	6	NUM
admet-337	184	8	trial	trial	NOUN
admet-337	184	9	demonstrated	demonstrate	VERB
admet-337	184	10	a	a	DET
admet-337	184	11	significant	significant	ADJ
admet-337	184	12	pfs	pfs	ADJ
admet-337	184	13	benefit	benefit	NOUN
admet-337	184	14	for	for	ADP
admet-337	184	15	first	first	ADJ
admet-337	184	16	-	-	PUNCT
admet-337	184	17	line	line	NOUN
admet-337	184	18	afatinib	afatinib	NOUN
admet-337	184	19	versus	versus	ADP
admet-337	184	20	cisplatin	cisplatin	NOUN
admet-337	184	21	and	and	CCONJ
admet-337	184	22	gemcitabine	gemcitabine	NOUN
admet-337	184	23	in	in	ADP
admet-337	184	24	asian	asian	ADJ
admet-337	184	25	patients	patient	NOUN
admet-337	184	26	[	[	X
admet-337	184	27	75	75	NUM
admet-337	184	28	]	]	PUNCT
admet-337	184	29	.	.	PUNCT
admet-337	185	1	a	a	DET
admet-337	185	2	combined	combined	ADJ
admet-337	185	3	analysis	analysis	NOUN
admet-337	185	4	of	of	ADP
admet-337	185	5	lux	lux	NOUN
admet-337	185	6	-	-	PUNCT
admet-337	185	7	lung	lung	NOUN
admet-337	185	8	3	3	NUM
admet-337	185	9	and	and	CCONJ
admet-337	185	10	lux	lux	PROPN
admet-337	185	11	-	-	PUNCT
admet-337	185	12	lung	lung	NOUN
admet-337	185	13	6	6	NUM
admet-337	185	14	demonstrated	demonstrate	VERB
admet-337	185	15	an	an	DET
admet-337	185	16	overall	overall	ADJ
admet-337	185	17	survival	survival	NOUN
admet-337	185	18	benefit	benefit	NOUN
admet-337	185	19	for	for	ADP
admet-337	185	20	patients	patient	NOUN
admet-337	185	21	with	with	ADP
admet-337	185	22	exon	exon	NOUN
admet-337	185	23	19	19	NUM
admet-337	185	24	deletion	deletion	NOUN
admet-337	185	25	but	but	CCONJ
admet-337	185	26	not	not	PART
admet-337	185	27	with	with	ADP
admet-337	185	28	the	the	DET
admet-337	185	29	l858r	l858r	NOUN
admet-337	185	30	point	point	NOUN
admet-337	185	31	mutation	mutation	NOUN
admet-337	185	32	[	[	X
admet-337	185	33	76	76	NUM
admet-337	185	34	]	]	PUNCT
admet-337	185	35	.	.	PUNCT
admet-337	186	1	in	in	ADP
admet-337	186	2	the	the	DET
admet-337	186	3	randomized	randomized	ADJ
admet-337	186	4	phase	phase	NOUN
admet-337	186	5	iib	iib	PROPN
admet-337	186	6	lux	lux	PROPN
admet-337	186	7	-	-	PUNCT
admet-337	186	8	lung	lung	NOUN
admet-337	186	9	7	7	NUM
admet-337	186	10	trial	trial	NOUN
admet-337	186	11	,	,	PUNCT
admet-337	186	12	which	which	PRON
admet-337	186	13	compared	compare	VERB
admet-337	186	14	first	first	ADJ
admet-337	186	15	-	-	PUNCT
admet-337	186	16	line	line	NOUN
admet-337	186	17	afatinib	afatinib	NOUN
admet-337	186	18	vs	vs	ADP
admet-337	186	19	gefitinib	gefitinib	NOUN
admet-337	186	20	admet	admet	PROPN
admet-337	186	21	&	&	CCONJ
admet-337	186	22	dmpk	dmpk	PROPN
admet-337	186	23	4(3	4(3	NUM
admet-337	186	24	)	)	PUNCT
admet-337	186	25	(	(	PUNCT
admet-337	186	26	2016	2016	NUM
admet-337	186	27	)	)	PUNCT
admet-337	186	28	186	186	NUM
admet-337	186	29	-	-	SYM
admet-337	186	30	211	211	NUM
admet-337	186	31	tki	tki	NOUN
admet-337	186	32	for	for	ADP
admet-337	186	33	egfrand	egfrand	ADJ
admet-337	186	34	alk	alk	PROPN
admet-337	186	35	-	-	PUNCT
admet-337	186	36	mutated	mutate	VERB
admet-337	186	37	cell	cell	NOUN
admet-337	186	38	cancer	cancer	NOUN
admet-337	186	39	doi	doi	NOUN
admet-337	186	40	:	:	PUNCT
admet-337	186	41	10.5599	10.5599	NUM
admet-337	186	42	/	/	SYM
admet-337	186	43	admet.4.3.337	admet.4.3.337	NUM
admet-337	186	44	193	193	NUM
admet-337	186	45	in	in	ADP
admet-337	186	46	egfr	egfr	ADJ
admet-337	186	47	-	-	PUNCT
admet-337	186	48	mutated	mutate	VERB
admet-337	186	49	nsclc	nsclc	NOUN
admet-337	186	50	,	,	PUNCT
admet-337	186	51	afatinib	afatinib	NOUN
admet-337	186	52	produced	produce	VERB
admet-337	186	53	superior	superior	ADJ
admet-337	186	54	pfs	pf	NOUN
admet-337	186	55	at	at	ADP
admet-337	186	56	12	12	NUM
admet-337	186	57	,	,	PUNCT
admet-337	186	58	18	18	NUM
admet-337	186	59	and	and	CCONJ
admet-337	186	60	24	24	NUM
admet-337	186	61	months	month	NOUN
admet-337	187	1	[	[	X
admet-337	187	2	77	77	NUM
admet-337	187	3	]	]	PUNCT
admet-337	187	4	.	.	PUNCT
admet-337	188	1	afatinib	afatinib	NOUN
admet-337	188	2	also	also	ADV
admet-337	188	3	recently	recently	ADV
admet-337	188	4	gained	gain	VERB
admet-337	188	5	fda	fda	PROPN
admet-337	188	6	approval	approval	NOUN
admet-337	188	7	in	in	ADP
admet-337	188	8	april	april	PROPN
admet-337	188	9	2016	2016	NUM
admet-337	188	10	for	for	ADP
admet-337	188	11	second	second	ADJ
admet-337	188	12	-	-	PUNCT
admet-337	188	13	line	line	NOUN
admet-337	188	14	treatment	treatment	NOUN
admet-337	188	15	of	of	ADP
admet-337	188	16	advanced	advanced	ADJ
admet-337	188	17	squamous	squamous	ADJ
admet-337	188	18	cell	cell	NOUN
admet-337	188	19	nsclc	nsclc	NOUN
admet-337	188	20	.	.	PUNCT
admet-337	189	1	compared	compare	VERB
admet-337	189	2	with	with	ADP
admet-337	189	3	erlotinib	erlotinib	NOUN
admet-337	189	4	,	,	PUNCT
admet-337	189	5	afatinib	afatinib	NOUN
admet-337	189	6	prolonged	prolong	VERB
admet-337	189	7	both	both	CCONJ
admet-337	189	8	pfs	pfs	PROPN
admet-337	189	9	and	and	CCONJ
admet-337	189	10	os	os	NOUN
admet-337	189	11	in	in	ADP
admet-337	189	12	patients	patient	NOUN
admet-337	189	13	with	with	ADP
admet-337	189	14	advanced	advanced	ADJ
admet-337	189	15	squamous	squamous	ADJ
admet-337	189	16	cell	cell	NOUN
admet-337	189	17	lung	lung	NOUN
admet-337	189	18	cancer	cancer	NOUN
admet-337	189	19	[	[	X
admet-337	189	20	78	78	NUM
admet-337	189	21	]	]	PUNCT
admet-337	189	22	.	.	PUNCT
admet-337	190	1	patients	patient	NOUN
admet-337	190	2	who	who	PRON
admet-337	190	3	develop	develop	VERB
admet-337	190	4	acquired	acquire	VERB
admet-337	190	5	resistance	resistance	NOUN
admet-337	190	6	to	to	ADP
admet-337	190	7	erlotinib	erlotinib	NOUN
admet-337	190	8	or	or	CCONJ
admet-337	190	9	gefitinib	gefitinib	NOUN
admet-337	190	10	have	have	VERB
admet-337	190	11	little	little	ADJ
admet-337	190	12	response	response	NOUN
admet-337	190	13	(	(	PUNCT
admet-337	190	14	8	8	NUM
admet-337	190	15	%	%	NOUN
admet-337	190	16	)	)	PUNCT
admet-337	190	17	to	to	ADP
admet-337	190	18	single	single	ADJ
admet-337	190	19	-	-	PUNCT
admet-337	190	20	agent	agent	NOUN
admet-337	190	21	afatinib	afatinib	NOUN
admet-337	190	22	[	[	X
admet-337	190	23	79	79	NUM
admet-337	190	24	]	]	PUNCT
admet-337	190	25	.	.	PUNCT
admet-337	191	1	however	however	ADV
admet-337	191	2	,	,	PUNCT
admet-337	191	3	dual	dual	ADJ
admet-337	191	4	inhibition	inhibition	NOUN
admet-337	191	5	of	of	ADP
admet-337	191	6	egfr	egfr	NOUN
admet-337	191	7	with	with	ADP
admet-337	191	8	afatinib	afatinib	NOUN
admet-337	191	9	and	and	CCONJ
admet-337	191	10	cetuximab	cetuximab	NOUN
admet-337	191	11	induced	induce	VERB
admet-337	191	12	responses	response	NOUN
admet-337	191	13	in	in	ADP
admet-337	191	14	patients	patient	NOUN
admet-337	191	15	who	who	PRON
admet-337	191	16	previously	previously	ADV
admet-337	191	17	progressed	progress	VERB
admet-337	191	18	on	on	ADP
admet-337	191	19	erlotinib	erlotinib	NOUN
admet-337	191	20	or	or	CCONJ
admet-337	191	21	gefitinib	gefitinib	NOUN
admet-337	191	22	.	.	PUNCT
admet-337	192	1	responses	response	NOUN
admet-337	192	2	of	of	ADP
admet-337	192	3	32	32	NUM
admet-337	192	4	%	%	NOUN
admet-337	192	5	and	and	CCONJ
admet-337	192	6	25	25	NUM
admet-337	192	7	%	%	NOUN
admet-337	192	8	were	be	AUX
admet-337	192	9	witnessed	witness	VERB
admet-337	192	10	in	in	ADP
admet-337	192	11	t790m	t790m	ADJ
admet-337	192	12	-	-	PUNCT
admet-337	192	13	positive	positive	ADJ
admet-337	192	14	and	and	CCONJ
admet-337	192	15	t790m	t790m	ADJ
admet-337	192	16	-	-	PUNCT
admet-337	192	17	negative	negative	ADJ
admet-337	192	18	tumors	tumor	NOUN
admet-337	192	19	,	,	PUNCT
admet-337	192	20	respectively	respectively	ADV
admet-337	192	21	[	[	X
admet-337	192	22	80	80	NUM
admet-337	192	23	]	]	PUNCT
admet-337	192	24	.	.	PUNCT
admet-337	193	1	clinical	clinical	ADJ
admet-337	193	2	safety	safety	NOUN
admet-337	193	3	diarrhea	diarrhea	PROPN
admet-337	193	4	occurs	occur	VERB
admet-337	193	5	commonly	commonly	ADV
admet-337	193	6	with	with	ADP
admet-337	193	7	afatinib	afatinib	NOUN
admet-337	193	8	.	.	PUNCT
admet-337	194	1	all	all	DET
admet-337	194	2	-	-	PUNCT
admet-337	194	3	grade	grade	NOUN
admet-337	194	4	diarrhea	diarrhea	NOUN
admet-337	194	5	has	have	AUX
admet-337	194	6	been	be	AUX
admet-337	194	7	reported	report	VERB
admet-337	194	8	as	as	ADV
admet-337	194	9	high	high	ADJ
admet-337	194	10	as	as	ADP
admet-337	194	11	95	95	NUM
admet-337	194	12	%	%	NOUN
admet-337	194	13	with	with	ADP
admet-337	194	14	grade	grade	NOUN
admet-337	194	15	3	3	NUM
admet-337	194	16	to	to	PART
admet-337	194	17	5	5	NUM
admet-337	194	18	diarrhea	diarrhea	NOUN
admet-337	194	19	of	of	ADP
admet-337	194	20	14	14	NUM
admet-337	194	21	%	%	NOUN
admet-337	194	22	in	in	ADP
admet-337	194	23	clinical	clinical	ADJ
admet-337	194	24	trials	trial	NOUN
admet-337	194	25	.	.	PUNCT
admet-337	195	1	rash	rash	ADJ
admet-337	195	2	/	/	SYM
admet-337	195	3	acne	acne	NOUN
admet-337	195	4	(	(	PUNCT
admet-337	195	5	all	all	DET
admet-337	195	6	-	-	PUNCT
admet-337	195	7	grade	grade	NOUN
admet-337	195	8	:	:	PUNCT
admet-337	195	9	89	89	NUM
admet-337	195	10	%	%	NOUN
admet-337	195	11	,	,	PUNCT
admet-337	195	12	grade	grade	NOUN
admet-337	195	13	3	3	NUM
admet-337	195	14	-	-	SYM
admet-337	195	15	5	5	NUM
admet-337	195	16	:	:	SYM
admet-337	195	17	16	16	NUM
admet-337	195	18	%	%	NOUN
admet-337	195	19	)	)	PUNCT
admet-337	195	20	and	and	CCONJ
admet-337	195	21	stomatitis	stomatitis	NOUN
admet-337	195	22	(	(	PUNCT
admet-337	195	23	all	all	DET
admet-337	195	24	-	-	PUNCT
admet-337	195	25	grade	grade	NOUN
admet-337	195	26	:	:	PUNCT
admet-337	195	27	51	51	NUM
admet-337	195	28	-	-	SYM
admet-337	195	29	72	72	NUM
admet-337	195	30	%	%	NOUN
admet-337	195	31	,	,	PUNCT
admet-337	195	32	grade	grade	NOUN
admet-337	195	33	3	3	NUM
admet-337	195	34	-	-	SYM
admet-337	195	35	5	5	NUM
admet-337	195	36	:	:	SYM
admet-337	195	37	8	8	NUM
admet-337	195	38	%	%	NOUN
admet-337	195	39	)	)	PUNCT
admet-337	195	40	are	be	AUX
admet-337	195	41	frequently	frequently	ADV
admet-337	195	42	encountered	encounter	VERB
admet-337	195	43	[	[	X
admet-337	195	44	74,75	74,75	NOUN
admet-337	195	45	]	]	PUNCT
admet-337	195	46	.	.	PUNCT
admet-337	196	1	rare	rare	ADJ
admet-337	196	2	adverse	adverse	ADJ
admet-337	196	3	effects	effect	NOUN
admet-337	196	4	include	include	VERB
admet-337	196	5	decrease	decrease	NOUN
admet-337	196	6	in	in	ADP
admet-337	196	7	left	left	ADJ
admet-337	196	8	ventricular	ventricular	ADJ
admet-337	196	9	ejection	ejection	NOUN
admet-337	196	10	fraction	fraction	NOUN
admet-337	196	11	,	,	PUNCT
admet-337	196	12	interstitial	interstitial	ADJ
admet-337	196	13	lung	lung	NOUN
admet-337	196	14	disease	disease	NOUN
admet-337	196	15	and	and	CCONJ
admet-337	196	16	fatal	fatal	ADJ
admet-337	196	17	hepatotoxicity	hepatotoxicity	NOUN
admet-337	196	18	.	.	PUNCT
admet-337	197	1	pharmacology	pharmacology	NOUN
admet-337	197	2	afatinib	afatinib	NOUN
admet-337	197	3	,	,	PUNCT
admet-337	197	4	(	(	PUNCT
admet-337	197	5	e)-n-[4-(3	e)-n-[4-(3	NOUN
admet-337	197	6	-	-	PUNCT
admet-337	197	7	chloro-4	chloro-4	ADP
admet-337	197	8	-	-	PUNCT
admet-337	197	9	fluoroanilino)-7-[(3s)-oxolan-3	fluoroanilino)-7-[(3s)-oxolan-3	PROPN
admet-337	197	10	-	-	PUNCT
admet-337	197	11	yl]oxyquinazolin-6	yl]oxyquinazolin-6	PRON
admet-337	197	12	-	-	PUNCT
admet-337	197	13	yl]-4	yl]-4	NUM
admet-337	197	14	-	-	PUNCT
admet-337	197	15	dimethylami	dimethylami	NOUN
admet-337	197	16	-	-	PUNCT
admet-337	197	17	no)but-2	no)but-2	ADV
admet-337	197	18	-	-	PUNCT
admet-337	197	19	enamide	enamide	NOUN
admet-337	198	1	[	[	X
admet-337	198	2	bibw	bibw	NOUN
admet-337	198	3	2992	2992	NUM
admet-337	198	4	,	,	PUNCT
admet-337	198	5	gilotrif	gilotrif	PROPN
admet-337	198	6	,	,	PUNCT
admet-337	198	7	(	(	PUNCT
admet-337	198	8	boehringer	boehringer	PROPN
admet-337	198	9	ingelheim	ingelheim	PROPN
admet-337	198	10	)	)	PUNCT
admet-337	198	11	]	]	X
admet-337	198	12	,	,	PUNCT
admet-337	198	13	irreversibly	irreversibly	ADV
admet-337	198	14	inhibits	inhibit	VERB
admet-337	198	15	erbb1	erbb1	NOUN
admet-337	198	16	(	(	PUNCT
admet-337	198	17	egfr	egfr	NOUN
admet-337	198	18	)	)	PUNCT
admet-337	198	19	,	,	PUNCT
admet-337	198	20	erbb2	erbb2	X
admet-337	198	21	(	(	PUNCT
admet-337	198	22	her2	her2	PROPN
admet-337	198	23	)	)	PUNCT
admet-337	198	24	,	,	PUNCT
admet-337	198	25	and	and	CCONJ
admet-337	198	26	erbb4	erbb4	PROPN
admet-337	198	27	(	(	PUNCT
admet-337	198	28	her4	her4	PROPN
admet-337	198	29	)	)	PUNCT
admet-337	198	30	.	.	PUNCT
admet-337	199	1	as	as	SCONJ
admet-337	199	2	opposed	oppose	VERB
admet-337	199	3	to	to	ADP
admet-337	199	4	first	first	ADJ
admet-337	199	5	-	-	PUNCT
admet-337	199	6	generation	generation	NOUN
admet-337	199	7	egfr	egfr	NOUN
admet-337	199	8	tkis	tkis	NOUN
admet-337	199	9	,	,	PUNCT
admet-337	199	10	afatinib	afatinib	PROPN
admet-337	199	11	forms	form	VERB
admet-337	199	12	an	an	DET
admet-337	199	13	irreversible	irreversible	ADJ
admet-337	199	14	covalent	covalent	NOUN
admet-337	199	15	bond	bond	NOUN
admet-337	199	16	at	at	ADP
admet-337	199	17	the	the	DET
admet-337	199	18	atp	atp	NOUN
admet-337	199	19	-	-	PUNCT
admet-337	199	20	binding	bind	VERB
admet-337	199	21	site	site	NOUN
admet-337	199	22	of	of	ADP
admet-337	199	23	egfr	egfr	NOUN
admet-337	199	24	.	.	PUNCT
admet-337	200	1	the	the	DET
admet-337	200	2	acrylamide	acrylamide	NOUN
admet-337	200	3	group	group	NOUN
admet-337	200	4	permits	permit	VERB
admet-337	200	5	afatinib	afatinib	NOUN
admet-337	200	6	to	to	PART
admet-337	200	7	form	form	VERB
admet-337	200	8	a	a	DET
admet-337	200	9	covalent	covalent	ADJ
admet-337	200	10	bond	bond	NOUN
admet-337	200	11	at	at	ADP
admet-337	200	12	the	the	DET
admet-337	200	13	tyrosine	tyrosine	PROPN
admet-337	200	14	kinase	kinase	PROPN
admet-337	200	15	site	site	NOUN
admet-337	200	16	and	and	CCONJ
admet-337	200	17	is	be	AUX
admet-337	200	18	important	important	ADJ
admet-337	200	19	in	in	ADP
admet-337	200	20	its	its	PRON
admet-337	200	21	activity	activity	NOUN
admet-337	200	22	against	against	ADP
admet-337	200	23	t790	t790	NUM
admet-337	200	24	m	m	NOUN
admet-337	200	25	,	,	PUNCT
admet-337	200	26	her2	her2	PROPN
admet-337	200	27	,	,	PUNCT
admet-337	200	28	and	and	CCONJ
admet-337	200	29	erbb4	erbb4	VERB
admet-337	201	1	[	[	X
admet-337	201	2	81	81	NUM
admet-337	201	3	]	]	PUNCT
admet-337	201	4	.	.	PUNCT
admet-337	202	1	afatinib	afatinib	NOUN
admet-337	202	2	demonstrates	demonstrate	VERB
admet-337	202	3	a	a	DET
admet-337	202	4	similar	similar	ADJ
admet-337	202	5	ic50	ic50	PROPN
admet-337	202	6	for	for	ADP
admet-337	202	7	wild	wild	ADJ
admet-337	202	8	-	-	PUNCT
admet-337	202	9	type	type	NOUN
admet-337	202	10	egfr	egfr	NOUN
admet-337	202	11	and	and	CCONJ
admet-337	202	12	l858r	l858r	NOUN
admet-337	202	13	-	-	PUNCT
admet-337	202	14	mutated	mutate	VERB
admet-337	202	15	egfr	egfr	NOUN
admet-337	202	16	,	,	PUNCT
admet-337	202	17	but	but	CCONJ
admet-337	202	18	it	it	PRON
admet-337	202	19	is	be	AUX
admet-337	202	20	100	100	NUM
admet-337	202	21	-	-	PUNCT
admet-337	202	22	times	time	NOUN
admet-337	202	23	more	more	ADV
admet-337	202	24	potent	potent	ADJ
admet-337	202	25	against	against	ADP
admet-337	202	26	t790m	t790m	PROPN
admet-337	202	27	-	-	PUNCT
admet-337	202	28	mutated	mutate	VERB
admet-337	202	29	egfr	egfr	NOUN
admet-337	202	30	.	.	PUNCT
admet-337	203	1	however	however	ADV
admet-337	203	2	,	,	PUNCT
admet-337	203	3	clinically	clinically	ADV
admet-337	203	4	meaningful	meaningful	ADJ
admet-337	203	5	inhibition	inhibition	NOUN
admet-337	203	6	of	of	ADP
admet-337	203	7	t790	t790	NUM
admet-337	203	8	m	m	NOUN
admet-337	203	9	with	with	ADP
admet-337	203	10	higher	high	ADJ
admet-337	203	11	dose	dose	NOUN
admet-337	203	12	afatinib	afatinib	NOUN
admet-337	203	13	is	be	AUX
admet-337	203	14	unable	unable	ADJ
admet-337	203	15	to	to	PART
admet-337	203	16	be	be	AUX
admet-337	203	17	achieved	achieve	VERB
admet-337	203	18	without	without	ADP
admet-337	203	19	substantial	substantial	ADJ
admet-337	203	20	toxicity	toxicity	NOUN
admet-337	203	21	[	[	X
admet-337	203	22	80	80	NUM
admet-337	203	23	]	]	PUNCT
admet-337	203	24	.	.	PUNCT
admet-337	204	1	afatinib	afatinib	NOUN
admet-337	204	2	also	also	ADV
admet-337	204	3	inhibits	inhibit	VERB
admet-337	204	4	her3	her3	ADJ
admet-337	204	5	activity	activity	NOUN
admet-337	204	6	.	.	PUNCT
admet-337	205	1	her3	her3	PROPN
admet-337	205	2	activates	activate	VERB
admet-337	205	3	the	the	DET
admet-337	205	4	pi3k	pi3k	PROPN
admet-337	205	5	/	/	SYM
admet-337	205	6	akt	akt	PROPN
admet-337	205	7	survival	survival	NOUN
admet-337	205	8	pathway	pathway	NOUN
admet-337	205	9	in	in	ADP
admet-337	205	10	nsclc	nsclc	NOUN
admet-337	205	11	.	.	PUNCT
admet-337	206	1	this	this	DET
admet-337	206	2	receptor	receptor	NOUN
admet-337	206	3	lacks	lack	VERB
admet-337	206	4	intrinsic	intrinsic	ADJ
admet-337	206	5	kinase	kinase	NOUN
admet-337	206	6	activity	activity	NOUN
admet-337	206	7	and	and	CCONJ
admet-337	206	8	its	its	PRON
admet-337	206	9	activity	activity	NOUN
admet-337	206	10	depends	depend	VERB
admet-337	206	11	upon	upon	SCONJ
admet-337	206	12	transphosphorylation	transphosphorylation	NOUN
admet-337	206	13	by	by	ADP
admet-337	206	14	heterodimerization	heterodimerization	NOUN
admet-337	206	15	with	with	ADP
admet-337	206	16	egfr	egfr	PROPN
admet-337	206	17	,	,	PUNCT
admet-337	206	18	her2	her2	VERB
admet-337	206	19	and	and	CCONJ
admet-337	206	20	met	meet	VERB
admet-337	206	21	.	.	PUNCT
admet-337	207	1	outside	outside	ADP
admet-337	207	2	of	of	ADP
admet-337	207	3	the	the	DET
admet-337	207	4	erbb	erbb	PROPN
admet-337	207	5	family	family	NOUN
admet-337	207	6	of	of	ADP
admet-337	207	7	receptors	receptor	NOUN
admet-337	207	8	,	,	PUNCT
admet-337	207	9	afatinib	afatinib	NOUN
admet-337	207	10	does	do	AUX
admet-337	207	11	not	not	PART
admet-337	207	12	significantly	significantly	ADV
admet-337	207	13	inhibit	inhibit	VERB
admet-337	207	14	other	other	ADJ
admet-337	207	15	tyrosine	tyrosine	NOUN
admet-337	207	16	or	or	CCONJ
admet-337	207	17	serine	serine	NOUN
admet-337	207	18	/	/	SYM
admet-337	207	19	threonine	threonine	ADJ
admet-337	207	20	kinases	kinase	NOUN
admet-337	208	1	[	[	X
admet-337	208	2	82	82	NUM
admet-337	208	3	]	]	PUNCT
admet-337	208	4	.	.	PUNCT
admet-337	209	1	the	the	DET
admet-337	209	2	recommended	recommend	VERB
admet-337	209	3	starting	starting	NOUN
admet-337	209	4	dose	dose	NOUN
admet-337	209	5	of	of	ADP
admet-337	209	6	afatinib	afatinib	NOUN
admet-337	209	7	is	be	AUX
admet-337	209	8	40	40	NUM
admet-337	209	9	mg	mg	NOUN
admet-337	209	10	administered	administer	VERB
admet-337	209	11	orally	orally	ADV
admet-337	209	12	daily	daily	ADV
admet-337	209	13	,	,	PUNCT
admet-337	209	14	and	and	CCONJ
admet-337	209	15	peak	peak	NOUN
admet-337	209	16	plasma	plasma	NOUN
admet-337	209	17	concentrations	concentration	NOUN
admet-337	209	18	are	be	AUX
admet-337	209	19	reached	reach	VERB
admet-337	209	20	2	2	NUM
admet-337	209	21	to	to	PART
admet-337	209	22	5	5	NUM
admet-337	209	23	hours	hour	NOUN
admet-337	209	24	later	later	ADV
admet-337	209	25	.	.	PUNCT
admet-337	210	1	absorption	absorption	NOUN
admet-337	210	2	is	be	AUX
admet-337	210	3	decreased	decrease	VERB
admet-337	210	4	with	with	ADP
admet-337	210	5	high	high	ADJ
admet-337	210	6	-	-	PUNCT
admet-337	210	7	fat	fat	NOUN
admet-337	210	8	meals	meal	NOUN
admet-337	210	9	and	and	CCONJ
admet-337	210	10	the	the	DET
admet-337	210	11	drug	drug	NOUN
admet-337	210	12	should	should	AUX
admet-337	210	13	not	not	PART
admet-337	210	14	be	be	AUX
admet-337	210	15	taken	take	VERB
admet-337	210	16	with	with	ADP
admet-337	210	17	food	food	NOUN
admet-337	210	18	.	.	PUNCT
admet-337	211	1	solubility	solubility	NOUN
admet-337	211	2	of	of	ADP
admet-337	211	3	afatinib	afatinib	NOUN
admet-337	211	4	is	be	AUX
admet-337	211	5	not	not	PART
admet-337	211	6	affected	affect	VERB
admet-337	211	7	by	by	ADP
admet-337	211	8	physiologic	physiologic	ADJ
admet-337	211	9	gastric	gastric	ADJ
admet-337	211	10	ph	ph	ADJ
admet-337	211	11	levels	level	NOUN
admet-337	211	12	;	;	PUNCT
admet-337	211	13	therefore	therefore	ADV
admet-337	211	14	,	,	PUNCT
admet-337	211	15	antacids	antacid	NOUN
admet-337	211	16	do	do	AUX
admet-337	211	17	not	not	PART
admet-337	211	18	affect	affect	VERB
admet-337	211	19	absorption	absorption	NOUN
admet-337	211	20	.	.	PUNCT
admet-337	212	1	upon	upon	SCONJ
admet-337	212	2	absorption	absorption	NOUN
admet-337	212	3	,	,	PUNCT
admet-337	212	4	afatinib	afatinib	NOUN
admet-337	212	5	is	be	AUX
admet-337	212	6	heavily	heavily	ADV
admet-337	212	7	protein	protein	NOUN
admet-337	212	8	bound	bind	VERB
admet-337	212	9	(	(	PUNCT
admet-337	212	10	~95	~95	X
admet-337	212	11	%	%	NOUN
admet-337	212	12	)	)	PUNCT
admet-337	212	13	,	,	PUNCT
admet-337	212	14	bioavailability	bioavailability	NOUN
admet-337	212	15	is	be	AUX
admet-337	212	16	92	92	NUM
admet-337	212	17	%	%	NOUN
admet-337	212	18	,	,	PUNCT
admet-337	212	19	and	and	CCONJ
admet-337	212	20	half	half	ADJ
admet-337	212	21	-	-	PUNCT
admet-337	212	22	life	life	NOUN
admet-337	212	23	is	be	AUX
admet-337	212	24	37	37	NUM
admet-337	212	25	hours	hour	NOUN
admet-337	212	26	[	[	X
admet-337	212	27	83	83	NUM
admet-337	212	28	]	]	PUNCT
admet-337	212	29	.	.	PUNCT
admet-337	213	1	unlike	unlike	ADP
admet-337	213	2	the	the	DET
admet-337	213	3	reversible	reversible	ADJ
admet-337	213	4	egfr	egfr	NOUN
admet-337	213	5	tkis	tkis	NOUN
admet-337	213	6	,	,	PUNCT
admet-337	213	7	afatinib	afatinib	PROPN
admet-337	213	8	is	be	AUX
admet-337	213	9	not	not	PART
admet-337	213	10	significantly	significantly	ADV
admet-337	213	11	metabolized	metabolize	VERB
admet-337	213	12	through	through	ADP
admet-337	213	13	the	the	DET
admet-337	213	14	cyp	cyp	ADJ
admet-337	213	15	pathway	pathway	NOUN
admet-337	213	16	,	,	PUNCT
admet-337	213	17	and	and	CCONJ
admet-337	213	18	therefore	therefore	ADV
admet-337	213	19	,	,	PUNCT
admet-337	213	20	cyp	cyp	ADJ
admet-337	213	21	inhibitors	inhibitor	NOUN
admet-337	213	22	and	and	CCONJ
admet-337	213	23	inducers	inducer	NOUN
admet-337	213	24	have	have	VERB
admet-337	213	25	little	little	ADJ
admet-337	213	26	impact	impact	NOUN
admet-337	213	27	on	on	ADP
admet-337	213	28	plasma	plasma	NOUN
admet-337	213	29	levels	level	NOUN
admet-337	213	30	of	of	ADP
admet-337	213	31	afatinib	afatinib	NOUN
admet-337	213	32	.	.	PUNCT
admet-337	214	1	metabolism	metabolism	NOUN
admet-337	214	2	of	of	ADP
admet-337	214	3	afatinib	afatinib	NOUN
admet-337	214	4	is	be	AUX
admet-337	214	5	primarily	primarily	ADV
admet-337	214	6	mediated	mediate	VERB
admet-337	214	7	by	by	ADP
admet-337	214	8	non	non	ADJ
admet-337	214	9	-	-	ADJ
admet-337	214	10	enzyme	enzyme	ADJ
admet-337	214	11	catalyzed	catalyze	VERB
admet-337	214	12	michael	michael	PROPN
admet-337	214	13	adduct	adduct	VERB
admet-337	214	14	formation	formation	NOUN
admet-337	214	15	to	to	ADP
admet-337	214	16	nucleophilic	nucleophilic	ADJ
admet-337	214	17	,	,	PUNCT
admet-337	214	18	electron	electron	NOUN
admet-337	214	19	-	-	PUNCT
admet-337	214	20	rich	rich	ADJ
admet-337	214	21	small	small	ADJ
admet-337	214	22	molecules	molecule	NOUN
admet-337	214	23	and	and	CCONJ
admet-337	214	24	proteins	protein	NOUN
admet-337	214	25	.	.	PUNCT
admet-337	215	1	however	however	ADV
admet-337	215	2	,	,	PUNCT
admet-337	215	3	89	89	NUM
admet-337	215	4	%	%	NOUN
admet-337	215	5	of	of	ADP
admet-337	215	6	afatinib	afatinib	NOUN
admet-337	215	7	is	be	AUX
admet-337	215	8	excreted	excrete	VERB
admet-337	215	9	as	as	ADP
admet-337	215	10	the	the	DET
admet-337	215	11	unchanged	unchanged	ADJ
admet-337	215	12	parent	parent	NOUN
admet-337	215	13	compound	compound	NOUN
admet-337	215	14	(	(	PUNCT
admet-337	215	15	85	85	NUM
admet-337	215	16	%	%	NOUN
admet-337	215	17	feces	fece	NOUN
admet-337	215	18	,	,	PUNCT
admet-337	215	19	4	4	NUM
admet-337	215	20	%	%	NOUN
admet-337	215	21	urine	urine	NOUN
admet-337	215	22	)	)	PUNCT
admet-337	216	1	[	[	X
admet-337	216	2	84	84	NUM
admet-337	216	3	]	]	PUNCT
admet-337	216	4	.	.	PUNCT
admet-337	217	1	afatinib	afatinib	PROPN
admet-337	217	2	serves	serve	VERB
admet-337	217	3	as	as	ADP
admet-337	217	4	a	a	DET
admet-337	217	5	substrate	substrate	NOUN
admet-337	217	6	and	and	CCONJ
admet-337	217	7	inhibits	inhibit	VERB
admet-337	217	8	both	both	DET
admet-337	217	9	p	p	NOUN
admet-337	217	10	-	-	PUNCT
admet-337	217	11	gp	gp	NOUN
admet-337	217	12	and	and	CCONJ
admet-337	217	13	brcp	brcp	VERB
admet-337	217	14	.	.	PUNCT
admet-337	218	1	inhibitors	inhibitor	NOUN
admet-337	218	2	of	of	ADP
admet-337	218	3	p	p	NOUN
admet-337	218	4	-	-	PUNCT
admet-337	218	5	gp	gp	NOUN
admet-337	218	6	,	,	PUNCT
admet-337	218	7	such	such	ADJ
admet-337	218	8	as	as	SCONJ
admet-337	218	9	ritonavir	ritonavir	PROPN
admet-337	218	10	can	can	AUX
admet-337	218	11	increase	increase	VERB
admet-337	218	12	concentrations	concentration	NOUN
admet-337	218	13	of	of	ADP
admet-337	218	14	afatinib	afatinib	NOUN
admet-337	218	15	,	,	PUNCT
admet-337	218	16	while	while	SCONJ
admet-337	218	17	inducers	inducer	NOUN
admet-337	218	18	of	of	ADP
admet-337	218	19	p	p	NOUN
admet-337	218	20	-	-	PUNCT
admet-337	218	21	gp	gp	NOUN
admet-337	218	22	reduce	reduce	VERB
admet-337	218	23	afatinib	afatinib	NOUN
admet-337	218	24	levels	level	NOUN
admet-337	218	25	.	.	PUNCT
admet-337	219	1	the	the	DET
admet-337	219	2	clinical	clinical	ADJ
admet-337	219	3	consequences	consequence	NOUN
admet-337	219	4	of	of	ADP
admet-337	219	5	concurrent	concurrent	ADJ
admet-337	219	6	use	use	NOUN
admet-337	219	7	of	of	ADP
admet-337	219	8	afatinib	afatinib	NOUN
admet-337	219	9	with	with	ADP
admet-337	219	10	p	p	NOUN
admet-337	219	11	-	-	PUNCT
admet-337	219	12	gp	gp	NOUN
admet-337	219	13	inducers	inducer	NOUN
admet-337	219	14	/	/	SYM
admet-337	219	15	inhibitors	inhibitor	NOUN
admet-337	219	16	are	be	AUX
admet-337	219	17	questionable	questionable	ADJ
admet-337	219	18	,	,	PUNCT
admet-337	219	19	and	and	CCONJ
admet-337	219	20	these	these	DET
admet-337	219	21	drugs	drug	NOUN
admet-337	219	22	can	can	AUX
admet-337	219	23	be	be	AUX
admet-337	219	24	administered	administer	VERB
admet-337	219	25	6	6	NUM
admet-337	219	26	-	-	SYM
admet-337	219	27	12	12	NUM
admet-337	219	28	hours	hour	NOUN
admet-337	219	29	apart	apart	ADV
admet-337	219	30	to	to	PART
admet-337	219	31	avoid	avoid	VERB
admet-337	219	32	significant	significant	ADJ
admet-337	219	33	interactions	interaction	NOUN
admet-337	219	34	[	[	X
admet-337	219	35	85	85	NUM
admet-337	219	36	]	]	PUNCT
admet-337	219	37	.	.	PUNCT
admet-337	220	1	in	in	ADP
admet-337	220	2	patients	patient	NOUN
admet-337	220	3	with	with	ADP
admet-337	220	4	renal	renal	ADJ
admet-337	220	5	impairment	impairment	NOUN
admet-337	220	6	with	with	ADP
admet-337	220	7	egfr	egfr	NOUN
admet-337	220	8	of	of	ADP
admet-337	220	9	15	15	NUM
admet-337	220	10	-	-	SYM
admet-337	220	11	29	29	NUM
admet-337	220	12	ml	ml	NOUN
admet-337	220	13	/	/	SYM
admet-337	220	14	minute/1.73	minute/1.73	PROPN
admet-337	220	15	m2	m2	PROPN
admet-337	220	16	,	,	PUNCT
admet-337	220	17	a	a	DET
admet-337	220	18	dose	dose	NOUN
admet-337	220	19	reduction	reduction	NOUN
admet-337	220	20	to	to	ADP
admet-337	220	21	30	30	NUM
admet-337	220	22	mg	mg	NOUN
admet-337	220	23	daily	daily	PROPN
admet-337	220	24	is	be	AUX
admet-337	220	25	recommended	recommend	VERB
admet-337	220	26	.	.	PUNCT
admet-337	221	1	canadian	canadian	ADJ
admet-337	221	2	labeling	labeling	NOUN
admet-337	221	3	recommends	recommend	VERB
admet-337	221	4	against	against	ADP
admet-337	221	5	use	use	NOUN
admet-337	221	6	of	of	ADP
admet-337	221	7	afatinib	afatinib	NOUN
admet-337	221	8	if	if	SCONJ
admet-337	221	9	crcl	crcl	NOUN
admet-337	221	10	is	be	AUX
admet-337	221	11	less	less	ADJ
admet-337	221	12	than	than	ADP
admet-337	221	13	30	30	NUM
admet-337	221	14	ml	ml	NOUN
admet-337	221	15	/	/	SYM
admet-337	221	16	min	min	NOUN
admet-337	221	17	.	.	PUNCT
admet-337	222	1	the	the	DET
admet-337	222	2	drug	drug	NOUN
admet-337	222	3	has	have	AUX
admet-337	222	4	not	not	PART
admet-337	222	5	been	be	AUX
admet-337	222	6	well	well	ADV
admet-337	222	7	-	-	PUNCT
admet-337	222	8	studied	study	VERB
admet-337	222	9	in	in	ADP
admet-337	222	10	patients	patient	NOUN
admet-337	222	11	undergoing	undergo	VERB
admet-337	222	12	hemodialysis	hemodialysis	NOUN
admet-337	222	13	.	.	PUNCT
admet-337	223	1	caution	caution	NOUN
admet-337	223	2	is	be	AUX
admet-337	223	3	advised	advise	VERB
admet-337	223	4	in	in	ADP
admet-337	223	5	patients	patient	NOUN
admet-337	223	6	with	with	ADP
admet-337	223	7	hepatic	hepatic	ADJ
admet-337	223	8	impairment	impairment	NOUN
admet-337	223	9	,	,	PUNCT
admet-337	223	10	but	but	CCONJ
admet-337	223	11	no	no	DET
admet-337	223	12	specific	specific	ADJ
admet-337	223	13	dose	dose	NOUN
admet-337	223	14	adjustments	adjustment	NOUN
admet-337	223	15	are	be	AUX
admet-337	223	16	recommended	recommend	VERB
admet-337	223	17	.	.	PUNCT
admet-337	224	1	canadian	canadian	ADJ
admet-337	224	2	labeling	labeling	NOUN
admet-337	224	3	advises	advise	VERB
admet-337	224	4	against	against	ADP
admet-337	224	5	grace	grace	NOUN
admet-337	224	6	dy	dy	NOUN
admet-337	224	7	et	et	PROPN
admet-337	224	8	al	al	PROPN
admet-337	224	9	.	.	PROPN
admet-337	224	10	admet	admet	PROPN
admet-337	224	11	&	&	CCONJ
admet-337	224	12	dmpk	dmpk	PROPN
admet-337	224	13	4(3	4(3	NUM
admet-337	224	14	)	)	PUNCT
admet-337	224	15	(	(	PUNCT
admet-337	224	16	2016	2016	NUM
admet-337	224	17	)	)	PUNCT
admet-337	224	18	186	186	NUM
admet-337	224	19	-	-	SYM
admet-337	224	20	211	211	NUM
admet-337	224	21	194	194	NUM
admet-337	224	22	afatinib	afatinib	NOUN
admet-337	224	23	use	use	NOUN
admet-337	224	24	in	in	ADP
admet-337	224	25	patients	patient	NOUN
admet-337	224	26	with	with	ADP
admet-337	224	27	child	child	NOUN
admet-337	224	28	-	-	PUNCT
admet-337	224	29	pugh	pugh	PROPN
admet-337	224	30	class	class	PROPN
admet-337	224	31	c	c	PROPN
admet-337	224	32	cirrhosis	cirrhosis	NOUN
admet-337	224	33	.	.	PUNCT
admet-337	225	1	cns	cns	NOUN
admet-337	225	2	penetration	penetration	NOUN
admet-337	225	3	the	the	DET
admet-337	225	4	lux	lux	NOUN
admet-337	225	5	-	-	PUNCT
admet-337	225	6	lung	lung	NOUN
admet-337	225	7	trials	trial	NOUN
admet-337	225	8	allowed	allow	VERB
admet-337	225	9	enrollment	enrollment	NOUN
admet-337	225	10	of	of	ADP
admet-337	225	11	patients	patient	NOUN
admet-337	225	12	with	with	ADP
admet-337	225	13	stable	stable	ADJ
admet-337	225	14	brain	brain	NOUN
admet-337	225	15	metastases	metastasis	NOUN
admet-337	225	16	.	.	PUNCT
admet-337	226	1	the	the	DET
admet-337	226	2	lux	lux	VERB
admet-337	226	3	-	-	PUNCT
admet-337	226	4	lung	lung	NOUN
admet-337	226	5	3	3	NUM
admet-337	226	6	trial	trial	NOUN
admet-337	226	7	enrolled	enrol	VERB
admet-337	226	8	35	35	NUM
admet-337	226	9	patients	patient	NOUN
admet-337	226	10	with	with	ADP
admet-337	226	11	brain	brain	NOUN
admet-337	226	12	metastases	metastasis	NOUN
admet-337	226	13	who	who	PRON
admet-337	226	14	were	be	AUX
admet-337	226	15	treated	treat	VERB
admet-337	226	16	with	with	ADP
admet-337	226	17	either	either	CCONJ
admet-337	226	18	first	first	ADJ
admet-337	226	19	-	-	PUNCT
admet-337	226	20	line	line	NOUN
admet-337	226	21	afatinib	afatinib	NOUN
admet-337	226	22	or	or	CCONJ
admet-337	226	23	cisplatin	cisplatin	NOUN
admet-337	226	24	and	and	CCONJ
admet-337	226	25	pemetrexed	pemetrexed	NOUN
admet-337	226	26	.	.	PUNCT
admet-337	227	1	the	the	DET
admet-337	227	2	median	median	PROPN
admet-337	227	3	pfs	pfs	PROPN
admet-337	227	4	was	be	AUX
admet-337	227	5	11.1	11.1	NUM
admet-337	227	6	months	month	NOUN
admet-337	227	7	in	in	ADP
admet-337	227	8	the	the	DET
admet-337	227	9	afatinib	afatinib	NOUN
admet-337	227	10	group	group	NOUN
admet-337	227	11	and	and	CCONJ
admet-337	227	12	5.4	5.4	NUM
admet-337	227	13	months	month	NOUN
admet-337	227	14	in	in	ADP
admet-337	227	15	the	the	DET
admet-337	227	16	chemotherapy	chemotherapy	NOUN
admet-337	227	17	group	group	NOUN
admet-337	227	18	(	(	PUNCT
admet-337	227	19	hr	hr	NOUN
admet-337	227	20	,	,	PUNCT
admet-337	227	21	0.52	0.52	NUM
admet-337	227	22	;	;	PUNCT
admet-337	227	23	p=0.13	p=0.13	NOUN
admet-337	227	24	)	)	PUNCT
admet-337	227	25	.	.	PUNCT
admet-337	228	1	in	in	ADP
admet-337	228	2	an	an	DET
admet-337	228	3	analysis	analysis	NOUN
admet-337	228	4	541	541	NUM
admet-337	228	5	patients	patient	NOUN
admet-337	228	6	treated	treat	VERB
admet-337	228	7	on	on	ADP
admet-337	228	8	the	the	DET
admet-337	228	9	afatinib	afatinib	NOUN
admet-337	228	10	compassionate	compassionate	ADJ
admet-337	228	11	use	use	NOUN
admet-337	228	12	program	program	NOUN
admet-337	228	13	,	,	PUNCT
admet-337	228	14	100	100	NUM
admet-337	228	15	patients	patient	NOUN
admet-337	228	16	who	who	PRON
admet-337	228	17	had	have	VERB
admet-337	228	18	brain	brain	NOUN
admet-337	228	19	or	or	CCONJ
admet-337	228	20	leptomeningeal	leptomeningeal	NOUN
admet-337	228	21	metastases	metastasis	NOUN
admet-337	228	22	were	be	AUX
admet-337	228	23	identified	identify	VERB
admet-337	228	24	(	(	PUNCT
admet-337	228	25	74	74	NUM
admet-337	228	26	%	%	NOUN
admet-337	228	27	had	have	AUX
admet-337	228	28	documented	document	VERB
admet-337	228	29	egfr	egfr	NOUN
admet-337	228	30	activating	activate	VERB
admet-337	228	31	mutation	mutation	NOUN
admet-337	228	32	)	)	PUNCT
admet-337	228	33	.	.	PUNCT
admet-337	229	1	thirty	thirty	NUM
admet-337	229	2	-	-	PUNCT
admet-337	229	3	five	five	NUM
admet-337	229	4	percent	percent	NOUN
admet-337	229	5	of	of	ADP
admet-337	229	6	evaluable	evaluable	ADJ
admet-337	229	7	patients	patient	NOUN
admet-337	229	8	developed	develop	VERB
admet-337	229	9	a	a	DET
admet-337	229	10	cns	cns	NOUN
admet-337	229	11	response	response	NOUN
admet-337	229	12	with	with	ADP
admet-337	229	13	median	median	ADJ
admet-337	229	14	duration	duration	NOUN
admet-337	229	15	response	response	NOUN
admet-337	229	16	of	of	ADP
admet-337	229	17	120	120	NUM
admet-337	229	18	days	day	NOUN
admet-337	229	19	.	.	PUNCT
admet-337	230	1	one	one	NUM
admet-337	230	2	patient	patient	NOUN
admet-337	230	3	who	who	PRON
admet-337	230	4	developed	develop	VERB
admet-337	230	5	a	a	DET
admet-337	230	6	response	response	NOUN
admet-337	230	7	on	on	ADP
admet-337	230	8	40	40	NUM
admet-337	230	9	mg	mg	NOUN
admet-337	230	10	of	of	ADP
admet-337	230	11	oral	oral	ADJ
admet-337	230	12	afatinib	afatinib	NOUN
admet-337	230	13	,	,	PUNCT
admet-337	230	14	achieved	achieve	VERB
admet-337	230	15	a	a	DET
admet-337	230	16	csf	csf	ADJ
admet-337	230	17	afatinib	afatinib	NOUN
admet-337	230	18	concentration	concentration	NOUN
admet-337	230	19	of	of	ADP
admet-337	230	20	about	about	ADV
admet-337	230	21	1	1	NUM
admet-337	230	22	nm	nm	NOUN
admet-337	230	23	[	[	X
admet-337	230	24	86	86	NUM
admet-337	230	25	]	]	PUNCT
admet-337	230	26	.	.	PUNCT
admet-337	231	1	mechanisms	mechanism	NOUN
admet-337	231	2	of	of	ADP
admet-337	231	3	resistance	resistance	NOUN
admet-337	231	4	a	a	DET
admet-337	231	5	study	study	NOUN
admet-337	231	6	evaluating	evaluate	VERB
admet-337	231	7	tumor	tumor	NOUN
admet-337	231	8	samples	sample	NOUN
admet-337	231	9	from	from	ADP
admet-337	231	10	42	42	NUM
admet-337	231	11	patients	patient	NOUN
admet-337	231	12	who	who	PRON
admet-337	231	13	experienced	experience	VERB
admet-337	231	14	disease	disease	NOUN
admet-337	231	15	progression	progression	NOUN
admet-337	231	16	on	on	ADP
admet-337	231	17	afatinib	afatinib	NOUN
admet-337	231	18	shed	shed	VERB
admet-337	231	19	light	light	NOUN
admet-337	231	20	on	on	ADP
admet-337	231	21	acquired	acquire	VERB
admet-337	231	22	resistance	resistance	NOUN
admet-337	231	23	mechanisms	mechanism	NOUN
admet-337	231	24	to	to	ADP
admet-337	231	25	afatinib	afatinib	NOUN
admet-337	231	26	.	.	PUNCT
admet-337	232	1	t790	t790	NUM
admet-337	232	2	m	m	NUM
admet-337	232	3	egfr	egfr	ADJ
admet-337	232	4	mutation	mutation	NOUN
admet-337	232	5	was	be	AUX
admet-337	232	6	detected	detect	VERB
admet-337	232	7	in	in	ADP
admet-337	232	8	47.6	47.6	NUM
admet-337	232	9	%	%	NOUN
admet-337	232	10	of	of	ADP
admet-337	232	11	specimens	specimen	NOUN
admet-337	232	12	.	.	PUNCT
admet-337	233	1	there	there	PRON
admet-337	233	2	was	be	VERB
admet-337	233	3	no	no	DET
admet-337	233	4	association	association	NOUN
admet-337	233	5	with	with	ADP
admet-337	233	6	previous	previous	ADJ
admet-337	233	7	first	first	ADJ
admet-337	233	8	-	-	PUNCT
admet-337	233	9	generation	generation	NOUN
admet-337	233	10	egfr	egfr	NOUN
admet-337	233	11	tki	tki	NOUN
admet-337	233	12	use	use	NOUN
admet-337	233	13	and	and	CCONJ
admet-337	233	14	detection	detection	NOUN
admet-337	233	15	of	of	ADP
admet-337	233	16	t790	t790	NUM
admet-337	233	17	m	m	NOUN
admet-337	233	18	after	after	ADP
admet-337	233	19	resistance	resistance	NOUN
admet-337	233	20	to	to	ADP
admet-337	233	21	afatinib	afatinib	NOUN
admet-337	233	22	.	.	PUNCT
admet-337	234	1	there	there	PRON
admet-337	234	2	were	be	VERB
admet-337	234	3	no	no	DET
admet-337	234	4	mutations	mutation	NOUN
admet-337	234	5	detected	detect	VERB
admet-337	234	6	in	in	ADP
admet-337	234	7	pik3ca	pik3ca	PROPN
admet-337	234	8	,	,	PUNCT
admet-337	234	9	her2	her2	PROPN
admet-337	234	10	,	,	PUNCT
admet-337	234	11	braf	braf	NOUN
admet-337	234	12	,	,	PUNCT
admet-337	234	13	kras	kras	PROPN
admet-337	234	14	,	,	PUNCT
admet-337	234	15	nras	nras	PROPN
admet-337	234	16	,	,	PUNCT
admet-337	234	17	mek1	mek1	NOUN
admet-337	234	18	,	,	PUNCT
admet-337	234	19	akt2	akt2	PROPN
admet-337	234	20	,	,	PUNCT
admet-337	234	21	jak2	jak2	NOUN
admet-337	234	22	or	or	CCONJ
admet-337	234	23	lbk1	lbk1	PROPN
admet-337	234	24	[	[	X
admet-337	234	25	87	87	NUM
admet-337	234	26	]	]	PUNCT
admet-337	234	27	.	.	PUNCT
admet-337	235	1	pre	pre	ADJ
admet-337	235	2	-	-	ADJ
admet-337	235	3	clinical	clinical	ADJ
admet-337	235	4	models	model	NOUN
admet-337	235	5	have	have	AUX
admet-337	235	6	suggested	suggest	VERB
admet-337	235	7	that	that	PRON
admet-337	235	8	met	meet	VERB
admet-337	235	9	amplification	amplification	NOUN
admet-337	235	10	,	,	PUNCT
admet-337	235	11	upregulation	upregulation	NOUN
admet-337	235	12	of	of	ADP
admet-337	235	13	the	the	DET
admet-337	235	14	stat3	stat3	NOUN
admet-337	235	15	pathway	pathway	NOUN
admet-337	235	16	,	,	PUNCT
admet-337	235	17	and	and	CCONJ
admet-337	235	18	fgfr1	fgfr1	NOUN
admet-337	235	19	-	-	PUNCT
admet-337	235	20	induced	induce	VERB
admet-337	235	21	survival	survival	NOUN
admet-337	235	22	signals	signal	NOUN
admet-337	235	23	contribute	contribute	VERB
admet-337	235	24	to	to	ADP
admet-337	235	25	afatinib	afatinib	PROPN
admet-337	235	26	resistance	resistance	NOUN
admet-337	236	1	[	[	X
admet-337	236	2	88	88	NUM
admet-337	236	3	-	-	SYM
admet-337	236	4	90	90	NUM
admet-337	236	5	]	]	PUNCT
admet-337	236	6	.	.	PUNCT
admet-337	237	1	osimertinib	osimertinib	NOUN
admet-337	237	2	clinical	clinical	ADJ
admet-337	237	3	efficacy	efficacy	NOUN
admet-337	237	4	osimertinib	osimertinib	NOUN
admet-337	237	5	was	be	AUX
admet-337	237	6	the	the	DET
admet-337	237	7	first	first	ADJ
admet-337	237	8	“	"	PUNCT
admet-337	237	9	third	third	ADJ
admet-337	237	10	-	-	PUNCT
admet-337	237	11	generation	generation	NOUN
admet-337	237	12	”	"	PUNCT
admet-337	237	13	egfr	egfr	NOUN
admet-337	237	14	tki	tki	PROPN
admet-337	237	15	to	to	PART
admet-337	237	16	make	make	VERB
admet-337	237	17	it	it	PRON
admet-337	237	18	to	to	ADP
admet-337	237	19	market	market	NOUN
admet-337	237	20	.	.	PUNCT
admet-337	238	1	the	the	DET
admet-337	238	2	third	third	ADJ
admet-337	238	3	generation	generation	NOUN
admet-337	238	4	tkis	tkis	NOUN
admet-337	238	5	are	be	AUX
admet-337	238	6	designed	design	VERB
admet-337	238	7	to	to	PART
admet-337	238	8	irreversibly	irreversibly	ADV
admet-337	238	9	target	target	VERB
admet-337	238	10	mutant	mutant	ADJ
admet-337	238	11	egfr	egfr	NOUN
admet-337	238	12	(	(	PUNCT
admet-337	238	13	exon	exon	NOUN
admet-337	238	14	19	19	NUM
admet-337	238	15	deletion	deletion	NOUN
admet-337	238	16	,	,	PUNCT
admet-337	238	17	l858r	l858r	NOUN
admet-337	238	18	and	and	CCONJ
admet-337	238	19	t790	t790	NUM
admet-337	238	20	m	m	NOUN
admet-337	238	21	)	)	PUNCT
admet-337	238	22	,	,	PUNCT
admet-337	238	23	while	while	SCONJ
admet-337	238	24	sparing	spare	VERB
admet-337	238	25	wildtype	wildtype	NOUN
admet-337	238	26	egfr	egfr	NOUN
admet-337	238	27	.	.	PUNCT
admet-337	239	1	in	in	ADP
admet-337	239	2	mouse	mouse	NOUN
admet-337	239	3	models	model	NOUN
admet-337	239	4	of	of	ADP
admet-337	239	5	egfr	egfr	NOUN
admet-337	239	6	-	-	PUNCT
admet-337	239	7	mutated	mutate	VERB
admet-337	239	8	nsclc	nsclc	NOUN
admet-337	239	9	,	,	PUNCT
admet-337	239	10	osimertinib	osimertinib	NOUN
admet-337	239	11	had	have	VERB
admet-337	239	12	similar	similar	ADJ
admet-337	239	13	antitumor	antitumor	NOUN
admet-337	239	14	activity	activity	NOUN
admet-337	239	15	as	as	ADP
admet-337	239	16	afatinib	afatinib	NOUN
admet-337	239	17	against	against	ADP
admet-337	239	18	l858r	l858r	NOUN
admet-337	239	19	but	but	CCONJ
admet-337	239	20	more	more	ADJ
admet-337	239	21	activity	activity	NOUN
admet-337	239	22	against	against	ADP
admet-337	239	23	t790	t790	NUM
admet-337	239	24	m	m	NOUN
admet-337	239	25	nsclc	nsclc	NOUN
admet-337	239	26	[	[	X
admet-337	239	27	91	91	NUM
admet-337	239	28	]	]	PUNCT
admet-337	239	29	.	.	PUNCT
admet-337	240	1	the	the	DET
admet-337	240	2	phase	phase	NOUN
admet-337	240	3	i	i	PRON
admet-337	240	4	component	component	NOUN
admet-337	240	5	of	of	ADP
admet-337	240	6	the	the	DET
admet-337	240	7	aura	aura	NOUN
admet-337	240	8	trial	trial	NOUN
admet-337	240	9	had	have	AUX
admet-337	240	10	dose	dose	VERB
admet-337	240	11	escalation	escalation	NOUN
admet-337	240	12	and	and	CCONJ
admet-337	240	13	expansion	expansion	NOUN
admet-337	240	14	cohorts	cohort	NOUN
admet-337	240	15	,	,	PUNCT
admet-337	240	16	which	which	PRON
admet-337	240	17	enrolled	enrol	VERB
admet-337	240	18	253	253	NUM
admet-337	240	19	patients	patient	NOUN
admet-337	240	20	with	with	ADP
admet-337	240	21	locally	locally	ADV
admet-337	240	22	advanced	advanced	ADJ
admet-337	240	23	or	or	CCONJ
admet-337	240	24	metastatic	metastatic	ADJ
admet-337	240	25	egfr	egfr	NOUN
admet-337	240	26	-	-	PUNCT
admet-337	240	27	mutated	mutate	VERB
admet-337	240	28	nsclc	nsclc	NOUN
admet-337	240	29	who	who	PRON
admet-337	240	30	had	have	VERB
admet-337	240	31	disease	disease	NOUN
admet-337	240	32	progression	progression	NOUN
admet-337	240	33	on	on	ADP
admet-337	240	34	an	an	DET
admet-337	240	35	egfr	egfr	ADJ
admet-337	240	36	tki	tki	NOUN
admet-337	240	37	.	.	PUNCT
admet-337	241	1	a	a	DET
admet-337	241	2	total	total	NOUN
admet-337	241	3	of	of	ADP
admet-337	241	4	127	127	NUM
admet-337	241	5	(	(	PUNCT
admet-337	241	6	50.2	50.2	NUM
admet-337	241	7	%	%	NOUN
admet-337	241	8	)	)	PUNCT
admet-337	242	1	patients	patient	NOUN
admet-337	242	2	were	be	AUX
admet-337	242	3	confirmed	confirm	VERB
admet-337	242	4	to	to	PART
admet-337	242	5	have	have	VERB
admet-337	242	6	the	the	DET
admet-337	242	7	t790	t790	NUM
admet-337	242	8	m	m	NOUN
admet-337	242	9	mutation	mutation	NOUN
admet-337	242	10	.	.	PUNCT
admet-337	243	1	in	in	ADP
admet-337	243	2	all	all	DET
admet-337	243	3	patients	patient	NOUN
admet-337	243	4	,	,	PUNCT
admet-337	243	5	the	the	DET
admet-337	243	6	response	response	NOUN
admet-337	243	7	rate	rate	NOUN
admet-337	243	8	to	to	ADP
admet-337	243	9	osimertinib	osimertinib	NOUN
admet-337	243	10	was	be	AUX
admet-337	243	11	51	51	NUM
admet-337	243	12	%	%	NOUN
admet-337	243	13	.	.	PUNCT
admet-337	244	1	in	in	ADP
admet-337	244	2	patients	patient	NOUN
admet-337	244	3	harboring	harbor	VERB
admet-337	244	4	a	a	DET
admet-337	244	5	t790	t790	NUM
admet-337	244	6	m	m	NOUN
admet-337	244	7	mutation	mutation	NOUN
admet-337	244	8	,	,	PUNCT
admet-337	244	9	the	the	DET
admet-337	244	10	response	response	NOUN
admet-337	244	11	rate	rate	NOUN
admet-337	244	12	to	to	ADP
admet-337	244	13	osimertinib	osimertinib	NOUN
admet-337	244	14	was	be	AUX
admet-337	244	15	61	61	NUM
admet-337	244	16	%	%	NOUN
admet-337	244	17	,	,	PUNCT
admet-337	244	18	but	but	CCONJ
admet-337	244	19	in	in	ADP
admet-337	244	20	patients	patient	NOUN
admet-337	244	21	without	without	ADP
admet-337	244	22	detectable	detectable	ADJ
admet-337	244	23	t790	t790	NUM
admet-337	244	24	m	m	NOUN
admet-337	244	25	,	,	PUNCT
admet-337	244	26	the	the	DET
admet-337	244	27	response	response	NOUN
admet-337	244	28	rate	rate	NOUN
admet-337	244	29	was	be	AUX
admet-337	244	30	only	only	ADV
admet-337	244	31	21	21	NUM
admet-337	244	32	%	%	NOUN
admet-337	244	33	.	.	PUNCT
admet-337	245	1	the	the	DET
admet-337	245	2	median	median	PROPN
admet-337	245	3	pfs	pfs	PROPN
admet-337	245	4	in	in	ADP
admet-337	245	5	t790m	t790m	ADJ
admet-337	245	6	-	-	PUNCT
admet-337	245	7	positive	positive	ADJ
admet-337	245	8	patients	patient	NOUN
admet-337	245	9	was	be	AUX
admet-337	245	10	9.6	9.6	NUM
admet-337	245	11	months	month	NOUN
admet-337	245	12	and	and	CCONJ
admet-337	245	13	2.8	2.8	NUM
admet-337	245	14	months	month	NOUN
admet-337	245	15	in	in	ADP
admet-337	245	16	t790m	t790m	ADJ
admet-337	245	17	-	-	PUNCT
admet-337	245	18	negative	negative	ADJ
admet-337	245	19	patients	patient	NOUN
admet-337	245	20	[	[	X
admet-337	245	21	12	12	NUM
admet-337	245	22	]	]	PUNCT
admet-337	245	23	.	.	PUNCT
admet-337	246	1	preliminary	preliminary	ADJ
admet-337	246	2	data	datum	NOUN
admet-337	246	3	from	from	ADP
admet-337	246	4	the	the	DET
admet-337	246	5	201	201	NUM
admet-337	246	6	patients	patient	NOUN
admet-337	246	7	enrolled	enrol	VERB
admet-337	246	8	in	in	ADP
admet-337	246	9	the	the	DET
admet-337	246	10	phase	phase	NOUN
admet-337	246	11	ii	ii	NOUN
admet-337	246	12	extension	extension	NOUN
admet-337	246	13	of	of	ADP
admet-337	246	14	aura	aura	NOUN
admet-337	246	15	demonstrated	demonstrate	VERB
admet-337	246	16	an	an	DET
admet-337	246	17	orr	orr	NOUN
admet-337	246	18	of	of	ADP
admet-337	246	19	58	58	NUM
admet-337	246	20	%	%	NOUN
admet-337	246	21	.	.	PUNCT
admet-337	247	1	the	the	DET
admet-337	247	2	phase	phase	NOUN
admet-337	247	3	ii	ii	PROPN
admet-337	247	4	aura2	aura2	PROPN
admet-337	247	5	trial	trial	NOUN
admet-337	247	6	also	also	ADV
admet-337	247	7	has	have	VERB
admet-337	247	8	preliminary	preliminary	ADJ
admet-337	247	9	data	datum	NOUN
admet-337	247	10	demonstrating	demonstrate	VERB
admet-337	247	11	a	a	DET
admet-337	247	12	64	64	NUM
admet-337	247	13	%	%	NOUN
admet-337	247	14	orr	orr	NOUN
admet-337	247	15	with	with	ADP
admet-337	247	16	osimertinib	osimertinib	NOUN
admet-337	247	17	.	.	PUNCT
admet-337	248	1	both	both	DET
admet-337	248	2	phase	phase	NOUN
admet-337	248	3	ii	ii	PROPN
admet-337	248	4	trials	trial	NOUN
admet-337	248	5	have	have	AUX
admet-337	248	6	not	not	PART
admet-337	248	7	yet	yet	ADV
admet-337	248	8	reached	reach	VERB
admet-337	248	9	sufficient	sufficient	ADJ
admet-337	248	10	maturity	maturity	NOUN
admet-337	248	11	to	to	PART
admet-337	248	12	determine	determine	VERB
admet-337	248	13	a	a	DET
admet-337	248	14	median	median	ADJ
admet-337	248	15	pfs	pfs	NOUN
admet-337	248	16	[	[	X
admet-337	248	17	92	92	NUM
admet-337	248	18	]	]	PUNCT
admet-337	248	19	.	.	PUNCT
admet-337	249	1	in	in	ADP
admet-337	249	2	november	november	PROPN
admet-337	249	3	2015	2015	NUM
admet-337	249	4	,	,	PUNCT
admet-337	249	5	osimertinib	osimertinib	NOUN
admet-337	249	6	was	be	AUX
admet-337	249	7	granted	grant	VERB
admet-337	249	8	accelerated	accelerated	AUX
admet-337	249	9	fda	fda	PROPN
admet-337	249	10	approval	approval	NOUN
admet-337	249	11	for	for	ADP
admet-337	249	12	treatment	treatment	NOUN
admet-337	249	13	of	of	ADP
admet-337	249	14	egfr	egfr	NOUN
admet-337	249	15	-	-	PUNCT
admet-337	249	16	mutated	mutate	VERB
admet-337	249	17	nsclc	nsclc	NOUN
admet-337	249	18	that	that	PRON
admet-337	249	19	has	have	AUX
admet-337	249	20	progressed	progress	VERB
admet-337	249	21	on	on	ADP
admet-337	249	22	a	a	DET
admet-337	249	23	previous	previous	ADJ
admet-337	249	24	egfr	egfr	NOUN
admet-337	249	25	tki	tki	PROPN
admet-337	249	26	.	.	PUNCT
admet-337	249	27	osimertinib	osimertinib	NOUN
admet-337	249	28	is	be	AUX
admet-337	249	29	currently	currently	ADV
admet-337	249	30	in	in	ADP
admet-337	249	31	phase	phase	NOUN
admet-337	249	32	iii	iii	NUM
admet-337	249	33	development	development	NOUN
admet-337	249	34	for	for	ADP
admet-337	249	35	adjuvant	adjuvant	ADJ
admet-337	249	36	treatment	treatment	NOUN
admet-337	249	37	as	as	ADV
admet-337	249	38	well	well	ADV
admet-337	249	39	as	as	ADP
admet-337	249	40	firstand	firstand	NOUN
admet-337	249	41	secondline	secondline	PROPN
admet-337	249	42	treatment	treatment	NOUN
admet-337	249	43	of	of	ADP
admet-337	249	44	advanced	advanced	ADJ
admet-337	249	45	egfr	egfr	NOUN
admet-337	249	46	-	-	PUNCT
admet-337	249	47	mutated	mutate	VERB
admet-337	249	48	nsclc	nsclc	NOUN
admet-337	249	49	.	.	PUNCT
admet-337	250	1	clinical	clinical	ADJ
admet-337	250	2	safety	safety	NOUN
admet-337	250	3	overall	overall	ADJ
admet-337	250	4	,	,	PUNCT
admet-337	250	5	osimertinib	osimertinib	NOUN
admet-337	250	6	is	be	AUX
admet-337	250	7	well	well	ADV
admet-337	250	8	-	-	PUNCT
admet-337	250	9	tolerated	tolerate	VERB
admet-337	250	10	.	.	PUNCT
admet-337	251	1	all	all	DET
admet-337	251	2	-	-	PUNCT
admet-337	251	3	grade	grade	NOUN
admet-337	251	4	diarrhea	diarrhea	NOUN
admet-337	251	5	occurs	occur	VERB
admet-337	251	6	in	in	ADP
admet-337	251	7	42	42	NUM
admet-337	251	8	%	%	NOUN
admet-337	251	9	of	of	ADP
admet-337	251	10	patients	patient	NOUN
admet-337	251	11	,	,	PUNCT
admet-337	251	12	with	with	ADP
admet-337	251	13	only	only	ADV
admet-337	251	14	1	1	NUM
admet-337	251	15	%	%	NOUN
admet-337	251	16	experiencing	experience	VERB
admet-337	251	17	grade	grade	NOUN
admet-337	251	18	3	3	NUM
admet-337	251	19	or	or	CCONJ
admet-337	251	20	4	4	NUM
admet-337	251	21	diarrhea	diarrhea	NOUN
admet-337	251	22	.	.	PUNCT
admet-337	252	1	similarly	similarly	ADV
admet-337	252	2	41	41	NUM
admet-337	252	3	%	%	NOUN
admet-337	252	4	of	of	ADP
admet-337	252	5	patients	patient	NOUN
admet-337	252	6	will	will	AUX
admet-337	252	7	experience	experience	VERB
admet-337	252	8	a	a	DET
admet-337	252	9	rash	rash	NOUN
admet-337	252	10	but	but	CCONJ
admet-337	252	11	only	only	ADV
admet-337	252	12	0.5	0.5	NUM
admet-337	252	13	%	%	NOUN
admet-337	252	14	will	will	AUX
admet-337	252	15	develop	develop	VERB
admet-337	252	16	grade	grade	NOUN
admet-337	252	17	3	3	NUM
admet-337	252	18	or	or	CCONJ
admet-337	252	19	4	4	NUM
admet-337	252	20	rash	rash	ADJ
admet-337	252	21	.	.	PUNCT
admet-337	253	1	dose	dose	NOUN
admet-337	253	2	reductions	reduction	NOUN
admet-337	253	3	are	be	AUX
admet-337	253	4	necessary	necessary	ADJ
admet-337	253	5	in	in	ADP
admet-337	253	6	only	only	ADV
admet-337	253	7	4	4	NUM
admet-337	253	8	%	%	NOUN
admet-337	253	9	of	of	ADP
admet-337	253	10	patient	patient	NOUN
admet-337	253	11	on	on	ADP
admet-337	253	12	osimertinib	osimertinib	NOUN
admet-337	253	13	.	.	PUNCT
admet-337	254	1	prolongation	prolongation	NOUN
admet-337	254	2	of	of	ADP
admet-337	254	3	the	the	DET
admet-337	254	4	qtc	qtc	PROPN
admet-337	254	5	interval	interval	NOUN
admet-337	254	6	was	be	AUX
admet-337	254	7	the	the	DET
admet-337	254	8	most	most	ADV
admet-337	254	9	common	common	ADJ
admet-337	254	10	reason	reason	NOUN
admet-337	254	11	for	for	ADP
admet-337	254	12	dose	dose	NOUN
admet-337	254	13	reduction	reduction	NOUN
admet-337	254	14	,	,	PUNCT
admet-337	254	15	and	and	CCONJ
admet-337	254	16	occurred	occur	VERB
admet-337	254	17	in	in	ADP
admet-337	254	18	2.2	2.2	NUM
admet-337	254	19	%	%	NOUN
admet-337	254	20	of	of	ADP
admet-337	254	21	patients	patient	NOUN
admet-337	254	22	.	.	PUNCT
admet-337	255	1	as	as	ADP
admet-337	255	2	with	with	ADP
admet-337	255	3	other	other	ADJ
admet-337	255	4	egfr	egfr	ADJ
admet-337	255	5	tkis	tkis	NOUN
admet-337	255	6	,	,	PUNCT
admet-337	255	7	fatal	fatal	ADJ
admet-337	255	8	pneumonitis	pneumonitis	NOUN
admet-337	255	9	has	have	AUX
admet-337	255	10	occurred	occur	VERB
admet-337	255	11	in	in	ADP
admet-337	255	12	patients	patient	NOUN
admet-337	255	13	with	with	ADP
admet-337	255	14	osimertinib	osimertinib	NOUN
admet-337	255	15	but	but	CCONJ
admet-337	255	16	is	be	AUX
admet-337	255	17	rare	rare	ADJ
admet-337	255	18	admet	admet	NOUN
admet-337	255	19	&	&	CCONJ
admet-337	255	20	dmpk	dmpk	PROPN
admet-337	255	21	4(3	4(3	NUM
admet-337	255	22	)	)	PUNCT
admet-337	255	23	(	(	PUNCT
admet-337	255	24	2016	2016	NUM
admet-337	255	25	)	)	PUNCT
admet-337	255	26	186	186	NUM
admet-337	255	27	-	-	SYM
admet-337	255	28	211	211	NUM
admet-337	255	29	tki	tki	NOUN
admet-337	255	30	for	for	ADP
admet-337	255	31	egfrand	egfrand	ADJ
admet-337	255	32	alk	alk	PROPN
admet-337	255	33	-	-	PUNCT
admet-337	255	34	mutated	mutate	VERB
admet-337	255	35	cell	cell	NOUN
admet-337	255	36	cancer	cancer	NOUN
admet-337	255	37	doi	doi	NOUN
admet-337	255	38	:	:	PUNCT
admet-337	255	39	10.5599	10.5599	NUM
admet-337	255	40	/	/	SYM
admet-337	255	41	admet.4.3.337	admet.4.3.337	CCONJ
admet-337	255	42	195	195	NUM
admet-337	255	43	(	(	PUNCT
admet-337	255	44	1	1	NUM
admet-337	255	45	%	%	NOUN
admet-337	255	46	)	)	PUNCT
admet-337	255	47	.	.	PUNCT
admet-337	256	1	fatal	fatal	ADJ
admet-337	256	2	stroke	stroke	NOUN
admet-337	256	3	and	and	CCONJ
admet-337	256	4	pneumonias	pneumonia	NOUN
admet-337	256	5	have	have	AUX
admet-337	256	6	also	also	ADV
admet-337	256	7	occurred	occur	VERB
admet-337	256	8	in	in	ADP
admet-337	256	9	patients	patient	NOUN
admet-337	256	10	on	on	ADP
admet-337	256	11	the	the	DET
admet-337	256	12	drug	drug	NOUN
admet-337	256	13	.	.	PUNCT
admet-337	257	1	cardiomyopathy	cardiomyopathy	ADJ
admet-337	257	2	,	,	PUNCT
admet-337	257	3	with	with	ADP
admet-337	257	4	a	a	DET
admet-337	257	5	decline	decline	NOUN
admet-337	257	6	in	in	ADP
admet-337	257	7	left	left	ADJ
admet-337	257	8	ventricular	ventricular	ADJ
admet-337	257	9	function	function	NOUN
admet-337	257	10	by	by	ADP
admet-337	257	11	>	>	PROPN
admet-337	257	12	10	10	NUM
admet-337	257	13	%	%	NOUN
admet-337	257	14	was	be	AUX
admet-337	257	15	also	also	ADV
admet-337	257	16	rarely	rarely	ADV
admet-337	257	17	encountered	encounter	VERB
admet-337	257	18	.	.	PUNCT
admet-337	258	1	discontinuation	discontinuation	NOUN
admet-337	258	2	of	of	ADP
admet-337	258	3	osimertinib	osimertinib	NOUN
admet-337	258	4	,	,	PUNCT
admet-337	258	5	due	due	ADJ
admet-337	258	6	mostly	mostly	ADV
admet-337	258	7	to	to	ADP
admet-337	258	8	pneumonitis	pneumonitis	NOUN
admet-337	258	9	and	and	CCONJ
admet-337	258	10	stroke	stroke	NOUN
admet-337	258	11	,	,	PUNCT
admet-337	258	12	was	be	AUX
admet-337	258	13	necessary	necessary	ADJ
admet-337	258	14	in	in	ADP
admet-337	258	15	5.6	5.6	NUM
admet-337	258	16	%	%	NOUN
admet-337	258	17	of	of	ADP
admet-337	258	18	patients	patient	NOUN
admet-337	258	19	enrolled	enrol	VERB
admet-337	258	20	in	in	ADP
admet-337	258	21	the	the	DET
admet-337	258	22	key	key	ADJ
admet-337	258	23	clinical	clinical	ADJ
admet-337	258	24	trials	trial	NOUN
admet-337	258	25	to	to	ADP
admet-337	258	26	date	date	NOUN
admet-337	258	27	[	[	X
admet-337	258	28	12,92,93	12,92,93	NUM
admet-337	258	29	]	]	PUNCT
admet-337	258	30	.	.	PUNCT
admet-337	259	1	pharmacology	pharmacology	NOUN
admet-337	259	2	osimertinib	osimertinib	PROPN
admet-337	259	3	,	,	PUNCT
admet-337	259	4	n-[2-[2-(dimethylamino)ethyl	n-[2-[2-(dimethylamino)ethyl	PROPN
admet-337	259	5	-	-	PUNCT
admet-337	259	6	methylamino]-4	methylamino]-4	PROPN
admet-337	259	7	-	-	PUNCT
admet-337	259	8	methoxy-5-[[4-(1	methoxy-5-[[4-(1	NOUN
admet-337	259	9	-	-	PUNCT
admet-337	259	10	methylindol-3	methylindol-3	NOUN
admet-337	259	11	-	-	PUNCT
admet-337	259	12	yl)-pyrimidin-2	yl)-pyrimidin-2	NOUN
admet-337	259	13	-	-	PUNCT
admet-337	259	14	yl]amino]phenyl]prop-2	yl]amino]phenyl]prop-2	NOUN
admet-337	259	15	-	-	PUNCT
admet-337	259	16	enamide	enamide	NOUN
admet-337	260	1	[	[	X
admet-337	260	2	azd-9291	azd-9291	NOUN
admet-337	260	3	,	,	PUNCT
admet-337	260	4	tagrisso	tagrisso	PROPN
admet-337	260	5	,	,	PUNCT
admet-337	260	6	(	(	PUNCT
admet-337	260	7	astrazeneca	astrazeneca	NOUN
admet-337	260	8	)	)	PUNCT
admet-337	260	9	]	]	PUNCT
admet-337	260	10	,	,	PUNCT
admet-337	260	11	irreversibly	irreversibly	ADV
admet-337	260	12	inhibits	inhibit	VERB
admet-337	260	13	mutated	mutate	VERB
admet-337	260	14	egfr	egfr	ADV
admet-337	260	15	by	by	ADP
admet-337	260	16	covalently	covalently	ADV
admet-337	260	17	bonding	bonding	NOUN
admet-337	260	18	with	with	ADP
admet-337	260	19	the	the	DET
admet-337	260	20	cysteine-797	cysteine-797	ADJ
admet-337	260	21	residue	residue	NOUN
admet-337	260	22	in	in	ADP
admet-337	260	23	the	the	DET
admet-337	260	24	atp	atp	NOUN
admet-337	260	25	binding	bind	VERB
admet-337	260	26	site	site	NOUN
admet-337	260	27	.	.	PUNCT
admet-337	261	1	the	the	DET
admet-337	261	2	drug	drug	NOUN
admet-337	261	3	’s	’s	PART
admet-337	261	4	affinity	affinity	NOUN
admet-337	261	5	for	for	ADP
admet-337	261	6	t790	t790	NUM
admet-337	261	7	m	m	NOUN
admet-337	261	8	may	may	AUX
admet-337	261	9	be	be	AUX
admet-337	261	10	related	relate	VERB
admet-337	261	11	to	to	AUX
admet-337	261	12	hydrophobic	hydrophobic	VERB
admet-337	261	13	interactions	interaction	NOUN
admet-337	261	14	between	between	ADP
admet-337	261	15	the	the	DET
admet-337	261	16	methionine	methionine	NOUN
admet-337	261	17	moiety	moiety	NOUN
admet-337	261	18	on	on	ADP
admet-337	261	19	t790m	t790m	PROPN
admet-337	261	20	-	-	PUNCT
admet-337	261	21	mutated	mutate	VERB
admet-337	261	22	egfr	egfr	NOUN
admet-337	261	23	and	and	CCONJ
admet-337	261	24	the	the	DET
admet-337	261	25	pyrimidine	pyrimidine	NOUN
admet-337	261	26	component	component	NOUN
admet-337	261	27	of	of	ADP
admet-337	261	28	osimertinib	osimertinib	NOUN
admet-337	261	29	.	.	PUNCT
admet-337	262	1	it	it	PRON
admet-337	262	2	has	have	VERB
admet-337	262	3	nearly	nearly	ADV
admet-337	262	4	200	200	NUM
admet-337	262	5	-	-	NUM
admet-337	262	6	fold	fold	VERB
admet-337	262	7	greater	great	ADJ
admet-337	262	8	affinity	affinity	NOUN
admet-337	262	9	for	for	ADP
admet-337	262	10	egfr	egfr	NOUN
admet-337	262	11	with	with	ADP
admet-337	262	12	l858r	l858r	PROPN
admet-337	262	13	/	/	SYM
admet-337	262	14	t790	t790	NUM
admet-337	262	15	m	m	NOUN
admet-337	262	16	mutation	mutation	NOUN
admet-337	262	17	than	than	ADP
admet-337	262	18	wild	wild	ADJ
admet-337	262	19	-	-	PUNCT
admet-337	262	20	type	type	NOUN
admet-337	262	21	egfr	egfr	NOUN
admet-337	262	22	in	in	ADP
admet-337	262	23	vitro	vitro	X
admet-337	262	24	[	[	X
admet-337	262	25	91	91	NUM
admet-337	262	26	]	]	PUNCT
admet-337	262	27	.	.	PUNCT
admet-337	263	1	osimertinib	osimertinib	NOUN
admet-337	263	2	also	also	ADV
admet-337	263	3	inhibits	inhibit	VERB
admet-337	263	4	her2	her2	PROPN
admet-337	263	5	,	,	PUNCT
admet-337	263	6	her3	her3	PROPN
admet-337	263	7	,	,	PUNCT
admet-337	263	8	her4	her4	PROPN
admet-337	263	9	,	,	PUNCT
admet-337	263	10	ack1	ack1	PROPN
admet-337	263	11	and	and	CCONJ
admet-337	263	12	blk	blk	NOUN
admet-337	263	13	in	in	ADP
admet-337	263	14	vitro	vitro	X
admet-337	263	15	[	[	X
admet-337	263	16	94	94	NUM
admet-337	263	17	]	]	PUNCT
admet-337	263	18	.	.	PUNCT
admet-337	264	1	the	the	DET
admet-337	264	2	manufacturer	manufacturer	NOUN
admet-337	264	3	-	-	PUNCT
admet-337	264	4	recommended	recommend	VERB
admet-337	264	5	oral	oral	ADJ
admet-337	264	6	dose	dose	NOUN
admet-337	264	7	of	of	ADP
admet-337	264	8	osimertinib	osimertinib	NOUN
admet-337	264	9	is	be	AUX
admet-337	264	10	80	80	NUM
admet-337	264	11	mg	mg	NOUN
admet-337	264	12	daily	daily	ADV
admet-337	264	13	.	.	PUNCT
admet-337	265	1	antacids	antacid	NOUN
admet-337	265	2	do	do	AUX
admet-337	265	3	not	not	PART
admet-337	265	4	impact	impact	VERB
admet-337	265	5	drug	drug	NOUN
admet-337	265	6	absorption	absorption	NOUN
admet-337	265	7	.	.	PUNCT
admet-337	266	1	intake	intake	NOUN
admet-337	266	2	of	of	ADP
admet-337	266	3	high	high	ADJ
admet-337	266	4	fat	fat	ADJ
admet-337	266	5	foods	food	NOUN
admet-337	266	6	prior	prior	ADV
admet-337	266	7	to	to	ADP
admet-337	266	8	osimertinib	osimertinib	NOUN
admet-337	266	9	administration	administration	NOUN
admet-337	266	10	mildly	mildly	ADV
admet-337	266	11	increases	increase	VERB
admet-337	266	12	osimertinib	osimertinib	NOUN
admet-337	266	13	plasma	plasma	NOUN
admet-337	266	14	concentration	concentration	NOUN
admet-337	266	15	by	by	ADP
admet-337	266	16	about	about	ADV
admet-337	266	17	14	14	NUM
admet-337	266	18	%	%	NOUN
admet-337	266	19	[	[	X
admet-337	266	20	95	95	NUM
admet-337	266	21	]	]	PUNCT
admet-337	266	22	.	.	PUNCT
admet-337	267	1	after	after	ADP
admet-337	267	2	administration	administration	NOUN
admet-337	267	3	,	,	PUNCT
admet-337	267	4	maximum	maximum	ADJ
admet-337	267	5	plasma	plasma	NOUN
admet-337	267	6	concentration	concentration	NOUN
admet-337	267	7	is	be	AUX
admet-337	267	8	reached	reach	VERB
admet-337	267	9	in	in	ADP
admet-337	267	10	approximately	approximately	ADV
admet-337	267	11	6	6	NUM
admet-337	267	12	hours	hour	NOUN
admet-337	267	13	,	,	PUNCT
admet-337	267	14	the	the	DET
admet-337	267	15	volume	volume	NOUN
admet-337	267	16	of	of	ADP
admet-337	267	17	distribution	distribution	NOUN
admet-337	267	18	is	be	AUX
admet-337	267	19	986	986	NUM
admet-337	267	20	l	l	NOUN
admet-337	267	21	,	,	PUNCT
admet-337	267	22	and	and	CCONJ
admet-337	267	23	the	the	DET
admet-337	267	24	half	half	ADJ
admet-337	267	25	-	-	PUNCT
admet-337	267	26	life	life	NOUN
admet-337	267	27	is	be	AUX
admet-337	267	28	48	48	NUM
admet-337	267	29	hours	hour	NOUN
admet-337	268	1	[	[	X
admet-337	268	2	12,94	12,94	NUM
admet-337	268	3	]	]	X
admet-337	268	4	.	.	PUNCT
admet-337	269	1	metabolism	metabolism	NOUN
admet-337	269	2	primarily	primarily	ADV
admet-337	269	3	occurs	occur	VERB
admet-337	269	4	via	via	ADP
admet-337	269	5	oxidation	oxidation	NOUN
admet-337	269	6	in	in	ADP
admet-337	269	7	the	the	DET
admet-337	269	8	liver	liver	NOUN
admet-337	269	9	through	through	ADP
admet-337	269	10	cyp3a4	cyp3a4	PROPN
admet-337	269	11	.	.	PUNCT
admet-337	270	1	the	the	DET
admet-337	270	2	two	two	NUM
admet-337	270	3	active	active	ADJ
admet-337	270	4	metabolites	metabolite	NOUN
admet-337	270	5	of	of	ADP
admet-337	270	6	osimertinib	osimertinib	NOUN
admet-337	270	7	are	be	AUX
admet-337	270	8	az7550	az7550	NOUN
admet-337	270	9	and	and	CCONJ
admet-337	270	10	az5104	az5104	PROPN
admet-337	270	11	,	,	PUNCT
admet-337	270	12	the	the	DET
admet-337	270	13	latter	latter	NOUN
admet-337	270	14	of	of	ADP
admet-337	270	15	which	which	PRON
admet-337	270	16	causes	cause	VERB
admet-337	270	17	more	more	ADJ
admet-337	270	18	wild	wild	ADJ
admet-337	270	19	-	-	PUNCT
admet-337	270	20	type	type	NOUN
admet-337	270	21	egfr	egfr	NOUN
admet-337	270	22	inhibition	inhibition	NOUN
admet-337	270	23	than	than	ADP
admet-337	270	24	the	the	DET
admet-337	270	25	parent	parent	NOUN
admet-337	270	26	drug	drug	NOUN
admet-337	270	27	[	[	X
admet-337	270	28	91	91	NUM
admet-337	270	29	]	]	PUNCT
admet-337	270	30	.	.	PUNCT
admet-337	271	1	there	there	PRON
admet-337	271	2	is	be	VERB
admet-337	271	3	no	no	DET
admet-337	271	4	difference	difference	NOUN
admet-337	271	5	in	in	ADP
admet-337	271	6	absorption	absorption	NOUN
admet-337	271	7	or	or	CCONJ
admet-337	271	8	metabolism	metabolism	NOUN
admet-337	271	9	of	of	ADP
admet-337	271	10	osimertinib	osimertinib	NOUN
admet-337	271	11	based	base	VERB
admet-337	271	12	on	on	ADP
admet-337	271	13	age	age	NOUN
admet-337	271	14	,	,	PUNCT
admet-337	271	15	ethnicity	ethnicity	NOUN
admet-337	271	16	,	,	PUNCT
admet-337	271	17	or	or	CCONJ
admet-337	271	18	tobacco	tobacco	NOUN
admet-337	271	19	use	use	NOUN
admet-337	271	20	.	.	PUNCT
admet-337	272	1	osimertinib	osimertinib	NOUN
admet-337	272	2	is	be	AUX
admet-337	272	3	a	a	DET
admet-337	272	4	substrate	substrate	NOUN
admet-337	272	5	for	for	ADP
admet-337	272	6	p	p	NOUN
admet-337	272	7	-	-	PUNCT
admet-337	272	8	gp	gp	NOUN
admet-337	272	9	and	and	CCONJ
admet-337	272	10	brcp	brcp	VERB
admet-337	272	11	,	,	PUNCT
admet-337	272	12	and	and	CCONJ
admet-337	272	13	it	it	PRON
admet-337	272	14	inhibits	inhibit	VERB
admet-337	272	15	brcp	brcp	X
admet-337	272	16	but	but	CCONJ
admet-337	272	17	not	not	PART
admet-337	272	18	p	p	NOUN
admet-337	272	19	-	-	PUNCT
admet-337	272	20	gp	gp	NOUN
admet-337	272	21	.	.	PUNCT
admet-337	273	1	osimertinib	osimertinib	NOUN
admet-337	273	2	is	be	AUX
admet-337	273	3	eliminated	eliminate	VERB
admet-337	273	4	in	in	ADP
admet-337	273	5	feces	fece	NOUN
admet-337	273	6	(	(	PUNCT
admet-337	273	7	68	68	NUM
admet-337	273	8	%	%	NOUN
admet-337	273	9	)	)	PUNCT
admet-337	273	10	and	and	CCONJ
admet-337	273	11	in	in	ADP
admet-337	273	12	the	the	DET
admet-337	273	13	urine	urine	NOUN
admet-337	273	14	(	(	PUNCT
admet-337	273	15	14	14	NUM
admet-337	273	16	%	%	NOUN
admet-337	273	17	)	)	PUNCT
admet-337	273	18	with	with	ADP
admet-337	273	19	only	only	ADV
admet-337	273	20	2	2	NUM
admet-337	273	21	%	%	NOUN
admet-337	273	22	of	of	ADP
admet-337	273	23	the	the	DET
admet-337	273	24	drug	drug	NOUN
admet-337	273	25	being	be	AUX
admet-337	273	26	unchanged	unchanged	ADJ
admet-337	273	27	at	at	ADP
admet-337	273	28	elimination	elimination	NOUN
admet-337	273	29	.	.	PUNCT
admet-337	274	1	moderate	moderate	ADJ
admet-337	274	2	renal	renal	ADJ
admet-337	274	3	impairment	impairment	NOUN
admet-337	274	4	(	(	PUNCT
admet-337	274	5	creatinine	creatinine	NOUN
admet-337	274	6	clearance	clearance	NOUN
admet-337	274	7	>	>	X
admet-337	274	8	30	30	NUM
admet-337	274	9	ml	ml	NOUN
admet-337	274	10	/	/	SYM
admet-337	274	11	min	min	NOUN
admet-337	274	12	)	)	PUNCT
admet-337	274	13	and	and	CCONJ
admet-337	274	14	mild	mild	ADJ
admet-337	274	15	hepatic	hepatic	ADJ
admet-337	274	16	impairment	impairment	NOUN
admet-337	274	17	do	do	AUX
admet-337	274	18	not	not	PART
admet-337	274	19	appear	appear	VERB
admet-337	274	20	to	to	PART
admet-337	274	21	impact	impact	VERB
admet-337	274	22	drug	drug	NOUN
admet-337	274	23	levels	level	NOUN
admet-337	274	24	or	or	CCONJ
admet-337	274	25	toxicity	toxicity	NOUN
admet-337	274	26	.	.	PUNCT
admet-337	275	1	osimertinib	osimertinib	NOUN
admet-337	275	2	use	use	NOUN
admet-337	275	3	in	in	ADP
admet-337	275	4	severe	severe	ADJ
admet-337	275	5	renal	renal	ADJ
admet-337	275	6	impairment	impairment	NOUN
admet-337	275	7	(	(	PUNCT
admet-337	275	8	crcl<30	crcl<30	ADJ
admet-337	275	9	ml	ml	NOUN
admet-337	275	10	/	/	SYM
admet-337	275	11	min	min	NOUN
admet-337	275	12	)	)	PUNCT
admet-337	275	13	or	or	CCONJ
admet-337	275	14	moderate	moderate	ADJ
admet-337	275	15	to	to	ADP
admet-337	275	16	severe	severe	ADJ
admet-337	275	17	hepatic	hepatic	ADJ
admet-337	275	18	impairment	impairment	NOUN
admet-337	275	19	has	have	AUX
admet-337	275	20	not	not	PART
admet-337	275	21	been	be	AUX
admet-337	275	22	studied	study	VERB
admet-337	275	23	[	[	PUNCT
admet-337	275	24	94	94	NUM
admet-337	275	25	]	]	PUNCT
admet-337	275	26	.	.	PUNCT
admet-337	276	1	cns	cns	PROPN
admet-337	276	2	penetration	penetration	NOUN
admet-337	276	3	in	in	ADP
admet-337	276	4	a	a	DET
admet-337	276	5	mouse	mouse	NOUN
admet-337	276	6	model	model	NOUN
admet-337	276	7	,	,	PUNCT
admet-337	276	8	osimertinib	osimertinib	NOUN
admet-337	276	9	’s	’s	PART
admet-337	276	10	distribution	distribution	NOUN
admet-337	276	11	to	to	ADP
admet-337	276	12	the	the	DET
admet-337	276	13	brain	brain	NOUN
admet-337	276	14	was	be	AUX
admet-337	276	15	10	10	NUM
admet-337	276	16	-	-	PUNCT
admet-337	276	17	times	time	NOUN
admet-337	276	18	higher	high	ADJ
admet-337	276	19	than	than	ADP
admet-337	276	20	gefitinib	gefitinib	NOUN
admet-337	276	21	and	and	CCONJ
admet-337	276	22	response	response	NOUN
admet-337	276	23	in	in	ADP
admet-337	276	24	brain	brain	NOUN
admet-337	276	25	metastases	metastasis	NOUN
admet-337	276	26	were	be	AUX
admet-337	276	27	witnessed	witness	VERB
admet-337	276	28	with	with	ADP
admet-337	276	29	osimertinib	osimertinib	NOUN
admet-337	276	30	.	.	PUNCT
admet-337	277	1	in	in	ADP
admet-337	277	2	aura	aura	NOUN
admet-337	277	3	and	and	CCONJ
admet-337	277	4	aura2	aura2	PROPN
admet-337	277	5	,	,	PUNCT
admet-337	277	6	the	the	DET
admet-337	277	7	csf	csf	ADJ
admet-337	277	8	concentrations	concentration	NOUN
admet-337	277	9	of	of	ADP
admet-337	277	10	osimertinib	osimertinib	NOUN
admet-337	277	11	in	in	ADP
admet-337	277	12	two	two	NUM
admet-337	277	13	patients	patient	NOUN
admet-337	277	14	were	be	AUX
admet-337	277	15	0.2	0.2	NUM
admet-337	277	16	and	and	CCONJ
admet-337	277	17	1	1	NUM
admet-337	277	18	%	%	NOUN
admet-337	277	19	of	of	ADP
admet-337	277	20	the	the	DET
admet-337	277	21	predicted	predict	VERB
admet-337	277	22	plasma	plasma	NOUN
admet-337	277	23	concentrations	concentration	NOUN
admet-337	277	24	[	[	X
admet-337	277	25	94	94	NUM
admet-337	277	26	]	]	PUNCT
admet-337	277	27	.	.	PUNCT
admet-337	278	1	case	case	NOUN
admet-337	278	2	reports	report	NOUN
admet-337	278	3	of	of	ADP
admet-337	278	4	two	two	NUM
admet-337	278	5	patients	patient	NOUN
admet-337	278	6	t790m	t790m	ADV
admet-337	278	7	-	-	PUNCT
admet-337	278	8	mutated	mutate	VERB
admet-337	278	9	egfr	egfr	NOUN
admet-337	278	10	and	and	CCONJ
admet-337	278	11	untreated	untreated	ADJ
admet-337	278	12	brain	brain	NOUN
admet-337	278	13	metastases	metastasis	NOUN
admet-337	278	14	showed	show	VERB
admet-337	278	15	that	that	SCONJ
admet-337	278	16	osimertinib	osimertinib	NOUN
admet-337	278	17	80	80	NUM
admet-337	278	18	mg	mg	NOUN
admet-337	278	19	daily	daily	ADV
admet-337	278	20	induced	induce	VERB
admet-337	278	21	sustained	sustain	VERB
admet-337	278	22	partial	partial	ADJ
admet-337	278	23	responses	response	NOUN
admet-337	278	24	to	to	ADP
admet-337	278	25	both	both	CCONJ
admet-337	278	26	cns	cns	NOUN
admet-337	278	27	and	and	CCONJ
admet-337	278	28	systemic	systemic	ADJ
admet-337	278	29	disease	disease	NOUN
admet-337	278	30	[	[	X
admet-337	278	31	96	96	NUM
admet-337	278	32	]	]	PUNCT
admet-337	278	33	.	.	PUNCT
admet-337	279	1	the	the	DET
admet-337	279	2	phase	phase	NOUN
admet-337	279	3	i	i	PRON
admet-337	279	4	bloom	bloom	NOUN
admet-337	279	5	study	study	PROPN
admet-337	279	6	evaluated	evaluate	VERB
admet-337	279	7	osimertinib	osimertinib	NOUN
admet-337	279	8	160	160	NUM
admet-337	279	9	mg	mg	NOUN
admet-337	279	10	daily	daily	ADV
admet-337	279	11	for	for	ADP
admet-337	279	12	patients	patient	NOUN
admet-337	279	13	with	with	ADP
admet-337	279	14	egfr	egfr	ADJ
admet-337	279	15	-	-	PUNCT
admet-337	279	16	mutated	mutate	VERB
admet-337	279	17	nsclc	nsclc	NOUN
admet-337	279	18	with	with	ADP
admet-337	279	19	leptomeningeal	leptomeningeal	NOUN
admet-337	279	20	disease	disease	NOUN
admet-337	279	21	.	.	PUNCT
admet-337	280	1	all	all	DET
admet-337	280	2	patients	patient	NOUN
admet-337	280	3	had	have	AUX
admet-337	280	4	previously	previously	ADV
admet-337	280	5	received	receive	VERB
admet-337	280	6	an	an	DET
admet-337	280	7	egfr	egfr	ADJ
admet-337	280	8	tki	tki	NOUN
admet-337	280	9	.	.	PUNCT
admet-337	281	1	preliminary	preliminary	ADJ
admet-337	281	2	data	datum	NOUN
admet-337	281	3	from	from	ADP
admet-337	281	4	this	this	DET
admet-337	281	5	trial	trial	NOUN
admet-337	281	6	showed	show	VERB
admet-337	281	7	that	that	SCONJ
admet-337	281	8	in	in	ADP
admet-337	281	9	12	12	NUM
admet-337	281	10	patients	patient	NOUN
admet-337	281	11	who	who	PRON
admet-337	281	12	had	have	VERB
admet-337	281	13	12	12	NUM
admet-337	281	14	-	-	PUNCT
admet-337	281	15	week	week	NOUN
admet-337	281	16	imaging	imaging	NOUN
admet-337	281	17	assessment	assessment	NOUN
admet-337	281	18	,	,	PUNCT
admet-337	281	19	high	high	ADJ
admet-337	281	20	-	-	PUNCT
admet-337	281	21	dose	dose	NOUN
admet-337	281	22	osimertinib	osimertinib	NOUN
admet-337	281	23	produced	produce	VERB
admet-337	281	24	radiologic	radiologic	ADJ
admet-337	281	25	improvement	improvement	NOUN
admet-337	281	26	in	in	ADP
admet-337	281	27	cns	cns	NOUN
admet-337	281	28	disease	disease	NOUN
admet-337	281	29	in	in	ADP
admet-337	281	30	7	7	NUM
admet-337	281	31	patients	patient	NOUN
admet-337	281	32	(	(	PUNCT
admet-337	281	33	58.3	58.3	NUM
admet-337	281	34	%	%	NOUN
admet-337	281	35	)	)	PUNCT
admet-337	281	36	,	,	PUNCT
admet-337	281	37	stable	stable	ADJ
admet-337	281	38	disease	disease	NOUN
admet-337	281	39	in	in	ADP
admet-337	281	40	2	2	NUM
admet-337	281	41	patients	patient	NOUN
admet-337	281	42	(	(	PUNCT
admet-337	281	43	16.7	16.7	NUM
admet-337	281	44	%	%	NOUN
admet-337	281	45	)	)	PUNCT
admet-337	281	46	and	and	CCONJ
admet-337	281	47	3	3	NUM
admet-337	281	48	patients	patient	NOUN
admet-337	281	49	were	be	AUX
admet-337	281	50	not	not	PART
admet-337	281	51	evaluable	evaluable	ADJ
admet-337	281	52	.	.	PUNCT
admet-337	282	1	overall	overall	ADJ
admet-337	282	2	,	,	PUNCT
admet-337	282	3	the	the	DET
admet-337	282	4	higher	high	ADJ
admet-337	282	5	dose	dose	NOUN
admet-337	282	6	of	of	ADP
admet-337	282	7	osimertinib	osimertinib	NOUN
admet-337	282	8	was	be	AUX
admet-337	282	9	well	well	ADV
admet-337	282	10	-	-	PUNCT
admet-337	282	11	tolerated	tolerate	VERB
admet-337	282	12	,	,	PUNCT
admet-337	282	13	but	but	CCONJ
admet-337	282	14	5	5	NUM
admet-337	282	15	of	of	ADP
admet-337	282	16	20	20	NUM
admet-337	282	17	patients	patient	NOUN
admet-337	282	18	required	require	VERB
admet-337	282	19	dose	dose	NOUN
admet-337	282	20	interruptions	interruption	NOUN
admet-337	282	21	and	and	CCONJ
admet-337	282	22	only	only	ADV
admet-337	282	23	2	2	NUM
admet-337	282	24	required	require	VERB
admet-337	282	25	dose	dose	NOUN
admet-337	282	26	reductions	reduction	NOUN
admet-337	282	27	to	to	ADP
admet-337	282	28	80	80	NUM
admet-337	282	29	mg	mg	NOUN
admet-337	282	30	daily	daily	ADV
admet-337	282	31	.	.	PUNCT
admet-337	283	1	grade	grade	NOUN
admet-337	283	2	3	3	NUM
admet-337	283	3	neutropenia	neutropenia	NOUN
admet-337	283	4	was	be	AUX
admet-337	283	5	observed	observe	VERB
admet-337	283	6	in	in	ADP
admet-337	283	7	one	one	NUM
admet-337	283	8	patient	patient	NOUN
admet-337	283	9	on	on	ADP
admet-337	283	10	the	the	DET
admet-337	283	11	higher	high	ADJ
admet-337	283	12	dose	dose	NOUN
admet-337	283	13	of	of	ADP
admet-337	283	14	osimertinib	osimertinib	NOUN
admet-337	283	15	,	,	PUNCT
admet-337	283	16	but	but	CCONJ
admet-337	283	17	this	this	PRON
admet-337	283	18	resolved	resolve	VERB
admet-337	283	19	after	after	ADP
admet-337	283	20	3	3	NUM
admet-337	283	21	days	day	NOUN
admet-337	283	22	of	of	ADP
admet-337	283	23	holding	hold	VERB
admet-337	283	24	the	the	DET
admet-337	283	25	drug	drug	NOUN
admet-337	283	26	and	and	CCONJ
admet-337	283	27	did	do	AUX
admet-337	283	28	not	not	PART
admet-337	283	29	recur	recur	VERB
admet-337	283	30	after	after	ADP
admet-337	283	31	reducing	reduce	VERB
admet-337	283	32	the	the	DET
admet-337	283	33	dose	dose	NOUN
admet-337	283	34	to	to	ADP
admet-337	283	35	80	80	NUM
admet-337	283	36	mg	mg	PROPN
admet-337	284	1	[	[	X
admet-337	284	2	97	97	NUM
admet-337	284	3	]	]	PUNCT
admet-337	284	4	.	.	PUNCT
admet-337	285	1	resistance	resistance	NOUN
admet-337	285	2	mechanisms	mechanism	NOUN
admet-337	285	3	currently	currently	ADV
admet-337	285	4	,	,	PUNCT
admet-337	285	5	the	the	DET
admet-337	285	6	most	most	ADV
admet-337	285	7	commonly	commonly	ADV
admet-337	285	8	reported	report	VERB
admet-337	285	9	acquired	acquire	VERB
admet-337	285	10	resistance	resistance	NOUN
admet-337	285	11	mutation	mutation	NOUN
admet-337	285	12	to	to	ADP
admet-337	285	13	osimertinib	osimertinib	NOUN
admet-337	285	14	is	be	AUX
admet-337	285	15	the	the	DET
admet-337	285	16	missense	missense	NOUN
admet-337	285	17	mutation	mutation	NOUN
admet-337	285	18	of	of	ADP
admet-337	285	19	cysteine	cysteine	NOUN
admet-337	285	20	for	for	ADP
admet-337	285	21	serine	serine	NOUN
admet-337	285	22	at	at	ADP
admet-337	285	23	position	position	NOUN
admet-337	285	24	797	797	NUM
admet-337	285	25	(	(	PUNCT
admet-337	285	26	c797s	c797s	PROPN
admet-337	285	27	)	)	PUNCT
admet-337	285	28	.	.	PUNCT
admet-337	286	1	this	this	DET
admet-337	286	2	substitution	substitution	NOUN
admet-337	286	3	prevents	prevent	VERB
admet-337	286	4	osimertinib	osimertinib	NOUN
admet-337	286	5	from	from	ADP
admet-337	286	6	forming	form	VERB
admet-337	286	7	a	a	DET
admet-337	286	8	covalent	covalent	NOUN
admet-337	286	9	bond	bond	NOUN
admet-337	286	10	at	at	ADP
admet-337	286	11	the	the	DET
admet-337	286	12	kinase	kinase	NOUN
admet-337	286	13	-	-	PUNCT
admet-337	286	14	binding	bind	VERB
admet-337	286	15	site	site	NOUN
admet-337	286	16	[	[	X
admet-337	286	17	98	98	NUM
admet-337	286	18	]	]	PUNCT
admet-337	286	19	.	.	PUNCT
admet-337	287	1	the	the	DET
admet-337	287	2	c797s	c797s	PROPN
admet-337	287	3	mutation	mutation	NOUN
admet-337	287	4	accounts	account	VERB
admet-337	287	5	for	for	ADP
admet-337	287	6	up	up	ADP
admet-337	287	7	to	to	PART
admet-337	287	8	40	40	NUM
admet-337	287	9	%	%	NOUN
admet-337	287	10	of	of	ADP
admet-337	287	11	acquired	acquire	VERB
admet-337	287	12	resistance	resistance	NOUN
admet-337	287	13	to	to	ADP
admet-337	287	14	osimertinib	osimertinib	NOUN
admet-337	287	15	in	in	ADP
admet-337	287	16	the	the	DET
admet-337	287	17	limited	limited	ADJ
admet-337	287	18	data	datum	NOUN
admet-337	287	19	on	on	ADP
admet-337	287	20	this	this	DET
admet-337	287	21	topic	topic	NOUN
admet-337	287	22	to	to	ADP
admet-337	287	23	date	date	NOUN
admet-337	287	24	[	[	X
admet-337	287	25	99	99	NUM
admet-337	287	26	]	]	PUNCT
admet-337	287	27	.	.	PUNCT
admet-337	288	1	clinically	clinically	ADV
admet-337	288	2	,	,	PUNCT
admet-337	288	3	loss	loss	NOUN
admet-337	288	4	of	of	ADP
admet-337	288	5	the	the	DET
admet-337	288	6	t790	t790	NUM
admet-337	288	7	m	m	NOUN
admet-337	288	8	grace	grace	NOUN
admet-337	288	9	dy	dy	NOUN
admet-337	288	10	et	et	PROPN
admet-337	288	11	al	al	PROPN
admet-337	288	12	.	.	PROPN
admet-337	288	13	admet	admet	PROPN
admet-337	288	14	&	&	CCONJ
admet-337	288	15	dmpk	dmpk	PROPN
admet-337	288	16	4(3	4(3	NUM
admet-337	288	17	)	)	PUNCT
admet-337	288	18	(	(	PUNCT
admet-337	288	19	2016	2016	NUM
admet-337	288	20	)	)	PUNCT
admet-337	288	21	186	186	NUM
admet-337	288	22	-	-	SYM
admet-337	288	23	211	211	NUM
admet-337	288	24	196	196	NUM
admet-337	288	25	mutation	mutation	NOUN
admet-337	288	26	has	have	AUX
admet-337	288	27	been	be	AUX
admet-337	288	28	observed	observe	VERB
admet-337	288	29	after	after	ADP
admet-337	288	30	treatment	treatment	NOUN
admet-337	288	31	with	with	ADP
admet-337	288	32	osimertinib	osimertinib	NOUN
admet-337	288	33	[	[	X
admet-337	288	34	99	99	NUM
admet-337	288	35	]	]	PUNCT
admet-337	288	36	.	.	PUNCT
admet-337	289	1	in	in	ADP
admet-337	289	2	pc9	pc9	PROPN
admet-337	289	3	and	and	CCONJ
admet-337	289	4	nci	nci	PROPN
admet-337	289	5	-	-	PUNCT
admet-337	289	6	h1975	h1975	PROPN
admet-337	289	7	cell	cell	NOUN
admet-337	289	8	lines	line	NOUN
admet-337	289	9	,	,	PUNCT
admet-337	289	10	acquired	acquire	VERB
admet-337	289	11	nras	nras	PROPN
admet-337	289	12	and	and	CCONJ
admet-337	289	13	kras	kras	PROPN
admet-337	289	14	mutations	mutation	NOUN
admet-337	289	15	were	be	AUX
admet-337	289	16	noted	note	VERB
admet-337	289	17	after	after	ADP
admet-337	289	18	exposure	exposure	NOUN
admet-337	289	19	to	to	ADP
admet-337	289	20	osimertinib	osimertinib	NOUN
admet-337	289	21	.	.	PUNCT
admet-337	290	1	a	a	DET
admet-337	290	2	number	number	NOUN
admet-337	290	3	of	of	ADP
admet-337	290	4	these	these	DET
admet-337	290	5	resistant	resistant	ADJ
admet-337	290	6	cell	cell	NOUN
admet-337	290	7	lines	line	NOUN
admet-337	290	8	were	be	AUX
admet-337	290	9	sensitive	sensitive	ADJ
admet-337	290	10	to	to	ADP
admet-337	290	11	combination	combination	NOUN
admet-337	290	12	of	of	ADP
admet-337	290	13	osimertinib	osimertinib	NOUN
admet-337	290	14	and	and	CCONJ
admet-337	290	15	the	the	DET
admet-337	290	16	mek	mek	PROPN
admet-337	290	17	inhibitor	inhibitor	NOUN
admet-337	290	18	selumetinib	selumetinib	PROPN
admet-337	290	19	[	[	X
admet-337	290	20	100	100	NUM
admet-337	290	21	]	]	PUNCT
admet-337	290	22	.	.	PUNCT
admet-337	291	1	investigational	investigational	ADJ
admet-337	291	2	agents	agent	NOUN
admet-337	291	3	(	(	PUNCT
admet-337	291	4	table	table	NOUN
admet-337	291	5	2	2	NUM
admet-337	291	6	)	)	PUNCT
admet-337	291	7	another	another	DET
admet-337	291	8	third	third	ADJ
admet-337	291	9	generation	generation	NOUN
admet-337	291	10	egfr	egfr	X
admet-337	291	11	tki	tki	PROPN
admet-337	291	12	,	,	PUNCT
admet-337	291	13	olmutinib	olmutinib	PROPN
admet-337	291	14	(	(	PUNCT
admet-337	291	15	bi	bi	NOUN
admet-337	291	16	1482694	1482694	NUM
admet-337	291	17	/	/	SYM
admet-337	291	18	hm61713	hm61713	PROPN
admet-337	291	19	)	)	PUNCT
admet-337	291	20	,	,	PUNCT
admet-337	291	21	gained	gain	VERB
admet-337	291	22	fda	fda	PROPN
admet-337	291	23	breakthrough	breakthrough	NOUN
admet-337	291	24	therapy	therapy	NOUN
admet-337	291	25	designation	designation	NOUN
admet-337	291	26	in	in	ADP
admet-337	291	27	december	december	PROPN
admet-337	291	28	2015	2015	NUM
admet-337	291	29	.	.	PUNCT
admet-337	292	1	like	like	ADP
admet-337	292	2	osimertinib	osimertinib	NOUN
admet-337	292	3	,	,	PUNCT
admet-337	292	4	olmutinib	olmutinib	VERB
admet-337	292	5	targets	target	NOUN
admet-337	292	6	mutant	mutant	ADJ
admet-337	292	7	egfr	egfr	NOUN
admet-337	292	8	and	and	CCONJ
admet-337	292	9	t790	t790	NUM
admet-337	292	10	m	m	NOUN
admet-337	292	11	while	while	SCONJ
admet-337	292	12	sparing	spare	VERB
admet-337	292	13	wild	wild	ADJ
admet-337	292	14	-	-	PUNCT
admet-337	292	15	type	type	NOUN
admet-337	292	16	egfr	egfr	NOUN
admet-337	292	17	.	.	PUNCT
admet-337	293	1	in	in	ADP
admet-337	293	2	the	the	DET
admet-337	293	3	phase	phase	NOUN
admet-337	293	4	i	i	PRON
admet-337	293	5	/	/	SYM
admet-337	293	6	ii	ii	PROPN
admet-337	293	7	hm	hm	ADJ
admet-337	293	8	-	-	ADJ
admet-337	293	9	emsi-101	emsi-101	ADJ
admet-337	293	10	trial	trial	NOUN
admet-337	293	11	,	,	PUNCT
admet-337	293	12	patients	patient	NOUN
admet-337	293	13	with	with	ADP
admet-337	293	14	egfr	egfr	ADJ
admet-337	293	15	-	-	PUNCT
admet-337	293	16	mutated	mutate	VERB
admet-337	293	17	nsclc	nsclc	NOUN
admet-337	293	18	who	who	PRON
admet-337	293	19	progressed	progress	VERB
admet-337	293	20	on	on	ADP
admet-337	293	21	a	a	DET
admet-337	293	22	previous	previous	ADJ
admet-337	293	23	egfr	egfr	NOUN
admet-337	293	24	tki	tki	NOUN
admet-337	293	25	received	receive	VERB
admet-337	293	26	olmutinib	olmutinib	NOUN
admet-337	293	27	.	.	PUNCT
admet-337	294	1	as	as	ADP
admet-337	294	2	of	of	ADP
admet-337	294	3	june	june	PROPN
admet-337	294	4	2016	2016	NUM
admet-337	294	5	,	,	PUNCT
admet-337	294	6	76	76	NUM
admet-337	294	7	patients	patient	NOUN
admet-337	294	8	had	have	AUX
admet-337	294	9	received	receive	VERB
admet-337	294	10	the	the	DET
admet-337	294	11	drug	drug	NOUN
admet-337	294	12	at	at	ADP
admet-337	294	13	the	the	DET
admet-337	294	14	recommended	recommend	VERB
admet-337	294	15	phase	phase	NOUN
admet-337	294	16	ii	ii	PROPN
admet-337	294	17	dose	dose	NOUN
admet-337	294	18	of	of	ADP
admet-337	294	19	800	800	NUM
admet-337	294	20	mg	mg	NOUN
admet-337	294	21	daily	daily	ADV
admet-337	294	22	.	.	PUNCT
admet-337	295	1	the	the	DET
admet-337	295	2	drug	drug	NOUN
admet-337	295	3	produced	produce	VERB
admet-337	295	4	an	an	DET
admet-337	295	5	orr	orr	NOUN
admet-337	295	6	of	of	ADP
admet-337	295	7	62	62	NUM
admet-337	295	8	%	%	NOUN
admet-337	295	9	with	with	ADP
admet-337	295	10	a	a	DET
admet-337	295	11	dcr	dcr	NOUN
admet-337	295	12	of	of	ADP
admet-337	295	13	91	91	NUM
admet-337	295	14	%	%	NOUN
admet-337	295	15	by	by	ADP
admet-337	295	16	independent	independent	ADJ
admet-337	295	17	assessments	assessment	NOUN
admet-337	295	18	.	.	PUNCT
admet-337	296	1	few	few	ADJ
admet-337	296	2	grade	grade	NOUN
admet-337	296	3	3	3	NUM
admet-337	296	4	or	or	CCONJ
admet-337	296	5	4	4	NUM
admet-337	296	6	toxicities	toxicity	NOUN
admet-337	296	7	were	be	AUX
admet-337	296	8	observed	observe	VERB
admet-337	296	9	,	,	PUNCT
admet-337	296	10	including	include	VERB
admet-337	296	11	a	a	DET
admet-337	296	12	5	5	NUM
admet-337	296	13	%	%	NOUN
admet-337	296	14	risk	risk	NOUN
admet-337	296	15	of	of	ADP
admet-337	296	16	grade	grade	NOUN
admet-337	296	17	3	3	NUM
admet-337	296	18	or	or	CCONJ
admet-337	296	19	4	4	NUM
admet-337	296	20	skin	skin	NOUN
admet-337	296	21	rash	rash	NOUN
admet-337	296	22	[	[	X
admet-337	296	23	101	101	NUM
admet-337	296	24	]	]	PUNCT
admet-337	296	25	.	.	PUNCT
admet-337	297	1	the	the	DET
admet-337	297	2	phase	phase	NOUN
admet-337	297	3	ii	ii	PROPN
admet-337	297	4	eluxa	eluxa	NOUN
admet-337	297	5	1	1	NUM
admet-337	297	6	(	(	PUNCT
admet-337	297	7	hm	hm	INTJ
admet-337	297	8	-	-	PUNCT
admet-337	297	9	emsi-202	emsi-202	NOUN
admet-337	297	10	)	)	PUNCT
admet-337	297	11	trial	trial	NOUN
admet-337	297	12	is	be	AUX
admet-337	297	13	open	open	ADJ
admet-337	297	14	for	for	ADP
admet-337	297	15	patient	patient	ADJ
admet-337	297	16	recruitment	recruitment	NOUN
admet-337	297	17	and	and	CCONJ
admet-337	297	18	is	be	AUX
admet-337	297	19	investigating	investigate	VERB
admet-337	297	20	the	the	DET
admet-337	297	21	efficacy	efficacy	NOUN
admet-337	297	22	of	of	ADP
admet-337	297	23	olmutinib	olmutinib	NOUN
admet-337	297	24	in	in	ADP
admet-337	297	25	patients	patient	NOUN
admet-337	297	26	who	who	PRON
admet-337	297	27	have	have	AUX
admet-337	297	28	developed	develop	VERB
admet-337	297	29	t790	t790	NUM
admet-337	297	30	m	m	NOUN
admet-337	297	31	after	after	ADP
admet-337	297	32	exposure	exposure	NOUN
admet-337	297	33	to	to	ADP
admet-337	297	34	first	first	ADJ
admet-337	297	35	-	-	PUNCT
admet-337	297	36	line	line	NOUN
admet-337	297	37	egfr	egfr	NOUN
admet-337	297	38	tkis	tkis	NOUN
admet-337	298	1	[	[	X
admet-337	298	2	102	102	NUM
admet-337	298	3	]	]	PUNCT
admet-337	298	4	.	.	PUNCT
admet-337	299	1	multiple	multiple	ADJ
admet-337	299	2	monotherapy	monotherapy	NOUN
admet-337	299	3	trials	trial	NOUN
admet-337	299	4	of	of	ADP
admet-337	299	5	olmutinib	olmutinib	NOUN
admet-337	299	6	are	be	AUX
admet-337	299	7	being	be	AUX
admet-337	299	8	planned	plan	VERB
admet-337	299	9	,	,	PUNCT
admet-337	299	10	including	include	VERB
admet-337	299	11	phase	phase	NOUN
admet-337	299	12	iii	iii	NUM
admet-337	299	13	studies	study	NOUN
admet-337	299	14	comparing	compare	VERB
admet-337	299	15	olmutinib	olmutinib	NOUN
admet-337	299	16	with	with	ADP
admet-337	299	17	platinum	platinum	NOUN
admet-337	299	18	-	-	PUNCT
admet-337	299	19	based	base	VERB
admet-337	299	20	chemotherapy	chemotherapy	NOUN
admet-337	299	21	in	in	ADP
admet-337	299	22	a	a	DET
admet-337	299	23	second	second	ADJ
admet-337	299	24	-	-	PUNCT
admet-337	299	25	line	line	NOUN
admet-337	299	26	setting	setting	NOUN
admet-337	299	27	and	and	CCONJ
admet-337	299	28	comparing	compare	VERB
admet-337	299	29	olmutinib	olmutinib	NOUN
admet-337	299	30	with	with	ADP
admet-337	299	31	afatinib	afatinib	NOUN
admet-337	299	32	in	in	ADP
admet-337	299	33	the	the	DET
admet-337	299	34	first	first	ADJ
admet-337	299	35	-	-	PUNCT
admet-337	299	36	line	line	NOUN
admet-337	299	37	treatment	treatment	NOUN
admet-337	299	38	of	of	ADP
admet-337	299	39	egfr	egfr	NOUN
admet-337	299	40	-	-	PUNCT
admet-337	299	41	mutated	mutate	VERB
admet-337	299	42	nsclc	nsclc	NOUN
admet-337	299	43	.	.	PUNCT
admet-337	300	1	investigators	investigator	NOUN
admet-337	300	2	are	be	AUX
admet-337	300	3	also	also	ADV
admet-337	300	4	planning	plan	VERB
admet-337	300	5	on	on	ADP
admet-337	300	6	trials	trial	NOUN
admet-337	300	7	evaluating	evaluate	VERB
admet-337	300	8	olmutinib	olmutinib	NOUN
admet-337	300	9	in	in	ADP
admet-337	300	10	combination	combination	NOUN
admet-337	300	11	with	with	ADP
admet-337	300	12	various	various	ADJ
admet-337	300	13	agents	agent	NOUN
admet-337	300	14	,	,	PUNCT
admet-337	300	15	including	include	VERB
admet-337	300	16	pembrolizumab	pembrolizumab	NOUN
admet-337	300	17	,	,	PUNCT
admet-337	300	18	bevacizumab	bevacizumab	PROPN
admet-337	300	19	,	,	PUNCT
admet-337	300	20	nintedanib	nintedanib	NOUN
admet-337	300	21	,	,	PUNCT
admet-337	300	22	afatinib	afatinib	NOUN
admet-337	300	23	,	,	PUNCT
admet-337	300	24	and	and	CCONJ
admet-337	300	25	the	the	DET
admet-337	300	26	igf	igf	PROPN
admet-337	300	27	ligand	ligand	NOUN
admet-337	300	28	-	-	PUNCT
admet-337	300	29	neutralizing	neutralize	VERB
admet-337	300	30	antibody	antibody	NOUN
admet-337	300	31	bi836845	bi836845	NOUN
admet-337	300	32	.	.	PUNCT
admet-337	300	33	table	table	NOUN
admet-337	301	1	2	2	NUM
admet-337	301	2	.	.	NOUN
admet-337	301	3	egfr	egfr	PROPN
admet-337	301	4	tkis	tkis	PROPN
admet-337	301	5	in	in	ADP
admet-337	301	6	development	development	NOUN
admet-337	301	7	drug	drug	NOUN
admet-337	301	8	name	name	NOUN
admet-337	301	9	targets	target	VERB
admet-337	301	10	clinical	clinical	ADJ
admet-337	301	11	activity	activity	NOUN
admet-337	301	12	select	select	VERB
admet-337	301	13	ongoing	ongoing	ADJ
admet-337	301	14	/	/	SYM
admet-337	301	15	future	future	ADJ
admet-337	301	16	trials	trial	NOUN
admet-337	301	17	olmutinib	olmutinib	VERB
admet-337	301	18	(	(	PUNCT
admet-337	301	19	bi	bi	NOUN
admet-337	301	20	482694	482694	NUM
admet-337	301	21	/	/	SYM
admet-337	301	22	hm61713	hm61713	PROPN
admet-337	301	23	)	)	PUNCT
admet-337	302	1	[	[	X
admet-337	302	2	102	102	NUM
admet-337	302	3	]	]	PUNCT
admet-337	302	4	mutant	mutant	NOUN
admet-337	302	5	egfr	egfr	VERB
admet-337	302	6	t790	t790	NUM
admet-337	302	7	m	m	NOUN
admet-337	302	8	phase	phase	NOUN
admet-337	302	9	i	i	PRON
admet-337	302	10	/	/	SYM
admet-337	302	11	ii	ii	PROPN
admet-337	302	12	(	(	PUNCT
admet-337	302	13	n=76	n=76	NOUN
admet-337	302	14	)	)	PUNCT
admet-337	302	15	orr	orr	NOUN
admet-337	302	16	62	62	NUM
admet-337	302	17	%	%	NOUN
admet-337	302	18	,	,	PUNCT
admet-337	302	19	dcr	dcr	PROPN
admet-337	302	20	91	91	NUM
admet-337	302	21	%	%	NOUN
admet-337	302	22	ongoing	ongoing	ADJ
admet-337	302	23	phase	phase	NOUN
admet-337	302	24	ii	ii	PROPN
admet-337	302	25	eluxa	eluxa	NOUN
admet-337	302	26	1	1	NUM
admet-337	302	27	(	(	PUNCT
admet-337	302	28	nct02485652	nct02485652	ADV
admet-337	302	29	)	)	PUNCT
admet-337	302	30	planned	plan	VERB
admet-337	302	31	:	:	PUNCT
admet-337	302	32	olmutinib	olmutinib	NOUN
admet-337	302	33	vs	vs	ADP
admet-337	302	34	platinum	platinum	NOUN
admet-337	302	35	regimen	regiman	NOUN
admet-337	302	36	in	in	ADP
admet-337	302	37	2	2	NUM
admet-337	302	38	nd	nd	NOUN
admet-337	302	39	line	line	NOUN
admet-337	302	40	;	;	PUNCT
admet-337	302	41	olmutinib	olmutinib	NOUN
admet-337	302	42	vs	vs	ADP
admet-337	302	43	afatinib	afatinib	NOUN
admet-337	302	44	in	in	ADP
admet-337	302	45	1	1	NUM
admet-337	302	46	st	st	NOUN
admet-337	302	47	line	line	NOUN
admet-337	302	48	;	;	PUNCT
admet-337	302	49	combinations	combination	NOUN
admet-337	302	50	with	with	ADP
admet-337	302	51	:	:	PUNCT
admet-337	302	52	pembrolizumab	pembrolizumab	NOUN
admet-337	302	53	,	,	PUNCT
admet-337	302	54	bevacizumab	bevacizumab	PROPN
admet-337	302	55	,	,	PUNCT
admet-337	302	56	nintedanib	nintedanib	NOUN
admet-337	302	57	,	,	PUNCT
admet-337	302	58	afatinib	afatinib	NOUN
admet-337	302	59	,	,	PUNCT
admet-337	302	60	bi836845	bi836845	PROPN
admet-337	302	61	asp8273	asp8273	NOUN
admet-337	303	1	[	[	X
admet-337	303	2	103	103	NUM
admet-337	303	3	]	]	PUNCT
admet-337	303	4	mutant	mutant	NOUN
admet-337	303	5	egfr	egfr	VERB
admet-337	303	6	t790	t790	NUM
admet-337	303	7	m	m	NOUN
admet-337	303	8	phase	phase	NOUN
admet-337	303	9	i	i	PRON
admet-337	303	10	orr	orr	VERB
admet-337	303	11	50	50	NUM
admet-337	303	12	%	%	NOUN
admet-337	303	13	(	(	PUNCT
admet-337	303	14	n=36	n=36	PROPN
admet-337	303	15	)	)	PUNCT
admet-337	303	16	;	;	PUNCT
admet-337	303	17	in	in	ADP
admet-337	303	18	t790	t790	NUM
admet-337	303	19	m	m	NOUN
admet-337	303	20	orr	orr	NOUN
admet-337	303	21	80	80	NUM
admet-337	303	22	%	%	NOUN
admet-337	303	23	(	(	PUNCT
admet-337	303	24	n=15	n=15	NUM
admet-337	303	25	)	)	PUNCT
admet-337	303	26	ongoing	ongoing	ADJ
admet-337	303	27	phase	phase	NOUN
admet-337	303	28	ii	ii	PROPN
admet-337	303	29	(	(	PUNCT
admet-337	303	30	nct02192697	nct02192697	ADV
admet-337	303	31	)	)	PUNCT
admet-337	303	32	;	;	PUNCT
admet-337	303	33	ongoing	ongoing	ADJ
admet-337	303	34	1	1	NUM
admet-337	303	35	st	st	NOUN
admet-337	303	36	line	line	NOUN
admet-337	303	37	study	study	NOUN
admet-337	303	38	(	(	PUNCT
admet-337	303	39	solar	solar	ADJ
admet-337	303	40	)	)	PUNCT
admet-337	303	41	(	(	PUNCT
admet-337	303	42	nct02588261	nct02588261	NOUN
admet-337	303	43	)	)	PUNCT
admet-337	303	44	asp8273	asp8273	NOUN
admet-337	303	45	vs	vs	ADP
admet-337	303	46	erlotinib	erlotinib	NOUN
admet-337	303	47	or	or	CCONJ
admet-337	303	48	gefitinib	gefitinib	NOUN
admet-337	303	49	egf816	egf816	PROPN
admet-337	303	50	[	[	X
admet-337	303	51	104	104	NUM
admet-337	303	52	]	]	PUNCT
admet-337	303	53	mutant	mutant	NOUN
admet-337	303	54	egfr	egfr	VERB
admet-337	303	55	t790	t790	NUM
admet-337	303	56	m	m	NOUN
admet-337	303	57	phase	phase	NOUN
admet-337	303	58	i	i	PRON
admet-337	303	59	/	/	SYM
admet-337	303	60	ii	ii	PROPN
admet-337	303	61	(	(	PUNCT
admet-337	303	62	n=22	n=22	PROPN
admet-337	303	63	)	)	PUNCT
admet-337	303	64	orr	orr	NOUN
admet-337	303	65	55	55	NUM
admet-337	303	66	%	%	NOUN
admet-337	303	67	,	,	PUNCT
admet-337	303	68	dcr	dcr	PROPN
admet-337	303	69	86	86	NUM
admet-337	303	70	%	%	NOUN
admet-337	303	71	ongoing	ongoing	ADJ
admet-337	303	72	phase	phase	NOUN
admet-337	303	73	i	i	PRON
admet-337	303	74	/	/	SYM
admet-337	303	75	ii	ii	PROPN
admet-337	303	76	(	(	PUNCT
admet-337	303	77	nct02108964	nct02108964	NOUN
admet-337	303	78	)	)	PUNCT
admet-337	303	79	azd3759	azd3759	VERB
admet-337	303	80	[	[	X
admet-337	303	81	106	106	NUM
admet-337	303	82	]	]	PUNCT
admet-337	303	83	mutant	mutant	NOUN
admet-337	303	84	egfr	egfr	X
admet-337	303	85	high	high	ADJ
admet-337	303	86	cns	cns	NOUN
admet-337	303	87	penetration	penetration	NOUN
admet-337	303	88	phase	phase	NOUN
admet-337	304	1	i	i	PRON
admet-337	304	2	(	(	PUNCT
admet-337	304	3	n=2	n=2	ADV
admet-337	304	4	)	)	PUNCT
admet-337	304	5	1	1	NUM
admet-337	304	6	intracranial	intracranial	ADJ
admet-337	304	7	pr	pr	NOUN
admet-337	304	8	and	and	CCONJ
admet-337	304	9	1	1	NUM
admet-337	304	10	intracranial	intracranial	ADJ
admet-337	304	11	sd	sd	ADP
admet-337	304	12	ongoing	ongoing	ADJ
admet-337	304	13	phase	phase	NOUN
admet-337	304	14	i	i	PRON
admet-337	304	15	nct02228369	nct02228369	NOUN
admet-337	304	16	)	)	PUNCT
admet-337	304	17	epitinib	epitinib	NOUN
admet-337	304	18	(	(	PUNCT
admet-337	304	19	hpml-813	hpml-813	ADJ
admet-337	304	20	)	)	PUNCT
admet-337	305	1	[	[	X
admet-337	305	2	105	105	NUM
admet-337	305	3	]	]	PUNCT
admet-337	305	4	mutant	mutant	NOUN
admet-337	305	5	egfr	egfr	X
admet-337	305	6	high	high	ADJ
admet-337	305	7	cns	cns	NOUN
admet-337	305	8	penetration	penetration	NOUN
admet-337	305	9	phase	phase	NOUN
admet-337	305	10	i	i	PRON
admet-337	305	11	(	(	PUNCT
admet-337	305	12	n=12	n=12	NOUN
admet-337	305	13	)	)	PUNCT
admet-337	305	14	71	71	NUM
admet-337	305	15	%	%	NOUN
admet-337	305	16	tki	tki	NOUN
admet-337	305	17	naïve	naïve	ADJ
admet-337	305	18	pts	pt	NOUN
admet-337	305	19	achieved	achieve	VERB
admet-337	305	20	pr	pr	NOUN
admet-337	305	21	in	in	ADP
admet-337	305	22	cns	cns	NOUN
admet-337	305	23	;	;	PUNCT
admet-337	305	24	100	100	NUM
admet-337	305	25	%	%	NOUN
admet-337	305	26	pts	pts	ADP
admet-337	305	27	w	w	NOUN
admet-337	305	28	/	/	SYM
admet-337	305	29	previous	previous	ADJ
admet-337	305	30	tki	tki	PROPN
admet-337	305	31	exposure	exposure	NOUN
admet-337	305	32	achieved	achieve	VERB
admet-337	305	33	sd	sd	NOUN
admet-337	305	34	in	in	ADP
admet-337	305	35	cns	cns	NOUN
admet-337	305	36	ongoing	ongoing	ADJ
admet-337	305	37	phase	phase	NOUN
admet-337	305	38	i	i	PRON
admet-337	305	39	(	(	PUNCT
admet-337	305	40	nct02590952	nct02590952	NOUN
admet-337	305	41	)	)	PUNCT
admet-337	305	42	tarloxotinib	tarloxotinib	NOUN
admet-337	305	43	bromide	bromide	NOUN
admet-337	305	44	(	(	PUNCT
admet-337	305	45	th-4000	th-4000	NOUN
admet-337	305	46	)	)	PUNCT
admet-337	306	1	[	[	X
admet-337	306	2	107	107	NUM
admet-337	306	3	]	]	X
admet-337	306	4	wild	wild	ADJ
admet-337	306	5	-	-	PUNCT
admet-337	306	6	type	type	NOUN
admet-337	306	7	egfr	egfr	ADJ
admet-337	306	8	mutant	mutant	NOUN
admet-337	306	9	egfr	egfr	NOUN
admet-337	306	10	(	(	PUNCT
admet-337	306	11	nont790	nont790	NOUN
admet-337	306	12	m	m	NOUN
admet-337	306	13	)	)	PUNCT
admet-337	306	14	her2	her2	VERB
admet-337	306	15	n	n	CCONJ
admet-337	306	16	/	/	SYM
admet-337	306	17	a	a	DET
admet-337	306	18	ongoing	ongoing	ADJ
admet-337	306	19	phase	phase	NOUN
admet-337	306	20	ii	ii	NOUN
admet-337	306	21	(	(	PUNCT
admet-337	306	22	nct02454842	nct02454842	ADJ
admet-337	306	23	)	)	PUNCT
admet-337	306	24	admet	admet	PROPN
admet-337	306	25	&	&	CCONJ
admet-337	306	26	dmpk	dmpk	PROPN
admet-337	306	27	4(3	4(3	NUM
admet-337	306	28	)	)	PUNCT
admet-337	306	29	(	(	PUNCT
admet-337	306	30	2016	2016	NUM
admet-337	306	31	)	)	PUNCT
admet-337	306	32	186	186	NUM
admet-337	306	33	-	-	SYM
admet-337	306	34	211	211	NUM
admet-337	306	35	tki	tki	NOUN
admet-337	306	36	for	for	ADP
admet-337	306	37	egfrand	egfrand	ADJ
admet-337	306	38	alk	alk	PROPN
admet-337	306	39	-	-	PUNCT
admet-337	306	40	mutated	mutate	VERB
admet-337	306	41	cell	cell	NOUN
admet-337	306	42	cancer	cancer	NOUN
admet-337	306	43	doi	doi	NOUN
admet-337	306	44	:	:	PUNCT
admet-337	306	45	10.5599	10.5599	NUM
admet-337	306	46	/	/	SYM
admet-337	306	47	admet.4.3.337	admet.4.3.337	NUM
admet-337	306	48	197	197	NUM
admet-337	306	49	other	other	ADJ
admet-337	306	50	third	third	ADJ
admet-337	306	51	-	-	PUNCT
admet-337	306	52	generation	generation	NOUN
admet-337	306	53	egfr	egfr	NOUN
admet-337	306	54	tkis	tkis	NOUN
admet-337	306	55	in	in	ADP
admet-337	306	56	development	development	NOUN
admet-337	306	57	,	,	PUNCT
admet-337	306	58	including	include	VERB
admet-337	306	59	asp8273	asp8273	NOUN
admet-337	306	60	and	and	CCONJ
admet-337	306	61	egf816	egf816	PROPN
admet-337	306	62	,	,	PUNCT
admet-337	306	63	have	have	VERB
admet-337	306	64	selective	selective	ADJ
admet-337	306	65	activity	activity	NOUN
admet-337	306	66	against	against	ADP
admet-337	306	67	mutant	mutant	ADJ
admet-337	306	68	egfr	egfr	NOUN
admet-337	306	69	(	(	PUNCT
admet-337	306	70	l858r	l858r	NOUN
admet-337	306	71	,	,	PUNCT
admet-337	306	72	del	del	PROPN
admet-337	306	73	exon	exon	PROPN
admet-337	306	74	19	19	NUM
admet-337	306	75	)	)	PUNCT
admet-337	306	76	as	as	ADV
admet-337	306	77	well	well	ADV
admet-337	306	78	as	as	ADP
admet-337	306	79	t790	t790	NUM
admet-337	306	80	m	m	NOUN
admet-337	306	81	without	without	ADP
admet-337	306	82	affecting	affect	VERB
admet-337	306	83	wild	wild	ADJ
admet-337	306	84	-	-	PUNCT
admet-337	306	85	type	type	NOUN
admet-337	306	86	egfr	egfr	NOUN
admet-337	306	87	.	.	PUNCT
admet-337	307	1	these	these	DET
admet-337	307	2	compounds	compound	NOUN
admet-337	307	3	have	have	AUX
admet-337	307	4	produced	produce	VERB
admet-337	307	5	orrs	orr	NOUN
admet-337	307	6	of	of	ADP
admet-337	307	7	35.5	35.5	NUM
admet-337	307	8	to	to	PART
admet-337	307	9	44	44	NUM
admet-337	307	10	%	%	NOUN
admet-337	307	11	,	,	PUNCT
admet-337	307	12	dcrs	dcrs	NOUN
admet-337	307	13	of	of	ADP
admet-337	307	14	65	65	NUM
admet-337	307	15	to	to	PART
admet-337	307	16	91	91	NUM
admet-337	307	17	%	%	NOUN
admet-337	307	18	and	and	CCONJ
admet-337	307	19	median	median	ADJ
admet-337	307	20	pfs	pf	NOUN
admet-337	307	21	of	of	ADP
admet-337	307	22	6.7	6.7	NUM
admet-337	307	23	months	month	NOUN
admet-337	307	24	to	to	ADP
admet-337	307	25	9.2	9.2	NUM
admet-337	307	26	months	month	NOUN
admet-337	307	27	,	,	PUNCT
admet-337	307	28	respectively	respectively	ADV
admet-337	307	29	[	[	X
admet-337	307	30	103,104	103,104	NUM
admet-337	307	31	]	]	PUNCT
admet-337	307	32	.	.	PUNCT
admet-337	308	1	epitinib	epitinib	PROPN
admet-337	308	2	(	(	PUNCT
admet-337	308	3	hmpl-813	hmpl-813	NOUN
admet-337	308	4	)	)	PUNCT
admet-337	308	5	is	be	AUX
admet-337	308	6	an	an	DET
admet-337	308	7	egfr	egfr	ADJ
admet-337	308	8	tki	tki	NOUN
admet-337	308	9	that	that	PRON
admet-337	308	10	was	be	AUX
admet-337	308	11	specifically	specifically	ADV
admet-337	308	12	designed	design	VERB
admet-337	308	13	for	for	ADP
admet-337	308	14	high	high	ADJ
admet-337	308	15	cns	cns	NOUN
admet-337	308	16	penetration	penetration	NOUN
admet-337	308	17	.	.	PUNCT
admet-337	309	1	in	in	ADP
admet-337	309	2	a	a	DET
admet-337	309	3	phase	phase	NOUN
admet-337	309	4	i	i	PRON
admet-337	309	5	study	study	VERB
admet-337	309	6	(	(	PUNCT
admet-337	309	7	nct02590952	nct02590952	NOUN
admet-337	309	8	)	)	PUNCT
admet-337	309	9	,	,	PUNCT
admet-337	309	10	the	the	DET
admet-337	309	11	drug	drug	NOUN
admet-337	309	12	was	be	AUX
admet-337	309	13	well	well	ADV
admet-337	309	14	-	-	PUNCT
admet-337	309	15	tolerated	tolerate	VERB
admet-337	309	16	,	,	PUNCT
admet-337	309	17	with	with	ADP
admet-337	309	18	grade	grade	NOUN
admet-337	309	19	3	3	NUM
admet-337	309	20	elevation	elevation	NOUN
admet-337	309	21	in	in	ADP
admet-337	309	22	liver	liver	NOUN
admet-337	309	23	function	function	NOUN
admet-337	309	24	tests	test	NOUN
admet-337	309	25	in	in	ADP
admet-337	309	26	2	2	NUM
admet-337	309	27	to	to	PART
admet-337	309	28	5	5	NUM
admet-337	309	29	%	%	NOUN
admet-337	309	30	of	of	ADP
admet-337	309	31	patients	patient	NOUN
admet-337	309	32	.	.	PUNCT
admet-337	310	1	in	in	ADP
admet-337	310	2	the	the	DET
admet-337	310	3	dose	dose	NOUN
admet-337	310	4	expansion	expansion	NOUN
admet-337	310	5	arm	arm	NOUN
admet-337	310	6	of	of	ADP
admet-337	310	7	the	the	DET
admet-337	310	8	study	study	NOUN
admet-337	310	9	,	,	PUNCT
admet-337	310	10	12	12	NUM
admet-337	310	11	patients	patient	NOUN
admet-337	310	12	were	be	AUX
admet-337	310	13	evaluable	evaluable	ADJ
admet-337	310	14	as	as	ADP
admet-337	310	15	of	of	ADP
admet-337	310	16	october	october	PROPN
admet-337	310	17	2015	2015	NUM
admet-337	310	18	.	.	PUNCT
admet-337	311	1	of	of	ADP
admet-337	311	2	these	these	PRON
admet-337	311	3	,	,	PUNCT
admet-337	311	4	5	5	NUM
admet-337	311	5	patients	patient	NOUN
admet-337	311	6	who	who	PRON
admet-337	311	7	were	be	AUX
admet-337	311	8	tki	tki	PROPN
admet-337	311	9	naïve	naïve	PROPN
admet-337	311	10	achieved	achieve	VERB
admet-337	311	11	a	a	DET
admet-337	311	12	pr	pr	NOUN
admet-337	311	13	both	both	CCONJ
admet-337	311	14	systemically	systemically	ADV
admet-337	311	15	and	and	CCONJ
admet-337	311	16	in	in	ADP
admet-337	311	17	the	the	DET
admet-337	311	18	cns	cns	NOUN
admet-337	311	19	.	.	PUNCT
admet-337	312	1	in	in	ADP
admet-337	312	2	5	5	NUM
admet-337	312	3	patients	patient	NOUN
admet-337	312	4	who	who	PRON
admet-337	312	5	had	have	VERB
admet-337	312	6	previous	previous	ADJ
admet-337	312	7	tki	tki	NOUN
admet-337	312	8	exposure	exposure	NOUN
admet-337	312	9	,	,	PUNCT
admet-337	312	10	all	all	PRON
admet-337	312	11	had	have	VERB
admet-337	312	12	stable	stable	ADJ
admet-337	312	13	disease	disease	NOUN
admet-337	312	14	in	in	ADP
admet-337	312	15	the	the	DET
admet-337	312	16	brain	brain	NOUN
admet-337	313	1	[	[	X
admet-337	313	2	105	105	NUM
admet-337	313	3	]	]	PUNCT
admet-337	313	4	.	.	PUNCT
admet-337	314	1	azd3759	azd3759	PROPN
admet-337	314	2	is	be	AUX
admet-337	314	3	another	another	DET
admet-337	314	4	egfr	egfr	ADJ
admet-337	314	5	tki	tki	NOUN
admet-337	314	6	designed	design	VERB
admet-337	314	7	to	to	PART
admet-337	314	8	have	have	VERB
admet-337	314	9	high	high	ADJ
admet-337	314	10	bbb	bbb	NOUN
admet-337	314	11	penetration	penetration	NOUN
admet-337	314	12	.	.	PUNCT
admet-337	315	1	in	in	ADP
admet-337	315	2	a	a	DET
admet-337	315	3	phase	phase	NOUN
admet-337	315	4	i	i	PRON
admet-337	315	5	trial	trial	NOUN
admet-337	315	6	(	(	PUNCT
admet-337	315	7	nct02228369	nct02228369	PROPN
admet-337	315	8	)	)	PUNCT
admet-337	315	9	of	of	ADP
admet-337	315	10	patients	patient	NOUN
admet-337	315	11	with	with	ADP
admet-337	315	12	egfr	egfr	ADJ
admet-337	315	13	-	-	PUNCT
admet-337	315	14	mutated	mutate	VERB
admet-337	315	15	nsclc	nsclc	NOUN
admet-337	315	16	and	and	CCONJ
admet-337	315	17	brain	brain	NOUN
admet-337	315	18	metastases	metastasis	NOUN
admet-337	315	19	,	,	PUNCT
admet-337	315	20	of	of	ADP
admet-337	315	21	the	the	DET
admet-337	315	22	2	2	NUM
admet-337	315	23	evaluable	evaluable	ADJ
admet-337	315	24	patients	patient	NOUN
admet-337	315	25	with	with	ADP
admet-337	315	26	brain	brain	NOUN
admet-337	315	27	metastases	metastasis	NOUN
admet-337	315	28	reported	report	VERB
admet-337	315	29	to	to	ADP
admet-337	315	30	date	date	NOUN
admet-337	315	31	,	,	PUNCT
admet-337	315	32	1	1	NUM
admet-337	315	33	patient	patient	NOUN
admet-337	315	34	achieved	achieve	VERB
admet-337	315	35	an	an	DET
admet-337	315	36	intracranial	intracranial	ADJ
admet-337	315	37	pr	pr	NOUN
admet-337	315	38	and	and	CCONJ
admet-337	315	39	the	the	DET
admet-337	315	40	other	other	ADJ
admet-337	315	41	had	have	VERB
admet-337	315	42	stable	stable	ADJ
admet-337	315	43	cns	cns	NOUN
admet-337	315	44	disease	disease	NOUN
admet-337	315	45	.	.	PUNCT
admet-337	316	1	the	the	DET
admet-337	316	2	trough	trough	NOUN
admet-337	316	3	csf	csf	VERB
admet-337	316	4	concentration	concentration	NOUN
admet-337	316	5	of	of	ADP
admet-337	316	6	azd3759	azd3759	NOUN
admet-337	316	7	was	be	AUX
admet-337	316	8	between	between	ADP
admet-337	316	9	6	6	NUM
admet-337	316	10	and	and	CCONJ
admet-337	316	11	7.7	7.7	NUM
admet-337	316	12	nm	nm	NOUN
admet-337	316	13	,	,	PUNCT
admet-337	316	14	which	which	PRON
admet-337	316	15	is	be	AUX
admet-337	316	16	close	close	ADJ
admet-337	316	17	to	to	ADP
admet-337	316	18	the	the	DET
admet-337	316	19	mutant	mutant	NOUN
admet-337	316	20	egfr	egfr	NOUN
admet-337	316	21	ic50	ic50	PROPN
admet-337	316	22	of	of	ADP
admet-337	316	23	azd3759	azd3759	NOUN
admet-337	316	24	[	[	X
admet-337	316	25	106	106	NUM
admet-337	316	26	]	]	PUNCT
admet-337	316	27	.	.	PUNCT
admet-337	317	1	tarloxotinib	tarloxotinib	NOUN
admet-337	317	2	bromide	bromide	NOUN
admet-337	317	3	(	(	PUNCT
admet-337	317	4	th-4000	th-4000	PROPN
admet-337	317	5	)	)	PUNCT
admet-337	317	6	is	be	AUX
admet-337	317	7	a	a	DET
admet-337	317	8	prodrug	prodrug	NOUN
admet-337	317	9	that	that	PRON
admet-337	317	10	is	be	AUX
admet-337	317	11	converted	convert	VERB
admet-337	317	12	to	to	ADP
admet-337	317	13	an	an	DET
admet-337	317	14	irreversible	irreversible	ADJ
admet-337	317	15	tki	tki	NOUN
admet-337	317	16	of	of	ADP
admet-337	317	17	wild	wild	ADJ
admet-337	317	18	-	-	PUNCT
admet-337	317	19	type	type	NOUN
admet-337	317	20	egfr	egfr	NOUN
admet-337	317	21	,	,	PUNCT
admet-337	317	22	mutant	mutant	ADJ
admet-337	317	23	egfr	egfr	NOUN
admet-337	317	24	and	and	CCONJ
admet-337	317	25	her2	her2	VERB
admet-337	317	26	under	under	ADP
admet-337	317	27	hypoxic	hypoxic	ADJ
admet-337	317	28	conditions	condition	NOUN
admet-337	317	29	.	.	PUNCT
admet-337	318	1	as	as	SCONJ
admet-337	318	2	the	the	DET
admet-337	318	3	tumor	tumor	NOUN
admet-337	318	4	environment	environment	NOUN
admet-337	318	5	is	be	AUX
admet-337	318	6	typically	typically	ADV
admet-337	318	7	hypoxic	hypoxic	ADJ
admet-337	318	8	,	,	PUNCT
admet-337	318	9	it	it	PRON
admet-337	318	10	is	be	AUX
admet-337	318	11	hypothesized	hypothesize	VERB
admet-337	318	12	that	that	SCONJ
admet-337	318	13	greater	great	ADJ
admet-337	318	14	intra	intra	ADJ
admet-337	318	15	-	-	ADJ
admet-337	318	16	tumoral	tumoral	ADJ
admet-337	318	17	tki	tki	PROPN
admet-337	318	18	exposure	exposure	NOUN
admet-337	318	19	and	and	CCONJ
admet-337	318	20	a	a	DET
admet-337	318	21	greater	great	ADJ
admet-337	318	22	therapeutic	therapeutic	ADJ
admet-337	318	23	index	index	NOUN
admet-337	318	24	will	will	AUX
admet-337	318	25	be	be	AUX
admet-337	318	26	achieved	achieve	VERB
admet-337	318	27	with	with	ADP
admet-337	318	28	this	this	DET
admet-337	318	29	drug	drug	NOUN
admet-337	318	30	,	,	PUNCT
admet-337	318	31	and	and	CCONJ
admet-337	318	32	egfr	egfr	PROPN
admet-337	318	33	tki	tki	PROPN
admet-337	318	34	resistance	resistance	NOUN
admet-337	318	35	has	have	AUX
admet-337	318	36	been	be	AUX
admet-337	318	37	overcome	overcome	VERB
admet-337	318	38	with	with	ADP
admet-337	318	39	th-4000	th-4000	NOUN
admet-337	318	40	in	in	ADP
admet-337	318	41	animal	animal	NOUN
admet-337	318	42	models	model	NOUN
admet-337	318	43	.	.	PUNCT
admet-337	319	1	it	it	PRON
admet-337	319	2	is	be	AUX
admet-337	319	3	currently	currently	ADV
admet-337	319	4	being	be	AUX
admet-337	319	5	investigated	investigate	VERB
admet-337	319	6	in	in	ADP
admet-337	319	7	a	a	DET
admet-337	319	8	phase	phase	NOUN
admet-337	319	9	ii	ii	PROPN
admet-337	319	10	study	study	NOUN
admet-337	319	11	(	(	PUNCT
admet-337	319	12	nct02454842	nct02454842	ADV
admet-337	319	13	)	)	PUNCT
admet-337	319	14	for	for	ADP
admet-337	319	15	patients	patient	NOUN
admet-337	319	16	with	with	ADP
admet-337	319	17	egfr	egfr	ADJ
admet-337	319	18	-	-	PUNCT
admet-337	319	19	mutated	mutate	VERB
admet-337	319	20	nsclc	nsclc	NOUN
admet-337	319	21	who	who	PRON
admet-337	319	22	have	have	VERB
admet-337	319	23	nont790	nont790	PROPN
admet-337	319	24	m	m	PRON
admet-337	319	25	mediated	mediate	VERB
admet-337	319	26	resistance	resistance	NOUN
admet-337	319	27	to	to	ADP
admet-337	319	28	first	first	ADJ
admet-337	319	29	-	-	PUNCT
admet-337	319	30	line	line	NOUN
admet-337	319	31	egfr	egfr	NOUN
admet-337	319	32	tki	tki	PROPN
admet-337	320	1	[	[	X
admet-337	320	2	107	107	NUM
admet-337	320	3	]	]	PUNCT
admet-337	320	4	.	.	PUNCT
admet-337	321	1	alk	alk	VERB
admet-337	321	2	fusion	fusion	NOUN
admet-337	321	3	protein	protein	NOUN
admet-337	321	4	in	in	ADP
admet-337	321	5	2007	2007	NUM
admet-337	321	6	,	,	PUNCT
admet-337	321	7	another	another	DET
admet-337	321	8	key	key	ADJ
admet-337	321	9	molecular	molecular	ADJ
admet-337	321	10	driver	driver	NOUN
admet-337	321	11	of	of	ADP
admet-337	321	12	nsclc	nsclc	NOUN
admet-337	321	13	was	be	AUX
admet-337	321	14	identified	identify	VERB
admet-337	321	15	.	.	PUNCT
admet-337	322	1	an	an	DET
admet-337	322	2	inversion	inversion	NOUN
admet-337	322	3	within	within	ADP
admet-337	322	4	chromosome	chromosome	NOUN
admet-337	322	5	2p	2p	NUM
admet-337	322	6	causes	cause	VERB
admet-337	322	7	the	the	DET
admet-337	322	8	fusion	fusion	NOUN
admet-337	322	9	of	of	ADP
admet-337	322	10	the	the	DET
admet-337	322	11	echinoderm	echinoderm	NOUN
admet-337	322	12	microtubule	microtubule	NOUN
admet-337	322	13	-	-	PUNCT
admet-337	322	14	associated	associate	VERB
admet-337	322	15	protein	protein	NOUN
admet-337	322	16	-	-	PUNCT
admet-337	322	17	like	like	ADJ
admet-337	322	18	4	4	NUM
admet-337	322	19	(	(	PUNCT
admet-337	322	20	eml4	eml4	PROPN
admet-337	322	21	)	)	PUNCT
admet-337	322	22	gene	gene	NOUN
admet-337	322	23	and	and	CCONJ
admet-337	322	24	the	the	DET
admet-337	322	25	anaplastic	anaplastic	ADJ
admet-337	322	26	lymphoma	lymphoma	NOUN
admet-337	322	27	kinase	kinase	PROPN
admet-337	322	28	(	(	PUNCT
admet-337	322	29	alk	alk	PROPN
admet-337	322	30	)	)	PUNCT
admet-337	322	31	gene	gene	NOUN
admet-337	322	32	[	[	X
admet-337	322	33	6,108	6,108	NUM
admet-337	322	34	]	]	PUNCT
admet-337	322	35	.	.	PUNCT
admet-337	323	1	at	at	ADV
admet-337	323	2	least	least	ADJ
admet-337	323	3	8	8	NUM
admet-337	323	4	different	different	ADJ
admet-337	323	5	eml4	eml4	NOUN
admet-337	323	6	-	-	PUNCT
admet-337	323	7	alk	alk	PROPN
admet-337	323	8	fusion	fusion	NOUN
admet-337	323	9	variants	variant	NOUN
admet-337	323	10	have	have	AUX
admet-337	323	11	been	be	AUX
admet-337	323	12	identified	identify	VERB
admet-337	323	13	.	.	PUNCT
admet-337	324	1	all	all	DET
admet-337	324	2	variants	variant	NOUN
admet-337	324	3	harbor	harbor	VERB
admet-337	324	4	a	a	DET
admet-337	324	5	breakpoint	breakpoint	NOUN
admet-337	324	6	at	at	ADP
admet-337	324	7	intron	intron	NOUN
admet-337	324	8	19	19	NUM
admet-337	324	9	of	of	ADP
admet-337	324	10	alk	alk	NOUN
admet-337	324	11	and	and	CCONJ
admet-337	324	12	variable	variable	ADJ
admet-337	324	13	intron	intron	ADJ
admet-337	324	14	breakpoints	breakpoint	NOUN
admet-337	324	15	in	in	ADP
admet-337	324	16	eml4	eml4	PROPN
admet-337	324	17	[	[	X
admet-337	324	18	109,110	109,110	NUM
admet-337	324	19	]	]	PUNCT
admet-337	324	20	.	.	PUNCT
admet-337	325	1	the	the	DET
admet-337	325	2	eml4	eml4	PROPN
admet-337	325	3	-	-	PUNCT
admet-337	325	4	alk	alk	PROPN
admet-337	325	5	oncogene	oncogene	NOUN
admet-337	325	6	generates	generate	VERB
admet-337	325	7	the	the	DET
admet-337	325	8	eml4	eml4	PROPN
admet-337	325	9	-	-	PUNCT
admet-337	325	10	alk	alk	NOUN
admet-337	325	11	fusion	fusion	NOUN
admet-337	325	12	protein	protein	NOUN
admet-337	325	13	and	and	CCONJ
admet-337	325	14	all	all	DET
admet-337	325	15	variants	variant	NOUN
admet-337	325	16	of	of	ADP
admet-337	325	17	this	this	DET
admet-337	325	18	protein	protein	NOUN
admet-337	325	19	contain	contain	VERB
admet-337	325	20	an	an	DET
admet-337	325	21	eml4	eml4	PROPN
admet-337	325	22	transmembrane	transmembrane	NOUN
admet-337	325	23	domain	domain	NOUN
admet-337	325	24	and	and	CCONJ
admet-337	325	25	an	an	DET
admet-337	325	26	intracellular	intracellular	ADJ
admet-337	325	27	alk	alk	NOUN
admet-337	325	28	tyrosine	tyrosine	PROPN
admet-337	325	29	kinase	kinase	PROPN
admet-337	325	30	domain	domain	PROPN
admet-337	325	31	.	.	PUNCT
admet-337	326	1	the	the	DET
admet-337	326	2	eml4	eml4	PROPN
admet-337	326	3	domain	domain	NOUN
admet-337	326	4	promotes	promote	VERB
admet-337	326	5	self	self	NOUN
admet-337	326	6	-	-	PUNCT
admet-337	326	7	association	association	NOUN
admet-337	326	8	of	of	ADP
admet-337	326	9	the	the	DET
admet-337	326	10	alk	alk	PROPN
admet-337	326	11	tyrosine	tyrosine	PROPN
admet-337	326	12	kinase	kinase	PROPN
admet-337	326	13	domain	domain	PROPN
admet-337	326	14	driving	driving	NOUN
admet-337	326	15	autophosphorylation	autophosphorylation	NOUN
admet-337	326	16	and	and	CCONJ
admet-337	326	17	downstream	downstream	ADJ
admet-337	326	18	signaling	signal	VERB
admet-337	326	19	,	,	PUNCT
admet-337	326	20	promoting	promote	VERB
admet-337	326	21	oncogenesis	oncogenesis	NOUN
admet-337	326	22	through	through	ADP
admet-337	326	23	pi3k	pi3k	PROPN
admet-337	326	24	/	/	SYM
admet-337	326	25	akt	akt	PROPN
admet-337	326	26	and	and	CCONJ
admet-337	326	27	jak	jak	PROPN
admet-337	326	28	/	/	SYM
admet-337	326	29	stat	stat	PROPN
admet-337	326	30	pathways	pathway	NOUN
admet-337	327	1	[	[	X
admet-337	327	2	6,111	6,111	NUM
admet-337	327	3	]	]	PUNCT
admet-337	327	4	.	.	PUNCT
admet-337	328	1	the	the	DET
admet-337	328	2	eml4	eml4	PROPN
admet-337	328	3	-	-	PUNCT
admet-337	328	4	alk	alk	PROPN
admet-337	328	5	fusion	fusion	NOUN
admet-337	328	6	mutation	mutation	NOUN
admet-337	328	7	occurs	occur	VERB
admet-337	328	8	in	in	ADP
admet-337	328	9	approximately	approximately	ADV
admet-337	328	10	3	3	NUM
admet-337	328	11	to	to	PART
admet-337	328	12	7	7	NUM
admet-337	328	13	%	%	NOUN
admet-337	328	14	of	of	ADP
admet-337	328	15	nsclc	nsclc	NOUN
admet-337	328	16	(	(	PUNCT
admet-337	328	17	typically	typically	ADV
admet-337	328	18	adenocarcinoma	adenocarcinoma	ADJ
admet-337	328	19	)	)	PUNCT
admet-337	328	20	with	with	ADP
admet-337	328	21	a	a	DET
admet-337	328	22	predilection	predilection	NOUN
admet-337	328	23	for	for	ADP
admet-337	328	24	younger	young	ADJ
admet-337	328	25	patients	patient	NOUN
admet-337	328	26	with	with	ADP
admet-337	328	27	low	low	ADJ
admet-337	328	28	tobacco	tobacco	NOUN
admet-337	328	29	exposure	exposure	NOUN
admet-337	328	30	[	[	X
admet-337	328	31	112	112	NUM
admet-337	328	32	]	]	PUNCT
admet-337	328	33	.	.	PUNCT
admet-337	329	1	currently	currently	ADV
admet-337	329	2	,	,	PUNCT
admet-337	329	3	there	there	PRON
admet-337	329	4	are	be	VERB
admet-337	329	5	three	three	NUM
admet-337	329	6	alk	alk	NOUN
admet-337	329	7	tkis	tkis	NOUN
admet-337	329	8	,	,	PUNCT
admet-337	329	9	which	which	PRON
admet-337	329	10	have	have	VERB
admet-337	329	11	widespread	widespread	ADJ
admet-337	329	12	clinical	clinical	ADJ
admet-337	329	13	approval	approval	NOUN
admet-337	329	14	for	for	ADP
admet-337	329	15	the	the	DET
admet-337	329	16	treatment	treatment	NOUN
admet-337	329	17	of	of	ADP
admet-337	329	18	alk	alk	NOUN
admet-337	329	19	-	-	PUNCT
admet-337	329	20	positive	positive	ADJ
admet-337	329	21	nsclc	nsclc	NOUN
admet-337	329	22	(	(	PUNCT
admet-337	329	23	table	table	NOUN
admet-337	329	24	3	3	NUM
admet-337	329	25	)	)	PUNCT
admet-337	329	26	.	.	PUNCT
admet-337	330	1	alk	alk	VERB
admet-337	330	2	tkis	tkis	PROPN
admet-337	330	3	crizotinib	crizotinib	VERB
admet-337	330	4	clinical	clinical	ADJ
admet-337	330	5	efficacy	efficacy	NOUN
admet-337	330	6	crizotinib	crizotinib	NOUN
admet-337	330	7	first	first	ADV
admet-337	330	8	gained	gain	VERB
admet-337	330	9	accelerated	accelerate	VERB
admet-337	330	10	fda	fda	PROPN
admet-337	330	11	approval	approval	NOUN
admet-337	330	12	in	in	ADP
admet-337	330	13	august	august	PROPN
admet-337	330	14	2011	2011	NUM
admet-337	330	15	for	for	ADP
admet-337	330	16	all	all	DET
admet-337	330	17	patients	patient	NOUN
admet-337	330	18	with	with	ADP
admet-337	330	19	advanced	advanced	ADJ
admet-337	330	20	alkpositive	alkpositive	ADJ
admet-337	330	21	nsclc	nsclc	NOUN
admet-337	330	22	based	base	VERB
admet-337	330	23	on	on	ADP
admet-337	330	24	two	two	NUM
admet-337	330	25	small	small	ADJ
admet-337	330	26	phase	phase	NOUN
admet-337	330	27	i	i	PRON
admet-337	330	28	/	/	SYM
admet-337	330	29	ii	ii	PROPN
admet-337	330	30	clinical	clinical	ADJ
admet-337	330	31	trials	trial	NOUN
admet-337	330	32	,	,	PUNCT
admet-337	330	33	which	which	PRON
admet-337	330	34	demonstrated	demonstrate	VERB
admet-337	330	35	response	response	NOUN
admet-337	330	36	rates	rate	NOUN
admet-337	330	37	of	of	ADP
admet-337	330	38	50	50	NUM
admet-337	330	39	to	to	PART
admet-337	330	40	60	60	NUM
admet-337	330	41	%	%	NOUN
admet-337	330	42	and	and	CCONJ
admet-337	330	43	pfs	pf	VERB
admet-337	330	44	of	of	ADP
admet-337	330	45	over	over	ADP
admet-337	330	46	9	9	NUM
admet-337	330	47	months	month	NOUN
admet-337	331	1	[	[	X
admet-337	331	2	113,114	113,114	NUM
admet-337	331	3	]	]	PUNCT
admet-337	331	4	.	.	PUNCT
admet-337	332	1	regular	regular	ADJ
admet-337	332	2	approval	approval	NOUN
admet-337	332	3	for	for	ADP
admet-337	332	4	the	the	DET
admet-337	332	5	same	same	ADJ
admet-337	332	6	indication	indication	NOUN
admet-337	332	7	was	be	AUX
admet-337	332	8	granted	grant	VERB
admet-337	332	9	by	by	ADP
admet-337	332	10	the	the	DET
admet-337	332	11	fda	fda	PROPN
admet-337	332	12	in	in	ADP
admet-337	332	13	november	november	PROPN
admet-337	332	14	2013	2013	NUM
admet-337	332	15	due	due	ADP
admet-337	332	16	to	to	ADP
admet-337	332	17	evidence	evidence	NOUN
admet-337	332	18	presented	present	VERB
admet-337	332	19	in	in	ADP
admet-337	332	20	the	the	DET
admet-337	332	21	phase	phase	NOUN
admet-337	332	22	iii	iii	NOUN
admet-337	332	23	,	,	PUNCT
admet-337	332	24	open	open	ADJ
admet-337	332	25	label	label	NOUN
admet-337	332	26	profile	profile	NOUN
admet-337	332	27	1007	1007	NUM
admet-337	332	28	trial	trial	NOUN
admet-337	332	29	that	that	PRON
admet-337	332	30	compared	compare	VERB
admet-337	332	31	crizotinib	crizotinib	NOUN
admet-337	332	32	to	to	ADP
admet-337	332	33	docetaxel	docetaxel	NOUN
admet-337	332	34	or	or	CCONJ
admet-337	332	35	pemetrexed	pemetrexe	VERB
admet-337	332	36	for	for	ADP
admet-337	332	37	use	use	NOUN
admet-337	332	38	in	in	ADP
admet-337	332	39	advanced	advanced	ADJ
admet-337	332	40	alk	alk	VERB
admet-337	332	41	-	-	PUNCT
admet-337	332	42	positive	positive	ADJ
admet-337	332	43	nsclc	nsclc	NOUN
admet-337	332	44	.	.	PUNCT
admet-337	333	1	in	in	ADP
admet-337	333	2	347	347	NUM
admet-337	333	3	previously	previously	ADV
admet-337	333	4	treated	treat	VERB
admet-337	333	5	alk	alk	ADJ
admet-337	333	6	-	-	PUNCT
admet-337	333	7	positive	positive	ADJ
admet-337	333	8	patients	patient	NOUN
admet-337	333	9	,	,	PUNCT
admet-337	333	10	crizotinib	crizotinib	VERB
admet-337	333	11	produced	produce	VERB
admet-337	333	12	superior	superior	ADJ
admet-337	333	13	response	response	NOUN
admet-337	333	14	rates	rate	NOUN
admet-337	333	15	compared	compare	VERB
admet-337	333	16	with	with	ADP
admet-337	333	17	chemotherapy	chemotherapy	NOUN
admet-337	333	18	(	(	PUNCT
admet-337	333	19	orr	orr	PROPN
admet-337	333	20	65	65	NUM
admet-337	333	21	grace	grace	NOUN
admet-337	333	22	dy	dy	NOUN
admet-337	333	23	et	et	PROPN
admet-337	333	24	al	al	PROPN
admet-337	333	25	.	.	PROPN
admet-337	333	26	admet	admet	PROPN
admet-337	333	27	&	&	CCONJ
admet-337	333	28	dmpk	dmpk	PROPN
admet-337	333	29	4(3	4(3	NUM
admet-337	333	30	)	)	PUNCT
admet-337	333	31	(	(	PUNCT
admet-337	333	32	2016	2016	NUM
admet-337	333	33	)	)	PUNCT
admet-337	333	34	186	186	NUM
admet-337	333	35	-	-	SYM
admet-337	333	36	211	211	NUM
admet-337	333	37	198	198	NUM
admet-337	333	38	vs	vs	ADP
admet-337	333	39	20	20	NUM
admet-337	333	40	%	%	NOUN
admet-337	333	41	,	,	PUNCT
admet-337	333	42	respectively	respectively	ADV
admet-337	333	43	)	)	PUNCT
admet-337	333	44	.	.	PUNCT
admet-337	334	1	the	the	DET
admet-337	334	2	median	median	PROPN
admet-337	334	3	pfs	pfs	PROPN
admet-337	334	4	with	with	ADP
admet-337	334	5	crizotinib	crizotinib	NOUN
admet-337	334	6	was	be	AUX
admet-337	334	7	7.7	7.7	NUM
admet-337	334	8	months	month	NOUN
admet-337	334	9	vs	vs	ADP
admet-337	334	10	3.0	3.0	NUM
admet-337	334	11	months	month	NOUN
admet-337	334	12	with	with	ADP
admet-337	334	13	chemotherapy	chemotherapy	NOUN
admet-337	334	14	(	(	PUNCT
admet-337	334	15	hr	hr	NOUN
admet-337	334	16	for	for	ADP
admet-337	334	17	progression	progression	NOUN
admet-337	334	18	or	or	CCONJ
admet-337	334	19	death	death	NOUN
admet-337	334	20	with	with	ADP
admet-337	334	21	crizotinib	crizotinib	NOUN
admet-337	334	22	,	,	PUNCT
admet-337	334	23	0.49	0.49	NUM
admet-337	334	24	;	;	PUNCT
admet-337	334	25	95	95	NUM
admet-337	334	26	%	%	NOUN
admet-337	334	27	ci	ci	NOUN
admet-337	334	28	,	,	PUNCT
admet-337	334	29	0.37	0.37	NUM
admet-337	334	30	-	-	SYM
admet-337	334	31	0.64	0.64	NUM
admet-337	334	32	;	;	PUNCT
admet-337	334	33	p<0.001	p<0.001	X
admet-337	334	34	)	)	PUNCT
admet-337	335	1	[	[	X
admet-337	335	2	115	115	NUM
admet-337	335	3	]	]	PUNCT
admet-337	335	4	.	.	PUNCT
admet-337	336	1	in	in	ADP
admet-337	336	2	the	the	DET
admet-337	336	3	first	first	ADJ
admet-337	336	4	-	-	PUNCT
admet-337	336	5	line	line	NOUN
admet-337	336	6	treatment	treatment	NOUN
admet-337	336	7	setting	setting	NOUN
admet-337	336	8	,	,	PUNCT
admet-337	336	9	profile	profile	NOUN
admet-337	336	10	1014	1014	NUM
admet-337	336	11	compared	compare	VERB
admet-337	336	12	crizotinib	crizotinib	NOUN
admet-337	336	13	to	to	ADP
admet-337	336	14	pemetrexed	pemetrexed	ADJ
admet-337	336	15	plus	plus	CCONJ
admet-337	336	16	platinum	platinum	NOUN
admet-337	336	17	demonstrating	demonstrate	VERB
admet-337	336	18	superior	superior	ADJ
admet-337	336	19	orr	orr	PROPN
admet-337	336	20	(	(	PUNCT
admet-337	336	21	74	74	NUM
admet-337	336	22	%	%	NOUN
admet-337	336	23	vs	vs	ADP
admet-337	336	24	45	45	NUM
admet-337	336	25	%	%	NOUN
admet-337	336	26	;	;	PUNCT
admet-337	336	27	p<0.0001	p<0.0001	NOUN
admet-337	336	28	)	)	PUNCT
admet-337	336	29	and	and	CCONJ
admet-337	336	30	pfs	pfs	PROPN
admet-337	336	31	(	(	PUNCT
admet-337	336	32	10.9	10.9	NUM
admet-337	336	33	vs	vs	ADP
admet-337	336	34	7	7	NUM
admet-337	336	35	months	month	NOUN
admet-337	336	36	;	;	PUNCT
admet-337	336	37	hr	hr	NOUN
admet-337	336	38	0.45;95	0.45;95	X
admet-337	336	39	%	%	NOUN
admet-337	336	40	ci	ci	NOUN
admet-337	336	41	,	,	PUNCT
admet-337	336	42	0.35	0.35	NUM
admet-337	336	43	-	-	SYM
admet-337	336	44	0.60	0.60	NUM
admet-337	336	45	)	)	PUNCT
admet-337	336	46	with	with	ADP
admet-337	336	47	crizotinib	crizotinib	NOUN
admet-337	337	1	[	[	X
admet-337	337	2	116	116	NUM
admet-337	337	3	]	]	PUNCT
admet-337	337	4	.	.	PUNCT
admet-337	338	1	table	table	NOUN
admet-337	338	2	3	3	NUM
admet-337	338	3	.	.	PUNCT
admet-337	338	4	alk	alk	PROPN
admet-337	338	5	tki	tki	PROPN
admet-337	338	6	characteristics	characteristic	NOUN
admet-337	338	7	alk	alk	VERB
admet-337	338	8	tki	tki	PROPN
admet-337	338	9	name	name	NOUN
admet-337	338	10	crizotinib	crizotinib	NOUN
admet-337	338	11	ceritinib	ceritinib	VERB
admet-337	338	12	alectinib	alectinib	NOUN
admet-337	338	13	primary	primary	ADJ
admet-337	338	14	targets	target	NOUN
admet-337	338	15	alk	alk	VERB
admet-337	338	16	c	c	VERB
admet-337	338	17	-	-	PUNCT
admet-337	338	18	met	meet	VERB
admet-337	338	19	ros1	ros1	PROPN
admet-337	338	20	alk	alk	PROPN
admet-337	338	21	(	(	PUNCT
admet-337	338	22	including	include	VERB
admet-337	338	23	crizotinib	crizotinib	VERB
admet-337	338	24	resistance	resistance	NOUN
admet-337	338	25	mutations	mutation	NOUN
admet-337	338	26	)	)	PUNCT
admet-337	338	27	igf-1r	igf-1r	PROPN
admet-337	338	28	insr	insr	NOUN
admet-337	338	29	ros1	ros1	PROPN
admet-337	338	30	alk	alk	PROPN
admet-337	338	31	(	(	PUNCT
admet-337	338	32	including	include	VERB
admet-337	338	33	crizotinib	crizotinib	VERB
admet-337	338	34	resistance	resistance	NOUN
admet-337	338	35	mutations	mutation	NOUN
admet-337	338	36	)	)	PUNCT
admet-337	338	37	ret	ret	NOUN
admet-337	338	38	type	type	NOUN
admet-337	338	39	of	of	ADP
admet-337	338	40	inhibition	inhibition	NOUN
admet-337	338	41	atp	atp	NOUN
admet-337	338	42	-	-	PUNCT
admet-337	338	43	competitive	competitive	ADJ
admet-337	338	44	atp	atp	NOUN
admet-337	338	45	-	-	PUNCT
admet-337	338	46	competitive	competitive	ADJ
admet-337	338	47	atp	atp	NOUN
admet-337	338	48	-	-	PUNCT
admet-337	338	49	competitive	competitive	ADJ
admet-337	338	50	clinical	clinical	ADJ
admet-337	338	51	approval	approval	NOUN
admet-337	338	52	first	first	ADJ
admet-337	338	53	-	-	PUNCT
admet-337	338	54	line	line	NOUN
admet-337	338	55	treatment	treatment	NOUN
admet-337	338	56	of	of	ADP
admet-337	338	57	advanced	advanced	ADJ
admet-337	338	58	alkpositive	alkpositive	ADJ
admet-337	338	59	nsclc	nsclc	NOUN
admet-337	338	60	second	second	ADJ
admet-337	338	61	-	-	PUNCT
admet-337	338	62	line	line	NOUN
admet-337	338	63	treatment	treatment	NOUN
admet-337	338	64	of	of	ADP
admet-337	338	65	advanced	advanced	ADJ
admet-337	338	66	alkpositive	alkpositive	ADJ
admet-337	338	67	nsclc	nsclc	NOUN
admet-337	338	68	second	second	ADJ
admet-337	338	69	-	-	PUNCT
admet-337	338	70	line	line	NOUN
admet-337	338	71	treatment	treatment	NOUN
admet-337	338	72	of	of	ADP
admet-337	338	73	advanced	advanced	ADJ
admet-337	338	74	alkpositive	alkpositive	ADJ
admet-337	338	75	nsclc	nsclc	NOUN
admet-337	338	76	alk	alk	PROPN
admet-337	338	77	ic50	ic50	PROPN
admet-337	338	78	(	(	PUNCT
admet-337	338	79	cell	cell	NOUN
admet-337	338	80	free	free	ADJ
admet-337	338	81	assay)[23	assay)[23	PROPN
admet-337	338	82	]	]	PUNCT
admet-337	338	83	3.6	3.6	NUM
admet-337	338	84	nm	nm	NOUN
admet-337	338	85	0.15	0.15	NUM
admet-337	338	86	nm	nm	NOUN
admet-337	338	87	1.9	1.9	NUM
admet-337	338	88	nm	nm	ADJ
admet-337	338	89	drug	drug	NOUN
admet-337	338	90	interactions	interaction	NOUN
admet-337	338	91	cyp3a4	cyp3a4	VERB
admet-337	338	92	inducers	inducer	NOUN
admet-337	338	93	/	/	SYM
admet-337	338	94	inhibitors	inhibitor	NOUN
admet-337	338	95	p	p	NOUN
admet-337	338	96	-	-	PUNCT
admet-337	338	97	gp	gp	NOUN
admet-337	338	98	inducers	inducer	NOUN
admet-337	338	99	/	/	SYM
admet-337	338	100	inhibitors	inhibitor	NOUN
admet-337	338	101	cyp3a4	cyp3a4	VERB
admet-337	338	102	inducers	inducer	NOUN
admet-337	338	103	/	/	SYM
admet-337	338	104	inhibitors	inhibitor	NOUN
admet-337	338	105	p	p	NOUN
admet-337	338	106	-	-	PUNCT
admet-337	338	107	gp	gp	NOUN
admet-337	338	108	inducers	inducer	NOUN
admet-337	338	109	/	/	SYM
admet-337	338	110	inhibitors	inhibitor	NOUN
admet-337	338	111	cyp3a4	cyp3a4	VERB
admet-337	338	112	minor	minor	ADJ
admet-337	338	113	substrate	substrate	NOUN
admet-337	338	114	,	,	PUNCT
admet-337	338	115	no	no	DET
admet-337	338	116	significant	significant	ADJ
admet-337	338	117	interactions	interaction	NOUN
admet-337	338	118	with	with	ADP
admet-337	338	119	inducers	inducer	NOUN
admet-337	338	120	/	/	SYM
admet-337	338	121	inhibitors	inhibitor	NOUN
admet-337	338	122	food	food	NOUN
admet-337	338	123	interactions	interaction	NOUN
admet-337	338	124	take	take	VERB
admet-337	338	125	with	with	ADP
admet-337	338	126	or	or	CCONJ
admet-337	338	127	without	without	ADP
admet-337	338	128	food	food	NOUN
admet-337	338	129	.	.	PUNCT
admet-337	339	1	high	high	ADJ
admet-337	339	2	fat	fat	ADJ
admet-337	339	3	meal	meal	NOUN
admet-337	339	4	increases	increase	VERB
admet-337	339	5	bioavailability	bioavailability	NOUN
admet-337	339	6	.	.	PUNCT
admet-337	340	1	take	take	VERB
admet-337	340	2	on	on	ADP
admet-337	340	3	empty	empty	ADJ
admet-337	340	4	stomach	stomach	NOUN
admet-337	340	5	.	.	PUNCT
admet-337	341	1	high	high	ADJ
admet-337	341	2	fat	fat	ADJ
admet-337	341	3	meal	meal	NOUN
admet-337	341	4	increases	increase	VERB
admet-337	341	5	bioavailability	bioavailability	NOUN
admet-337	341	6	.	.	PUNCT
admet-337	342	1	take	take	VERB
admet-337	342	2	with	with	ADP
admet-337	342	3	food	food	NOUN
admet-337	342	4	.	.	PUNCT
admet-337	343	1	metabolism	metabolism	NOUN
admet-337	343	2	liver	liver	NOUN
admet-337	343	3	cyp3a4/5	cyp3a4/5	NOUN
admet-337	343	4	liver	liver	NOUN
admet-337	343	5	cyp3a4	cyp3a4	NOUN
admet-337	343	6	liver	liver	NOUN
admet-337	343	7	cyp3a4	cyp3a4	NOUN
admet-337	343	8	method	method	NOUN
admet-337	343	9	of	of	ADP
admet-337	343	10	elimination	elimination	NOUN
admet-337	343	11	63	63	NUM
admet-337	343	12	%	%	NOUN
admet-337	343	13	feces	fece	NOUN
admet-337	343	14	(	(	PUNCT
admet-337	343	15	53	53	NUM
admet-337	343	16	%	%	NOUN
admet-337	343	17	unchanged	unchanged	ADJ
admet-337	343	18	)	)	PUNCT
admet-337	343	19	22	22	NUM
admet-337	343	20	%	%	NOUN
admet-337	343	21	urine	urine	NOUN
admet-337	343	22	(	(	PUNCT
admet-337	343	23	2	2	NUM
admet-337	343	24	%	%	NOUN
admet-337	343	25	unchanged	unchanged	ADJ
admet-337	343	26	drug	drug	NOUN
admet-337	343	27	)	)	PUNCT
admet-337	343	28	92	92	NUM
admet-337	343	29	%	%	NOUN
admet-337	343	30	feces	fece	NOUN
admet-337	343	31	(	(	PUNCT
admet-337	343	32	68	68	NUM
admet-337	343	33	%	%	NOUN
admet-337	343	34	unchanged	unchanged	ADJ
admet-337	343	35	)	)	PUNCT
admet-337	343	36	1	1	NUM
admet-337	343	37	%	%	NOUN
admet-337	343	38	urine	urine	NOUN
admet-337	343	39	98	98	NUM
admet-337	343	40	%	%	NOUN
admet-337	343	41	feces	fece	NOUN
admet-337	343	42	(	(	PUNCT
admet-337	343	43	84	84	NUM
admet-337	343	44	%	%	NOUN
admet-337	343	45	unchanged	unchanged	ADJ
admet-337	343	46	)	)	PUNCT
admet-337	343	47	<	<	X
admet-337	343	48	1	1	NUM
admet-337	343	49	%	%	NOUN
admet-337	343	50	urine	urine	NOUN
admet-337	343	51	cns	cns	NOUN
admet-337	343	52	penetration	penetration	NOUN
admet-337	343	53	0.06	0.06	NUM
admet-337	343	54	-	-	SYM
admet-337	343	55	0.26	0.26	NUM
admet-337	343	56	%	%	NOUN
admet-337	343	57	cns	cns	NOUN
admet-337	343	58	penetration	penetration	NOUN
admet-337	343	59	intracranial	intracranial	ADJ
admet-337	343	60	disease	disease	NOUN
admet-337	343	61	control	control	VERB
admet-337	343	62	80	80	NUM
admet-337	343	63	%	%	NOUN
admet-337	343	64	.	.	PUNCT
admet-337	344	1	csf	csf	ADJ
admet-337	344	2	concentrations	concentration	NOUN
admet-337	344	3	unpublished	unpublished	ADJ
admet-337	344	4	to	to	ADP
admet-337	344	5	date	date	NOUN
admet-337	344	6	.	.	PUNCT
admet-337	345	1	86	86	NUM
admet-337	345	2	%	%	NOUN
admet-337	345	3	cns	cns	NOUN
admet-337	345	4	penetration	penetration	NOUN
admet-337	345	5	in	in	ADP
admet-337	345	6	4	4	NUM
admet-337	345	7	patient	patient	ADJ
admet-337	345	8	study	study	NOUN
admet-337	345	9	clinical	clinical	ADJ
admet-337	345	10	safety	safety	NOUN
admet-337	345	11	crizotinib	crizotinib	NOUN
admet-337	345	12	produces	produce	VERB
admet-337	345	13	unique	unique	ADJ
admet-337	345	14	visual	visual	ADJ
admet-337	345	15	disturbances	disturbance	NOUN
admet-337	345	16	in	in	ADP
admet-337	345	17	up	up	ADP
admet-337	345	18	to	to	PART
admet-337	345	19	70	70	NUM
admet-337	345	20	%	%	NOUN
admet-337	345	21	of	of	ADP
admet-337	345	22	patients	patient	NOUN
admet-337	345	23	,	,	PUNCT
admet-337	345	24	though	though	SCONJ
admet-337	345	25	these	these	PRON
admet-337	345	26	are	be	AUX
admet-337	345	27	rarely	rarely	ADV
admet-337	345	28	severe	severe	ADJ
admet-337	345	29	.	.	PUNCT
admet-337	346	1	the	the	DET
admet-337	346	2	visual	visual	ADJ
admet-337	346	3	disturbances	disturbance	NOUN
admet-337	346	4	are	be	AUX
admet-337	346	5	pronounced	pronounce	VERB
admet-337	346	6	with	with	ADP
admet-337	346	7	changes	change	NOUN
admet-337	346	8	in	in	ADP
admet-337	346	9	ambient	ambient	ADJ
admet-337	346	10	lighting	lighting	NOUN
admet-337	346	11	and	and	CCONJ
admet-337	346	12	can	can	AUX
admet-337	346	13	present	present	VERB
admet-337	346	14	as	as	ADP
admet-337	346	15	floaters	floater	NOUN
admet-337	346	16	,	,	PUNCT
admet-337	346	17	trails	trail	NOUN
admet-337	346	18	or	or	CCONJ
admet-337	346	19	flashes	flash	NOUN
admet-337	346	20	of	of	ADP
admet-337	346	21	light	light	NOUN
admet-337	346	22	in	in	ADP
admet-337	346	23	the	the	DET
admet-337	346	24	peripheral	peripheral	ADJ
admet-337	346	25	vision	vision	NOUN
admet-337	346	26	.	.	PUNCT
admet-337	347	1	vision	vision	NOUN
admet-337	347	2	changes	change	NOUN
admet-337	347	3	tend	tend	VERB
admet-337	347	4	to	to	PART
admet-337	347	5	be	be	AUX
admet-337	347	6	mild	mild	ADJ
admet-337	347	7	,	,	PUNCT
admet-337	347	8	brief	brief	ADJ
admet-337	347	9	,	,	PUNCT
admet-337	347	10	and	and	CCONJ
admet-337	347	11	self	self	NOUN
admet-337	347	12	-	-	PUNCT
admet-337	347	13	limited	limit	VERB
admet-337	347	14	and	and	CCONJ
admet-337	347	15	no	no	DET
admet-337	347	16	associated	associated	ADJ
admet-337	347	17	ophthalmologic	ophthalmologic	ADJ
admet-337	347	18	changes	change	NOUN
admet-337	347	19	were	be	AUX
admet-337	347	20	identified	identify	VERB
admet-337	347	21	in	in	ADP
admet-337	347	22	patients	patient	NOUN
admet-337	347	23	on	on	ADP
admet-337	347	24	the	the	DET
admet-337	347	25	profile	profile	ADJ
admet-337	347	26	1005	1005	NUM
admet-337	347	27	study	study	NOUN
admet-337	347	28	.	.	PUNCT
admet-337	348	1	dose	dose	NOUN
admet-337	348	2	adjustment	adjustment	NOUN
admet-337	348	3	is	be	AUX
admet-337	348	4	rarely	rarely	ADV
admet-337	348	5	needed	need	VERB
admet-337	348	6	for	for	ADP
admet-337	348	7	vision	vision	NOUN
admet-337	348	8	changes	change	NOUN
admet-337	348	9	[	[	X
admet-337	348	10	113,116,117	113,116,117	NUM
admet-337	348	11	]	]	PUNCT
admet-337	348	12	.	.	PUNCT
admet-337	349	1	diarrhea	diarrhea	PROPN
admet-337	349	2	,	,	PUNCT
admet-337	349	3	peripheral	peripheral	ADJ
admet-337	349	4	edema	edema	NOUN
admet-337	349	5	,	,	PUNCT
admet-337	349	6	and	and	CCONJ
admet-337	349	7	vomiting	vomiting	NOUN
admet-337	349	8	occur	occur	VERB
admet-337	349	9	in	in	ADP
admet-337	349	10	approximately	approximately	ADV
admet-337	349	11	50	50	NUM
admet-337	349	12	to	to	PART
admet-337	349	13	60	60	NUM
admet-337	349	14	%	%	NOUN
admet-337	349	15	of	of	ADP
admet-337	349	16	patients	patient	NOUN
admet-337	349	17	,	,	PUNCT
admet-337	349	18	but	but	CCONJ
admet-337	349	19	reach	reach	VERB
admet-337	349	20	grade	grade	NOUN
admet-337	349	21	3	3	NUM
admet-337	349	22	or	or	CCONJ
admet-337	349	23	4	4	NUM
admet-337	349	24	toxicity	toxicity	NOUN
admet-337	349	25	in	in	ADP
admet-337	349	26	less	less	ADJ
admet-337	349	27	than	than	ADP
admet-337	349	28	5	5	NUM
admet-337	349	29	%	%	NOUN
admet-337	349	30	of	of	ADP
admet-337	349	31	patients	patient	NOUN
admet-337	349	32	.	.	PUNCT
admet-337	350	1	grade	grade	NOUN
admet-337	350	2	3	3	NUM
admet-337	350	3	or	or	CCONJ
admet-337	350	4	4	4	NUM
admet-337	350	5	elevations	elevation	NOUN
admet-337	350	6	of	of	ADP
admet-337	350	7	aminotransferase	aminotransferase	NOUN
admet-337	350	8	levels	level	NOUN
admet-337	350	9	occur	occur	VERB
admet-337	350	10	in	in	ADP
admet-337	350	11	up	up	ADP
admet-337	350	12	to	to	PART
admet-337	350	13	15	15	NUM
admet-337	350	14	%	%	NOUN
admet-337	350	15	of	of	ADP
admet-337	350	16	patients	patient	NOUN
admet-337	350	17	receiving	receive	VERB
admet-337	350	18	crizotinib	crizotinib	NOUN
admet-337	350	19	and	and	CCONJ
admet-337	350	20	can	can	AUX
admet-337	350	21	be	be	AUX
admet-337	350	22	managed	manage	VERB
admet-337	350	23	with	with	ADP
admet-337	350	24	dose	dose	NOUN
admet-337	350	25	interruptions	interruption	NOUN
admet-337	350	26	or	or	CCONJ
admet-337	350	27	reductions	reduction	NOUN
admet-337	350	28	.	.	PUNCT
admet-337	351	1	treatment	treatment	NOUN
admet-337	351	2	discontinuation	discontinuation	NOUN
admet-337	351	3	is	be	AUX
admet-337	351	4	rarely	rarely	ADV
admet-337	351	5	necessary	necessary	ADJ
admet-337	351	6	for	for	ADP
admet-337	351	7	liver	liver	NOUN
admet-337	351	8	function	function	NOUN
admet-337	351	9	abnormalities	abnormality	NOUN
admet-337	351	10	[	[	X
admet-337	351	11	113,116	113,116	NUM
admet-337	351	12	]	]	PUNCT
admet-337	351	13	.	.	PUNCT
admet-337	352	1	symptomatic	symptomatic	ADJ
admet-337	352	2	hypogonadism	hypogonadism	NOUN
admet-337	352	3	has	have	AUX
admet-337	352	4	been	be	AUX
admet-337	352	5	linked	link	VERB
admet-337	352	6	to	to	PART
admet-337	352	7	crizotinib	crizotinib	VERB
admet-337	352	8	use	use	NOUN
admet-337	352	9	in	in	ADP
admet-337	352	10	male	male	ADJ
admet-337	352	11	patients	patient	NOUN
admet-337	352	12	.	.	PUNCT
admet-337	353	1	in	in	ADP
admet-337	353	2	one	one	NUM
admet-337	353	3	study	study	NOUN
admet-337	353	4	,	,	PUNCT
admet-337	353	5	84	84	NUM
admet-337	353	6	%	%	NOUN
admet-337	353	7	of	of	ADP
admet-337	353	8	male	male	ADJ
admet-337	353	9	patients	patient	NOUN
admet-337	353	10	were	be	AUX
admet-337	353	11	found	find	VERB
admet-337	353	12	to	to	PART
admet-337	353	13	have	have	VERB
admet-337	353	14	low	low	ADJ
admet-337	353	15	free	free	ADJ
admet-337	353	16	testosterone	testosterone	NOUN
admet-337	353	17	levels	level	NOUN
admet-337	353	18	while	while	SCONJ
admet-337	353	19	taking	take	VERB
admet-337	353	20	crizotinib	crizotinib	NOUN
admet-337	353	21	with	with	ADP
admet-337	353	22	concomitant	concomitant	ADJ
admet-337	353	23	decline	decline	NOUN
admet-337	353	24	in	in	ADP
admet-337	353	25	fsh	fsh	NOUN
admet-337	353	26	and	and	CCONJ
admet-337	353	27	lh	lh	PROPN
admet-337	353	28	,	,	PUNCT
admet-337	353	29	suggesting	suggest	VERB
admet-337	353	30	that	that	SCONJ
admet-337	353	31	crizotinib	crizotinib	NOUN
admet-337	353	32	may	may	AUX
admet-337	353	33	induce	induce	VERB
admet-337	353	34	secondary	secondary	ADJ
admet-337	353	35	hypogonadism	hypogonadism	NOUN
admet-337	353	36	[	[	X
admet-337	353	37	118	118	NUM
admet-337	353	38	]	]	PUNCT
admet-337	353	39	.	.	PUNCT
admet-337	354	1	therefore	therefore	ADV
admet-337	354	2	,	,	PUNCT
admet-337	354	3	monitoring	monitoring	NOUN
admet-337	354	4	of	of	ADP
admet-337	354	5	free	free	ADJ
admet-337	354	6	testosterone	testosterone	NOUN
admet-337	354	7	may	may	AUX
admet-337	354	8	be	be	AUX
admet-337	354	9	necessary	necessary	ADJ
admet-337	354	10	in	in	ADP
admet-337	354	11	males	male	NOUN
admet-337	354	12	taking	take	VERB
admet-337	354	13	admet	admet	PROPN
admet-337	354	14	&	&	CCONJ
admet-337	354	15	dmpk	dmpk	PROPN
admet-337	354	16	4(3	4(3	NUM
admet-337	354	17	)	)	PUNCT
admet-337	354	18	(	(	PUNCT
admet-337	354	19	2016	2016	NUM
admet-337	354	20	)	)	PUNCT
admet-337	354	21	186	186	NUM
admet-337	354	22	-	-	SYM
admet-337	354	23	211	211	NUM
admet-337	354	24	tki	tki	NOUN
admet-337	354	25	for	for	ADP
admet-337	354	26	egfrand	egfrand	ADJ
admet-337	354	27	alk	alk	PROPN
admet-337	354	28	-	-	PUNCT
admet-337	354	29	mutated	mutate	VERB
admet-337	354	30	cell	cell	NOUN
admet-337	354	31	cancer	cancer	NOUN
admet-337	354	32	doi	doi	NOUN
admet-337	354	33	:	:	PUNCT
admet-337	354	34	10.5599	10.5599	NUM
admet-337	354	35	/	/	SYM
admet-337	354	36	admet.4.3.337	admet.4.3.337	CCONJ
admet-337	354	37	199	199	NUM
admet-337	354	38	crizotinib	crizotinib	NOUN
admet-337	354	39	,	,	PUNCT
admet-337	354	40	particularly	particularly	ADV
admet-337	354	41	in	in	ADP
admet-337	354	42	patients	patient	NOUN
admet-337	354	43	with	with	ADP
admet-337	354	44	symptoms	symptom	NOUN
admet-337	354	45	suggestive	suggestive	ADJ
admet-337	354	46	of	of	ADP
admet-337	354	47	androgen	androgen	NOUN
admet-337	354	48	deficiency	deficiency	NOUN
admet-337	354	49	.	.	PUNCT
admet-337	355	1	rare	rare	ADJ
admet-337	355	2	fatal	fatal	ADJ
admet-337	355	3	interstitial	interstitial	ADJ
admet-337	355	4	lung	lung	NOUN
admet-337	355	5	disease	disease	NOUN
admet-337	355	6	/	/	SYM
admet-337	355	7	pneumonitis	pneumonitis	NOUN
admet-337	355	8	has	have	AUX
admet-337	355	9	been	be	AUX
admet-337	355	10	reported	report	VERB
admet-337	355	11	[	[	X
admet-337	355	12	119	119	NUM
admet-337	355	13	]	]	PUNCT
admet-337	355	14	.	.	PUNCT
admet-337	356	1	bradycardia	bradycardia	PROPN
admet-337	356	2	and	and	CCONJ
admet-337	356	3	q	q	NOUN
admet-337	356	4	-	-	PUNCT
admet-337	356	5	t	t	NOUN
admet-337	356	6	prolongation	prolongation	NOUN
admet-337	356	7	can	can	AUX
admet-337	356	8	occur	occur	VERB
admet-337	356	9	in	in	ADP
admet-337	356	10	about	about	ADV
admet-337	356	11	5	5	NUM
admet-337	356	12	%	%	NOUN
admet-337	356	13	of	of	ADP
admet-337	356	14	patients	patient	NOUN
admet-337	356	15	taking	take	VERB
admet-337	356	16	crizotinib	crizotinib	NOUN
admet-337	356	17	[	[	X
admet-337	356	18	120	120	NUM
admet-337	356	19	]	]	PUNCT
admet-337	356	20	.	.	PUNCT
admet-337	357	1	pharmacology	pharmacology	NOUN
admet-337	357	2	crizotinib	crizotinib	PROPN
admet-337	357	3	,	,	PUNCT
admet-337	357	4	3-[(1r)-1-(2,6	3-[(1r)-1-(2,6	PROPN
admet-337	357	5	-	-	PUNCT
admet-337	357	6	dichloro-3	dichloro-3	PROPN
admet-337	357	7	-	-	PUNCT
admet-337	357	8	fluorophenyl)ethoxy]-5-(1	fluorophenyl)ethoxy]-5-(1	NOUN
admet-337	357	9	-	-	PUNCT
admet-337	357	10	piperidin-4	piperidin-4	VERB
admet-337	357	11	-	-	PUNCT
admet-337	357	12	ylopyrazol-4	ylopyrazol-4	NUM
admet-337	357	13	-	-	PUNCT
admet-337	357	14	yl)pyridine-2amine	yl)pyridine-2amine	NOUN
admet-337	358	1	[	[	X
admet-337	358	2	pf-2341066	pf-2341066	NOUN
admet-337	358	3	,	,	PUNCT
admet-337	358	4	xalkori	xalkori	X
admet-337	358	5	,	,	PUNCT
admet-337	358	6	(	(	PUNCT
admet-337	358	7	pfizer	pfizer	NOUN
admet-337	358	8	)	)	PUNCT
admet-337	358	9	]	]	PUNCT
admet-337	358	10	competes	compete	VERB
admet-337	358	11	with	with	ADP
admet-337	358	12	atp	atp	PROPN
admet-337	358	13	at	at	ADP
admet-337	358	14	the	the	DET
admet-337	358	15	catalytic	catalytic	ADJ
admet-337	358	16	domain	domain	NOUN
admet-337	358	17	of	of	ADP
admet-337	358	18	the	the	DET
admet-337	358	19	alk	alk	PROPN
admet-337	358	20	tyrosine	tyrosine	PROPN
admet-337	358	21	kinase	kinase	PROPN
admet-337	358	22	and	and	CCONJ
admet-337	358	23	mesenchymal	mesenchymal	ADJ
admet-337	358	24	-	-	ADJ
admet-337	358	25	epithelial	epithelial	ADJ
admet-337	358	26	transition	transition	NOUN
admet-337	358	27	factor	factor	NOUN
admet-337	358	28	(	(	PUNCT
admet-337	358	29	c	c	X
admet-337	358	30	-	-	PUNCT
admet-337	358	31	met	meet	VERB
admet-337	358	32	)	)	PUNCT
admet-337	358	33	kinase	kinase	NOUN
admet-337	359	1	[	[	X
admet-337	359	2	111	111	NUM
admet-337	359	3	]	]	PUNCT
admet-337	359	4	.	.	PUNCT
admet-337	360	1	identified	identify	VERB
admet-337	360	2	as	as	ADP
admet-337	360	3	a	a	DET
admet-337	360	4	potent	potent	ADJ
admet-337	360	5	inhibitor	inhibitor	NOUN
admet-337	360	6	of	of	ADP
admet-337	360	7	alk	alk	PROPN
admet-337	360	8	and	and	CCONJ
admet-337	360	9	c	c	AUX
admet-337	360	10	-	-	PUNCT
admet-337	360	11	met	meet	VERB
admet-337	360	12	in	in	ADP
admet-337	360	13	biochemical	biochemical	ADJ
admet-337	360	14	enzymatic	enzymatic	ADJ
admet-337	360	15	screens	screen	NOUN
admet-337	360	16	,	,	PUNCT
admet-337	360	17	crizotinib	crizotinib	PROPN
admet-337	360	18	inhibits	inhibit	VERB
admet-337	360	19	tyrosine	tyrosine	NOUN
admet-337	360	20	phosphorylation	phosphorylation	NOUN
admet-337	360	21	of	of	ADP
admet-337	360	22	npm	npm	PROPN
admet-337	360	23	-	-	PUNCT
admet-337	360	24	alk	alk	NOUN
admet-337	360	25	(	(	PUNCT
admet-337	360	26	a	a	DET
admet-337	360	27	fusion	fusion	NOUN
admet-337	360	28	protein	protein	NOUN
admet-337	360	29	present	present	ADJ
admet-337	360	30	in	in	ADP
admet-337	360	31	some	some	DET
admet-337	360	32	cases	case	NOUN
admet-337	360	33	of	of	ADP
admet-337	360	34	anaplastic	anaplastic	ADJ
admet-337	360	35	large	large	ADJ
admet-337	360	36	cell	cell	NOUN
admet-337	360	37	lymphoma	lymphoma	NOUN
admet-337	360	38	)	)	PUNCT
admet-337	360	39	with	with	ADP
admet-337	360	40	mean	mean	PROPN
admet-337	360	41	ic50	ic50	PROPN
admet-337	360	42	values	value	NOUN
admet-337	360	43	between	between	ADP
admet-337	360	44	25	25	NUM
admet-337	360	45	to	to	PART
admet-337	360	46	50	50	NUM
admet-337	360	47	nm	nm	NOUN
admet-337	360	48	and	and	CCONJ
admet-337	360	49	c	c	AUX
admet-337	360	50	-	-	PUNCT
admet-337	360	51	met	meet	VERB
admet-337	360	52	with	with	ADP
admet-337	360	53	mean	mean	PROPN
admet-337	360	54	ic50	ic50	PROPN
admet-337	360	55	values	value	NOUN
admet-337	360	56	of	of	ADP
admet-337	360	57	5	5	NUM
admet-337	360	58	to	to	PART
admet-337	360	59	20	20	NUM
admet-337	360	60	nm	nm	NOUN
admet-337	361	1	[	[	X
admet-337	361	2	121	121	NUM
admet-337	361	3	-	-	SYM
admet-337	361	4	123	123	NUM
admet-337	361	5	]	]	PUNCT
admet-337	361	6	.	.	PUNCT
admet-337	362	1	the	the	DET
admet-337	362	2	eml4	eml4	PROPN
admet-337	362	3	-	-	PUNCT
admet-337	362	4	alk	alk	NOUN
admet-337	362	5	fusion	fusion	NOUN
admet-337	362	6	protein	protein	NOUN
admet-337	362	7	is	be	AUX
admet-337	362	8	inhibited	inhibit	VERB
admet-337	362	9	less	less	ADV
admet-337	362	10	potently	potently	ADV
admet-337	362	11	by	by	ADP
admet-337	362	12	crizotinib	crizotinib	NOUN
admet-337	362	13	,	,	PUNCT
admet-337	362	14	with	with	ADP
admet-337	362	15	ic50	ic50	PROPN
admet-337	362	16	values	value	NOUN
admet-337	362	17	between	between	ADP
admet-337	362	18	250	250	NUM
admet-337	362	19	to	to	PART
admet-337	362	20	340	340	NUM
admet-337	362	21	nm	nm	NOUN
admet-337	363	1	[	[	X
admet-337	363	2	124,125	124,125	NUM
admet-337	363	3	]	]	PUNCT
admet-337	363	4	.	.	PUNCT
admet-337	364	1	the	the	DET
admet-337	364	2	recommended	recommend	VERB
admet-337	364	3	dose	dose	NOUN
admet-337	364	4	of	of	ADP
admet-337	364	5	crizotinib	crizotinib	NOUN
admet-337	364	6	is	be	AUX
admet-337	364	7	250	250	NUM
admet-337	364	8	mg	mg	NOUN
admet-337	364	9	administered	administer	VERB
admet-337	364	10	twice	twice	ADV
admet-337	364	11	daily	daily	ADV
admet-337	364	12	.	.	PUNCT
admet-337	365	1	food	food	NOUN
admet-337	365	2	does	do	AUX
admet-337	365	3	not	not	PART
admet-337	365	4	have	have	VERB
admet-337	365	5	a	a	DET
admet-337	365	6	significant	significant	ADJ
admet-337	365	7	impact	impact	NOUN
admet-337	365	8	on	on	ADP
admet-337	365	9	absorption	absorption	NOUN
admet-337	365	10	.	.	PUNCT
admet-337	366	1	bioavailability	bioavailability	NOUN
admet-337	366	2	of	of	ADP
admet-337	366	3	crizotinib	crizotinib	NOUN
admet-337	366	4	is	be	AUX
admet-337	366	5	43	43	NUM
admet-337	366	6	%	%	NOUN
admet-337	366	7	and	and	CCONJ
admet-337	366	8	peak	peak	NOUN
admet-337	366	9	plasma	plasma	NOUN
admet-337	366	10	concentration	concentration	NOUN
admet-337	366	11	is	be	AUX
admet-337	366	12	reached	reach	VERB
admet-337	366	13	at	at	ADP
admet-337	366	14	a	a	DET
admet-337	366	15	median	median	NOUN
admet-337	366	16	of	of	ADP
admet-337	366	17	4	4	NUM
admet-337	366	18	hours	hour	NOUN
admet-337	366	19	.	.	PUNCT
admet-337	367	1	the	the	DET
admet-337	367	2	drug	drug	NOUN
admet-337	367	3	is	be	AUX
admet-337	367	4	heavily	heavily	ADV
admet-337	367	5	protein	protein	NOUN
admet-337	367	6	bound	bind	VERB
admet-337	367	7	(	(	PUNCT
admet-337	367	8	91	91	NUM
admet-337	367	9	%	%	NOUN
admet-337	367	10	)	)	PUNCT
admet-337	367	11	with	with	ADP
admet-337	367	12	a	a	DET
admet-337	367	13	volume	volume	NOUN
admet-337	367	14	of	of	ADP
admet-337	367	15	distribution	distribution	NOUN
admet-337	367	16	of	of	ADP
admet-337	367	17	1772l	1772l	NUM
admet-337	367	18	and	and	CCONJ
admet-337	367	19	a	a	DET
admet-337	367	20	terminal	terminal	ADJ
admet-337	367	21	halflife	halflife	NOUN
admet-337	367	22	of	of	ADP
admet-337	367	23	42	42	NUM
admet-337	367	24	hours	hour	NOUN
admet-337	367	25	[	[	X
admet-337	367	26	126	126	NUM
admet-337	367	27	]	]	PUNCT
admet-337	367	28	.	.	PUNCT
admet-337	368	1	crizotinib	crizotinib	PROPN
admet-337	368	2	undergoes	undergo	VERB
admet-337	368	3	extensive	extensive	ADJ
admet-337	368	4	hepatic	hepatic	ADJ
admet-337	368	5	metabolism	metabolism	NOUN
admet-337	368	6	through	through	ADP
admet-337	368	7	the	the	DET
admet-337	368	8	cyp3a4/5	cyp3a4/5	NOUN
admet-337	368	9	pathway	pathway	NOUN
admet-337	368	10	,	,	PUNCT
admet-337	368	11	and	and	CCONJ
admet-337	368	12	cyp3a4	cyp3a4	NOUN
admet-337	368	13	inducers	inducer	NOUN
admet-337	368	14	and	and	CCONJ
admet-337	368	15	inhibitors	inhibitor	NOUN
admet-337	368	16	interact	interact	VERB
admet-337	368	17	with	with	ADP
admet-337	368	18	crizotinib	crizotinib	NOUN
admet-337	368	19	[	[	X
admet-337	368	20	126,127	126,127	NUM
admet-337	368	21	]	]	SYM
admet-337	368	22	.	.	PUNCT
admet-337	369	1	steady	steady	ADJ
admet-337	369	2	-	-	PUNCT
admet-337	369	3	state	state	NOUN
admet-337	369	4	is	be	AUX
admet-337	369	5	achieved	achieve	VERB
admet-337	369	6	within	within	ADP
admet-337	369	7	15	15	NUM
admet-337	369	8	days	day	NOUN
admet-337	369	9	,	,	PUNCT
admet-337	369	10	and	and	CCONJ
admet-337	369	11	crizotinib	crizotinib	VERB
admet-337	369	12	exhibits	exhibit	VERB
admet-337	369	13	a	a	DET
admet-337	369	14	non	non	ADJ
admet-337	369	15	-	-	ADJ
admet-337	369	16	linear	linear	ADJ
admet-337	369	17	pk	pk	NOUN
admet-337	369	18	,	,	PUNCT
admet-337	369	19	meaning	mean	VERB
admet-337	369	20	the	the	DET
admet-337	369	21	rate	rate	NOUN
admet-337	369	22	of	of	ADP
admet-337	369	23	clearance	clearance	NOUN
admet-337	369	24	decreases	decrease	VERB
admet-337	369	25	with	with	ADP
admet-337	369	26	multiple	multiple	ADJ
admet-337	369	27	dosing	dosing	NOUN
admet-337	369	28	.	.	PUNCT
admet-337	370	1	the	the	DET
admet-337	370	2	geometric	geometric	ADJ
admet-337	370	3	mean	mean	NOUN
admet-337	370	4	values	value	NOUN
admet-337	370	5	for	for	ADP
admet-337	370	6	cl	cl	NOUN
admet-337	370	7	/	/	SYM
admet-337	370	8	f	f	PROPN
admet-337	370	9	declined	decline	VERB
admet-337	370	10	from	from	ADP
admet-337	370	11	100	100	NUM
admet-337	370	12	l	l	NOUN
admet-337	370	13	/	/	SYM
admet-337	370	14	hr	hr	NOUN
admet-337	370	15	after	after	ADP
admet-337	370	16	a	a	DET
admet-337	370	17	single	single	ADJ
admet-337	370	18	dose	dose	NOUN
admet-337	370	19	of	of	ADP
admet-337	370	20	crizotinib	crizotinib	NOUN
admet-337	370	21	to	to	ADP
admet-337	370	22	64.5	64.5	NUM
admet-337	370	23	l	l	NOUN
admet-337	370	24	/	/	SYM
admet-337	370	25	hr	hr	NOUN
admet-337	370	26	and	and	CCONJ
admet-337	370	27	60.1	60.1	NUM
admet-337	370	28	l	l	NOUN
admet-337	370	29	/	/	SYM
admet-337	370	30	hr	hr	NOUN
admet-337	370	31	after	after	ADP
admet-337	370	32	15	15	NUM
admet-337	370	33	and	and	CCONJ
admet-337	370	34	28	28	NUM
admet-337	370	35	days	day	NOUN
admet-337	370	36	of	of	ADP
admet-337	370	37	dosing	dosing	NOUN
admet-337	370	38	,	,	PUNCT
admet-337	370	39	respectively	respectively	ADV
admet-337	370	40	.	.	PUNCT
admet-337	371	1	this	this	DET
admet-337	371	2	phenomenon	phenomenon	NOUN
admet-337	371	3	may	may	AUX
admet-337	371	4	be	be	AUX
admet-337	371	5	due	due	ADJ
admet-337	371	6	to	to	ADP
admet-337	371	7	autoinhibition	autoinhibition	NOUN
admet-337	371	8	of	of	ADP
admet-337	371	9	cyp3a4	cyp3a4	PROPN
admet-337	371	10	.	.	PUNCT
admet-337	372	1	age	age	NOUN
admet-337	372	2	,	,	PUNCT
admet-337	372	3	gender	gender	NOUN
admet-337	372	4	,	,	PUNCT
admet-337	372	5	race	race	NOUN
admet-337	372	6	and	and	CCONJ
admet-337	372	7	body	body	NOUN
admet-337	372	8	weight	weight	NOUN
admet-337	372	9	do	do	AUX
admet-337	372	10	not	not	PART
admet-337	372	11	appear	appear	VERB
admet-337	372	12	to	to	PART
admet-337	372	13	influence	influence	VERB
admet-337	372	14	the	the	DET
admet-337	372	15	pk	pk	NOUN
admet-337	372	16	of	of	ADP
admet-337	372	17	crizotinib	crizotinib	NOUN
admet-337	372	18	[	[	X
admet-337	372	19	128	128	NUM
admet-337	372	20	]	]	PUNCT
admet-337	372	21	.	.	PUNCT
admet-337	373	1	63	63	NUM
admet-337	373	2	%	%	NOUN
admet-337	373	3	of	of	ADP
admet-337	373	4	the	the	DET
admet-337	373	5	drug	drug	NOUN
admet-337	373	6	is	be	AUX
admet-337	373	7	eliminated	eliminate	VERB
admet-337	373	8	via	via	ADP
admet-337	373	9	the	the	DET
admet-337	373	10	feces	fece	NOUN
admet-337	373	11	(	(	PUNCT
admet-337	373	12	53	53	NUM
admet-337	373	13	%	%	NOUN
admet-337	373	14	unchanged	unchanged	ADJ
admet-337	373	15	)	)	PUNCT
admet-337	373	16	and	and	CCONJ
admet-337	373	17	22	22	NUM
admet-337	373	18	%	%	NOUN
admet-337	373	19	in	in	ADP
admet-337	373	20	the	the	DET
admet-337	373	21	urine	urine	NOUN
admet-337	373	22	(	(	PUNCT
admet-337	373	23	2.3	2.3	NUM
admet-337	373	24	%	%	NOUN
admet-337	373	25	unchanged	unchanged	ADJ
admet-337	373	26	)	)	PUNCT
admet-337	374	1	[	[	X
admet-337	374	2	126	126	NUM
admet-337	374	3	]	]	PUNCT
admet-337	374	4	.	.	PUNCT
admet-337	375	1	given	give	VERB
admet-337	375	2	the	the	DET
admet-337	375	3	extensive	extensive	ADJ
admet-337	375	4	hepatic	hepatic	ADJ
admet-337	375	5	metabolism	metabolism	NOUN
admet-337	375	6	of	of	ADP
admet-337	375	7	crizotinib	crizotinib	NOUN
admet-337	375	8	,	,	PUNCT
admet-337	375	9	caution	caution	NOUN
admet-337	375	10	is	be	AUX
admet-337	375	11	advised	advise	VERB
admet-337	375	12	in	in	ADP
admet-337	375	13	patients	patient	NOUN
admet-337	375	14	with	with	ADP
admet-337	375	15	liver	liver	NOUN
admet-337	375	16	dysfunction	dysfunction	NOUN
admet-337	375	17	,	,	PUNCT
admet-337	375	18	though	though	SCONJ
admet-337	375	19	no	no	DET
admet-337	375	20	specific	specific	ADJ
admet-337	375	21	dose	dose	NOUN
admet-337	375	22	adjustments	adjustment	NOUN
admet-337	375	23	are	be	AUX
admet-337	375	24	recommended	recommend	VERB
admet-337	375	25	.	.	PUNCT
admet-337	376	1	likewise	likewise	ADV
admet-337	376	2	,	,	PUNCT
admet-337	376	3	crizotinib	crizotinib	NOUN
admet-337	376	4	has	have	AUX
admet-337	376	5	not	not	PART
admet-337	376	6	been	be	AUX
admet-337	376	7	well	well	ADV
admet-337	376	8	-	-	PUNCT
admet-337	376	9	studied	study	VERB
admet-337	376	10	in	in	ADP
admet-337	376	11	patients	patient	NOUN
admet-337	376	12	with	with	ADP
admet-337	376	13	renal	renal	ADJ
admet-337	376	14	impairment	impairment	NOUN
admet-337	376	15	,	,	PUNCT
admet-337	376	16	and	and	CCONJ
admet-337	376	17	close	close	ADJ
admet-337	376	18	monitoring	monitoring	NOUN
admet-337	376	19	is	be	AUX
admet-337	376	20	advised	advise	VERB
admet-337	376	21	in	in	ADP
admet-337	376	22	this	this	DET
admet-337	376	23	setting	setting	NOUN
admet-337	376	24	.	.	PUNCT
admet-337	377	1	cns	cns	NOUN
admet-337	377	2	penetration	penetration	NOUN
admet-337	377	3	overall	overall	ADV
admet-337	377	4	,	,	PUNCT
admet-337	377	5	crizotinib	crizotinib	PROPN
admet-337	377	6	has	have	VERB
admet-337	377	7	poor	poor	ADJ
admet-337	377	8	cns	cns	NOUN
admet-337	377	9	penetration	penetration	NOUN
admet-337	377	10	.	.	PUNCT
admet-337	378	1	in	in	ADP
admet-337	378	2	a	a	DET
admet-337	378	3	29	29	NUM
admet-337	378	4	-	-	PUNCT
admet-337	378	5	year	year	NOUN
admet-337	378	6	-	-	PUNCT
admet-337	378	7	old	old	ADJ
admet-337	378	8	patient	patient	NOUN
admet-337	378	9	with	with	ADP
admet-337	378	10	metastatic	metastatic	ADJ
admet-337	378	11	alk	alk	VERB
admet-337	378	12	-	-	PUNCT
admet-337	378	13	positive	positive	ADJ
admet-337	378	14	nsclc	nsclc	NOUN
admet-337	378	15	,	,	PUNCT
admet-337	378	16	new	new	ADJ
admet-337	378	17	brain	brain	NOUN
admet-337	378	18	and	and	CCONJ
admet-337	378	19	leptomeningeal	leptomeningeal	NOUN
admet-337	378	20	metastases	metastasis	NOUN
admet-337	378	21	developed	develop	VERB
admet-337	378	22	7.5	7.5	NUM
admet-337	378	23	months	month	NOUN
admet-337	378	24	after	after	ADP
admet-337	378	25	starting	start	VERB
admet-337	378	26	crizotinib	crizotinib	PROPN
admet-337	378	27	.	.	PUNCT
admet-337	379	1	his	his	PRON
admet-337	379	2	plasma	plasma	NOUN
admet-337	379	3	crizotinib	crizotinib	VERB
admet-337	379	4	concentration	concentration	NOUN
admet-337	379	5	was	be	AUX
admet-337	379	6	237	237	NUM
admet-337	379	7	ng	ng	NOUN
admet-337	379	8	/	/	SYM
admet-337	379	9	ml	ml	PROPN
admet-337	379	10	,	,	PUNCT
admet-337	379	11	but	but	CCONJ
admet-337	379	12	his	his	PRON
admet-337	379	13	csf	csf	ADJ
admet-337	379	14	concentration	concentration	NOUN
admet-337	379	15	was	be	AUX
admet-337	379	16	only	only	ADV
admet-337	379	17	0.616	0.616	NUM
admet-337	379	18	ng	ng	PROPN
admet-337	379	19	/	/	SYM
admet-337	379	20	ml	ml	PROPN
admet-337	379	21	,	,	PUNCT
admet-337	379	22	with	with	ADP
admet-337	379	23	a	a	DET
admet-337	379	24	csf	csf	NOUN
admet-337	379	25	-	-	PUNCT
admet-337	379	26	to	to	ADP
admet-337	379	27	-	-	PUNCT
admet-337	379	28	plasma	plasma	NOUN
admet-337	379	29	crizotinib	crizotinib	NOUN
admet-337	379	30	ratio	ratio	NOUN
admet-337	379	31	of	of	ADP
admet-337	379	32	0.0026	0.0026	NUM
admet-337	379	33	[	[	X
admet-337	379	34	125	125	NUM
admet-337	379	35	]	]	PUNCT
admet-337	379	36	.	.	PUNCT
admet-337	380	1	despite	despite	SCONJ
admet-337	380	2	poor	poor	ADJ
admet-337	380	3	cns	cns	NOUN
admet-337	380	4	penetration	penetration	NOUN
admet-337	380	5	,	,	PUNCT
admet-337	380	6	crizotinib	crizotinib	NOUN
admet-337	380	7	has	have	AUX
admet-337	380	8	been	be	AUX
admet-337	380	9	reported	report	VERB
admet-337	380	10	to	to	PART
admet-337	380	11	induce	induce	VERB
admet-337	380	12	responses	response	NOUN
admet-337	380	13	in	in	ADP
admet-337	380	14	previously	previously	ADV
admet-337	380	15	untreated	untreated	ADJ
admet-337	380	16	cns	cns	NOUN
admet-337	380	17	disease	disease	NOUN
admet-337	380	18	.	.	PUNCT
admet-337	381	1	in	in	ADP
admet-337	381	2	a	a	DET
admet-337	381	3	58	58	NUM
admet-337	381	4	-	-	PUNCT
admet-337	381	5	year	year	NOUN
admet-337	381	6	-	-	PUNCT
admet-337	381	7	old	old	ADJ
admet-337	381	8	patient	patient	NOUN
admet-337	381	9	with	with	ADP
admet-337	381	10	an	an	DET
admet-337	381	11	asymptomatic	asymptomatic	ADJ
admet-337	381	12	solitary	solitary	ADJ
admet-337	381	13	brain	brain	NOUN
admet-337	381	14	metastasis	metastasis	NOUN
admet-337	381	15	and	and	CCONJ
admet-337	381	16	leptomeningeal	leptomeningeal	ADJ
admet-337	381	17	carcinomatosis	carcinomatosis	NOUN
admet-337	381	18	,	,	PUNCT
admet-337	381	19	crizotinib	crizotinib	PROPN
admet-337	381	20	was	be	AUX
admet-337	381	21	initiated	initiate	VERB
admet-337	381	22	,	,	PUNCT
admet-337	381	23	and	and	CCONJ
admet-337	381	24	a	a	DET
admet-337	381	25	complete	complete	ADJ
admet-337	381	26	cns	cns	NOUN
admet-337	381	27	response	response	NOUN
admet-337	381	28	was	be	AUX
admet-337	381	29	achieved	achieve	VERB
admet-337	381	30	despite	despite	SCONJ
admet-337	381	31	a	a	DET
admet-337	381	32	crizotinib	crizotinib	NOUN
admet-337	381	33	csf	csf	NOUN
admet-337	381	34	-	-	PUNCT
admet-337	381	35	to	to	ADP
admet-337	381	36	-	-	PUNCT
admet-337	381	37	serum	serum	NOUN
admet-337	381	38	ratio	ratio	NOUN
admet-337	381	39	of	of	ADP
admet-337	381	40	0.0006	0.0006	NUM
admet-337	382	1	[	[	X
admet-337	382	2	129	129	NUM
admet-337	382	3	]	]	PUNCT
admet-337	382	4	.	.	PUNCT
admet-337	383	1	a	a	DET
admet-337	383	2	retrospective	retrospective	ADJ
admet-337	383	3	analysis	analysis	NOUN
admet-337	383	4	of	of	ADP
admet-337	383	5	alk	alk	NOUN
admet-337	383	6	-	-	PUNCT
admet-337	383	7	positive	positive	ADJ
admet-337	383	8	patients	patient	NOUN
admet-337	383	9	with	with	ADP
admet-337	383	10	asymptomatic	asymptomatic	ADJ
admet-337	383	11	cns	cns	NOUN
admet-337	383	12	metastases	metastasis	NOUN
admet-337	383	13	who	who	PRON
admet-337	383	14	received	receive	VERB
admet-337	383	15	crizotinib	crizotinib	NOUN
admet-337	383	16	on	on	ADP
admet-337	383	17	the	the	DET
admet-337	383	18	profile	profile	NOUN
admet-337	383	19	1005	1005	NUM
admet-337	383	20	and	and	CCONJ
admet-337	383	21	1007	1007	NUM
admet-337	383	22	trials	trial	NOUN
admet-337	383	23	showed	show	VERB
admet-337	383	24	that	that	SCONJ
admet-337	383	25	275	275	NUM
admet-337	383	26	(	(	PUNCT
admet-337	383	27	31	31	NUM
admet-337	383	28	%	%	NOUN
admet-337	383	29	)	)	PUNCT
admet-337	383	30	of	of	ADP
admet-337	383	31	the	the	DET
admet-337	383	32	888	888	NUM
admet-337	383	33	had	have	VERB
admet-337	383	34	asymptomatic	asymptomatic	ADJ
admet-337	383	35	brain	brain	NOUN
admet-337	383	36	metastases	metastasis	NOUN
admet-337	383	37	upon	upon	SCONJ
admet-337	383	38	enrollment	enrollment	NOUN
admet-337	383	39	on	on	ADP
admet-337	383	40	these	these	DET
admet-337	383	41	trials	trial	NOUN
admet-337	383	42	.	.	PUNCT
admet-337	384	1	in	in	ADP
admet-337	384	2	patients	patient	NOUN
admet-337	384	3	with	with	ADP
admet-337	384	4	untreated	untreated	ADJ
admet-337	384	5	brain	brain	NOUN
admet-337	384	6	metastases	metastasis	NOUN
admet-337	384	7	,	,	PUNCT
admet-337	384	8	crizotinib	crizotinib	VERB
admet-337	384	9	produced	produce	VERB
admet-337	384	10	intracranial	intracranial	ADJ
admet-337	384	11	disease	disease	NOUN
admet-337	384	12	control	control	NOUN
admet-337	384	13	in	in	ADP
admet-337	384	14	56	56	NUM
admet-337	384	15	%	%	NOUN
admet-337	384	16	at	at	ADP
admet-337	384	17	12	12	NUM
admet-337	384	18	weeks	week	NOUN
admet-337	384	19	.	.	PUNCT
admet-337	385	1	the	the	DET
admet-337	385	2	median	median	ADJ
admet-337	385	3	intracranial	intracranial	ADJ
admet-337	385	4	time	time	NOUN
admet-337	385	5	to	to	ADP
admet-337	385	6	progression	progression	NOUN
admet-337	385	7	was	be	AUX
admet-337	385	8	7	7	NUM
admet-337	385	9	months	month	NOUN
admet-337	385	10	in	in	ADP
admet-337	385	11	this	this	DET
admet-337	385	12	population	population	NOUN
admet-337	385	13	.	.	PUNCT
admet-337	386	1	in	in	ADP
admet-337	386	2	patients	patient	NOUN
admet-337	386	3	who	who	PRON
admet-337	386	4	had	have	AUX
admet-337	386	5	received	receive	VERB
admet-337	386	6	brain	brain	NOUN
admet-337	386	7	radiotherapy	radiotherapy	NOUN
admet-337	386	8	prior	prior	ADV
admet-337	386	9	to	to	ADP
admet-337	386	10	enrollment	enrollment	NOUN
admet-337	386	11	in	in	ADP
admet-337	386	12	these	these	DET
admet-337	386	13	trials	trial	NOUN
admet-337	386	14	,	,	PUNCT
admet-337	386	15	cns	cns	PROPN
admet-337	386	16	disease	disease	NOUN
admet-337	386	17	control	control	NOUN
admet-337	386	18	was	be	AUX
admet-337	386	19	attained	attain	VERB
admet-337	386	20	in	in	ADP
admet-337	386	21	62	62	NUM
admet-337	386	22	%	%	NOUN
admet-337	386	23	with	with	ADP
admet-337	386	24	median	median	ADJ
admet-337	386	25	time	time	NOUN
admet-337	386	26	to	to	ADP
admet-337	386	27	progression	progression	NOUN
admet-337	386	28	of	of	ADP
admet-337	386	29	13.2	13.2	NUM
admet-337	386	30	months	month	NOUN
admet-337	386	31	.	.	PUNCT
admet-337	387	1	however	however	ADV
admet-337	387	2	,	,	PUNCT
admet-337	387	3	due	due	ADP
admet-337	387	4	to	to	ADP
admet-337	387	5	poor	poor	ADJ
admet-337	387	6	cns	cns	NOUN
admet-337	387	7	penetration	penetration	NOUN
admet-337	387	8	of	of	ADP
admet-337	387	9	crizotinib	crizotinib	NOUN
admet-337	387	10	,	,	PUNCT
admet-337	387	11	among	among	ADP
admet-337	387	12	patients	patient	NOUN
admet-337	387	13	without	without	ADP
admet-337	387	14	brain	brain	NOUN
admet-337	387	15	metastases	metastasis	NOUN
admet-337	387	16	at	at	ADP
admet-337	387	17	enrollment	enrollment	NOUN
admet-337	387	18	,	,	PUNCT
admet-337	387	19	20	20	NUM
admet-337	387	20	%	%	NOUN
admet-337	387	21	developed	develop	VERB
admet-337	387	22	cns	cns	NOUN
admet-337	387	23	disease	disease	NOUN
admet-337	387	24	while	while	SCONJ
admet-337	387	25	taking	take	VERB
admet-337	387	26	crizotinib	crizotinib	NOUN
admet-337	387	27	[	[	X
admet-337	387	28	130	130	NUM
admet-337	387	29	]	]	PUNCT
admet-337	387	30	.	.	PUNCT
admet-337	388	1	second	second	ADJ
admet-337	388	2	-	-	PUNCT
admet-337	388	3	generation	generation	NOUN
admet-337	388	4	alk	alk	NOUN
admet-337	388	5	inhibitors	inhibitor	NOUN
admet-337	388	6	have	have	VERB
admet-337	388	7	better	well	ADJ
admet-337	388	8	cns	cns	NOUN
admet-337	388	9	penetration	penetration	NOUN
admet-337	388	10	and	and	CCONJ
admet-337	388	11	activity	activity	NOUN
admet-337	388	12	.	.	PUNCT
admet-337	389	1	resistance	resistance	NOUN
admet-337	389	2	mechanisms	mechanism	NOUN
admet-337	389	3	alk	alk	ADJ
admet-337	389	4	-	-	PUNCT
admet-337	389	5	positive	positive	ADJ
admet-337	389	6	tumors	tumor	NOUN
admet-337	389	7	can	can	AUX
admet-337	389	8	develop	develop	VERB
admet-337	389	9	alk	alk	VERB
admet-337	389	10	dependent	dependent	ADJ
admet-337	389	11	and	and	CCONJ
admet-337	389	12	alk	alk	VERB
admet-337	389	13	independent	independent	ADJ
admet-337	389	14	mechanisms	mechanism	NOUN
admet-337	389	15	of	of	ADP
admet-337	389	16	crizotinib	crizotinib	ADJ
admet-337	389	17	grace	grace	NOUN
admet-337	390	1	dy	dy	NOUN
admet-337	390	2	et	et	PROPN
admet-337	390	3	al	al	PROPN
admet-337	390	4	.	.	PROPN
admet-337	390	5	admet	admet	PROPN
admet-337	390	6	&	&	CCONJ
admet-337	390	7	dmpk	dmpk	PROPN
admet-337	390	8	4(3	4(3	NUM
admet-337	390	9	)	)	PUNCT
admet-337	390	10	(	(	PUNCT
admet-337	390	11	2016	2016	NUM
admet-337	390	12	)	)	PUNCT
admet-337	390	13	186	186	NUM
admet-337	390	14	-	-	SYM
admet-337	390	15	211	211	NUM
admet-337	390	16	200	200	NUM
admet-337	390	17	resistance	resistance	NOUN
admet-337	390	18	.	.	PUNCT
admet-337	391	1	crizotinib	crizotinib	VERB
admet-337	391	2	resistance	resistance	NOUN
admet-337	391	3	predominantly	predominantly	ADV
admet-337	391	4	occurs	occur	VERB
admet-337	391	5	through	through	ADP
admet-337	391	6	acquired	acquire	VERB
admet-337	391	7	mutations	mutation	NOUN
admet-337	391	8	in	in	ADP
admet-337	391	9	the	the	DET
admet-337	391	10	alk	alk	PROPN
admet-337	391	11	kinase	kinase	PROPN
admet-337	391	12	domain	domain	NOUN
admet-337	391	13	at	at	ADP
admet-337	391	14	the	the	DET
admet-337	391	15	atp	atp	NOUN
admet-337	391	16	-	-	PUNCT
admet-337	391	17	binding	bind	VERB
admet-337	391	18	pocket	pocket	NOUN
admet-337	391	19	,	,	PUNCT
admet-337	391	20	which	which	PRON
admet-337	391	21	prevents	prevent	VERB
admet-337	391	22	binding	bind	VERB
admet-337	391	23	of	of	ADP
admet-337	391	24	the	the	DET
admet-337	391	25	drug	drug	NOUN
admet-337	391	26	.	.	PUNCT
admet-337	392	1	these	these	DET
admet-337	392	2	mutations	mutation	NOUN
admet-337	392	3	include	include	VERB
admet-337	392	4	the	the	DET
admet-337	392	5	l1196	l1196	NUM
admet-337	392	6	m	m	NOUN
admet-337	392	7	point	point	NOUN
admet-337	392	8	mutation	mutation	NOUN
admet-337	392	9	,	,	PUNCT
admet-337	392	10	which	which	PRON
admet-337	392	11	is	be	AUX
admet-337	392	12	homologous	homologous	ADJ
admet-337	392	13	to	to	ADP
admet-337	392	14	the	the	DET
admet-337	392	15	tki	tki	PROPN
admet-337	392	16	resistance	resistance	NOUN
admet-337	392	17	mutations	mutation	NOUN
admet-337	392	18	t790	t790	NUM
admet-337	392	19	m	m	NOUN
admet-337	392	20	in	in	ADP
admet-337	392	21	egfr	egfr	ADJ
admet-337	392	22	-	-	PUNCT
admet-337	392	23	mutated	mutate	VERB
admet-337	392	24	nsclc	nsclc	NOUN
admet-337	392	25	and	and	CCONJ
admet-337	392	26	t315i	t315i	PRON
admet-337	392	27	in	in	ADP
admet-337	392	28	chronic	chronic	ADJ
admet-337	392	29	myelogenous	myelogenous	ADJ
admet-337	392	30	leukemia	leukemia	NOUN
admet-337	392	31	[	[	X
admet-337	392	32	131,132	131,132	NUM
admet-337	392	33	]	]	PUNCT
admet-337	392	34	.	.	PUNCT
admet-337	393	1	other	other	ADJ
admet-337	393	2	acquired	acquire	VERB
admet-337	393	3	alk	alk	PROPN
admet-337	393	4	kinase	kinase	PROPN
admet-337	393	5	mutations	mutation	NOUN
admet-337	393	6	that	that	PRON
admet-337	393	7	confer	confer	VERB
admet-337	393	8	resistance	resistance	NOUN
admet-337	393	9	to	to	ADP
admet-337	393	10	crizotinib	crizotinib	VERB
admet-337	393	11	include	include	VERB
admet-337	393	12	c1156y	c1156y	PROPN
admet-337	393	13	,	,	PUNCT
admet-337	393	14	l1152r	l1152r	PROPN
admet-337	393	15	,	,	PUNCT
admet-337	393	16	i1171	i1171	PROPN
admet-337	393	17	t	t	PROPN
admet-337	393	18	,	,	PUNCT
admet-337	393	19	s1206y	s1206y	NOUN
admet-337	393	20	,	,	PUNCT
admet-337	393	21	f1174l	f1174l	NOUN
admet-337	393	22	and	and	CCONJ
admet-337	393	23	g1269a	g1269a	PROPN
admet-337	394	1	[	[	X
admet-337	394	2	131,133	131,133	NUM
admet-337	394	3	-	-	SYM
admet-337	394	4	136	136	NUM
admet-337	394	5	]	]	PUNCT
admet-337	394	6	.	.	PUNCT
admet-337	395	1	the	the	DET
admet-337	395	2	g1202r	g1202r	PROPN
admet-337	395	3	crizotinib	crizotinib	PROPN
admet-337	395	4	-	-	PUNCT
admet-337	395	5	resistance	resistance	NOUN
admet-337	395	6	mutation	mutation	NOUN
admet-337	395	7	also	also	ADV
admet-337	395	8	confers	confer	VERB
admet-337	395	9	resistance	resistance	NOUN
admet-337	395	10	to	to	ADP
admet-337	395	11	second	second	ADJ
admet-337	395	12	generation	generation	NOUN
admet-337	395	13	alk	alk	VERB
admet-337	395	14	tkis	tkis	NOUN
admet-337	396	1	[	[	X
admet-337	396	2	137	137	NUM
admet-337	396	3	]	]	PUNCT
admet-337	396	4	.	.	PUNCT
admet-337	397	1	increase	increase	NOUN
admet-337	397	2	in	in	ADP
admet-337	397	3	alk	alk	NOUN
admet-337	397	4	copy	copy	NOUN
admet-337	397	5	number	number	NOUN
admet-337	397	6	has	have	AUX
admet-337	397	7	also	also	ADV
admet-337	397	8	been	be	AUX
admet-337	397	9	demonstrated	demonstrate	VERB
admet-337	397	10	in	in	ADP
admet-337	397	11	patients	patient	NOUN
admet-337	397	12	who	who	PRON
admet-337	397	13	develop	develop	VERB
admet-337	397	14	crizotinib	crizotinib	ADJ
admet-337	397	15	resistance	resistance	NOUN
admet-337	397	16	[	[	X
admet-337	397	17	132	132	NUM
admet-337	397	18	]	]	PUNCT
admet-337	397	19	.	.	PUNCT
admet-337	398	1	in	in	ADP
admet-337	398	2	humans	human	NOUN
admet-337	398	3	,	,	PUNCT
admet-337	398	4	alk	alk	VERB
admet-337	398	5	independent	independent	ADJ
admet-337	398	6	mechanisms	mechanism	NOUN
admet-337	398	7	of	of	ADP
admet-337	398	8	resistance	resistance	NOUN
admet-337	398	9	include	include	VERB
admet-337	398	10	kras	kra	NOUN
admet-337	398	11	mutations	mutation	NOUN
admet-337	398	12	and	and	CCONJ
admet-337	398	13	development	development	NOUN
admet-337	398	14	of	of	ADP
admet-337	398	15	egfr	egfr	ADJ
admet-337	398	16	mutation	mutation	NOUN
admet-337	398	17	without	without	ADP
admet-337	398	18	evidence	evidence	NOUN
admet-337	398	19	of	of	ADP
admet-337	398	20	persistent	persistent	ADJ
admet-337	398	21	alk	alk	NOUN
admet-337	398	22	gene	gene	NOUN
admet-337	398	23	rearrangement	rearrangement	NOUN
admet-337	398	24	[	[	X
admet-337	398	25	132	132	NUM
admet-337	398	26	]	]	PUNCT
admet-337	398	27	.	.	PUNCT
admet-337	399	1	in	in	ADP
admet-337	399	2	a	a	DET
admet-337	399	3	mouse	mouse	NOUN
admet-337	399	4	model	model	NOUN
admet-337	399	5	,	,	PUNCT
admet-337	399	6	crizotinib	crizotinib	VERB
admet-337	399	7	resistance	resistance	NOUN
admet-337	399	8	was	be	AUX
admet-337	399	9	induced	induce	VERB
admet-337	399	10	through	through	ADP
admet-337	399	11	activation	activation	NOUN
admet-337	399	12	of	of	ADP
admet-337	399	13	the	the	DET
admet-337	399	14	egfr	egfr	NOUN
admet-337	399	15	signaling	signal	VERB
admet-337	399	16	pathway	pathway	NOUN
admet-337	399	17	,	,	PUNCT
admet-337	399	18	which	which	PRON
admet-337	399	19	could	could	AUX
admet-337	399	20	be	be	AUX
admet-337	399	21	overcome	overcome	VERB
admet-337	399	22	by	by	ADP
admet-337	399	23	combination	combination	NOUN
admet-337	399	24	therapy	therapy	NOUN
admet-337	399	25	with	with	ADP
admet-337	399	26	crizotinib	crizotinib	NOUN
admet-337	399	27	and	and	CCONJ
admet-337	399	28	the	the	DET
admet-337	399	29	heat	heat	NOUN
admet-337	399	30	shock	shock	NOUN
admet-337	399	31	protein	protein	NOUN
admet-337	399	32	90	90	NUM
admet-337	399	33	(	(	PUNCT
admet-337	399	34	hsp90	hsp90	ADJ
admet-337	399	35	)	)	PUNCT
admet-337	399	36	inhibitor	inhibitor	NOUN
admet-337	399	37	ganetespib	ganetespib	ADJ
admet-337	399	38	.	.	PUNCT
admet-337	400	1	hsp90	hsp90	PROPN
admet-337	400	2	is	be	AUX
admet-337	400	3	a	a	DET
admet-337	400	4	chaperone	chaperone	NOUN
admet-337	400	5	protein	protein	NOUN
admet-337	400	6	that	that	PRON
admet-337	400	7	regulates	regulate	VERB
admet-337	400	8	the	the	DET
admet-337	400	9	folding	folding	NOUN
admet-337	400	10	and	and	CCONJ
admet-337	400	11	stability	stability	NOUN
admet-337	400	12	of	of	ADP
admet-337	400	13	multiple	multiple	ADJ
admet-337	400	14	“	"	PUNCT
admet-337	400	15	client	client	NOUN
admet-337	400	16	proteins	protein	NOUN
admet-337	400	17	,	,	PUNCT
admet-337	400	18	”	"	PUNCT
admet-337	400	19	including	include	VERB
admet-337	400	20	egfr	egfr	NOUN
admet-337	400	21	,	,	PUNCT
admet-337	400	22	eml4	eml4	PROPN
admet-337	400	23	-	-	PUNCT
admet-337	400	24	alk	alk	PROPN
admet-337	400	25	,	,	PUNCT
admet-337	400	26	her2	her2	PROPN
admet-337	400	27	,	,	PUNCT
admet-337	400	28	and	and	CCONJ
admet-337	400	29	braf	braf	NOUN
admet-337	400	30	and	and	CCONJ
admet-337	400	31	can	can	AUX
admet-337	400	32	therefore	therefore	ADV
admet-337	400	33	target	target	VERB
admet-337	400	34	multiple	multiple	ADJ
admet-337	400	35	pathways	pathway	NOUN
admet-337	400	36	of	of	ADP
admet-337	400	37	drug	drug	NOUN
admet-337	400	38	resistance	resistance	NOUN
admet-337	400	39	[	[	X
admet-337	400	40	138	138	NUM
admet-337	400	41	]	]	PUNCT
admet-337	400	42	.	.	PUNCT
admet-337	401	1	insulinlike	insulinlike	PROPN
admet-337	401	2	growth	growth	NOUN
admet-337	401	3	factor	factor	NOUN
admet-337	401	4	1	1	NUM
admet-337	401	5	receptor	receptor	NOUN
admet-337	401	6	activation	activation	NOUN
admet-337	401	7	has	have	AUX
admet-337	401	8	been	be	AUX
admet-337	401	9	identified	identify	VERB
admet-337	401	10	as	as	ADP
admet-337	401	11	a	a	DET
admet-337	401	12	possible	possible	ADJ
admet-337	401	13	resistance	resistance	NOUN
admet-337	401	14	mechanism	mechanism	NOUN
admet-337	401	15	to	to	PART
admet-337	401	16	crizotinib	crizotinib	VERB
admet-337	401	17	,	,	PUNCT
admet-337	401	18	and	and	CCONJ
admet-337	401	19	serves	serve	VERB
admet-337	401	20	as	as	ADP
admet-337	401	21	a	a	DET
admet-337	401	22	target	target	NOUN
admet-337	401	23	of	of	ADP
admet-337	401	24	the	the	DET
admet-337	401	25	second	second	ADJ
admet-337	401	26	-	-	PUNCT
admet-337	401	27	generation	generation	NOUN
admet-337	401	28	alk	alk	NOUN
admet-337	401	29	inhibitor	inhibitor	NOUN
admet-337	401	30	ceritinib	ceritinib	NOUN
admet-337	401	31	(	(	PUNCT
admet-337	401	32	detailed	detailed	ADJ
admet-337	401	33	below	below	ADV
admet-337	401	34	)	)	PUNCT
admet-337	402	1	[	[	X
admet-337	402	2	139	139	NUM
admet-337	402	3	]	]	PUNCT
admet-337	402	4	.	.	PUNCT
admet-337	403	1	ceritinib	ceritinib	PROPN
admet-337	403	2	clinical	clinical	ADJ
admet-337	403	3	efficacy	efficacy	NOUN
admet-337	403	4	ceritinib	ceritinib	NOUN
admet-337	403	5	was	be	AUX
admet-337	403	6	the	the	DET
admet-337	403	7	first	first	ADJ
admet-337	403	8	second	second	ADJ
admet-337	403	9	-	-	PUNCT
admet-337	403	10	generation	generation	NOUN
admet-337	403	11	alk	alk	NOUN
admet-337	403	12	tki	tki	NOUN
admet-337	403	13	approved	approve	VERB
admet-337	403	14	for	for	ADP
admet-337	403	15	clinical	clinical	ADJ
admet-337	403	16	use	use	NOUN
admet-337	403	17	in	in	ADP
admet-337	403	18	the	the	DET
admet-337	403	19	us	us	PROPN
admet-337	403	20	.	.	PUNCT
admet-337	404	1	preclinical	preclinical	ADJ
admet-337	404	2	data	datum	NOUN
admet-337	404	3	demonstrated	demonstrate	VERB
admet-337	404	4	that	that	SCONJ
admet-337	404	5	certinib	certinib	PROPN
admet-337	404	6	overcomes	overcome	VERB
admet-337	404	7	crizotinib	crizotinib	ADJ
admet-337	404	8	-	-	PUNCT
admet-337	404	9	resistance	resistance	NOUN
admet-337	404	10	mutations	mutation	NOUN
admet-337	404	11	,	,	PUNCT
admet-337	404	12	particularly	particularly	ADV
admet-337	404	13	l1196	l1196	NOUN
admet-337	404	14	m	m	ADJ
admet-337	404	15	,	,	PUNCT
admet-337	404	16	g1269a	g1269a	INTJ
admet-337	404	17	,	,	PUNCT
admet-337	404	18	s1206y	s1206y	NOUN
admet-337	404	19	and	and	CCONJ
admet-337	404	20	i1171	i1171	PROPN
admet-337	404	21	t	t	PROPN
admet-337	404	22	but	but	CCONJ
admet-337	404	23	not	not	PART
admet-337	404	24	g1202r	g1202r	NOUN
admet-337	404	25	and	and	CCONJ
admet-337	404	26	f1174c	f1174c	X
admet-337	405	1	[	[	X
admet-337	405	2	136	136	NUM
admet-337	405	3	]	]	PUNCT
admet-337	405	4	.	.	PUNCT
admet-337	406	1	in	in	ADP
admet-337	406	2	april	april	PROPN
admet-337	406	3	2014	2014	NUM
admet-337	406	4	,	,	PUNCT
admet-337	406	5	the	the	DET
admet-337	406	6	fda	fda	PROPN
admet-337	406	7	granted	grant	VERB
admet-337	406	8	accelerated	accelerate	VERB
admet-337	406	9	approval	approval	NOUN
admet-337	406	10	to	to	ADP
admet-337	406	11	ceritinib	ceritinib	NOUN
admet-337	406	12	for	for	ADP
admet-337	406	13	the	the	DET
admet-337	406	14	treatment	treatment	NOUN
admet-337	406	15	of	of	ADP
admet-337	406	16	patients	patient	NOUN
admet-337	406	17	with	with	ADP
admet-337	406	18	metastatic	metastatic	ADJ
admet-337	406	19	alk	alk	VERB
admet-337	406	20	-	-	PUNCT
admet-337	406	21	positive	positive	ADJ
admet-337	406	22	nsclc	nsclc	NOUN
admet-337	406	23	who	who	PRON
admet-337	406	24	were	be	AUX
admet-337	406	25	intolerant	intolerant	ADJ
admet-337	406	26	to	to	ADP
admet-337	406	27	or	or	CCONJ
admet-337	406	28	experienced	experienced	ADJ
admet-337	406	29	disease	disease	NOUN
admet-337	406	30	progression	progression	NOUN
admet-337	406	31	on	on	ADP
admet-337	406	32	crizotinib	crizotinib	NOUN
admet-337	406	33	.	.	PUNCT
admet-337	407	1	this	this	DET
admet-337	407	2	approval	approval	NOUN
admet-337	407	3	was	be	AUX
admet-337	407	4	based	base	VERB
admet-337	407	5	on	on	ADP
admet-337	407	6	the	the	DET
admet-337	407	7	single	single	ADJ
admet-337	407	8	-	-	PUNCT
admet-337	407	9	arm	arm	NOUN
admet-337	407	10	,	,	PUNCT
admet-337	407	11	multicenter	multicenter	NOUN
admet-337	407	12	phase	phase	NOUN
admet-337	407	13	i	i	PRON
admet-337	407	14	ascend-1	ascend-1	VERB
admet-337	407	15	trial	trial	NOUN
admet-337	407	16	that	that	PRON
admet-337	407	17	enrolled	enrol	VERB
admet-337	407	18	a	a	DET
admet-337	407	19	total	total	NOUN
admet-337	407	20	of	of	ADP
admet-337	407	21	130	130	NUM
admet-337	407	22	patients	patient	NOUN
admet-337	407	23	with	with	ADP
admet-337	407	24	advanced	advanced	ADJ
admet-337	407	25	alk	alk	NOUN
admet-337	407	26	-	-	PUNCT
admet-337	407	27	rearranged	rearrange	VERB
admet-337	407	28	nsclc	nsclc	NOUN
admet-337	407	29	,	,	PUNCT
admet-337	407	30	including	include	VERB
admet-337	407	31	patients	patient	NOUN
admet-337	407	32	who	who	PRON
admet-337	407	33	had	have	AUX
admet-337	407	34	experienced	experience	VERB
admet-337	407	35	disease	disease	NOUN
admet-337	407	36	progression	progression	NOUN
admet-337	407	37	during	during	ADP
admet-337	407	38	crizotinib	crizotinib	ADJ
admet-337	407	39	treatment	treatment	NOUN
admet-337	407	40	.	.	PUNCT
admet-337	408	1	the	the	DET
admet-337	408	2	orr	orr	PROPN
admet-337	408	3	for	for	ADP
admet-337	408	4	patients	patient	NOUN
admet-337	408	5	who	who	PRON
admet-337	408	6	received	receive	VERB
admet-337	408	7	at	at	ADV
admet-337	408	8	least	least	ADV
admet-337	408	9	400	400	NUM
admet-337	408	10	mg	mg	NOUN
admet-337	408	11	of	of	ADP
admet-337	408	12	ceritinib	ceritinib	PROPN
admet-337	408	13	daily	daily	ADV
admet-337	408	14	was	be	AUX
admet-337	408	15	58	58	NUM
admet-337	408	16	%	%	NOUN
admet-337	408	17	,	,	PUNCT
admet-337	408	18	while	while	SCONJ
admet-337	408	19	the	the	DET
admet-337	408	20	response	response	NOUN
admet-337	408	21	rate	rate	NOUN
admet-337	408	22	for	for	ADP
admet-337	408	23	patients	patient	NOUN
admet-337	408	24	who	who	PRON
admet-337	408	25	had	have	AUX
admet-337	408	26	previously	previously	ADV
admet-337	408	27	received	receive	VERB
admet-337	408	28	crizotinib	crizotinib	NOUN
admet-337	408	29	was	be	AUX
admet-337	408	30	56	56	NUM
admet-337	408	31	%	%	NOUN
admet-337	408	32	.	.	PUNCT
admet-337	409	1	median	median	PROPN
admet-337	409	2	pfs	pfs	PROPN
admet-337	409	3	was	be	AUX
admet-337	409	4	7.0	7.0	NUM
admet-337	409	5	months	month	NOUN
admet-337	409	6	(	(	PUNCT
admet-337	409	7	95	95	NUM
admet-337	409	8	%	%	NOUN
admet-337	409	9	ci	ci	NOUN
admet-337	409	10	,	,	PUNCT
admet-337	409	11	5.6	5.6	NUM
admet-337	409	12	to	to	PART
admet-337	409	13	9.5	9.5	NUM
admet-337	409	14	)	)	PUNCT
admet-337	410	1	[	[	X
admet-337	410	2	14	14	NUM
admet-337	410	3	]	]	PUNCT
admet-337	410	4	.	.	PUNCT
admet-337	411	1	in	in	ADP
admet-337	411	2	this	this	DET
admet-337	411	3	trial	trial	NOUN
admet-337	411	4	,	,	PUNCT
admet-337	411	5	tumor	tumor	NOUN
admet-337	411	6	response	response	NOUN
admet-337	411	7	was	be	AUX
admet-337	411	8	noted	note	VERB
admet-337	411	9	regardless	regardless	ADV
admet-337	411	10	of	of	ADP
admet-337	411	11	the	the	DET
admet-337	411	12	underlying	underlying	ADJ
admet-337	411	13	mechanism	mechanism	NOUN
admet-337	411	14	of	of	ADP
admet-337	411	15	acquired	acquire	VERB
admet-337	411	16	crizotinib	crizotinib	NOUN
admet-337	411	17	resistance	resistance	NOUN
admet-337	411	18	,	,	PUNCT
admet-337	411	19	and	and	CCONJ
admet-337	411	20	patients	patient	NOUN
admet-337	411	21	with	with	ADP
admet-337	411	22	alk	alk	NOUN
admet-337	411	23	gene	gene	NOUN
admet-337	411	24	amplification	amplification	NOUN
admet-337	411	25	and	and	CCONJ
admet-337	411	26	alk	alk	VERB
admet-337	411	27	tyrosine	tyrosine	PROPN
admet-337	411	28	kinase	kinase	PROPN
admet-337	411	29	domain	domain	PROPN
admet-337	411	30	mutations	mutation	NOUN
admet-337	411	31	developed	develop	VERB
admet-337	411	32	responses	response	NOUN
admet-337	411	33	to	to	ADP
admet-337	411	34	ceritinib	ceritinib	NOUN
admet-337	411	35	.	.	PUNCT
admet-337	412	1	given	give	VERB
admet-337	412	2	the	the	DET
admet-337	412	3	excellent	excellent	ADJ
admet-337	412	4	responses	response	NOUN
admet-337	412	5	witnessed	witness	VERB
admet-337	412	6	in	in	ADP
admet-337	412	7	crizotinib	crizotinib	NOUN
admet-337	412	8	-	-	PUNCT
admet-337	412	9	treated	treat	VERB
admet-337	412	10	patients	patient	NOUN
admet-337	412	11	,	,	PUNCT
admet-337	412	12	the	the	DET
admet-337	412	13	main	main	ADJ
admet-337	412	14	mechanism	mechanism	NOUN
admet-337	412	15	of	of	ADP
admet-337	412	16	crizotinib	crizotinib	ADJ
admet-337	412	17	resistance	resistance	NOUN
admet-337	412	18	appears	appear	VERB
admet-337	412	19	to	to	PART
admet-337	412	20	be	be	AUX
admet-337	412	21	alk	alk	VERB
admet-337	412	22	dependent	dependent	ADJ
admet-337	412	23	,	,	PUNCT
admet-337	412	24	and	and	CCONJ
admet-337	412	25	may	may	AUX
admet-337	412	26	be	be	AUX
admet-337	412	27	overcome	overcome	VERB
admet-337	412	28	with	with	ADP
admet-337	412	29	a	a	DET
admet-337	412	30	more	more	ADV
admet-337	412	31	potent	potent	ADJ
admet-337	412	32	alk	alk	NOUN
admet-337	412	33	inhibitor	inhibitor	NOUN
admet-337	412	34	,	,	PUNCT
admet-337	412	35	such	such	ADJ
admet-337	412	36	as	as	ADP
admet-337	412	37	ceritinib	ceritinib	NOUN
admet-337	412	38	[	[	X
admet-337	412	39	14	14	NUM
admet-337	412	40	]	]	PUNCT
admet-337	412	41	.	.	PUNCT
admet-337	413	1	updated	update	VERB
admet-337	413	2	data	datum	NOUN
admet-337	413	3	from	from	ADP
admet-337	413	4	this	this	DET
admet-337	413	5	trial	trial	NOUN
admet-337	413	6	,	,	PUNCT
admet-337	413	7	including	include	VERB
admet-337	413	8	246	246	NUM
admet-337	413	9	patients	patient	NOUN
admet-337	413	10	,	,	PUNCT
admet-337	413	11	showed	show	VERB
admet-337	413	12	an	an	DET
admet-337	413	13	orr	orr	NOUN
admet-337	413	14	of	of	ADP
admet-337	413	15	58.5	58.5	NUM
admet-337	413	16	%	%	NOUN
admet-337	413	17	in	in	ADP
admet-337	413	18	all	all	DET
admet-337	413	19	patients	patient	NOUN
admet-337	413	20	,	,	PUNCT
admet-337	413	21	with	with	ADP
admet-337	413	22	a	a	DET
admet-337	413	23	median	median	ADJ
admet-337	413	24	duration	duration	NOUN
admet-337	413	25	of	of	ADP
admet-337	413	26	response	response	NOUN
admet-337	413	27	of	of	ADP
admet-337	413	28	9.7	9.7	NUM
admet-337	413	29	months	month	NOUN
admet-337	413	30	,	,	PUNCT
admet-337	413	31	time	time	NOUN
admet-337	413	32	to	to	ADP
admet-337	413	33	first	first	ADJ
admet-337	413	34	response	response	NOUN
admet-337	413	35	of	of	ADP
admet-337	413	36	6.1	6.1	NUM
admet-337	413	37	weeks	week	NOUN
admet-337	413	38	and	and	CCONJ
admet-337	413	39	median	median	ADJ
admet-337	413	40	pfs	pf	NOUN
admet-337	413	41	of	of	ADP
admet-337	413	42	8.2	8.2	NUM
admet-337	413	43	months	month	NOUN
admet-337	413	44	[	[	X
admet-337	413	45	140	140	NUM
admet-337	413	46	]	]	PUNCT
admet-337	413	47	.	.	PUNCT
admet-337	414	1	ascend-2	ascend-2	PRON
admet-337	414	2	was	be	AUX
admet-337	414	3	a	a	DET
admet-337	414	4	single	single	ADJ
admet-337	414	5	-	-	PUNCT
admet-337	414	6	arm	arm	NOUN
admet-337	414	7	,	,	PUNCT
admet-337	414	8	multicenter	multicenter	NOUN
admet-337	414	9	phase	phase	NOUN
admet-337	414	10	ii	ii	NOUN
admet-337	414	11	trial	trial	NOUN
admet-337	414	12	of	of	ADP
admet-337	414	13	140	140	NUM
admet-337	414	14	patients	patient	NOUN
admet-337	414	15	that	that	PRON
admet-337	414	16	evaluated	evaluate	VERB
admet-337	414	17	efficacy	efficacy	NOUN
admet-337	414	18	and	and	CCONJ
admet-337	414	19	safety	safety	NOUN
admet-337	414	20	of	of	ADP
admet-337	414	21	ceritinib	ceritinib	NOUN
admet-337	414	22	in	in	ADP
admet-337	414	23	alk	alk	NOUN
admet-337	414	24	-	-	PUNCT
admet-337	414	25	positive	positive	ADJ
admet-337	414	26	nsclc	nsclc	NOUN
admet-337	414	27	who	who	PRON
admet-337	414	28	progressed	progress	VERB
admet-337	414	29	after	after	ADP
admet-337	414	30	chemotherapy	chemotherapy	NOUN
admet-337	414	31	and	and	CCONJ
admet-337	414	32	crizotinib	crizotinib	PROPN
admet-337	414	33	.	.	PUNCT
admet-337	415	1	the	the	DET
admet-337	415	2	orr	orr	PROPN
admet-337	415	3	was	be	AUX
admet-337	415	4	38.6	38.6	NUM
admet-337	415	5	%	%	NOUN
admet-337	415	6	with	with	ADP
admet-337	415	7	median	median	PROPN
admet-337	415	8	pfs	pfs	PROPN
admet-337	415	9	of	of	ADP
admet-337	415	10	5.7	5.7	NUM
admet-337	415	11	months	month	NOUN
admet-337	415	12	.	.	PUNCT
admet-337	416	1	the	the	DET
admet-337	416	2	trial	trial	NOUN
admet-337	416	3	also	also	ADV
admet-337	416	4	allowed	allow	VERB
admet-337	416	5	patients	patient	NOUN
admet-337	416	6	with	with	ADP
admet-337	416	7	untreated	untreated	ADJ
admet-337	416	8	brain	brain	NOUN
admet-337	416	9	metastases	metastasis	NOUN
admet-337	416	10	to	to	PART
admet-337	416	11	participate	participate	VERB
admet-337	416	12	(	(	PUNCT
admet-337	416	13	71.4	71.4	NUM
admet-337	416	14	%	%	NOUN
admet-337	416	15	had	have	AUX
admet-337	416	16	baseline	baseline	ADJ
admet-337	416	17	brain	brain	NOUN
admet-337	416	18	metastases	metastasis	NOUN
admet-337	416	19	,	,	PUNCT
admet-337	416	20	28	28	NUM
admet-337	416	21	%	%	NOUN
admet-337	416	22	had	have	VERB
admet-337	416	23	untreated	untreated	ADJ
admet-337	416	24	brain	brain	NOUN
admet-337	416	25	metastases	metastasis	NOUN
admet-337	416	26	)	)	PUNCT
admet-337	416	27	.	.	PUNCT
admet-337	417	1	median	median	PROPN
admet-337	417	2	pfs	pfs	PROPN
admet-337	417	3	was	be	AUX
admet-337	417	4	5.4	5.4	NUM
admet-337	417	5	months	month	NOUN
admet-337	417	6	in	in	ADP
admet-337	417	7	patients	patient	NOUN
admet-337	417	8	with	with	ADP
admet-337	417	9	brain	brain	NOUN
admet-337	417	10	metastases	metastasis	NOUN
admet-337	417	11	versus	versus	ADP
admet-337	417	12	11.3	11.3	NUM
admet-337	417	13	months	month	NOUN
admet-337	417	14	in	in	ADP
admet-337	417	15	patients	patient	NOUN
admet-337	417	16	without	without	ADP
admet-337	417	17	brain	brain	NOUN
admet-337	417	18	metastases	metastasis	NOUN
admet-337	417	19	[	[	X
admet-337	417	20	141	141	NUM
admet-337	417	21	]	]	PUNCT
admet-337	417	22	.	.	PUNCT
admet-337	418	1	ascend-3	ascend-3	NUM
admet-337	418	2	examined	examine	VERB
admet-337	418	3	ceritinib	ceritinib	NOUN
admet-337	418	4	use	use	VERB
admet-337	418	5	for	for	ADP
admet-337	418	6	metastatic	metastatic	ADJ
admet-337	418	7	,	,	PUNCT
admet-337	418	8	alkpositive	alkpositive	ADJ
admet-337	418	9	nsclc	nsclc	NOUN
admet-337	418	10	patients	patient	NOUN
admet-337	418	11	who	who	PRON
admet-337	418	12	were	be	AUX
admet-337	418	13	alk	alk	VERB
admet-337	418	14	tki	tki	NOUN
admet-337	418	15	-	-	ADJ
admet-337	418	16	naïve	naïve	ADJ
admet-337	418	17	,	,	PUNCT
admet-337	418	18	including	include	VERB
admet-337	418	19	those	those	PRON
admet-337	418	20	with	with	ADP
admet-337	418	21	brain	brain	NOUN
admet-337	418	22	metastases	metastasis	NOUN
admet-337	418	23	.	.	PUNCT
admet-337	419	1	at	at	ADP
admet-337	419	2	presentation	presentation	NOUN
admet-337	419	3	,	,	PUNCT
admet-337	419	4	124	124	NUM
admet-337	419	5	patients	patient	NOUN
admet-337	419	6	had	have	AUX
admet-337	419	7	enrolled	enrol	VERB
admet-337	419	8	in	in	ADP
admet-337	419	9	the	the	DET
admet-337	419	10	trial	trial	NOUN
admet-337	419	11	.	.	PUNCT
admet-337	420	1	in	in	ADP
admet-337	420	2	this	this	DET
admet-337	420	3	study	study	NOUN
admet-337	420	4	population	population	NOUN
admet-337	420	5	,	,	PUNCT
admet-337	420	6	the	the	DET
admet-337	420	7	orr	orr	PROPN
admet-337	420	8	was	be	AUX
admet-337	420	9	63.7	63.7	NUM
admet-337	420	10	%	%	NOUN
admet-337	420	11	with	with	ADP
admet-337	420	12	disease	disease	NOUN
admet-337	420	13	control	control	NOUN
admet-337	420	14	rate	rate	NOUN
admet-337	420	15	of	of	ADP
admet-337	420	16	89.5	89.5	NUM
admet-337	420	17	%	%	NOUN
admet-337	420	18	,	,	PUNCT
admet-337	420	19	and	and	CCONJ
admet-337	420	20	the	the	DET
admet-337	420	21	median	median	ADJ
admet-337	420	22	pfs	pfs	PROPN
admet-337	420	23	was	be	AUX
admet-337	420	24	11.1	11.1	NUM
admet-337	420	25	months	month	NOUN
admet-337	421	1	[	[	X
admet-337	421	2	142	142	NUM
admet-337	421	3	]	]	PUNCT
admet-337	421	4	.	.	PUNCT
admet-337	422	1	admet	admet	PROPN
admet-337	422	2	&	&	CCONJ
admet-337	422	3	dmpk	dmpk	PROPN
admet-337	422	4	4(3	4(3	NUM
admet-337	422	5	)	)	PUNCT
admet-337	422	6	(	(	PUNCT
admet-337	422	7	2016	2016	NUM
admet-337	422	8	)	)	PUNCT
admet-337	422	9	186	186	NUM
admet-337	422	10	-	-	SYM
admet-337	422	11	211	211	NUM
admet-337	422	12	tki	tki	NOUN
admet-337	422	13	for	for	ADP
admet-337	422	14	egfrand	egfrand	ADJ
admet-337	422	15	alk	alk	PROPN
admet-337	422	16	-	-	PUNCT
admet-337	422	17	mutated	mutate	VERB
admet-337	422	18	cell	cell	NOUN
admet-337	422	19	cancer	cancer	NOUN
admet-337	422	20	doi	doi	NOUN
admet-337	422	21	:	:	PUNCT
admet-337	422	22	10.5599	10.5599	NUM
admet-337	422	23	/	/	SYM
admet-337	422	24	admet.4.3.337	admet.4.3.337	CCONJ
admet-337	422	25	201	201	NUM
admet-337	422	26	clinical	clinical	ADJ
admet-337	422	27	safety	safety	NOUN
admet-337	422	28	like	like	ADP
admet-337	422	29	many	many	ADJ
admet-337	422	30	other	other	ADJ
admet-337	422	31	tkis	tkis	NOUN
admet-337	422	32	,	,	PUNCT
admet-337	422	33	ceritinib	ceritinib	PROPN
admet-337	422	34	induces	induce	VERB
admet-337	422	35	nausea	nausea	NOUN
admet-337	422	36	,	,	PUNCT
admet-337	422	37	diarrhea	diarrhea	NOUN
admet-337	422	38	,	,	PUNCT
admet-337	422	39	and	and	CCONJ
admet-337	422	40	vomiting	vomiting	NOUN
admet-337	422	41	.	.	PUNCT
admet-337	423	1	while	while	SCONJ
admet-337	423	2	60	60	NUM
admet-337	423	3	to	to	PART
admet-337	423	4	80	80	NUM
admet-337	423	5	%	%	NOUN
admet-337	423	6	of	of	ADP
admet-337	423	7	patients	patient	NOUN
admet-337	423	8	experience	experience	VERB
admet-337	423	9	these	these	DET
admet-337	423	10	symptoms	symptom	NOUN
admet-337	423	11	on	on	ADP
admet-337	423	12	ceritinib	ceritinib	NOUN
admet-337	423	13	,	,	PUNCT
admet-337	423	14	only	only	ADV
admet-337	423	15	5	5	NUM
admet-337	423	16	to	to	PART
admet-337	423	17	7	7	NUM
admet-337	423	18	%	%	NOUN
admet-337	423	19	of	of	ADP
admet-337	423	20	patients	patient	NOUN
admet-337	423	21	experience	experience	VERB
admet-337	423	22	grade	grade	NOUN
admet-337	423	23	3	3	NUM
admet-337	423	24	or	or	CCONJ
admet-337	423	25	4	4	NUM
admet-337	423	26	nausea	nausea	NOUN
admet-337	423	27	,	,	PUNCT
admet-337	423	28	diarrhea	diarrhea	NOUN
admet-337	423	29	or	or	CCONJ
admet-337	423	30	vomiting	vomiting	NOUN
admet-337	423	31	.	.	PUNCT
admet-337	424	1	approximately	approximately	ADV
admet-337	424	2	58	58	NUM
admet-337	424	3	%	%	NOUN
admet-337	424	4	of	of	ADP
admet-337	424	5	patients	patient	NOUN
admet-337	424	6	taking	take	VERB
admet-337	424	7	ceritinib	ceritinib	NOUN
admet-337	424	8	at	at	ADP
admet-337	424	9	the	the	DET
admet-337	424	10	recommended	recommend	VERB
admet-337	424	11	starting	starting	NOUN
admet-337	424	12	dose	dose	NOUN
admet-337	424	13	of	of	ADP
admet-337	424	14	750	750	NUM
admet-337	424	15	mg	mg	NOUN
admet-337	424	16	daily	daily	ADV
admet-337	424	17	required	require	VERB
admet-337	424	18	at	at	ADV
admet-337	424	19	least	least	ADV
admet-337	424	20	one	one	NUM
admet-337	424	21	dose	dose	NOUN
admet-337	424	22	reduction	reduction	NOUN
admet-337	424	23	[	[	X
admet-337	424	24	143	143	NUM
admet-337	424	25	]	]	PUNCT
admet-337	424	26	.	.	PUNCT
admet-337	425	1	ceritinib	ceritinib	PROPN
admet-337	425	2	was	be	AUX
admet-337	425	3	discontinued	discontinue	VERB
admet-337	425	4	entirely	entirely	ADV
admet-337	425	5	in	in	ADP
admet-337	425	6	only	only	ADV
admet-337	425	7	7	7	NUM
admet-337	425	8	to	to	PART
admet-337	425	9	8	8	NUM
admet-337	425	10	%	%	NOUN
admet-337	425	11	of	of	ADP
admet-337	425	12	patients	patient	NOUN
admet-337	425	13	on	on	ADP
admet-337	425	14	clinical	clinical	ADJ
admet-337	425	15	trial	trial	NOUN
admet-337	425	16	due	due	ADP
admet-337	425	17	to	to	ADP
admet-337	425	18	adverse	adverse	ADJ
admet-337	425	19	events	event	NOUN
admet-337	425	20	[	[	X
admet-337	425	21	14,140	14,140	NUM
admet-337	425	22	-	-	SYM
admet-337	425	23	142	142	NUM
admet-337	425	24	]	]	PUNCT
admet-337	425	25	.	.	PUNCT
admet-337	426	1	severe	severe	ADJ
admet-337	426	2	interstitial	interstitial	ADJ
admet-337	426	3	lung	lung	NOUN
admet-337	426	4	disease	disease	NOUN
admet-337	426	5	,	,	PUNCT
admet-337	426	6	which	which	PRON
admet-337	426	7	may	may	AUX
admet-337	426	8	be	be	AUX
admet-337	426	9	related	relate	VERB
admet-337	426	10	to	to	ADP
admet-337	426	11	ceritinib	ceritinib	PROPN
admet-337	426	12	has	have	AUX
admet-337	426	13	also	also	ADV
admet-337	426	14	been	be	AUX
admet-337	426	15	reported	report	VERB
admet-337	426	16	,	,	PUNCT
admet-337	426	17	but	but	CCONJ
admet-337	426	18	the	the	DET
admet-337	426	19	incidence	incidence	NOUN
admet-337	426	20	is	be	AUX
admet-337	426	21	less	less	ADJ
admet-337	426	22	than	than	ADP
admet-337	426	23	5	5	NUM
admet-337	426	24	%	%	NOUN
admet-337	426	25	.	.	PUNCT
admet-337	427	1	grade	grade	NOUN
admet-337	427	2	3	3	NUM
admet-337	427	3	or	or	CCONJ
admet-337	427	4	4	4	NUM
admet-337	427	5	transaminitis	transaminitis	NOUN
admet-337	427	6	occurs	occur	VERB
admet-337	427	7	in	in	ADP
admet-337	427	8	approximately	approximately	ADV
admet-337	427	9	21	21	NUM
admet-337	427	10	%	%	NOUN
admet-337	427	11	of	of	ADP
admet-337	427	12	patients	patient	NOUN
admet-337	427	13	.	.	PUNCT
admet-337	428	1	like	like	INTJ
admet-337	428	2	crizotinib	crizotinib	NOUN
admet-337	428	3	,	,	PUNCT
admet-337	428	4	low	low	ADJ
admet-337	428	5	risks	risk	NOUN
admet-337	428	6	of	of	ADP
admet-337	428	7	bradycardia	bradycardia	NOUN
admet-337	428	8	and	and	CCONJ
admet-337	428	9	q	q	NOUN
admet-337	428	10	-	-	PUNCT
admet-337	428	11	t	t	NOUN
admet-337	428	12	prolongation	prolongation	NOUN
admet-337	428	13	have	have	AUX
admet-337	428	14	been	be	AUX
admet-337	428	15	observed	observe	VERB
admet-337	428	16	.	.	PUNCT
admet-337	429	1	ceritinib	ceritinib	NOUN
admet-337	429	2	also	also	ADV
admet-337	429	3	affects	affect	VERB
admet-337	429	4	the	the	DET
admet-337	429	5	insulin	insulin	NOUN
admet-337	429	6	-	-	PUNCT
admet-337	429	7	like	like	ADJ
admet-337	429	8	growth	growth	NOUN
admet-337	429	9	factor	factor	NOUN
admet-337	429	10	1	1	NUM
admet-337	429	11	receptor	receptor	NOUN
admet-337	429	12	(	(	PUNCT
admet-337	429	13	igf-1r	igf-1r	PROPN
admet-337	429	14	)	)	PUNCT
admet-337	429	15	and	and	CCONJ
admet-337	429	16	insulin	insulin	NOUN
admet-337	429	17	receptor	receptor	NOUN
admet-337	429	18	(	(	PUNCT
admet-337	429	19	insr	insr	NOUN
admet-337	429	20	)	)	PUNCT
admet-337	429	21	,	,	PUNCT
admet-337	429	22	and	and	CCONJ
admet-337	429	23	grade	grade	NOUN
admet-337	429	24	3	3	NUM
admet-337	429	25	or	or	CCONJ
admet-337	429	26	4	4	NUM
admet-337	429	27	hyperglycemia	hyperglycemia	NOUN
admet-337	429	28	was	be	AUX
admet-337	429	29	witnessed	witness	VERB
admet-337	429	30	in	in	ADP
admet-337	429	31	up	up	ADP
admet-337	429	32	to	to	PART
admet-337	429	33	13	13	NUM
admet-337	429	34	%	%	NOUN
admet-337	429	35	of	of	ADP
admet-337	429	36	patients	patient	NOUN
admet-337	429	37	.	.	PUNCT
admet-337	430	1	underlying	underlie	VERB
admet-337	430	2	diabetes	diabetes	NOUN
admet-337	430	3	may	may	AUX
admet-337	430	4	exacerbate	exacerbate	VERB
admet-337	430	5	this	this	DET
admet-337	430	6	effect	effect	NOUN
admet-337	430	7	.	.	PUNCT
admet-337	431	1	elevated	elevated	ADJ
admet-337	431	2	lipase	lipase	NOUN
admet-337	431	3	and	and	CCONJ
admet-337	431	4	fatal	fatal	ADJ
admet-337	431	5	pancreatitis	pancreatitis	PROPN
admet-337	431	6	have	have	AUX
admet-337	431	7	been	be	AUX
admet-337	431	8	reported	report	VERB
admet-337	431	9	in	in	ADP
admet-337	431	10	clinical	clinical	ADJ
admet-337	431	11	trials	trial	NOUN
admet-337	431	12	[	[	X
admet-337	431	13	14,140	14,140	NUM
admet-337	431	14	]	]	PUNCT
admet-337	431	15	.	.	PUNCT
admet-337	432	1	pharmacology	pharmacology	NOUN
admet-337	432	2	ceritinib	ceritinib	NOUN
admet-337	432	3	,	,	PUNCT
admet-337	432	4	5	5	NUM
admet-337	432	5	-	-	PUNCT
admet-337	432	6	chloro-2	chloro-2	VERB
admet-337	432	7	-	-	PUNCT
admet-337	432	8	n-(5	n-(5	NOUN
admet-337	432	9	-	-	PUNCT
admet-337	432	10	methyl-4	methyl-4	NOUN
admet-337	432	11	-	-	PUNCT
admet-337	432	12	piperidin-4	piperidin-4	NOUN
admet-337	432	13	-	-	PUNCT
admet-337	432	14	yl-2	yl-2	PROPN
admet-337	432	15	-	-	PUNCT
admet-337	432	16	propan-2	propan-2	ADV
admet-337	432	17	-	-	PUNCT
admet-337	432	18	yloxyphenyl)-4	yloxyphenyl)-4	ADJ
admet-337	432	19	-	-	PUNCT
admet-337	432	20	n-(2	n-(2	NOUN
admet-337	432	21	-	-	PUNCT
admet-337	432	22	propan-2	propan-2	NOUN
admet-337	432	23	-	-	PUNCT
admet-337	432	24	ylsulfo	ylsulfo	NOUN
admet-337	432	25	-	-	PUNCT
admet-337	432	26	nylphenyl)-pyrimidine-2,4	nylphenyl)-pyrimidine-2,4	ADV
admet-337	432	27	-	-	PUNCT
admet-337	432	28	diamine	diamine	NOUN
admet-337	432	29	[	[	X
admet-337	432	30	ldk378	ldk378	PROPN
admet-337	432	31	,	,	PUNCT
admet-337	432	32	zykadia	zykadia	PROPN
admet-337	432	33	,	,	PUNCT
admet-337	432	34	(	(	PUNCT
admet-337	432	35	novartis	novartis	PROPN
admet-337	432	36	)	)	PUNCT
admet-337	432	37	]	]	PUNCT
admet-337	432	38	is	be	AUX
admet-337	432	39	a	a	DET
admet-337	432	40	second	second	ADJ
admet-337	432	41	-	-	PUNCT
admet-337	432	42	generation	generation	NOUN
admet-337	432	43	alk	alk	NOUN
admet-337	432	44	inhibitor	inhibitor	NOUN
admet-337	432	45	that	that	PRON
admet-337	432	46	competitively	competitively	ADV
admet-337	432	47	inhibits	inhibit	VERB
admet-337	432	48	the	the	DET
admet-337	432	49	alk	alk	PROPN
admet-337	432	50	tyrosine	tyrosine	PROPN
admet-337	432	51	kinase	kinase	PROPN
admet-337	432	52	domain	domain	PROPN
admet-337	432	53	through	through	ADP
admet-337	432	54	phosphorylation	phosphorylation	NOUN
admet-337	432	55	.	.	PUNCT
admet-337	433	1	it	it	PRON
admet-337	433	2	also	also	ADV
admet-337	433	3	inhibits	inhibit	VERB
admet-337	433	4	igf-1r	igf-1r	PROPN
admet-337	433	5	,	,	PUNCT
admet-337	433	6	insr	insr	NOUN
admet-337	433	7	and	and	CCONJ
admet-337	433	8	the	the	DET
admet-337	433	9	ros1	ros1	NOUN
admet-337	433	10	receptor	receptor	NOUN
admet-337	433	11	.	.	PUNCT
admet-337	434	1	unlike	unlike	ADP
admet-337	434	2	crizotinib	crizotinib	NOUN
admet-337	434	3	,	,	PUNCT
admet-337	434	4	it	it	PRON
admet-337	434	5	does	do	AUX
admet-337	434	6	not	not	PART
admet-337	434	7	inhibit	inhibit	VERB
admet-337	434	8	c	c	ADV
admet-337	434	9	-	-	PUNCT
admet-337	434	10	met	meet	VERB
admet-337	434	11	[	[	PUNCT
admet-337	434	12	136,143	136,143	NUM
admet-337	434	13	]	]	PUNCT
admet-337	434	14	.	.	PUNCT
admet-337	435	1	ceritinib	ceritinib	PROPN
admet-337	435	2	more	more	ADV
admet-337	435	3	potently	potently	ADV
admet-337	435	4	inhibits	inhibit	VERB
admet-337	435	5	alk	alk	NOUN
admet-337	435	6	than	than	ADP
admet-337	435	7	crizotinib	crizotinib	NOUN
admet-337	435	8	,	,	PUNCT
admet-337	435	9	as	as	SCONJ
admet-337	435	10	ceritinib	ceritinib	NOUN
admet-337	435	11	produces	produce	VERB
admet-337	435	12	ic50	ic50	PROPN
admet-337	435	13	values	value	NOUN
admet-337	435	14	of	of	ADP
admet-337	435	15	0.15	0.15	NUM
admet-337	435	16	nm	nm	NOUN
admet-337	435	17	in	in	ADP
admet-337	435	18	enzymatic	enzymatic	ADJ
admet-337	435	19	assays	assay	NOUN
admet-337	435	20	(	(	PUNCT
admet-337	435	21	crizotinib	crizotinib	VERB
admet-337	435	22	ic50	ic50	PROPN
admet-337	435	23	3.6	3.6	NUM
admet-337	435	24	nm	nm	NOUN
admet-337	435	25	)	)	PUNCT
admet-337	435	26	and	and	CCONJ
admet-337	436	1	ic50	ic50	PROPN
admet-337	436	2	of	of	ADP
admet-337	436	3	25	25	NUM
admet-337	436	4	nm	nm	NOUN
admet-337	436	5	in	in	ADP
admet-337	436	6	cell	cell	NOUN
admet-337	436	7	lines	line	NOUN
admet-337	436	8	[	[	X
admet-337	436	9	136,144	136,144	NUM
admet-337	436	10	]	]	PUNCT
admet-337	436	11	.	.	PUNCT
admet-337	437	1	the	the	DET
admet-337	437	2	recommended	recommend	VERB
admet-337	437	3	starting	starting	NOUN
admet-337	437	4	dose	dose	NOUN
admet-337	437	5	is	be	AUX
admet-337	437	6	750	750	NUM
admet-337	437	7	mg	mg	NOUN
admet-337	437	8	administered	administer	VERB
admet-337	437	9	orally	orally	ADV
admet-337	437	10	once	once	ADV
admet-337	437	11	daily	daily	ADV
admet-337	437	12	.	.	PUNCT
admet-337	438	1	its	its	PRON
admet-337	438	2	absorption	absorption	NOUN
admet-337	438	3	is	be	AUX
admet-337	438	4	increased	increase	VERB
admet-337	438	5	when	when	SCONJ
admet-337	438	6	administered	administer	VERB
admet-337	438	7	with	with	ADP
admet-337	438	8	a	a	DET
admet-337	438	9	meal	meal	NOUN
admet-337	438	10	,	,	PUNCT
admet-337	438	11	with	with	ADP
admet-337	438	12	peak	peak	NOUN
admet-337	438	13	plasma	plasma	NOUN
admet-337	438	14	activity	activity	NOUN
admet-337	438	15	increasing	increase	VERB
admet-337	438	16	by	by	ADP
admet-337	438	17	41	41	NUM
admet-337	438	18	to	to	PART
admet-337	438	19	43	43	NUM
admet-337	438	20	%	%	NOUN
admet-337	438	21	compared	compare	VERB
admet-337	438	22	to	to	ADP
admet-337	438	23	a	a	DET
admet-337	438	24	fasting	fast	VERB
admet-337	438	25	state	state	NOUN
admet-337	438	26	.	.	PUNCT
admet-337	439	1	the	the	DET
admet-337	439	2	drug	drug	NOUN
admet-337	439	3	should	should	AUX
admet-337	439	4	,	,	PUNCT
admet-337	439	5	therefore	therefore	ADV
admet-337	439	6	,	,	PUNCT
admet-337	439	7	be	be	AUX
admet-337	439	8	taken	take	VERB
admet-337	439	9	on	on	ADP
admet-337	439	10	an	an	DET
admet-337	439	11	empty	empty	ADJ
admet-337	439	12	stomach	stomach	NOUN
admet-337	439	13	.	.	PUNCT
admet-337	440	1	oral	oral	ADJ
admet-337	440	2	bioavailability	bioavailability	NOUN
admet-337	440	3	is	be	AUX
admet-337	440	4	unknown	unknown	ADJ
admet-337	440	5	,	,	PUNCT
admet-337	440	6	but	but	CCONJ
admet-337	440	7	peak	peak	NOUN
admet-337	440	8	plasma	plasma	NOUN
admet-337	440	9	levels	level	NOUN
admet-337	440	10	are	be	AUX
admet-337	440	11	achieved	achieve	VERB
admet-337	440	12	at	at	ADP
admet-337	440	13	4	4	NUM
admet-337	440	14	to	to	PART
admet-337	440	15	6	6	NUM
admet-337	440	16	hours	hour	NOUN
admet-337	440	17	after	after	ADP
admet-337	440	18	dosing	dose	VERB
admet-337	440	19	.	.	PUNCT
admet-337	441	1	ceritinib	ceritinib	PROPN
admet-337	441	2	is	be	AUX
admet-337	441	3	97	97	NUM
admet-337	441	4	%	%	NOUN
admet-337	441	5	protein	protein	NOUN
admet-337	441	6	-	-	PUNCT
admet-337	441	7	bound	bind	VERB
admet-337	441	8	upon	upon	SCONJ
admet-337	441	9	absorption	absorption	NOUN
admet-337	441	10	,	,	PUNCT
admet-337	441	11	has	have	AUX
admet-337	441	12	a	a	DET
admet-337	441	13	volume	volume	NOUN
admet-337	441	14	of	of	ADP
admet-337	441	15	distribution	distribution	NOUN
admet-337	441	16	of	of	ADP
admet-337	441	17	4230l	4230l	NUM
admet-337	441	18	,	,	PUNCT
admet-337	441	19	and	and	CCONJ
admet-337	441	20	reaches	reach	VERB
admet-337	441	21	steady	steady	ADJ
admet-337	441	22	state	state	NOUN
admet-337	441	23	at	at	ADP
admet-337	441	24	15	15	NUM
admet-337	441	25	days	day	NOUN
admet-337	441	26	.	.	PUNCT
admet-337	442	1	it	it	PRON
admet-337	442	2	is	be	AUX
admet-337	442	3	primarily	primarily	ADV
admet-337	442	4	metabolized	metabolize	VERB
admet-337	442	5	in	in	ADP
admet-337	442	6	the	the	DET
admet-337	442	7	liver	liver	NOUN
admet-337	442	8	by	by	ADP
admet-337	442	9	cyp3a4	cyp3a4	NOUN
admet-337	442	10	and	and	CCONJ
admet-337	442	11	serves	serve	VERB
admet-337	442	12	as	as	ADP
admet-337	442	13	a	a	DET
admet-337	442	14	substrate	substrate	NOUN
admet-337	442	15	for	for	ADP
admet-337	442	16	pglycoprotein	pglycoprotein	NOUN
admet-337	442	17	.	.	PUNCT
admet-337	443	1	the	the	DET
admet-337	443	2	drug	drug	NOUN
admet-337	443	3	may	may	AUX
admet-337	443	4	inhibit	inhibit	VERB
admet-337	443	5	cyp3a	cyp3a	NOUN
admet-337	443	6	and	and	CCONJ
admet-337	443	7	cyp2c9	cyp2c9	NOUN
admet-337	443	8	at	at	ADP
admet-337	443	9	the	the	DET
admet-337	443	10	recommended	recommended	ADJ
admet-337	443	11	dosing	dosing	NOUN
admet-337	443	12	.	.	PUNCT
admet-337	444	1	ceritinib	ceritinib	PROPN
admet-337	444	2	has	have	VERB
admet-337	444	3	a	a	DET
admet-337	444	4	terminal	terminal	ADJ
admet-337	444	5	half	half	ADJ
admet-337	444	6	-	-	PUNCT
admet-337	444	7	life	life	NOUN
admet-337	444	8	of	of	ADP
admet-337	444	9	41	41	NUM
admet-337	444	10	hours	hour	NOUN
admet-337	444	11	,	,	PUNCT
admet-337	444	12	and	and	CCONJ
admet-337	444	13	like	like	ADP
admet-337	444	14	crizotinib	crizotinib	NOUN
admet-337	444	15	,	,	PUNCT
admet-337	444	16	has	have	VERB
admet-337	444	17	a	a	DET
admet-337	444	18	nonlinear	nonlinear	ADJ
admet-337	444	19	pk	pk	NOUN
admet-337	444	20	over	over	ADP
admet-337	444	21	time	time	NOUN
admet-337	444	22	,	,	PUNCT
admet-337	444	23	with	with	ADP
admet-337	444	24	a	a	DET
admet-337	444	25	cl	cl	NOUN
admet-337	444	26	/	/	SYM
admet-337	444	27	f	f	NOUN
admet-337	444	28	of	of	ADP
admet-337	444	29	88.5	88.5	NUM
admet-337	444	30	l	l	NOUN
admet-337	444	31	/	/	SYM
admet-337	444	32	hr	hr	NOUN
admet-337	444	33	after	after	ADP
admet-337	444	34	one	one	NUM
admet-337	444	35	dose	dose	NOUN
admet-337	444	36	and	and	CCONJ
admet-337	444	37	a	a	DET
admet-337	444	38	cl	cl	NOUN
admet-337	444	39	/	/	SYM
admet-337	444	40	f	f	NOUN
admet-337	444	41	of	of	ADP
admet-337	444	42	33.2l	33.2l	NUM
admet-337	444	43	/	/	SYM
admet-337	444	44	hr	hr	NOUN
admet-337	444	45	at	at	ADP
admet-337	444	46	steady	steady	ADJ
admet-337	444	47	state	state	NOUN
admet-337	444	48	.	.	PUNCT
admet-337	445	1	following	follow	VERB
admet-337	445	2	administration	administration	NOUN
admet-337	445	3	,	,	PUNCT
admet-337	445	4	92.3	92.3	NUM
admet-337	445	5	%	%	NOUN
admet-337	445	6	of	of	ADP
admet-337	445	7	the	the	DET
admet-337	445	8	drug	drug	NOUN
admet-337	445	9	is	be	AUX
admet-337	445	10	eliminated	eliminate	VERB
admet-337	445	11	in	in	ADP
admet-337	445	12	the	the	DET
admet-337	445	13	feces	fece	NOUN
admet-337	445	14	(	(	PUNCT
admet-337	445	15	68	68	NUM
admet-337	445	16	%	%	NOUN
admet-337	445	17	unchanged	unchanged	ADJ
admet-337	445	18	)	)	PUNCT
admet-337	446	1	[	[	X
admet-337	446	2	143,144	143,144	NUM
admet-337	446	3	]	]	PUNCT
admet-337	446	4	.	.	PUNCT
admet-337	447	1	no	no	DET
admet-337	447	2	dose	dose	NOUN
admet-337	447	3	adjustments	adjustment	NOUN
admet-337	447	4	for	for	ADP
admet-337	447	5	hepatic	hepatic	ADJ
admet-337	447	6	or	or	CCONJ
admet-337	447	7	renal	renal	ADJ
admet-337	447	8	failure	failure	NOUN
admet-337	447	9	have	have	AUX
admet-337	447	10	been	be	AUX
admet-337	447	11	recommended	recommend	VERB
admet-337	447	12	.	.	PUNCT
admet-337	448	1	cns	cns	NOUN
admet-337	448	2	penetration	penetration	NOUN
admet-337	448	3	the	the	DET
admet-337	448	4	ascend	ascend	NOUN
admet-337	448	5	trials	trial	NOUN
admet-337	448	6	allowed	allow	VERB
admet-337	448	7	patients	patient	NOUN
admet-337	448	8	with	with	ADP
admet-337	448	9	untreated	untreated	ADJ
admet-337	448	10	,	,	PUNCT
admet-337	448	11	asymptomatic	asymptomatic	ADJ
admet-337	448	12	brain	brain	NOUN
admet-337	448	13	metastases	metastasis	NOUN
admet-337	448	14	to	to	PART
admet-337	448	15	enroll	enroll	VERB
admet-337	448	16	.	.	PUNCT
admet-337	449	1	in	in	ADP
admet-337	449	2	ascend-2	ascend-2	NUM
admet-337	449	3	,	,	PUNCT
admet-337	449	4	intracranial	intracranial	ADJ
admet-337	449	5	disease	disease	NOUN
admet-337	449	6	control	control	NOUN
admet-337	449	7	was	be	AUX
admet-337	449	8	attained	attain	VERB
admet-337	449	9	in	in	ADP
admet-337	449	10	80	80	NUM
admet-337	449	11	%	%	NOUN
admet-337	449	12	of	of	ADP
admet-337	449	13	patients	patient	NOUN
admet-337	449	14	with	with	ADP
admet-337	449	15	brain	brain	NOUN
admet-337	449	16	lesions	lesion	NOUN
admet-337	449	17	.	.	PUNCT
admet-337	450	1	in	in	ADP
admet-337	450	2	5	5	NUM
admet-337	450	3	of	of	ADP
admet-337	450	4	the	the	DET
admet-337	450	5	6	6	NUM
admet-337	450	6	patients	patient	NOUN
admet-337	450	7	with	with	ADP
admet-337	450	8	brain	brain	NOUN
admet-337	450	9	lesions	lesion	NOUN
admet-337	450	10	that	that	PRON
admet-337	450	11	had	have	AUX
admet-337	450	12	not	not	PART
admet-337	450	13	previously	previously	ADV
admet-337	450	14	been	be	AUX
admet-337	450	15	treated	treat	VERB
admet-337	450	16	,	,	PUNCT
admet-337	450	17	2	2	NUM
admet-337	450	18	complete	complete	ADJ
admet-337	450	19	responses	response	NOUN
admet-337	450	20	and	and	CCONJ
admet-337	450	21	3	3	NUM
admet-337	450	22	partial	partial	ADJ
admet-337	450	23	responses	response	NOUN
admet-337	450	24	were	be	AUX
admet-337	450	25	achieved	achieve	VERB
admet-337	450	26	with	with	ADP
admet-337	450	27	ceritinib	ceritinib	NOUN
admet-337	450	28	[	[	X
admet-337	450	29	141	141	NUM
admet-337	450	30	]	]	PUNCT
admet-337	450	31	.	.	PUNCT
admet-337	451	1	likewise	likewise	ADV
admet-337	451	2	,	,	PUNCT
admet-337	451	3	in	in	ADP
admet-337	451	4	ascend-3	ascend-3	NUM
admet-337	451	5	,	,	PUNCT
admet-337	451	6	the	the	DET
admet-337	451	7	intracranial	intracranial	ADJ
admet-337	451	8	disease	disease	NOUN
admet-337	451	9	control	control	NOUN
admet-337	451	10	rate	rate	NOUN
admet-337	451	11	was	be	AUX
admet-337	451	12	80	80	NUM
admet-337	451	13	%	%	NOUN
admet-337	451	14	,	,	PUNCT
admet-337	451	15	and	and	CCONJ
admet-337	451	16	2	2	NUM
admet-337	451	17	partial	partial	ADJ
admet-337	451	18	responses	response	NOUN
admet-337	451	19	were	be	AUX
admet-337	451	20	achieved	achieve	VERB
admet-337	451	21	with	with	ADP
admet-337	451	22	ceritinib	ceritinib	NOUN
admet-337	451	23	.	.	PUNCT
admet-337	452	1	all	all	DET
admet-337	452	2	responses	response	NOUN
admet-337	452	3	in	in	ADP
admet-337	452	4	the	the	DET
admet-337	452	5	brain	brain	NOUN
admet-337	452	6	matched	match	VERB
admet-337	452	7	or	or	CCONJ
admet-337	452	8	exceeded	exceed	VERB
admet-337	452	9	the	the	DET
admet-337	452	10	responses	response	NOUN
admet-337	452	11	achieved	achieve	VERB
admet-337	452	12	systemically	systemically	ADV
admet-337	452	13	[	[	X
admet-337	452	14	142	142	NUM
admet-337	452	15	]	]	PUNCT
admet-337	452	16	.	.	PUNCT
admet-337	453	1	to	to	ADP
admet-337	453	2	date	date	NOUN
admet-337	453	3	,	,	PUNCT
admet-337	453	4	csf	csf	ADJ
admet-337	453	5	measurements	measurement	NOUN
admet-337	453	6	of	of	ADP
admet-337	453	7	ceritinib	ceritinib	NOUN
admet-337	453	8	after	after	SCONJ
admet-337	453	9	oral	oral	ADJ
admet-337	453	10	administration	administration	NOUN
admet-337	453	11	are	be	AUX
admet-337	453	12	unavailable	unavailable	ADJ
admet-337	453	13	.	.	PUNCT
admet-337	454	1	resistance	resistance	NOUN
admet-337	454	2	mechanisms	mechanism	NOUN
admet-337	454	3	in	in	ADP
admet-337	454	4	10	10	NUM
admet-337	454	5	patients	patient	NOUN
admet-337	454	6	who	who	PRON
admet-337	454	7	developed	develop	VERB
admet-337	454	8	disease	disease	NOUN
admet-337	454	9	progression	progression	NOUN
admet-337	454	10	while	while	SCONJ
admet-337	454	11	taking	take	VERB
admet-337	454	12	ceritinib	ceritinib	NOUN
admet-337	454	13	(	(	PUNCT
admet-337	454	14	median	median	ADJ
admet-337	454	15	duration	duration	NOUN
admet-337	454	16	of	of	ADP
admet-337	454	17	treatment	treatment	NOUN
admet-337	454	18	7.5	7.5	NUM
admet-337	454	19	months	month	NOUN
admet-337	454	20	)	)	PUNCT
admet-337	454	21	,	,	PUNCT
admet-337	454	22	tumor	tumor	NOUN
admet-337	454	23	analysis	analysis	NOUN
admet-337	454	24	revealed	reveal	VERB
admet-337	454	25	several	several	ADJ
admet-337	454	26	novel	novel	ADJ
admet-337	454	27	alk	alk	NOUN
admet-337	454	28	resistance	resistance	NOUN
admet-337	454	29	mutations	mutation	NOUN
admet-337	454	30	in	in	ADP
admet-337	454	31	the	the	DET
admet-337	454	32	tyrosine	tyrosine	NOUN
admet-337	454	33	kinase	kinase	PROPN
admet-337	454	34	domain	domain	PROPN
admet-337	454	35	.	.	PUNCT
admet-337	455	1	a	a	DET
admet-337	455	2	total	total	NOUN
admet-337	455	3	of	of	ADP
admet-337	455	4	11	11	NUM
admet-337	455	5	samples	sample	NOUN
admet-337	455	6	were	be	AUX
admet-337	455	7	obtained	obtain	VERB
admet-337	455	8	in	in	ADP
admet-337	455	9	the	the	DET
admet-337	455	10	10	10	NUM
admet-337	455	11	patients	patient	NOUN
admet-337	455	12	,	,	PUNCT
admet-337	455	13	and	and	CCONJ
admet-337	455	14	in	in	ADP
admet-337	455	15	5	5	NUM
admet-337	455	16	of	of	ADP
admet-337	455	17	11	11	NUM
admet-337	455	18	samples	sample	NOUN
admet-337	455	19	,	,	PUNCT
admet-337	455	20	secondary	secondary	ADJ
admet-337	455	21	mutations	mutation	NOUN
admet-337	455	22	in	in	ADP
admet-337	455	23	the	the	DET
admet-337	455	24	alk	alk	PROPN
admet-337	455	25	tyrosine	tyrosine	PROPN
admet-337	455	26	kinase	kinase	PROPN
admet-337	455	27	domain	domain	PROPN
admet-337	455	28	were	be	AUX
admet-337	455	29	identified	identify	VERB
admet-337	455	30	.	.	PUNCT
admet-337	456	1	of	of	ADP
admet-337	456	2	these	these	DET
admet-337	456	3	mutations	mutation	NOUN
admet-337	456	4	,	,	PUNCT
admet-337	456	5	3	3	NUM
admet-337	456	6	were	be	AUX
admet-337	456	7	g1202r	g1202r	PROPN
admet-337	456	8	,	,	PUNCT
admet-337	456	9	1	1	NUM
admet-337	456	10	was	be	AUX
admet-337	456	11	f1174c	f1174c	ADJ
admet-337	456	12	,	,	PUNCT
admet-337	456	13	and	and	CCONJ
admet-337	456	14	1	1	NUM
admet-337	456	15	was	be	AUX
admet-337	456	16	grace	grace	NOUN
admet-337	456	17	dy	dy	NOUN
admet-337	456	18	et	et	PROPN
admet-337	456	19	al	al	PROPN
admet-337	456	20	.	.	PROPN
admet-337	456	21	admet	admet	PROPN
admet-337	456	22	&	&	CCONJ
admet-337	456	23	dmpk	dmpk	PROPN
admet-337	456	24	4(3	4(3	NUM
admet-337	456	25	)	)	PUNCT
admet-337	456	26	(	(	PUNCT
admet-337	456	27	2016	2016	NUM
admet-337	456	28	)	)	PUNCT
admet-337	456	29	186	186	NUM
admet-337	456	30	-	-	SYM
admet-337	456	31	211	211	NUM
admet-337	457	1	202	202	NUM
admet-337	457	2	f1174v	f1174v	X
admet-337	457	3	.	.	PROPN
admet-337	458	1	two	two	NUM
admet-337	458	2	of	of	ADP
admet-337	458	3	the	the	DET
admet-337	458	4	patients	patient	NOUN
admet-337	458	5	had	have	VERB
admet-337	458	6	s1206y	s1206y	ADV
admet-337	458	7	and	and	CCONJ
admet-337	458	8	g1269a	g1269a	ADJ
admet-337	458	9	mutations	mutation	NOUN
admet-337	458	10	prior	prior	ADV
admet-337	458	11	to	to	ADP
admet-337	458	12	ceritinib	ceritinib	NOUN
admet-337	458	13	,	,	PUNCT
admet-337	458	14	which	which	PRON
admet-337	458	15	were	be	AUX
admet-337	458	16	no	no	ADV
admet-337	458	17	longer	long	ADV
admet-337	458	18	present	present	ADJ
admet-337	458	19	on	on	ADP
admet-337	458	20	post	post	ADJ
admet-337	458	21	-	-	ADJ
admet-337	458	22	ceritinib	ceritinib	ADJ
admet-337	458	23	tumor	tumor	NOUN
admet-337	458	24	samples	sample	NOUN
admet-337	458	25	.	.	PUNCT
admet-337	459	1	alk	alk	NOUN
admet-337	459	2	amplification	amplification	NOUN
admet-337	459	3	was	be	AUX
admet-337	459	4	not	not	PART
admet-337	459	5	witnessed	witness	VERB
admet-337	459	6	in	in	ADP
admet-337	459	7	this	this	DET
admet-337	459	8	population	population	NOUN
admet-337	460	1	[	[	X
admet-337	460	2	145	145	NUM
admet-337	460	3	]	]	PUNCT
admet-337	460	4	.	.	PUNCT
admet-337	461	1	alectinib	alectinib	PROPN
admet-337	461	2	clinical	clinical	ADJ
admet-337	461	3	efficacy	efficacy	NOUN
admet-337	461	4	alectinib	alectinib	NOUN
admet-337	461	5	is	be	AUX
admet-337	461	6	another	another	DET
admet-337	461	7	potent	potent	NOUN
admet-337	461	8	,	,	PUNCT
admet-337	461	9	second	second	ADJ
admet-337	461	10	-	-	PUNCT
admet-337	461	11	generation	generation	NOUN
admet-337	461	12	oral	oral	ADJ
admet-337	461	13	alk	alk	NOUN
admet-337	461	14	tki	tki	PROPN
admet-337	461	15	that	that	SCONJ
admet-337	461	16	,	,	PUNCT
admet-337	461	17	like	like	ADP
admet-337	461	18	ceritinib	ceritinib	NOUN
admet-337	461	19	,	,	PUNCT
admet-337	461	20	inhibits	inhibit	VERB
admet-337	461	21	wild	wild	ADJ
admet-337	461	22	-	-	PUNCT
admet-337	461	23	type	type	NOUN
admet-337	461	24	alk	alk	NOUN
admet-337	461	25	as	as	ADV
admet-337	461	26	well	well	ADV
admet-337	461	27	as	as	ADP
admet-337	461	28	the	the	DET
admet-337	461	29	crizotinib	crizotinib	NOUN
admet-337	461	30	resistance	resistance	NOUN
admet-337	461	31	mutations	mutation	NOUN
admet-337	461	32	l1196	l1196	PROPN
admet-337	461	33	m	m	PROPN
admet-337	461	34	,	,	PUNCT
admet-337	461	35	l1152r	l1152r	PROPN
admet-337	461	36	,	,	PUNCT
admet-337	461	37	g1296a	g1296a	NOUN
admet-337	461	38	and	and	CCONJ
admet-337	461	39	c1156y	c1156y	X
admet-337	462	1	[	[	X
admet-337	462	2	146,147	146,147	NUM
admet-337	462	3	]	]	PUNCT
admet-337	462	4	.	.	PUNCT
admet-337	463	1	in	in	ADP
admet-337	463	2	a	a	DET
admet-337	463	3	phase	phase	NOUN
admet-337	463	4	i	i	PRON
admet-337	463	5	/	/	SYM
admet-337	463	6	ii	ii	PROPN
admet-337	463	7	study	study	NOUN
admet-337	463	8	performed	perform	VERB
admet-337	463	9	on	on	ADP
admet-337	463	10	a	a	DET
admet-337	463	11	japanese	japanese	ADJ
admet-337	463	12	population	population	NOUN
admet-337	463	13	of	of	ADP
admet-337	463	14	alk	alk	PROPN
admet-337	463	15	tki	tki	PROPN
admet-337	463	16	naïve	naïve	ADJ
admet-337	463	17	patients	patient	NOUN
admet-337	463	18	,	,	PUNCT
admet-337	463	19	alectinib	alectinib	NOUN
admet-337	463	20	at	at	ADP
admet-337	463	21	a	a	DET
admet-337	463	22	dose	dose	NOUN
admet-337	463	23	of	of	ADP
admet-337	463	24	300	300	NUM
admet-337	463	25	mg	mg	NOUN
admet-337	463	26	twice	twice	ADV
admet-337	463	27	daily	daily	ADV
admet-337	463	28	produced	produce	VERB
admet-337	463	29	an	an	DET
admet-337	463	30	orr	orr	NOUN
admet-337	463	31	of	of	ADP
admet-337	463	32	93.5	93.5	NUM
admet-337	463	33	%	%	NOUN
admet-337	464	1	[	[	X
admet-337	464	2	148	148	NUM
admet-337	464	3	]	]	PUNCT
admet-337	464	4	.	.	PUNCT
admet-337	465	1	another	another	DET
admet-337	465	2	phase	phase	NOUN
admet-337	465	3	i	i	PRON
admet-337	465	4	/	/	SYM
admet-337	465	5	ii	ii	PROPN
admet-337	465	6	study	study	NOUN
admet-337	465	7	examining	examine	VERB
admet-337	465	8	alectinib	alectinib	NOUN
admet-337	465	9	600	600	NUM
admet-337	465	10	mg	mg	NOUN
admet-337	465	11	twice	twice	ADV
admet-337	465	12	daily	daily	ADV
admet-337	465	13	for	for	ADP
admet-337	465	14	alk	alk	NOUN
admet-337	465	15	-	-	PUNCT
admet-337	465	16	positive	positive	ADJ
admet-337	465	17	patients	patient	NOUN
admet-337	465	18	who	who	PRON
admet-337	465	19	had	have	AUX
admet-337	465	20	previously	previously	ADV
admet-337	465	21	progressed	progress	VERB
admet-337	465	22	on	on	ADP
admet-337	465	23	or	or	CCONJ
admet-337	465	24	were	be	AUX
admet-337	465	25	intolerant	intolerant	ADJ
admet-337	465	26	to	to	PART
admet-337	465	27	crizotinib	crizotinib	VERB
admet-337	465	28	showed	show	VERB
admet-337	465	29	orr	orr	PROPN
admet-337	465	30	of	of	ADP
admet-337	465	31	55	55	NUM
admet-337	465	32	%	%	NOUN
admet-337	465	33	[	[	X
admet-337	465	34	149	149	NUM
admet-337	465	35	]	]	PUNCT
admet-337	465	36	.	.	PUNCT
admet-337	466	1	based	base	VERB
admet-337	466	2	on	on	ADP
admet-337	466	3	these	these	DET
admet-337	466	4	data	datum	NOUN
admet-337	466	5	,	,	PUNCT
admet-337	466	6	in	in	ADP
admet-337	466	7	december	december	PROPN
admet-337	466	8	2015	2015	NUM
admet-337	466	9	,	,	PUNCT
admet-337	466	10	the	the	DET
admet-337	466	11	fda	fda	PROPN
admet-337	466	12	granted	grant	VERB
admet-337	466	13	accelerated	accelerate	VERB
admet-337	466	14	approval	approval	NOUN
admet-337	466	15	to	to	ADP
admet-337	466	16	alectinib	alectinib	NOUN
admet-337	466	17	for	for	ADP
admet-337	466	18	treatment	treatment	NOUN
admet-337	466	19	of	of	ADP
admet-337	466	20	alk	alk	NOUN
admet-337	466	21	-	-	PUNCT
admet-337	466	22	positive	positive	ADJ
admet-337	466	23	nsclc	nsclc	NOUN
admet-337	466	24	patients	patient	NOUN
admet-337	466	25	who	who	PRON
admet-337	466	26	experience	experience	VERB
admet-337	466	27	disease	disease	NOUN
admet-337	466	28	progression	progression	NOUN
admet-337	466	29	on	on	ADP
admet-337	466	30	or	or	CCONJ
admet-337	466	31	intolerance	intolerance	NOUN
admet-337	466	32	to	to	PART
admet-337	466	33	crizotinib	crizotinib	VERB
admet-337	466	34	.	.	PUNCT
admet-337	467	1	subsequently	subsequently	ADV
admet-337	467	2	,	,	PUNCT
admet-337	467	3	a	a	DET
admet-337	467	4	phase	phase	NOUN
admet-337	467	5	ii	ii	NOUN
admet-337	467	6	trial	trial	NOUN
admet-337	467	7	of	of	ADP
admet-337	467	8	87	87	NUM
admet-337	467	9	patients	patient	NOUN
admet-337	467	10	evaluating	evaluate	VERB
admet-337	467	11	alectinib	alectinib	NOUN
admet-337	467	12	for	for	ADP
admet-337	467	13	alk	alk	NOUN
admet-337	467	14	-	-	PUNCT
admet-337	467	15	positive	positive	ADJ
admet-337	467	16	nsclc	nsclc	NOUN
admet-337	467	17	patients	patient	NOUN
admet-337	467	18	who	who	PRON
admet-337	467	19	had	have	AUX
admet-337	467	20	progressed	progress	VERB
admet-337	467	21	on	on	ADP
admet-337	467	22	either	either	DET
admet-337	467	23	chemotherapy	chemotherapy	NOUN
admet-337	467	24	or	or	CCONJ
admet-337	467	25	crizotinib	crizotinib	NOUN
admet-337	467	26	showed	show	VERB
admet-337	467	27	an	an	DET
admet-337	467	28	orr	orr	NOUN
admet-337	467	29	of	of	ADP
admet-337	467	30	48	48	NUM
admet-337	468	1	[	[	X
admet-337	468	2	150	150	NUM
admet-337	468	3	]	]	PUNCT
admet-337	468	4	.	.	PUNCT
admet-337	469	1	recently	recently	ADV
admet-337	469	2	,	,	PUNCT
admet-337	469	3	results	result	NOUN
admet-337	469	4	of	of	ADP
admet-337	469	5	the	the	DET
admet-337	469	6	j	j	PROPN
admet-337	469	7	-	-	PROPN
admet-337	469	8	alex	alex	PROPN
admet-337	469	9	study	study	PROPN
admet-337	469	10	,	,	PUNCT
admet-337	469	11	a	a	DET
admet-337	469	12	randomized	randomize	VERB
admet-337	469	13	open	open	ADJ
admet-337	469	14	-	-	PUNCT
admet-337	469	15	label	label	NOUN
admet-337	469	16	phase	phase	NOUN
admet-337	469	17	iii	iii	NOUN
admet-337	469	18	trial	trial	NOUN
admet-337	469	19	were	be	AUX
admet-337	469	20	presented	present	VERB
admet-337	469	21	at	at	ADP
admet-337	469	22	the	the	DET
admet-337	469	23	american	american	ADJ
admet-337	469	24	society	society	NOUN
admet-337	469	25	of	of	ADP
admet-337	469	26	clinical	clinical	ADJ
admet-337	469	27	oncology	oncology	NOUN
admet-337	469	28	annual	annual	ADJ
admet-337	469	29	meeting	meeting	NOUN
admet-337	469	30	.	.	PUNCT
admet-337	470	1	this	this	DET
admet-337	470	2	trial	trial	NOUN
admet-337	470	3	randomized	randomize	VERB
admet-337	470	4	207	207	NUM
admet-337	470	5	japanese	japanese	ADJ
admet-337	470	6	patients	patient	NOUN
admet-337	470	7	with	with	ADP
admet-337	470	8	advanced	advanced	ADJ
admet-337	470	9	alk	alk	VERB
admet-337	470	10	-	-	PUNCT
admet-337	470	11	positive	positive	ADJ
admet-337	470	12	nsclc	nsclc	NOUN
admet-337	470	13	who	who	PRON
admet-337	470	14	were	be	AUX
admet-337	470	15	alk	alk	VERB
admet-337	470	16	tki	tki	X
admet-337	470	17	naïve	naïve	ADJ
admet-337	470	18	to	to	ADP
admet-337	470	19	alectinib	alectinib	NOUN
admet-337	470	20	300	300	NUM
admet-337	470	21	mg	mg	NOUN
admet-337	470	22	twice	twice	ADV
admet-337	470	23	daily	daily	ADV
admet-337	470	24	or	or	CCONJ
admet-337	470	25	crizotinib	crizotinib	VERB
admet-337	470	26	250	250	NUM
admet-337	470	27	mg	mg	NOUN
admet-337	470	28	twice	twice	ADV
admet-337	470	29	daily	daily	ADV
admet-337	470	30	.	.	PUNCT
admet-337	471	1	the	the	DET
admet-337	471	2	primary	primary	ADJ
admet-337	471	3	endpoint	endpoint	NOUN
admet-337	471	4	of	of	ADP
admet-337	471	5	the	the	DET
admet-337	471	6	study	study	NOUN
admet-337	471	7	was	be	AUX
admet-337	471	8	pfs	pf	VERB
admet-337	471	9	,	,	PUNCT
admet-337	471	10	and	and	CCONJ
admet-337	471	11	alectinib	alectinib	NOUN
admet-337	471	12	produced	produce	VERB
admet-337	471	13	a	a	DET
admet-337	471	14	statistically	statistically	ADV
admet-337	471	15	superior	superior	ADJ
admet-337	471	16	pfs	pf	NOUN
admet-337	471	17	with	with	ADP
admet-337	471	18	a	a	DET
admet-337	471	19	pfs	pfs	ADJ
admet-337	471	20	hr	hr	NOUN
admet-337	471	21	of	of	ADP
admet-337	471	22	alectinib	alectinib	NOUN
admet-337	471	23	compared	compare	VERB
admet-337	471	24	to	to	ADP
admet-337	471	25	crizotinib	crizotinib	NOUN
admet-337	471	26	of	of	ADP
admet-337	471	27	0.34	0.34	NUM
admet-337	471	28	(	(	PUNCT
admet-337	471	29	99.6826	99.6826	NUM
admet-337	471	30	%	%	NOUN
admet-337	471	31	ci	ci	NOUN
admet-337	471	32	:	:	PUNCT
admet-337	471	33	0.17	0.17	NUM
admet-337	471	34	-	-	SYM
admet-337	471	35	0.70	0.70	NUM
admet-337	471	36	,	,	PUNCT
admet-337	471	37	stratified	stratify	VERB
admet-337	471	38	log	log	NOUN
admet-337	471	39	-	-	PUNCT
admet-337	471	40	rank	rank	NOUN
admet-337	471	41	p<0.0001	p<0.0001	NOUN
admet-337	471	42	)	)	PUNCT
admet-337	471	43	.	.	PUNCT
admet-337	472	1	the	the	DET
admet-337	472	2	median	median	PROPN
admet-337	472	3	pfs	pfs	PROPN
admet-337	472	4	of	of	ADP
admet-337	472	5	alectinib	alectinib	NOUN
admet-337	472	6	was	be	AUX
admet-337	472	7	not	not	PART
admet-337	472	8	reached	reach	VERB
admet-337	472	9	(	(	PUNCT
admet-337	472	10	95	95	NUM
admet-337	472	11	%	%	NOUN
admet-337	472	12	ci	ci	NOUN
admet-337	472	13	:	:	PUNCT
admet-337	472	14	20.3	20.3	NUM
admet-337	472	15	-	-	PUNCT
admet-337	472	16	not	not	PART
admet-337	472	17	estimated	estimate	VERB
admet-337	472	18	)	)	PUNCT
admet-337	472	19	and	and	CCONJ
admet-337	472	20	the	the	DET
admet-337	472	21	median	median	ADJ
admet-337	472	22	pfs	pfs	PROPN
admet-337	472	23	of	of	ADP
admet-337	472	24	crizotinib	crizotinib	PROPN
admet-337	472	25	was	be	AUX
admet-337	472	26	10.2	10.2	NUM
admet-337	472	27	months	month	NOUN
admet-337	472	28	(	(	PUNCT
admet-337	472	29	95	95	NUM
admet-337	472	30	%	%	NOUN
admet-337	472	31	ci	ci	NOUN
admet-337	472	32	:	:	PUNCT
admet-337	472	33	8.2	8.2	NUM
admet-337	472	34	-	-	SYM
admet-337	472	35	12	12	NUM
admet-337	472	36	)	)	PUNCT
admet-337	473	1	[	[	X
admet-337	473	2	151	151	NUM
admet-337	473	3	]	]	PUNCT
admet-337	473	4	.	.	PUNCT
admet-337	474	1	based	base	VERB
admet-337	474	2	on	on	ADP
admet-337	474	3	these	these	DET
admet-337	474	4	results	result	NOUN
admet-337	474	5	,	,	PUNCT
admet-337	474	6	enthusiasm	enthusiasm	NOUN
admet-337	474	7	exists	exist	VERB
admet-337	474	8	for	for	ADP
admet-337	474	9	moving	move	VERB
admet-337	474	10	alectinib	alectinib	NOUN
admet-337	474	11	to	to	ADP
admet-337	474	12	front	front	ADJ
admet-337	474	13	-	-	PUNCT
admet-337	474	14	line	line	NOUN
admet-337	474	15	treatment	treatment	NOUN
admet-337	474	16	for	for	ADP
admet-337	474	17	alk	alk	NOUN
admet-337	474	18	-	-	PUNCT
admet-337	474	19	positive	positive	ADJ
admet-337	474	20	nsclc	nsclc	NOUN
admet-337	474	21	,	,	PUNCT
admet-337	474	22	and	and	CCONJ
admet-337	474	23	a	a	DET
admet-337	474	24	global	global	ADJ
admet-337	474	25	,	,	PUNCT
admet-337	474	26	randomized	randomize	VERB
admet-337	474	27	phase	phase	NOUN
admet-337	474	28	iii	iii	NOUN
admet-337	474	29	trial	trial	NOUN
admet-337	474	30	comparing	compare	VERB
admet-337	474	31	alectinib	alectinib	NOUN
admet-337	474	32	to	to	ADP
admet-337	474	33	crizotinib	crizotinib	VERB
admet-337	474	34	is	be	AUX
admet-337	474	35	underway	underway	ADJ
admet-337	474	36	(	(	PUNCT
admet-337	474	37	nct02075840	nct02075840	NOUN
admet-337	474	38	)	)	PUNCT
admet-337	474	39	.	.	PUNCT
admet-337	475	1	clinical	clinical	ADJ
admet-337	475	2	safety	safety	NOUN
admet-337	475	3	alectinib	alectinib	NOUN
admet-337	475	4	carries	carry	VERB
admet-337	475	5	a	a	DET
admet-337	475	6	favorable	favorable	ADJ
admet-337	475	7	side	side	NOUN
admet-337	475	8	effect	effect	NOUN
admet-337	475	9	profile	profile	NOUN
admet-337	475	10	with	with	ADP
admet-337	475	11	significantly	significantly	ADV
admet-337	475	12	less	less	ADJ
admet-337	475	13	gi	gi	NOUN
admet-337	475	14	toxicity	toxicity	NOUN
admet-337	475	15	than	than	ADP
admet-337	475	16	crizotinib	crizotinib	ADJ
admet-337	475	17	.	.	PUNCT
admet-337	476	1	fatigue	fatigue	NOUN
admet-337	476	2	is	be	AUX
admet-337	476	3	the	the	DET
admet-337	476	4	commonest	common	ADJ
admet-337	476	5	adverse	adverse	ADJ
admet-337	476	6	event	event	NOUN
admet-337	476	7	encountered	encounter	VERB
admet-337	476	8	and	and	CCONJ
admet-337	476	9	occurs	occur	VERB
admet-337	476	10	in	in	ADP
admet-337	476	11	approximately	approximately	ADV
admet-337	476	12	30	30	NUM
admet-337	476	13	%	%	NOUN
admet-337	476	14	of	of	ADP
admet-337	476	15	patients	patient	NOUN
admet-337	476	16	(	(	PUNCT
admet-337	476	17	all	all	DET
admet-337	476	18	grade	grade	NOUN
admet-337	476	19	1	1	NUM
admet-337	476	20	-	-	SYM
admet-337	476	21	2	2	NUM
admet-337	476	22	)	)	PUNCT
admet-337	476	23	.	.	PUNCT
admet-337	477	1	grade	grade	NOUN
admet-337	477	2	1	1	NUM
admet-337	477	3	-	-	SYM
admet-337	477	4	2	2	NUM
admet-337	477	5	myalgias	myalgia	NOUN
admet-337	477	6	,	,	PUNCT
admet-337	477	7	peripheral	peripheral	ADJ
admet-337	477	8	edema	edema	NOUN
admet-337	477	9	,	,	PUNCT
admet-337	477	10	increased	increase	VERB
admet-337	477	11	creatine	creatine	PROPN
admet-337	477	12	kinase	kinase	PROPN
admet-337	477	13	,	,	PUNCT
admet-337	477	14	nausea	nausea	NOUN
admet-337	477	15	,	,	PUNCT
admet-337	477	16	elevated	elevated	ADJ
admet-337	477	17	aminotransferases	aminotransferase	NOUN
admet-337	477	18	,	,	PUNCT
admet-337	477	19	constipation	constipation	NOUN
admet-337	477	20	and	and	CCONJ
admet-337	477	21	photosensitivity	photosensitivity	NOUN
admet-337	477	22	occur	occur	VERB
admet-337	477	23	in	in	ADP
admet-337	477	24	13	13	NUM
admet-337	477	25	-	-	SYM
admet-337	477	26	36	36	NUM
admet-337	477	27	%	%	NOUN
admet-337	477	28	of	of	ADP
admet-337	477	29	patients	patient	NOUN
admet-337	477	30	.	.	PUNCT
admet-337	478	1	grade	grade	NOUN
admet-337	478	2	3	3	NUM
admet-337	478	3	or	or	CCONJ
admet-337	478	4	4	4	NUM
admet-337	478	5	events	event	NOUN
admet-337	478	6	are	be	AUX
admet-337	478	7	rare	rare	ADJ
admet-337	478	8	and	and	CCONJ
admet-337	478	9	occur	occur	VERB
admet-337	478	10	at	at	ADP
admet-337	478	11	an	an	DET
admet-337	478	12	incidence	incidence	NOUN
admet-337	478	13	of	of	ADP
admet-337	478	14	less	less	ADJ
admet-337	478	15	than	than	ADP
admet-337	478	16	5	5	NUM
admet-337	478	17	%	%	NOUN
admet-337	478	18	with	with	ADP
admet-337	478	19	the	the	DET
admet-337	478	20	exception	exception	NOUN
admet-337	478	21	of	of	ADP
admet-337	478	22	aminotransferase	aminotransferase	NOUN
admet-337	478	23	abnormalities	abnormality	NOUN
admet-337	478	24	occurring	occur	VERB
admet-337	478	25	in	in	ADP
admet-337	478	26	5	5	NUM
admet-337	478	27	to	to	PART
admet-337	478	28	6	6	NUM
admet-337	478	29	%	%	NOUN
admet-337	478	30	of	of	ADP
admet-337	478	31	cases	case	NOUN
admet-337	478	32	.	.	PUNCT
admet-337	479	1	fatal	fatal	ADJ
admet-337	479	2	hemorrhage	hemorrhage	NOUN
admet-337	479	3	was	be	AUX
admet-337	479	4	witnessed	witness	VERB
admet-337	479	5	in	in	ADP
admet-337	479	6	one	one	NUM
admet-337	479	7	patient	patient	NOUN
admet-337	479	8	who	who	PRON
admet-337	479	9	was	be	AUX
admet-337	479	10	on	on	ADP
admet-337	479	11	anticoagulants	anticoagulant	NOUN
admet-337	479	12	.	.	PUNCT
admet-337	480	1	in	in	ADP
admet-337	480	2	the	the	DET
admet-337	480	3	phase	phase	NOUN
admet-337	480	4	ii	ii	NOUN
admet-337	480	5	trial	trial	NOUN
admet-337	480	6	,	,	PUNCT
admet-337	480	7	dose	dose	NOUN
admet-337	480	8	interruption	interruption	NOUN
admet-337	480	9	was	be	AUX
admet-337	480	10	needed	need	VERB
admet-337	480	11	for	for	ADP
admet-337	480	12	36	36	NUM
admet-337	480	13	%	%	NOUN
admet-337	480	14	of	of	ADP
admet-337	480	15	patients	patient	NOUN
admet-337	480	16	and	and	CCONJ
admet-337	480	17	dose	dose	NOUN
admet-337	480	18	reduction	reduction	NOUN
admet-337	480	19	occurred	occur	VERB
admet-337	480	20	in	in	ADP
admet-337	480	21	16	16	NUM
admet-337	480	22	%	%	NOUN
admet-337	480	23	of	of	ADP
admet-337	480	24	patients	patient	NOUN
admet-337	480	25	.	.	PUNCT
admet-337	481	1	the	the	DET
admet-337	481	2	medication	medication	NOUN
admet-337	481	3	was	be	AUX
admet-337	481	4	discontinued	discontinue	VERB
admet-337	481	5	in	in	ADP
admet-337	481	6	2	2	NUM
admet-337	481	7	to	to	PART
admet-337	481	8	9	9	NUM
admet-337	481	9	%	%	NOUN
admet-337	481	10	of	of	ADP
admet-337	481	11	patients	patient	NOUN
admet-337	481	12	due	due	ADJ
admet-337	481	13	to	to	ADP
admet-337	481	14	adverse	adverse	ADJ
admet-337	481	15	events	event	NOUN
admet-337	481	16	[	[	X
admet-337	481	17	148	148	NUM
admet-337	481	18	-	-	SYM
admet-337	481	19	150	150	NUM
admet-337	481	20	]	]	PUNCT
admet-337	481	21	.	.	PUNCT
admet-337	482	1	pharmacology	pharmacology	NOUN
admet-337	482	2	alectinib	alectinib	NOUN
admet-337	482	3	,	,	PUNCT
admet-337	482	4	9	9	NUM
admet-337	482	5	-	-	PUNCT
admet-337	482	6	ethyl-6,6	ethyl-6,6	NOUN
admet-337	482	7	-	-	PUNCT
admet-337	482	8	dimethyl-8-(4	dimethyl-8-(4	VERB
admet-337	482	9	-	-	PUNCT
admet-337	482	10	morpholin-4	morpholin-4	NUM
admet-337	482	11	-	-	PUNCT
admet-337	482	12	ylpiperidin-1	ylpiperidin-1	NOUN
admet-337	482	13	-	-	PUNCT
admet-337	482	14	yl)-11	yl)-11	PROPN
admet-337	482	15	-	-	PUNCT
admet-337	482	16	oxo-5h	oxo-5h	NOUN
admet-337	482	17	-	-	PUNCT
admet-337	482	18	benzo[b]carbazole-3carbonitrile	benzo[b]carbazole-3carbonitrile	PROPN
admet-337	483	1	[	[	X
admet-337	483	2	ch5424802	ch5424802	ADJ
admet-337	483	3	,	,	PUNCT
admet-337	483	4	alecensa	alecensa	VERB
admet-337	483	5	,	,	PUNCT
admet-337	483	6	(	(	PUNCT
admet-337	483	7	roche	roche	NOUN
admet-337	483	8	)	)	PUNCT
admet-337	483	9	]	]	PUNCT
admet-337	483	10	competitively	competitively	ADV
admet-337	483	11	inhibits	inhibit	VERB
admet-337	483	12	the	the	DET
admet-337	483	13	tyrosine	tyrosine	NOUN
admet-337	483	14	kinase	kinase	PROPN
admet-337	483	15	domain	domain	NOUN
admet-337	483	16	of	of	ADP
admet-337	483	17	the	the	DET
admet-337	483	18	alk	alk	NOUN
admet-337	483	19	fusion	fusion	NOUN
admet-337	483	20	protein	protein	NOUN
admet-337	483	21	.	.	PUNCT
admet-337	484	1	it	it	PRON
admet-337	484	2	is	be	AUX
admet-337	484	3	a	a	DET
admet-337	484	4	more	more	ADV
admet-337	484	5	potent	potent	ADJ
admet-337	484	6	alk	alk	NOUN
admet-337	484	7	inhibitor	inhibitor	NOUN
admet-337	484	8	than	than	SCONJ
admet-337	484	9	crizotinib	crizotinib	VERB
admet-337	484	10	with	with	ADP
admet-337	484	11	an	an	DET
admet-337	484	12	in	in	ADP
admet-337	484	13	vitro	vitro	X
admet-337	484	14	kinase	kinase	PROPN
admet-337	484	15	ic50	ic50	PROPN
admet-337	484	16	of	of	ADP
admet-337	484	17	1.9	1.9	NUM
admet-337	484	18	nm	nm	NOUN
admet-337	484	19	and	and	CCONJ
admet-337	484	20	ic50	ic50	PROPN
admet-337	484	21	of	of	ADP
admet-337	484	22	3.0	3.0	NUM
admet-337	484	23	nm	nm	NOUN
admet-337	484	24	in	in	ADP
admet-337	484	25	cell	cell	NOUN
admet-337	484	26	lines	line	NOUN
admet-337	484	27	.	.	PUNCT
admet-337	485	1	it	it	PRON
admet-337	485	2	demonstrates	demonstrate	VERB
admet-337	485	3	high	high	ADJ
admet-337	485	4	target	target	NOUN
admet-337	485	5	selectivity	selectivity	NOUN
admet-337	485	6	with	with	ADP
admet-337	485	7	weak	weak	ADJ
admet-337	485	8	or	or	CCONJ
admet-337	485	9	no	no	PRON
admet-337	485	10	inhibition	inhibition	NOUN
admet-337	485	11	of	of	ADP
admet-337	485	12	over	over	ADP
admet-337	485	13	20	20	NUM
admet-337	485	14	other	other	ADJ
admet-337	485	15	kinases	kinase	NOUN
admet-337	485	16	,	,	PUNCT
admet-337	485	17	including	include	VERB
admet-337	485	18	ros1	ros1	PROPN
admet-337	485	19	and	and	CCONJ
admet-337	485	20	met	meet	VERB
admet-337	485	21	[	[	PUNCT
admet-337	485	22	152	152	NUM
admet-337	485	23	]	]	PUNCT
admet-337	485	24	.	.	PUNCT
admet-337	486	1	however	however	ADV
admet-337	486	2	,	,	PUNCT
admet-337	486	3	recently	recently	ADV
admet-337	486	4	,	,	PUNCT
admet-337	486	5	it	it	PRON
admet-337	486	6	was	be	AUX
admet-337	486	7	discovered	discover	VERB
admet-337	486	8	that	that	SCONJ
admet-337	486	9	alectinib	alectinib	NOUN
admet-337	486	10	potently	potently	ADV
admet-337	486	11	inhibits	inhibit	VERB
admet-337	486	12	ret	ret	PROPN
admet-337	486	13	kinase	kinase	PROPN
admet-337	486	14	activity	activity	NOUN
admet-337	486	15	with	with	ADP
admet-337	486	16	an	an	DET
admet-337	486	17	ic50	ic50	PROPN
admet-337	486	18	of	of	ADP
admet-337	486	19	4.8	4.8	NUM
admet-337	486	20	nm	nm	NOUN
admet-337	486	21	,	,	PUNCT
admet-337	486	22	and	and	CCONJ
admet-337	486	23	is	be	AUX
admet-337	486	24	active	active	ADJ
admet-337	486	25	against	against	ADP
admet-337	486	26	oncogenic	oncogenic	ADJ
admet-337	486	27	ret	ret	NOUN
admet-337	486	28	-	-	PUNCT
admet-337	486	29	rearrangements	rearrangement	NOUN
admet-337	486	30	observed	observe	VERB
admet-337	486	31	in	in	ADP
admet-337	486	32	nsclc	nsclc	NOUN
admet-337	486	33	[	[	X
admet-337	486	34	153	153	NUM
admet-337	486	35	]	]	PUNCT
admet-337	486	36	.	.	PUNCT
admet-337	487	1	the	the	DET
admet-337	487	2	recommended	recommend	VERB
admet-337	487	3	dose	dose	NOUN
admet-337	487	4	is	be	AUX
admet-337	487	5	600	600	NUM
admet-337	487	6	mg	mg	NOUN
admet-337	487	7	twice	twice	ADV
admet-337	487	8	daily	daily	ADV
admet-337	487	9	with	with	ADP
admet-337	487	10	food	food	NOUN
admet-337	487	11	.	.	PUNCT
admet-337	488	1	it	it	PRON
admet-337	488	2	is	be	AUX
admet-337	488	3	metabolized	metabolize	VERB
admet-337	488	4	to	to	ADP
admet-337	488	5	its	its	PRON
admet-337	488	6	major	major	ADJ
admet-337	488	7	active	active	ADJ
admet-337	488	8	metabolite	metabolite	NOUN
admet-337	488	9	,	,	PUNCT
admet-337	488	10	m4	m4	PROPN
admet-337	488	11	,	,	PUNCT
admet-337	488	12	in	in	ADP
admet-337	488	13	the	the	DET
admet-337	488	14	liver	liver	NOUN
admet-337	488	15	by	by	ADP
admet-337	488	16	cyp3a4	cyp3a4	PROPN
admet-337	488	17	[	[	X
admet-337	488	18	154	154	NUM
admet-337	488	19	]	]	PUNCT
admet-337	488	20	.	.	PUNCT
admet-337	489	1	the	the	DET
admet-337	489	2	maximum	maximum	ADJ
admet-337	489	3	plasma	plasma	NOUN
admet-337	489	4	concentration	concentration	NOUN
admet-337	489	5	at	at	ADP
admet-337	489	6	steady	steady	ADJ
admet-337	489	7	-	-	PUNCT
admet-337	489	8	state	state	NOUN
admet-337	489	9	is	be	AUX
admet-337	489	10	665ng	665ng	NOUN
admet-337	489	11	/	/	SYM
admet-337	489	12	ml	ml	PROPN
admet-337	490	1	(	(	PUNCT
admet-337	490	2	44	44	NUM
admet-337	490	3	%	%	NOUN
admet-337	490	4	)	)	PUNCT
admet-337	491	1	and	and	CCONJ
admet-337	491	2	for	for	ADP
admet-337	491	3	m4	m4	PROPN
admet-337	491	4	is	be	AUX
admet-337	491	5	246	246	NUM
admet-337	491	6	ng	ng	PROPN
admet-337	491	7	/	/	SYM
admet-337	491	8	ml	ml	PROPN
admet-337	491	9	(	(	PUNCT
admet-337	491	10	45	45	NUM
admet-337	491	11	%	%	NOUN
admet-337	491	12	)	)	PUNCT
admet-337	491	13	,	,	PUNCT
admet-337	491	14	and	and	CCONJ
admet-337	491	15	the	the	DET
admet-337	491	16	drug	drug	NOUN
admet-337	491	17	reaches	reach	VERB
admet-337	491	18	steady	steady	ADJ
admet-337	491	19	-	-	PUNCT
admet-337	491	20	state	state	NOUN
admet-337	491	21	after	after	ADP
admet-337	491	22	7	7	NUM
admet-337	491	23	days	day	NOUN
admet-337	491	24	.	.	PUNCT
admet-337	492	1	under	under	ADP
admet-337	492	2	fed	fed	PROPN
admet-337	492	3	conditions	condition	NOUN
admet-337	492	4	,	,	PUNCT
admet-337	492	5	the	the	DET
admet-337	492	6	bioavailability	bioavailability	NOUN
admet-337	492	7	of	of	ADP
admet-337	492	8	alectinib	alectinib	NOUN
admet-337	492	9	is	be	AUX
admet-337	492	10	37	37	NUM
admet-337	492	11	%	%	NOUN
admet-337	492	12	,	,	PUNCT
admet-337	492	13	and	and	CCONJ
admet-337	492	14	a	a	DET
admet-337	492	15	high	high	ADJ
admet-337	492	16	-	-	PUNCT
admet-337	492	17	calorie	calorie	NOUN
admet-337	492	18	,	,	PUNCT
admet-337	492	19	high	high	ADJ
admet-337	492	20	-	-	PUNCT
admet-337	492	21	fat	fat	NOUN
admet-337	492	22	meal	meal	NOUN
admet-337	492	23	increased	increase	VERB
admet-337	492	24	exposure	exposure	NOUN
admet-337	492	25	admet	admet	PROPN
admet-337	492	26	&	&	CCONJ
admet-337	492	27	dmpk	dmpk	PROPN
admet-337	492	28	4(3	4(3	NUM
admet-337	492	29	)	)	PUNCT
admet-337	492	30	(	(	PUNCT
admet-337	492	31	2016	2016	NUM
admet-337	492	32	)	)	PUNCT
admet-337	492	33	186	186	NUM
admet-337	492	34	-	-	SYM
admet-337	492	35	211	211	NUM
admet-337	492	36	tki	tki	NOUN
admet-337	492	37	for	for	ADP
admet-337	492	38	egfrand	egfrand	ADJ
admet-337	492	39	alk	alk	PROPN
admet-337	492	40	-	-	PUNCT
admet-337	492	41	mutated	mutate	VERB
admet-337	492	42	cell	cell	NOUN
admet-337	492	43	cancer	cancer	NOUN
admet-337	492	44	doi	doi	NOUN
admet-337	492	45	:	:	PUNCT
admet-337	492	46	10.5599	10.5599	NUM
admet-337	492	47	/	/	SYM
admet-337	492	48	admet.4.3.337	admet.4.3.337	PRON
admet-337	492	49	203	203	NUM
admet-337	492	50	of	of	ADP
admet-337	492	51	the	the	DET
admet-337	492	52	drug	drug	NOUN
admet-337	492	53	by	by	ADP
admet-337	492	54	3	3	NUM
admet-337	492	55	-	-	NOUN
admet-337	492	56	fold	fold	VERB
admet-337	492	57	[	[	X
admet-337	492	58	154	154	NUM
admet-337	492	59	]	]	PUNCT
admet-337	492	60	.	.	PUNCT
admet-337	493	1	the	the	DET
admet-337	493	2	volume	volume	NOUN
admet-337	493	3	of	of	ADP
admet-337	493	4	distribution	distribution	NOUN
admet-337	493	5	for	for	ADP
admet-337	493	6	alectinib	alectinib	NOUN
admet-337	493	7	is	be	AUX
admet-337	493	8	4,016	4,016	NUM
admet-337	493	9	l	l	NOUN
admet-337	493	10	and	and	CCONJ
admet-337	493	11	10,093l	10,093l	NUM
admet-337	493	12	for	for	ADP
admet-337	493	13	the	the	DET
admet-337	493	14	m4	m4	PROPN
admet-337	493	15	metabolite	metabolite	NOUN
admet-337	493	16	.	.	PUNCT
admet-337	494	1	alectinib	alectinib	NOUN
admet-337	494	2	also	also	ADV
admet-337	494	3	demonstrates	demonstrate	VERB
admet-337	494	4	nonlinear	nonlinear	ADJ
admet-337	494	5	pk	pk	NOUN
admet-337	494	6	with	with	ADP
admet-337	494	7	apparent	apparent	ADJ
admet-337	494	8	clearance	clearance	NOUN
admet-337	494	9	of	of	ADP
admet-337	494	10	81.9l	81.9l	NUM
admet-337	494	11	/	/	SYM
admet-337	494	12	hr	hr	NOUN
admet-337	494	13	for	for	ADP
admet-337	494	14	alectinib	alectinib	NOUN
admet-337	494	15	and	and	CCONJ
admet-337	494	16	217	217	NUM
admet-337	494	17	l	l	NOUN
admet-337	494	18	/	/	SYM
admet-337	494	19	hr	hr	NOUN
admet-337	494	20	for	for	ADP
admet-337	494	21	m4	m4	PROPN
admet-337	494	22	.	.	PUNCT
admet-337	495	1	after	after	ADP
admet-337	495	2	administration	administration	NOUN
admet-337	495	3	,	,	PUNCT
admet-337	495	4	84	84	NUM
admet-337	495	5	%	%	NOUN
admet-337	495	6	of	of	ADP
admet-337	495	7	the	the	DET
admet-337	495	8	drug	drug	NOUN
admet-337	495	9	is	be	AUX
admet-337	495	10	eliminated	eliminate	VERB
admet-337	495	11	in	in	ADP
admet-337	495	12	the	the	DET
admet-337	495	13	feces	fece	NOUN
admet-337	495	14	as	as	ADP
admet-337	495	15	unchanged	unchanged	ADJ
admet-337	495	16	alectinib	alectinib	NOUN
admet-337	495	17	and	and	CCONJ
admet-337	495	18	6	6	NUM
admet-337	495	19	%	%	NOUN
admet-337	495	20	as	as	ADP
admet-337	495	21	m4	m4	PROPN
admet-337	495	22	[	[	X
admet-337	495	23	148,149,154	148,149,154	NUM
admet-337	495	24	]	]	X
admet-337	495	25	.	.	PUNCT
admet-337	496	1	despite	despite	SCONJ
admet-337	496	2	its	its	PRON
admet-337	496	3	metabolism	metabolism	NOUN
admet-337	496	4	by	by	ADP
admet-337	496	5	cyp3a	cyp3a	NOUN
admet-337	496	6	,	,	PUNCT
admet-337	496	7	co	co	NOUN
admet-337	496	8	-	-	NOUN
admet-337	496	9	administration	administration	NOUN
admet-337	496	10	with	with	ADP
admet-337	496	11	strong	strong	ADJ
admet-337	496	12	cyp3a	cyp3a	NOUN
admet-337	496	13	inhibitors	inhibitor	NOUN
admet-337	496	14	and	and	CCONJ
admet-337	496	15	inducers	inducer	NOUN
admet-337	496	16	have	have	AUX
admet-337	496	17	not	not	PART
admet-337	496	18	been	be	AUX
admet-337	496	19	found	find	VERB
admet-337	496	20	to	to	PART
admet-337	496	21	significantly	significantly	ADV
admet-337	496	22	alter	alter	VERB
admet-337	496	23	alectinib	alectinib	NOUN
admet-337	496	24	levels	level	NOUN
admet-337	496	25	.	.	PUNCT
admet-337	497	1	alectinib	alectinib	NOUN
admet-337	497	2	does	do	AUX
admet-337	497	3	inhibit	inhibit	VERB
admet-337	497	4	p	p	NOUN
admet-337	497	5	-	-	PUNCT
admet-337	497	6	gp	gp	NOUN
admet-337	497	7	and	and	CCONJ
admet-337	497	8	brcp	brcp	VERB
admet-337	497	9	.	.	PUNCT
admet-337	498	1	no	no	DET
admet-337	498	2	dose	dose	NOUN
admet-337	498	3	adjustments	adjustment	NOUN
admet-337	498	4	have	have	AUX
admet-337	498	5	been	be	AUX
admet-337	498	6	recommended	recommend	VERB
admet-337	498	7	for	for	ADP
admet-337	498	8	hepatic	hepatic	ADJ
admet-337	498	9	or	or	CCONJ
admet-337	498	10	renal	renal	ADJ
admet-337	498	11	impairment	impairment	NOUN
admet-337	498	12	[	[	X
admet-337	498	13	154	154	NUM
admet-337	498	14	]	]	PUNCT
admet-337	498	15	.	.	PUNCT
admet-337	499	1	cns	cns	PROPN
admet-337	499	2	penetration	penetration	NOUN
admet-337	499	3	alectinib	alectinib	NOUN
admet-337	499	4	has	have	VERB
admet-337	499	5	higher	high	ADJ
admet-337	499	6	cns	cns	NOUN
admet-337	499	7	responses	response	NOUN
admet-337	499	8	than	than	ADP
admet-337	499	9	crizotinib	crizotinib	ADJ
admet-337	499	10	.	.	PUNCT
admet-337	500	1	in	in	ADP
admet-337	500	2	one	one	NUM
admet-337	500	3	of	of	ADP
admet-337	500	4	the	the	DET
admet-337	500	5	phase	phase	NOUN
admet-337	500	6	i	i	PROPN
admet-337	500	7	/	/	SYM
admet-337	500	8	ii	ii	PROPN
admet-337	500	9	studies	study	NOUN
admet-337	500	10	,	,	PUNCT
admet-337	500	11	21	21	NUM
admet-337	500	12	patients	patient	NOUN
admet-337	500	13	were	be	AUX
admet-337	500	14	enrolled	enrol	VERB
admet-337	500	15	with	with	ADP
admet-337	500	16	cns	cns	NOUN
admet-337	500	17	metastases	metastasis	NOUN
admet-337	500	18	.	.	PUNCT
admet-337	501	1	of	of	ADP
admet-337	501	2	these	these	DET
admet-337	501	3	patients	patient	NOUN
admet-337	501	4	,	,	PUNCT
admet-337	501	5	12	12	NUM
admet-337	501	6	(	(	PUNCT
admet-337	501	7	57	57	NUM
admet-337	501	8	%	%	NOUN
admet-337	501	9	)	)	PUNCT
admet-337	501	10	had	have	VERB
admet-337	501	11	progressive	progressive	ADJ
admet-337	501	12	cns	cns	NOUN
admet-337	501	13	disease	disease	NOUN
admet-337	501	14	at	at	ADP
admet-337	501	15	enrollment	enrollment	NOUN
admet-337	501	16	.	.	PUNCT
admet-337	502	1	in	in	ADP
admet-337	502	2	the	the	DET
admet-337	502	3	21	21	NUM
admet-337	502	4	patients	patient	NOUN
admet-337	502	5	with	with	ADP
admet-337	502	6	cns	cns	NOUN
admet-337	502	7	disease	disease	NOUN
admet-337	502	8	,	,	PUNCT
admet-337	502	9	alectinib	alectinib	NOUN
admet-337	502	10	produced	produce	VERB
admet-337	502	11	a	a	DET
admet-337	502	12	cns	cns	NOUN
admet-337	502	13	orr	orr	NOUN
admet-337	502	14	of	of	ADP
admet-337	502	15	52	52	NUM
admet-337	502	16	%	%	NOUN
admet-337	502	17	with	with	ADP
admet-337	502	18	six	six	NUM
admet-337	502	19	(	(	PUNCT
admet-337	502	20	29	29	NUM
admet-337	502	21	%	%	NOUN
admet-337	502	22	)	)	PUNCT
admet-337	502	23	complete	complete	ADJ
admet-337	502	24	responses	response	NOUN
admet-337	502	25	and	and	CCONJ
admet-337	502	26	five	five	NUM
admet-337	502	27	(	(	PUNCT
admet-337	502	28	24	24	NUM
admet-337	502	29	%	%	NOUN
admet-337	502	30	)	)	PUNCT
admet-337	502	31	partial	partial	ADJ
admet-337	502	32	responses	response	NOUN
admet-337	502	33	.	.	PUNCT
admet-337	503	1	overall	overall	ADJ
admet-337	503	2	cns	cns	PROPN
admet-337	503	3	disease	disease	NOUN
admet-337	503	4	control	control	NOUN
admet-337	503	5	rate	rate	NOUN
admet-337	503	6	was	be	AUX
admet-337	503	7	90	90	NUM
admet-337	503	8	%	%	NOUN
admet-337	503	9	.	.	PUNCT
admet-337	504	1	in	in	ADP
admet-337	504	2	the	the	DET
admet-337	504	3	four	four	NUM
admet-337	504	4	patients	patient	NOUN
admet-337	504	5	who	who	PRON
admet-337	504	6	had	have	AUX
admet-337	504	7	not	not	PART
admet-337	504	8	received	receive	VERB
admet-337	504	9	prior	prior	ADJ
admet-337	504	10	brain	brain	NOUN
admet-337	504	11	radiotherapy	radiotherapy	NOUN
admet-337	504	12	,	,	PUNCT
admet-337	504	13	a	a	DET
admet-337	504	14	complete	complete	ADJ
admet-337	504	15	response	response	NOUN
admet-337	504	16	was	be	AUX
admet-337	504	17	achieved	achieve	VERB
admet-337	504	18	in	in	ADP
admet-337	504	19	two	two	NUM
admet-337	504	20	patients	patient	NOUN
admet-337	504	21	and	and	CCONJ
admet-337	504	22	one	one	NUM
admet-337	504	23	had	have	VERB
admet-337	504	24	a	a	DET
admet-337	504	25	partial	partial	ADJ
admet-337	504	26	response	response	NOUN
admet-337	504	27	.	.	PUNCT
admet-337	505	1	in	in	ADP
admet-337	505	2	this	this	DET
admet-337	505	3	study	study	NOUN
admet-337	505	4	,	,	PUNCT
admet-337	505	5	at	at	ADP
admet-337	505	6	the	the	DET
admet-337	505	7	600	600	NUM
admet-337	505	8	mg	mg	NOUN
admet-337	505	9	twice	twice	ADV
admet-337	505	10	daily	daily	ADV
admet-337	505	11	dose	dose	NOUN
admet-337	505	12	of	of	ADP
admet-337	505	13	alectinib	alectinib	NOUN
admet-337	505	14	,	,	PUNCT
admet-337	505	15	the	the	DET
admet-337	505	16	csf	csf	ADJ
admet-337	505	17	trough	trough	NOUN
admet-337	505	18	concentration	concentration	NOUN
admet-337	505	19	of	of	ADP
admet-337	505	20	alectinib	alectinib	NOUN
admet-337	505	21	was	be	AUX
admet-337	505	22	2.69	2.69	NUM
admet-337	505	23	nm	nm	NOUN
admet-337	505	24	/	/	SYM
admet-337	505	25	l	l	NOUN
admet-337	505	26	,	,	PUNCT
admet-337	505	27	which	which	PRON
admet-337	505	28	is	be	AUX
admet-337	505	29	nearly	nearly	ADV
admet-337	505	30	the	the	DET
admet-337	505	31	same	same	ADJ
admet-337	505	32	as	as	ADP
admet-337	505	33	the	the	DET
admet-337	505	34	unbound	unbound	NOUN
admet-337	505	35	systemic	systemic	ADJ
admet-337	505	36	trough	trough	NOUN
admet-337	505	37	of	of	ADP
admet-337	505	38	alectinib	alectinib	NOUN
admet-337	505	39	of	of	ADP
admet-337	505	40	3.12	3.12	NUM
admet-337	505	41	nm	nm	NOUN
admet-337	505	42	/	/	SYM
admet-337	505	43	l	l	NOUN
admet-337	505	44	,	,	PUNCT
admet-337	505	45	and	and	CCONJ
admet-337	505	46	exceeds	exceed	VERB
admet-337	505	47	the	the	DET
admet-337	505	48	ic50	ic50	PROPN
admet-337	505	49	for	for	ADP
admet-337	505	50	alk	alk	NOUN
admet-337	505	51	inhibition	inhibition	NOUN
admet-337	505	52	for	for	ADP
admet-337	505	53	alectinib	alectinib	NOUN
admet-337	505	54	in	in	ADP
admet-337	505	55	cell	cell	NOUN
admet-337	505	56	-	-	PUNCT
admet-337	505	57	free	free	ADJ
admet-337	505	58	assays	assay	NOUN
admet-337	505	59	(	(	PUNCT
admet-337	505	60	1.9	1.9	NUM
admet-337	505	61	nm	nm	NOUN
admet-337	505	62	/	/	SYM
admet-337	505	63	l	l	NOUN
admet-337	505	64	)	)	PUNCT
admet-337	506	1	[	[	X
admet-337	506	2	149	149	NUM
admet-337	506	3	]	]	PUNCT
admet-337	506	4	.	.	PUNCT
admet-337	507	1	in	in	ADP
admet-337	507	2	the	the	DET
admet-337	507	3	japanese	japanese	ADJ
admet-337	507	4	phase	phase	NOUN
admet-337	507	5	i	i	PRON
admet-337	507	6	/	/	SYM
admet-337	507	7	ii	ii	PROPN
admet-337	507	8	alectinib	alectinib	PROPN
admet-337	507	9	study	study	NOUN
admet-337	507	10	,	,	PUNCT
admet-337	507	11	15	15	NUM
admet-337	507	12	patients	patient	NOUN
admet-337	507	13	had	have	AUX
admet-337	507	14	known	know	VERB
admet-337	507	15	brain	brain	NOUN
admet-337	507	16	metastases	metastasis	NOUN
admet-337	507	17	,	,	PUNCT
admet-337	507	18	12	12	NUM
admet-337	507	19	of	of	ADP
admet-337	507	20	whom	whom	PRON
admet-337	507	21	had	have	VERB
admet-337	507	22	previous	previous	ADJ
admet-337	507	23	brain	brain	NOUN
admet-337	507	24	radiation	radiation	NOUN
admet-337	507	25	.	.	PUNCT
admet-337	508	1	no	no	DET
admet-337	508	2	cns	cns	NOUN
admet-337	508	3	disease	disease	NOUN
admet-337	508	4	progression	progression	NOUN
admet-337	508	5	was	be	AUX
admet-337	508	6	witnessed	witness	VERB
admet-337	508	7	on	on	ADP
admet-337	508	8	alectinib	alectinib	NOUN
admet-337	508	9	.	.	PUNCT
admet-337	509	1	of	of	ADP
admet-337	509	2	the	the	DET
admet-337	509	3	3	3	NUM
admet-337	509	4	patients	patient	NOUN
admet-337	509	5	who	who	PRON
admet-337	509	6	did	do	AUX
admet-337	509	7	not	not	PART
admet-337	509	8	receive	receive	VERB
admet-337	509	9	radiation	radiation	NOUN
admet-337	509	10	to	to	ADP
admet-337	509	11	the	the	DET
admet-337	509	12	brain	brain	NOUN
admet-337	509	13	,	,	PUNCT
admet-337	509	14	2	2	NUM
admet-337	509	15	continued	continue	VERB
admet-337	509	16	on	on	ADP
admet-337	509	17	study	study	NOUN
admet-337	509	18	for	for	ADP
admet-337	509	19	more	more	ADJ
admet-337	509	20	than	than	ADP
admet-337	509	21	300	300	NUM
admet-337	509	22	days	day	NOUN
admet-337	509	23	without	without	ADP
admet-337	509	24	cns	cns	NOUN
admet-337	509	25	disease	disease	NOUN
admet-337	509	26	progression	progression	NOUN
admet-337	509	27	[	[	X
admet-337	509	28	148	148	NUM
admet-337	509	29	]	]	PUNCT
admet-337	509	30	.	.	PUNCT
admet-337	510	1	in	in	ADP
admet-337	510	2	the	the	DET
admet-337	510	3	phase	phase	NOUN
admet-337	510	4	ii	ii	PROPN
admet-337	510	5	study	study	NOUN
admet-337	510	6	,	,	PUNCT
admet-337	510	7	16	16	NUM
admet-337	510	8	patients	patient	NOUN
admet-337	510	9	had	have	VERB
admet-337	510	10	measurable	measurable	ADJ
admet-337	510	11	cns	cns	NOUN
admet-337	510	12	disease	disease	NOUN
admet-337	510	13	at	at	ADP
admet-337	510	14	baseline	baseline	NOUN
admet-337	510	15	.	.	PUNCT
admet-337	511	1	overall	overall	ADJ
admet-337	511	2	,	,	PUNCT
admet-337	511	3	100	100	NUM
admet-337	511	4	%	%	NOUN
admet-337	511	5	of	of	ADP
admet-337	511	6	patients	patient	NOUN
admet-337	511	7	achieved	achieve	VERB
admet-337	511	8	disease	disease	NOUN
admet-337	511	9	control	control	NOUN
admet-337	511	10	in	in	ADP
admet-337	511	11	the	the	DET
admet-337	511	12	cns	cns	NOUN
admet-337	511	13	and	and	CCONJ
admet-337	511	14	75	75	NUM
admet-337	511	15	%	%	NOUN
admet-337	511	16	of	of	ADP
admet-337	511	17	patients	patient	NOUN
admet-337	511	18	achieved	achieve	VERB
admet-337	511	19	intracranial	intracranial	ADJ
admet-337	511	20	disease	disease	NOUN
admet-337	511	21	response	response	NOUN
admet-337	511	22	.	.	PUNCT
admet-337	512	1	four	four	NUM
admet-337	512	2	(	(	PUNCT
admet-337	512	3	25	25	NUM
admet-337	512	4	%	%	NOUN
admet-337	512	5	)	)	PUNCT
admet-337	512	6	of	of	ADP
admet-337	512	7	these	these	DET
admet-337	512	8	patients	patient	NOUN
admet-337	512	9	achieved	achieve	VERB
admet-337	512	10	complete	complete	ADJ
admet-337	512	11	cns	cns	NOUN
admet-337	512	12	response	response	NOUN
admet-337	512	13	and	and	CCONJ
admet-337	512	14	eight	eight	NUM
admet-337	512	15	(	(	PUNCT
admet-337	512	16	50	50	NUM
admet-337	512	17	%	%	NOUN
admet-337	512	18	)	)	PUNCT
admet-337	512	19	developed	develop	VERB
admet-337	512	20	partial	partial	ADJ
admet-337	512	21	response	response	NOUN
admet-337	512	22	in	in	ADP
admet-337	512	23	the	the	DET
admet-337	512	24	cns	cns	NOUN
admet-337	512	25	.	.	PUNCT
admet-337	513	1	the	the	DET
admet-337	513	2	median	median	ADJ
admet-337	513	3	duration	duration	NOUN
admet-337	513	4	of	of	ADP
admet-337	513	5	cns	cns	PROPN
admet-337	513	6	response	response	NOUN
admet-337	513	7	was	be	AUX
admet-337	513	8	11.1	11.1	NUM
admet-337	513	9	months	month	NOUN
admet-337	514	1	[	[	X
admet-337	514	2	150	150	NUM
admet-337	514	3	]	]	PUNCT
admet-337	514	4	.	.	PUNCT
admet-337	515	1	therefore	therefore	ADV
admet-337	515	2	,	,	PUNCT
admet-337	515	3	durable	durable	ADJ
admet-337	515	4	cns	cns	NOUN
admet-337	515	5	control	control	NOUN
admet-337	515	6	and	and	CCONJ
admet-337	515	7	even	even	ADV
admet-337	515	8	complete	complete	ADJ
admet-337	515	9	cns	cns	NOUN
admet-337	515	10	responses	response	NOUN
admet-337	515	11	are	be	AUX
admet-337	515	12	attainable	attainable	ADJ
admet-337	515	13	with	with	ADP
admet-337	515	14	alectinib	alectinib	NOUN
admet-337	515	15	.	.	PUNCT
admet-337	516	1	resistance	resistance	NOUN
admet-337	516	2	mechanisms	mechanism	NOUN
admet-337	516	3	(	(	PUNCT
admet-337	516	4	table	table	NOUN
admet-337	516	5	4	4	NUM
admet-337	516	6	)	)	PUNCT
admet-337	516	7	in	in	ADP
admet-337	516	8	a	a	DET
admet-337	516	9	cell	cell	NOUN
admet-337	516	10	line	line	NOUN
admet-337	516	11	study	study	NOUN
admet-337	516	12	,	,	PUNCT
admet-337	516	13	an	an	DET
admet-337	516	14	acquired	acquire	VERB
admet-337	516	15	v1180l	v1180l	PROPN
admet-337	516	16	mutation	mutation	NOUN
admet-337	516	17	was	be	AUX
admet-337	516	18	inducible	inducible	ADJ
admet-337	516	19	with	with	ADP
admet-337	516	20	alectinib	alectinib	NOUN
admet-337	516	21	exposure	exposure	NOUN
admet-337	516	22	.	.	PUNCT
admet-337	517	1	this	this	DET
admet-337	517	2	mutation	mutation	NOUN
admet-337	517	3	exists	exist	VERB
admet-337	517	4	in	in	ADP
admet-337	517	5	the	the	DET
admet-337	517	6	alk	alk	PROPN
admet-337	517	7	tyrosine	tyrosine	PROPN
admet-337	517	8	kinase	kinase	PROPN
admet-337	517	9	domain	domain	PROPN
admet-337	517	10	at	at	ADP
admet-337	517	11	the	the	DET
admet-337	517	12	back	back	NOUN
admet-337	517	13	of	of	ADP
admet-337	517	14	the	the	DET
admet-337	517	15	atp	atp	NOUN
admet-337	517	16	binding	bind	VERB
admet-337	517	17	pocket	pocket	NOUN
admet-337	517	18	,	,	PUNCT
admet-337	517	19	and	and	CCONJ
admet-337	517	20	sterically	sterically	ADV
admet-337	517	21	interferes	interfere	VERB
admet-337	517	22	with	with	ADP
admet-337	517	23	the	the	DET
admet-337	517	24	ability	ability	NOUN
admet-337	517	25	of	of	ADP
admet-337	517	26	both	both	DET
admet-337	517	27	alectinib	alectinib	NOUN
admet-337	517	28	and	and	CCONJ
admet-337	517	29	crizotinib	crizotinib	VERB
admet-337	517	30	to	to	PART
admet-337	517	31	bind	bind	VERB
admet-337	517	32	effectively	effectively	ADV
admet-337	517	33	to	to	ADP
admet-337	517	34	the	the	DET
admet-337	517	35	kinase	kinase	NOUN
admet-337	517	36	and	and	CCONJ
admet-337	517	37	mediates	mediate	VERB
admet-337	517	38	a	a	DET
admet-337	517	39	high	high	ADJ
admet-337	517	40	-	-	PUNCT
admet-337	517	41	level	level	NOUN
admet-337	517	42	resistance	resistance	NOUN
admet-337	517	43	.	.	PUNCT
admet-337	518	1	an	an	DET
admet-337	518	2	i1171	i1171	PROPN
admet-337	518	3	t	t	PROPN
admet-337	518	4	mutation	mutation	NOUN
admet-337	518	5	was	be	AUX
admet-337	518	6	isolated	isolate	VERB
admet-337	518	7	in	in	ADP
admet-337	518	8	a	a	DET
admet-337	518	9	tumor	tumor	NOUN
admet-337	518	10	specimen	speciman	NOUN
admet-337	518	11	in	in	ADP
admet-337	518	12	a	a	DET
admet-337	518	13	patient	patient	NOUN
admet-337	518	14	who	who	PRON
admet-337	518	15	had	have	AUX
admet-337	518	16	relapsed	relapse	VERB
admet-337	518	17	on	on	ADP
admet-337	518	18	alectinib	alectinib	NOUN
admet-337	518	19	.	.	PUNCT
admet-337	519	1	this	this	DET
admet-337	519	2	mutation	mutation	NOUN
admet-337	519	3	is	be	AUX
admet-337	519	4	thought	think	VERB
admet-337	519	5	to	to	PART
admet-337	519	6	disrupt	disrupt	VERB
admet-337	519	7	the	the	DET
admet-337	519	8	hydrogen	hydrogen	NOUN
admet-337	519	9	bond	bond	NOUN
admet-337	519	10	between	between	ADP
admet-337	519	11	alectinib	alectinib	NOUN
admet-337	519	12	and	and	CCONJ
admet-337	519	13	e1167	e1167	ADJ
admet-337	519	14	.	.	PUNCT
admet-337	520	1	compared	compare	VERB
admet-337	520	2	with	with	ADP
admet-337	520	3	v1180l	v1180l	PROPN
admet-337	520	4	,	,	PUNCT
admet-337	520	5	the	the	DET
admet-337	520	6	i1171	i1171	PROPN
admet-337	520	7	t	t	NOUN
admet-337	520	8	mutation	mutation	NOUN
admet-337	520	9	confers	confer	VERB
admet-337	520	10	an	an	DET
admet-337	520	11	intermediate	intermediate	ADJ
admet-337	520	12	level	level	NOUN
admet-337	520	13	of	of	ADP
admet-337	520	14	alectinib	alectinib	NOUN
admet-337	520	15	resistance	resistance	NOUN
admet-337	520	16	[	[	X
admet-337	520	17	155	155	NUM
admet-337	520	18	]	]	PUNCT
admet-337	520	19	.	.	PUNCT
admet-337	521	1	however	however	ADV
admet-337	521	2	,	,	PUNCT
admet-337	521	3	ceritinib	ceritinib	PROPN
admet-337	521	4	inhibits	inhibit	VERB
admet-337	521	5	i1171	i1171	PROPN
admet-337	521	6	t	t	PROPN
admet-337	522	1	[	[	X
admet-337	522	2	136	136	NUM
admet-337	522	3	]	]	PUNCT
admet-337	522	4	.	.	PUNCT
admet-337	523	1	g1202r	g1202r	NOUN
admet-337	523	2	is	be	AUX
admet-337	523	3	an	an	DET
admet-337	523	4	acquired	acquire	VERB
admet-337	523	5	mutation	mutation	NOUN
admet-337	523	6	that	that	PRON
admet-337	523	7	drives	drive	VERB
admet-337	523	8	crizotinib	crizotinib	VERB
admet-337	523	9	resistance	resistance	NOUN
admet-337	523	10	but	but	CCONJ
admet-337	523	11	has	have	AUX
admet-337	523	12	also	also	ADV
admet-337	523	13	been	be	AUX
admet-337	523	14	demonstrated	demonstrate	VERB
admet-337	523	15	to	to	PART
admet-337	523	16	confer	confer	VERB
admet-337	523	17	high	high	ADJ
admet-337	523	18	-	-	PUNCT
admet-337	523	19	level	level	NOUN
admet-337	523	20	in	in	ADP
admet-337	523	21	vitro	vitro	X
admet-337	523	22	and	and	CCONJ
admet-337	523	23	in	in	ADP
admet-337	523	24	vivo	vivo	ADJ
admet-337	523	25	resistance	resistance	NOUN
admet-337	523	26	to	to	ADP
admet-337	523	27	alectinib	alectinib	NOUN
admet-337	523	28	and	and	CCONJ
admet-337	523	29	ceritinib	ceritinib	VERB
admet-337	523	30	[	[	X
admet-337	523	31	137	137	NUM
admet-337	523	32	]	]	PUNCT
admet-337	523	33	.	.	PUNCT
admet-337	524	1	a	a	DET
admet-337	524	2	case	case	NOUN
admet-337	524	3	of	of	ADP
admet-337	524	4	met	meet	VERB
admet-337	524	5	amplification	amplification	NOUN
admet-337	524	6	has	have	AUX
admet-337	524	7	been	be	AUX
admet-337	524	8	reported	report	VERB
admet-337	524	9	in	in	ADP
admet-337	524	10	an	an	DET
admet-337	524	11	alectinib	alectinib	NOUN
admet-337	524	12	-	-	PUNCT
admet-337	524	13	resistant	resistant	ADJ
admet-337	524	14	tumor	tumor	NOUN
admet-337	524	15	.	.	PUNCT
admet-337	525	1	it	it	PRON
admet-337	525	2	is	be	AUX
admet-337	525	3	unclear	unclear	ADJ
admet-337	525	4	if	if	SCONJ
admet-337	525	5	met	meet	VERB
admet-337	525	6	was	be	AUX
admet-337	525	7	the	the	DET
admet-337	525	8	driver	driver	NOUN
admet-337	525	9	of	of	ADP
admet-337	525	10	resistance	resistance	NOUN
admet-337	525	11	,	,	PUNCT
admet-337	525	12	however	however	ADV
admet-337	525	13	,	,	PUNCT
admet-337	525	14	the	the	DET
admet-337	525	15	patient	patient	NOUN
admet-337	525	16	did	do	AUX
admet-337	525	17	have	have	VERB
admet-337	525	18	a	a	DET
admet-337	525	19	5	5	NUM
admet-337	525	20	month	month	NOUN
admet-337	525	21	duration	duration	NOUN
admet-337	525	22	of	of	ADP
admet-337	525	23	response	response	NOUN
admet-337	525	24	to	to	ADP
admet-337	525	25	the	the	DET
admet-337	525	26	c	c	NOUN
admet-337	525	27	-	-	PUNCT
admet-337	525	28	met	meet	VERB
admet-337	525	29	inhibitor	inhibitor	NOUN
admet-337	525	30	crizotinib	crizotinib	NOUN
admet-337	525	31	[	[	X
admet-337	525	32	156	156	NUM
admet-337	525	33	]	]	PUNCT
admet-337	525	34	.	.	PUNCT
admet-337	526	1	given	give	VERB
admet-337	526	2	the	the	DET
admet-337	526	3	variety	variety	NOUN
admet-337	526	4	of	of	ADP
admet-337	526	5	secondary	secondary	ADJ
admet-337	526	6	alk	alk	NOUN
admet-337	526	7	mutations	mutation	NOUN
admet-337	526	8	encountered	encounter	VERB
admet-337	526	9	,	,	PUNCT
admet-337	526	10	and	and	CCONJ
admet-337	526	11	the	the	DET
admet-337	526	12	varying	vary	VERB
admet-337	526	13	susceptibilities	susceptibility	NOUN
admet-337	526	14	to	to	ADP
admet-337	526	15	second	second	ADJ
admet-337	526	16	generation	generation	NOUN
admet-337	526	17	and	and	CCONJ
admet-337	526	18	investigational	investigational	ADJ
admet-337	526	19	alk	alk	NOUN
admet-337	526	20	tkis	tkis	PROPN
admet-337	526	21	,	,	PUNCT
admet-337	526	22	it	it	PRON
admet-337	526	23	is	be	AUX
admet-337	526	24	important	important	ADJ
admet-337	526	25	to	to	PART
admet-337	526	26	consider	consider	VERB
admet-337	526	27	serial	serial	ADJ
admet-337	526	28	tumor	tumor	NOUN
admet-337	526	29	molecular	molecular	ADJ
admet-337	526	30	profiling	profiling	NOUN
admet-337	526	31	at	at	ADP
admet-337	526	32	each	each	DET
admet-337	526	33	step	step	NOUN
admet-337	526	34	of	of	ADP
admet-337	526	35	disease	disease	NOUN
admet-337	526	36	progression	progression	NOUN
admet-337	526	37	.	.	PUNCT
admet-337	527	1	grace	grace	NOUN
admet-337	527	2	dy	dy	NOUN
admet-337	527	3	et	et	PROPN
admet-337	527	4	al	al	PROPN
admet-337	527	5	.	.	PROPN
admet-337	527	6	admet	admet	PROPN
admet-337	527	7	&	&	CCONJ
admet-337	527	8	dmpk	dmpk	PROPN
admet-337	527	9	4(3	4(3	NUM
admet-337	527	10	)	)	PUNCT
admet-337	527	11	(	(	PUNCT
admet-337	527	12	2016	2016	NUM
admet-337	527	13	)	)	PUNCT
admet-337	527	14	186	186	NUM
admet-337	527	15	-	-	SYM
admet-337	527	16	211	211	NUM
admet-337	527	17	204	204	NUM
admet-337	527	18	table	table	NOUN
admet-337	527	19	4	4	NUM
admet-337	527	20	.	.	NUM
admet-337	527	21	selected	select	VERB
admet-337	527	22	alk	alk	PROPN
admet-337	527	23	resistance	resistance	NOUN
admet-337	527	24	mutations	mutation	NOUN
admet-337	528	1	[	[	X
admet-337	528	2	157	157	NUM
admet-337	528	3	-	-	SYM
admet-337	528	4	162	162	NUM
admet-337	528	5	]	]	PUNCT
admet-337	528	6	alk	alk	VERB
admet-337	528	7	mutation	mutation	NOUN
admet-337	528	8	treatment	treatment	NOUN
admet-337	528	9	for	for	ADP
admet-337	528	10	mutation	mutation	NOUN
admet-337	528	11	l1196	l1196	PROPN
admet-337	528	12	m	m	PROPN
admet-337	528	13	alectinib	alectinib	NOUN
admet-337	528	14	,	,	PUNCT
admet-337	528	15	ceritinib	ceritinib	NOUN
admet-337	528	16	,	,	PUNCT
admet-337	528	17	brigatinib	brigatinib	NOUN
admet-337	528	18	,	,	PUNCT
admet-337	528	19	lorlatinib	lorlatinib	NOUN
admet-337	528	20	,	,	PUNCT
admet-337	528	21	jh	jh	PROPN
admet-337	528	22	-	-	PUNCT
admet-337	528	23	viii-157	viii-157	NOUN
admet-337	528	24	-	-	PUNCT
admet-337	528	25	02	02	NUM
admet-337	528	26	*	*	PROPN
admet-337	528	27	g1269a	g1269a	PROPN
admet-337	528	28	alectinib	alectinib	NOUN
admet-337	528	29	,	,	PUNCT
admet-337	528	30	ceritinib	ceritinib	NOUN
admet-337	528	31	,	,	PUNCT
admet-337	528	32	brigatinib	brigatinib	NOUN
admet-337	528	33	,	,	PUNCT
admet-337	528	34	lorlatinib	lorlatinib	NOUN
admet-337	528	35	,	,	PUNCT
admet-337	528	36	jh	jh	PROPN
admet-337	528	37	-	-	PUNCT
admet-337	528	38	viii-157	viii-157	PROPN
admet-337	528	39	-	-	PUNCT
admet-337	528	40	02	02	NUM
admet-337	528	41	*	*	NUM
admet-337	528	42	1151tins	1151tins	NUM
admet-337	528	43	alectinib	alectinib	NOUN
admet-337	528	44	,	,	PUNCT
admet-337	528	45	lorlatinib	lorlatinib	PROPN
admet-337	528	46	i1171t	i1171t	PROPN
admet-337	528	47	/	/	SYM
admet-337	528	48	n	n	CCONJ
admet-337	528	49	/	/	SYM
admet-337	528	50	s	s	PART
admet-337	528	51	ceritinib	ceritinib	NOUN
admet-337	528	52	,	,	PUNCT
admet-337	528	53	brigatinib	brigatinib	NOUN
admet-337	528	54	s1206y	s1206y	PRON
admet-337	528	55	alectinib	alectinib	NOUN
admet-337	528	56	,	,	PUNCT
admet-337	528	57	ceritinib	ceritinib	NOUN
admet-337	528	58	,	,	PUNCT
admet-337	528	59	brigatinib	brigatinib	NOUN
admet-337	528	60	,	,	PUNCT
admet-337	528	61	lorlatinib	lorlatinib	NOUN
admet-337	528	62	,	,	PUNCT
admet-337	528	63	jh	jh	PROPN
admet-337	528	64	-	-	PUNCT
admet-337	528	65	viii-157	viii-157	NOUN
admet-337	528	66	-	-	PUNCT
admet-337	528	67	02	02	NUM
admet-337	528	68	*	*	NOUN
admet-337	528	69	s1206f	s1206f	NOUN
admet-337	528	70	brigatinib	brigatinib	NOUN
admet-337	528	71	c1156y	c1156y	NOUN
admet-337	528	72	alectinib	alectinib	NOUN
admet-337	528	73	,	,	PUNCT
admet-337	528	74	ceritinib	ceritinib	NOUN
admet-337	528	75	,	,	PUNCT
admet-337	528	76	lorlatinib	lorlatinib	NOUN
admet-337	528	77	,	,	PUNCT
admet-337	528	78	jh	jh	PROPN
admet-337	528	79	-	-	PUNCT
admet-337	528	80	viii-157	viii-157	PROPN
admet-337	528	81	-	-	PUNCT
admet-337	528	82	02	02	NUM
admet-337	528	83	*	*	PUNCT
admet-337	529	1	l1152r	l1152r	NOUN
admet-337	529	2	alectinib	alectinib	NOUN
admet-337	529	3	,	,	PUNCT
admet-337	529	4	lorlatinib	lorlatinib	NOUN
admet-337	529	5	l1198f	l1198f	PROPN
admet-337	529	6	crizotinib	crizotinib	VERB
admet-337	529	7	f1174c	f1174c	PROPN
admet-337	529	8	brigatinib	brigatinib	NOUN
admet-337	529	9	f1174l	f1174l	X
admet-337	529	10	/	/	SYM
admet-337	529	11	v	v	NOUN
admet-337	529	12	alectinib	alectinib	NOUN
admet-337	529	13	,	,	PUNCT
admet-337	529	14	brigatinib	brigatinib	NOUN
admet-337	529	15	,	,	PUNCT
admet-337	529	16	lorlatinib	lorlatinib	NOUN
admet-337	529	17	,	,	PUNCT
admet-337	529	18	jh	jh	PROPN
admet-337	529	19	-	-	PUNCT
admet-337	529	20	viii-157	viii-157	NOUN
admet-337	529	21	-	-	PUNCT
admet-337	529	22	02	02	NUM
admet-337	529	23	*	*	ADJ
admet-337	529	24	r1275q	r1275q	NOUN
admet-337	529	25	alectinib	alectinib	NOUN
admet-337	529	26	,	,	PUNCT
admet-337	529	27	brigatinib	brigatinib	PROPN
admet-337	529	28	g1202r	g1202r	PROPN
admet-337	529	29	brigatinib	brigatinib	PROPN
admet-337	529	30	,	,	PUNCT
admet-337	529	31	lorlatinib	lorlatinib	NOUN
admet-337	529	32	,	,	PUNCT
admet-337	529	33	jh	jh	PROPN
admet-337	529	34	-	-	PUNCT
admet-337	529	35	viii-157	viii-157	NOUN
admet-337	529	36	-	-	PUNCT
admet-337	529	37	02	02	NUM
admet-337	529	38	*	*	PROPN
admet-337	529	39	*	*	PUNCT
admet-337	529	40	structural	structural	ADJ
admet-337	529	41	analogue	analogue	NOUN
admet-337	529	42	of	of	ADP
admet-337	529	43	alectinib	alectinib	NOUN
admet-337	529	44	,	,	PUNCT
admet-337	529	45	not	not	PART
admet-337	529	46	currently	currently	ADV
admet-337	529	47	in	in	ADP
admet-337	529	48	clinical	clinical	ADJ
admet-337	529	49	testing	testing	NOUN
admet-337	529	50	investigational	investigational	ADJ
admet-337	529	51	agents	agent	NOUN
admet-337	529	52	(	(	PUNCT
admet-337	529	53	table	table	NOUN
admet-337	529	54	5	5	NUM
admet-337	529	55	)	)	PUNCT
admet-337	529	56	brigatinib	brigatinib	NOUN
admet-337	529	57	(	(	PUNCT
admet-337	529	58	ap26113	ap26113	PROPN
admet-337	529	59	)	)	PUNCT
admet-337	529	60	is	be	AUX
admet-337	529	61	a	a	DET
admet-337	529	62	second	second	ADJ
admet-337	529	63	-	-	PUNCT
admet-337	529	64	generation	generation	NOUN
admet-337	529	65	alk	alk	NOUN
admet-337	529	66	tki	tki	NOUN
admet-337	529	67	that	that	PRON
admet-337	529	68	also	also	ADV
admet-337	529	69	inhibits	inhibit	VERB
admet-337	529	70	egfr	egfr	NOUN
admet-337	529	71	as	as	ADV
admet-337	529	72	well	well	ADV
admet-337	529	73	as	as	ADP
admet-337	529	74	various	various	ADJ
admet-337	529	75	alk	alk	NOUN
admet-337	529	76	mutations	mutation	NOUN
admet-337	529	77	resistant	resistant	ADJ
admet-337	529	78	to	to	AUX
admet-337	529	79	crizotinib	crizotinib	VERB
admet-337	529	80	,	,	PUNCT
admet-337	529	81	alectinib	alectinib	NOUN
admet-337	529	82	and	and	CCONJ
admet-337	529	83	ceritinib	ceritinib	NOUN
admet-337	529	84	,	,	PUNCT
admet-337	529	85	including	include	VERB
admet-337	529	86	the	the	DET
admet-337	529	87	g1202r	g1202r	PROPN
admet-337	529	88	mutation	mutation	NOUN
admet-337	529	89	.	.	PUNCT
admet-337	530	1	preclinically	preclinically	PROPN
admet-337	530	2	,	,	PUNCT
admet-337	530	3	it	it	PRON
admet-337	530	4	has	have	AUX
admet-337	530	5	demonstrated	demonstrate	VERB
admet-337	530	6	inhibition	inhibition	NOUN
admet-337	530	7	of	of	ADP
admet-337	530	8	egfr	egfr	ADJ
admet-337	530	9	t790	t790	NUM
admet-337	530	10	m	m	NOUN
admet-337	530	11	resistance	resistance	NOUN
admet-337	530	12	mutation	mutation	NOUN
admet-337	530	13	as	as	ADV
admet-337	530	14	well	well	ADV
admet-337	530	15	as	as	ADP
admet-337	530	16	potent	potent	ADJ
admet-337	530	17	activity	activity	NOUN
admet-337	530	18	against	against	ADP
admet-337	530	19	ros1	ros1	PROPN
admet-337	530	20	with	with	ADP
admet-337	530	21	ic50	ic50	PROPN
admet-337	530	22	of	of	ADP
admet-337	530	23	1.9	1.9	NUM
admet-337	530	24	nm	nm	NOUN
admet-337	530	25	[	[	X
admet-337	530	26	161	161	NUM
admet-337	530	27	]	]	PUNCT
admet-337	530	28	.	.	PUNCT
admet-337	531	1	early	early	ADJ
admet-337	531	2	clinical	clinical	ADJ
admet-337	531	3	data	datum	NOUN
admet-337	531	4	showed	show	VERB
admet-337	531	5	disappointing	disappointing	ADJ
admet-337	531	6	activity	activity	NOUN
admet-337	531	7	for	for	ADP
admet-337	531	8	brigatinib	brigatinib	NOUN
admet-337	531	9	in	in	ADP
admet-337	531	10	egfr	egfr	NOUN
admet-337	531	11	-	-	PUNCT
admet-337	531	12	mutated	mutate	VERB
admet-337	531	13	patients	patient	NOUN
admet-337	531	14	,	,	PUNCT
admet-337	531	15	and	and	CCONJ
admet-337	531	16	it	it	PRON
admet-337	531	17	has	have	AUX
admet-337	531	18	been	be	AUX
admet-337	531	19	predominantly	predominantly	ADV
admet-337	531	20	developed	develop	VERB
admet-337	531	21	as	as	ADP
admet-337	531	22	an	an	DET
admet-337	531	23	alk	alk	NOUN
admet-337	531	24	inhibitor	inhibitor	NOUN
admet-337	531	25	[	[	X
admet-337	531	26	163	163	NUM
admet-337	531	27	]	]	PUNCT
admet-337	531	28	.	.	PUNCT
admet-337	532	1	a	a	DET
admet-337	532	2	phase	phase	NOUN
admet-337	532	3	i	i	PRON
admet-337	532	4	trial	trial	NOUN
admet-337	532	5	investigating	investigate	VERB
admet-337	532	6	brigatinib	brigatinib	NOUN
admet-337	532	7	for	for	ADP
admet-337	532	8	advanced	advanced	ADJ
admet-337	532	9	alk	alk	VERB
admet-337	532	10	-	-	PUNCT
admet-337	532	11	positive	positive	ADJ
admet-337	532	12	patients	patient	NOUN
admet-337	532	13	who	who	PRON
admet-337	532	14	had	have	VERB
admet-337	532	15	disease	disease	NOUN
admet-337	532	16	progression	progression	NOUN
admet-337	532	17	after	after	ADP
admet-337	532	18	crizotinib	crizotinib	NOUN
admet-337	532	19	or	or	CCONJ
admet-337	532	20	chemotherapy	chemotherapy	NOUN
admet-337	532	21	showed	show	VERB
admet-337	532	22	an	an	DET
admet-337	532	23	orr	orr	NOUN
admet-337	532	24	of	of	ADP
admet-337	532	25	74	74	NUM
admet-337	532	26	%	%	NOUN
admet-337	532	27	and	and	CCONJ
admet-337	532	28	median	median	ADJ
admet-337	532	29	pfs	pf	NOUN
admet-337	532	30	of	of	ADP
admet-337	532	31	13.4	13.4	NUM
admet-337	532	32	months	month	NOUN
admet-337	532	33	[	[	X
admet-337	532	34	163	163	NUM
admet-337	532	35	]	]	PUNCT
admet-337	532	36	.	.	PUNCT
admet-337	533	1	the	the	DET
admet-337	533	2	phase	phase	NOUN
admet-337	533	3	ii	ii	PROPN
admet-337	533	4	study	study	NOUN
admet-337	533	5	(	(	PUNCT
admet-337	533	6	nct02094573	nct02094573	NOUN
admet-337	533	7	)	)	PUNCT
admet-337	533	8	is	be	AUX
admet-337	533	9	ongoing	ongoing	ADJ
admet-337	533	10	,	,	PUNCT
admet-337	533	11	but	but	CCONJ
admet-337	533	12	preliminary	preliminary	ADJ
admet-337	533	13	results	result	NOUN
admet-337	533	14	were	be	AUX
admet-337	533	15	recently	recently	ADV
admet-337	533	16	presented	present	VERB
admet-337	533	17	.	.	PUNCT
admet-337	534	1	as	as	ADP
admet-337	534	2	of	of	ADP
admet-337	534	3	december	december	PROPN
admet-337	534	4	2015	2015	NUM
admet-337	534	5	,	,	PUNCT
admet-337	534	6	222	222	NUM
admet-337	534	7	patients	patient	NOUN
admet-337	534	8	were	be	AUX
admet-337	534	9	randomized	randomize	VERB
admet-337	534	10	to	to	ADP
admet-337	534	11	either	either	PRON
admet-337	534	12	90	90	NUM
admet-337	534	13	mg	mg	NUM
admet-337	534	14	/	/	SYM
admet-337	534	15	day	day	NOUN
admet-337	534	16	or	or	CCONJ
admet-337	534	17	180	180	NUM
admet-337	534	18	mg	mg	NUM
admet-337	534	19	/	/	SYM
admet-337	534	20	day	day	NOUN
admet-337	534	21	of	of	ADP
admet-337	534	22	brigatinib	brigatinib	NOUN
admet-337	534	23	for	for	ADP
admet-337	534	24	the	the	DET
admet-337	534	25	treatment	treatment	NOUN
admet-337	534	26	of	of	ADP
admet-337	534	27	crizotinib	crizotinib	NOUN
admet-337	534	28	-	-	ADJ
admet-337	534	29	resistant	resistant	ADJ
admet-337	534	30	alkpositive	alkpositive	ADJ
admet-337	534	31	nsclc	nsclc	NOUN
admet-337	534	32	.	.	PUNCT
admet-337	535	1	the	the	DET
admet-337	535	2	orr	orr	PROPN
admet-337	535	3	was	be	AUX
admet-337	535	4	46	46	NUM
admet-337	535	5	%	%	NOUN
admet-337	535	6	and	and	CCONJ
admet-337	535	7	the	the	DET
admet-337	535	8	median	median	ADJ
admet-337	535	9	pfs	pfs	PROPN
admet-337	535	10	was	be	AUX
admet-337	535	11	8.8	8.8	NUM
admet-337	535	12	months	month	NOUN
admet-337	535	13	for	for	ADP
admet-337	535	14	those	those	PRON
admet-337	535	15	who	who	PRON
admet-337	535	16	received	receive	VERB
admet-337	535	17	90	90	NUM
admet-337	535	18	mg	mg	NUM
admet-337	535	19	/	/	SYM
admet-337	535	20	day	day	NOUN
admet-337	535	21	of	of	ADP
admet-337	535	22	brigatinib	brigatinib	NOUN
admet-337	535	23	versus	versus	ADP
admet-337	535	24	an	an	DET
admet-337	535	25	orr	orr	NOUN
admet-337	535	26	of	of	ADP
admet-337	535	27	54	54	NUM
admet-337	535	28	%	%	NOUN
admet-337	535	29	and	and	CCONJ
admet-337	535	30	median	median	ADJ
admet-337	535	31	pfs	pf	NOUN
admet-337	535	32	of	of	ADP
admet-337	535	33	11.1	11.1	NUM
admet-337	535	34	months	month	NOUN
admet-337	535	35	for	for	ADP
admet-337	535	36	those	those	PRON
admet-337	535	37	who	who	PRON
admet-337	535	38	received	receive	VERB
admet-337	535	39	180	180	NUM
admet-337	535	40	mg	mg	NUM
admet-337	535	41	/	/	SYM
admet-337	535	42	day	day	NOUN
admet-337	535	43	.	.	PUNCT
admet-337	536	1	in	in	ADP
admet-337	536	2	the	the	DET
admet-337	536	3	higher	high	ADJ
admet-337	536	4	dose	dose	NOUN
admet-337	536	5	group	group	NOUN
admet-337	536	6	,	,	PUNCT
admet-337	536	7	grade	grade	NOUN
admet-337	536	8	3	3	NUM
admet-337	536	9	or	or	CCONJ
admet-337	536	10	higher	high	ADJ
admet-337	536	11	toxicity	toxicity	NOUN
admet-337	536	12	for	for	ADP
admet-337	536	13	increased	increase	VERB
admet-337	536	14	cpk	cpk	PROPN
admet-337	536	15	(	(	PUNCT
admet-337	536	16	8	8	NUM
admet-337	536	17	%	%	NOUN
admet-337	536	18	)	)	PUNCT
admet-337	536	19	and	and	CCONJ
admet-337	536	20	pneumonitis	pneumonitis	NOUN
admet-337	536	21	(	(	PUNCT
admet-337	536	22	3	3	NUM
admet-337	536	23	%	%	NOUN
admet-337	536	24	)	)	PUNCT
admet-337	536	25	was	be	AUX
admet-337	536	26	noteworthy	noteworthy	ADJ
admet-337	536	27	.	.	PUNCT
admet-337	537	1	many	many	ADJ
admet-337	537	2	of	of	ADP
admet-337	537	3	the	the	DET
admet-337	537	4	pulmonary	pulmonary	ADJ
admet-337	537	5	events	event	NOUN
admet-337	537	6	occurred	occur	VERB
admet-337	537	7	within	within	ADP
admet-337	537	8	7	7	NUM
admet-337	537	9	days	day	NOUN
admet-337	537	10	of	of	ADP
admet-337	537	11	treatment	treatment	NOUN
admet-337	537	12	initiation	initiation	NOUN
admet-337	537	13	.	.	PUNCT
admet-337	538	1	a	a	DET
admet-337	538	2	phase	phase	NOUN
admet-337	538	3	iii	iii	NUM
admet-337	538	4	study	study	NOUN
admet-337	538	5	is	be	AUX
admet-337	538	6	planned	plan	VERB
admet-337	538	7	comparing	compare	VERB
admet-337	538	8	brigatinib	brigatinib	NOUN
admet-337	538	9	versus	versus	ADP
admet-337	538	10	crizotinib	crizotinib	VERB
admet-337	538	11	for	for	ADP
admet-337	538	12	tki	tki	NOUN
admet-337	538	13	-	-	ADJ
admet-337	538	14	naïve	naïve	ADJ
admet-337	538	15	,	,	PUNCT
admet-337	538	16	advanced	advanced	ADJ
admet-337	538	17	alk	alk	ADJ
admet-337	538	18	-	-	PUNCT
admet-337	538	19	positive	positive	ADJ
admet-337	538	20	nsclc	nsclc	NOUN
admet-337	539	1	[	[	X
admet-337	539	2	162	162	NUM
admet-337	539	3	]	]	PUNCT
admet-337	539	4	.	.	PUNCT
admet-337	540	1	lorlatinib	lorlatinib	NOUN
admet-337	540	2	(	(	PUNCT
admet-337	540	3	pf-06463922	pf-06463922	PROPN
admet-337	540	4	)	)	PUNCT
admet-337	540	5	is	be	AUX
admet-337	540	6	a	a	DET
admet-337	540	7	third	third	ADJ
admet-337	540	8	-	-	PUNCT
admet-337	540	9	generation	generation	NOUN
admet-337	540	10	alk	alk	PROPN
admet-337	540	11	/	/	SYM
admet-337	540	12	ros1	ros1	PROPN
admet-337	540	13	tki	tki	NOUN
admet-337	540	14	with	with	ADP
admet-337	540	15	activity	activity	NOUN
admet-337	540	16	against	against	ADP
admet-337	540	17	most	most	ADJ
admet-337	540	18	alk	alk	VERB
admet-337	540	19	crizotinibresistance	crizotinibresistance	NOUN
admet-337	540	20	mutations	mutation	NOUN
admet-337	540	21	that	that	PRON
admet-337	540	22	was	be	AUX
admet-337	540	23	designed	design	VERB
admet-337	540	24	to	to	PART
admet-337	540	25	have	have	VERB
admet-337	540	26	high	high	ADJ
admet-337	540	27	cns	cns	NOUN
admet-337	540	28	penetration	penetration	NOUN
admet-337	540	29	.	.	PUNCT
admet-337	541	1	in	in	ADP
admet-337	541	2	an	an	DET
admet-337	541	3	ongoing	ongoing	ADJ
admet-337	541	4	phase	phase	NOUN
admet-337	541	5	i	i	PRON
admet-337	541	6	/	/	SYM
admet-337	541	7	ii	ii	PROPN
admet-337	541	8	study	study	NOUN
admet-337	541	9	(	(	PUNCT
admet-337	541	10	nct01970865	nct01970865	ADJ
admet-337	541	11	)	)	PUNCT
admet-337	541	12	,	,	PUNCT
admet-337	541	13	54	54	NUM
admet-337	541	14	patients	patient	NOUN
admet-337	541	15	who	who	PRON
admet-337	541	16	had	have	VERB
admet-337	541	17	advanced	advanced	ADJ
admet-337	541	18	alk	alk	NOUN
admet-337	541	19	or	or	CCONJ
admet-337	541	20	ros1	ros1	VERB
admet-337	541	21	positive	positive	ADJ
admet-337	541	22	nsclc	nsclc	NOUN
admet-337	541	23	received	receive	VERB
admet-337	541	24	lorlatinib	lorlatinib	NOUN
admet-337	541	25	,	,	PUNCT
admet-337	541	26	producing	produce	VERB
admet-337	541	27	an	an	DET
admet-337	541	28	orr	orr	NOUN
admet-337	541	29	of	of	ADP
admet-337	541	30	50	50	NUM
admet-337	541	31	%	%	NOUN
admet-337	541	32	with	with	ADP
admet-337	541	33	an	an	DET
admet-337	541	34	intracranial	intracranial	ADJ
admet-337	541	35	orr	orr	NOUN
admet-337	541	36	of	of	ADP
admet-337	541	37	44	44	NUM
admet-337	541	38	%	%	NOUN
admet-337	541	39	(	(	PUNCT
admet-337	541	40	22	22	NUM
admet-337	541	41	%	%	NOUN
admet-337	541	42	cr	cr	PRON
admet-337	541	43	)	)	PUNCT
admet-337	541	44	.	.	PUNCT
admet-337	542	1	response	response	NOUN
admet-337	542	2	was	be	AUX
admet-337	542	3	witnessed	witness	VERB
admet-337	542	4	in	in	ADP
admet-337	542	5	patients	patient	NOUN
admet-337	542	6	with	with	ADP
admet-337	542	7	the	the	DET
admet-337	542	8	g1202r	g1202r	PROPN
admet-337	542	9	mutation	mutation	NOUN
admet-337	542	10	[	[	X
admet-337	542	11	164	164	NUM
admet-337	542	12	]	]	PUNCT
admet-337	542	13	.	.	PUNCT
admet-337	543	1	grade	grade	NOUN
admet-337	543	2	3	3	NUM
admet-337	543	3	or	or	CCONJ
admet-337	543	4	4	4	NUM
admet-337	543	5	hypercholestrolemia	hypercholestrolemia	NOUN
admet-337	543	6	occurred	occur	VERB
admet-337	543	7	in	in	ADP
admet-337	543	8	9	9	NUM
admet-337	543	9	%	%	NOUN
admet-337	543	10	of	of	ADP
admet-337	543	11	patients	patient	NOUN
admet-337	543	12	.	.	PUNCT
admet-337	544	1	the	the	DET
admet-337	544	2	phase	phase	NOUN
admet-337	544	3	ii	ii	PROPN
admet-337	544	4	component	component	NOUN
admet-337	544	5	of	of	ADP
admet-337	544	6	the	the	DET
admet-337	544	7	trial	trial	NOUN
admet-337	544	8	is	be	AUX
admet-337	544	9	currently	currently	ADV
admet-337	544	10	enrolling	enrol	VERB
admet-337	544	11	patients	patient	NOUN
admet-337	544	12	.	.	PUNCT
admet-337	545	1	the	the	DET
admet-337	545	2	l1198f	l1198f	ADJ
admet-337	545	3	mutation	mutation	NOUN
admet-337	545	4	confers	confer	VERB
admet-337	545	5	resistance	resistance	NOUN
admet-337	545	6	to	to	ADP
admet-337	545	7	lorlatinib	lorlatinib	NOUN
admet-337	545	8	.	.	PUNCT
admet-337	546	1	interestingly	interestingly	ADV
admet-337	546	2	,	,	PUNCT
admet-337	546	3	this	this	DET
admet-337	546	4	mutation	mutation	NOUN
admet-337	546	5	resensitizes	resensitize	VERB
admet-337	546	6	the	the	DET
admet-337	546	7	alk	alk	PROPN
admet-337	546	8	kinase	kinase	PROPN
admet-337	546	9	domain	domain	PROPN
admet-337	546	10	to	to	PART
admet-337	546	11	crizotinib	crizotinib	VERB
admet-337	546	12	,	,	PUNCT
admet-337	546	13	and	and	CCONJ
admet-337	546	14	a	a	DET
admet-337	546	15	clinical	clinical	ADJ
admet-337	546	16	response	response	NOUN
admet-337	546	17	with	with	ADP
admet-337	546	18	crizotinib	crizotinib	NOUN
admet-337	546	19	has	have	AUX
admet-337	546	20	been	be	AUX
admet-337	546	21	witnessed	witness	VERB
admet-337	546	22	in	in	ADP
admet-337	546	23	a	a	DET
admet-337	546	24	patient	patient	NOUN
admet-337	546	25	with	with	ADP
admet-337	546	26	a	a	DET
admet-337	546	27	l1198f	l1198f	ADJ
admet-337	546	28	lorlatinib	lorlatinib	NOUN
admet-337	546	29	-	-	PUNCT
admet-337	546	30	resistance	resistance	NOUN
admet-337	546	31	mutation	mutation	NOUN
admet-337	546	32	[	[	X
admet-337	546	33	160	160	NUM
admet-337	546	34	]	]	X
admet-337	546	35	.	.	PUNCT
admet-337	547	1	x-396	x-396	PUNCT
admet-337	547	2	is	be	AUX
admet-337	547	3	another	another	DET
admet-337	547	4	tki	tki	NOUN
admet-337	547	5	that	that	PRON
admet-337	547	6	potently	potently	ADV
admet-337	547	7	inhibits	inhibit	VERB
admet-337	547	8	alk	alk	PROPN
admet-337	547	9	,	,	PUNCT
admet-337	547	10	including	include	VERB
admet-337	547	11	the	the	DET
admet-337	547	12	crizotinib	crizotinib	NOUN
admet-337	547	13	-	-	PUNCT
admet-337	547	14	resistance	resistance	NOUN
admet-337	547	15	mutations	mutation	NOUN
admet-337	547	16	,	,	PUNCT
admet-337	547	17	l1196	l1196	NOUN
admet-337	547	18	m	m	NOUN
admet-337	547	19	and	and	CCONJ
admet-337	547	20	c1156y	c1156y	NOUN
admet-337	547	21	.	.	PROPN
admet-337	548	1	in	in	ADP
admet-337	548	2	a	a	DET
admet-337	548	3	multicenter	multicenter	ADJ
admet-337	548	4	phase	phase	NOUN
admet-337	548	5	i	i	PROPN
admet-337	548	6	/	/	SYM
admet-337	548	7	ii	ii	NOUN
admet-337	548	8	trial	trial	NOUN
admet-337	548	9	,	,	PUNCT
admet-337	548	10	among	among	ADP
admet-337	548	11	6	6	NUM
admet-337	548	12	alk	alk	VERB
admet-337	548	13	-	-	PUNCT
admet-337	548	14	positive	positive	ADJ
admet-337	548	15	nsclc	nsclc	NOUN
admet-337	548	16	patients	patient	NOUN
admet-337	548	17	who	who	PRON
admet-337	548	18	received	receive	VERB
admet-337	548	19	at	at	ADV
admet-337	548	20	least	least	ADV
admet-337	548	21	200	200	NUM
admet-337	548	22	mg	mg	NOUN
admet-337	548	23	of	of	ADP
admet-337	548	24	x-396	x-396	PROPN
admet-337	548	25	,	,	PUNCT
admet-337	548	26	pr	pr	NOUN
admet-337	548	27	was	be	AUX
admet-337	548	28	achieved	achieve	VERB
admet-337	548	29	in	in	ADP
admet-337	548	30	83	83	NUM
admet-337	548	31	%	%	NOUN
admet-337	548	32	with	with	ADP
admet-337	548	33	the	the	DET
admet-337	548	34	remainder	remainder	NOUN
admet-337	548	35	achieving	achieve	VERB
admet-337	548	36	stable	stable	ADJ
admet-337	548	37	disease	disease	NOUN
admet-337	548	38	.	.	PUNCT
admet-337	549	1	enrollment	enrollment	NOUN
admet-337	549	2	for	for	ADP
admet-337	549	3	this	this	DET
admet-337	549	4	admet	admet	PROPN
admet-337	549	5	&	&	CCONJ
admet-337	549	6	dmpk	dmpk	PROPN
admet-337	549	7	4(3	4(3	NUM
admet-337	549	8	)	)	PUNCT
admet-337	549	9	(	(	PUNCT
admet-337	549	10	2016	2016	NUM
admet-337	549	11	)	)	PUNCT
admet-337	549	12	186	186	NUM
admet-337	549	13	-	-	SYM
admet-337	549	14	211	211	NUM
admet-337	549	15	tki	tki	NOUN
admet-337	549	16	for	for	ADP
admet-337	549	17	egfrand	egfrand	ADJ
admet-337	549	18	alk	alk	PROPN
admet-337	549	19	-	-	PUNCT
admet-337	549	20	mutated	mutate	VERB
admet-337	549	21	cell	cell	NOUN
admet-337	549	22	cancer	cancer	NOUN
admet-337	549	23	doi	doi	NOUN
admet-337	549	24	:	:	PUNCT
admet-337	549	25	10.5599	10.5599	NUM
admet-337	549	26	/	/	SYM
admet-337	549	27	admet.4.3.337	admet.4.3.337	CCONJ
admet-337	549	28	205	205	NUM
admet-337	549	29	trial	trial	NOUN
admet-337	549	30	is	be	AUX
admet-337	549	31	ongoing	ongoing	ADJ
admet-337	549	32	(	(	PUNCT
admet-337	549	33	nct01625234	nct01625234	NOUN
admet-337	549	34	)	)	PUNCT
admet-337	550	1	[	[	X
admet-337	550	2	165	165	NUM
admet-337	550	3	]	]	PUNCT
admet-337	550	4	.	.	PUNCT
admet-337	550	5	asp3026	asp3026	PROPN
admet-337	550	6	is	be	AUX
admet-337	550	7	another	another	DET
admet-337	550	8	alk	alk	NOUN
admet-337	550	9	inhibitor	inhibitor	NOUN
admet-337	550	10	that	that	PRON
admet-337	550	11	achieved	achieve	VERB
admet-337	550	12	an	an	DET
admet-337	550	13	orr	orr	NOUN
admet-337	550	14	of	of	ADP
admet-337	550	15	44	44	NUM
admet-337	550	16	%	%	NOUN
admet-337	550	17	in	in	ADP
admet-337	550	18	15	15	NUM
admet-337	550	19	alk	alk	VERB
admet-337	550	20	-	-	PUNCT
admet-337	550	21	positive	positive	ADJ
admet-337	550	22	patients	patient	NOUN
admet-337	550	23	who	who	PRON
admet-337	550	24	progressed	progress	VERB
admet-337	550	25	on	on	ADP
admet-337	550	26	crizotinib	crizotinib	NOUN
admet-337	550	27	in	in	ADP
admet-337	550	28	a	a	DET
admet-337	550	29	phase	phase	NOUN
admet-337	550	30	i	i	PRON
admet-337	550	31	trial	trial	NOUN
admet-337	550	32	(	(	PUNCT
admet-337	550	33	nct01401504	nct01401504	NOUN
admet-337	550	34	)	)	PUNCT
admet-337	551	1	[	[	X
admet-337	551	2	166	166	NUM
admet-337	551	3	]	]	PUNCT
admet-337	551	4	.	.	PUNCT
admet-337	551	5	table	table	NOUN
admet-337	551	6	5	5	NUM
admet-337	551	7	.	.	PUNCT
admet-337	552	1	alk	alk	VERB
admet-337	552	2	tkis	tkis	NOUN
admet-337	552	3	in	in	ADP
admet-337	552	4	clinical	clinical	ADJ
admet-337	552	5	development	development	NOUN
admet-337	552	6	drug	drug	NOUN
admet-337	552	7	name	name	NOUN
admet-337	552	8	targets	target	VERB
admet-337	552	9	clinical	clinical	ADJ
admet-337	552	10	activity	activity	NOUN
admet-337	552	11	select	select	VERB
admet-337	552	12	ongoing	ongoing	ADJ
admet-337	552	13	/	/	SYM
admet-337	552	14	future	future	ADJ
admet-337	552	15	trials	trial	NOUN
admet-337	552	16	brigatinib	brigatinib	NOUN
admet-337	552	17	(	(	PUNCT
admet-337	552	18	asp26113	asp26113	NOUN
admet-337	552	19	)	)	PUNCT
admet-337	553	1	[	[	X
admet-337	553	2	162,163	162,163	NUM
admet-337	553	3	]	]	PUNCT
admet-337	553	4	alk	alk	VERB
admet-337	553	5	egfr	egfr	PROPN
admet-337	553	6	alk	alk	VERB
admet-337	553	7	l1196	l1196	PROPN
admet-337	553	8	m	m	NOUN
admet-337	553	9	egfr	egfr	VERB
admet-337	553	10	t790	t790	NUM
admet-337	553	11	m	m	NOUN
admet-337	553	12	phase	phase	NOUN
admet-337	553	13	i	i	PRON
admet-337	553	14	:	:	PUNCT
admet-337	553	15	orr	orr	PROPN
admet-337	553	16	74	74	NUM
admet-337	553	17	%	%	NOUN
admet-337	553	18	,	,	PUNCT
admet-337	553	19	median	median	PROPN
admet-337	553	20	pfs	pfs	PROPN
admet-337	553	21	13.4	13.4	NUM
admet-337	553	22	mo	mo	NOUN
admet-337	553	23	;	;	PUNCT
admet-337	553	24	phase	phase	PROPN
admet-337	553	25	ii	ii	PROPN
admet-337	553	26	:	:	PUNCT
admet-337	553	27	orr	orr	PROPN
admet-337	553	28	46	46	NUM
admet-337	553	29	-	-	SYM
admet-337	553	30	54	54	NUM
admet-337	553	31	%	%	NOUN
admet-337	553	32	median	median	NOUN
admet-337	553	33	pfs	pfs	PROPN
admet-337	553	34	8.8	8.8	NUM
admet-337	553	35	-	-	PUNCT
admet-337	553	36	11.1	11.1	NUM
admet-337	553	37	mo	mo	PROPN
admet-337	553	38	ongoing	ongoing	ADJ
admet-337	553	39	phase	phase	NOUN
admet-337	553	40	ii	ii	PROPN
admet-337	553	41	(	(	PUNCT
admet-337	553	42	nct02094573	nct02094573	NOUN
admet-337	553	43	)	)	PUNCT
admet-337	553	44	;	;	PUNCT
admet-337	553	45	planned	plan	VERB
admet-337	553	46	phase	phase	NOUN
admet-337	553	47	iii	iii	NUM
admet-337	553	48	trial	trial	NOUN
admet-337	553	49	brigatinib	brigatinib	NOUN
admet-337	553	50	vs	vs	ADP
admet-337	553	51	crizotinib	crizotinib	NOUN
admet-337	553	52	in	in	ADP
admet-337	553	53	tki	tki	PROPN
admet-337	553	54	naïve	naïve	ADJ
admet-337	553	55	patients	patient	NOUN
admet-337	553	56	lorlatinib	lorlatinib	NOUN
admet-337	553	57	(	(	PUNCT
admet-337	553	58	pf-06463922	pf-06463922	PROPN
admet-337	553	59	)	)	PUNCT
admet-337	554	1	[	[	X
admet-337	554	2	164	164	NUM
admet-337	554	3	]	]	PUNCT
admet-337	554	4	alk	alk	VERB
admet-337	554	5	ros1	ros1	PROPN
admet-337	554	6	crizotinib	crizotinib	PROPN
admet-337	554	7	-	-	PUNCT
admet-337	554	8	resistance	resistance	NOUN
admet-337	554	9	mutations	mutation	NOUN
admet-337	554	10	phase	phase	NOUN
admet-337	554	11	i	i	PRON
admet-337	554	12	/	/	SYM
admet-337	554	13	ii	ii	PROPN
admet-337	554	14	:	:	PUNCT
admet-337	554	15	orr	orr	NOUN
admet-337	554	16	50	50	NUM
admet-337	554	17	%	%	NOUN
admet-337	554	18	systemic	systemic	ADJ
admet-337	554	19	intracranial	intracranial	NOUN
admet-337	554	20	orr	orr	PROPN
admet-337	554	21	44	44	NUM
admet-337	554	22	%	%	NOUN
admet-337	554	23	ongoing	ongoing	ADJ
admet-337	554	24	phase	phase	NOUN
admet-337	554	25	ii	ii	PROPN
admet-337	554	26	(	(	PUNCT
admet-337	554	27	nct01970865	nct01970865	ADJ
admet-337	554	28	)	)	PUNCT
admet-337	554	29	x-396	x-396	PUNCT
admet-337	555	1	[	[	X
admet-337	555	2	165	165	NUM
admet-337	555	3	]	]	PUNCT
admet-337	555	4	alk	alk	NOUN
admet-337	555	5	crizotinib	crizotinib	NOUN
admet-337	555	6	-	-	PUNCT
admet-337	555	7	resistance	resistance	NOUN
admet-337	555	8	mutations	mutation	NOUN
admet-337	555	9	phase	phase	NOUN
admet-337	555	10	i	i	PRON
admet-337	555	11	/	/	SYM
admet-337	555	12	ii	ii	PROPN
admet-337	555	13	(	(	PUNCT
admet-337	555	14	n=6	n=6	NOUN
admet-337	555	15	)	)	PUNCT
admet-337	555	16	orr	orr	NOUN
admet-337	555	17	83	83	NUM
admet-337	555	18	%	%	NOUN
admet-337	555	19	ongoing	ongoing	ADJ
admet-337	555	20	phase	phase	NOUN
admet-337	555	21	ii	ii	PROPN
admet-337	555	22	(	(	PUNCT
admet-337	555	23	nct01625234	nct01625234	PROPN
admet-337	555	24	)	)	PUNCT
admet-337	555	25	asp3026	asp3026	PROPN
admet-337	556	1	[	[	X
admet-337	556	2	166	166	NUM
admet-337	556	3	]	]	PUNCT
admet-337	556	4	alk	alk	NOUN
admet-337	556	5	crizotinib	crizotinib	NOUN
admet-337	556	6	-	-	PUNCT
admet-337	556	7	resistance	resistance	NOUN
admet-337	556	8	mutations	mutation	NOUN
admet-337	556	9	phase	phase	NOUN
admet-337	556	10	i	i	PRON
admet-337	556	11	(	(	PUNCT
admet-337	556	12	n=15	n=15	PROPN
admet-337	556	13	)	)	PUNCT
admet-337	556	14	orr	orr	NOUN
admet-337	556	15	44	44	NUM
admet-337	556	16	%	%	NOUN
admet-337	556	17	no	no	PRON
admet-337	556	18	currently	currently	ADV
admet-337	556	19	active	active	ADJ
admet-337	556	20	trials	trial	NOUN
admet-337	556	21	entrectinib	entrectinib	NOUN
admet-337	556	22	(	(	PUNCT
admet-337	556	23	rxdx-101	rxdx-101	NOUN
admet-337	556	24	,	,	PUNCT
admet-337	556	25	nms	nms	PROPN
admet-337	556	26	-	-	PUNCT
admet-337	556	27	e628	e628	PROPN
admet-337	556	28	)	)	PUNCT
admet-337	557	1	[	[	X
admet-337	557	2	169	169	NUM
admet-337	557	3	]	]	PUNCT
admet-337	557	4	alk	alk	PROPN
admet-337	557	5	ros1	ros1	PROPN
admet-337	557	6	trka	trka	PROPN
admet-337	557	7	,	,	PUNCT
admet-337	557	8	trkb	trkb	NOUN
admet-337	557	9	,	,	PUNCT
admet-337	557	10	trkc	trkc	NOUN
admet-337	557	11	phase	phase	NOUN
admet-337	557	12	i	i	PRON
admet-337	557	13	1	1	NUM
admet-337	557	14	of	of	ADP
admet-337	557	15	1	1	NUM
admet-337	557	16	pt	pt	NOUN
admet-337	557	17	with	with	ADP
admet-337	557	18	alk+	alk+	NOUN
admet-337	557	19	nsclc	nsclc	NOUN
admet-337	557	20	developed	develop	VERB
admet-337	557	21	pr	pr	NOUN
admet-337	557	22	phase	phase	NOUN
admet-337	557	23	i	i	PRON
admet-337	557	24	/	/	SYM
admet-337	557	25	ii	ii	PROPN
admet-337	557	26	startk-1	startk-1	NUM
admet-337	557	27	(	(	PUNCT
admet-337	557	28	nct02097810	nct02097810	NOUN
admet-337	557	29	)	)	PUNCT
admet-337	557	30	tsr-011	tsr-011	ADP
admet-337	558	1	[	[	X
admet-337	558	2	168	168	NUM
admet-337	558	3	]	]	PUNCT
admet-337	558	4	alk	alk	PROPN
admet-337	558	5	trka	trka	NOUN
admet-337	558	6	,	,	PUNCT
admet-337	558	7	trkb	trkb	NOUN
admet-337	558	8	,	,	PUNCT
admet-337	558	9	trkc	trkc	NOUN
admet-337	558	10	phase	phase	NOUN
admet-337	558	11	i	i	PRON
admet-337	558	12	/	/	SYM
admet-337	558	13	ii	ii	PROPN
admet-337	558	14	120	120	NUM
admet-337	558	15	mg	mg	NOUN
admet-337	558	16	:	:	PUNCT
admet-337	558	17	orr	orr	PROPN
admet-337	558	18	3	3	NUM
admet-337	558	19	of	of	ADP
admet-337	558	20	3	3	NUM
admet-337	558	21	pt	pt	NOUN
admet-337	558	22	<	<	NOUN
admet-337	558	23	120	120	NUM
admet-337	558	24	mg	mg	NUM
admet-337	558	25	:	:	PUNCT
admet-337	558	26	orr	orr	NOUN
admet-337	558	27	5	5	NUM
admet-337	558	28	of	of	ADP
admet-337	558	29	9	9	NUM
admet-337	558	30	pt	pt	NOUN
admet-337	558	31	ongoing	ongoing	ADJ
admet-337	558	32	phase	phase	NOUN
admet-337	558	33	i	i	PRON
admet-337	558	34	/	/	SYM
admet-337	558	35	ii	ii	PROPN
admet-337	558	36	(	(	PUNCT
admet-337	558	37	nct02048488	nct02048488	NOUN
admet-337	558	38	)	)	PUNCT
admet-337	558	39	entrectinib	entrectinib	NOUN
admet-337	558	40	(	(	PUNCT
admet-337	558	41	rxdx-101	rxdx-101	NOUN
admet-337	558	42	,	,	PUNCT
admet-337	558	43	nms	nms	PROPN
admet-337	558	44	-	-	PUNCT
admet-337	558	45	e628	e628	PROPN
admet-337	558	46	)	)	PUNCT
admet-337	558	47	and	and	CCONJ
admet-337	558	48	tsr-011	tsr-011	PRON
admet-337	558	49	are	be	AUX
admet-337	558	50	inhibitors	inhibitor	NOUN
admet-337	558	51	of	of	ADP
admet-337	558	52	alk	alk	NOUN
admet-337	558	53	as	as	ADV
admet-337	558	54	well	well	ADV
admet-337	558	55	as	as	ADP
admet-337	558	56	the	the	DET
admet-337	558	57	tropomysin	tropomysin	NOUN
admet-337	558	58	receptor	receptor	NOUN
admet-337	558	59	kinases	kinase	NOUN
admet-337	558	60	(	(	PUNCT
admet-337	558	61	trk	trk	PROPN
admet-337	558	62	)	)	PUNCT
admet-337	558	63	trka	trka	NOUN
admet-337	558	64	,	,	PUNCT
admet-337	558	65	trkb	trkb	NOUN
admet-337	558	66	and	and	CCONJ
admet-337	558	67	trkc	trkc	NOUN
admet-337	558	68	.	.	PUNCT
admet-337	559	1	recently	recently	ADV
admet-337	559	2	,	,	PUNCT
admet-337	559	3	gene	gene	NOUN
admet-337	559	4	fusions	fusion	NOUN
admet-337	559	5	between	between	ADP
admet-337	559	6	the	the	DET
admet-337	559	7	kinase	kinase	PROPN
admet-337	559	8	domain	domain	NOUN
admet-337	559	9	of	of	ADP
admet-337	559	10	the	the	DET
admet-337	559	11	ntrk1	ntrk1	NOUN
admet-337	559	12	gene	gene	NOUN
admet-337	559	13	and	and	CCONJ
admet-337	559	14	other	other	ADJ
admet-337	559	15	genes	gene	NOUN
admet-337	559	16	,	,	PUNCT
admet-337	559	17	including	include	VERB
admet-337	559	18	mprip	mprip	NOUN
admet-337	559	19	and	and	CCONJ
admet-337	559	20	cd74	cd74	PROPN
admet-337	559	21	have	have	AUX
admet-337	559	22	been	be	AUX
admet-337	559	23	discovered	discover	VERB
admet-337	559	24	in	in	ADP
admet-337	559	25	up	up	ADP
admet-337	559	26	to	to	PART
admet-337	559	27	3	3	NUM
admet-337	559	28	%	%	NOUN
admet-337	559	29	of	of	ADP
admet-337	559	30	lung	lung	NOUN
admet-337	559	31	cancer	cancer	NOUN
admet-337	559	32	patients	patient	NOUN
admet-337	559	33	,	,	PUNCT
admet-337	559	34	and	and	CCONJ
admet-337	559	35	appear	appear	VERB
admet-337	559	36	to	to	PART
admet-337	559	37	be	be	AUX
admet-337	559	38	independent	independent	ADJ
admet-337	559	39	of	of	ADP
admet-337	559	40	other	other	ADJ
admet-337	559	41	driver	driver	NOUN
admet-337	559	42	mutations	mutation	NOUN
admet-337	559	43	.	.	PUNCT
admet-337	560	1	these	these	DET
admet-337	560	2	fusions	fusion	NOUN
admet-337	560	3	create	create	VERB
admet-337	560	4	constitutively	constitutively	ADV
admet-337	560	5	active	active	ADJ
admet-337	560	6	trk	trk	NOUN
admet-337	560	7	proteins	protein	NOUN
admet-337	560	8	that	that	PRON
admet-337	560	9	drive	drive	VERB
admet-337	560	10	tumorigenesis	tumorigenesis	NOUN
admet-337	560	11	and	and	CCONJ
admet-337	560	12	serve	serve	VERB
admet-337	560	13	as	as	ADP
admet-337	560	14	targets	target	NOUN
admet-337	560	15	for	for	ADP
admet-337	560	16	trk	trk	NOUN
admet-337	560	17	inhibitors	inhibitor	NOUN
admet-337	560	18	[	[	X
admet-337	560	19	167	167	NUM
admet-337	560	20	]	]	PUNCT
admet-337	560	21	.	.	PUNCT
admet-337	561	1	a	a	DET
admet-337	561	2	phase	phase	NOUN
admet-337	561	3	i	i	NOUN
admet-337	561	4	/	/	SYM
admet-337	561	5	ii	ii	PROPN
admet-337	561	6	trial	trial	NOUN
admet-337	561	7	(	(	PUNCT
admet-337	561	8	nct02048488	nct02048488	NOUN
admet-337	561	9	)	)	PUNCT
admet-337	561	10	is	be	AUX
admet-337	561	11	ongoing	ongoing	ADJ
admet-337	561	12	for	for	ADP
admet-337	561	13	tsr-011	tsr-011	NUM
admet-337	561	14	,	,	PUNCT
admet-337	561	15	but	but	CCONJ
admet-337	561	16	preliminary	preliminary	ADJ
admet-337	561	17	results	result	NOUN
admet-337	561	18	in	in	ADP
admet-337	561	19	alk	alk	ADJ
admet-337	561	20	-	-	PUNCT
admet-337	561	21	positive	positive	ADJ
admet-337	561	22	patients	patient	NOUN
admet-337	561	23	showed	show	VERB
admet-337	561	24	3	3	NUM
admet-337	561	25	of	of	ADP
admet-337	561	26	3	3	NUM
admet-337	561	27	evaluable	evaluable	ADJ
admet-337	561	28	patients	patient	NOUN
admet-337	561	29	developed	develop	VERB
admet-337	561	30	a	a	DET
admet-337	561	31	response	response	NOUN
admet-337	561	32	at	at	ADP
admet-337	561	33	the	the	DET
admet-337	561	34	120	120	NUM
admet-337	561	35	mg	mg	NOUN
admet-337	561	36	or	or	CCONJ
admet-337	561	37	above	above	ADP
admet-337	561	38	daily	daily	PROPN
admet-337	561	39	dose	dose	NOUN
admet-337	561	40	and	and	CCONJ
admet-337	561	41	5	5	NUM
admet-337	561	42	of	of	ADP
admet-337	561	43	9	9	NUM
admet-337	561	44	patients	patient	NOUN
admet-337	561	45	achieved	achieve	VERB
admet-337	561	46	stable	stable	ADJ
admet-337	561	47	disease	disease	NOUN
admet-337	561	48	at	at	ADP
admet-337	561	49	lower	low	ADJ
admet-337	561	50	doses	dose	NOUN
admet-337	561	51	[	[	X
admet-337	561	52	168	168	NUM
admet-337	561	53	]	]	PUNCT
admet-337	561	54	.	.	PUNCT
admet-337	562	1	multiple	multiple	ADJ
admet-337	562	2	early	early	ADJ
admet-337	562	3	phase	phase	NOUN
admet-337	562	4	trials	trial	NOUN
admet-337	562	5	for	for	ADP
admet-337	562	6	entrectinib	entrectinib	NOUN
admet-337	562	7	are	be	AUX
admet-337	562	8	also	also	ADV
admet-337	562	9	in	in	ADP
admet-337	562	10	progress	progress	NOUN
admet-337	562	11	.	.	PUNCT
admet-337	563	1	preliminary	preliminary	ADJ
admet-337	563	2	data	datum	NOUN
admet-337	563	3	from	from	ADP
admet-337	563	4	the	the	DET
admet-337	563	5	phase	phase	NOUN
admet-337	563	6	i	i	PRON
admet-337	563	7	alka-372	alka-372	NOUN
admet-337	563	8	-	-	PUNCT
admet-337	563	9	001	001	NUM
admet-337	563	10	trial	trial	NOUN
admet-337	563	11	demonstrated	demonstrate	VERB
admet-337	563	12	a	a	DET
admet-337	563	13	partial	partial	ADJ
admet-337	563	14	response	response	NOUN
admet-337	563	15	in	in	ADP
admet-337	563	16	an	an	DET
admet-337	563	17	alk	alk	VERB
admet-337	563	18	-	-	PUNCT
admet-337	563	19	positive	positive	ADJ
admet-337	563	20	nsclc	nsclc	NOUN
admet-337	563	21	patient	patient	NOUN
admet-337	563	22	[	[	X
admet-337	563	23	169	169	NUM
admet-337	563	24	]	]	PUNCT
admet-337	563	25	.	.	PUNCT
admet-337	564	1	another	another	DET
admet-337	564	2	phase	phase	NOUN
admet-337	564	3	i	i	PRON
admet-337	564	4	/	/	SYM
admet-337	564	5	ii	ii	PROPN
admet-337	564	6	trial	trial	NOUN
admet-337	564	7	examining	examine	VERB
admet-337	564	8	the	the	DET
admet-337	564	9	safety	safety	NOUN
admet-337	564	10	and	and	CCONJ
admet-337	564	11	efficacy	efficacy	NOUN
admet-337	564	12	of	of	ADP
admet-337	564	13	entrectinib	entrectinib	NOUN
admet-337	564	14	for	for	ADP
admet-337	564	15	advanced	advanced	ADJ
admet-337	564	16	malignancies	malignancy	NOUN
admet-337	564	17	positive	positive	ADJ
admet-337	564	18	for	for	ADP
admet-337	564	19	ntrk1	ntrk1	PROPN
admet-337	564	20	,	,	PUNCT
admet-337	564	21	ntrk2	ntrk2	PROPN
admet-337	564	22	,	,	PUNCT
admet-337	564	23	ntrk3	ntrk3	PROPN
admet-337	564	24	,	,	PUNCT
admet-337	564	25	ros1	ros1	PROPN
admet-337	564	26	or	or	CCONJ
admet-337	564	27	alk	alk	NOUN
admet-337	564	28	is	be	AUX
admet-337	564	29	underway	underway	ADJ
admet-337	564	30	(	(	PUNCT
admet-337	564	31	startk-1	startk-1	NOUN
admet-337	564	32	,	,	PUNCT
admet-337	564	33	nct02097810	nct02097810	NOUN
admet-337	564	34	)	)	PUNCT
admet-337	564	35	.	.	PUNCT
admet-337	565	1	immunotherapy	immunotherapy	NOUN
admet-337	565	2	and	and	CCONJ
admet-337	565	3	the	the	DET
admet-337	565	4	future	future	NOUN
admet-337	565	5	of	of	ADP
admet-337	565	6	egfr	egfr	NOUN
admet-337	565	7	and	and	CCONJ
admet-337	565	8	alk	alk	VERB
admet-337	565	9	tkis	tkis	ADP
admet-337	565	10	the	the	DET
admet-337	565	11	therapeutic	therapeutic	ADJ
admet-337	565	12	landscape	landscape	NOUN
admet-337	565	13	for	for	ADP
admet-337	565	14	nsclc	nsclc	NOUN
admet-337	565	15	has	have	AUX
admet-337	565	16	recently	recently	ADV
admet-337	565	17	expanded	expand	VERB
admet-337	565	18	with	with	ADP
admet-337	565	19	the	the	DET
admet-337	565	20	introduction	introduction	NOUN
admet-337	565	21	of	of	ADP
admet-337	565	22	immunotherapeutic	immunotherapeutic	ADJ
admet-337	565	23	agents	agent	NOUN
admet-337	565	24	,	,	PUNCT
admet-337	565	25	including	include	VERB
admet-337	565	26	the	the	DET
admet-337	565	27	programmed	program	VERB
admet-337	565	28	cell	cell	NOUN
admet-337	565	29	death	death	NOUN
admet-337	565	30	protein	protein	NOUN
admet-337	565	31	(	(	PUNCT
admet-337	565	32	pd-1	pd-1	NOUN
admet-337	565	33	)	)	PUNCT
admet-337	565	34	inhibitors	inhibitor	NOUN
admet-337	565	35	nivolumab	nivolumab	ADV
admet-337	565	36	and	and	CCONJ
admet-337	565	37	pembrolizumab	pembrolizumab	NOUN
admet-337	565	38	.	.	PUNCT
admet-337	566	1	these	these	DET
admet-337	566	2	drugs	drug	NOUN
admet-337	566	3	are	be	AUX
admet-337	566	4	now	now	ADV
admet-337	566	5	commonly	commonly	ADV
admet-337	566	6	used	use	VERB
admet-337	566	7	for	for	ADP
admet-337	566	8	second	second	ADJ
admet-337	566	9	-	-	PUNCT
admet-337	566	10	line	line	NOUN
admet-337	566	11	treatment	treatment	NOUN
admet-337	566	12	of	of	ADP
admet-337	566	13	advanced	advanced	ADJ
admet-337	566	14	nsclc	nsclc	NOUN
admet-337	566	15	,	,	PUNCT
admet-337	566	16	as	as	SCONJ
admet-337	566	17	they	they	PRON
admet-337	566	18	both	both	PRON
admet-337	566	19	prolong	prolong	VERB
admet-337	566	20	overall	overall	ADJ
admet-337	566	21	survival	survival	NOUN
admet-337	566	22	compared	compare	VERB
admet-337	566	23	to	to	ADP
admet-337	566	24	standard	standard	ADJ
admet-337	566	25	second	second	ADJ
admet-337	566	26	-	-	PUNCT
admet-337	566	27	line	line	NOUN
admet-337	566	28	chemotherapy	chemotherapy	NOUN
admet-337	567	1	[	[	X
admet-337	567	2	171	171	NUM
admet-337	567	3	-	-	SYM
admet-337	567	4	173	173	NUM
admet-337	567	5	]	]	PUNCT
admet-337	567	6	.	.	PUNCT
admet-337	568	1	nivolumab	nivolumab	NOUN
admet-337	568	2	also	also	ADV
admet-337	568	3	appears	appear	VERB
admet-337	568	4	to	to	PART
admet-337	568	5	have	have	VERB
admet-337	568	6	activity	activity	NOUN
admet-337	568	7	in	in	ADP
admet-337	568	8	first	first	ADJ
admet-337	568	9	-	-	PUNCT
admet-337	568	10	line	line	NOUN
admet-337	568	11	treatment	treatment	NOUN
admet-337	568	12	of	of	ADP
admet-337	568	13	advanced	advanced	ADJ
admet-337	568	14	nsclc	nsclc	NOUN
admet-337	568	15	[	[	X
admet-337	568	16	174,175	174,175	NUM
admet-337	568	17	]	]	PUNCT
admet-337	568	18	.	.	PUNCT
admet-337	569	1	clinical	clinical	ADJ
admet-337	569	2	trials	trial	NOUN
admet-337	569	3	assessing	assess	VERB
admet-337	569	4	neoadjuvant	neoadjuvant	ADJ
admet-337	569	5	and	and	CCONJ
admet-337	569	6	adjuvant	adjuvant	ADJ
admet-337	569	7	uses	use	NOUN
admet-337	569	8	of	of	ADP
admet-337	569	9	immune	immune	ADJ
admet-337	569	10	checkpoint	checkpoint	NOUN
admet-337	569	11	inhibitors	inhibitor	NOUN
admet-337	569	12	are	be	AUX
admet-337	569	13	currently	currently	ADV
admet-337	569	14	in	in	ADP
admet-337	569	15	progress	progress	NOUN
admet-337	569	16	(	(	PUNCT
admet-337	569	17	nct02595944	nct02595944	ADJ
admet-337	569	18	,	,	PUNCT
admet-337	569	19	nct02504372	nct02504372	ADJ
admet-337	569	20	,	,	PUNCT
admet-337	569	21	nct02818920	nct02818920	NOUN
admet-337	569	22	,	,	PUNCT
admet-337	569	23	nct02486718	nct02486718	ADV
admet-337	569	24	,	,	PUNCT
admet-337	569	25	nct02273375	nct02273375	ADJ
admet-337	569	26	,	,	PUNCT
admet-337	569	27	nct02572843	nct02572843	NOUN
admet-337	569	28	)	)	PUNCT
admet-337	569	29	.	.	PUNCT
admet-337	570	1	the	the	DET
admet-337	570	2	future	future	NOUN
admet-337	570	3	of	of	ADP
admet-337	570	4	nsclc	nsclc	NOUN
admet-337	570	5	will	will	AUX
admet-337	570	6	be	be	AUX
admet-337	570	7	closely	closely	ADV
admet-337	570	8	tied	tie	VERB
admet-337	570	9	to	to	ADP
admet-337	570	10	immunotherapy	immunotherapy	NOUN
admet-337	570	11	,	,	PUNCT
admet-337	570	12	and	and	CCONJ
admet-337	570	13	the	the	DET
admet-337	570	14	roles	role	NOUN
admet-337	570	15	of	of	ADP
admet-337	570	16	egfr	egfr	NOUN
admet-337	570	17	and	and	CCONJ
admet-337	570	18	alk	alk	VERB
admet-337	570	19	tkis	tkis	NOUN
admet-337	570	20	could	could	AUX
admet-337	570	21	be	be	AUX
admet-337	570	22	called	call	VERB
admet-337	570	23	into	into	ADP
admet-337	570	24	question	question	NOUN
admet-337	570	25	.	.	PUNCT
admet-337	571	1	however	however	ADV
admet-337	571	2	,	,	PUNCT
admet-337	571	3	currently	currently	ADV
admet-337	571	4	,	,	PUNCT
admet-337	571	5	the	the	DET
admet-337	571	6	efficacy	efficacy	NOUN
admet-337	571	7	of	of	ADP
admet-337	571	8	immunotherapy	immunotherapy	NOUN
admet-337	571	9	for	for	ADP
admet-337	571	10	the	the	DET
admet-337	571	11	treatment	treatment	NOUN
admet-337	571	12	of	of	ADP
admet-337	571	13	egfrand	egfrand	ADJ
admet-337	571	14	alk	alk	PROPN
admet-337	571	15	-	-	PUNCT
admet-337	571	16	mutated	mutate	VERB
admet-337	571	17	nsclc	nsclc	NOUN
admet-337	571	18	is	be	AUX
admet-337	571	19	unclear	unclear	ADJ
admet-337	571	20	.	.	PUNCT
admet-337	572	1	grace	grace	NOUN
admet-337	572	2	dy	dy	NOUN
admet-337	572	3	et	et	PROPN
admet-337	572	4	al	al	PROPN
admet-337	572	5	.	.	PROPN
admet-337	572	6	admet	admet	PROPN
admet-337	572	7	&	&	CCONJ
admet-337	572	8	dmpk	dmpk	PROPN
admet-337	572	9	4(3	4(3	NUM
admet-337	572	10	)	)	PUNCT
admet-337	572	11	(	(	PUNCT
admet-337	572	12	2016	2016	NUM
admet-337	572	13	)	)	PUNCT
admet-337	572	14	186	186	NUM
admet-337	572	15	-	-	SYM
admet-337	572	16	211	211	NUM
admet-337	572	17	206	206	NUM
admet-337	572	18	subgroup	subgroup	NOUN
admet-337	572	19	analyses	analysis	NOUN
admet-337	572	20	from	from	ADP
admet-337	572	21	check	check	NOUN
admet-337	572	22	mate	mate	NOUN
admet-337	572	23	057	057	NUM
admet-337	572	24	and	and	CCONJ
admet-337	572	25	keynote-010	keynote-010	PROPN
admet-337	572	26	suggest	suggest	VERB
admet-337	572	27	patients	patient	NOUN
admet-337	572	28	with	with	ADP
admet-337	572	29	egfr	egfr	ADJ
admet-337	572	30	mutations	mutation	NOUN
admet-337	572	31	may	may	AUX
admet-337	572	32	not	not	PART
admet-337	572	33	benefit	benefit	VERB
admet-337	572	34	as	as	ADV
admet-337	572	35	much	much	ADV
admet-337	572	36	from	from	ADP
admet-337	572	37	nivolumab	nivolumab	NOUN
admet-337	572	38	and	and	CCONJ
admet-337	572	39	pembrolizumab	pembrolizumab	NOUN
admet-337	572	40	as	as	ADP
admet-337	572	41	wild	wild	ADJ
admet-337	572	42	-	-	PUNCT
admet-337	572	43	type	type	NOUN
admet-337	572	44	egfr	egfr	ADJ
admet-337	572	45	patients	patient	NOUN
admet-337	572	46	.	.	PUNCT
admet-337	573	1	the	the	DET
admet-337	573	2	data	datum	NOUN
admet-337	573	3	should	should	AUX
admet-337	573	4	be	be	AUX
admet-337	573	5	interpreted	interpret	VERB
admet-337	573	6	with	with	ADP
admet-337	573	7	caution	caution	NOUN
admet-337	573	8	as	as	SCONJ
admet-337	573	9	the	the	DET
admet-337	573	10	subgroups	subgroup	NOUN
admet-337	573	11	were	be	AUX
admet-337	573	12	small	small	ADJ
admet-337	573	13	and	and	CCONJ
admet-337	573	14	the	the	DET
admet-337	573	15	confidence	confidence	NOUN
admet-337	573	16	intervals	interval	NOUN
admet-337	573	17	on	on	ADP
admet-337	573	18	the	the	DET
admet-337	573	19	hazard	hazard	NOUN
admet-337	573	20	ratios	ratio	NOUN
admet-337	573	21	were	be	AUX
admet-337	573	22	wide	wide	ADJ
admet-337	573	23	[	[	X
admet-337	573	24	171,173	171,173	NUM
admet-337	573	25	]	]	PUNCT
admet-337	573	26	.	.	PUNCT
admet-337	574	1	the	the	DET
admet-337	574	2	mutational	mutational	ADJ
admet-337	574	3	burden	burden	NOUN
admet-337	574	4	and	and	CCONJ
admet-337	574	5	neoantigen	neoantigen	NOUN
admet-337	574	6	expression	expression	NOUN
admet-337	574	7	of	of	ADP
admet-337	574	8	tumors	tumor	NOUN
admet-337	574	9	appear	appear	VERB
admet-337	574	10	to	to	PART
admet-337	574	11	be	be	AUX
admet-337	574	12	correlated	correlate	VERB
admet-337	574	13	to	to	PART
admet-337	574	14	response	response	VERB
admet-337	574	15	to	to	ADP
admet-337	574	16	immune	immune	ADJ
admet-337	574	17	checkpoint	checkpoint	NOUN
admet-337	574	18	blockade	blockade	NOUN
admet-337	574	19	,	,	PUNCT
admet-337	574	20	which	which	PRON
admet-337	574	21	can	can	AUX
admet-337	574	22	be	be	AUX
admet-337	574	23	driven	drive	VERB
admet-337	574	24	by	by	ADP
admet-337	574	25	tobacco	tobacco	NOUN
admet-337	574	26	exposure	exposure	NOUN
admet-337	574	27	[	[	X
admet-337	574	28	176,177	176,177	NUM
admet-337	574	29	]	]	PUNCT
admet-337	574	30	.	.	PUNCT
admet-337	575	1	egfr	egfr	PROPN
admet-337	575	2	and	and	CCONJ
admet-337	575	3	alk	alk	PROPN
admet-337	575	4	-	-	PUNCT
admet-337	575	5	mutated	mutate	VERB
admet-337	575	6	nsclcs	nsclcs	NOUN
admet-337	575	7	are	be	AUX
admet-337	575	8	associated	associate	VERB
admet-337	575	9	with	with	ADP
admet-337	575	10	low	low	ADJ
admet-337	575	11	tobacco	tobacco	NOUN
admet-337	575	12	exposure	exposure	NOUN
admet-337	575	13	,	,	PUNCT
admet-337	575	14	and	and	CCONJ
admet-337	575	15	these	these	DET
admet-337	575	16	tumors	tumor	NOUN
admet-337	575	17	can	can	AUX
admet-337	575	18	have	have	VERB
admet-337	575	19	lower	low	ADJ
admet-337	575	20	mutational	mutational	ADJ
admet-337	575	21	loads	load	NOUN
admet-337	575	22	,	,	PUNCT
admet-337	575	23	which	which	PRON
admet-337	575	24	may	may	AUX
admet-337	575	25	partially	partially	ADV
admet-337	575	26	explain	explain	VERB
admet-337	575	27	lower	low	ADJ
admet-337	575	28	response	response	NOUN
admet-337	575	29	to	to	ADP
admet-337	575	30	immune	immune	ADJ
admet-337	575	31	checkpoint	checkpoint	NOUN
admet-337	575	32	blockade	blockade	NOUN
admet-337	575	33	.	.	PUNCT
admet-337	576	1	however	however	ADV
admet-337	576	2	,	,	PUNCT
admet-337	576	3	multiple	multiple	ADJ
admet-337	576	4	studies	study	NOUN
admet-337	576	5	have	have	AUX
admet-337	576	6	demonstrated	demonstrate	VERB
admet-337	576	7	that	that	SCONJ
admet-337	576	8	both	both	CCONJ
admet-337	576	9	egfr	egfr	NOUN
admet-337	576	10	and	and	CCONJ
admet-337	576	11	alk	alk	VERB
admet-337	576	12	activation	activation	NOUN
admet-337	576	13	can	can	AUX
admet-337	576	14	increase	increase	VERB
admet-337	576	15	expression	expression	NOUN
admet-337	576	16	of	of	ADP
admet-337	576	17	pd	pd	PROPN
admet-337	576	18	-	-	PROPN
admet-337	576	19	l1	l1	PROPN
admet-337	576	20	[	[	X
admet-337	576	21	178	178	NUM
admet-337	576	22	-	-	SYM
admet-337	576	23	181	181	NUM
admet-337	576	24	]	]	PUNCT
admet-337	576	25	.	.	PUNCT
admet-337	577	1	combination	combination	NOUN
admet-337	577	2	therapy	therapy	NOUN
admet-337	577	3	with	with	ADP
admet-337	577	4	immune	immune	ADJ
admet-337	577	5	checkpoint	checkpoint	NOUN
admet-337	577	6	blockade	blockade	NOUN
admet-337	577	7	and	and	CCONJ
admet-337	577	8	egfr	egfr	ADJ
admet-337	577	9	tki	tki	PROPN
admet-337	577	10	is	be	AUX
admet-337	577	11	under	under	ADP
admet-337	577	12	investigation	investigation	NOUN
admet-337	577	13	.	.	PUNCT
admet-337	578	1	in	in	ADP
admet-337	578	2	the	the	DET
admet-337	578	3	multi	multi	ADJ
admet-337	578	4	-	-	ADJ
admet-337	578	5	arm	arm	ADJ
admet-337	578	6	phase	phase	NOUN
admet-337	578	7	ib	ib	PROPN
admet-337	578	8	tatton	tatton	PROPN
admet-337	578	9	trial	trial	PROPN
admet-337	578	10	,	,	PUNCT
admet-337	578	11	34	34	NUM
admet-337	578	12	patients	patient	NOUN
admet-337	578	13	received	receive	VERB
admet-337	578	14	a	a	DET
admet-337	578	15	combination	combination	NOUN
admet-337	578	16	of	of	ADP
admet-337	578	17	the	the	DET
admet-337	578	18	anti	anti	ADJ
admet-337	578	19	-	-	ADJ
admet-337	578	20	pd	pd	ADJ
admet-337	578	21	-	-	PUNCT
admet-337	578	22	l1	l1	PROPN
admet-337	578	23	monoclonal	monoclonal	NOUN
admet-337	578	24	antibody	antibody	NOUN
admet-337	578	25	durvalumab	durvalumab	NOUN
admet-337	578	26	and	and	CCONJ
admet-337	578	27	osimertinib	osimertinib	NOUN
admet-337	578	28	.	.	PUNCT
admet-337	579	1	at	at	ADP
admet-337	579	2	the	the	DET
admet-337	579	3	time	time	NOUN
admet-337	579	4	of	of	ADP
admet-337	579	5	the	the	DET
admet-337	579	6	study	study	NOUN
admet-337	579	7	presentation	presentation	NOUN
admet-337	579	8	at	at	ADP
admet-337	579	9	the	the	DET
admet-337	579	10	2016	2016	NUM
admet-337	579	11	european	european	ADJ
admet-337	579	12	lung	lung	PROPN
admet-337	579	13	cancer	cancer	NOUN
admet-337	579	14	conference	conference	NOUN
admet-337	579	15	(	(	PUNCT
admet-337	579	16	elcc	elcc	PROPN
admet-337	579	17	)	)	PUNCT
admet-337	579	18	,	,	PUNCT
admet-337	579	19	31	31	NUM
admet-337	579	20	patients	patient	NOUN
admet-337	579	21	were	be	AUX
admet-337	579	22	evaluable	evaluable	ADJ
admet-337	579	23	for	for	ADP
admet-337	579	24	response	response	NOUN
admet-337	579	25	.	.	PUNCT
admet-337	580	1	the	the	DET
admet-337	580	2	combination	combination	NOUN
admet-337	580	3	had	have	VERB
admet-337	580	4	promising	promising	ADJ
admet-337	580	5	activity	activity	NOUN
admet-337	580	6	,	,	PUNCT
admet-337	580	7	with	with	SCONJ
admet-337	580	8	partial	partial	ADJ
admet-337	580	9	response	response	NOUN
admet-337	580	10	witnessed	witness	VERB
admet-337	580	11	in	in	ADP
admet-337	580	12	64.5	64.5	NUM
admet-337	580	13	%	%	NOUN
admet-337	580	14	of	of	ADP
admet-337	580	15	patients	patient	NOUN
admet-337	580	16	,	,	PUNCT
admet-337	580	17	however	however	ADV
admet-337	580	18	,	,	PUNCT
admet-337	580	19	grade	grade	NOUN
admet-337	580	20	3/4	3/4	NUM
admet-337	580	21	interstitial	interstitial	ADJ
admet-337	580	22	lung	lung	NOUN
admet-337	580	23	disease	disease	NOUN
admet-337	580	24	was	be	AUX
admet-337	580	25	reported	report	VERB
admet-337	580	26	in	in	ADP
admet-337	580	27	14.7	14.7	NUM
admet-337	580	28	%	%	NOUN
admet-337	580	29	of	of	ADP
admet-337	580	30	patients	patient	NOUN
admet-337	580	31	[	[	X
admet-337	580	32	182	182	NUM
admet-337	580	33	]	]	PUNCT
admet-337	580	34	.	.	PUNCT
admet-337	581	1	much	much	ADJ
admet-337	581	2	is	be	AUX
admet-337	581	3	to	to	PART
admet-337	581	4	be	be	AUX
admet-337	581	5	learned	learn	VERB
admet-337	581	6	about	about	ADP
admet-337	581	7	immunotherapy	immunotherapy	NOUN
admet-337	581	8	and	and	CCONJ
admet-337	581	9	alkand	alkand	NOUN
admet-337	581	10	egfrmutated	egfrmutate	VERB
admet-337	581	11	lung	lung	NOUN
admet-337	581	12	cancer	cancer	NOUN
admet-337	581	13	,	,	PUNCT
admet-337	581	14	therefore	therefore	ADV
admet-337	581	15	,	,	PUNCT
admet-337	581	16	tkis	tkis	PROPN
admet-337	581	17	will	will	AUX
admet-337	581	18	continue	continue	VERB
admet-337	581	19	to	to	PART
admet-337	581	20	represent	represent	VERB
admet-337	581	21	the	the	DET
admet-337	581	22	core	core	ADJ
admet-337	581	23	treatment	treatment	NOUN
admet-337	581	24	of	of	ADP
admet-337	581	25	egfrand	egfrand	ADJ
admet-337	581	26	alkmutated	alkmutate	VERB
admet-337	581	27	nsclc	nsclc	NOUN
admet-337	581	28	for	for	ADP
admet-337	581	29	the	the	DET
admet-337	581	30	foreseeable	foreseeable	ADJ
admet-337	581	31	future	future	NOUN
admet-337	581	32	.	.	PUNCT
admet-337	582	1	conclusion	conclusion	NOUN
admet-337	582	2	discovery	discovery	NOUN
admet-337	582	3	of	of	ADP
admet-337	582	4	the	the	DET
admet-337	582	5	egfr	egfr	NOUN
admet-337	582	6	and	and	CCONJ
admet-337	582	7	alk	alk	VERB
admet-337	582	8	activating	activate	VERB
admet-337	582	9	mutations	mutation	NOUN
admet-337	582	10	and	and	CCONJ
admet-337	582	11	their	their	PRON
admet-337	582	12	respective	respective	ADJ
admet-337	582	13	tkis	tkis	NOUN
admet-337	582	14	have	have	AUX
admet-337	582	15	substantially	substantially	ADV
admet-337	582	16	improved	improve	VERB
admet-337	582	17	outcomes	outcome	NOUN
admet-337	582	18	for	for	ADP
admet-337	582	19	a	a	DET
admet-337	582	20	select	select	ADJ
admet-337	582	21	group	group	NOUN
admet-337	582	22	of	of	ADP
admet-337	582	23	nsclc	nsclc	NOUN
admet-337	582	24	patients	patient	NOUN
admet-337	582	25	.	.	PUNCT
admet-337	583	1	despite	despite	SCONJ
admet-337	583	2	these	these	DET
admet-337	583	3	advances	advance	NOUN
admet-337	583	4	,	,	PUNCT
admet-337	583	5	challenges	challenge	NOUN
admet-337	583	6	remain	remain	VERB
admet-337	583	7	for	for	ADP
admet-337	583	8	these	these	DET
admet-337	583	9	patients	patient	NOUN
admet-337	583	10	.	.	PUNCT
admet-337	584	1	immunotherapy	immunotherapy	NOUN
admet-337	584	2	,	,	PUNCT
admet-337	584	3	which	which	PRON
admet-337	584	4	has	have	AUX
admet-337	584	5	recently	recently	ADV
admet-337	584	6	advanced	advance	VERB
admet-337	584	7	the	the	DET
admet-337	584	8	treatment	treatment	NOUN
admet-337	584	9	of	of	ADP
admet-337	584	10	nsclc	nsclc	NOUN
admet-337	584	11	,	,	PUNCT
admet-337	584	12	does	do	AUX
admet-337	584	13	not	not	PART
admet-337	584	14	appear	appear	VERB
admet-337	584	15	to	to	PART
admet-337	584	16	be	be	AUX
admet-337	584	17	as	as	ADV
admet-337	584	18	active	active	ADJ
admet-337	584	19	in	in	ADP
admet-337	584	20	alk	alk	PROPN
admet-337	584	21	and	and	CCONJ
admet-337	584	22	egfr	egfr	ADJ
admet-337	584	23	mutated	mutate	VERB
admet-337	584	24	patients	patient	NOUN
admet-337	584	25	.	.	PUNCT
admet-337	585	1	acquired	acquire	VERB
admet-337	585	2	mutations	mutation	NOUN
admet-337	585	3	universally	universally	ADV
admet-337	585	4	lead	lead	VERB
admet-337	585	5	to	to	ADP
admet-337	585	6	drug	drug	NOUN
admet-337	585	7	resistance	resistance	NOUN
admet-337	585	8	to	to	PART
admet-337	585	9	alk	alk	VERB
admet-337	585	10	and	and	CCONJ
admet-337	585	11	egfr	egfr	ADJ
admet-337	585	12	tkis	tkis	PROPN
admet-337	585	13	,	,	PUNCT
admet-337	585	14	resulting	result	VERB
admet-337	585	15	in	in	ADP
admet-337	585	16	disease	disease	NOUN
admet-337	585	17	progression	progression	NOUN
admet-337	585	18	and	and	CCONJ
admet-337	585	19	death	death	NOUN
admet-337	585	20	.	.	PUNCT
admet-337	586	1	with	with	ADP
admet-337	586	2	improvement	improvement	NOUN
admet-337	586	3	in	in	ADP
admet-337	586	4	tumor	tumor	NOUN
admet-337	586	5	genome	genome	NOUN
admet-337	586	6	sequencing	sequence	VERB
admet-337	586	7	technology	technology	NOUN
admet-337	586	8	,	,	PUNCT
admet-337	586	9	novel	novel	ADJ
admet-337	586	10	resistance	resistance	NOUN
admet-337	586	11	mutations	mutation	NOUN
admet-337	586	12	will	will	AUX
admet-337	586	13	continue	continue	VERB
admet-337	586	14	to	to	PART
admet-337	586	15	be	be	AUX
admet-337	586	16	identified	identify	VERB
admet-337	586	17	.	.	PUNCT
admet-337	587	1	inevitably	inevitably	ADV
admet-337	587	2	,	,	PUNCT
admet-337	587	3	new	new	ADJ
admet-337	587	4	tkis	tkis	NOUN
admet-337	587	5	will	will	AUX
admet-337	587	6	be	be	AUX
admet-337	587	7	developed	develop	VERB
admet-337	587	8	that	that	PRON
admet-337	587	9	will	will	AUX
admet-337	587	10	target	target	VERB
admet-337	587	11	the	the	DET
admet-337	587	12	most	most	ADV
admet-337	587	13	commonly	commonly	ADV
admet-337	587	14	encountered	encounter	VERB
admet-337	587	15	resistance	resistance	NOUN
admet-337	587	16	mutations	mutation	NOUN
admet-337	587	17	as	as	ADV
admet-337	587	18	well	well	ADV
admet-337	587	19	as	as	ADP
admet-337	587	20	disease	disease	NOUN
admet-337	587	21	relapse	relapse	NOUN
admet-337	587	22	in	in	ADP
admet-337	587	23	cns	cns	PROPN
admet-337	587	24	,	,	PUNCT
admet-337	587	25	and	and	CCONJ
admet-337	587	26	indeed	indeed	ADV
admet-337	587	27	,	,	PUNCT
admet-337	587	28	many	many	ADJ
admet-337	587	29	egfr	egfr	NOUN
admet-337	587	30	and	and	CCONJ
admet-337	587	31	alk	alk	VERB
admet-337	587	32	tkis	tkis	PROPN
admet-337	587	33	are	be	AUX
admet-337	587	34	currently	currently	ADV
admet-337	587	35	in	in	ADP
admet-337	587	36	development	development	NOUN
admet-337	587	37	addressing	address	VERB
admet-337	587	38	these	these	DET
admet-337	587	39	twin	twin	ADJ
admet-337	587	40	issues	issue	NOUN
admet-337	587	41	.	.	PUNCT
admet-337	588	1	however	however	ADV
admet-337	588	2	,	,	PUNCT
admet-337	588	3	innovative	innovative	ADJ
admet-337	588	4	treatment	treatment	NOUN
admet-337	588	5	approaches	approach	NOUN
admet-337	588	6	are	be	AUX
admet-337	588	7	necessary	necessary	ADJ
admet-337	588	8	to	to	PART
admet-337	588	9	continue	continue	VERB
admet-337	588	10	to	to	PART
admet-337	588	11	improve	improve	VERB
admet-337	588	12	survival	survival	NOUN
admet-337	588	13	.	.	PUNCT
admet-337	589	1	combination	combination	NOUN
admet-337	589	2	therapies	therapy	NOUN
admet-337	589	3	with	with	ADP
admet-337	589	4	tkis	tkis	NOUN
admet-337	589	5	and	and	CCONJ
admet-337	589	6	novel	novel	ADJ
admet-337	589	7	agents	agent	NOUN
admet-337	589	8	,	,	PUNCT
admet-337	589	9	including	include	VERB
admet-337	589	10	immunotherapy	immunotherapy	NOUN
admet-337	589	11	,	,	PUNCT
admet-337	589	12	may	may	AUX
admet-337	589	13	be	be	AUX
admet-337	589	14	needed	need	VERB
admet-337	589	15	to	to	PART
admet-337	589	16	overcome	overcome	VERB
admet-337	589	17	the	the	DET
admet-337	589	18	multiple	multiple	ADJ
admet-337	589	19	molecular	molecular	ADJ
admet-337	589	20	pathways	pathway	NOUN
admet-337	589	21	that	that	PRON
admet-337	589	22	ultimately	ultimately	ADV
admet-337	589	23	drive	drive	VERB
admet-337	589	24	carcinogenesis	carcinogenesis	NOUN
admet-337	589	25	.	.	PUNCT
admet-337	590	1	references	reference	NOUN
admet-337	590	2	[	[	X
admet-337	590	3	1	1	NUM
admet-337	590	4	]	]	PUNCT
admet-337	590	5	s.	s.	PROPN
admet-337	590	6	mcguire	mcguire	PROPN
admet-337	590	7	,	,	PUNCT
admet-337	590	8	world	world	NOUN
admet-337	590	9	cancer	cancer	NOUN
admet-337	590	10	report	report	NOUN
admet-337	590	11	2014	2014	NUM
admet-337	590	12	.	.	PUNCT
admet-337	591	1	geneva	geneva	PROPN
admet-337	591	2	,	,	PUNCT
admet-337	591	3	switzerland	switzerland	PROPN
admet-337	591	4	:	:	PUNCT
admet-337	591	5	world	world	PROPN
admet-337	591	6	health	health	PROPN
admet-337	591	7	organization	organization	PROPN
admet-337	591	8	,	,	PUNCT
admet-337	591	9	international	international	ADJ
admet-337	591	10	agency	agency	NOUN
admet-337	591	11	for	for	ADP
admet-337	591	12	research	research	NOUN
admet-337	591	13	on	on	ADP
admet-337	591	14	cancer	cancer	NOUN
admet-337	591	15	,	,	PUNCT
admet-337	591	16	who	who	PRON
admet-337	591	17	press	press	VERB
admet-337	591	18	,	,	PUNCT
admet-337	591	19	2015	2015	NUM
admet-337	591	20	.	.	PUNCT
admet-337	592	1	adv	adv	PROPN
admet-337	592	2	.	.	PUNCT
admet-337	593	1	nutr	nutr	PROPN
admet-337	593	2	.	.	PROPN
admet-337	593	3	7	7	NUM
admet-337	593	4	(	(	PUNCT
admet-337	593	5	2016	2016	NUM
admet-337	593	6	)	)	PUNCT
admet-337	593	7	418	418	NUM
admet-337	593	8	-	-	SYM
admet-337	593	9	419	419	NUM
admet-337	593	10	.	.	PUNCT
admet-337	594	1	[	[	X
admet-337	594	2	2	2	NUM
admet-337	594	3	]	]	X
admet-337	594	4	r.l	r.l	PROPN
admet-337	594	5	.	.	PROPN
admet-337	594	6	siegel	siegel	PROPN
admet-337	594	7	,	,	PUNCT
admet-337	594	8	k.d	k.d	PROPN
admet-337	594	9	.	.	PROPN
admet-337	594	10	miller	miller	PROPN
admet-337	594	11	,	,	PUNCT
admet-337	594	12	a.	a.	PROPN
admet-337	594	13	jemal	jemal	PROPN
admet-337	594	14	,	,	PUNCT
admet-337	594	15	ca	ca	NOUN
admet-337	594	16	cancer	cancer	NOUN
admet-337	594	17	.	.	PUNCT
admet-337	595	1	j.	j.	PROPN
admet-337	595	2	clin	clin	PROPN
admet-337	595	3	.	.	PUNCT
admet-337	596	1	66	66	NUM
admet-337	596	2	(	(	PUNCT
admet-337	596	3	2016	2016	NUM
admet-337	596	4	)	)	PUNCT
admet-337	596	5	7	7	NUM
admet-337	596	6	-	-	SYM
admet-337	596	7	30	30	NUM
admet-337	596	8	.	.	PUNCT
admet-337	597	1	[	[	X
admet-337	597	2	3	3	X
admet-337	597	3	]	]	PUNCT
admet-337	597	4	k.	k.	NOUN
admet-337	597	5	chansky	chansky	PROPN
admet-337	597	6	,	,	PUNCT
admet-337	597	7	j.p	j.p	PROPN
admet-337	597	8	.	.	PROPN
admet-337	597	9	sculier	sculier	PROPN
admet-337	597	10	,	,	PUNCT
admet-337	597	11	j.j	j.j	PROPN
admet-337	597	12	.	.	PROPN
admet-337	597	13	crowley	crowley	PROPN
admet-337	597	14	,	,	PUNCT
admet-337	597	15	et	et	PROPN
admet-337	597	16	al	al	PROPN
admet-337	597	17	.	.	PUNCT
admet-337	598	1	j.	j.	PROPN
admet-337	598	2	thorac	thorac	PROPN
admet-337	598	3	.	.	PUNCT
admet-337	599	1	oncol	oncol	ADJ
admet-337	599	2	.	.	PUNCT
admet-337	600	1	4	4	NUM
admet-337	600	2	(	(	PUNCT
admet-337	600	3	2009	2009	NUM
admet-337	600	4	)	)	PUNCT
admet-337	600	5	792	792	NUM
admet-337	600	6	-	-	SYM
admet-337	600	7	801	801	NUM
admet-337	600	8	.	.	PUNCT
admet-337	601	1	[	[	X
admet-337	601	2	4	4	NUM
admet-337	601	3	]	]	X
admet-337	601	4	j.g	j.g	PROPN
admet-337	601	5	.	.	PROPN
admet-337	601	6	paez	paez	PROPN
admet-337	601	7	,	,	PUNCT
admet-337	601	8	p.a	p.a	PROPN
admet-337	601	9	.	.	PROPN
admet-337	601	10	janne	janne	PROPN
admet-337	601	11	,	,	PUNCT
admet-337	601	12	j.c	j.c	PROPN
admet-337	601	13	.	.	PROPN
admet-337	601	14	lee	lee	PROPN
admet-337	601	15	,	,	PUNCT
admet-337	601	16	et	et	PROPN
admet-337	601	17	al	al	PROPN
admet-337	601	18	.	.	PROPN
admet-337	601	19	science	science	PROPN
admet-337	601	20	304	304	NUM
admet-337	601	21	(	(	PUNCT
admet-337	601	22	2004	2004	NUM
admet-337	601	23	)	)	PUNCT
admet-337	601	24	1497	1497	NUM
admet-337	601	25	-	-	SYM
admet-337	601	26	1500	1500	NUM
admet-337	601	27	.	.	PUNCT
admet-337	602	1	[	[	X
admet-337	602	2	5	5	X
admet-337	602	3	]	]	X
admet-337	602	4	j.y	j.y	PROPN
admet-337	602	5	.	.	PROPN
admet-337	602	6	douillard	douillard	PROPN
admet-337	602	7	,	,	PUNCT
admet-337	602	8	g.	g.	PROPN
admet-337	602	9	ostoros	ostoros	PROPN
admet-337	602	10	,	,	PUNCT
admet-337	602	11	m.	m.	PROPN
admet-337	602	12	cobo	cobo	PROPN
admet-337	602	13	,	,	PUNCT
admet-337	602	14	et	et	PROPN
admet-337	602	15	al	al	PROPN
admet-337	602	16	.	.	PROPN
admet-337	603	1	br	br	PROPN
admet-337	603	2	.	.	PUNCT
admet-337	604	1	j.	j.	PROPN
admet-337	604	2	cancer	cancer	PROPN
admet-337	604	3	.	.	PUNCT
admet-337	605	1	110	110	NUM
admet-337	605	2	(	(	PUNCT
admet-337	605	3	2014	2014	NUM
admet-337	605	4	)	)	PUNCT
admet-337	605	5	55	55	NUM
admet-337	605	6	-	-	SYM
admet-337	605	7	62	62	NUM
admet-337	605	8	.	.	PUNCT
admet-337	606	1	[	[	X
admet-337	606	2	6	6	NUM
admet-337	606	3	]	]	PUNCT
admet-337	606	4	m.	m.	NOUN
admet-337	606	5	soda	soda	NOUN
admet-337	606	6	,	,	PUNCT
admet-337	606	7	y.l	y.l	PROPN
admet-337	606	8	.	.	PROPN
admet-337	606	9	choi	choi	PROPN
admet-337	606	10	,	,	PUNCT
admet-337	606	11	m.	m.	NOUN
admet-337	606	12	enomoto	enomoto	NOUN
admet-337	606	13	,	,	PUNCT
admet-337	606	14	et	et	PROPN
admet-337	606	15	al	al	PROPN
admet-337	606	16	.	.	PUNCT
admet-337	606	17	nature	nature	NOUN
admet-337	606	18	448	448	NUM
admet-337	606	19	(	(	PUNCT
admet-337	606	20	2007	2007	NUM
admet-337	606	21	)	)	PUNCT
admet-337	606	22	561	561	NUM
admet-337	606	23	-	-	SYM
admet-337	606	24	566	566	NUM
admet-337	606	25	.	.	PUNCT
admet-337	607	1	[	[	X
admet-337	607	2	7	7	X
admet-337	607	3	]	]	PUNCT
admet-337	607	4	k.	k.	PROPN
admet-337	607	5	cetin	cetin	PROPN
admet-337	607	6	,	,	PUNCT
admet-337	607	7	d.s	d.s	PROPN
admet-337	607	8	.	.	PROPN
admet-337	607	9	ettinger	ettinger	PROPN
admet-337	607	10	,	,	PUNCT
admet-337	607	11	y.j	y.j	PROPN
admet-337	607	12	.	.	PROPN
admet-337	607	13	hei	hei	PROPN
admet-337	607	14	,	,	PUNCT
admet-337	607	15	c.d	c.d	PROPN
admet-337	607	16	.	.	PROPN
admet-337	607	17	o'malley	o'malley	PROPN
admet-337	607	18	,	,	PUNCT
admet-337	607	19	clin	clin	PROPN
admet-337	607	20	.	.	PUNCT
admet-337	608	1	epidemiol	epidemiol	PROPN
admet-337	608	2	.	.	PROPN
admet-337	609	1	3	3	NUM
admet-337	609	2	(	(	PUNCT
admet-337	609	3	2011	2011	NUM
admet-337	609	4	)	)	PUNCT
admet-337	609	5	139	139	NUM
admet-337	609	6	-	-	SYM
admet-337	609	7	148	148	NUM
admet-337	609	8	.	.	PUNCT
admet-337	610	1	[	[	X
admet-337	610	2	8	8	NUM
admet-337	610	3	]	]	X
admet-337	610	4	g.v	g.v	PROPN
admet-337	610	5	.	.	PROPN
admet-337	610	6	scagliotti	scagliotti	PROPN
admet-337	610	7	,	,	PUNCT
admet-337	610	8	p.	p.	PROPN
admet-337	610	9	parikh	parikh	PROPN
admet-337	610	10	,	,	PUNCT
admet-337	610	11	j.	j.	PROPN
admet-337	610	12	von	von	PROPN
admet-337	610	13	pawel	pawel	PROPN
admet-337	610	14	,	,	PUNCT
admet-337	610	15	et	et	PROPN
admet-337	610	16	al	al	PROPN
admet-337	610	17	.	.	PUNCT
admet-337	611	1	j.	j.	PROPN
admet-337	611	2	clin	clin	PROPN
admet-337	611	3	.	.	PUNCT
admet-337	612	1	oncol	oncol	ADJ
admet-337	612	2	.	.	PUNCT
admet-337	613	1	26	26	NUM
admet-337	613	2	(	(	PUNCT
admet-337	613	3	2008	2008	NUM
admet-337	613	4	)	)	PUNCT
admet-337	613	5	3543	3543	NUM
admet-337	613	6	-	-	SYM
admet-337	613	7	3551	3551	NUM
admet-337	613	8	.	.	PUNCT
admet-337	614	1	[	[	X
admet-337	614	2	9	9	NUM
admet-337	614	3	]	]	SYM
admet-337	614	4	j.d	j.d	PROPN
admet-337	614	5	.	.	PROPN
admet-337	614	6	patel	patel	PROPN
admet-337	614	7	,	,	PUNCT
admet-337	614	8	m.a	m.a	PROPN
admet-337	614	9	.	.	PROPN
admet-337	614	10	socinski	socinski	PROPN
admet-337	614	11	,	,	PUNCT
admet-337	614	12	e.b	e.b	PROPN
admet-337	614	13	.	.	PUNCT
admet-337	614	14	garon	garon	PROPN
admet-337	614	15	,	,	PUNCT
admet-337	614	16	et	et	PROPN
admet-337	614	17	al	al	PROPN
admet-337	614	18	.	.	PUNCT
admet-337	615	1	j.	j.	PROPN
admet-337	615	2	clin	clin	PROPN
admet-337	615	3	.	.	PUNCT
admet-337	616	1	oncol	oncol	ADJ
admet-337	616	2	.	.	PUNCT
admet-337	617	1	31	31	NUM
admet-337	617	2	(	(	PUNCT
admet-337	617	3	2013	2013	NUM
admet-337	617	4	)	)	PUNCT
admet-337	617	5	4349	4349	NUM
admet-337	617	6	-	-	SYM
admet-337	617	7	4357	4357	NUM
admet-337	617	8	.	.	PUNCT
admet-337	618	1	[	[	X
admet-337	618	2	10	10	NUM
admet-337	618	3	]	]	X
admet-337	618	4	n.	n.	NOUN
admet-337	618	5	thatcher	thatcher	PROPN
admet-337	618	6	,	,	PUNCT
admet-337	618	7	f.r	f.r	PROPN
admet-337	618	8	.	.	PROPN
admet-337	618	9	hirsch	hirsch	PROPN
admet-337	618	10	,	,	PUNCT
admet-337	618	11	a.v	a.v	PROPN
admet-337	618	12	.	.	PROPN
admet-337	618	13	luft	luft	PROPN
admet-337	618	14	,	,	PUNCT
admet-337	618	15	et	et	PROPN
admet-337	618	16	al	al	PROPN
admet-337	618	17	.	.	PUNCT
admet-337	619	1	lancet	lancet	PROPN
admet-337	619	2	oncol	oncol	PROPN
admet-337	619	3	.	.	PUNCT
admet-337	620	1	16	16	NUM
admet-337	620	2	(	(	PUNCT
admet-337	620	3	2015	2015	NUM
admet-337	620	4	)	)	PUNCT
admet-337	620	5	763	763	NUM
admet-337	620	6	-	-	SYM
admet-337	620	7	774	774	NUM
admet-337	620	8	.	.	PUNCT
admet-337	621	1	[	[	X
admet-337	621	2	11	11	NUM
admet-337	621	3	]	]	X
admet-337	621	4	y.l	y.l	PROPN
admet-337	621	5	.	.	PROPN
admet-337	621	6	wu	wu	PROPN
admet-337	621	7	,	,	PUNCT
admet-337	621	8	c.	c.	PROPN
admet-337	621	9	zhou	zhou	PROPN
admet-337	621	10	,	,	PUNCT
admet-337	621	11	c.k	c.k	PROPN
admet-337	621	12	.	.	PROPN
admet-337	621	13	liam	liam	PROPN
admet-337	621	14	,	,	PUNCT
admet-337	621	15	et	et	PROPN
admet-337	621	16	al	al	PROPN
admet-337	621	17	.	.	PUNCT
admet-337	621	18	ann	ann	PROPN
admet-337	621	19	.	.	PUNCT
admet-337	622	1	oncol	oncol	PROPN
admet-337	622	2	.	.	PUNCT
admet-337	623	1	26	26	NUM
admet-337	623	2	(	(	PUNCT
admet-337	623	3	2015	2015	NUM
admet-337	623	4	)	)	PUNCT
admet-337	623	5	1883	1883	NUM
admet-337	623	6	-	-	SYM
admet-337	623	7	1889	1889	NUM
admet-337	623	8	.	.	PUNCT
admet-337	624	1	[	[	X
admet-337	624	2	12	12	NUM
admet-337	624	3	]	]	X
admet-337	624	4	p.a	p.a	PROPN
admet-337	624	5	.	.	PUNCT
admet-337	624	6	janne	janne	PROPN
admet-337	624	7	,	,	PUNCT
admet-337	624	8	j.c	j.c	PROPN
admet-337	624	9	.	.	PROPN
admet-337	624	10	yang	yang	PROPN
admet-337	624	11	,	,	PUNCT
admet-337	624	12	d.w	d.w	PROPN
admet-337	624	13	.	.	PUNCT
admet-337	625	1	kim	kim	PROPN
admet-337	625	2	,	,	PUNCT
admet-337	625	3	et	et	PROPN
admet-337	625	4	al	al	PROPN
admet-337	625	5	.	.	PUNCT
admet-337	625	6	n.	n.	PROPN
admet-337	625	7	engl	engl	PROPN
admet-337	625	8	.	.	PUNCT
admet-337	626	1	j.	j.	PROPN
admet-337	626	2	med	med	PROPN
admet-337	626	3	.	.	PUNCT
admet-337	627	1	372	372	NUM
admet-337	627	2	(	(	PUNCT
admet-337	627	3	2015	2015	NUM
admet-337	627	4	)	)	PUNCT
admet-337	627	5	1689	1689	NUM
admet-337	627	6	-	-	SYM
admet-337	627	7	1699	1699	NUM
admet-337	627	8	.	.	PUNCT
admet-337	628	1	admet	admet	PROPN
admet-337	628	2	&	&	CCONJ
admet-337	628	3	dmpk	dmpk	PROPN
admet-337	628	4	4(3	4(3	NUM
admet-337	628	5	)	)	PUNCT
admet-337	628	6	(	(	PUNCT
admet-337	628	7	2016	2016	NUM
admet-337	628	8	)	)	PUNCT
admet-337	628	9	186	186	NUM
admet-337	628	10	-	-	SYM
admet-337	628	11	211	211	NUM
admet-337	628	12	tki	tki	NOUN
admet-337	628	13	for	for	ADP
admet-337	628	14	egfrand	egfrand	ADJ
admet-337	628	15	alk	alk	PROPN
admet-337	628	16	-	-	PUNCT
admet-337	628	17	mutated	mutate	VERB
admet-337	628	18	cell	cell	NOUN
admet-337	628	19	cancer	cancer	NOUN
admet-337	628	20	doi	doi	NOUN
admet-337	628	21	:	:	PUNCT
admet-337	628	22	10.5599	10.5599	NUM
admet-337	628	23	/	/	SYM
admet-337	628	24	admet.4.3.337	admet.4.3.337	NUM
admet-337	628	25	207	207	NUM
admet-337	628	26	[	[	SYM
admet-337	628	27	13	13	NUM
admet-337	628	28	]	]	X
admet-337	628	29	l.v	l.v	PROPN
admet-337	628	30	.	.	PROPN
admet-337	628	31	sequist	sequist	PROPN
admet-337	628	32	,	,	PUNCT
admet-337	628	33	j.c	j.c	PROPN
admet-337	628	34	.	.	PROPN
admet-337	628	35	soria	soria	PROPN
admet-337	628	36	,	,	PUNCT
admet-337	628	37	j.w	j.w	PROPN
admet-337	628	38	.	.	PROPN
admet-337	628	39	goldman	goldman	PROPN
admet-337	628	40	,	,	PUNCT
admet-337	628	41	et	et	PROPN
admet-337	628	42	al	al	PROPN
admet-337	628	43	.	.	PUNCT
admet-337	628	44	n.	n.	PROPN
admet-337	628	45	engl	engl	PROPN
admet-337	628	46	.	.	PUNCT
admet-337	629	1	j.	j.	PROPN
admet-337	629	2	med	med	PROPN
admet-337	629	3	.	.	PUNCT
admet-337	630	1	2015;372:1700	2015;372:1700	NUM
admet-337	630	2	-	-	SYM
admet-337	630	3	1709	1709	NUM
admet-337	630	4	.	.	PUNCT
admet-337	631	1	[	[	X
admet-337	631	2	14	14	NUM
admet-337	631	3	]	]	X
admet-337	631	4	a.t	a.t	PROPN
admet-337	631	5	.	.	PROPN
admet-337	631	6	shaw	shaw	PROPN
admet-337	631	7	,	,	PUNCT
admet-337	631	8	d.w	d.w	PROPN
admet-337	631	9	.	.	PUNCT
admet-337	632	1	kim	kim	PROPN
admet-337	632	2	,	,	PUNCT
admet-337	632	3	r.	r.	PROPN
admet-337	632	4	mehra	mehra	PROPN
admet-337	632	5	,	,	PUNCT
admet-337	632	6	et	et	PROPN
admet-337	632	7	al	al	PROPN
admet-337	632	8	.	.	PUNCT
admet-337	632	9	n.	n.	PROPN
admet-337	632	10	engl	engl	PROPN
admet-337	632	11	.	.	PUNCT
admet-337	633	1	j.	j.	PROPN
admet-337	633	2	med	med	PROPN
admet-337	633	3	.	.	PUNCT
admet-337	634	1	370	370	NUM
admet-337	634	2	(	(	PUNCT
admet-337	634	3	2014	2014	NUM
admet-337	634	4	)	)	PUNCT
admet-337	634	5	1189	1189	NUM
admet-337	634	6	-	-	SYM
admet-337	634	7	1197	1197	NUM
admet-337	634	8	.	.	PUNCT
admet-337	635	1	[	[	X
admet-337	635	2	15	15	NUM
admet-337	635	3	]	]	X
admet-337	635	4	j.f	j.f	PROPN
admet-337	635	5	.	.	PROPN
admet-337	635	6	gainor	gainor	PROPN
admet-337	635	7	,	,	PUNCT
admet-337	635	8	d.s	d.s	PROPN
admet-337	635	9	.	.	PROPN
admet-337	635	10	tan	tan	PROPN
admet-337	635	11	,	,	PUNCT
admet-337	635	12	t.	t.	PROPN
admet-337	635	13	de	de	PROPN
admet-337	635	14	pas	pas	PROPN
admet-337	635	15	,	,	PUNCT
admet-337	635	16	et	et	PROPN
admet-337	635	17	al	al	PROPN
admet-337	635	18	.	.	PUNCT
admet-337	635	19	clin	clin	PROPN
admet-337	635	20	.	.	PUNCT
admet-337	636	1	cancer	cancer	NOUN
admet-337	636	2	res	re	NOUN
admet-337	636	3	.	.	PROPN
admet-337	637	1	21	21	NUM
admet-337	637	2	(	(	PUNCT
admet-337	637	3	2015	2015	NUM
admet-337	637	4	)	)	PUNCT
admet-337	637	5	2745	2745	NUM
admet-337	637	6	-	-	SYM
admet-337	637	7	2752	2752	NUM
admet-337	637	8	.	.	PUNCT
admet-337	638	1	[	[	X
admet-337	638	2	16	16	NUM
admet-337	638	3	]	]	PUNCT
admet-337	638	4	s.	s.	PROPN
admet-337	638	5	cohen	cohen	PROPN
admet-337	638	6	,	,	PUNCT
admet-337	638	7	dev	dev	PROPN
admet-337	638	8	.	.	PUNCT
admet-337	638	9	biol	biol	PROPN
admet-337	638	10	.	.	PUNCT
admet-337	639	1	12	12	NUM
admet-337	639	2	(	(	PUNCT
admet-337	639	3	1965	1965	NUM
admet-337	639	4	)	)	PUNCT
admet-337	639	5	394	394	NUM
admet-337	639	6	-	-	SYM
admet-337	639	7	407	407	NUM
admet-337	639	8	.	.	PUNCT
admet-337	640	1	[	[	X
admet-337	640	2	17	17	NUM
admet-337	640	3	]	]	PUNCT
admet-337	640	4	j.	j.	PROPN
admet-337	640	5	mendelsohn	mendelsohn	PROPN
admet-337	640	6	,	,	PUNCT
admet-337	640	7	j.	j.	PROPN
admet-337	640	8	baselga	baselga	PROPN
admet-337	640	9	,	,	PUNCT
admet-337	640	10	oncogene	oncogene	NOUN
admet-337	640	11	19	19	NUM
admet-337	640	12	(	(	PUNCT
admet-337	640	13	2000	2000	NUM
admet-337	640	14	)	)	PUNCT
admet-337	640	15	6550	6550	NUM
admet-337	640	16	-	-	SYM
admet-337	640	17	6565	6565	NUM
admet-337	640	18	.	.	PUNCT
admet-337	641	1	[	[	X
admet-337	641	2	18	18	NUM
admet-337	641	3	]	]	X
admet-337	641	4	j.	j.	PROPN
admet-337	641	5	downward	downward	PROPN
admet-337	641	6	,	,	PUNCT
admet-337	641	7	p.	p.	PROPN
admet-337	641	8	parker	parker	PROPN
admet-337	641	9	,	,	PUNCT
admet-337	641	10	m.d	m.d	PROPN
admet-337	641	11	.	.	PROPN
admet-337	641	12	waterfield	waterfield	PROPN
admet-337	641	13	,	,	PUNCT
admet-337	641	14	nature	nature	NOUN
admet-337	641	15	311	311	NUM
admet-337	641	16	(	(	PUNCT
admet-337	641	17	1984	1984	NUM
admet-337	641	18	)	)	PUNCT
admet-337	641	19	483	483	NUM
admet-337	641	20	-	-	SYM
admet-337	641	21	485	485	NUM
admet-337	641	22	.	.	PUNCT
admet-337	642	1	[	[	X
admet-337	642	2	19	19	NUM
admet-337	642	3	]	]	PUNCT
admet-337	642	4	m.	m.	NOUN
admet-337	642	5	scaltriti	scaltriti	PROPN
admet-337	642	6	,	,	PUNCT
admet-337	642	7	j.	j.	PROPN
admet-337	642	8	baselga	baselga	PROPN
admet-337	642	9	,	,	PUNCT
admet-337	642	10	clin	clin	PROPN
admet-337	642	11	.	.	PUNCT
admet-337	643	1	cancer	cancer	NOUN
admet-337	643	2	res	re	NOUN
admet-337	643	3	.	.	PROPN
admet-337	644	1	12	12	NUM
admet-337	644	2	(	(	PUNCT
admet-337	644	3	2006	2006	NUM
admet-337	644	4	)	)	PUNCT
admet-337	644	5	5268	5268	NUM
admet-337	644	6	-	-	SYM
admet-337	644	7	5272	5272	NUM
admet-337	644	8	.	.	PUNCT
admet-337	645	1	[	[	X
admet-337	645	2	20	20	NUM
admet-337	645	3	]	]	X
admet-337	645	4	t.j	t.j	PROPN
admet-337	645	5	.	.	PROPN
admet-337	645	6	lynch	lynch	PROPN
admet-337	645	7	,	,	PUNCT
admet-337	645	8	d.w	d.w	PROPN
admet-337	645	9	.	.	PROPN
admet-337	645	10	bell	bell	PROPN
admet-337	645	11	,	,	PUNCT
admet-337	645	12	r.	r.	PROPN
admet-337	645	13	sordella	sordella	PROPN
admet-337	645	14	,	,	PUNCT
admet-337	645	15	et	et	PROPN
admet-337	645	16	al	al	PROPN
admet-337	645	17	.	.	PUNCT
admet-337	645	18	n.	n.	PROPN
admet-337	645	19	engl	engl	PROPN
admet-337	645	20	.	.	PUNCT
admet-337	646	1	j.	j.	PROPN
admet-337	646	2	med	med	PROPN
admet-337	646	3	.	.	PUNCT
admet-337	647	1	350	350	NUM
admet-337	647	2	(	(	PUNCT
admet-337	647	3	2004	2004	NUM
admet-337	647	4	)	)	PUNCT
admet-337	647	5	2129	2129	NUM
admet-337	647	6	-	-	SYM
admet-337	647	7	2139	2139	NUM
admet-337	647	8	.	.	PUNCT
admet-337	648	1	[	[	X
admet-337	648	2	21	21	NUM
admet-337	648	3	]	]	X
admet-337	648	4	w.	w.	PROPN
admet-337	648	5	pao	pao	PROPN
admet-337	648	6	,	,	PUNCT
admet-337	648	7	v.	v.	PROPN
admet-337	648	8	miller	miller	PROPN
admet-337	648	9	,	,	PUNCT
admet-337	648	10	m.	m.	NOUN
admet-337	648	11	zakowski	zakowski	PROPN
admet-337	648	12	,	,	PUNCT
admet-337	648	13	et	et	PROPN
admet-337	648	14	al	al	PROPN
admet-337	648	15	.	.	PROPN
admet-337	648	16	proc	proc	PROPN
admet-337	648	17	.	.	PUNCT
admet-337	649	1	natl	natl	PROPN
admet-337	649	2	.	.	PUNCT
admet-337	650	1	acad	acad	PROPN
admet-337	650	2	.	.	PUNCT
admet-337	651	1	sci	sci	PROPN
admet-337	651	2	.	.	PUNCT
admet-337	651	3	u.s.a	u.s.a	PROPN
admet-337	651	4	.	.	PUNCT
admet-337	652	1	101	101	NUM
admet-337	652	2	(	(	PUNCT
admet-337	652	3	2004	2004	NUM
admet-337	652	4	)	)	PUNCT
admet-337	652	5	13306	13306	NUM
admet-337	652	6	-	-	SYM
admet-337	652	7	13311	13311	NUM
admet-337	652	8	.	.	PUNCT
admet-337	653	1	[	[	X
admet-337	653	2	22	22	NUM
admet-337	653	3	]	]	X
admet-337	653	4	s.v	s.v	PROPN
admet-337	653	5	.	.	PROPN
admet-337	653	6	sharma	sharma	PROPN
admet-337	653	7	,	,	PUNCT
admet-337	653	8	d.w	d.w	PROPN
admet-337	653	9	.	.	PROPN
admet-337	653	10	bell	bell	PROPN
admet-337	653	11	,	,	PUNCT
admet-337	653	12	j.	j.	PROPN
admet-337	653	13	settleman	settleman	PROPN
admet-337	653	14	,	,	PUNCT
admet-337	653	15	d.a	d.a	PROPN
admet-337	653	16	.	.	PROPN
admet-337	653	17	haber	haber	PROPN
admet-337	653	18	,	,	PUNCT
admet-337	653	19	nat	nat	PROPN
admet-337	653	20	.	.	PUNCT
admet-337	653	21	rev	rev	PROPN
admet-337	653	22	.	.	PUNCT
admet-337	653	23	cancer	cancer	NOUN
admet-337	653	24	.	.	PUNCT
admet-337	654	1	7	7	NUM
admet-337	654	2	(	(	PUNCT
admet-337	654	3	2007	2007	NUM
admet-337	654	4	)	)	PUNCT
admet-337	654	5	169	169	NUM
admet-337	654	6	-	-	SYM
admet-337	654	7	181	181	NUM
admet-337	654	8	.	.	PUNCT
admet-337	655	1	[	[	X
admet-337	655	2	23	23	NUM
admet-337	655	3	]	]	PUNCT
admet-337	655	4	t.	t.	PROPN
admet-337	655	5	hirano	hirano	PROPN
admet-337	655	6	,	,	PUNCT
admet-337	655	7	h.	h.	PROPN
admet-337	655	8	yasuda	yasuda	PROPN
admet-337	655	9	,	,	PUNCT
admet-337	655	10	t.	t.	PROPN
admet-337	655	11	tani	tani	PROPN
admet-337	655	12	,	,	PUNCT
admet-337	655	13	et	et	PROPN
admet-337	655	14	al	al	PROPN
admet-337	655	15	.	.	PROPN
admet-337	655	16	oncotarget	oncotarget	PROPN
admet-337	655	17	.	.	PUNCT
admet-337	656	1	6	6	NUM
admet-337	656	2	(	(	PUNCT
admet-337	656	3	2015	2015	NUM
admet-337	656	4	)	)	PUNCT
admet-337	656	5	38789	38789	NUM
admet-337	656	6	-	-	SYM
admet-337	656	7	38803	38803	NUM
admet-337	656	8	.	.	PUNCT
admet-337	657	1	[	[	X
admet-337	657	2	24	24	NUM
admet-337	657	3	]	]	SYM
admet-337	657	4	d.b	d.b	PROPN
admet-337	657	5	.	.	PROPN
admet-337	657	6	costa	costa	PROPN
admet-337	657	7	,	,	PUNCT
admet-337	657	8	s.t	s.t	PROPN
admet-337	657	9	.	.	PROPN
admet-337	657	10	schumer	schumer	PROPN
admet-337	657	11	,	,	PUNCT
admet-337	657	12	d.g	d.g	PROPN
admet-337	657	13	.	.	PROPN
admet-337	657	14	tenen	tenen	PROPN
admet-337	657	15	,	,	PUNCT
admet-337	657	16	s.	s.	PROPN
admet-337	657	17	kobayashi	kobayashi	PROPN
admet-337	657	18	,	,	PUNCT
admet-337	657	19	j.	j.	PROPN
admet-337	657	20	clin	clin	PROPN
admet-337	657	21	.	.	PUNCT
admet-337	658	1	oncol	oncol	ADJ
admet-337	658	2	.	.	PUNCT
admet-337	659	1	26	26	NUM
admet-337	659	2	(	(	PUNCT
admet-337	659	3	2008	2008	NUM
admet-337	659	4	)	)	PUNCT
admet-337	659	5	1182	1182	NUM
admet-337	659	6	-	-	SYM
admet-337	659	7	4	4	NUM
admet-337	660	1	;	;	PUNCT
admet-337	660	2	author	author	NOUN
admet-337	660	3	reply	reply	VERB
admet-337	660	4	1184	1184	NUM
admet-337	660	5	-	-	SYM
admet-337	660	6	6	6	NUM
admet-337	660	7	.	.	PUNCT
admet-337	661	1	[	[	X
admet-337	661	2	25	25	NUM
admet-337	661	3	]	]	X
admet-337	661	4	f.a	f.a	PROPN
admet-337	661	5	.	.	PROPN
admet-337	661	6	shepherd	shepherd	PROPN
admet-337	661	7	,	,	PUNCT
admet-337	661	8	j.	j.	PROPN
admet-337	661	9	rodrigues	rodrigues	PROPN
admet-337	661	10	pereira	pereira	PROPN
admet-337	661	11	,	,	PUNCT
admet-337	661	12	t.	t.	PROPN
admet-337	661	13	ciuleanu	ciuleanu	PROPN
admet-337	661	14	,	,	PUNCT
admet-337	661	15	et	et	PROPN
admet-337	661	16	al	al	PROPN
admet-337	661	17	.	.	PUNCT
admet-337	661	18	n.	n.	PROPN
admet-337	661	19	engl	engl	PROPN
admet-337	661	20	.	.	PUNCT
admet-337	662	1	j.	j.	PROPN
admet-337	662	2	med	med	PROPN
admet-337	662	3	.	.	PUNCT
admet-337	663	1	353	353	NUM
admet-337	663	2	(	(	PUNCT
admet-337	663	3	2005	2005	NUM
admet-337	663	4	)	)	PUNCT
admet-337	663	5	123	123	NUM
admet-337	663	6	-	-	SYM
admet-337	663	7	132	132	NUM
admet-337	663	8	.	.	PUNCT
admet-337	664	1	[	[	X
admet-337	664	2	26	26	NUM
admet-337	664	3	]	]	X
admet-337	664	4	f.	f.	PROPN
admet-337	664	5	cappuzzo	cappuzzo	PROPN
admet-337	664	6	,	,	PUNCT
admet-337	664	7	t.	t.	NOUN
admet-337	664	8	ciuleanu	ciuleanu	PROPN
admet-337	664	9	,	,	PUNCT
admet-337	664	10	l.	l.	PROPN
admet-337	664	11	stelmakh	stelmakh	PROPN
admet-337	664	12	,	,	PUNCT
admet-337	664	13	et	et	PROPN
admet-337	664	14	al	al	PROPN
admet-337	664	15	.	.	PUNCT
admet-337	665	1	lancet	lancet	PROPN
admet-337	665	2	oncol	oncol	PROPN
admet-337	665	3	.	.	PUNCT
admet-337	666	1	11	11	NUM
admet-337	666	2	(	(	PUNCT
admet-337	666	3	2010	2010	NUM
admet-337	666	4	)	)	PUNCT
admet-337	666	5	521	521	NUM
admet-337	666	6	-	-	SYM
admet-337	666	7	529	529	NUM
admet-337	666	8	.	.	PUNCT
admet-337	667	1	[	[	X
admet-337	667	2	27	27	NUM
admet-337	667	3	]	]	X
admet-337	667	4	r.	r.	PROPN
admet-337	667	5	rosell	rosell	PROPN
admet-337	667	6	,	,	PUNCT
admet-337	667	7	e.	e.	PROPN
admet-337	667	8	carcereny	carcereny	PROPN
admet-337	667	9	,	,	PUNCT
admet-337	667	10	r.	r.	PROPN
admet-337	667	11	gervais	gervais	PROPN
admet-337	667	12	,	,	PUNCT
admet-337	667	13	et	et	PROPN
admet-337	667	14	al	al	PROPN
admet-337	667	15	.	.	PUNCT
admet-337	668	1	lancet	lancet	PROPN
admet-337	668	2	oncol	oncol	PROPN
admet-337	668	3	.	.	PUNCT
admet-337	669	1	13	13	NUM
admet-337	669	2	(	(	PUNCT
admet-337	669	3	2012	2012	NUM
admet-337	669	4	)	)	PUNCT
admet-337	669	5	239	239	NUM
admet-337	669	6	-	-	SYM
admet-337	669	7	246	246	NUM
admet-337	669	8	.	.	PUNCT
admet-337	670	1	[	[	X
admet-337	670	2	28	28	NUM
admet-337	670	3	]	]	X
admet-337	670	4	c.	c.	PROPN
admet-337	670	5	zhou	zhou	PROPN
admet-337	670	6	,	,	PUNCT
admet-337	670	7	y.l	y.l	PROPN
admet-337	670	8	.	.	PROPN
admet-337	670	9	wu	wu	PROPN
admet-337	670	10	,	,	PUNCT
admet-337	670	11	g.	g.	PROPN
admet-337	670	12	chen	chen	PROPN
admet-337	670	13	,	,	PUNCT
admet-337	670	14	et	et	PROPN
admet-337	670	15	al	al	PROPN
admet-337	670	16	.	.	PUNCT
admet-337	671	1	lancet	lancet	PROPN
admet-337	671	2	oncol	oncol	PROPN
admet-337	671	3	.	.	PUNCT
admet-337	672	1	12	12	NUM
admet-337	672	2	(	(	PUNCT
admet-337	672	3	2011	2011	NUM
admet-337	672	4	)	)	PUNCT
admet-337	672	5	735	735	NUM
admet-337	672	6	-	-	SYM
admet-337	672	7	742	742	NUM
admet-337	672	8	.	.	PUNCT
admet-337	673	1	[	[	X
admet-337	673	2	29	29	NUM
admet-337	673	3	]	]	X
admet-337	673	4	y.l	y.l	PROPN
admet-337	673	5	.	.	PROPN
admet-337	673	6	wu	wu	PROPN
admet-337	673	7	,	,	PUNCT
admet-337	673	8	c.	c.	PROPN
admet-337	673	9	zhou	zhou	PROPN
admet-337	673	10	,	,	PUNCT
admet-337	673	11	c.k	c.k	PROPN
admet-337	673	12	.	.	PROPN
admet-337	673	13	liam	liam	PROPN
admet-337	673	14	,	,	PUNCT
admet-337	673	15	et	et	PROPN
admet-337	673	16	al	al	PROPN
admet-337	673	17	.	.	PUNCT
admet-337	673	18	ann	ann	PROPN
admet-337	673	19	.	.	PUNCT
admet-337	674	1	oncol	oncol	PROPN
admet-337	674	2	.	.	PUNCT
admet-337	675	1	26	26	NUM
admet-337	675	2	(	(	PUNCT
admet-337	675	3	2015	2015	NUM
admet-337	675	4	)	)	PUNCT
admet-337	675	5	1883	1883	NUM
admet-337	675	6	-	-	SYM
admet-337	675	7	1889	1889	NUM
admet-337	675	8	.	.	PUNCT
admet-337	676	1	[	[	X
admet-337	676	2	30	30	NUM
admet-337	676	3	]	]	X
admet-337	676	4	n.m	n.m	PROPN
admet-337	676	5	.	.	PROPN
admet-337	676	6	de	de	X
admet-337	676	7	noronha	noronha	NOUN
admet-337	676	8	e	e	NOUN
admet-337	676	9	menezes	menezes	PROPN
admet-337	676	10	,	,	PUNCT
admet-337	676	11	r.	r.	PROPN
admet-337	676	12	lima	lima	PROPN
admet-337	676	13	,	,	PUNCT
admet-337	676	14	a.	a.	PROPN
admet-337	676	15	moreira	moreira	PROPN
admet-337	676	16	,	,	PUNCT
admet-337	676	17	et	et	PROPN
admet-337	676	18	al	al	PROPN
admet-337	676	19	.	.	PROPN
admet-337	676	20	eur	eur	PROPN
admet-337	676	21	.	.	PUNCT
admet-337	677	1	j.	j.	PROPN
admet-337	677	2	dermatol	dermatol	PROPN
admet-337	677	3	.	.	PUNCT
admet-337	678	1	19	19	NUM
admet-337	678	2	(	(	PUNCT
admet-337	678	3	2009	2009	NUM
admet-337	678	4	)	)	PUNCT
admet-337	678	5	248	248	NUM
admet-337	678	6	-	-	SYM
admet-337	678	7	251	251	NUM
admet-337	678	8	.	.	PUNCT
admet-337	679	1	[	[	X
admet-337	679	2	31	31	NUM
admet-337	679	3	]	]	X
admet-337	679	4	k.d	k.d	PROPN
admet-337	679	5	.	.	PROPN
admet-337	679	6	carey	carey	PROPN
admet-337	679	7	,	,	PUNCT
admet-337	679	8	a.j	a.j	PROPN
admet-337	679	9	.	.	PROPN
admet-337	679	10	garton	garton	PROPN
admet-337	679	11	,	,	PUNCT
admet-337	679	12	m.s	m.s	PROPN
admet-337	679	13	.	.	PROPN
admet-337	679	14	romero	romero	PROPN
admet-337	679	15	,	,	PUNCT
admet-337	679	16	et	et	PROPN
admet-337	679	17	al	al	PROPN
admet-337	679	18	.	.	PUNCT
admet-337	679	19	cancer	cancer	NOUN
admet-337	679	20	res	re	NOUN
admet-337	679	21	.	.	PUNCT
admet-337	680	1	66	66	NUM
admet-337	680	2	(	(	PUNCT
admet-337	680	3	2006	2006	NUM
admet-337	680	4	)	)	PUNCT
admet-337	680	5	8163	8163	NUM
admet-337	680	6	-	-	SYM
admet-337	680	7	8171	8171	NUM
admet-337	680	8	.	.	PUNCT
admet-337	681	1	[	[	X
admet-337	681	2	32	32	NUM
admet-337	681	3	]	]	PUNCT
admet-337	681	4	n.	n.	PROPN
admet-337	681	5	yamamoto	yamamoto	PROPN
admet-337	681	6	,	,	PUNCT
admet-337	681	7	m.	m.	PROPN
admet-337	681	8	honma	honma	PROPN
admet-337	681	9	,	,	PUNCT
admet-337	681	10	h.suzuki	h.suzuki	PROPN
admet-337	681	11	,	,	PUNCT
admet-337	681	12	mol	mol	PROPN
admet-337	681	13	.	.	PUNCT
admet-337	681	14	pharmacol	pharmacol	PROPN
admet-337	681	15	.	.	PROPN
admet-337	682	1	80	80	NUM
admet-337	683	1	(	(	PUNCT
admet-337	683	2	2011	2011	NUM
admet-337	683	3	)	)	PUNCT
admet-337	683	4	466	466	NUM
admet-337	683	5	-	-	SYM
admet-337	683	6	475	475	NUM
admet-337	683	7	.	.	PUNCT
admet-337	684	1	[	[	X
admet-337	684	2	33	33	NUM
admet-337	684	3	]	]	X
admet-337	684	4	j.r	j.r	PROPN
admet-337	684	5	.	.	PROPN
admet-337	684	6	johnson	johnson	PROPN
admet-337	684	7	,	,	PUNCT
admet-337	684	8	m.	m.	PROPN
admet-337	684	9	cohen	cohen	PROPN
admet-337	684	10	,	,	PUNCT
admet-337	684	11	r.	r.	PROPN
admet-337	684	12	sridhara	sridhara	PROPN
admet-337	684	13	,	,	PUNCT
admet-337	684	14	et	et	PROPN
admet-337	684	15	al	al	PROPN
admet-337	684	16	.	.	PUNCT
admet-337	685	1	clin	clin	PROPN
admet-337	685	2	.	.	PUNCT
admet-337	686	1	cancer	cancer	NOUN
admet-337	686	2	res	re	NOUN
admet-337	686	3	.	.	PUNCT
admet-337	687	1	11	11	NUM
admet-337	687	2	(	(	PUNCT
admet-337	687	3	2005	2005	NUM
admet-337	687	4	)	)	PUNCT
admet-337	687	5	6414	6414	NUM
admet-337	687	6	-	-	SYM
admet-337	687	7	6421	6421	NUM
admet-337	687	8	.	.	PUNCT
admet-337	688	1	[	[	X
admet-337	688	2	34	34	NUM
admet-337	688	3	]	]	X
admet-337	688	4	m.	m.	PROPN
admet-337	688	5	ranson	ranson	PROPN
admet-337	688	6	,	,	PUNCT
admet-337	688	7	h.	h.	PROPN
admet-337	688	8	shaw	shaw	PROPN
admet-337	688	9	,	,	PUNCT
admet-337	688	10	j.	j.	PROPN
admet-337	688	11	wolf	wolf	PROPN
admet-337	688	12	,	,	PUNCT
admet-337	688	13	et	et	PROPN
admet-337	688	14	al	al	PROPN
admet-337	688	15	.	.	PUNCT
admet-337	688	16	cancer	cancer	PROPN
admet-337	688	17	chemother	chemother	PROPN
admet-337	688	18	.	.	PUNCT
admet-337	689	1	pharmacol	pharmacol	PROPN
admet-337	689	2	.	.	PUNCT
admet-337	690	1	66	66	NUM
admet-337	690	2	(	(	PUNCT
admet-337	690	3	2010	2010	NUM
admet-337	690	4	)	)	PUNCT
admet-337	690	5	53	53	NUM
admet-337	690	6	-	-	SYM
admet-337	690	7	58	58	NUM
admet-337	690	8	.	.	PUNCT
admet-337	691	1	[	[	X
admet-337	691	2	35	35	NUM
admet-337	691	3	]	]	X
admet-337	691	4	j.	j.	PROPN
admet-337	691	5	ling	ling	PROPN
admet-337	691	6	,	,	PUNCT
admet-337	691	7	s.	s.	PROPN
admet-337	691	8	fettner	fettner	PROPN
admet-337	691	9	,	,	PUNCT
admet-337	691	10	b.l	b.l	PROPN
admet-337	691	11	.	.	PROPN
admet-337	691	12	lum	lum	PROPN
admet-337	691	13	,	,	PUNCT
admet-337	691	14	m.	m.	NOUN
admet-337	691	15	riek	riek	NOUN
admet-337	691	16	,	,	PUNCT
admet-337	691	17	a.	a.	NOUN
admet-337	691	18	rakhit	rakhit	PROPN
admet-337	691	19	,	,	PUNCT
admet-337	691	20	anticancer	anticancer	NOUN
admet-337	691	21	drugs	drug	NOUN
admet-337	691	22	.	.	PUNCT
admet-337	692	1	19	19	NUM
admet-337	692	2	(	(	PUNCT
admet-337	692	3	2008	2008	NUM
admet-337	692	4	)	)	PUNCT
admet-337	692	5	209	209	NUM
admet-337	692	6	-	-	SYM
admet-337	692	7	216	216	NUM
admet-337	692	8	.	.	PUNCT
admet-337	693	1	[	[	X
admet-337	693	2	36	36	NUM
admet-337	693	3	]	]	X
admet-337	693	4	r.w	r.w	PROPN
admet-337	693	5	.	.	PROPN
admet-337	693	6	van	van	PROPN
admet-337	693	7	leeuwen	leeuwen	PROPN
admet-337	693	8	,	,	PUNCT
admet-337	693	9	r.	r.	PROPN
admet-337	693	10	peric	peric	PROPN
admet-337	693	11	,	,	PUNCT
admet-337	693	12	k.g	k.g	PROPN
admet-337	693	13	.	.	PROPN
admet-337	693	14	hussaarts	hussaart	NOUN
admet-337	693	15	,	,	PUNCT
admet-337	693	16	et	et	PROPN
admet-337	693	17	al	al	PROPN
admet-337	693	18	.	.	PUNCT
admet-337	694	1	j.	j.	PROPN
admet-337	694	2	clin	clin	PROPN
admet-337	694	3	.	.	PUNCT
admet-337	695	1	oncol	oncol	ADJ
admet-337	695	2	.	.	PUNCT
admet-337	696	1	34	34	NUM
admet-337	696	2	(	(	PUNCT
admet-337	696	3	2016	2016	NUM
admet-337	696	4	)	)	PUNCT
admet-337	696	5	1309	1309	NUM
admet-337	696	6	-	-	SYM
admet-337	696	7	1314	1314	NUM
admet-337	696	8	.	.	PUNCT
admet-337	697	1	[	[	X
admet-337	697	2	37	37	NUM
admet-337	697	3	]	]	X
admet-337	697	4	j.f	j.f	PROPN
admet-337	697	5	.	.	PROPN
admet-337	697	6	lu	lu	PROPN
admet-337	697	7	,	,	PUNCT
admet-337	697	8	s.m	s.m	PROPN
admet-337	697	9	.	.	PROPN
admet-337	697	10	eppler	eppler	PROPN
admet-337	697	11	,	,	PUNCT
admet-337	697	12	j.	j.	PROPN
admet-337	697	13	wolf	wolf	PROPN
admet-337	697	14	,	,	PUNCT
admet-337	697	15	et	et	PROPN
admet-337	697	16	al	al	PROPN
admet-337	697	17	.	.	PUNCT
admet-337	697	18	clin	clin	PROPN
admet-337	697	19	.	.	PUNCT
admet-337	698	1	pharmacol	pharmacol	PROPN
admet-337	698	2	.	.	PUNCT
admet-337	699	1	ther	ther	PROPN
admet-337	699	2	.	.	PUNCT
admet-337	700	1	80	80	NUM
admet-337	700	2	(	(	PUNCT
admet-337	700	3	2006	2006	NUM
admet-337	700	4	)	)	PUNCT
admet-337	700	5	136	136	NUM
admet-337	700	6	-	-	SYM
admet-337	700	7	145	145	NUM
admet-337	700	8	.	.	PUNCT
admet-337	701	1	[	[	X
admet-337	701	2	38	38	NUM
admet-337	701	3	]	]	X
admet-337	701	4	o.	o.	PROPN
admet-337	701	5	mir	mir	PROPN
admet-337	701	6	,	,	PUNCT
admet-337	701	7	b.	b.	PROPN
admet-337	701	8	blanchet	blanchet	PROPN
admet-337	701	9	,	,	PUNCT
admet-337	701	10	f.	f.	PROPN
admet-337	701	11	goldwasser	goldwasser	PROPN
admet-337	701	12	,	,	PUNCT
admet-337	701	13	n.	n.	PROPN
admet-337	701	14	engl	engl	PROPN
admet-337	701	15	.	.	PUNCT
admet-337	702	1	j.	j.	PROPN
admet-337	702	2	med	med	PROPN
admet-337	702	3	.	.	PUNCT
admet-337	703	1	365	365	NUM
admet-337	703	2	(	(	PUNCT
admet-337	703	3	2011	2011	NUM
admet-337	703	4	)	)	PUNCT
admet-337	703	5	379	379	NUM
admet-337	703	6	-	-	SYM
admet-337	703	7	380	380	NUM
admet-337	703	8	.	.	PUNCT
admet-337	704	1	[	[	X
admet-337	704	2	39	39	NUM
admet-337	704	3	]	]	X
admet-337	704	4	c.l	c.l	PROPN
admet-337	704	5	.	.	PROPN
admet-337	704	6	o'bryant	o'bryant	PROPN
admet-337	704	7	,	,	PUNCT
admet-337	704	8	p.	p.	NOUN
admet-337	704	9	haluska	haluska	PROPN
admet-337	704	10	,	,	PUNCT
admet-337	704	11	l.	l.	PROPN
admet-337	704	12	rosen	rosen	PROPN
admet-337	704	13	,	,	PUNCT
admet-337	704	14	et	et	PROPN
admet-337	704	15	al	al	PROPN
admet-337	704	16	.	.	PUNCT
admet-337	704	17	cancer	cancer	PROPN
admet-337	704	18	chemother	chemother	PROPN
admet-337	704	19	.	.	PUNCT
admet-337	705	1	pharmacol	pharmacol	PROPN
admet-337	705	2	.	.	PUNCT
admet-337	706	1	69	69	NUM
admet-337	706	2	(	(	PUNCT
admet-337	706	3	2012	2012	NUM
admet-337	706	4	)	)	PUNCT
admet-337	706	5	605	605	NUM
admet-337	706	6	-	-	PUNCT
admet-337	706	7	612	612	NUM
admet-337	706	8	.	.	PUNCT
admet-337	707	1	[	[	X
admet-337	707	2	40	40	NUM
admet-337	707	3	]	]	PUNCT
admet-337	707	4	s.	s.	PROPN
admet-337	707	5	marchetti	marchetti	PROPN
admet-337	707	6	,	,	PUNCT
admet-337	707	7	n.a	n.a	PROPN
admet-337	707	8	.	.	PROPN
admet-337	707	9	de	de	PROPN
admet-337	707	10	vries	vries	PROPN
admet-337	707	11	,	,	PUNCT
admet-337	707	12	t.	t.	NOUN
admet-337	707	13	buckle	buckle	NOUN
admet-337	707	14	,	,	PUNCT
admet-337	707	15	et	et	PROPN
admet-337	707	16	al	al	PROPN
admet-337	707	17	.	.	PROPN
admet-337	707	18	mol	mol	PROPN
admet-337	707	19	.	.	PUNCT
admet-337	708	1	cancer	cancer	NOUN
admet-337	708	2	.	.	PUNCT
admet-337	709	1	ther	ther	INTJ
admet-337	709	2	.	.	PUNCT
admet-337	710	1	7	7	NUM
admet-337	710	2	(	(	PUNCT
admet-337	710	3	2008	2008	NUM
admet-337	710	4	)	)	PUNCT
admet-337	710	5	2280	2280	NUM
admet-337	710	6	-	-	SYM
admet-337	710	7	2287	2287	NUM
admet-337	710	8	.	.	PUNCT
admet-337	711	1	[	[	X
admet-337	711	2	41	41	NUM
admet-337	711	3	]	]	PUNCT
admet-337	711	4	a.	a.	PROPN
admet-337	711	5	hamada	hamada	PROPN
admet-337	711	6	,	,	PUNCT
admet-337	711	7	j.	j.	PROPN
admet-337	711	8	sasaki	sasaki	PROPN
admet-337	711	9	,	,	PUNCT
admet-337	711	10	s.	s.	PROPN
admet-337	711	11	saeki	saeki	PROPN
admet-337	711	12	,	,	PUNCT
admet-337	711	13	et	et	PROPN
admet-337	711	14	al	al	PROPN
admet-337	711	15	.	.	PROPN
admet-337	711	16	pharmacogenomics	pharmacogenomic	NOUN
admet-337	711	17	13	13	NUM
admet-337	711	18	(	(	PUNCT
admet-337	711	19	2012	2012	NUM
admet-337	711	20	)	)	PUNCT
admet-337	711	21	615	615	NUM
admet-337	711	22	-	-	SYM
admet-337	711	23	624	624	NUM
admet-337	711	24	.	.	PUNCT
admet-337	712	1	[	[	X
admet-337	712	2	42	42	NUM
admet-337	712	3	]	]	PUNCT
admet-337	712	4	m.	m.	NOUN
admet-337	712	5	fukudo	fukudo	PROPN
admet-337	712	6	,	,	PUNCT
admet-337	712	7	y.	y.	PROPN
admet-337	712	8	ikemi	ikemi	PROPN
admet-337	712	9	,	,	PUNCT
admet-337	712	10	y.	y.	PROPN
admet-337	712	11	togashi	togashi	PROPN
admet-337	712	12	,	,	PUNCT
admet-337	712	13	et	et	PROPN
admet-337	712	14	al	al	PROPN
admet-337	712	15	.	.	PUNCT
admet-337	713	1	clin	clin	PROPN
admet-337	713	2	.	.	PUNCT
admet-337	714	1	pharmacokinet	pharmacokinet	PROPN
admet-337	714	2	.	.	PUNCT
admet-337	715	1	52	52	NUM
admet-337	715	2	(	(	PUNCT
admet-337	715	3	2013	2013	NUM
admet-337	715	4	)	)	PUNCT
admet-337	715	5	593	593	NUM
admet-337	715	6	-	-	SYM
admet-337	715	7	609	609	NUM
admet-337	715	8	.	.	PUNCT
admet-337	716	1	[	[	X
admet-337	716	2	43	43	NUM
admet-337	716	3	]	]	X
admet-337	716	4	j.	j.	PROPN
admet-337	716	5	li	li	PROPN
admet-337	716	6	,	,	PUNCT
admet-337	716	7	m.	m.	NOUN
admet-337	716	8	zhao	zhao	PROPN
admet-337	716	9	,	,	PUNCT
admet-337	716	10	p.	p.	NOUN
admet-337	716	11	he	he	PRON
admet-337	716	12	,	,	PUNCT
admet-337	716	13	m.	m.	PROPN
admet-337	716	14	hidalgo	hidalgo	PROPN
admet-337	716	15	,	,	PUNCT
admet-337	716	16	clin	clin	PROPN
admet-337	716	17	.	.	PUNCT
admet-337	717	1	cancer	cancer	NOUN
admet-337	717	2	res	re	NOUN
admet-337	717	3	.	.	PROPN
admet-337	718	1	13	13	NUM
admet-337	718	2	(	(	PUNCT
admet-337	718	3	2007	2007	NUM
admet-337	718	4	)	)	PUNCT
admet-337	718	5	3731	3731	NUM
admet-337	718	6	-	-	SYM
admet-337	718	7	3737	3737	NUM
admet-337	718	8	.	.	PUNCT
admet-337	719	1	[	[	X
admet-337	719	2	44	44	NUM
admet-337	719	3	]	]	PUNCT
admet-337	719	4	j.	j.	PROPN
admet-337	719	5	ling	ling	PROPN
admet-337	719	6	,	,	PUNCT
admet-337	719	7	k.a	k.a	PROPN
admet-337	719	8	.	.	PROPN
admet-337	719	9	johnson	johnson	PROPN
admet-337	719	10	,	,	PUNCT
admet-337	719	11	z.	z.	PROPN
admet-337	719	12	miao	miao	PROPN
admet-337	719	13	,	,	PUNCT
admet-337	719	14	et	et	PROPN
admet-337	719	15	al	al	PROPN
admet-337	719	16	.	.	PROPN
admet-337	719	17	drug	drug	PROPN
admet-337	719	18	metab	metab	PROPN
admet-337	719	19	.	.	PUNCT
admet-337	720	1	dispos	dispos	PROPN
admet-337	720	2	.	.	PUNCT
admet-337	721	1	34	34	NUM
admet-337	721	2	(	(	PUNCT
admet-337	721	3	2006	2006	NUM
admet-337	721	4	)	)	PUNCT
admet-337	721	5	420	420	NUM
admet-337	721	6	-	-	SYM
admet-337	721	7	426	426	NUM
admet-337	721	8	.	.	PUNCT
admet-337	722	1	[	[	X
admet-337	722	2	45	45	NUM
admet-337	722	3	]	]	X
admet-337	722	4	y.	y.	PROPN
admet-337	722	5	togashi	togashi	PROPN
admet-337	722	6	,	,	PUNCT
admet-337	722	7	k.	k.	PROPN
admet-337	722	8	masago	masago	PROPN
admet-337	722	9	,	,	PUNCT
admet-337	722	10	m.	m.	NOUN
admet-337	722	11	fukudo	fukudo	PROPN
admet-337	722	12	,	,	PUNCT
admet-337	722	13	et	et	PROPN
admet-337	722	14	al	al	PROPN
admet-337	722	15	.	.	PUNCT
admet-337	723	1	j.	j.	PROPN
admet-337	723	2	thorac	thorac	PROPN
admet-337	723	3	.	.	PUNCT
admet-337	724	1	oncol	oncol	ADJ
admet-337	724	2	.	.	PUNCT
admet-337	725	1	5	5	NUM
admet-337	725	2	(	(	PUNCT
admet-337	725	3	2010	2010	NUM
admet-337	725	4	)	)	PUNCT
admet-337	725	5	601	601	NUM
admet-337	725	6	-	-	SYM
admet-337	725	7	605	605	NUM
admet-337	725	8	.	.	PUNCT
admet-337	726	1	[	[	X
admet-337	726	2	46	46	NUM
admet-337	726	3	]	]	X
admet-337	726	4	y.	y.	PROPN
admet-337	726	5	togashi	togashi	PROPN
admet-337	726	6	,	,	PUNCT
admet-337	726	7	k.	k.	PROPN
admet-337	726	8	masago	masago	PROPN
admet-337	726	9	,	,	PUNCT
admet-337	726	10	m.	m.	NOUN
admet-337	726	11	fukudo	fukudo	PROPN
admet-337	726	12	,	,	PUNCT
admet-337	726	13	et	et	PROPN
admet-337	726	14	al	al	PROPN
admet-337	726	15	.	.	PUNCT
admet-337	727	1	j.	j.	PROPN
admet-337	727	2	thorac	thorac	PROPN
admet-337	727	3	.	.	PUNCT
admet-337	728	1	oncol	oncol	ADJ
admet-337	728	2	.	.	PUNCT
admet-337	729	1	5	5	NUM
admet-337	729	2	(	(	PUNCT
admet-337	729	3	2010	2010	NUM
admet-337	729	4	)	)	PUNCT
admet-337	729	5	950	950	NUM
admet-337	729	6	-	-	PUNCT
admet-337	729	7	955	955	NUM
admet-337	729	8	.	.	PUNCT
admet-337	730	1	[	[	X
admet-337	730	2	47	47	NUM
admet-337	730	3	]	]	X
admet-337	730	4	j.e	j.e	PROPN
admet-337	730	5	.	.	PROPN
admet-337	730	6	kim	kim	PROPN
admet-337	730	7	,	,	PUNCT
admet-337	730	8	d.h	d.h	PROPN
admet-337	730	9	.	.	PROPN
admet-337	730	10	lee	lee	PROPN
admet-337	730	11	,	,	PUNCT
admet-337	730	12	y.	y.	PROPN
admet-337	730	13	choi	choi	PROPN
admet-337	730	14	,	,	PUNCT
admet-337	731	1	et	et	PROPN
admet-337	731	2	al	al	PROPN
admet-337	731	3	.	.	PUNCT
admet-337	731	4	lung	lung	PROPN
admet-337	731	5	cancer	cancer	NOUN
admet-337	731	6	65	65	NUM
admet-337	731	7	(	(	PUNCT
admet-337	731	8	2009	2009	NUM
admet-337	731	9	)	)	PUNCT
admet-337	731	10	351	351	NUM
admet-337	731	11	-	-	SYM
admet-337	731	12	354	354	NUM
admet-337	731	13	.	.	PUNCT
admet-337	732	1	[	[	X
admet-337	732	2	48	48	NUM
admet-337	732	3	]	]	X
admet-337	732	4	n.	n.	PROPN
admet-337	732	5	dhruva	dhruva	PROPN
admet-337	732	6	,	,	PUNCT
admet-337	732	7	m.a	m.a	PROPN
admet-337	732	8	.	.	PROPN
admet-337	732	9	socinski	socinski	PROPN
admet-337	732	10	,	,	PUNCT
admet-337	732	11	j.	j.	PROPN
admet-337	732	12	clin	clin	PROPN
admet-337	732	13	.	.	PUNCT
admet-337	733	1	oncol	oncol	ADJ
admet-337	733	2	.	.	PUNCT
admet-337	734	1	27	27	NUM
admet-337	734	2	(	(	PUNCT
admet-337	734	3	2009	2009	NUM
admet-337	734	4	)	)	PUNCT
admet-337	734	5	e31	e31	PROPN
admet-337	734	6	-	-	SYM
admet-337	734	7	2	2	NUM
admet-337	734	8	.	.	PUNCT
admet-337	735	1	[	[	X
admet-337	735	2	49	49	NUM
admet-337	735	3	]	]	PUNCT
admet-337	735	4	a.	a.	NOUN
admet-337	735	5	hata	hata	PROPN
admet-337	735	6	,	,	PUNCT
admet-337	735	7	r.	r.	PROPN
admet-337	735	8	kaji	kaji	PROPN
admet-337	735	9	,	,	PUNCT
admet-337	735	10	s.	s.	PROPN
admet-337	735	11	fujita	fujita	PROPN
admet-337	735	12	,	,	PUNCT
admet-337	735	13	n.	n.	PROPN
admet-337	735	14	katakami	katakami	PROPN
admet-337	735	15	,	,	PUNCT
admet-337	735	16	j.	j.	PROPN
admet-337	735	17	thorac	thorac	PROPN
admet-337	735	18	.	.	PUNCT
admet-337	736	1	oncol	oncol	ADJ
admet-337	736	2	.	.	PUNCT
admet-337	737	1	6	6	NUM
admet-337	737	2	(	(	PUNCT
admet-337	737	3	2011	2011	NUM
admet-337	737	4	)	)	PUNCT
admet-337	737	5	653	653	NUM
admet-337	737	6	-	-	SYM
admet-337	737	7	654	654	NUM
admet-337	737	8	.	.	PUNCT
admet-337	738	1	[	[	X
admet-337	738	2	50	50	NUM
admet-337	738	3	]	]	PUNCT
admet-337	738	4	c.	c.	PROPN
admet-337	738	5	grommes	gromme	NOUN
admet-337	738	6	,	,	PUNCT
admet-337	738	7	g.r	g.r	PROPN
admet-337	738	8	.	.	PROPN
admet-337	738	9	oxnard	oxnard	PROPN
admet-337	738	10	,	,	PUNCT
admet-337	738	11	m.g	m.g	PROPN
admet-337	738	12	.	.	PROPN
admet-337	738	13	kris	kris	PROPN
admet-337	738	14	,	,	PUNCT
admet-337	738	15	et	et	PROPN
admet-337	738	16	al	al	PROPN
admet-337	738	17	.	.	PROPN
admet-337	738	18	neuro	neuro	PROPN
admet-337	738	19	oncol	oncol	PROPN
admet-337	738	20	.	.	PUNCT
admet-337	739	1	13	13	NUM
admet-337	739	2	(	(	PUNCT
admet-337	739	3	2011	2011	NUM
admet-337	739	4	)	)	PUNCT
admet-337	739	5	1364	1364	NUM
admet-337	739	6	-	-	SYM
admet-337	739	7	1369	1369	NUM
admet-337	739	8	.	.	PUNCT
admet-337	740	1	[	[	X
admet-337	740	2	51	51	NUM
admet-337	740	3	]	]	X
admet-337	740	4	c.h	c.h	PROPN
admet-337	740	5	.	.	PROPN
admet-337	740	6	yun	yun	PROPN
admet-337	740	7	,	,	PUNCT
admet-337	740	8	k.e	k.e	PROPN
admet-337	740	9	.	.	PROPN
admet-337	740	10	mengwasser	mengwasser	PROPN
admet-337	740	11	,	,	PUNCT
admet-337	740	12	a.v	a.v	PROPN
admet-337	740	13	.	.	PROPN
admet-337	740	14	toms	toms	PROPN
admet-337	740	15	,	,	PUNCT
admet-337	740	16	et	et	PROPN
admet-337	740	17	al	al	PROPN
admet-337	740	18	.	.	PROPN
admet-337	740	19	proc	proc	PROPN
admet-337	740	20	.	.	PUNCT
admet-337	741	1	natl	natl	PROPN
admet-337	741	2	.	.	PUNCT
admet-337	742	1	acad	acad	PROPN
admet-337	742	2	.	.	PUNCT
admet-337	743	1	sci	sci	PROPN
admet-337	743	2	.	.	PUNCT
admet-337	743	3	u.s.a	u.s.a	PROPN
admet-337	743	4	.	.	PROPN
admet-337	744	1	105	105	NUM
admet-337	744	2	(	(	PUNCT
admet-337	744	3	2008	2008	NUM
admet-337	744	4	)	)	PUNCT
admet-337	744	5	2070	2070	NUM
admet-337	744	6	-	-	SYM
admet-337	744	7	2075	2075	NUM
admet-337	744	8	.	.	PUNCT
admet-337	745	1	[	[	X
admet-337	745	2	52	52	NUM
admet-337	745	3	]	]	PUNCT
admet-337	745	4	w.	w.	PROPN
admet-337	745	5	pao	pao	PROPN
admet-337	745	6	,	,	PUNCT
admet-337	745	7	v.a	v.a	PROPN
admet-337	745	8	.	.	PROPN
admet-337	745	9	miller	miller	PROPN
admet-337	745	10	,	,	PUNCT
admet-337	745	11	k.a	k.a	PROPN
admet-337	745	12	.	.	PROPN
admet-337	745	13	politi	politi	PROPN
admet-337	745	14	,	,	PUNCT
admet-337	745	15	et	et	PROPN
admet-337	745	16	al	al	PROPN
admet-337	745	17	.	.	PROPN
admet-337	746	1	plos	plos	PROPN
admet-337	746	2	med	med	PROPN
admet-337	746	3	.	.	PUNCT
admet-337	747	1	(	(	PUNCT
admet-337	747	2	2005	2005	NUM
admet-337	747	3	)	)	PUNCT
admet-337	747	4	2	2	NUM
admet-337	747	5	:	:	PUNCT
admet-337	747	6	e73	e73	NUM
admet-337	747	7	.	.	PUNCT
admet-337	748	1	[	[	X
admet-337	748	2	53	53	NUM
admet-337	748	3	]	]	PUNCT
admet-337	748	4	j.	j.	PROPN
admet-337	748	5	stamos	stamos	PROPN
admet-337	748	6	,	,	PUNCT
admet-337	748	7	m.x	m.x	PROPN
admet-337	748	8	.sliwkowski	.sliwkowski	PROPN
admet-337	748	9	,	,	PUNCT
admet-337	748	10	c.	c.	PROPN
admet-337	748	11	eigenbrot	eigenbrot	PROPN
admet-337	748	12	,	,	PUNCT
admet-337	748	13	j.	j.	PROPN
admet-337	748	14	biol	biol	PROPN
admet-337	748	15	.	.	PUNCT
admet-337	749	1	chem	chem	PROPN
admet-337	749	2	.	.	PUNCT
admet-337	750	1	277	277	NUM
admet-337	750	2	(	(	PUNCT
admet-337	750	3	2002	2002	NUM
admet-337	750	4	)	)	PUNCT
admet-337	750	5	46265	46265	NUM
admet-337	750	6	-	-	SYM
admet-337	750	7	46272	46272	NUM
admet-337	750	8	.	.	PUNCT
admet-337	751	1	[	[	X
admet-337	751	2	54	54	NUM
admet-337	751	3	]	]	PUNCT
admet-337	751	4	j.	j.	PROPN
admet-337	751	5	bean	bean	PROPN
admet-337	751	6	,	,	PUNCT
admet-337	751	7	c.	c.	PROPN
admet-337	751	8	brennan	brennan	PROPN
admet-337	751	9	,	,	PUNCT
admet-337	751	10	j.y	j.y	PROPN
admet-337	751	11	.	.	PROPN
admet-337	751	12	shih	shih	PROPN
admet-337	751	13	,	,	PUNCT
admet-337	751	14	et	et	PROPN
admet-337	751	15	al	al	PROPN
admet-337	751	16	.	.	PROPN
admet-337	751	17	proc	proc	PROPN
admet-337	751	18	.	.	PUNCT
admet-337	752	1	natl	natl	PROPN
admet-337	752	2	.	.	PUNCT
admet-337	753	1	acad	acad	PROPN
admet-337	753	2	.	.	PUNCT
admet-337	754	1	sci	sci	PROPN
admet-337	754	2	.	.	PUNCT
admet-337	754	3	u.s.a	u.s.a	PROPN
admet-337	754	4	.	.	PROPN
admet-337	755	1	104	104	NUM
admet-337	755	2	(	(	PUNCT
admet-337	755	3	2007	2007	NUM
admet-337	755	4	)	)	PUNCT
admet-337	755	5	20932	20932	NUM
admet-337	755	6	-	-	SYM
admet-337	755	7	20937	20937	NUM
admet-337	755	8	.	.	PUNCT
admet-337	756	1	[	[	X
admet-337	756	2	55	55	NUM
admet-337	756	3	]	]	X
admet-337	756	4	j.f	j.f	PROPN
admet-337	756	5	.	.	PROPN
admet-337	756	6	gainor	gainor	PROPN
admet-337	756	7	,	,	PUNCT
admet-337	756	8	m.j	m.j	PROPN
admet-337	756	9	.	.	PROPN
admet-337	756	10	niederst	niederst	PROPN
admet-337	756	11	,	,	PUNCT
admet-337	756	12	j.k	j.k	PROPN
admet-337	756	13	.	.	PROPN
admet-337	756	14	lennerz	lennerz	PROPN
admet-337	756	15	,	,	PUNCT
admet-337	756	16	et	et	PROPN
admet-337	756	17	al	al	PROPN
admet-337	756	18	.	.	PUNCT
admet-337	756	19	j.	j.	PROPN
admet-337	756	20	thorac	thorac	PROPN
admet-337	756	21	.	.	PUNCT
admet-337	757	1	oncol	oncol	ADJ
admet-337	757	2	.	.	PUNCT
admet-337	758	1	11	11	NUM
admet-337	758	2	(	(	PUNCT
admet-337	758	3	2016	2016	NUM
admet-337	758	4	)	)	PUNCT
admet-337	758	5	e83	e83	NOUN
admet-337	758	6	-	-	PUNCT
admet-337	758	7	5	5	NUM
admet-337	758	8	.	.	PUNCT
admet-337	759	1	grace	grace	NOUN
admet-337	759	2	dy	dy	NOUN
admet-337	759	3	et	et	PROPN
admet-337	759	4	al	al	PROPN
admet-337	759	5	.	.	PROPN
admet-337	759	6	admet	admet	PROPN
admet-337	759	7	&	&	CCONJ
admet-337	759	8	dmpk	dmpk	PROPN
admet-337	759	9	4(3	4(3	NUM
admet-337	759	10	)	)	PUNCT
admet-337	759	11	(	(	PUNCT
admet-337	759	12	2016	2016	NUM
admet-337	759	13	)	)	PUNCT
admet-337	759	14	186	186	NUM
admet-337	759	15	-	-	SYM
admet-337	759	16	211	211	NUM
admet-337	759	17	208	208	NUM
admet-337	759	18	[	[	X
admet-337	759	19	56	56	NUM
admet-337	759	20	]	]	X
admet-337	759	21	m.h	m.h	PROPN
admet-337	759	22	.	.	PROPN
admet-337	759	23	cohen	cohen	PROPN
admet-337	759	24	,	,	PUNCT
admet-337	759	25	g.a	g.a	PROPN
admet-337	759	26	.	.	PROPN
admet-337	759	27	williams	williams	PROPN
admet-337	759	28	,	,	PUNCT
admet-337	759	29	r.	r.	PROPN
admet-337	759	30	sridhara	sridhara	PROPN
admet-337	759	31	,	,	PUNCT
admet-337	759	32	et	et	PROPN
admet-337	759	33	al	al	PROPN
admet-337	759	34	.	.	PUNCT
admet-337	760	1	clin	clin	PROPN
admet-337	760	2	.	.	PUNCT
admet-337	761	1	cancer	cancer	NOUN
admet-337	761	2	res	re	NOUN
admet-337	761	3	.	.	PUNCT
admet-337	762	1	10	10	NUM
admet-337	762	2	(	(	PUNCT
admet-337	762	3	2004	2004	NUM
admet-337	762	4	)	)	PUNCT
admet-337	762	5	1212	1212	NUM
admet-337	762	6	-	-	SYM
admet-337	762	7	1218	1218	NUM
admet-337	762	8	.	.	PUNCT
admet-337	763	1	[	[	X
admet-337	763	2	57	57	NUM
admet-337	763	3	]	]	X
admet-337	763	4	m.g	m.g	PROPN
admet-337	763	5	.	.	PROPN
admet-337	763	6	kris	kris	PROPN
admet-337	763	7	,	,	PUNCT
admet-337	763	8	r.b	r.b	PROPN
admet-337	763	9	.	.	PROPN
admet-337	763	10	natale	natale	PROPN
admet-337	763	11	,	,	PUNCT
admet-337	763	12	r.s	r.s	PROPN
admet-337	763	13	.	.	PROPN
admet-337	763	14	herbst	herbst	PROPN
admet-337	763	15	,	,	PUNCT
admet-337	763	16	et	et	PROPN
admet-337	763	17	al	al	PROPN
admet-337	763	18	.	.	PROPN
admet-337	763	19	jama	jama	PROPN
admet-337	763	20	290	290	NUM
admet-337	763	21	(	(	PUNCT
admet-337	763	22	2003	2003	NUM
admet-337	763	23	)	)	PUNCT
admet-337	763	24	2149	2149	NUM
admet-337	763	25	-	-	SYM
admet-337	763	26	2158	2158	NUM
admet-337	763	27	.	.	PUNCT
admet-337	764	1	[	[	X
admet-337	764	2	58	58	NUM
admet-337	764	3	]	]	X
admet-337	764	4	t.s	t.s	PROPN
admet-337	764	5	.	.	PROPN
admet-337	764	6	mok	mok	PROPN
admet-337	764	7	,	,	PUNCT
admet-337	764	8	y.l	y.l	PROPN
admet-337	764	9	.	.	PROPN
admet-337	764	10	wu	wu	PROPN
admet-337	764	11	,	,	PUNCT
admet-337	764	12	s.	s.	PROPN
admet-337	764	13	thongprasert	thongprasert	PROPN
admet-337	764	14	,	,	PUNCT
admet-337	764	15	et	et	PROPN
admet-337	764	16	al	al	PROPN
admet-337	764	17	.	.	PUNCT
admet-337	764	18	n.	n.	PROPN
admet-337	764	19	engl	engl	PROPN
admet-337	764	20	.	.	PUNCT
admet-337	765	1	j.	j.	PROPN
admet-337	765	2	med	med	PROPN
admet-337	765	3	.	.	PROPN
admet-337	766	1	361	361	NUM
admet-337	766	2	(	(	PUNCT
admet-337	766	3	2009	2009	NUM
admet-337	766	4	)	)	PUNCT
admet-337	766	5	947	947	NUM
admet-337	766	6	-	-	SYM
admet-337	766	7	957	957	NUM
admet-337	766	8	.	.	PUNCT
admet-337	767	1	[	[	X
admet-337	767	2	59	59	NUM
admet-337	767	3	]	]	PUNCT
admet-337	767	4	t.	t.	PROPN
admet-337	767	5	mitsudomi	mitsudomi	PROPN
admet-337	767	6	,	,	PUNCT
admet-337	767	7	s.	s.	PROPN
admet-337	767	8	morita	morita	PROPN
admet-337	767	9	,	,	PUNCT
admet-337	767	10	y.	y.	PROPN
admet-337	767	11	yatabe	yatabe	PROPN
admet-337	767	12	,	,	PUNCT
admet-337	767	13	et	et	PROPN
admet-337	767	14	al	al	PROPN
admet-337	767	15	.	.	PUNCT
admet-337	768	1	lancet	lancet	PROPN
admet-337	768	2	oncol	oncol	PROPN
admet-337	768	3	.	.	PUNCT
admet-337	769	1	11	11	NUM
admet-337	769	2	(	(	PUNCT
admet-337	769	3	2010	2010	NUM
admet-337	769	4	)	)	PUNCT
admet-337	769	5	121	121	NUM
admet-337	769	6	-	-	SYM
admet-337	769	7	128	128	NUM
admet-337	769	8	.	.	PUNCT
admet-337	770	1	[	[	X
admet-337	770	2	60	60	NUM
admet-337	770	3	]	]	PUNCT
admet-337	770	4	m.	m.	NOUN
admet-337	770	5	maemondo	maemondo	NOUN
admet-337	770	6	,	,	PUNCT
admet-337	770	7	a.	a.	NOUN
admet-337	770	8	inoue	inoue	PROPN
admet-337	770	9	,	,	PUNCT
admet-337	770	10	k.	k.	PROPN
admet-337	770	11	kobayashi	kobayashi	PROPN
admet-337	770	12	,	,	PUNCT
admet-337	770	13	et	et	PROPN
admet-337	770	14	al	al	PROPN
admet-337	770	15	.	.	PUNCT
admet-337	770	16	n.	n.	PROPN
admet-337	770	17	engl	engl	PROPN
admet-337	770	18	.	.	PUNCT
admet-337	771	1	j.	j.	PROPN
admet-337	771	2	med	med	PROPN
admet-337	771	3	.	.	PUNCT
admet-337	772	1	362	362	NUM
admet-337	772	2	(	(	PUNCT
admet-337	772	3	2010	2010	NUM
admet-337	772	4	)	)	PUNCT
admet-337	772	5	2380	2380	NUM
admet-337	772	6	-	-	SYM
admet-337	772	7	2388	2388	NUM
admet-337	772	8	.	.	PUNCT
admet-337	773	1	[	[	X
admet-337	773	2	61	61	NUM
admet-337	773	3	]	]	X
admet-337	773	4	j.y	j.y	PROPN
admet-337	773	5	.	.	PROPN
admet-337	773	6	han	han	PROPN
admet-337	773	7	,	,	PUNCT
admet-337	773	8	k.	k.	PROPN
admet-337	773	9	park	park	PROPN
admet-337	773	10	,	,	PUNCT
admet-337	773	11	s.w	s.w	PROPN
admet-337	773	12	.	.	PROPN
admet-337	773	13	kim	kim	PROPN
admet-337	773	14	,	,	PUNCT
admet-337	773	15	et	et	PROPN
admet-337	773	16	al	al	PROPN
admet-337	773	17	.	.	PUNCT
admet-337	774	1	j.	j.	PROPN
admet-337	774	2	clin	clin	PROPN
admet-337	774	3	.	.	PUNCT
admet-337	775	1	oncol	oncol	ADJ
admet-337	775	2	.	.	PUNCT
admet-337	776	1	30	30	NUM
admet-337	776	2	(	(	PUNCT
admet-337	776	3	2012	2012	NUM
admet-337	776	4	)	)	PUNCT
admet-337	776	5	1122	1122	NUM
admet-337	776	6	-	-	SYM
admet-337	776	7	1128	1128	NUM
admet-337	776	8	.	.	PUNCT
admet-337	777	1	[	[	X
admet-337	777	2	62	62	NUM
admet-337	777	3	]	]	PUNCT
admet-337	777	4	c.	c.	PROPN
admet-337	777	5	xue	xue	PROPN
admet-337	777	6	,	,	PUNCT
admet-337	777	7	s.	s.	PROPN
admet-337	777	8	hong	hong	PROPN
admet-337	777	9	,	,	PUNCT
admet-337	777	10	n.	n.	PROPN
admet-337	777	11	li	li	PROPN
admet-337	777	12	,	,	PUNCT
admet-337	777	13	et	et	PROPN
admet-337	777	14	al	al	PROPN
admet-337	777	15	.	.	PUNCT
admet-337	777	16	sci	sci	PROPN
admet-337	777	17	.	.	PUNCT
admet-337	777	18	rep	rep	PROPN
admet-337	777	19	.	.	PROPN
admet-337	777	20	5	5	NUM
admet-337	777	21	(	(	PUNCT
admet-337	777	22	2015	2015	NUM
admet-337	777	23	)	)	PUNCT
admet-337	777	24	10648	10648	NUM
admet-337	777	25	.	.	PUNCT
admet-337	778	1	[	[	X
admet-337	778	2	63	63	NUM
admet-337	778	3	]	]	PUNCT
admet-337	778	4	m.	m.	NOUN
admet-337	778	5	fukuoka	fukuoka	PROPN
admet-337	778	6	,	,	PUNCT
admet-337	778	7	s.	s.	PROPN
admet-337	778	8	yano	yano	PROPN
admet-337	778	9	,	,	PUNCT
admet-337	778	10	g.	g.	PROPN
admet-337	778	11	giaccone	giaccone	PROPN
admet-337	778	12	,	,	PUNCT
admet-337	778	13	et	et	PROPN
admet-337	778	14	al	al	PROPN
admet-337	778	15	.	.	PUNCT
admet-337	779	1	j.	j.	PROPN
admet-337	779	2	clin	clin	PROPN
admet-337	779	3	.	.	PUNCT
admet-337	780	1	oncol	oncol	ADJ
admet-337	780	2	.	.	PUNCT
admet-337	781	1	21	21	NUM
admet-337	781	2	(	(	PUNCT
admet-337	781	3	2003	2003	NUM
admet-337	781	4	)	)	PUNCT
admet-337	781	5	2237	2237	NUM
admet-337	781	6	-	-	SYM
admet-337	781	7	2246	2246	NUM
admet-337	781	8	.	.	PUNCT
admet-337	782	1	[	[	X
admet-337	782	2	64	64	NUM
admet-337	782	3	]	]	X
admet-337	782	4	j.y	j.y	PROPN
admet-337	782	5	.	.	PROPN
admet-337	782	6	douillard	douillard	PROPN
admet-337	782	7	,	,	PUNCT
admet-337	782	8	g.	g.	PROPN
admet-337	782	9	ostoros	ostoros	PROPN
admet-337	782	10	,	,	PUNCT
admet-337	782	11	m.	m.	PROPN
admet-337	782	12	cobo	cobo	PROPN
admet-337	782	13	,	,	PUNCT
admet-337	782	14	et	et	PROPN
admet-337	782	15	al	al	PROPN
admet-337	782	16	.	.	PROPN
admet-337	783	1	br	br	PROPN
admet-337	783	2	.	.	PUNCT
admet-337	784	1	j.	j.	PROPN
admet-337	784	2	cancer	cancer	PROPN
admet-337	784	3	.	.	PUNCT
admet-337	785	1	110	110	NUM
admet-337	785	2	(	(	PUNCT
admet-337	785	3	2014	2014	NUM
admet-337	785	4	)	)	PUNCT
admet-337	785	5	55	55	NUM
admet-337	785	6	-	-	SYM
admet-337	785	7	62	62	NUM
admet-337	785	8	.	.	PUNCT
admet-337	786	1	[	[	X
admet-337	786	2	65	65	NUM
admet-337	786	3	]	]	X
admet-337	786	4	h.	h.	PROPN
admet-337	786	5	swaisland	swaisland	PROPN
admet-337	786	6	,	,	PUNCT
admet-337	786	7	a.	a.	NOUN
admet-337	786	8	laight	laight	PROPN
admet-337	786	9	,	,	PUNCT
admet-337	786	10	l.	l.	PROPN
admet-337	786	11	stafford	stafford	PROPN
admet-337	786	12	,	,	PUNCT
admet-337	786	13	et	et	PROPN
admet-337	786	14	al	al	PROPN
admet-337	786	15	.	.	PUNCT
admet-337	787	1	clin	clin	PROPN
admet-337	787	2	.	.	PUNCT
admet-337	788	1	pharmacokinet	pharmacokinet	PROPN
admet-337	788	2	.	.	PUNCT
admet-337	789	1	40	40	NUM
admet-337	789	2	(	(	PUNCT
admet-337	789	3	2001	2001	NUM
admet-337	789	4	)	)	PUNCT
admet-337	789	5	297	297	NUM
admet-337	789	6	-	-	SYM
admet-337	789	7	306	306	NUM
admet-337	789	8	.	.	PUNCT
admet-337	790	1	[	[	X
admet-337	790	2	66	66	NUM
admet-337	790	3	]	]	X
admet-337	790	4	h.c	h.c	PROPN
admet-337	790	5	.	.	PROPN
admet-337	790	6	swaisland	swaisland	PROPN
admet-337	790	7	,	,	PUNCT
admet-337	790	8	r.p	r.p	PROPN
admet-337	790	9	.	.	PROPN
admet-337	790	10	smith	smith	PROPN
admet-337	790	11	,	,	PUNCT
admet-337	790	12	a.	a.	NOUN
admet-337	790	13	laight	laight	PROPN
admet-337	790	14	,	,	PUNCT
admet-337	790	15	et	et	PROPN
admet-337	790	16	al	al	PROPN
admet-337	790	17	.	.	PUNCT
admet-337	791	1	clin	clin	PROPN
admet-337	791	2	.	.	PUNCT
admet-337	792	1	pharmacokinet	pharmacokinet	PROPN
admet-337	792	2	.	.	PUNCT
admet-337	793	1	44	44	NUM
admet-337	793	2	(	(	PUNCT
admet-337	793	3	2005	2005	NUM
admet-337	793	4	)	)	PUNCT
admet-337	793	5	1165	1165	NUM
admet-337	793	6	-	-	SYM
admet-337	793	7	1177	1177	NUM
admet-337	793	8	.	.	PUNCT
admet-337	794	1	[	[	X
admet-337	794	2	67	67	NUM
admet-337	794	3	]	]	PUNCT
admet-337	794	4	j.	j.	PROPN
admet-337	794	5	li	li	PROPN
admet-337	794	6	,	,	PUNCT
admet-337	794	7	j.	j.	PROPN
admet-337	794	8	brahmer	brahmer	PROPN
admet-337	794	9	,	,	PUNCT
admet-337	794	10	w.	w.	PROPN
admet-337	794	11	messersmith	messersmith	PROPN
admet-337	794	12	,	,	PUNCT
admet-337	794	13	m.	m.	PROPN
admet-337	794	14	hidalgo	hidalgo	PROPN
admet-337	794	15	,	,	PUNCT
admet-337	794	16	s.d	s.d	PROPN
admet-337	794	17	.	.	PROPN
admet-337	794	18	baker	baker	PROPN
admet-337	794	19	,	,	PUNCT
admet-337	794	20	invest	invest	VERB
admet-337	794	21	.	.	PUNCT
admet-337	795	1	new	new	ADJ
admet-337	795	2	drugs	drug	NOUN
admet-337	795	3	.	.	PUNCT
admet-337	796	1	24	24	NUM
admet-337	796	2	(	(	PUNCT
admet-337	796	3	2006	2006	NUM
admet-337	796	4	)	)	PUNCT
admet-337	796	5	291	291	NUM
admet-337	796	6	-	-	SYM
admet-337	796	7	297	297	NUM
admet-337	796	8	.	.	PUNCT
admet-337	797	1	[	[	X
admet-337	797	2	68	68	NUM
admet-337	797	3	]	]	X
admet-337	797	4	d.	d.	PROPN
admet-337	797	5	mckillop	mckillop	PROPN
admet-337	797	6	,	,	PUNCT
admet-337	797	7	a.d	a.d	PROPN
admet-337	797	8	.	.	PROPN
admet-337	797	9	mccormick	mccormick	PROPN
admet-337	797	10	,	,	PUNCT
admet-337	797	11	a.	a.	PROPN
admet-337	797	12	millar	millar	PROPN
admet-337	797	13	,	,	PUNCT
admet-337	797	14	g.s	g.s	PROPN
admet-337	797	15	.	.	PROPN
admet-337	797	16	miles	miles	PROPN
admet-337	797	17	,	,	PUNCT
admet-337	797	18	p.j	p.j	PROPN
admet-337	797	19	.	.	PROPN
admet-337	797	20	phillips	phillips	PROPN
admet-337	797	21	,	,	PUNCT
admet-337	797	22	m.hutchison	m.hutchison	PROPN
admet-337	797	23	,	,	PUNCT
admet-337	797	24	xenobiotica	xenobiotica	PROPN
admet-337	797	25	35	35	NUM
admet-337	797	26	(	(	PUNCT
admet-337	797	27	2005	2005	NUM
admet-337	797	28	)	)	PUNCT
admet-337	797	29	39	39	NUM
admet-337	797	30	-	-	SYM
admet-337	797	31	50	50	NUM
admet-337	797	32	.	.	PUNCT
admet-337	798	1	[	[	X
admet-337	798	2	69	69	NUM
admet-337	798	3	]	]	X
admet-337	798	4	d.	d.	PROPN
admet-337	798	5	mckillop	mckillop	PROPN
admet-337	798	6	,	,	PUNCT
admet-337	798	7	s.p	s.p	PROPN
admet-337	798	8	.	.	PROPN
admet-337	798	9	guy	guy	PROPN
admet-337	798	10	,	,	PUNCT
admet-337	798	11	m.p	m.p	PROPN
admet-337	798	12	.	.	PROPN
admet-337	798	13	spence	spence	PROPN
admet-337	798	14	,	,	PUNCT
admet-337	798	15	et	et	PROPN
admet-337	798	16	al	al	PROPN
admet-337	798	17	.	.	PUNCT
admet-337	799	1	xenobiotica	xenobiotica	PROPN
admet-337	799	2	36	36	NUM
admet-337	799	3	(	(	PUNCT
admet-337	799	4	2006	2006	NUM
admet-337	799	5	)	)	PUNCT
admet-337	799	6	29	29	NUM
admet-337	799	7	-	-	SYM
admet-337	799	8	39	39	NUM
admet-337	799	9	.	.	PUNCT
admet-337	800	1	[	[	X
admet-337	800	2	70	70	X
admet-337	800	3	]	]	X
admet-337	800	4	y.	y.	PROPN
admet-337	800	5	togashi	togashi	PROPN
admet-337	800	6	,	,	PUNCT
admet-337	800	7	k.	k.	PROPN
admet-337	800	8	masago	masago	PROPN
admet-337	800	9	,	,	PUNCT
admet-337	800	10	s.	s.	PROPN
admet-337	800	11	masuda	masuda	PROPN
admet-337	800	12	,	,	PUNCT
admet-337	800	13	et	et	PROPN
admet-337	801	1	al	al	PROPN
admet-337	801	2	.	.	PUNCT
admet-337	801	3	cancer	cancer	PROPN
admet-337	801	4	chemother	chemother	PROPN
admet-337	801	5	.	.	PUNCT
admet-337	802	1	pharmacol	pharmacol	PROPN
admet-337	802	2	.	.	PUNCT
admet-337	803	1	70	70	NUM
admet-337	803	2	(	(	PUNCT
admet-337	803	3	2012	2012	NUM
admet-337	803	4	)	)	PUNCT
admet-337	803	5	399	399	NUM
admet-337	803	6	-	-	SYM
admet-337	803	7	405	405	NUM
admet-337	803	8	.	.	PUNCT
admet-337	804	1	[	[	X
admet-337	804	2	71	71	NUM
admet-337	804	3	]	]	X
admet-337	804	4	d.m	d.m	PROPN
admet-337	804	5	.	.	PROPN
admet-337	804	6	jackman	jackman	PROPN
admet-337	804	7	,	,	PUNCT
admet-337	804	8	a.j	a.j	PROPN
admet-337	804	9	.	.	PROPN
admet-337	804	10	holmes	holmes	PROPN
admet-337	804	11	,	,	PUNCT
admet-337	804	12	n.	n.	PROPN
admet-337	804	13	lindeman	lindeman	NOUN
admet-337	804	14	,	,	PUNCT
admet-337	804	15	et	et	PROPN
admet-337	804	16	al	al	PROPN
admet-337	804	17	.	.	PUNCT
admet-337	805	1	j.	j.	PROPN
admet-337	805	2	clin	clin	PROPN
admet-337	805	3	.	.	PUNCT
admet-337	806	1	oncol	oncol	ADJ
admet-337	806	2	.	.	PUNCT
admet-337	807	1	24	24	NUM
admet-337	807	2	(	(	PUNCT
admet-337	807	3	2006	2006	NUM
admet-337	807	4	)	)	PUNCT
admet-337	807	5	4517	4517	NUM
admet-337	807	6	-	-	SYM
admet-337	807	7	4520	4520	NUM
admet-337	807	8	.	.	PUNCT
admet-337	808	1	[	[	X
admet-337	808	2	72	72	NUM
admet-337	808	3	]	]	X
admet-337	808	4	s.	s.	PROPN
admet-337	808	5	kobayashi	kobayashi	PROPN
admet-337	808	6	,	,	PUNCT
admet-337	808	7	t.j	t.j	PROPN
admet-337	808	8	.	.	PROPN
admet-337	808	9	boggon	boggon	PROPN
admet-337	808	10	,	,	PUNCT
admet-337	808	11	t.	t.	PROPN
admet-337	808	12	dayaram	dayaram	PROPN
admet-337	808	13	,	,	PUNCT
admet-337	808	14	et	et	PROPN
admet-337	808	15	al	al	PROPN
admet-337	808	16	.	.	PUNCT
admet-337	808	17	n.	n.	PROPN
admet-337	808	18	engl	engl	PROPN
admet-337	808	19	.	.	PUNCT
admet-337	809	1	j.	j.	PROPN
admet-337	809	2	med	med	PROPN
admet-337	809	3	.	.	PUNCT
admet-337	810	1	352	352	NUM
admet-337	810	2	(	(	PUNCT
admet-337	810	3	2005	2005	NUM
admet-337	810	4	)	)	PUNCT
admet-337	810	5	786	786	NUM
admet-337	810	6	-	-	SYM
admet-337	810	7	792	792	NUM
admet-337	810	8	.	.	PUNCT
admet-337	811	1	[	[	X
admet-337	811	2	73	73	NUM
admet-337	811	3	]	]	X
admet-337	811	4	j.a	j.a	PROPN
admet-337	811	5	.	.	PROPN
admet-337	811	6	engelman	engelman	PROPN
admet-337	811	7	,	,	PUNCT
admet-337	811	8	k.	k.	PROPN
admet-337	811	9	zejnullahu	zejnullahu	PROPN
admet-337	811	10	,	,	PUNCT
admet-337	811	11	t.	t.	PROPN
admet-337	811	12	mitsudomi	mitsudomi	PROPN
admet-337	811	13	,	,	PUNCT
admet-337	811	14	et	et	PROPN
admet-337	811	15	al	al	PROPN
admet-337	811	16	.	.	PROPN
admet-337	811	17	science	science	PROPN
admet-337	811	18	316	316	NUM
admet-337	811	19	(	(	PUNCT
admet-337	811	20	2007	2007	NUM
admet-337	811	21	)	)	PUNCT
admet-337	811	22	1039	1039	NUM
admet-337	811	23	-	-	SYM
admet-337	811	24	1043	1043	NUM
admet-337	811	25	.	.	PUNCT
admet-337	812	1	[	[	X
admet-337	812	2	74	74	NUM
admet-337	812	3	]	]	X
admet-337	812	4	l.v	l.v	PROPN
admet-337	812	5	.	.	PROPN
admet-337	812	6	sequist	sequist	PROPN
admet-337	812	7	,	,	PUNCT
admet-337	812	8	j.c	j.c	PROPN
admet-337	812	9	.	.	PROPN
admet-337	812	10	yang	yang	PROPN
admet-337	812	11	,	,	PUNCT
admet-337	812	12	n.	n.	PROPN
admet-337	812	13	yamamoto	yamamoto	PROPN
admet-337	812	14	,	,	PUNCT
admet-337	812	15	et	et	PROPN
admet-337	812	16	al	al	PROPN
admet-337	812	17	.	.	PUNCT
admet-337	812	18	j.	j.	PROPN
admet-337	812	19	clin	clin	PROPN
admet-337	812	20	.	.	PUNCT
admet-337	813	1	oncol	oncol	ADJ
admet-337	813	2	.	.	PUNCT
admet-337	814	1	31	31	NUM
admet-337	814	2	(	(	PUNCT
admet-337	814	3	2013	2013	NUM
admet-337	814	4	)	)	PUNCT
admet-337	814	5	3327	3327	NUM
admet-337	814	6	-	-	SYM
admet-337	814	7	3334	3334	NUM
admet-337	814	8	.	.	PUNCT
admet-337	815	1	[	[	X
admet-337	815	2	75	75	NUM
admet-337	815	3	]	]	X
admet-337	815	4	y.l	y.l	PROPN
admet-337	815	5	.	.	PROPN
admet-337	815	6	wu	wu	PROPN
admet-337	815	7	,	,	PUNCT
admet-337	815	8	c.	c.	PROPN
admet-337	815	9	zhou	zhou	PROPN
admet-337	815	10	,	,	PUNCT
admet-337	815	11	c.p	c.p	PROPN
admet-337	815	12	.	.	PROPN
admet-337	815	13	hu	hu	PROPN
admet-337	815	14	,	,	PUNCT
admet-337	815	15	et	et	PROPN
admet-337	815	16	al	al	PROPN
admet-337	815	17	.	.	PUNCT
admet-337	816	1	lancet	lancet	PROPN
admet-337	816	2	oncol	oncol	PROPN
admet-337	816	3	.	.	PUNCT
admet-337	817	1	15	15	NUM
admet-337	817	2	(	(	PUNCT
admet-337	817	3	2014	2014	NUM
admet-337	817	4	)	)	PUNCT
admet-337	817	5	213	213	NUM
admet-337	817	6	-	-	SYM
admet-337	817	7	222	222	NUM
admet-337	817	8	.	.	PUNCT
admet-337	818	1	[	[	X
admet-337	818	2	76	76	NUM
admet-337	818	3	]	]	X
admet-337	818	4	j.c	j.c	PROPN
admet-337	818	5	.	.	PROPN
admet-337	818	6	yang	yang	PROPN
admet-337	818	7	,	,	PUNCT
admet-337	818	8	y.l	y.l	PROPN
admet-337	818	9	.	.	PROPN
admet-337	818	10	wu	wu	PROPN
admet-337	818	11	,	,	PUNCT
admet-337	818	12	m.	m.	NOUN
admet-337	818	13	schuler	schuler	NOUN
admet-337	818	14	,	,	PUNCT
admet-337	818	15	et	et	PROPN
admet-337	818	16	al	al	PROPN
admet-337	818	17	.	.	PUNCT
admet-337	818	18	lancet	lancet	PROPN
admet-337	818	19	oncol	oncol	PROPN
admet-337	818	20	.	.	PUNCT
admet-337	819	1	16	16	NUM
admet-337	819	2	(	(	PUNCT
admet-337	819	3	2015	2015	NUM
admet-337	819	4	)	)	PUNCT
admet-337	819	5	141	141	NUM
admet-337	819	6	-	-	SYM
admet-337	819	7	151	151	NUM
admet-337	819	8	.	.	PUNCT
admet-337	820	1	[	[	X
admet-337	820	2	77	77	NUM
admet-337	820	3	]	]	X
admet-337	820	4	k.	k.	PROPN
admet-337	820	5	park	park	PROPN
admet-337	820	6	,	,	PUNCT
admet-337	820	7	e.h	e.h	PROPN
admet-337	820	8	.	.	PROPN
admet-337	820	9	tan	tan	PROPN
admet-337	820	10	,	,	PUNCT
admet-337	820	11	k.	k.	PROPN
admet-337	820	12	o'byrne	o'byrne	PROPN
admet-337	820	13	,	,	PUNCT
admet-337	820	14	et	et	PROPN
admet-337	820	15	al	al	PROPN
admet-337	820	16	.	.	PUNCT
admet-337	821	1	lancet	lancet	PROPN
admet-337	821	2	oncol	oncol	PROPN
admet-337	821	3	.	.	PUNCT
admet-337	822	1	17	17	NUM
admet-337	822	2	(	(	PUNCT
admet-337	822	3	2016	2016	NUM
admet-337	822	4	)	)	PUNCT
admet-337	822	5	577	577	NUM
admet-337	822	6	-	-	SYM
admet-337	822	7	589	589	NUM
admet-337	822	8	.	.	PUNCT
admet-337	823	1	[	[	X
admet-337	823	2	78	78	NUM
admet-337	823	3	]	]	X
admet-337	823	4	j.c	j.c	PROPN
admet-337	823	5	.	.	PROPN
admet-337	823	6	soria	soria	PROPN
admet-337	823	7	,	,	PUNCT
admet-337	823	8	e.	e.	PROPN
admet-337	823	9	felip	felip	PROPN
admet-337	823	10	,	,	PUNCT
admet-337	823	11	m.	m.	PROPN
admet-337	823	12	cobo	cobo	PROPN
admet-337	823	13	,	,	PUNCT
admet-337	823	14	et	et	PROPN
admet-337	823	15	al	al	PROPN
admet-337	823	16	.	.	PUNCT
admet-337	824	1	lancet	lancet	PROPN
admet-337	824	2	oncol	oncol	PROPN
admet-337	824	3	.	.	PUNCT
admet-337	825	1	16	16	NUM
admet-337	825	2	(	(	PUNCT
admet-337	825	3	2015	2015	NUM
admet-337	825	4	)	)	PUNCT
admet-337	825	5	897	897	NUM
admet-337	825	6	-	-	SYM
admet-337	825	7	907	907	NUM
admet-337	825	8	.	.	PUNCT
admet-337	826	1	[	[	X
admet-337	826	2	79	79	NUM
admet-337	826	3	]	]	X
admet-337	826	4	n.	n.	PROPN
admet-337	826	5	katakami	katakami	PROPN
admet-337	826	6	,	,	PUNCT
admet-337	826	7	s.	s.	PROPN
admet-337	826	8	atagi	atagi	PROPN
admet-337	826	9	,	,	PUNCT
admet-337	826	10	k.	k.	PROPN
admet-337	826	11	goto	goto	PROPN
admet-337	826	12	,	,	PUNCT
admet-337	826	13	et	et	PROPN
admet-337	826	14	al	al	PROPN
admet-337	826	15	.	.	PUNCT
admet-337	827	1	j.	j.	PROPN
admet-337	827	2	clin	clin	PROPN
admet-337	827	3	.	.	PUNCT
admet-337	828	1	oncol	oncol	ADJ
admet-337	828	2	.	.	PUNCT
admet-337	829	1	31	31	NUM
admet-337	829	2	(	(	PUNCT
admet-337	829	3	2013	2013	NUM
admet-337	829	4	)	)	PUNCT
admet-337	829	5	3335	3335	NUM
admet-337	829	6	-	-	SYM
admet-337	829	7	3341	3341	NUM
admet-337	829	8	.	.	PUNCT
admet-337	830	1	[	[	X
admet-337	830	2	80	80	NUM
admet-337	830	3	]	]	X
admet-337	830	4	y.y	y.y	PROPN
admet-337	830	5	.	.	PROPN
admet-337	830	6	janjigian	janjigian	PROPN
admet-337	830	7	,	,	PUNCT
admet-337	830	8	e.f	e.f	PROPN
admet-337	830	9	.	.	PROPN
admet-337	830	10	smit	smit	PROPN
admet-337	830	11	,	,	PUNCT
admet-337	830	12	h.j	h.j	PROPN
admet-337	830	13	.	.	PROPN
admet-337	830	14	groen	groen	PROPN
admet-337	830	15	,	,	PUNCT
admet-337	830	16	et	et	PROPN
admet-337	830	17	al	al	PROPN
admet-337	830	18	.	.	PUNCT
admet-337	830	19	cancer	cancer	NOUN
admet-337	830	20	.	.	PUNCT
admet-337	831	1	discov	discov	NOUN
admet-337	831	2	.	.	PUNCT
admet-337	832	1	4	4	NUM
admet-337	832	2	(	(	PUNCT
admet-337	832	3	2014	2014	NUM
admet-337	832	4	)	)	PUNCT
admet-337	832	5	1036	1036	NUM
admet-337	832	6	-	-	SYM
admet-337	832	7	1045	1045	NUM
admet-337	832	8	.	.	PUNCT
admet-337	833	1	[	[	X
admet-337	833	2	81	81	NUM
admet-337	833	3	]	]	PUNCT
admet-337	833	4	f.	f.	PROPN
admet-337	833	5	solca	solca	PROPN
admet-337	833	6	,	,	PUNCT
admet-337	833	7	g.	g.	PROPN
admet-337	833	8	dahl	dahl	PROPN
admet-337	833	9	,	,	PUNCT
admet-337	833	10	a.	a.	PROPN
admet-337	833	11	zoephel	zoephel	PROPN
admet-337	833	12	,	,	PUNCT
admet-337	833	13	et	et	PROPN
admet-337	833	14	al	al	PROPN
admet-337	833	15	.	.	PUNCT
admet-337	834	1	j.	j.	PROPN
admet-337	834	2	pharmacol	pharmacol	PROPN
admet-337	834	3	.	.	PUNCT
admet-337	835	1	exp	exp	PROPN
admet-337	835	2	.	.	PUNCT
admet-337	836	1	ther	ther	PROPN
admet-337	836	2	.	.	PUNCT
admet-337	837	1	343	343	NUM
admet-337	837	2	(	(	PUNCT
admet-337	837	3	2012	2012	NUM
admet-337	837	4	)	)	PUNCT
admet-337	837	5	342	342	NUM
admet-337	837	6	-	-	SYM
admet-337	837	7	350	350	NUM
admet-337	837	8	.	.	PUNCT
admet-337	838	1	[	[	X
admet-337	838	2	82	82	NUM
admet-337	838	3	]	]	X
admet-337	838	4	d.	d.	PROPN
admet-337	838	5	li	li	PROPN
admet-337	838	6	,	,	PUNCT
admet-337	838	7	l.	l.	PROPN
admet-337	838	8	ambrogio	ambrogio	PROPN
admet-337	838	9	,	,	PUNCT
admet-337	838	10	t.	t.	PROPN
admet-337	838	11	shimamura	shimamura	NOUN
admet-337	838	12	,	,	PUNCT
admet-337	838	13	et	et	PROPN
admet-337	838	14	al	al	PROPN
admet-337	838	15	.	.	PUNCT
admet-337	838	16	oncogene	oncogene	NOUN
admet-337	838	17	27	27	NUM
admet-337	838	18	(	(	PUNCT
admet-337	838	19	2008	2008	NUM
admet-337	838	20	)	)	PUNCT
admet-337	838	21	4702	4702	NUM
admet-337	838	22	-	-	SYM
admet-337	838	23	4711	4711	NUM
admet-337	838	24	.	.	PUNCT
admet-337	839	1	[	[	X
admet-337	839	2	83	83	NUM
admet-337	839	3	]	]	X
admet-337	839	4	s.	s.	PROPN
admet-337	839	5	wind	wind	PROPN
admet-337	839	6	,	,	PUNCT
admet-337	839	7	m.	m.	PROPN
admet-337	839	8	schmid	schmid	PROPN
admet-337	839	9	,	,	PUNCT
admet-337	839	10	j.	j.	PROPN
admet-337	839	11	erhardt	erhardt	PROPN
admet-337	839	12	,	,	PUNCT
admet-337	839	13	r.g	r.g	PROPN
admet-337	839	14	.	.	PROPN
admet-337	839	15	goeldner	goeldner	NOUN
admet-337	839	16	,	,	PUNCT
admet-337	839	17	p.	p.	NOUN
admet-337	839	18	stopfer	stopfer	NOUN
admet-337	839	19	,	,	PUNCT
admet-337	839	20	clin	clin	PROPN
admet-337	839	21	.	.	PUNCT
admet-337	839	22	pharmacokinet	pharmacokinet	PROPN
admet-337	839	23	.	.	PUNCT
admet-337	840	1	52	52	NUM
admet-337	840	2	(	(	PUNCT
admet-337	840	3	2013	2013	NUM
admet-337	840	4	)	)	PUNCT
admet-337	840	5	1101	1101	NUM
admet-337	840	6	-	-	PUNCT
admet-337	840	7	1109	1109	NUM
admet-337	840	8	.	.	PUNCT
admet-337	841	1	[	[	X
admet-337	841	2	84	84	NUM
admet-337	841	3	]	]	X
admet-337	841	4	p.	p.	NOUN
admet-337	841	5	stopfer	stopfer	NOUN
admet-337	841	6	,	,	PUNCT
admet-337	841	7	k.	k.	PROPN
admet-337	841	8	marzin	marzin	PROPN
admet-337	841	9	,	,	PUNCT
admet-337	841	10	h.	h.	PROPN
admet-337	841	11	narjes	narjes	PROPN
admet-337	841	12	,	,	PUNCT
admet-337	841	13	et	et	PROPN
admet-337	841	14	al	al	PROPN
admet-337	841	15	.	.	PUNCT
admet-337	841	16	cancer	cancer	PROPN
admet-337	841	17	chemother	chemother	PROPN
admet-337	841	18	.	.	PUNCT
admet-337	842	1	pharmacol	pharmacol	PROPN
admet-337	842	2	.	.	PUNCT
admet-337	843	1	69	69	NUM
admet-337	843	2	(	(	PUNCT
admet-337	843	3	2012	2012	NUM
admet-337	843	4	)	)	PUNCT
admet-337	843	5	1051	1051	NUM
admet-337	843	6	-	-	SYM
admet-337	843	7	1061	1061	NUM
admet-337	843	8	.	.	PUNCT
admet-337	844	1	[	[	X
admet-337	844	2	85	85	NUM
admet-337	844	3	]	]	PUNCT
admet-337	844	4	s.	s.	PROPN
admet-337	844	5	wind	wind	PROPN
admet-337	844	6	,	,	PUNCT
admet-337	844	7	t.	t.	NOUN
admet-337	844	8	giessmann	giessmann	PROPN
admet-337	844	9	,	,	PUNCT
admet-337	844	10	a.	a.	NOUN
admet-337	844	11	jungnik	jungnik	PROPN
admet-337	844	12	,	,	PUNCT
admet-337	844	13	et	et	PROPN
admet-337	844	14	al	al	PROPN
admet-337	844	15	.	.	PUNCT
admet-337	845	1	clin	clin	PROPN
admet-337	845	2	.	.	PUNCT
admet-337	846	1	drug	drug	PROPN
admet-337	846	2	investig	investig	PROPN
admet-337	846	3	.	.	PROPN
admet-337	847	1	34	34	NUM
admet-337	847	2	(	(	PUNCT
admet-337	847	3	2014	2014	NUM
admet-337	847	4	)	)	PUNCT
admet-337	847	5	173	173	NUM
admet-337	847	6	-	-	SYM
admet-337	847	7	182	182	NUM
admet-337	847	8	.	.	PUNCT
admet-337	848	1	[	[	X
admet-337	848	2	86	86	NUM
admet-337	848	3	]	]	PUNCT
admet-337	848	4	p.	p.	PROPN
admet-337	848	5	hoffknecht	hoffknecht	PROPN
admet-337	848	6	,	,	PUNCT
admet-337	848	7	a.	a.	NOUN
admet-337	848	8	tufman	tufman	NOUN
admet-337	848	9	,	,	PUNCT
admet-337	848	10	t.	t.	NOUN
admet-337	848	11	wehler	wehler	NOUN
admet-337	848	12	,	,	PUNCT
admet-337	848	13	et	et	PROPN
admet-337	848	14	al	al	PROPN
admet-337	848	15	.	.	PUNCT
admet-337	849	1	j.	j.	PROPN
admet-337	849	2	thorac	thorac	PROPN
admet-337	849	3	.	.	PUNCT
admet-337	850	1	oncol	oncol	ADJ
admet-337	850	2	.	.	PUNCT
admet-337	851	1	10	10	NUM
admet-337	851	2	(	(	PUNCT
admet-337	851	3	2015	2015	NUM
admet-337	851	4	)	)	PUNCT
admet-337	851	5	156	156	NUM
admet-337	851	6	-	-	SYM
admet-337	851	7	163	163	NUM
admet-337	851	8	.	.	PUNCT
admet-337	852	1	[	[	X
admet-337	852	2	87	87	NUM
admet-337	852	3	]	]	X
admet-337	852	4	s.g	s.g	PROPN
admet-337	852	5	.	.	PROPN
admet-337	852	6	wu	wu	PROPN
admet-337	852	7	,	,	PUNCT
admet-337	852	8	y.n	y.n	PROPN
admet-337	852	9	.	.	PROPN
admet-337	852	10	liu	liu	PROPN
admet-337	852	11	,	,	PUNCT
admet-337	852	12	m.f	m.f	PROPN
admet-337	852	13	.	.	PUNCT
admet-337	852	14	tsai	tsai	PROPN
admet-337	852	15	,	,	PUNCT
admet-337	852	16	et	et	PROPN
admet-337	852	17	al	al	PROPN
admet-337	852	18	.	.	PROPN
admet-337	852	19	oncotarget	oncotarget	PROPN
admet-337	852	20	.	.	PUNCT
admet-337	853	1	7	7	NUM
admet-337	853	2	(	(	PUNCT
admet-337	853	3	2016	2016	NUM
admet-337	853	4	)	)	PUNCT
admet-337	853	5	12404	12404	NUM
admet-337	853	6	-	-	SYM
admet-337	853	7	12413	12413	NUM
admet-337	853	8	.	.	PUNCT
admet-337	854	1	[	[	X
admet-337	854	2	88	88	NUM
admet-337	854	3	]	]	X
admet-337	854	4	s.m	s.m	PROPN
admet-337	854	5	.	.	PUNCT
admet-337	854	6	kim	kim	PROPN
admet-337	854	7	,	,	PUNCT
admet-337	854	8	o.j	o.j	PROPN
admet-337	854	9	.	.	PROPN
admet-337	854	10	kwon	kwon	PROPN
admet-337	854	11	,	,	PUNCT
admet-337	854	12	y.k	y.k	PROPN
admet-337	854	13	.	.	PROPN
admet-337	854	14	hong	hong	PROPN
admet-337	854	15	,	,	PUNCT
admet-337	854	16	et	et	PROPN
admet-337	854	17	al	al	PROPN
admet-337	854	18	.	.	PROPN
admet-337	854	19	mol	mol	PROPN
admet-337	854	20	.	.	PUNCT
admet-337	854	21	cancer	cancer	NOUN
admet-337	854	22	.	.	PUNCT
admet-337	855	1	ther	ther	INTJ
admet-337	855	2	.	.	PUNCT
admet-337	856	1	11	11	NUM
admet-337	856	2	(	(	PUNCT
admet-337	856	3	2012	2012	NUM
admet-337	856	4	)	)	PUNCT
admet-337	856	5	2254	2254	NUM
admet-337	856	6	-	-	SYM
admet-337	856	7	2264	2264	NUM
admet-337	856	8	.	.	PUNCT
admet-337	857	1	[	[	X
admet-337	857	2	89	89	NUM
admet-337	857	3	]	]	PUNCT
admet-337	857	4	k.	k.	PROPN
admet-337	857	5	azuma	azuma	PROPN
admet-337	857	6	,	,	PUNCT
admet-337	857	7	a.	a.	PROPN
admet-337	857	8	kawahara	kawahara	PROPN
admet-337	857	9	,	,	PUNCT
admet-337	857	10	k.	k.	PROPN
admet-337	857	11	sonoda	sonoda	PROPN
admet-337	857	12	,	,	PUNCT
admet-337	857	13	et	et	PROPN
admet-337	857	14	al	al	PROPN
admet-337	857	15	.	.	PROPN
admet-337	857	16	oncotarget	oncotarget	PROPN
admet-337	857	17	.	.	PUNCT
admet-337	858	1	5	5	NUM
admet-337	858	2	(	(	PUNCT
admet-337	858	3	2014	2014	NUM
admet-337	858	4	)	)	PUNCT
admet-337	858	5	5908	5908	NUM
admet-337	858	6	-	-	SYM
admet-337	858	7	5919	5919	NUM
admet-337	858	8	.	.	PUNCT
admet-337	859	1	[	[	X
admet-337	859	2	90	90	NUM
admet-337	859	3	]	]	PUNCT
admet-337	859	4	s.	s.	PROPN
admet-337	859	5	huang	huang	PROPN
admet-337	859	6	,	,	PUNCT
admet-337	859	7	s.	s.	PROPN
admet-337	859	8	benavente	benavente	PROPN
admet-337	859	9	,	,	PUNCT
admet-337	859	10	e.a	e.a	PROPN
admet-337	859	11	.	.	PROPN
admet-337	859	12	armstrong	armstrong	PROPN
admet-337	859	13	,	,	PUNCT
admet-337	859	14	c.	c.	PROPN
admet-337	859	15	li	li	PROPN
admet-337	859	16	,	,	PUNCT
admet-337	859	17	d.l	d.l	PROPN
admet-337	859	18	.	.	PROPN
admet-337	859	19	wheeler	wheeler	NOUN
admet-337	859	20	,	,	PUNCT
admet-337	859	21	p.m.	p.m.	NOUN
admet-337	859	22	harari	harari	PROPN
admet-337	859	23	,	,	PUNCT
admet-337	859	24	cancer	cancer	NOUN
admet-337	859	25	res	re	NOUN
admet-337	859	26	.	.	PUNCT
admet-337	860	1	71	71	NUM
admet-337	860	2	(	(	PUNCT
admet-337	860	3	2011	2011	NUM
admet-337	860	4	)	)	PUNCT
admet-337	860	5	70717079	70717079	NUM
admet-337	860	6	.	.	PUNCT
admet-337	861	1	[	[	X
admet-337	861	2	91	91	NUM
admet-337	861	3	]	]	X
admet-337	861	4	d.a	d.a	PROPN
admet-337	861	5	.	.	PROPN
admet-337	861	6	cross	cross	PROPN
admet-337	861	7	,	,	PUNCT
admet-337	861	8	s.e	s.e	PROPN
admet-337	861	9	.	.	PROPN
admet-337	861	10	ashton	ashton	PROPN
admet-337	861	11	,	,	PUNCT
admet-337	861	12	s.	s.	PROPN
admet-337	861	13	ghiorghiu	ghiorghiu	PROPN
admet-337	861	14	,	,	PUNCT
admet-337	861	15	et	et	PROPN
admet-337	861	16	al	al	PROPN
admet-337	861	17	.	.	PUNCT
admet-337	861	18	cancer	cancer	NOUN
admet-337	861	19	discov	discov	NOUN
admet-337	861	20	.	.	PUNCT
admet-337	862	1	4	4	NUM
admet-337	862	2	(	(	PUNCT
admet-337	862	3	2014	2014	NUM
admet-337	862	4	)	)	PUNCT
admet-337	862	5	1046	1046	NUM
admet-337	862	6	-	-	SYM
admet-337	862	7	1061	1061	NUM
admet-337	862	8	.	.	PUNCT
admet-337	863	1	[	[	X
admet-337	863	2	92	92	NUM
admet-337	863	3	]	]	PUNCT
admet-337	863	4	r.	r.	PROPN
admet-337	863	5	lawrence	lawrence	PROPN
admet-337	863	6	,	,	PUNCT
admet-337	863	7	et	et	PROPN
admet-337	863	8	al	al	PROPN
admet-337	863	9	.	.	PUNCT
admet-337	864	1	j.	j.	PROPN
admet-337	864	2	thorac	thorac	PROPN
admet-337	864	3	.	.	PUNCT
admet-337	865	1	oncol	oncol	ADJ
admet-337	865	2	.	.	PUNCT
admet-337	866	1	10	10	NUM
admet-337	866	2	(	(	PUNCT
admet-337	866	3	2015	2015	NUM
admet-337	866	4	)	)	PUNCT
admet-337	866	5	s66	s66	NOUN
admet-337	866	6	-	-	PUNCT
admet-337	866	7	s890	s890	PROPN
admet-337	866	8	.	.	PUNCT
admet-337	867	1	[	[	X
admet-337	867	2	93	93	X
admet-337	867	3	]	]	PUNCT
admet-337	867	4	j.	j.	PROPN
admet-337	867	5	yang	yang	PROPN
admet-337	867	6	,	,	PUNCT
admet-337	867	7	s.s	s.s	PROPN
admet-337	867	8	.	.	PROPN
admet-337	867	9	ramalingam	ramalingam	PROPN
admet-337	867	10	,	,	PUNCT
admet-337	867	11	p.a	p.a	PROPN
admet-337	867	12	.	.	PROPN
admet-337	867	13	janne	janne	PROPN
admet-337	867	14	,	,	PUNCT
admet-337	867	15	m.	m.	NOUN
admet-337	867	16	cantarini	cantarini	PROPN
admet-337	867	17	,	,	PUNCT
admet-337	867	18	t.	t.	PROPN
admet-337	867	19	mitsudomi	mitsudomi	PROPN
admet-337	867	20	,	,	PUNCT
admet-337	867	21	j.	j.	PROPN
admet-337	867	22	thorac	thorac	PROPN
admet-337	867	23	.	.	PUNCT
admet-337	868	1	oncol	oncol	ADJ
admet-337	868	2	.	.	PUNCT
admet-337	869	1	11	11	NUM
admet-337	869	2	(	(	PUNCT
admet-337	869	3	2016	2016	NUM
admet-337	869	4	)	)	PUNCT
admet-337	870	1	s152	s152	PROPN
admet-337	870	2	-	-	SYM
admet-337	870	3	3	3	NUM
admet-337	870	4	.	.	PUNCT
admet-337	871	1	[	[	X
admet-337	871	2	94	94	NUM
admet-337	871	3	]	]	PUNCT
admet-337	871	4	s.l.greig	s.l.greig	NOUN
admet-337	871	5	,	,	PUNCT
admet-337	871	6	drugs	drug	NOUN
admet-337	871	7	76	76	NUM
admet-337	871	8	(	(	PUNCT
admet-337	871	9	2016	2016	NUM
admet-337	871	10	)	)	PUNCT
admet-337	871	11	263	263	NUM
admet-337	871	12	-	-	SYM
admet-337	871	13	273	273	NUM
admet-337	871	14	.	.	PUNCT
admet-337	872	1	[	[	X
admet-337	872	2	95	95	NUM
admet-337	872	3	]	]	X
admet-337	872	4	d.	d.	PROPN
admet-337	872	5	planchard	planchard	PROPN
admet-337	872	6	,	,	PUNCT
admet-337	872	7	k.h	k.h	PROPN
admet-337	872	8	.	.	PROPN
admet-337	872	9	brown	brown	PROPN
admet-337	872	10	,	,	PUNCT
admet-337	872	11	d.w	d.w	PROPN
admet-337	872	12	.	.	PUNCT
admet-337	872	13	kim	kim	PROPN
admet-337	872	14	,	,	PUNCT
admet-337	872	15	et	et	PROPN
admet-337	872	16	al	al	PROPN
admet-337	872	17	.	.	PUNCT
admet-337	872	18	cancer	cancer	PROPN
admet-337	872	19	chemother	chemother	PROPN
admet-337	872	20	pharmacol	pharmacol	PROPN
admet-337	872	21	.	.	PUNCT
admet-337	873	1	77	77	NUM
admet-337	873	2	(	(	PUNCT
admet-337	873	3	2016	2016	NUM
admet-337	873	4	)	)	PUNCT
admet-337	873	5	767	767	NUM
admet-337	873	6	-	-	SYM
admet-337	873	7	776	776	NUM
admet-337	873	8	.	.	PUNCT
admet-337	874	1	[	[	X
admet-337	874	2	96	96	NUM
admet-337	874	3	]	]	X
admet-337	874	4	b.	b.	PROPN
admet-337	874	5	ricciuti	ricciuti	PROPN
admet-337	874	6	,	,	PUNCT
admet-337	874	7	r.	r.	NOUN
admet-337	874	8	chiari	chiari	NOUN
admet-337	874	9	,	,	PUNCT
admet-337	874	10	p.	p.	NOUN
admet-337	874	11	chiarini	chiarini	PROPN
admet-337	874	12	,	,	PUNCT
admet-337	874	13	et	et	PROPN
admet-337	874	14	al	al	PROPN
admet-337	874	15	.	.	PUNCT
admet-337	875	1	clin	clin	PROPN
admet-337	875	2	.	.	PUNCT
admet-337	876	1	drug	drug	NOUN
admet-337	876	2	investig.36	investig.36	PROPN
admet-337	876	3	(	(	PUNCT
admet-337	876	4	2016	2016	NUM
admet-337	876	5	)	)	PUNCT
admet-337	876	6	683	683	NUM
admet-337	876	7	-	-	SYM
admet-337	876	8	686	686	NUM
admet-337	876	9	.	.	PUNCT
admet-337	877	1	admet	admet	PROPN
admet-337	877	2	&	&	CCONJ
admet-337	877	3	dmpk	dmpk	PROPN
admet-337	877	4	4(3	4(3	NUM
admet-337	877	5	)	)	PUNCT
admet-337	877	6	(	(	PUNCT
admet-337	877	7	2016	2016	NUM
admet-337	877	8	)	)	PUNCT
admet-337	877	9	186	186	NUM
admet-337	877	10	-	-	SYM
admet-337	877	11	211	211	NUM
admet-337	877	12	tki	tki	NOUN
admet-337	877	13	for	for	ADP
admet-337	877	14	egfrand	egfrand	ADJ
admet-337	877	15	alk	alk	PROPN
admet-337	877	16	-	-	PUNCT
admet-337	877	17	mutated	mutate	VERB
admet-337	877	18	cell	cell	NOUN
admet-337	877	19	cancer	cancer	NOUN
admet-337	877	20	doi	doi	NOUN
admet-337	877	21	:	:	PUNCT
admet-337	877	22	10.5599	10.5599	NUM
admet-337	877	23	/	/	SYM
admet-337	877	24	admet.4.3.337	admet.4.3.337	NUM
admet-337	877	25	209	209	NUM
admet-337	877	26	[	[	X
admet-337	877	27	97	97	NUM
admet-337	877	28	]	]	X
admet-337	877	29	j.c	j.c	PROPN
admet-337	877	30	.	.	PROPN
admet-337	877	31	yang	yang	PROPN
admet-337	877	32	,	,	PUNCT
admet-337	877	33	d.w	d.w	PROPN
admet-337	877	34	.	.	PUNCT
admet-337	878	1	kim	kim	PROPN
admet-337	878	2	,	,	PUNCT
admet-337	878	3	s.w	s.w	PROPN
admet-337	878	4	.	.	PROPN
admet-337	878	5	kim	kim	PROPN
admet-337	878	6	,	,	PUNCT
admet-337	878	7	et	et	PROPN
admet-337	878	8	al	al	PROPN
admet-337	878	9	.	.	PROPN
admet-337	878	10	osimertinib	osimertinib	NOUN
admet-337	878	11	activity	activity	NOUN
admet-337	878	12	in	in	ADP
admet-337	878	13	patients	patient	NOUN
admet-337	878	14	(	(	PUNCT
admet-337	878	15	pts	pt	NOUN
admet-337	878	16	)	)	PUNCT
admet-337	878	17	with	with	ADP
admet-337	878	18	leptomeningeal	leptomeningeal	NOUN
admet-337	878	19	(	(	PUNCT
admet-337	878	20	lm	lm	ADJ
admet-337	878	21	)	)	PUNCT
admet-337	878	22	disease	disease	NOUN
admet-337	878	23	from	from	ADP
admet-337	878	24	non	non	ADJ
admet-337	878	25	-	-	ADJ
admet-337	878	26	small	small	ADJ
admet-337	878	27	cell	cell	NOUN
admet-337	878	28	lung	lung	NOUN
admet-337	878	29	cancer	cancer	NOUN
admet-337	878	30	(	(	PUNCT
admet-337	878	31	nsclc	nsclc	NOUN
admet-337	878	32	):	):	PUNCT
admet-337	878	33	updated	update	VERB
admet-337	878	34	results	result	NOUN
admet-337	878	35	from	from	ADP
admet-337	878	36	bloom	bloom	NOUN
admet-337	878	37	,	,	PUNCT
admet-337	878	38	a	a	DET
admet-337	878	39	phase	phase	NOUN
admet-337	878	40	i	i	PRON
admet-337	878	41	study	study	VERB
admet-337	878	42	.	.	PUNCT
admet-337	879	1	american	american	ADJ
admet-337	879	2	society	society	NOUN
admet-337	879	3	of	of	ADP
admet-337	879	4	clinical	clinical	ADJ
admet-337	879	5	oncology	oncology	NOUN
admet-337	879	6	annual	annual	ADJ
admet-337	879	7	meeting	meeting	NOUN
admet-337	879	8	2016	2016	NUM
admet-337	879	9	.	.	PUNCT
admet-337	880	1	[	[	X
admet-337	880	2	98	98	NUM
admet-337	880	3	]	]	X
admet-337	880	4	h.a	h.a	PROPN
admet-337	880	5	.	.	PROPN
admet-337	880	6	yu	yu	PROPN
admet-337	880	7	,	,	PUNCT
admet-337	880	8	s.k	s.k	PROPN
admet-337	880	9	.	.	PROPN
admet-337	880	10	tian	tian	PROPN
admet-337	880	11	,	,	PUNCT
admet-337	880	12	a.e	a.e	PROPN
admet-337	880	13	.	.	PROPN
admet-337	880	14	drilon	drilon	PROPN
admet-337	880	15	,	,	PUNCT
admet-337	880	16	et	et	PROPN
admet-337	880	17	al	al	PROPN
admet-337	880	18	.	.	PROPN
admet-337	880	19	jama	jama	PROPN
admet-337	880	20	oncol	oncol	ADJ
admet-337	880	21	.	.	PUNCT
admet-337	881	1	1	1	NUM
admet-337	881	2	(	(	PUNCT
admet-337	881	3	2015	2015	NUM
admet-337	881	4	)	)	PUNCT
admet-337	881	5	982	982	NUM
admet-337	881	6	-	-	SYM
admet-337	881	7	984	984	NUM
admet-337	881	8	.	.	PUNCT
admet-337	882	1	[	[	X
admet-337	882	2	99	99	NUM
admet-337	882	3	]	]	X
admet-337	882	4	k.s	k.s	PROPN
admet-337	882	5	.	.	PROPN
admet-337	882	6	thress	thress	PROPN
admet-337	882	7	,	,	PUNCT
admet-337	882	8	c.p	c.p	PROPN
admet-337	882	9	.	.	PROPN
admet-337	882	10	paweletz	paweletz	PROPN
admet-337	882	11	,	,	PUNCT
admet-337	882	12	e.	e.	PROPN
admet-337	882	13	felip	felip	PROPN
admet-337	882	14	,	,	PUNCT
admet-337	882	15	et	et	PROPN
admet-337	882	16	al	al	PROPN
admet-337	882	17	.	.	PUNCT
admet-337	882	18	nat	nat	PROPN
admet-337	882	19	.	.	PUNCT
admet-337	883	1	med	med	PROPN
admet-337	883	2	.	.	PROPN
admet-337	884	1	21	21	NUM
admet-337	884	2	(	(	PUNCT
admet-337	884	3	2015	2015	NUM
admet-337	884	4	)	)	PUNCT
admet-337	884	5	560	560	NUM
admet-337	884	6	-	-	SYM
admet-337	884	7	562	562	NUM
admet-337	884	8	.	.	PUNCT
admet-337	885	1	[	[	X
admet-337	885	2	100	100	NUM
admet-337	885	3	]	]	X
admet-337	885	4	c.a	c.a	PROPN
admet-337	885	5	.	.	PROPN
admet-337	885	6	eberlein	eberlein	PROPN
admet-337	885	7	,	,	PUNCT
admet-337	885	8	d.	d.	PROPN
admet-337	885	9	stetson	stetson	PROPN
admet-337	885	10	,	,	PUNCT
admet-337	885	11	a.a	a.a	PROPN
admet-337	885	12	.	.	PROPN
admet-337	885	13	markovets	markovet	NOUN
admet-337	885	14	,	,	PUNCT
admet-337	885	15	et	et	PROPN
admet-337	885	16	al	al	PROPN
admet-337	885	17	.	.	PUNCT
admet-337	885	18	cancer	cancer	NOUN
admet-337	885	19	res	re	NOUN
admet-337	885	20	.	.	PUNCT
admet-337	886	1	75	75	NUM
admet-337	886	2	(	(	PUNCT
admet-337	886	3	2015	2015	NUM
admet-337	886	4	)	)	PUNCT
admet-337	886	5	2489	2489	NUM
admet-337	886	6	-	-	SYM
admet-337	886	7	2500	2500	NUM
admet-337	886	8	.	.	PUNCT
admet-337	887	1	[	[	X
admet-337	887	2	101	101	NUM
admet-337	887	3	]	]	PUNCT
admet-337	887	4	k.	k.	PROPN
admet-337	887	5	park	park	PROPN
admet-337	887	6	,	,	PUNCT
admet-337	887	7	j.s	j.s	PROPN
admet-337	887	8	.	.	PROPN
admet-337	887	9	lee	lee	PROPN
admet-337	887	10	,	,	PUNCT
admet-337	887	11	j.y	j.y	PROPN
admet-337	887	12	.	.	PROPN
admet-337	887	13	han	han	PROPN
admet-337	887	14	,	,	PUNCT
admet-337	887	15	et	et	PROPN
admet-337	887	16	al	al	PROPN
admet-337	887	17	.	.	PUNCT
admet-337	888	1	j.	j.	PROPN
admet-337	888	2	thorac	thorac	PROPN
admet-337	888	3	.	.	PUNCT
admet-337	889	1	oncol	oncol	ADJ
admet-337	889	2	.	.	PUNCT
admet-337	890	1	2016;11	2016;11	NUM
admet-337	890	2	:	:	PUNCT
admet-337	890	3	s113	s113	PROPN
admet-337	890	4	-	-	PUNCT
admet-337	890	5	0864(16)30243	0864(16)30243	ADP
admet-337	890	6	-	-	PUNCT
admet-337	890	7	x.	x.	NOUN
admet-337	890	8	epub	epub	PROPN
admet-337	890	9	2016	2016	NUM
admet-337	890	10	apr	apr	NOUN
admet-337	890	11	15	15	NUM
admet-337	890	12	.	.	PUNCT
admet-337	891	1	[	[	X
admet-337	891	2	102	102	NUM
admet-337	891	3	]	]	X
admet-337	891	4	k.	k.	PROPN
admet-337	891	5	park	park	PROPN
admet-337	891	6	,	,	PUNCT
admet-337	891	7	j.y	j.y	PROPN
admet-337	891	8	.	.	PROPN
admet-337	891	9	han	han	PROPN
admet-337	891	10	,	,	PUNCT
admet-337	891	11	d.w	d.w	PROPN
admet-337	891	12	.	.	PUNCT
admet-337	891	13	kim	kim	PROPN
admet-337	891	14	,	,	PUNCT
admet-337	891	15	et	et	PROPN
admet-337	891	16	al	al	PROPN
admet-337	891	17	.	.	PUNCT
admet-337	892	1	j.	j.	PROPN
admet-337	892	2	thorac	thorac	PROPN
admet-337	892	3	.	.	PUNCT
admet-337	893	1	oncol	oncol	ADJ
admet-337	893	2	.	.	PUNCT
admet-337	894	1	2016;11	2016;11	NUM
admet-337	894	2	:	:	PUNCT
admet-337	894	3	s139	s139	PROPN
admet-337	894	4	-	-	PUNCT
admet-337	894	5	0864(16)30299	0864(16)30299	NUM
admet-337	894	6	-	-	PUNCT
admet-337	894	7	4	4	NUM
admet-337	894	8	.	.	PUNCT
admet-337	895	1	epub	epub	NOUN
admet-337	895	2	2016	2016	NUM
admet-337	895	3	apr	apr	NOUN
admet-337	895	4	15	15	NUM
admet-337	895	5	.	.	PUNCT
admet-337	896	1	[	[	X
admet-337	896	2	103	103	NUM
admet-337	896	3	]	]	X
admet-337	896	4	h.a	h.a	PROPN
admet-337	896	5	.	.	PROPN
admet-337	896	6	yu	yu	PROPN
admet-337	896	7	,	,	PUNCT
admet-337	896	8	a.	a.	PROPN
admet-337	896	9	spira	spira	PROPN
admet-337	896	10	,	,	PUNCT
admet-337	896	11	l.	l.	PROPN
admet-337	896	12	horn	horn	PROPN
admet-337	896	13	,	,	PUNCT
admet-337	896	14	et	et	PROPN
admet-337	896	15	al	al	PROPN
admet-337	896	16	.	.	PUNCT
admet-337	896	17	antitumor	antitumor	PROPN
admet-337	896	18	activity	activity	NOUN
admet-337	896	19	of	of	ADP
admet-337	896	20	asp8273	asp8273	NOUN
admet-337	896	21	300	300	NUM
admet-337	896	22	mg	mg	NOUN
admet-337	896	23	in	in	ADP
admet-337	896	24	subjects	subject	NOUN
admet-337	896	25	with	with	ADP
admet-337	896	26	egfr	egfr	ADJ
admet-337	896	27	mutation	mutation	NOUN
admet-337	896	28	-	-	PUNCT
admet-337	896	29	positive	positive	ADJ
admet-337	896	30	non	non	ADJ
admet-337	896	31	-	-	ADJ
admet-337	896	32	small	small	ADJ
admet-337	896	33	cell	cell	NOUN
admet-337	896	34	lung	lung	NOUN
admet-337	896	35	cancer	cancer	NOUN
admet-337	896	36	:	:	PUNCT
admet-337	896	37	interim	interim	ADJ
admet-337	896	38	results	result	NOUN
admet-337	896	39	from	from	ADP
admet-337	896	40	an	an	DET
admet-337	896	41	ongoing	ongoing	ADJ
admet-337	896	42	phase	phase	NOUN
admet-337	896	43	1	1	NUM
admet-337	896	44	study	study	NOUN
admet-337	896	45	.	.	PUNCT
admet-337	897	1	american	american	ADJ
admet-337	897	2	society	society	NOUN
admet-337	897	3	of	of	ADP
admet-337	897	4	clinical	clinical	ADJ
admet-337	897	5	oncology	oncology	NOUN
admet-337	897	6	annual	annual	ADJ
admet-337	897	7	meeting	meeting	NOUN
admet-337	897	8	2016	2016	NUM
admet-337	897	9	.	.	PUNCT
admet-337	898	1	[	[	X
admet-337	898	2	104	104	NUM
admet-337	898	3	]	]	X
admet-337	898	4	d.s	d.s	PROPN
admet-337	898	5	.	.	PROPN
admet-337	898	6	tan	tan	PROPN
admet-337	898	7	,	,	PUNCT
admet-337	898	8	j.c	j.c	PROPN
admet-337	898	9	.	.	PROPN
admet-337	898	10	yang	yang	PROPN
admet-337	898	11	,	,	PUNCT
admet-337	898	12	n.	n.	PROPN
admet-337	898	13	leighl	leighl	PROPN
admet-337	898	14	,	,	PUNCT
admet-337	898	15	et	et	PROPN
admet-337	898	16	al	al	PROPN
admet-337	898	17	.	.	PROPN
admet-337	898	18	updated	update	VERB
admet-337	898	19	results	result	NOUN
admet-337	898	20	of	of	ADP
admet-337	898	21	a	a	DET
admet-337	898	22	phase	phase	NOUN
admet-337	898	23	1	1	NUM
admet-337	898	24	study	study	NOUN
admet-337	898	25	of	of	ADP
admet-337	898	26	egf816	egf816	PROPN
admet-337	898	27	,	,	PUNCT
admet-337	898	28	a	a	DET
admet-337	898	29	third	third	ADJ
admet-337	898	30	-	-	PUNCT
admet-337	898	31	generation	generation	NOUN
admet-337	898	32	,	,	PUNCT
admet-337	898	33	mutant	mutant	ADJ
admet-337	898	34	-	-	PUNCT
admet-337	898	35	selective	selective	ADJ
admet-337	898	36	egfr	egfr	ADJ
admet-337	898	37	tyrosine	tyrosine	PROPN
admet-337	898	38	kinase	kinase	PROPN
admet-337	898	39	inhibitor	inhibitor	PROPN
admet-337	898	40	(	(	PUNCT
admet-337	898	41	tki	tki	NOUN
admet-337	898	42	)	)	PUNCT
admet-337	898	43	,	,	PUNCT
admet-337	898	44	in	in	ADP
admet-337	898	45	advanced	advanced	ADJ
admet-337	898	46	non	non	ADJ
admet-337	898	47	-	-	ADJ
admet-337	898	48	small	small	ADJ
admet-337	898	49	cell	cell	NOUN
admet-337	898	50	lung	lung	NOUN
admet-337	898	51	cancer	cancer	NOUN
admet-337	898	52	(	(	PUNCT
admet-337	898	53	nsclc	nsclc	NOUN
admet-337	898	54	)	)	PUNCT
admet-337	898	55	harboring	harbor	VERB
admet-337	898	56	t790	t790	NUM
admet-337	898	57	m.	m.	NOUN
admet-337	898	58	american	american	ADJ
admet-337	898	59	society	society	NOUN
admet-337	898	60	of	of	ADP
admet-337	898	61	clinical	clinical	ADJ
admet-337	898	62	oncology	oncology	NOUN
admet-337	898	63	annual	annual	ADJ
admet-337	898	64	meeting	meeting	NOUN
admet-337	898	65	2016	2016	NUM
admet-337	898	66	.	.	PUNCT
admet-337	899	1	[	[	X
admet-337	899	2	105	105	NUM
admet-337	899	3	]	]	PUNCT
admet-337	899	4	q.	q.	PROPN
admet-337	899	5	zhou	zhou	PROPN
admet-337	899	6	,	,	PUNCT
admet-337	899	7	b.	b.	PROPN
admet-337	899	8	gan	gan	PROPN
admet-337	899	9	,	,	PUNCT
admet-337	899	10	l.	l.	PROPN
admet-337	899	11	yuan	yuan	PROPN
admet-337	899	12	,	,	PUNCT
admet-337	899	13	et	et	PROPN
admet-337	899	14	al	al	PROPN
admet-337	899	15	.	.	PUNCT
admet-337	900	1	the	the	DET
admet-337	900	2	safety	safety	NOUN
admet-337	900	3	profile	profile	NOUN
admet-337	900	4	of	of	ADP
admet-337	900	5	a	a	DET
admet-337	900	6	selective	selective	ADJ
admet-337	900	7	egfr	egfr	NOUN
admet-337	900	8	tki	tki	X
admet-337	900	9	epitinib	epitinib	NOUN
admet-337	900	10	(	(	PUNCT
admet-337	900	11	hmpl-813	hmpl-813	NOUN
admet-337	900	12	)	)	PUNCT
admet-337	900	13	in	in	ADP
admet-337	900	14	patients	patient	NOUN
admet-337	900	15	with	with	ADP
admet-337	900	16	advanced	advanced	ADJ
admet-337	900	17	solid	solid	ADJ
admet-337	900	18	tumors	tumor	NOUN
admet-337	900	19	and	and	CCONJ
admet-337	900	20	preliminary	preliminary	ADJ
admet-337	900	21	clinical	clinical	ADJ
admet-337	900	22	efficacy	efficacy	NOUN
admet-337	900	23	in	in	ADP
admet-337	900	24	egfrm+	egfrm+	NOUN
admet-337	900	25	nsclc	nsclc	NOUN
admet-337	900	26	patients	patient	NOUN
admet-337	900	27	with	with	ADP
admet-337	900	28	brain	brain	NOUN
admet-337	900	29	metastasis	metastasis	NOUN
admet-337	900	30	.	.	PUNCT
admet-337	901	1	american	american	ADJ
admet-337	901	2	society	society	NOUN
admet-337	901	3	of	of	ADP
admet-337	901	4	clinical	clinical	ADJ
admet-337	901	5	oncology	oncology	NOUN
admet-337	901	6	annual	annual	ADJ
admet-337	901	7	meeting	meeting	NOUN
admet-337	901	8	2016	2016	NUM
admet-337	901	9	.	.	PUNCT
admet-337	902	1	[	[	X
admet-337	902	2	106	106	NUM
admet-337	902	3	]	]	X
admet-337	902	4	d.w	d.w	PROPN
admet-337	902	5	.	.	PUNCT
admet-337	903	1	kim	kim	PROPN
admet-337	903	2	,	,	PUNCT
admet-337	903	3	j.c	j.c	PROPN
admet-337	903	4	.	.	PROPN
admet-337	903	5	yang	yang	PROPN
admet-337	903	6	,	,	PUNCT
admet-337	903	7	k.	k.	PROPN
admet-337	903	8	chen	chen	PROPN
admet-337	903	9	,	,	PUNCT
admet-337	903	10	et	et	PROPN
admet-337	903	11	al	al	PROPN
admet-337	903	12	.	.	PROPN
admet-337	903	13	azd3759	azd3759	PROPN
admet-337	903	14	,	,	PUNCT
admet-337	903	15	an	an	DET
admet-337	903	16	egfr	egfr	ADJ
admet-337	903	17	inhibitor	inhibitor	NOUN
admet-337	903	18	with	with	ADP
admet-337	903	19	blood	blood	NOUN
admet-337	903	20	brain	brain	NOUN
admet-337	903	21	barrier	barrier	NOUN
admet-337	903	22	(	(	PUNCT
admet-337	903	23	bbb	bbb	NOUN
admet-337	903	24	)	)	PUNCT
admet-337	903	25	penetration	penetration	NOUN
admet-337	903	26	for	for	ADP
admet-337	903	27	the	the	DET
admet-337	903	28	treatment	treatment	NOUN
admet-337	903	29	of	of	ADP
admet-337	903	30	non	non	ADJ
admet-337	903	31	-	-	ADJ
admet-337	903	32	small	small	ADJ
admet-337	903	33	cell	cell	NOUN
admet-337	903	34	lung	lung	NOUN
admet-337	903	35	cancer	cancer	NOUN
admet-337	903	36	(	(	PUNCT
admet-337	903	37	nsclc	nsclc	NOUN
admet-337	903	38	)	)	PUNCT
admet-337	903	39	with	with	ADP
admet-337	903	40	brain	brain	NOUN
admet-337	903	41	metastasis	metastasis	NOUN
admet-337	903	42	(	(	PUNCT
admet-337	903	43	bm	bm	NOUN
admet-337	903	44	):	):	PUNCT
admet-337	903	45	preclinical	preclinical	ADJ
admet-337	903	46	evidence	evidence	NOUN
admet-337	903	47	and	and	CCONJ
admet-337	903	48	clinical	clinical	ADJ
admet-337	903	49	cases	case	NOUN
admet-337	903	50	.	.	PUNCT
admet-337	904	1	american	american	ADJ
admet-337	904	2	society	society	NOUN
admet-337	904	3	of	of	ADP
admet-337	904	4	clinical	clinical	ADJ
admet-337	904	5	oncology	oncology	NOUN
admet-337	904	6	annual	annual	ADJ
admet-337	904	7	meeting	meeting	NOUN
admet-337	904	8	2015	2015	NUM
admet-337	904	9	.	.	PUNCT
admet-337	905	1	[	[	X
admet-337	905	2	107	107	X
admet-337	905	3	]	]	PUNCT
admet-337	905	4	s.	s.	PROPN
admet-337	905	5	liu	liu	PROPN
admet-337	905	6	,	,	PUNCT
admet-337	905	7	c.	c.	PROPN
admet-337	905	8	aggarwal	aggarwal	PROPN
admet-337	905	9	,	,	PUNCT
admet-337	905	10	c.	c.	PROPN
admet-337	905	11	brzezniak	brzezniak	PROPN
admet-337	905	12	,	,	PUNCT
admet-337	905	13	et	et	PROPN
admet-337	905	14	al	al	PROPN
admet-337	905	15	.	.	PROPN
admet-337	905	16	phase	phase	NOUN
admet-337	905	17	2	2	NUM
admet-337	905	18	study	study	NOUN
admet-337	905	19	of	of	ADP
admet-337	905	20	tarloxotinib	tarloxotinib	NOUN
admet-337	905	21	bromide	bromide	NOUN
admet-337	905	22	(	(	PUNCT
admet-337	905	23	trlx	trlx	NOUN
admet-337	905	24	)	)	PUNCT
admet-337	905	25	in	in	ADP
admet-337	905	26	patients	patient	NOUN
admet-337	905	27	(	(	PUNCT
admet-337	905	28	pts	pt	NOUN
admet-337	905	29	)	)	PUNCT
admet-337	905	30	with	with	ADP
admet-337	905	31	egfr	egfr	ADJ
admet-337	905	32	-	-	PUNCT
admet-337	905	33	mutant	mutant	NOUN
admet-337	905	34	,	,	PUNCT
admet-337	905	35	t790m	t790m	ADJ
admet-337	905	36	-	-	PUNCT
admet-337	905	37	negative	negative	ADJ
admet-337	905	38	nsclc	nsclc	NOUN
admet-337	905	39	progressing	progress	VERB
admet-337	905	40	on	on	ADP
admet-337	905	41	an	an	DET
admet-337	905	42	egfr	egfr	ADJ
admet-337	905	43	tki	tki	PROPN
admet-337	905	44	.	.	PUNCT
admet-337	905	45	american	american	ADJ
admet-337	905	46	society	society	PROPN
admet-337	905	47	of	of	ADP
admet-337	905	48	clinical	clinical	ADJ
admet-337	905	49	oncology	oncology	NOUN
admet-337	905	50	annual	annual	ADJ
admet-337	905	51	meeting	meeting	NOUN
admet-337	905	52	2016	2016	NUM
admet-337	905	53	.	.	PUNCT
admet-337	906	1	[	[	X
admet-337	906	2	108	108	NUM
admet-337	906	3	]	]	PUNCT
admet-337	906	4	k.	k.	PROPN
admet-337	906	5	rikova	rikova	PROPN
admet-337	906	6	,	,	PUNCT
admet-337	906	7	a.	a.	PROPN
admet-337	906	8	guo	guo	PROPN
admet-337	906	9	,	,	PUNCT
admet-337	906	10	q.	q.	PROPN
admet-337	906	11	zeng	zeng	PROPN
admet-337	906	12	,	,	PUNCT
admet-337	906	13	et	et	PROPN
admet-337	906	14	al	al	PROPN
admet-337	906	15	.	.	PROPN
admet-337	906	16	cell	cell	PROPN
admet-337	906	17	131	131	NUM
admet-337	906	18	(	(	PUNCT
admet-337	906	19	2007	2007	NUM
admet-337	906	20	)	)	PUNCT
admet-337	906	21	1190	1190	NUM
admet-337	906	22	-	-	SYM
admet-337	906	23	1203	1203	NUM
admet-337	906	24	.	.	PUNCT
admet-337	907	1	[	[	X
admet-337	907	2	109	109	NUM
admet-337	907	3	]	]	X
admet-337	907	4	j.m	j.m	PROPN
admet-337	907	5	.	.	PROPN
admet-337	907	6	heuckmann	heuckmann	PROPN
admet-337	907	7	,	,	PUNCT
admet-337	907	8	h.	h.	PROPN
admet-337	907	9	balke	balke	PROPN
admet-337	907	10	-	-	PUNCT
admet-337	907	11	want	want	PROPN
admet-337	907	12	,	,	PUNCT
admet-337	907	13	f.	f.	PROPN
admet-337	907	14	malchers	malchers	PROPN
admet-337	907	15	,	,	PUNCT
admet-337	907	16	et	et	PROPN
admet-337	907	17	al	al	PROPN
admet-337	907	18	.	.	PUNCT
admet-337	907	19	clin	clin	PROPN
admet-337	907	20	.	.	PUNCT
admet-337	908	1	cancer	cancer	NOUN
admet-337	908	2	res	re	NOUN
admet-337	908	3	.	.	PROPN
admet-337	909	1	18	18	NUM
admet-337	909	2	(	(	PUNCT
admet-337	909	3	2012	2012	NUM
admet-337	909	4	)	)	PUNCT
admet-337	909	5	4682	4682	NUM
admet-337	909	6	-	-	SYM
admet-337	909	7	4690	4690	NUM
admet-337	909	8	.	.	PUNCT
admet-337	910	1	[	[	X
admet-337	910	2	110	110	NUM
admet-337	910	3	]	]	X
admet-337	910	4	r.	r.	PROPN
admet-337	910	5	bayliss	bayliss	PROPN
admet-337	910	6	,	,	PUNCT
admet-337	910	7	j.	j.	PROPN
admet-337	910	8	choi	choi	PROPN
admet-337	910	9	,	,	PUNCT
admet-337	910	10	d.a	d.a	PROPN
admet-337	910	11	.	.	PROPN
admet-337	910	12	fennell	fennell	PROPN
admet-337	910	13	,	,	PUNCT
admet-337	910	14	a.m.	a.m.	PROPN
admet-337	910	15	fry	fry	PROPN
admet-337	910	16	,	,	PUNCT
admet-337	910	17	richards	richards	PROPN
admet-337	910	18	mw	mw	PROPN
admet-337	910	19	.	.	PROPN
admet-337	910	20	cell	cell	PROPN
admet-337	910	21	mol	mol	PROPN
admet-337	910	22	.	.	PROPN
admet-337	910	23	life	life	PROPN
admet-337	910	24	sci	sci	PROPN
admet-337	910	25	.	.	PROPN
admet-337	911	1	73	73	NUM
admet-337	911	2	(	(	PUNCT
admet-337	911	3	2016	2016	NUM
admet-337	911	4	)	)	PUNCT
admet-337	911	5	1209	1209	NUM
admet-337	911	6	-	-	SYM
admet-337	911	7	1224	1224	NUM
admet-337	911	8	.	.	PUNCT
admet-337	912	1	[	[	X
admet-337	912	2	111	111	NUM
admet-337	912	3	]	]	SYM
admet-337	912	4	a.t	a.t	PROPN
admet-337	912	5	.	.	PROPN
admet-337	912	6	shaw	shaw	PROPN
admet-337	912	7	,	,	PUNCT
admet-337	912	8	b.	b.	PROPN
admet-337	912	9	solomon	solomon	PROPN
admet-337	912	10	,	,	PUNCT
admet-337	912	11	clin	clin	PROPN
admet-337	912	12	.	.	PUNCT
admet-337	913	1	cancer	cancer	NOUN
admet-337	913	2	res	re	NOUN
admet-337	913	3	.	.	PROPN
admet-337	914	1	17	17	NUM
admet-337	914	2	(	(	PUNCT
admet-337	914	3	2011	2011	NUM
admet-337	914	4	)	)	PUNCT
admet-337	914	5	2081	2081	NUM
admet-337	914	6	-	-	SYM
admet-337	914	7	2086	2086	NUM
admet-337	914	8	.	.	PUNCT
admet-337	915	1	[	[	X
admet-337	915	2	112	112	NUM
admet-337	915	3	]	]	X
admet-337	915	4	e.l	e.l	PROPN
admet-337	915	5	.	.	PROPN
admet-337	915	6	kwak	kwak	PROPN
admet-337	915	7	,	,	PUNCT
admet-337	915	8	y.j	y.j	PROPN
admet-337	915	9	.	.	PROPN
admet-337	915	10	bang	bang	PROPN
admet-337	915	11	,	,	PUNCT
admet-337	915	12	d.r	d.r	PROPN
admet-337	915	13	.	.	PROPN
admet-337	915	14	camidge	camidge	PROPN
admet-337	915	15	,	,	PUNCT
admet-337	915	16	et	et	PROPN
admet-337	915	17	al	al	PROPN
admet-337	915	18	.	.	PUNCT
admet-337	915	19	n.	n.	PROPN
admet-337	915	20	engl	engl	PROPN
admet-337	915	21	.	.	PUNCT
admet-337	916	1	j.	j.	PROPN
admet-337	916	2	med	med	PROPN
admet-337	916	3	.	.	PUNCT
admet-337	917	1	363	363	NUM
admet-337	917	2	(	(	PUNCT
admet-337	917	3	2010	2010	NUM
admet-337	917	4	)	)	PUNCT
admet-337	917	5	1693	1693	NUM
admet-337	917	6	-	-	SYM
admet-337	917	7	1703	1703	NUM
admet-337	917	8	.	.	PUNCT
admet-337	918	1	[	[	X
admet-337	918	2	113	113	NUM
admet-337	918	3	]	]	X
admet-337	918	4	d.r	d.r	PROPN
admet-337	918	5	.	.	PROPN
admet-337	918	6	camidge	camidge	PROPN
admet-337	918	7	,	,	PUNCT
admet-337	918	8	y.j	y.j	PROPN
admet-337	918	9	.	.	PROPN
admet-337	918	10	bang	bang	PROPN
admet-337	918	11	,	,	PUNCT
admet-337	918	12	e.l	e.l	PROPN
admet-337	918	13	.	.	PROPN
admet-337	918	14	kwak	kwak	PROPN
admet-337	918	15	,	,	PUNCT
admet-337	918	16	et	et	PROPN
admet-337	918	17	al	al	PROPN
admet-337	918	18	.	.	PUNCT
admet-337	918	19	lancet	lancet	PROPN
admet-337	918	20	oncol	oncol	PROPN
admet-337	918	21	.	.	PUNCT
admet-337	919	1	13	13	NUM
admet-337	919	2	(	(	PUNCT
admet-337	919	3	2012	2012	NUM
admet-337	919	4	)	)	PUNCT
admet-337	919	5	1011	1011	NUM
admet-337	919	6	-	-	SYM
admet-337	919	7	1019	1019	NUM
admet-337	919	8	.	.	PUNCT
admet-337	920	1	[	[	X
admet-337	920	2	114	114	NUM
admet-337	920	3	]	]	PUNCT
admet-337	920	4	l.	l.	PROPN
admet-337	920	5	crino	crino	PROPN
admet-337	920	6	,	,	PUNCT
admet-337	920	7	d.w	d.w	PROPN
admet-337	920	8	.	.	PUNCT
admet-337	920	9	kim	kim	PROPN
admet-337	920	10	,	,	PUNCT
admet-337	920	11	g.j	g.j	PROPN
admet-337	920	12	.	.	PROPN
admet-337	920	13	riely	riely	PROPN
admet-337	920	14	.	.	PUNCT
admet-337	921	1	initial	initial	ADJ
admet-337	921	2	phase	phase	NOUN
admet-337	921	3	ii	ii	NOUN
admet-337	921	4	results	result	NOUN
admet-337	921	5	with	with	ADP
admet-337	921	6	crizotinib	crizotinib	NOUN
admet-337	921	7	in	in	ADP
admet-337	921	8	advanced	advanced	ADJ
admet-337	921	9	alk	alk	VERB
admet-337	921	10	-	-	PUNCT
admet-337	921	11	positive	positive	ADJ
admet-337	921	12	nonsmall	nonsmall	NOUN
admet-337	921	13	cell	cell	NOUN
admet-337	921	14	lung	lung	NOUN
admet-337	921	15	cancer	cancer	NOUN
admet-337	921	16	(	(	PUNCT
admet-337	921	17	nsclc	nsclc	NOUN
admet-337	921	18	):	):	PUNCT
admet-337	921	19	profile	profile	NOUN
admet-337	921	20	1005	1005	NUM
admet-337	921	21	.	.	PUNCT
admet-337	922	1	american	american	ADJ
admet-337	922	2	society	society	NOUN
admet-337	922	3	of	of	ADP
admet-337	922	4	clinical	clinical	ADJ
admet-337	922	5	oncology	oncology	NOUN
admet-337	922	6	annual	annual	ADJ
admet-337	922	7	meeting	meeting	NOUN
admet-337	922	8	2011	2011	NUM
admet-337	922	9	.	.	PUNCT
admet-337	923	1	[	[	X
admet-337	923	2	115	115	NUM
admet-337	923	3	]	]	X
admet-337	923	4	a.t	a.t	PROPN
admet-337	923	5	.	.	PROPN
admet-337	923	6	shaw	shaw	PROPN
admet-337	923	7	,	,	PUNCT
admet-337	923	8	d.w	d.w	PROPN
admet-337	923	9	.	.	PROPN
admet-337	923	10	kim	kim	PROPN
admet-337	923	11	,	,	PUNCT
admet-337	923	12	k.	k.	PROPN
admet-337	923	13	nakagawa	nakagawa	PROPN
admet-337	923	14	,	,	PUNCT
admet-337	923	15	et	et	PROPN
admet-337	923	16	al	al	PROPN
admet-337	923	17	.	.	PUNCT
admet-337	923	18	n.	n.	PROPN
admet-337	923	19	engl	engl	PROPN
admet-337	923	20	.	.	PUNCT
admet-337	924	1	j.	j.	PROPN
admet-337	924	2	med	med	PROPN
admet-337	924	3	.	.	PUNCT
admet-337	925	1	368	368	NUM
admet-337	925	2	(	(	PUNCT
admet-337	925	3	2013	2013	NUM
admet-337	925	4	)	)	PUNCT
admet-337	925	5	2385	2385	NUM
admet-337	925	6	-	-	SYM
admet-337	925	7	2394	2394	NUM
admet-337	925	8	.	.	PUNCT
admet-337	926	1	[	[	X
admet-337	926	2	116	116	X
admet-337	926	3	]	]	X
admet-337	926	4	b.j	b.j	PROPN
admet-337	926	5	.	.	PROPN
admet-337	926	6	solomon	solomon	PROPN
admet-337	926	7	,	,	PUNCT
admet-337	926	8	t.	t.	PROPN
admet-337	926	9	mok	mok	PROPN
admet-337	926	10	,	,	PUNCT
admet-337	926	11	d.w	d.w	PROPN
admet-337	926	12	.	.	PUNCT
admet-337	927	1	kim	kim	PROPN
admet-337	927	2	,	,	PUNCT
admet-337	927	3	et	et	PROPN
admet-337	927	4	al	al	PROPN
admet-337	927	5	.	.	PUNCT
admet-337	927	6	n.	n.	PROPN
admet-337	927	7	engl	engl	PROPN
admet-337	927	8	.	.	PUNCT
admet-337	928	1	j.	j.	PROPN
admet-337	928	2	med	med	PROPN
admet-337	928	3	.	.	PROPN
admet-337	929	1	371	371	NUM
admet-337	929	2	(	(	PUNCT
admet-337	929	3	2014	2014	NUM
admet-337	929	4	)	)	PUNCT
admet-337	929	5	2167	2167	NUM
admet-337	929	6	-	-	SYM
admet-337	929	7	2177	2177	NUM
admet-337	929	8	.	.	PUNCT
admet-337	930	1	[	[	X
admet-337	930	2	117	117	NUM
admet-337	930	3	]	]	X
admet-337	930	4	r.	r.	PROPN
admet-337	930	5	salgia	salgia	PROPN
admet-337	930	6	,	,	PUNCT
admet-337	930	7	b.j	b.j	PROPN
admet-337	930	8	.	.	PROPN
admet-337	930	9	solomon	solomon	PROPN
admet-337	930	10	,	,	PUNCT
admet-337	930	11	a.t	a.t	PROPN
admet-337	930	12	.	.	PROPN
admet-337	930	13	shaw	shaw	PROPN
admet-337	930	14	.	.	PROPN
admet-337	931	1	visual	visual	ADJ
admet-337	931	2	effects	effect	NOUN
admet-337	931	3	in	in	ADP
admet-337	931	4	anaplastic	anaplastic	ADJ
admet-337	931	5	lymphoma	lymphoma	NOUN
admet-337	931	6	kinase	kinase	NOUN
admet-337	931	7	(	(	PUNCT
admet-337	931	8	alk)-positive	alk)-positive	PROPN
admet-337	931	9	advanced	advanced	ADJ
admet-337	931	10	non	non	ADJ
admet-337	931	11	-	-	ADJ
admet-337	931	12	small	small	ADJ
admet-337	931	13	cell	cell	NOUN
admet-337	931	14	lung	lung	NOUN
admet-337	931	15	cancer	cancer	NOUN
admet-337	931	16	(	(	PUNCT
admet-337	931	17	nsclc	nsclc	NOUN
admet-337	931	18	)	)	PUNCT
admet-337	931	19	patients	patient	NOUN
admet-337	931	20	treated	treat	VERB
admet-337	931	21	with	with	ADP
admet-337	931	22	crizotinib	crizotinib	NOUN
admet-337	931	23	.	.	PUNCT
admet-337	932	1	american	american	ADJ
admet-337	932	2	society	society	NOUN
admet-337	932	3	of	of	ADP
admet-337	932	4	clinical	clinical	ADJ
admet-337	932	5	oncology	oncology	NOUN
admet-337	932	6	annual	annual	ADJ
admet-337	932	7	meeting	meeting	NOUN
admet-337	932	8	2012	2012	NUM
admet-337	932	9	.	.	PUNCT
admet-337	933	1	[	[	X
admet-337	933	2	118	118	NUM
admet-337	933	3	]	]	X
admet-337	933	4	a.j	a.j	PROPN
admet-337	933	5	.	.	PROPN
admet-337	933	6	weickhardt	weickhardt	PROPN
admet-337	933	7	,	,	PUNCT
admet-337	933	8	r.c	r.c	PROPN
admet-337	933	9	.	.	PROPN
admet-337	933	10	doebele	doebele	PROPN
admet-337	933	11	,	,	PUNCT
admet-337	933	12	w.t	w.t	PROPN
admet-337	933	13	.	.	PUNCT
admet-337	933	14	purcell	purcell	PROPN
admet-337	933	15	,	,	PUNCT
admet-337	933	16	et	et	PROPN
admet-337	933	17	al	al	PROPN
admet-337	933	18	.	.	PUNCT
admet-337	933	19	cancer	cancer	NOUN
admet-337	933	20	119	119	NUM
admet-337	933	21	(	(	PUNCT
admet-337	933	22	2013	2013	NUM
admet-337	933	23	)	)	PUNCT
admet-337	933	24	2383	2383	NUM
admet-337	933	25	-	-	SYM
admet-337	933	26	2390	2390	NUM
admet-337	933	27	.	.	PUNCT
admet-337	934	1	[	[	X
admet-337	934	2	119	119	NUM
admet-337	934	3	]	]	X
admet-337	934	4	a.	a.	NOUN
admet-337	934	5	tamiya	tamiya	PROPN
admet-337	934	6	,	,	PUNCT
admet-337	934	7	i.	i.	PROPN
admet-337	934	8	okamoto	okamoto	PROPN
admet-337	934	9	,	,	PUNCT
admet-337	934	10	m.	m.	PROPN
admet-337	934	11	miyazaki	miyazaki	PROPN
admet-337	934	12	,	,	PUNCT
admet-337	934	13	s.	s.	PROPN
admet-337	934	14	shimizu	shimizu	PROPN
admet-337	934	15	,	,	PUNCT
admet-337	934	16	m.	m.	PROPN
admet-337	934	17	kitaichi	kitaichi	PROPN
admet-337	934	18	,	,	PUNCT
admet-337	934	19	k.	k.	PROPN
admet-337	934	20	nakagawa	nakagawa	PROPN
admet-337	934	21	,	,	PUNCT
admet-337	934	22	j.	j.	PROPN
admet-337	934	23	clin	clin	PROPN
admet-337	934	24	.	.	PUNCT
admet-337	935	1	oncol	oncol	ADJ
admet-337	935	2	.	.	PUNCT
admet-337	936	1	31	31	NUM
admet-337	936	2	(	(	PUNCT
admet-337	936	3	2013	2013	NUM
admet-337	936	4	)	)	PUNCT
admet-337	936	5	e15	e15	PROPN
admet-337	936	6	-	-	PUNCT
admet-337	936	7	7	7	NUM
admet-337	936	8	.	.	PUNCT
admet-337	937	1	[	[	X
admet-337	937	2	120	120	NUM
admet-337	937	3	]	]	X
admet-337	937	4	s.h	s.h	PROPN
admet-337	937	5	.	.	PROPN
admet-337	937	6	ou	ou	PROPN
admet-337	937	7	,	,	PUNCT
admet-337	937	8	w.p	w.p	PROPN
admet-337	937	9	.	.	PROPN
admet-337	937	10	tong	tong	PROPN
admet-337	937	11	,	,	PUNCT
admet-337	937	12	m.	m.	NOUN
admet-337	937	13	azada	azada	PROPN
admet-337	937	14	,	,	PUNCT
admet-337	937	15	c.	c.	PROPN
admet-337	937	16	siwak	siwak	PROPN
admet-337	937	17	-	-	PUNCT
admet-337	937	18	tapp	tapp	PROPN
admet-337	937	19	,	,	PUNCT
admet-337	937	20	j.	j.	PROPN
admet-337	937	21	dy	dy	PROPN
admet-337	937	22	,	,	PUNCT
admet-337	937	23	j.a	j.a	PROPN
admet-337	937	24	.	.	PROPN
admet-337	937	25	stiber	stiber	PROPN
admet-337	937	26	,	,	PUNCT
admet-337	937	27	cancer	cancer	NOUN
admet-337	937	28	119	119	NUM
admet-337	937	29	(	(	PUNCT
admet-337	937	30	2013	2013	NUM
admet-337	937	31	)	)	PUNCT
admet-337	937	32	1969	1969	NUM
admet-337	937	33	-	-	SYM
admet-337	937	34	1975	1975	NUM
admet-337	937	35	.	.	PUNCT
admet-337	938	1	[	[	X
admet-337	938	2	121	121	NUM
admet-337	938	3	]	]	SYM
admet-337	938	4	h.y	h.y	PROPN
admet-337	938	5	.	.	PROPN
admet-337	938	6	zou	zou	PROPN
admet-337	938	7	,	,	PUNCT
admet-337	938	8	q.	q.	PROPN
admet-337	938	9	li	li	PROPN
admet-337	938	10	,	,	PUNCT
admet-337	938	11	j.h	j.h	PROPN
admet-337	938	12	.	.	PROPN
admet-337	938	13	lee	lee	PROPN
admet-337	938	14	,	,	PUNCT
admet-337	938	15	et	et	PROPN
admet-337	938	16	al	al	PROPN
admet-337	938	17	.	.	PUNCT
admet-337	939	1	cancer	cancer	NOUN
admet-337	939	2	res	re	NOUN
admet-337	939	3	.	.	PUNCT
admet-337	940	1	67	67	NUM
admet-337	940	2	(	(	PUNCT
admet-337	940	3	2007	2007	NUM
admet-337	940	4	)	)	PUNCT
admet-337	940	5	4408	4408	NUM
admet-337	940	6	-	-	SYM
admet-337	940	7	4417	4417	NUM
admet-337	940	8	.	.	PUNCT
admet-337	941	1	[	[	X
admet-337	941	2	122	122	NUM
admet-337	941	3	]	]	X
admet-337	941	4	j.g	j.g	PROPN
admet-337	941	5	.	.	PROPN
admet-337	941	6	christensen	christensen	PROPN
admet-337	941	7	,	,	PUNCT
admet-337	941	8	h.y	h.y	PROPN
admet-337	941	9	.	.	PROPN
admet-337	941	10	zou	zou	PROPN
admet-337	941	11	,	,	PUNCT
admet-337	941	12	m.e	m.e	PROPN
admet-337	941	13	.	.	PROPN
admet-337	941	14	arango	arango	PROPN
admet-337	941	15	,	,	PUNCT
admet-337	941	16	et	et	PROPN
admet-337	941	17	al	al	PROPN
admet-337	941	18	.	.	PROPN
admet-337	941	19	mol	mol	PROPN
admet-337	941	20	.	.	PUNCT
admet-337	942	1	cancer	cancer	NOUN
admet-337	942	2	ther	ther	PROPN
admet-337	942	3	.	.	PUNCT
admet-337	943	1	6	6	NUM
admet-337	943	2	(	(	PUNCT
admet-337	943	3	2007	2007	NUM
admet-337	943	4	)	)	PUNCT
admet-337	943	5	3314	3314	NUM
admet-337	943	6	-	-	SYM
admet-337	943	7	3322	3322	NUM
admet-337	943	8	.	.	PUNCT
admet-337	944	1	[	[	X
admet-337	944	2	123	123	NUM
admet-337	944	3	]	]	X
admet-337	944	4	j.j	j.j	PROPN
admet-337	944	5	.	.	PROPN
admet-337	944	6	cui	cui	PROPN
admet-337	944	7	,	,	PUNCT
admet-337	944	8	m.	m.	NOUN
admet-337	944	9	tran	tran	PROPN
admet-337	944	10	-	-	PUNCT
admet-337	944	11	dube	dube	PROPN
admet-337	944	12	,	,	PUNCT
admet-337	944	13	h.	h.	PROPN
admet-337	944	14	shen	shen	PROPN
admet-337	944	15	,	,	PUNCT
admet-337	944	16	et	et	PROPN
admet-337	944	17	al	al	PROPN
admet-337	944	18	.	.	PUNCT
admet-337	944	19	j.	j.	PROPN
admet-337	944	20	med	med	PROPN
admet-337	944	21	.	.	PROPN
admet-337	944	22	chem	chem	PROPN
admet-337	944	23	.	.	PUNCT
admet-337	945	1	54	54	NUM
admet-337	945	2	(	(	PUNCT
admet-337	945	3	2011	2011	NUM
admet-337	945	4	)	)	PUNCT
admet-337	945	5	6342	6342	NUM
admet-337	945	6	-	-	SYM
admet-337	945	7	6363	6363	NUM
admet-337	945	8	.	.	PUNCT
admet-337	946	1	[	[	X
admet-337	946	2	124	124	NUM
admet-337	946	3	]	]	X
admet-337	946	4	u.	u.	PROPN
admet-337	946	5	mcdermott	mcdermott	PROPN
admet-337	946	6	,	,	PUNCT
admet-337	946	7	a.j	a.j	PROPN
admet-337	946	8	.	.	PROPN
admet-337	946	9	iafrate	iafrate	PROPN
admet-337	946	10	,	,	PUNCT
admet-337	946	11	n.s	n.s	PROPN
admet-337	946	12	.	.	PROPN
admet-337	946	13	gray	gray	PROPN
admet-337	946	14	,	,	PUNCT
admet-337	946	15	et	et	PROPN
admet-337	946	16	al	al	PROPN
admet-337	946	17	.	.	PUNCT
admet-337	947	1	cancer	cancer	NOUN
admet-337	947	2	res	re	NOUN
admet-337	947	3	.	.	PUNCT
admet-337	948	1	68	68	NUM
admet-337	948	2	(	(	PUNCT
admet-337	948	3	2008	2008	NUM
admet-337	948	4	)	)	PUNCT
admet-337	948	5	3389	3389	NUM
admet-337	948	6	-	-	SYM
admet-337	948	7	3395	3395	NUM
admet-337	948	8	.	.	PUNCT
admet-337	949	1	[	[	X
admet-337	949	2	125	125	NUM
admet-337	949	3	]	]	SYM
admet-337	949	4	d.b	d.b	PROPN
admet-337	949	5	.	.	PROPN
admet-337	949	6	costa	costa	PROPN
admet-337	949	7	,	,	PUNCT
admet-337	949	8	s.	s.	PROPN
admet-337	949	9	kobayashi	kobayashi	PROPN
admet-337	949	10	,	,	PUNCT
admet-337	949	11	s.s	s.s	PROPN
admet-337	949	12	.	.	PROPN
admet-337	949	13	pandya	pandya	PROPN
admet-337	949	14	,	,	PUNCT
admet-337	949	15	et	et	PROPN
admet-337	949	16	al	al	PROPN
admet-337	949	17	.	.	PUNCT
admet-337	950	1	j.	j.	PROPN
admet-337	950	2	clin	clin	PROPN
admet-337	950	3	.	.	PUNCT
admet-337	951	1	oncol	oncol	ADJ
admet-337	951	2	.	.	PUNCT
admet-337	952	1	29	29	NUM
admet-337	952	2	(	(	PUNCT
admet-337	952	3	2011	2011	NUM
admet-337	952	4	)	)	PUNCT
admet-337	953	1	e443	e443	PROPN
admet-337	953	2	-	-	SYM
admet-337	953	3	5	5	NUM
admet-337	953	4	.	.	PUNCT
admet-337	954	1	grace	grace	NOUN
admet-337	954	2	dy	dy	NOUN
admet-337	954	3	et	et	PROPN
admet-337	954	4	al	al	PROPN
admet-337	954	5	.	.	PROPN
admet-337	954	6	admet	admet	PROPN
admet-337	954	7	&	&	CCONJ
admet-337	954	8	dmpk	dmpk	PROPN
admet-337	954	9	4(3	4(3	NUM
admet-337	954	10	)	)	PUNCT
admet-337	954	11	(	(	PUNCT
admet-337	954	12	2016	2016	NUM
admet-337	954	13	)	)	PUNCT
admet-337	954	14	186	186	NUM
admet-337	954	15	-	-	SYM
admet-337	954	16	211	211	NUM
admet-337	954	17	210	210	NUM
admet-337	955	1	[	[	X
admet-337	955	2	126	126	NUM
admet-337	955	3	]	]	X
admet-337	955	4	xalkori	xalkori	X
admet-337	955	5	(	(	PUNCT
admet-337	955	6	crizotinib	crizotinib	PROPN
admet-337	955	7	)	)	PUNCT
admet-337	956	1	[	[	X
admet-337	956	2	package	package	NOUN
admet-337	956	3	insert	insert	NOUN
admet-337	956	4	]	]	PUNCT
admet-337	956	5	.	.	PUNCT
admet-337	957	1	new	new	PROPN
admet-337	957	2	york	york	PROPN
admet-337	957	3	,	,	PUNCT
admet-337	957	4	ny	ny	PROPN
admet-337	957	5	:	:	PUNCT
admet-337	957	6	pfizer	pfizer	PROPN
admet-337	957	7	inc	inc	PROPN
admet-337	957	8	.	.	PROPN
admet-337	957	9	;	;	PUNCT
admet-337	957	10	2012	2012	NUM
admet-337	957	11	.	.	PUNCT
admet-337	958	1	[	[	X
admet-337	958	2	127	127	NUM
admet-337	958	3	]	]	X
admet-337	958	4	m.p	m.p	PROPN
admet-337	958	5	.	.	PROPN
admet-337	958	6	curran	curran	PROPN
admet-337	958	7	,	,	PUNCT
admet-337	958	8	drugs	drug	NOUN
admet-337	958	9	72	72	NUM
admet-337	958	10	(	(	PUNCT
admet-337	958	11	2012	2012	NUM
admet-337	958	12	)	)	PUNCT
admet-337	958	13	99	99	NUM
admet-337	958	14	-	-	SYM
admet-337	958	15	107	107	NUM
admet-337	958	16	.	.	PUNCT
admet-337	959	1	[	[	X
admet-337	959	2	128	128	NUM
admet-337	959	3	]	]	X
admet-337	959	4	c.	c.	PROPN
admet-337	959	5	li	li	PROPN
admet-337	959	6	,	,	PUNCT
admet-337	959	7	c.	c.	PROPN
admet-337	959	8	alvey	alvey	PROPN
admet-337	959	9	,	,	PUNCT
admet-337	959	10	a.	a.	PROPN
admet-337	959	11	bello	bello	PROPN
admet-337	959	12	,	,	PUNCT
admet-337	959	13	k.d	k.d	PROPN
admet-337	959	14	.	.	PROPN
admet-337	959	15	wilner	wilner	PROPN
admet-337	959	16	,	,	PUNCT
admet-337	959	17	w.	w.	PROPN
admet-337	959	18	tan	tan	PROPN
admet-337	959	19	.	.	PUNCT
admet-337	960	1	pharmacokinetics	pharmacokinetic	NOUN
admet-337	960	2	(	(	PUNCT
admet-337	960	3	pk	pk	NOUN
admet-337	960	4	)	)	PUNCT
admet-337	960	5	of	of	ADP
admet-337	960	6	crizotinib	crizotinib	NOUN
admet-337	960	7	(	(	PUNCT
admet-337	960	8	pf-02341066	pf-02341066	NOUN
admet-337	960	9	)	)	PUNCT
admet-337	960	10	in	in	ADP
admet-337	960	11	patients	patient	NOUN
admet-337	960	12	with	with	ADP
admet-337	960	13	advanced	advanced	ADJ
admet-337	960	14	non	non	ADJ
admet-337	960	15	-	-	ADJ
admet-337	960	16	small	small	ADJ
admet-337	960	17	cell	cell	NOUN
admet-337	960	18	lung	lung	NOUN
admet-337	960	19	cancer	cancer	NOUN
admet-337	960	20	(	(	PUNCT
admet-337	960	21	nsclc	nsclc	NOUN
admet-337	960	22	)	)	PUNCT
admet-337	960	23	and	and	CCONJ
admet-337	960	24	other	other	ADJ
admet-337	960	25	solid	solid	ADJ
admet-337	960	26	tumors	tumor	NOUN
admet-337	960	27	.	.	PUNCT
admet-337	961	1	american	american	ADJ
admet-337	961	2	society	society	NOUN
admet-337	961	3	of	of	ADP
admet-337	961	4	clinical	clinical	ADJ
admet-337	961	5	oncology	oncology	NOUN
admet-337	961	6	annual	annual	ADJ
admet-337	961	7	meeting	meeting	NOUN
admet-337	961	8	2011	2011	NUM
admet-337	961	9	.	.	PUNCT
admet-337	962	1	[	[	X
admet-337	962	2	129	129	NUM
admet-337	962	3	]	]	X
admet-337	962	4	g.	g.	PROPN
admet-337	962	5	metro	metro	PROPN
admet-337	962	6	,	,	PUNCT
admet-337	962	7	g.	g.	PROPN
admet-337	962	8	lunardi	lunardi	PROPN
admet-337	962	9	,	,	PUNCT
admet-337	962	10	p.	p.	PROPN
admet-337	962	11	floridi	floridi	PROPN
admet-337	962	12	,	,	PUNCT
admet-337	962	13	et	et	PROPN
admet-337	962	14	al	al	PROPN
admet-337	962	15	.	.	PUNCT
admet-337	963	1	j.	j.	PROPN
admet-337	963	2	thorac	thorac	PROPN
admet-337	963	3	.	.	PUNCT
admet-337	964	1	oncol	oncol	ADJ
admet-337	964	2	.	.	PUNCT
admet-337	965	1	10	10	NUM
admet-337	965	2	(	(	PUNCT
admet-337	965	3	2015	2015	NUM
admet-337	965	4	)	)	PUNCT
admet-337	965	5	e26	e26	PROPN
admet-337	965	6	-	-	PUNCT
admet-337	965	7	7	7	NUM
admet-337	965	8	.	.	PUNCT
admet-337	966	1	[	[	X
admet-337	966	2	130	130	NUM
admet-337	966	3	]	]	SYM
admet-337	966	4	d.b	d.b	PROPN
admet-337	966	5	.	.	PROPN
admet-337	966	6	costa	costa	PROPN
admet-337	966	7	,	,	PUNCT
admet-337	966	8	a.t	a.t	PROPN
admet-337	966	9	.	.	PROPN
admet-337	966	10	shaw	shaw	PROPN
admet-337	966	11	,	,	PUNCT
admet-337	966	12	s.h	s.h	PROPN
admet-337	966	13	.	.	PROPN
admet-337	966	14	ou	ou	PROPN
admet-337	966	15	,	,	PUNCT
admet-337	966	16	et	et	PROPN
admet-337	966	17	al	al	PROPN
admet-337	966	18	.	.	PUNCT
admet-337	967	1	j.	j.	PROPN
admet-337	967	2	clin	clin	PROPN
admet-337	967	3	.	.	PUNCT
admet-337	968	1	oncol	oncol	ADJ
admet-337	968	2	.	.	PUNCT
admet-337	969	1	33	33	NUM
admet-337	969	2	(	(	PUNCT
admet-337	969	3	2015	2015	NUM
admet-337	969	4	)	)	PUNCT
admet-337	969	5	1881	1881	NUM
admet-337	969	6	-	-	SYM
admet-337	969	7	1888	1888	NUM
admet-337	969	8	.	.	PUNCT
admet-337	970	1	[	[	X
admet-337	970	2	131	131	X
admet-337	970	3	]	]	X
admet-337	970	4	y.l	y.l	PROPN
admet-337	970	5	.	.	PROPN
admet-337	970	6	choi	choi	PROPN
admet-337	970	7	,	,	PUNCT
admet-337	970	8	m.	m.	NOUN
admet-337	970	9	soda	soda	NOUN
admet-337	970	10	,	,	PUNCT
admet-337	970	11	y.	y.	PROPN
admet-337	970	12	yamashita	yamashita	PROPN
admet-337	970	13	,	,	PUNCT
admet-337	970	14	et	et	PROPN
admet-337	970	15	al	al	PROPN
admet-337	970	16	.	.	PUNCT
admet-337	970	17	n.	n.	PROPN
admet-337	970	18	engl	engl	PROPN
admet-337	970	19	.	.	PUNCT
admet-337	971	1	j.	j.	PROPN
admet-337	971	2	med	med	PROPN
admet-337	971	3	.	.	PUNCT
admet-337	972	1	363	363	NUM
admet-337	972	2	(	(	PUNCT
admet-337	972	3	2010	2010	NUM
admet-337	972	4	)	)	PUNCT
admet-337	972	5	1734	1734	NUM
admet-337	972	6	-	-	SYM
admet-337	972	7	1739	1739	NUM
admet-337	972	8	.	.	PUNCT
admet-337	973	1	[	[	X
admet-337	973	2	132	132	NUM
admet-337	973	3	]	]	X
admet-337	973	4	r.c	r.c	PROPN
admet-337	973	5	.	.	PROPN
admet-337	973	6	doebele	doebele	PROPN
admet-337	973	7	,	,	PUNCT
admet-337	973	8	a.b	a.b	PROPN
admet-337	973	9	.	.	PROPN
admet-337	973	10	pilling	pilling	PROPN
admet-337	973	11	,	,	PUNCT
admet-337	973	12	d.l	d.l	PROPN
admet-337	973	13	.	.	PROPN
admet-337	973	14	aisner	aisner	PROPN
admet-337	973	15	,	,	PUNCT
admet-337	973	16	et	et	PROPN
admet-337	973	17	al	al	PROPN
admet-337	973	18	.	.	PUNCT
admet-337	974	1	clin	clin	PROPN
admet-337	974	2	.	.	PUNCT
admet-337	975	1	cancer	cancer	NOUN
admet-337	975	2	res	re	NOUN
admet-337	975	3	.	.	PROPN
admet-337	976	1	18	18	NUM
admet-337	976	2	(	(	PUNCT
admet-337	976	3	2012	2012	NUM
admet-337	976	4	)	)	PUNCT
admet-337	976	5	1472	1472	NUM
admet-337	976	6	-	-	SYM
admet-337	976	7	1482	1482	NUM
admet-337	976	8	.	.	PUNCT
admet-337	977	1	[	[	X
admet-337	977	2	133	133	NUM
admet-337	977	3	]	]	PUNCT
admet-337	977	4	t.	t.	PROPN
admet-337	977	5	sasaki	sasaki	PROPN
admet-337	977	6	,	,	PUNCT
admet-337	977	7	j.	j.	PROPN
admet-337	977	8	koivunen	koivunen	PROPN
admet-337	977	9	,	,	PUNCT
admet-337	977	10	a.	a.	NOUN
admet-337	977	11	ogino	ogino	PROPN
admet-337	977	12	,	,	PUNCT
admet-337	977	13	et	et	PROPN
admet-337	977	14	al	al	PROPN
admet-337	977	15	.	.	PUNCT
admet-337	977	16	cancer	cancer	NOUN
admet-337	977	17	res	re	NOUN
admet-337	977	18	.	.	PUNCT
admet-337	978	1	71	71	NUM
admet-337	978	2	(	(	PUNCT
admet-337	978	3	2011	2011	NUM
admet-337	978	4	)	)	PUNCT
admet-337	978	5	6051	6051	NUM
admet-337	978	6	-	-	SYM
admet-337	978	7	6060	6060	NUM
admet-337	978	8	.	.	PUNCT
admet-337	979	1	[	[	X
admet-337	979	2	134	134	NUM
admet-337	979	3	]	]	PUNCT
admet-337	979	4	s.	s.	PROPN
admet-337	979	5	kim	kim	PROPN
admet-337	979	6	,	,	PUNCT
admet-337	979	7	t.m	t.m	PROPN
admet-337	979	8	.	.	PROPN
admet-337	979	9	kim	kim	PROPN
admet-337	979	10	,	,	PUNCT
admet-337	979	11	d.w	d.w	PROPN
admet-337	979	12	.	.	PUNCT
admet-337	979	13	kim	kim	PROPN
admet-337	979	14	,	,	PUNCT
admet-337	979	15	et	et	PROPN
admet-337	979	16	al	al	PROPN
admet-337	979	17	.	.	PUNCT
admet-337	980	1	j.	j.	PROPN
admet-337	980	2	thorac	thorac	PROPN
admet-337	980	3	.	.	PUNCT
admet-337	981	1	oncol	oncol	ADJ
admet-337	981	2	.	.	PUNCT
admet-337	982	1	8	8	NUM
admet-337	982	2	(	(	PUNCT
admet-337	982	3	2013	2013	NUM
admet-337	982	4	)	)	PUNCT
admet-337	982	5	415	415	NUM
admet-337	982	6	-	-	SYM
admet-337	982	7	422	422	NUM
admet-337	982	8	.	.	PUNCT
admet-337	983	1	[	[	X
admet-337	983	2	135	135	NUM
admet-337	983	3	]	]	X
admet-337	983	4	d.	d.	PROPN
admet-337	983	5	huang	huang	PROPN
admet-337	983	6	,	,	PUNCT
admet-337	983	7	d.w	d.w	PROPN
admet-337	983	8	.	.	PROPN
admet-337	983	9	kim	kim	PROPN
admet-337	983	10	,	,	PUNCT
admet-337	983	11	a.	a.	NOUN
admet-337	983	12	kotsakis	kotsakis	PROPN
admet-337	983	13	,	,	PUNCT
admet-337	983	14	et	et	PROPN
admet-337	983	15	al	al	PROPN
admet-337	983	16	.	.	PUNCT
admet-337	983	17	genomics	genomic	NOUN
admet-337	983	18	102	102	NUM
admet-337	983	19	(	(	PUNCT
admet-337	983	20	2013	2013	NUM
admet-337	983	21	)	)	PUNCT
admet-337	983	22	157	157	NUM
admet-337	983	23	-	-	SYM
admet-337	983	24	162	162	NUM
admet-337	983	25	.	.	PUNCT
admet-337	984	1	[	[	X
admet-337	984	2	136	136	NUM
admet-337	984	3	]	]	PUNCT
admet-337	984	4	l.	l.	PROPN
admet-337	984	5	friboulet	friboulet	PROPN
admet-337	984	6	,	,	PUNCT
admet-337	984	7	n.	n.	PROPN
admet-337	984	8	li	li	PROPN
admet-337	984	9	,	,	PUNCT
admet-337	984	10	r.	r.	PROPN
admet-337	984	11	katayama	katayama	PROPN
admet-337	984	12	,	,	PUNCT
admet-337	984	13	et	et	PROPN
admet-337	984	14	al	al	PROPN
admet-337	984	15	.	.	PUNCT
admet-337	984	16	cancer	cancer	NOUN
admet-337	984	17	.	.	PUNCT
admet-337	985	1	discov	discov	NOUN
admet-337	985	2	.	.	PUNCT
admet-337	986	1	4	4	NUM
admet-337	986	2	(	(	PUNCT
admet-337	986	3	2014	2014	NUM
admet-337	986	4	)	)	PUNCT
admet-337	986	5	662	662	NUM
admet-337	986	6	-	-	SYM
admet-337	986	7	673	673	NUM
admet-337	986	8	.	.	PUNCT
admet-337	987	1	[	[	X
admet-337	987	2	137	137	NUM
admet-337	987	3	]	]	X
admet-337	987	4	s.h	s.h	PROPN
admet-337	987	5	.	.	PROPN
admet-337	987	6	ignatius	ignatius	PROPN
admet-337	987	7	ou	ou	PROPN
admet-337	987	8	,	,	PUNCT
admet-337	987	9	m.	m.	NOUN
admet-337	987	10	azada	azada	NOUN
admet-337	987	11	,	,	PUNCT
admet-337	987	12	d.j	d.j	PROPN
admet-337	987	13	.	.	PROPN
admet-337	987	14	hsiang	hsiang	PROPN
admet-337	987	15	,	,	PUNCT
admet-337	987	16	et	et	PROPN
admet-337	987	17	al	al	PROPN
admet-337	987	18	.	.	PUNCT
admet-337	988	1	j.	j.	PROPN
admet-337	988	2	thorac	thorac	PROPN
admet-337	988	3	.	.	PUNCT
admet-337	989	1	oncol	oncol	ADJ
admet-337	989	2	.	.	PUNCT
admet-337	990	1	9	9	NUM
admet-337	990	2	(	(	PUNCT
admet-337	990	3	2014	2014	NUM
admet-337	990	4	)	)	PUNCT
admet-337	990	5	549	549	NUM
admet-337	990	6	-	-	SYM
admet-337	990	7	553	553	NUM
admet-337	990	8	.	.	PUNCT
admet-337	991	1	[	[	X
admet-337	991	2	138	138	NUM
admet-337	991	3	]	]	X
admet-337	991	4	j.	j.	PROPN
admet-337	991	5	sang	sang	PROPN
admet-337	991	6	,	,	PUNCT
admet-337	991	7	j.	j.	PROPN
admet-337	991	8	acquaviva	acquaviva	PROPN
admet-337	991	9	,	,	PUNCT
admet-337	991	10	j.c	j.c	PROPN
admet-337	991	11	.	.	PROPN
admet-337	991	12	friedland	friedland	PROPN
admet-337	991	13	,	,	PUNCT
admet-337	991	14	et	et	PROPN
admet-337	991	15	al	al	PROPN
admet-337	991	16	.	.	PUNCT
admet-337	991	17	cancer	cancer	NOUN
admet-337	991	18	.	.	PUNCT
admet-337	992	1	discov	discov	NOUN
admet-337	992	2	.	.	PUNCT
admet-337	993	1	3	3	NUM
admet-337	993	2	(	(	PUNCT
admet-337	993	3	2013	2013	NUM
admet-337	993	4	)	)	PUNCT
admet-337	993	5	430	430	NUM
admet-337	993	6	-	-	SYM
admet-337	993	7	443	443	NUM
admet-337	993	8	.	.	PUNCT
admet-337	994	1	[	[	X
admet-337	994	2	139	139	NUM
admet-337	994	3	]	]	X
admet-337	994	4	c.m	c.m	PROPN
admet-337	994	5	.	.	PROPN
admet-337	994	6	lovly	lovly	PROPN
admet-337	994	7	,	,	PUNCT
admet-337	994	8	n.t	n.t	PROPN
admet-337	994	9	.	.	PROPN
admet-337	994	10	mcdonald	mcdonald	PROPN
admet-337	994	11	,	,	PUNCT
admet-337	994	12	h.	h.	PROPN
admet-337	994	13	chen	chen	PROPN
admet-337	994	14	,	,	PUNCT
admet-337	994	15	et	et	PROPN
admet-337	994	16	al	al	PROPN
admet-337	994	17	.	.	PUNCT
admet-337	995	1	nat	nat	PROPN
admet-337	995	2	.	.	PUNCT
admet-337	996	1	med	med	PROPN
admet-337	996	2	.	.	PROPN
admet-337	997	1	20	20	NUM
admet-337	997	2	(	(	PUNCT
admet-337	997	3	2014	2014	NUM
admet-337	997	4	)	)	PUNCT
admet-337	997	5	1027	1027	NUM
admet-337	997	6	-	-	SYM
admet-337	997	7	1034	1034	NUM
admet-337	997	8	.	.	PUNCT
admet-337	998	1	[	[	X
admet-337	998	2	140	140	NUM
admet-337	998	3	]	]	X
admet-337	998	4	e.	e.	PROPN
admet-337	998	5	felip	felip	PROPN
admet-337	998	6	,	,	PUNCT
admet-337	998	7	s.	s.	PROPN
admet-337	998	8	orlov	orlov	PROPN
admet-337	998	9	,	,	PUNCT
admet-337	998	10	k.	k.	PROPN
admet-337	998	11	park	park	PROPN
admet-337	998	12	,	,	PUNCT
admet-337	998	13	et	et	PROPN
admet-337	998	14	al	al	PROPN
admet-337	998	15	.	.	PROPN
admet-337	998	16	efficacy	efficacy	NOUN
admet-337	998	17	and	and	CCONJ
admet-337	998	18	safety	safety	NOUN
admet-337	998	19	of	of	ADP
admet-337	998	20	ceritinib	ceritinib	NOUN
admet-337	998	21	in	in	ADP
admet-337	998	22	patients	patient	NOUN
admet-337	998	23	(	(	PUNCT
admet-337	998	24	pts	pt	NOUN
admet-337	998	25	)	)	PUNCT
admet-337	998	26	with	with	ADP
admet-337	998	27	advanced	advanced	ADJ
admet-337	998	28	anaplastic	anaplastic	ADJ
admet-337	998	29	lymphoma	lymphoma	NOUN
admet-337	998	30	kinase	kinase	NOUN
admet-337	998	31	(	(	PUNCT
admet-337	998	32	alk)-rearranged	alk)-rearrange	VERB
admet-337	998	33	non	non	ADJ
admet-337	998	34	-	-	ADJ
admet-337	998	35	small	small	ADJ
admet-337	998	36	cell	cell	NOUN
admet-337	998	37	lung	lung	NOUN
admet-337	998	38	cancer	cancer	NOUN
admet-337	998	39	(	(	PUNCT
admet-337	998	40	nsclc	nsclc	NOUN
admet-337	998	41	):	):	PUNCT
admet-337	998	42	an	an	DET
admet-337	998	43	update	update	NOUN
admet-337	998	44	of	of	ADP
admet-337	998	45	ascend-1	ascend-1	PROPN
admet-337	998	46	.	.	NOUN
admet-337	998	47	2014	2014	NUM
admet-337	998	48	.	.	PUNCT
admet-337	999	1	[	[	X
admet-337	999	2	141	141	NUM
admet-337	999	3	]	]	X
admet-337	999	4	t.s	t.s	PROPN
admet-337	999	5	.	.	PROPN
admet-337	999	6	mok	mok	PROPN
admet-337	999	7	,	,	PUNCT
admet-337	999	8	d.r	d.r	PROPN
admet-337	999	9	.	.	PROPN
admet-337	999	10	spigel	spigel	NOUN
admet-337	999	11	,	,	PUNCT
admet-337	999	12	a.t	a.t	PROPN
admet-337	999	13	.	.	PROPN
admet-337	999	14	shaw	shaw	PROPN
admet-337	999	15	.	.	PROPN
admet-337	999	16	ascend-2	ascend-2	PROPN
admet-337	999	17	:	:	PUNCT
admet-337	999	18	a	a	DET
admet-337	999	19	single	single	ADJ
admet-337	999	20	-	-	PUNCT
admet-337	999	21	arm	arm	NOUN
admet-337	999	22	,	,	PUNCT
admet-337	999	23	open	open	ADJ
admet-337	999	24	-	-	PUNCT
admet-337	999	25	label	label	NOUN
admet-337	999	26	,	,	PUNCT
admet-337	999	27	multicenter	multicenter	NOUN
admet-337	999	28	phase	phase	NOUN
admet-337	999	29	ii	ii	PROPN
admet-337	999	30	study	study	NOUN
admet-337	999	31	of	of	ADP
admet-337	999	32	ceritinib	ceritinib	NOUN
admet-337	999	33	in	in	ADP
admet-337	999	34	adult	adult	NOUN
admet-337	999	35	patients	patient	NOUN
admet-337	999	36	(	(	PUNCT
admet-337	999	37	pts	pt	NOUN
admet-337	999	38	)	)	PUNCT
admet-337	999	39	with	with	ADP
admet-337	999	40	alk	alk	VERB
admet-337	999	41	-	-	PUNCT
admet-337	999	42	rearranged	rearrange	VERB
admet-337	999	43	(	(	PUNCT
admet-337	999	44	alk+	alk+	NOUN
admet-337	999	45	)	)	PUNCT
admet-337	999	46	non	non	ADJ
admet-337	999	47	-	-	ADJ
admet-337	999	48	small	small	ADJ
admet-337	999	49	cell	cell	NOUN
admet-337	999	50	lung	lung	NOUN
admet-337	999	51	cancer	cancer	NOUN
admet-337	999	52	(	(	PUNCT
admet-337	999	53	nsclc	nsclc	NOUN
admet-337	999	54	)	)	PUNCT
admet-337	999	55	previously	previously	ADV
admet-337	999	56	treated	treat	VERB
admet-337	999	57	with	with	ADP
admet-337	999	58	chemotherapy	chemotherapy	NOUN
admet-337	999	59	and	and	CCONJ
admet-337	999	60	crizotinib	crizotinib	PROPN
admet-337	999	61	(	(	PUNCT
admet-337	999	62	crz	crz	PROPN
admet-337	999	63	)	)	PUNCT
admet-337	999	64	.	.	PUNCT
admet-337	1000	1	american	american	ADJ
admet-337	1000	2	society	society	NOUN
admet-337	1000	3	of	of	ADP
admet-337	1000	4	clinical	clinical	ADJ
admet-337	1000	5	oncology	oncology	NOUN
admet-337	1000	6	annual	annual	ADJ
admet-337	1000	7	meeting	meeting	NOUN
admet-337	1000	8	2015	2015	NUM
admet-337	1000	9	.	.	PUNCT
admet-337	1001	1	[	[	X
admet-337	1001	2	142	142	NUM
admet-337	1001	3	]	]	PUNCT
admet-337	1001	4	e.	e.	PROPN
admet-337	1001	5	felip	felip	PROPN
admet-337	1001	6	,	,	PUNCT
admet-337	1001	7	s.	s.	PROPN
admet-337	1001	8	orlov	orlov	PROPN
admet-337	1001	9	,	,	PUNCT
admet-337	1001	10	k.	k.	PROPN
admet-337	1001	11	park	park	PROPN
admet-337	1001	12	,	,	PUNCT
admet-337	1001	13	et	et	PROPN
admet-337	1001	14	al	al	PROPN
admet-337	1001	15	.	.	PUNCT
admet-337	1002	1	ascend-3	ascend-3	PROPN
admet-337	1002	2	:	:	PUNCT
admet-337	1002	3	a	a	DET
admet-337	1002	4	single	single	ADJ
admet-337	1002	5	-	-	PUNCT
admet-337	1002	6	arm	arm	NOUN
admet-337	1002	7	,	,	PUNCT
admet-337	1002	8	open	open	ADJ
admet-337	1002	9	-	-	PUNCT
admet-337	1002	10	label	label	NOUN
admet-337	1002	11	,	,	PUNCT
admet-337	1002	12	multicenter	multicenter	NOUN
admet-337	1002	13	phase	phase	NOUN
admet-337	1002	14	ii	ii	PROPN
admet-337	1002	15	study	study	NOUN
admet-337	1002	16	of	of	ADP
admet-337	1002	17	ceritinib	ceritinib	NOUN
admet-337	1002	18	in	in	ADP
admet-337	1002	19	alki	alki	PROPN
admet-337	1002	20	-	-	PUNCT
admet-337	1002	21	naïve	naïve	ADJ
admet-337	1002	22	adult	adult	NOUN
admet-337	1002	23	patients	patient	NOUN
admet-337	1002	24	(	(	PUNCT
admet-337	1002	25	pts	pt	NOUN
admet-337	1002	26	)	)	PUNCT
admet-337	1002	27	with	with	ADP
admet-337	1002	28	alk	alk	VERB
admet-337	1002	29	-	-	PUNCT
admet-337	1002	30	rearranged	rearrange	VERB
admet-337	1002	31	(	(	PUNCT
admet-337	1002	32	alk+	alk+	NOUN
admet-337	1002	33	)	)	PUNCT
admet-337	1002	34	non	non	ADJ
admet-337	1002	35	-	-	ADJ
admet-337	1002	36	small	small	ADJ
admet-337	1002	37	cell	cell	NOUN
admet-337	1002	38	lung	lung	NOUN
admet-337	1002	39	cancer	cancer	NOUN
admet-337	1002	40	(	(	PUNCT
admet-337	1002	41	nsclc	nsclc	NOUN
admet-337	1002	42	)	)	PUNCT
admet-337	1002	43	.	.	PUNCT
admet-337	1003	1	american	american	ADJ
admet-337	1003	2	society	society	NOUN
admet-337	1003	3	of	of	ADP
admet-337	1003	4	clinical	clinical	ADJ
admet-337	1003	5	oncology	oncology	NOUN
admet-337	1003	6	annual	annual	ADJ
admet-337	1003	7	meeting	meeting	NOUN
admet-337	1003	8	2015	2015	NUM
admet-337	1003	9	.	.	PUNCT
admet-337	1004	1	[	[	X
admet-337	1004	2	143	143	NUM
admet-337	1004	3	]	]	X
admet-337	1004	4	zykadia	zykadia	X
admet-337	1004	5	(	(	PUNCT
admet-337	1004	6	ceritinib	ceritinib	PROPN
admet-337	1004	7	)	)	PUNCT
admet-337	1005	1	[	[	X
admet-337	1005	2	package	package	NOUN
admet-337	1005	3	insert	insert	NOUN
admet-337	1005	4	]	]	PUNCT
admet-337	1005	5	.	.	PUNCT
admet-337	1006	1	east	east	PROPN
admet-337	1006	2	hanover	hanover	PROPN
admet-337	1006	3	,	,	PUNCT
admet-337	1006	4	nj	nj	PROPN
admet-337	1006	5	:	:	PUNCT
admet-337	1006	6	novartis	novartis	NOUN
admet-337	1006	7	pharmaceuticals	pharmaceutical	NOUN
admet-337	1006	8	;	;	PUNCT
admet-337	1006	9	2014	2014	NUM
admet-337	1006	10	.	.	PUNCT
admet-337	1007	1	[	[	X
admet-337	1007	2	144	144	NUM
admet-337	1007	3	]	]	X
admet-337	1007	4	t.h	t.h	PROPN
admet-337	1007	5	.	.	PROPN
admet-337	1007	6	marsilje	marsilje	PROPN
admet-337	1007	7	,	,	PUNCT
admet-337	1007	8	w.	w.	PROPN
admet-337	1007	9	pei	pei	PROPN
admet-337	1007	10	,	,	PUNCT
admet-337	1007	11	b.	b.	PROPN
admet-337	1007	12	chen	chen	PROPN
admet-337	1007	13	,	,	PUNCT
admet-337	1007	14	et	et	PROPN
admet-337	1007	15	al	al	PROPN
admet-337	1007	16	.	.	PUNCT
admet-337	1008	1	j.	j.	PROPN
admet-337	1008	2	med	med	PROPN
admet-337	1008	3	.	.	PROPN
admet-337	1008	4	chem	chem	PROPN
admet-337	1008	5	.	.	PUNCT
admet-337	1009	1	56	56	NUM
admet-337	1009	2	(	(	PUNCT
admet-337	1009	3	2013	2013	NUM
admet-337	1009	4	)	)	PUNCT
admet-337	1009	5	5675	5675	NUM
admet-337	1009	6	-	-	SYM
admet-337	1009	7	5690	5690	NUM
admet-337	1009	8	.	.	PUNCT
admet-337	1010	1	[	[	X
admet-337	1010	2	145	145	NUM
admet-337	1010	3	]	]	X
admet-337	1010	4	j.f	j.f	PROPN
admet-337	1010	5	.	.	PROPN
admet-337	1010	6	gainor	gainor	PROPN
admet-337	1010	7	,	,	PUNCT
admet-337	1010	8	l.	l.	PROPN
admet-337	1010	9	friboulet	friboulet	PROPN
admet-337	1010	10	,	,	PUNCT
admet-337	1010	11	r.	r.	PROPN
admet-337	1010	12	katayama	katayama	PROPN
admet-337	1010	13	,	,	PUNCT
admet-337	1010	14	et	et	PROPN
admet-337	1010	15	al	al	PROPN
admet-337	1010	16	.	.	PROPN
admet-337	1010	17	evolution	evolution	NOUN
admet-337	1010	18	of	of	ADP
admet-337	1010	19	resistance	resistance	NOUN
admet-337	1010	20	in	in	ADP
admet-337	1010	21	alk	alk	NOUN
admet-337	1010	22	-	-	PUNCT
admet-337	1010	23	positive	positive	ADJ
admet-337	1010	24	patients	patient	NOUN
admet-337	1010	25	treated	treat	VERB
admet-337	1010	26	with	with	ADP
admet-337	1010	27	alk	alk	PROPN
admet-337	1010	28	tyrosine	tyrosine	PROPN
admet-337	1010	29	kinase	kinase	PROPN
admet-337	1010	30	inhibitors	inhibitor	NOUN
admet-337	1010	31	(	(	PUNCT
admet-337	1010	32	tkis	tkis	NOUN
admet-337	1010	33	)	)	PUNCT
admet-337	1010	34	.	.	PUNCT
admet-337	1011	1	american	american	ADJ
admet-337	1011	2	society	society	NOUN
admet-337	1011	3	of	of	ADP
admet-337	1011	4	clinical	clinical	ADJ
admet-337	1011	5	oncology	oncology	NOUN
admet-337	1011	6	annual	annual	ADJ
admet-337	1011	7	meeting	meeting	NOUN
admet-337	1011	8	2014	2014	NUM
admet-337	1011	9	.	.	PUNCT
admet-337	1012	1	[	[	X
admet-337	1012	2	146	146	NUM
admet-337	1012	3	]	]	PUNCT
admet-337	1012	4	t.	t.	PROPN
admet-337	1012	5	kodama	kodama	PROPN
admet-337	1012	6	,	,	PUNCT
admet-337	1012	7	t.	t.	PROPN
admet-337	1012	8	tsukaguchi	tsukaguchi	PROPN
admet-337	1012	9	,	,	PUNCT
admet-337	1012	10	m.	m.	PROPN
admet-337	1012	11	yoshida	yoshida	PROPN
admet-337	1012	12	,	,	PUNCT
admet-337	1012	13	o.	o.	PROPN
admet-337	1012	14	kondoh	kondoh	PROPN
admet-337	1012	15	,	,	PUNCT
admet-337	1012	16	h.	h.	PROPN
admet-337	1012	17	sakamoto	sakamoto	PROPN
admet-337	1012	18	,	,	PUNCT
admet-337	1012	19	cancer	cancer	NOUN
admet-337	1012	20	lett	lett	PROPN
admet-337	1012	21	.	.	PUNCT
admet-337	1013	1	351	351	NUM
admet-337	1013	2	(	(	PUNCT
admet-337	1013	3	2014	2014	NUM
admet-337	1013	4	)	)	PUNCT
admet-337	1013	5	215	215	NUM
admet-337	1013	6	-	-	SYM
admet-337	1013	7	221	221	NUM
admet-337	1013	8	.	.	PUNCT
admet-337	1014	1	[	[	X
admet-337	1014	2	147	147	NUM
admet-337	1014	3	]	]	X
admet-337	1014	4	h.	h.	PROPN
admet-337	1014	5	sakamoto	sakamoto	PROPN
admet-337	1014	6	,	,	PUNCT
admet-337	1014	7	t.	t.	PROPN
admet-337	1014	8	tsukaguchi	tsukaguchi	PROPN
admet-337	1014	9	,	,	PUNCT
admet-337	1014	10	s.	s.	PROPN
admet-337	1014	11	hiroshima	hiroshima	PROPN
admet-337	1014	12	,	,	PUNCT
admet-337	1014	13	et	et	PROPN
admet-337	1014	14	al	al	PROPN
admet-337	1014	15	.	.	PUNCT
admet-337	1014	16	cancer	cancer	NOUN
admet-337	1014	17	cell	cell	NOUN
admet-337	1014	18	.	.	PUNCT
admet-337	1015	1	19	19	NUM
admet-337	1015	2	(	(	PUNCT
admet-337	1015	3	2011	2011	NUM
admet-337	1015	4	)	)	PUNCT
admet-337	1015	5	679	679	NUM
admet-337	1015	6	-	-	SYM
admet-337	1015	7	690	690	NUM
admet-337	1015	8	.	.	PUNCT
admet-337	1016	1	[	[	X
admet-337	1016	2	148	148	NUM
admet-337	1016	3	]	]	PUNCT
admet-337	1016	4	t.	t.	PROPN
admet-337	1016	5	seto	seto	PROPN
admet-337	1016	6	,	,	PUNCT
admet-337	1016	7	k.	k.	PROPN
admet-337	1016	8	kiura	kiura	PROPN
admet-337	1016	9	,	,	PUNCT
admet-337	1016	10	m.	m.	NOUN
admet-337	1016	11	nishio	nishio	PROPN
admet-337	1016	12	,	,	PUNCT
admet-337	1016	13	et	et	PROPN
admet-337	1016	14	al	al	PROPN
admet-337	1016	15	.	.	PUNCT
admet-337	1017	1	lancet	lancet	PROPN
admet-337	1017	2	oncol	oncol	PROPN
admet-337	1017	3	.	.	PUNCT
admet-337	1018	1	14	14	NUM
admet-337	1018	2	(	(	PUNCT
admet-337	1018	3	2013	2013	NUM
admet-337	1018	4	)	)	PUNCT
admet-337	1018	5	590	590	NUM
admet-337	1018	6	-	-	SYM
admet-337	1018	7	598	598	NUM
admet-337	1018	8	.	.	PUNCT
admet-337	1019	1	[	[	X
admet-337	1019	2	149	149	NUM
admet-337	1019	3	]	]	X
admet-337	1019	4	s.m	s.m	PROPN
admet-337	1019	5	.	.	PROPN
admet-337	1019	6	gadgeel	gadgeel	PROPN
admet-337	1019	7	,	,	PUNCT
admet-337	1019	8	l.	l.	PROPN
admet-337	1019	9	gandhi	gandhi	PROPN
admet-337	1019	10	,	,	PUNCT
admet-337	1019	11	g.j	g.j	PROPN
admet-337	1019	12	.	.	PROPN
admet-337	1019	13	riely	riely	PROPN
admet-337	1019	14	,	,	PUNCT
admet-337	1019	15	et	et	PROPN
admet-337	1019	16	al	al	PROPN
admet-337	1019	17	.	.	PUNCT
admet-337	1020	1	lancet	lancet	PROPN
admet-337	1020	2	oncol	oncol	PROPN
admet-337	1020	3	.	.	PUNCT
admet-337	1021	1	15	15	NUM
admet-337	1021	2	(	(	PUNCT
admet-337	1021	3	2014	2014	NUM
admet-337	1021	4	)	)	PUNCT
admet-337	1021	5	1119	1119	NUM
admet-337	1021	6	-	-	SYM
admet-337	1021	7	1128	1128	NUM
admet-337	1021	8	.	.	PUNCT
admet-337	1022	1	[	[	X
admet-337	1022	2	150	150	NUM
admet-337	1022	3	]	]	SYM
admet-337	1022	4	a.t	a.t	PROPN
admet-337	1022	5	.	.	PROPN
admet-337	1022	6	shaw	shaw	PROPN
admet-337	1022	7	,	,	PUNCT
admet-337	1022	8	l.	l.	PROPN
admet-337	1022	9	gandhi	gandhi	PROPN
admet-337	1022	10	,	,	PUNCT
admet-337	1022	11	s.	s.	PROPN
admet-337	1022	12	gadgeel	gadgeel	PROPN
admet-337	1022	13	,	,	PUNCT
admet-337	1022	14	et	et	PROPN
admet-337	1022	15	al	al	PROPN
admet-337	1022	16	.	.	PUNCT
admet-337	1023	1	lancet	lancet	PROPN
admet-337	1023	2	oncol	oncol	PROPN
admet-337	1023	3	.	.	PUNCT
admet-337	1024	1	17	17	NUM
admet-337	1024	2	(	(	PUNCT
admet-337	1024	3	2016	2016	NUM
admet-337	1024	4	)	)	PUNCT
admet-337	1024	5	234	234	NUM
admet-337	1024	6	-	-	SYM
admet-337	1024	7	242	242	NUM
admet-337	1024	8	.	.	PUNCT
admet-337	1025	1	[	[	X
admet-337	1025	2	151	151	NUM
admet-337	1025	3	]	]	X
admet-337	1025	4	h.	h.	PROPN
admet-337	1025	5	nokihara	nokihara	PROPN
admet-337	1025	6	,	,	PUNCT
admet-337	1025	7	t.	t.	PROPN
admet-337	1025	8	hida	hida	PROPN
admet-337	1025	9	,	,	PUNCT
admet-337	1025	10	m.	m.	NOUN
admet-337	1025	11	kondo	kondo	PROPN
admet-337	1025	12	,	,	PUNCT
admet-337	1025	13	et	et	PROPN
admet-337	1025	14	al	al	PROPN
admet-337	1025	15	.	.	PUNCT
admet-337	1025	16	alectinib	alectinib	PROPN
admet-337	1025	17	(	(	PUNCT
admet-337	1025	18	alc	alc	NOUN
admet-337	1025	19	)	)	PUNCT
admet-337	1025	20	versus	versus	ADP
admet-337	1025	21	crizotinib	crizotinib	PROPN
admet-337	1025	22	(	(	PUNCT
admet-337	1025	23	crz	crz	PROPN
admet-337	1025	24	)	)	PUNCT
admet-337	1025	25	in	in	ADP
admet-337	1025	26	alk	alk	NOUN
admet-337	1025	27	-	-	PUNCT
admet-337	1025	28	inhibitor	inhibitor	NOUN
admet-337	1025	29	naive	naive	ADJ
admet-337	1025	30	alk	alk	VERB
admet-337	1025	31	-	-	PUNCT
admet-337	1025	32	positive	positive	ADJ
admet-337	1025	33	non	non	ADJ
admet-337	1025	34	-	-	ADJ
admet-337	1025	35	small	small	ADJ
admet-337	1025	36	cell	cell	NOUN
admet-337	1025	37	lung	lung	NOUN
admet-337	1025	38	cancer	cancer	NOUN
admet-337	1025	39	(	(	PUNCT
admet-337	1025	40	alk+	alk+	NOUN
admet-337	1025	41	nsclc	nsclc	NOUN
admet-337	1025	42	):	):	PUNCT
admet-337	1025	43	primary	primary	ADJ
admet-337	1025	44	results	result	NOUN
admet-337	1025	45	from	from	ADP
admet-337	1025	46	the	the	DET
admet-337	1025	47	j	j	PROPN
admet-337	1025	48	-	-	PROPN
admet-337	1025	49	alex	alex	PROPN
admet-337	1025	50	study	study	PROPN
admet-337	1025	51	.	.	PUNCT
admet-337	1026	1	american	american	ADJ
admet-337	1026	2	society	society	NOUN
admet-337	1026	3	of	of	ADP
admet-337	1026	4	clinical	clinical	ADJ
admet-337	1026	5	oncology	oncology	NOUN
admet-337	1026	6	annual	annual	ADJ
admet-337	1026	7	meeting	meeting	NOUN
admet-337	1026	8	2016	2016	NUM
admet-337	1026	9	.	.	PUNCT
admet-337	1027	1	[	[	X
admet-337	1027	2	152	152	NUM
admet-337	1027	3	]	]	PUNCT
admet-337	1027	4	k.	k.	PROPN
admet-337	1027	5	kinoshita	kinoshita	PROPN
admet-337	1027	6	,	,	PUNCT
admet-337	1027	7	k.	k.	PROPN
admet-337	1027	8	asoh	asoh	PROPN
admet-337	1027	9	,	,	PUNCT
admet-337	1027	10	n.	n.	PROPN
admet-337	1027	11	furuichi	furuichi	PROPN
admet-337	1027	12	,	,	PUNCT
admet-337	1027	13	et	et	PROPN
admet-337	1027	14	al	al	PROPN
admet-337	1027	15	.	.	PROPN
admet-337	1027	16	bioorg	bioorg	PROPN
admet-337	1027	17	.	.	PUNCT
admet-337	1028	1	med	med	PROPN
admet-337	1028	2	.	.	PUNCT
admet-337	1028	3	chem	chem	PROPN
admet-337	1028	4	.	.	PUNCT
admet-337	1029	1	20	20	NUM
admet-337	1029	2	(	(	PUNCT
admet-337	1029	3	2012	2012	NUM
admet-337	1029	4	)	)	PUNCT
admet-337	1029	5	1271	1271	NUM
admet-337	1029	6	-	-	SYM
admet-337	1029	7	1280	1280	NUM
admet-337	1029	8	.	.	PUNCT
admet-337	1030	1	[	[	X
admet-337	1030	2	153	153	NUM
admet-337	1030	3	]	]	PUNCT
admet-337	1030	4	t.	t.	PROPN
admet-337	1030	5	kodama	kodama	PROPN
admet-337	1030	6	,	,	PUNCT
admet-337	1030	7	t.	t.	PROPN
admet-337	1030	8	tsukaguchi	tsukaguchi	PROPN
admet-337	1030	9	,	,	PUNCT
admet-337	1030	10	y.	y.	PROPN
admet-337	1030	11	satoh	satoh	PROPN
admet-337	1030	12	,	,	PUNCT
admet-337	1030	13	et	et	PROPN
admet-337	1030	14	al	al	PROPN
admet-337	1030	15	.	.	PROPN
admet-337	1030	16	mol	mol	PROPN
admet-337	1030	17	.	.	PUNCT
admet-337	1031	1	cancer	cancer	NOUN
admet-337	1031	2	.	.	PUNCT
admet-337	1032	1	ther	ther	INTJ
admet-337	1032	2	.	.	PUNCT
admet-337	1033	1	13	13	NUM
admet-337	1033	2	(	(	PUNCT
admet-337	1033	3	2014	2014	NUM
admet-337	1033	4	)	)	PUNCT
admet-337	1033	5	2910	2910	NUM
admet-337	1033	6	-	-	SYM
admet-337	1033	7	2918	2918	NUM
admet-337	1033	8	.	.	PUNCT
admet-337	1034	1	[	[	X
admet-337	1034	2	154	154	NUM
admet-337	1034	3	]	]	X
admet-337	1034	4	alecensa	alecensa	X
admet-337	1034	5	(	(	PUNCT
admet-337	1034	6	alectinib	alectinib	NOUN
admet-337	1034	7	)	)	PUNCT
admet-337	1035	1	[	[	X
admet-337	1035	2	package	package	NOUN
admet-337	1035	3	insert	insert	NOUN
admet-337	1035	4	]	]	PUNCT
admet-337	1035	5	.	.	PUNCT
admet-337	1036	1	basel	basel	PROPN
admet-337	1036	2	,	,	PUNCT
admet-337	1036	3	switzerland	switzerland	PROPN
admet-337	1036	4	:	:	PUNCT
admet-337	1036	5	roche	roche	NOUN
admet-337	1036	6	;	;	PUNCT
admet-337	1036	7	2015	2015	NUM
admet-337	1036	8	.	.	PUNCT
admet-337	1037	1	[	[	X
admet-337	1037	2	155	155	NUM
admet-337	1037	3	]	]	X
admet-337	1037	4	r.	r.	PROPN
admet-337	1037	5	katayama	katayama	PROPN
admet-337	1037	6	,	,	PUNCT
admet-337	1037	7	l.	l.	PROPN
admet-337	1037	8	friboulet	friboulet	PROPN
admet-337	1037	9	,	,	PUNCT
admet-337	1037	10	s.	s.	PROPN
admet-337	1037	11	koike	koike	PROPN
admet-337	1037	12	,	,	PUNCT
admet-337	1037	13	et	et	PROPN
admet-337	1037	14	al	al	PROPN
admet-337	1037	15	.	.	PUNCT
admet-337	1037	16	clin	clin	PROPN
admet-337	1037	17	.	.	PUNCT
admet-337	1038	1	cancer	cancer	NOUN
admet-337	1038	2	res	re	NOUN
admet-337	1038	3	.	.	PROPN
admet-337	1039	1	20	20	NUM
admet-337	1039	2	(	(	PUNCT
admet-337	1039	3	2014	2014	NUM
admet-337	1039	4	)	)	PUNCT
admet-337	1039	5	5686	5686	NUM
admet-337	1039	6	-	-	SYM
admet-337	1039	7	5696	5696	NUM
admet-337	1039	8	.	.	PUNCT
admet-337	1040	1	[	[	X
admet-337	1040	2	156	156	NUM
admet-337	1040	3	]	]	PUNCT
admet-337	1040	4	t.	t.	NOUN
admet-337	1040	5	gouji	gouji	PROPN
admet-337	1040	6	,	,	PUNCT
admet-337	1040	7	s.	s.	PROPN
admet-337	1040	8	takashi	takashi	PROPN
admet-337	1040	9	,	,	PUNCT
admet-337	1040	10	t.	t.	PROPN
admet-337	1040	11	mitsuhiro	mitsuhiro	PROPN
admet-337	1040	12	,	,	PUNCT
admet-337	1040	13	i.	i.	NOUN
admet-337	1040	14	yukito	yukito	PROPN
admet-337	1040	15	,	,	PUNCT
admet-337	1040	16	j.t	j.t	PROPN
admet-337	1040	17	horac	horac	NOUN
admet-337	1040	18	.	.	PUNCT
admet-337	1041	1	oncol	oncol	ADJ
admet-337	1041	2	.	.	PUNCT
admet-337	1042	1	9	9	NUM
admet-337	1042	2	(	(	PUNCT
admet-337	1042	3	2014	2014	NUM
admet-337	1042	4	)	)	PUNCT
admet-337	1042	5	e27	e27	NOUN
admet-337	1042	6	-	-	SYM
admet-337	1042	7	8	8	NUM
admet-337	1042	8	.	.	PUNCT
admet-337	1043	1	[	[	X
admet-337	1043	2	157	157	NUM
admet-337	1043	3	]	]	X
admet-337	1043	4	h.y	h.y	PROPN
admet-337	1043	5	.	.	PROPN
admet-337	1043	6	zou	zou	PROPN
admet-337	1043	7	,	,	PUNCT
admet-337	1043	8	l.	l.	PROPN
admet-337	1043	9	friboulet	friboulet	PROPN
admet-337	1043	10	,	,	PUNCT
admet-337	1043	11	d.p	d.p	PROPN
admet-337	1043	12	.	.	PROPN
admet-337	1043	13	kodack	kodack	PROPN
admet-337	1043	14	,	,	PUNCT
admet-337	1043	15	et	et	PROPN
admet-337	1043	16	al	al	PROPN
admet-337	1043	17	.	.	PUNCT
admet-337	1043	18	cancer	cancer	NOUN
admet-337	1043	19	.	.	PUNCT
admet-337	1044	1	cell	cell	NOUN
admet-337	1044	2	.	.	PUNCT
admet-337	1045	1	28	28	NUM
admet-337	1045	2	(	(	PUNCT
admet-337	1045	3	2015	2015	NUM
admet-337	1045	4	)	)	PUNCT
admet-337	1045	5	70	70	NUM
admet-337	1045	6	-	-	SYM
admet-337	1045	7	81	81	NUM
admet-337	1045	8	.	.	PUNCT
admet-337	1046	1	[	[	X
admet-337	1046	2	158	158	NUM
admet-337	1046	3	]	]	X
admet-337	1046	4	d.	d.	PROPN
admet-337	1046	5	fontana	fontana	PROPN
admet-337	1046	6	,	,	PUNCT
admet-337	1046	7	m.	m.	NOUN
admet-337	1046	8	ceccon	ceccon	PROPN
admet-337	1046	9	,	,	PUNCT
admet-337	1046	10	c.	c.	PROPN
admet-337	1046	11	gambacorti	gambacorti	PROPN
admet-337	1046	12	-	-	PUNCT
admet-337	1046	13	passerini	passerini	NOUN
admet-337	1046	14	,	,	PUNCT
admet-337	1046	15	l.	l.	PROPN
admet-337	1046	16	mologni	mologni	PROPN
admet-337	1046	17	,	,	PUNCT
admet-337	1046	18	cancer	cancer	NOUN
admet-337	1046	19	.	.	PUNCT
admet-337	1046	20	med	med	PROPN
admet-337	1046	21	.	.	PROPN
admet-337	1047	1	4	4	NUM
admet-337	1047	2	(	(	PUNCT
admet-337	1047	3	2015	2015	NUM
admet-337	1047	4	)	)	PUNCT
admet-337	1047	5	953	953	NUM
admet-337	1047	6	-	-	PUNCT
admet-337	1047	7	965	965	NUM
admet-337	1047	8	.	.	PUNCT
admet-337	1048	1	admet	admet	PROPN
admet-337	1048	2	&	&	CCONJ
admet-337	1048	3	dmpk	dmpk	PROPN
admet-337	1048	4	4(3	4(3	NUM
admet-337	1048	5	)	)	PUNCT
admet-337	1048	6	(	(	PUNCT
admet-337	1048	7	2016	2016	NUM
admet-337	1048	8	)	)	PUNCT
admet-337	1048	9	186	186	NUM
admet-337	1048	10	-	-	SYM
admet-337	1048	11	211	211	NUM
admet-337	1048	12	tki	tki	NOUN
admet-337	1048	13	for	for	ADP
admet-337	1048	14	egfrand	egfrand	ADJ
admet-337	1048	15	alk	alk	PROPN
admet-337	1048	16	-	-	PUNCT
admet-337	1048	17	mutated	mutate	VERB
admet-337	1048	18	cell	cell	NOUN
admet-337	1048	19	cancer	cancer	NOUN
admet-337	1048	20	doi	doi	NOUN
admet-337	1048	21	:	:	PUNCT
admet-337	1048	22	10.5599	10.5599	NUM
admet-337	1048	23	/	/	SYM
admet-337	1048	24	admet.4.3.337	admet.4.3.337	NUM
admet-337	1048	25	211	211	NUM
admet-337	1048	26	[	[	SYM
admet-337	1048	27	159	159	NUM
admet-337	1048	28	]	]	X
admet-337	1048	29	j.m	j.m	PROPN
admet-337	1048	30	.	.	PROPN
admet-337	1048	31	hatcher	hatcher	PROPN
admet-337	1048	32	,	,	PUNCT
admet-337	1048	33	m.	m.	NOUN
admet-337	1048	34	bahcall	bahcall	PROPN
admet-337	1048	35	,	,	PUNCT
admet-337	1048	36	h.g	h.g	PROPN
admet-337	1048	37	.	.	PROPN
admet-337	1048	38	choi	choi	PROPN
admet-337	1048	39	,	,	PUNCT
admet-337	1048	40	et	et	PROPN
admet-337	1048	41	al	al	PROPN
admet-337	1048	42	.	.	PUNCT
admet-337	1049	1	j.	j.	PROPN
admet-337	1049	2	med	med	PROPN
admet-337	1049	3	.	.	PROPN
admet-337	1049	4	chem	chem	PROPN
admet-337	1049	5	.	.	PUNCT
admet-337	1050	1	58	58	NUM
admet-337	1050	2	(	(	PUNCT
admet-337	1050	3	2015	2015	NUM
admet-337	1050	4	)	)	PUNCT
admet-337	1050	5	9296	9296	NUM
admet-337	1050	6	-	-	SYM
admet-337	1050	7	9308	9308	NUM
admet-337	1050	8	.	.	PUNCT
admet-337	1051	1	[	[	X
admet-337	1051	2	160	160	NUM
admet-337	1051	3	]	]	X
admet-337	1051	4	a.t	a.t	PROPN
admet-337	1051	5	.	.	PROPN
admet-337	1051	6	shaw	shaw	PROPN
admet-337	1051	7	,	,	PUNCT
admet-337	1051	8	l.	l.	PROPN
admet-337	1051	9	friboulet	friboulet	PROPN
admet-337	1051	10	,	,	PUNCT
admet-337	1051	11	i.	i.	PROPN
admet-337	1051	12	leshchiner	leshchiner	NOUN
admet-337	1051	13	,	,	PUNCT
admet-337	1051	14	et	et	PROPN
admet-337	1051	15	al	al	PROPN
admet-337	1051	16	.	.	PUNCT
admet-337	1051	17	n.	n.	PROPN
admet-337	1051	18	engl	engl	PROPN
admet-337	1051	19	.	.	PUNCT
admet-337	1052	1	j.	j.	PROPN
admet-337	1052	2	med	med	PROPN
admet-337	1052	3	.	.	PUNCT
admet-337	1053	1	374	374	NUM
admet-337	1053	2	(	(	PUNCT
admet-337	1053	3	2016	2016	NUM
admet-337	1053	4	)	)	PUNCT
admet-337	1053	5	54	54	NUM
admet-337	1053	6	-	-	SYM
admet-337	1053	7	61	61	NUM
admet-337	1053	8	.	.	PUNCT
admet-337	1054	1	[	[	X
admet-337	1054	2	161	161	NUM
admet-337	1054	3	]	]	X
admet-337	1054	4	w.s	w.s	PROPN
admet-337	1054	5	.	.	PROPN
admet-337	1054	6	huang	huang	PROPN
admet-337	1054	7	,	,	PUNCT
admet-337	1054	8	s.	s.	PROPN
admet-337	1054	9	liu	liu	PROPN
admet-337	1054	10	,	,	PUNCT
admet-337	1054	11	d.	d.	PROPN
admet-337	1054	12	zou	zou	PROPN
admet-337	1054	13	,	,	PUNCT
admet-337	1054	14	et	et	PROPN
admet-337	1054	15	al	al	PROPN
admet-337	1054	16	.	.	PUNCT
admet-337	1054	17	j.	j.	PROPN
admet-337	1054	18	med	med	PROPN
admet-337	1054	19	.	.	PROPN
admet-337	1054	20	chem	chem	PROPN
admet-337	1054	21	.	.	PUNCT
admet-337	1055	1	59	59	NUM
admet-337	1055	2	(	(	PUNCT
admet-337	1055	3	2016	2016	NUM
admet-337	1055	4	)	)	PUNCT
admet-337	1055	5	4948	4948	NUM
admet-337	1055	6	-	-	SYM
admet-337	1055	7	4964	4964	NUM
admet-337	1055	8	.	.	PUNCT
admet-337	1056	1	[	[	X
admet-337	1056	2	162	162	NUM
admet-337	1056	3	]	]	X
admet-337	1056	4	d.w	d.w	PROPN
admet-337	1056	5	.	.	PUNCT
admet-337	1056	6	kim	kim	PROPN
admet-337	1056	7	,	,	PUNCT
admet-337	1056	8	m.	m.	NOUN
admet-337	1056	9	tiseo	tiseo	PROPN
admet-337	1056	10	,	,	PUNCT
admet-337	1056	11	m.j	m.j	PROPN
admet-337	1056	12	.	.	PROPN
admet-337	1056	13	ahn	ahn	PROPN
admet-337	1056	14	,	,	PUNCT
admet-337	1056	15	et	et	PROPN
admet-337	1056	16	al	al	PROPN
admet-337	1056	17	.	.	PROPN
admet-337	1056	18	brigatinib	brigatinib	PROPN
admet-337	1056	19	(	(	PUNCT
admet-337	1056	20	brg	brg	PROPN
admet-337	1056	21	)	)	PUNCT
admet-337	1056	22	in	in	ADP
admet-337	1056	23	patients	patient	NOUN
admet-337	1056	24	(	(	PUNCT
admet-337	1056	25	pts	pt	NOUN
admet-337	1056	26	)	)	PUNCT
admet-337	1056	27	with	with	ADP
admet-337	1056	28	crizotinib	crizotinib	NOUN
admet-337	1056	29	(	(	PUNCT
admet-337	1056	30	crz)-refractory	crz)-refractory	PROPN
admet-337	1056	31	alk+	alk+	VERB
admet-337	1056	32	non	non	ADJ
admet-337	1056	33	-	-	ADJ
admet-337	1056	34	small	small	ADJ
admet-337	1056	35	cell	cell	NOUN
admet-337	1056	36	lung	lung	NOUN
admet-337	1056	37	cancer	cancer	NOUN
admet-337	1056	38	(	(	PUNCT
admet-337	1056	39	nsclc	nsclc	NOUN
admet-337	1056	40	):	):	PUNCT
admet-337	1056	41	first	first	ADJ
admet-337	1056	42	report	report	NOUN
admet-337	1056	43	of	of	ADP
admet-337	1056	44	efficacy	efficacy	NOUN
admet-337	1056	45	and	and	CCONJ
admet-337	1056	46	safety	safety	NOUN
admet-337	1056	47	from	from	ADP
admet-337	1056	48	a	a	DET
admet-337	1056	49	pivotal	pivotal	ADJ
admet-337	1056	50	randomized	randomized	ADJ
admet-337	1056	51	phase	phase	NOUN
admet-337	1056	52	(	(	PUNCT
admet-337	1056	53	ph	ph	ADJ
admet-337	1056	54	)	)	PUNCT
admet-337	1056	55	2	2	NUM
admet-337	1056	56	trial	trial	NOUN
admet-337	1056	57	(	(	PUNCT
admet-337	1056	58	alta	alta	PROPN
admet-337	1056	59	)	)	PUNCT
admet-337	1056	60	.	.	PUNCT
admet-337	1057	1	american	american	ADJ
admet-337	1057	2	society	society	NOUN
admet-337	1057	3	of	of	ADP
admet-337	1057	4	clinical	clinical	ADJ
admet-337	1057	5	oncology	oncology	NOUN
admet-337	1057	6	annual	annual	ADJ
admet-337	1057	7	meeting	meeting	NOUN
admet-337	1057	8	2016	2016	NUM
admet-337	1057	9	.	.	PUNCT
admet-337	1058	1	[	[	X
admet-337	1058	2	163	163	NUM
admet-337	1058	3	]	]	X
admet-337	1058	4	d.r	d.r	PROPN
admet-337	1058	5	.	.	PROPN
admet-337	1058	6	camidge	camidge	PROPN
admet-337	1058	7	,	,	PUNCT
admet-337	1058	8	l.a	l.a	PROPN
admet-337	1058	9	.	.	PROPN
admet-337	1058	10	bazhenova	bazhenova	PROPN
admet-337	1058	11	,	,	PUNCT
admet-337	1058	12	r.	r.	PROPN
admet-337	1058	13	salgia	salgia	PROPN
admet-337	1058	14	,	,	PUNCT
admet-337	1058	15	et	et	PROPN
admet-337	1058	16	al	al	PROPN
admet-337	1058	17	.	.	PROPN
admet-337	1058	18	updated	update	VERB
admet-337	1058	19	results	result	NOUN
admet-337	1058	20	of	of	ADP
admet-337	1058	21	a	a	DET
admet-337	1058	22	first	first	ADJ
admet-337	1058	23	-	-	PUNCT
admet-337	1058	24	in	in	ADP
admet-337	1058	25	-	-	PUNCT
admet-337	1058	26	human	human	ADJ
admet-337	1058	27	dose	dose	NOUN
admet-337	1058	28	-	-	PUNCT
admet-337	1058	29	finding	find	VERB
admet-337	1058	30	study	study	NOUN
admet-337	1058	31	of	of	ADP
admet-337	1058	32	the	the	DET
admet-337	1058	33	alk	alk	PROPN
admet-337	1058	34	/	/	SYM
admet-337	1058	35	egfr	egfr	NOUN
admet-337	1058	36	inhibitor	inhibitor	NOUN
admet-337	1058	37	ap26113	ap26113	PROPN
admet-337	1058	38	in	in	ADP
admet-337	1058	39	patients	patient	NOUN
admet-337	1058	40	with	with	ADP
admet-337	1058	41	advanced	advanced	ADJ
admet-337	1058	42	malignancies	malignancy	NOUN
admet-337	1058	43	.	.	PUNCT
admet-337	1059	1	american	american	ADJ
admet-337	1059	2	society	society	NOUN
admet-337	1059	3	of	of	ADP
admet-337	1059	4	clinical	clinical	ADJ
admet-337	1059	5	oncology	oncology	NOUN
admet-337	1059	6	annual	annual	ADJ
admet-337	1059	7	meeting	meeting	NOUN
admet-337	1059	8	2013	2013	NUM
admet-337	1059	9	.	.	PUNCT
admet-337	1060	1	[	[	X
admet-337	1060	2	164	164	NUM
admet-337	1060	3	]	]	X
admet-337	1060	4	b.j	b.j	PROPN
admet-337	1060	5	.	.	PROPN
admet-337	1060	6	solomon	solomon	PROPN
admet-337	1060	7	,	,	PUNCT
admet-337	1060	8	t.m	t.m	PROPN
admet-337	1060	9	.	.	PROPN
admet-337	1060	10	bauer	bauer	PROPN
admet-337	1060	11	,	,	PUNCT
admet-337	1060	12	e.	e.	PROPN
admet-337	1060	13	felip	felip	PROPN
admet-337	1060	14	,	,	PUNCT
admet-337	1060	15	et	et	PROPN
admet-337	1060	16	al	al	PROPN
admet-337	1060	17	.	.	PROPN
admet-337	1060	18	safety	safety	NOUN
admet-337	1060	19	and	and	CCONJ
admet-337	1060	20	efficacy	efficacy	NOUN
admet-337	1060	21	of	of	ADP
admet-337	1060	22	lorlatinib	lorlatinib	NOUN
admet-337	1060	23	(	(	PUNCT
admet-337	1060	24	pf-06463922	pf-06463922	PROPN
admet-337	1060	25	)	)	PUNCT
admet-337	1060	26	from	from	ADP
admet-337	1060	27	the	the	DET
admet-337	1060	28	dose	dose	NOUN
admet-337	1060	29	-	-	PUNCT
admet-337	1060	30	escalation	escalation	NOUN
admet-337	1060	31	component	component	NOUN
admet-337	1060	32	of	of	ADP
admet-337	1060	33	a	a	DET
admet-337	1060	34	study	study	NOUN
admet-337	1060	35	in	in	ADP
admet-337	1060	36	patients	patient	NOUN
admet-337	1060	37	with	with	ADP
admet-337	1060	38	advanced	advanced	ADJ
admet-337	1060	39	alk+	alk+	NOUN
admet-337	1060	40	or	or	CCONJ
admet-337	1060	41	ros1	ros1	PROPN
admet-337	1060	42	+	+	CCONJ
admet-337	1060	43	non	non	ADJ
admet-337	1060	44	-	-	ADJ
admet-337	1060	45	small	small	ADJ
admet-337	1060	46	cell	cell	NOUN
admet-337	1060	47	lung	lung	NOUN
admet-337	1060	48	cancer	cancer	NOUN
admet-337	1060	49	(	(	PUNCT
admet-337	1060	50	nsclc	nsclc	NOUN
admet-337	1060	51	)	)	PUNCT
admet-337	1060	52	.	.	PUNCT
admet-337	1061	1	american	american	ADJ
admet-337	1061	2	society	society	NOUN
admet-337	1061	3	of	of	ADP
admet-337	1061	4	clinical	clinical	ADJ
admet-337	1061	5	oncology	oncology	NOUN
admet-337	1061	6	annual	annual	ADJ
admet-337	1061	7	meeting	meeting	NOUN
admet-337	1061	8	2016	2016	NUM
admet-337	1061	9	.	.	PUNCT
admet-337	1062	1	[	[	X
admet-337	1062	2	165	165	NUM
admet-337	1062	3	]	]	PUNCT
admet-337	1062	4	l.	l.	PROPN
admet-337	1062	5	horn	horn	PROPN
admet-337	1062	6	,	,	PUNCT
admet-337	1062	7	j.	j.	PROPN
admet-337	1062	8	infante	infante	PROPN
admet-337	1062	9	,	,	PUNCT
admet-337	1062	10	g.r	g.r	PROPN
admet-337	1062	11	.	.	PROPN
admet-337	1062	12	blumenschein	blumenschein	PROPN
admet-337	1062	13	,	,	PUNCT
admet-337	1062	14	et	et	PROPN
admet-337	1062	15	al	al	PROPN
admet-337	1062	16	.	.	PUNCT
admet-337	1063	1	a	a	DET
admet-337	1063	2	phase	phase	NOUN
admet-337	1063	3	i	i	PRON
admet-337	1063	4	trial	trial	NOUN
admet-337	1063	5	of	of	ADP
admet-337	1063	6	x-396	x-396	PROPN
admet-337	1063	7	,	,	PUNCT
admet-337	1063	8	a	a	DET
admet-337	1063	9	novel	novel	NOUN
admet-337	1063	10	alk	alk	NOUN
admet-337	1063	11	inhibitor	inhibitor	NOUN
admet-337	1063	12	,	,	PUNCT
admet-337	1063	13	in	in	ADP
admet-337	1063	14	patients	patient	NOUN
admet-337	1063	15	with	with	ADP
admet-337	1063	16	advanced	advanced	ADJ
admet-337	1063	17	solid	solid	ADJ
admet-337	1063	18	tumors	tumor	NOUN
admet-337	1063	19	.	.	PUNCT
admet-337	1064	1	american	american	ADJ
admet-337	1064	2	society	society	NOUN
admet-337	1064	3	of	of	ADP
admet-337	1064	4	clinical	clinical	ADJ
admet-337	1064	5	oncology	oncology	NOUN
admet-337	1064	6	annual	annual	ADJ
admet-337	1064	7	meeting	meeting	NOUN
admet-337	1064	8	2014	2014	NUM
admet-337	1064	9	.	.	PUNCT
admet-337	1065	1	[	[	X
admet-337	1065	2	166	166	NUM
admet-337	1065	3	]	]	PUNCT
admet-337	1065	4	m.	m.	NOUN
admet-337	1065	5	maitland	maitland	PROPN
admet-337	1065	6	,	,	PUNCT
admet-337	1065	7	s.h	s.h	PROPN
admet-337	1065	8	.	.	PROPN
admet-337	1065	9	ou	ou	PROPN
admet-337	1065	10	,	,	PUNCT
admet-337	1065	11	a.	a.	NOUN
admet-337	1065	12	tolcher	tolcher	NOUN
admet-337	1065	13	,	,	PUNCT
admet-337	1065	14	et	et	PROPN
admet-337	1065	15	al	al	PROPN
admet-337	1065	16	.	.	PROPN
admet-337	1065	17	safety	safety	PROPN
admet-337	1065	18	,	,	PUNCT
admet-337	1065	19	activity	activity	NOUN
admet-337	1065	20	,	,	PUNCT
admet-337	1065	21	and	and	CCONJ
admet-337	1065	22	pharmacokinetics	pharmacokinetic	NOUN
admet-337	1065	23	of	of	ADP
admet-337	1065	24	an	an	DET
admet-337	1065	25	oral	oral	ADJ
admet-337	1065	26	anaplastic	anaplastic	ADJ
admet-337	1065	27	lymphoma	lymphoma	NOUN
admet-337	1065	28	kinase	kinase	PROPN
admet-337	1065	29	(	(	PUNCT
admet-337	1065	30	alk	alk	PROPN
admet-337	1065	31	)	)	PUNCT
admet-337	1065	32	inhibitor	inhibitor	NOUN
admet-337	1065	33	,	,	PUNCT
admet-337	1065	34	asp3026	asp3026	PROPN
admet-337	1065	35	,	,	PUNCT
admet-337	1065	36	observed	observe	VERB
admet-337	1065	37	in	in	ADP
admet-337	1065	38	a	a	DET
admet-337	1065	39	“	"	PUNCT
admet-337	1065	40	fast	fast	ADJ
admet-337	1065	41	follower	follower	NOUN
admet-337	1065	42	”	"	PUNCT
admet-337	1065	43	phase	phase	NOUN
admet-337	1065	44	1	1	NUM
admet-337	1065	45	trial	trial	NOUN
admet-337	1065	46	design	design	NOUN
admet-337	1065	47	.	.	PUNCT
admet-337	1066	1	american	american	ADJ
admet-337	1066	2	society	society	NOUN
admet-337	1066	3	of	of	ADP
admet-337	1066	4	clinical	clinical	ADJ
admet-337	1066	5	oncology	oncology	NOUN
admet-337	1066	6	annual	annual	ADJ
admet-337	1066	7	meeting	meeting	NOUN
admet-337	1066	8	2014	2014	NUM
admet-337	1066	9	.	.	PUNCT
admet-337	1067	1	[	[	X
admet-337	1067	2	167	167	NUM
admet-337	1067	3	]	]	PUNCT
admet-337	1067	4	a.	a.	NOUN
admet-337	1067	5	vaishnavi	vaishnavi	NOUN
admet-337	1067	6	,	,	PUNCT
admet-337	1067	7	m.	m.	PROPN
admet-337	1067	8	capelletti	capelletti	PROPN
admet-337	1067	9	,	,	PUNCT
admet-337	1067	10	a.t	a.t	PROPN
admet-337	1067	11	.	.	PROPN
admet-337	1067	12	le	le	PROPN
admet-337	1067	13	,	,	PUNCT
admet-337	1067	14	et	et	PROPN
admet-337	1067	15	al	al	PROPN
admet-337	1067	16	.	.	PUNCT
admet-337	1068	1	nat	nat	PROPN
admet-337	1068	2	.	.	PUNCT
admet-337	1069	1	med	med	PROPN
admet-337	1069	2	.	.	PROPN
admet-337	1070	1	19	19	NUM
admet-337	1070	2	(	(	PUNCT
admet-337	1070	3	2013	2013	NUM
admet-337	1070	4	)	)	PUNCT
admet-337	1070	5	1469	1469	NUM
admet-337	1070	6	-	-	SYM
admet-337	1070	7	1472	1472	NUM
admet-337	1070	8	.	.	PUNCT
admet-337	1071	1	[	[	X
admet-337	1071	2	168	168	NUM
admet-337	1071	3	]	]	PUNCT
admet-337	1071	4	h.	h.	PROPN
admet-337	1071	5	arkenau	arkenau	PROPN
admet-337	1071	6	,	,	PUNCT
admet-337	1071	7	j.c	j.c	PROPN
admet-337	1071	8	.	.	PROPN
admet-337	1071	9	sachdev	sachdev	PROPN
admet-337	1071	10	,	,	PUNCT
admet-337	1071	11	m.m	m.m	PROPN
admet-337	1071	12	.	.	PROPN
admet-337	1071	13	mita	mita	PROPN
admet-337	1071	14	,	,	PUNCT
admet-337	1071	15	et	et	PROPN
admet-337	1071	16	al	al	PROPN
admet-337	1071	17	.	.	PROPN
admet-337	1071	18	phase	phase	NOUN
admet-337	1071	19	(	(	PUNCT
admet-337	1071	20	ph	ph	PROPN
admet-337	1071	21	)	)	PUNCT
admet-337	1071	22	1/2a	1/2a	NUM
admet-337	1071	23	study	study	NOUN
admet-337	1071	24	of	of	ADP
admet-337	1071	25	tsr-011	tsr-011	NUM
admet-337	1071	26	,	,	PUNCT
admet-337	1071	27	a	a	DET
admet-337	1071	28	potent	potent	ADJ
admet-337	1071	29	inhibitor	inhibitor	NOUN
admet-337	1071	30	of	of	ADP
admet-337	1071	31	alk	alk	PROPN
admet-337	1071	32	and	and	CCONJ
admet-337	1071	33	trk	trk	PROPN
admet-337	1071	34	,	,	PUNCT
admet-337	1071	35	in	in	ADP
admet-337	1071	36	advanced	advanced	ADJ
admet-337	1071	37	solid	solid	ADJ
admet-337	1071	38	tumors	tumor	NOUN
admet-337	1071	39	including	include	VERB
admet-337	1071	40	crizotinib	crizotinib	ADV
admet-337	1071	41	-	-	PUNCT
admet-337	1071	42	resistant	resistant	ADJ
admet-337	1071	43	alk	alk	NOUN
admet-337	1071	44	positive	positive	ADJ
admet-337	1071	45	non	non	ADJ
admet-337	1071	46	-	-	ADJ
admet-337	1071	47	small	small	ADJ
admet-337	1071	48	cell	cell	NOUN
admet-337	1071	49	lung	lung	NOUN
admet-337	1071	50	cancer	cancer	NOUN
admet-337	1071	51	.	.	PUNCT
admet-337	1072	1	american	american	ADJ
admet-337	1072	2	society	society	NOUN
admet-337	1072	3	of	of	ADP
admet-337	1072	4	clinical	clinical	ADJ
admet-337	1072	5	oncology	oncology	NOUN
admet-337	1072	6	annual	annual	ADJ
admet-337	1072	7	meeting	meeting	NOUN
admet-337	1072	8	2015	2015	NUM
admet-337	1072	9	.	.	PUNCT
admet-337	1073	1	[	[	X
admet-337	1073	2	169	169	NUM
admet-337	1073	3	]	]	X
admet-337	1073	4	f.	f.	PROPN
admet-337	1073	5	de	de	PROPN
admet-337	1073	6	braud	braud	PROPN
admet-337	1073	7	,	,	PUNCT
admet-337	1073	8	m.	m.	NOUN
admet-337	1073	9	niger	niger	PROPN
admet-337	1073	10	,	,	PUNCT
admet-337	1073	11	s.	s.	PROPN
admet-337	1073	12	damian	damian	PROPN
admet-337	1073	13	,	,	PUNCT
admet-337	1073	14	et	et	PROPN
admet-337	1073	15	al	al	PROPN
admet-337	1073	16	.	.	PROPN
admet-337	1073	17	alka-372	alka-372	NOUN
admet-337	1073	18	-	-	PUNCT
admet-337	1073	19	001	001	NUM
admet-337	1073	20	:	:	PUNCT
admet-337	1073	21	first	first	ADJ
admet-337	1073	22	-	-	PUNCT
admet-337	1073	23	in	in	ADP
admet-337	1073	24	-	-	PUNCT
admet-337	1073	25	human	human	ADJ
admet-337	1073	26	,	,	PUNCT
admet-337	1073	27	phase	phase	NOUN
admet-337	1073	28	i	i	PRON
admet-337	1073	29	study	study	VERB
admet-337	1073	30	of	of	ADP
admet-337	1073	31	entrectinib	entrectinib	NOUN
admet-337	1073	32	–	–	PUNCT
admet-337	1073	33	an	an	DET
admet-337	1073	34	oral	oral	ADJ
admet-337	1073	35	pan	pan	NOUN
admet-337	1073	36	-	-	ADJ
admet-337	1073	37	trk	trk	ADJ
admet-337	1073	38	,	,	PUNCT
admet-337	1073	39	ros1	ros1	PROPN
admet-337	1073	40	,	,	PUNCT
admet-337	1073	41	and	and	CCONJ
admet-337	1073	42	alk	alk	VERB
admet-337	1073	43	inhibitor	inhibitor	NOUN
admet-337	1073	44	–	–	PUNCT
admet-337	1073	45	in	in	ADP
admet-337	1073	46	patients	patient	NOUN
admet-337	1073	47	with	with	ADP
admet-337	1073	48	advanced	advanced	ADJ
admet-337	1073	49	solid	solid	ADJ
admet-337	1073	50	tumors	tumor	NOUN
admet-337	1073	51	with	with	ADP
admet-337	1073	52	relevant	relevant	ADJ
admet-337	1073	53	molecular	molecular	ADJ
admet-337	1073	54	alterations	alteration	NOUN
admet-337	1073	55	.	.	PUNCT
admet-337	1074	1	american	american	ADJ
admet-337	1074	2	society	society	NOUN
admet-337	1074	3	of	of	ADP
admet-337	1074	4	clinical	clinical	ADJ
admet-337	1074	5	oncology	oncology	NOUN
admet-337	1074	6	annual	annual	ADJ
admet-337	1074	7	meeting	meeting	NOUN
admet-337	1074	8	2016	2016	NUM
admet-337	1074	9	.	.	PUNCT
admet-337	1075	1	[	[	X
admet-337	1075	2	170	170	NUM
admet-337	1075	3	]	]	X
admet-337	1075	4	r.	r.	PROPN
admet-337	1075	5	van	van	PROPN
admet-337	1075	6	leeuwen	leeuwen	PROPN
admet-337	1075	7	,	,	PUNCT
admet-337	1075	8	t.	t.	PROPN
admet-337	1075	9	van	van	PROPN
admet-337	1075	10	gelder	gelder	PROPN
admet-337	1075	11	,	,	PUNCT
admet-337	1075	12	r.	r.	PROPN
admet-337	1075	13	mathijssen	mathijssen	PROPN
admet-337	1075	14	,	,	PUNCT
admet-337	1075	15	et	et	PROPN
admet-337	1075	16	al	al	PROPN
admet-337	1075	17	.	.	PUNCT
admet-337	1076	1	lancet	lancet	PROPN
admet-337	1076	2	oncol	oncol	PROPN
admet-337	1076	3	.	.	PUNCT
admet-337	1077	1	15	15	NUM
admet-337	1077	2	(	(	PUNCT
admet-337	1077	3	2014	2014	NUM
admet-337	1077	4	)	)	PUNCT
admet-337	1077	5	315	315	NUM
admet-337	1077	6	-	-	SYM
admet-337	1077	7	26	26	NUM
admet-337	1077	8	.	.	PUNCT
admet-337	1078	1	[	[	X
admet-337	1078	2	171	171	NUM
admet-337	1078	3	]	]	X
admet-337	1078	4	j.	j.	PROPN
admet-337	1078	5	brahmer	brahmer	PROPN
admet-337	1078	6	,	,	PUNCT
admet-337	1078	7	k.	k.	PROPN
admet-337	1078	8	reckamp	reckamp	PROPN
admet-337	1078	9	,	,	PUNCT
admet-337	1078	10	p.	p.	NOUN
admet-337	1078	11	baas	baas	NOUN
admet-337	1078	12	,	,	PUNCT
admet-337	1078	13	et	et	PROPN
admet-337	1078	14	al	al	PROPN
admet-337	1078	15	.	.	PUNCT
admet-337	1078	16	n.	n.	PROPN
admet-337	1078	17	engl	engl	PROPN
admet-337	1078	18	.	.	PUNCT
admet-337	1079	1	j.	j.	PROPN
admet-337	1079	2	med	med	PROPN
admet-337	1079	3	.	.	PUNCT
admet-337	1080	1	373	373	NUM
admet-337	1080	2	(	(	PUNCT
admet-337	1080	3	2015	2015	NUM
admet-337	1080	4	)	)	PUNCT
admet-337	1080	5	123	123	NUM
admet-337	1080	6	-	-	SYM
admet-337	1080	7	35	35	NUM
admet-337	1080	8	.	.	PUNCT
admet-337	1081	1	[	[	X
admet-337	1081	2	172	172	NUM
admet-337	1081	3	]	]	X
admet-337	1081	4	h.	h.	PROPN
admet-337	1081	5	borghaei	borghaei	PROPN
admet-337	1081	6	,	,	PUNCT
admet-337	1081	7	l.	l.	PROPN
admet-337	1081	8	paz	paz	PROPN
admet-337	1081	9	-	-	PUNCT
admet-337	1081	10	ares	ares	PROPN
admet-337	1081	11	,	,	PUNCT
admet-337	1081	12	l.	l.	PROPN
admet-337	1081	13	horn	horn	PROPN
admet-337	1081	14	,	,	PUNCT
admet-337	1081	15	et	et	PROPN
admet-337	1081	16	al	al	PROPN
admet-337	1081	17	.	.	PUNCT
admet-337	1081	18	n.	n.	PROPN
admet-337	1081	19	engl	engl	PROPN
admet-337	1081	20	.	.	PUNCT
admet-337	1082	1	j.	j.	PROPN
admet-337	1082	2	med	med	PROPN
admet-337	1082	3	.	.	PUNCT
admet-337	1083	1	373	373	NUM
admet-337	1083	2	(	(	PUNCT
admet-337	1083	3	2015	2015	NUM
admet-337	1083	4	)	)	PUNCT
admet-337	1083	5	1627	1627	NUM
admet-337	1083	6	-	-	SYM
admet-337	1083	7	39	39	NUM
admet-337	1083	8	.	.	PUNCT
admet-337	1084	1	[	[	X
admet-337	1084	2	173	173	NUM
admet-337	1084	3	]	]	X
admet-337	1084	4	r.	r.	PROPN
admet-337	1084	5	herbst	herbst	PROPN
admet-337	1084	6	,	,	PUNCT
admet-337	1084	7	p.	p.	NOUN
admet-337	1084	8	baas	baas	NOUN
admet-337	1084	9	,	,	PUNCT
admet-337	1084	10	d.	d.	PROPN
admet-337	1084	11	kim	kim	PROPN
admet-337	1084	12	,	,	PUNCT
admet-337	1084	13	et	et	PROPN
admet-337	1084	14	al	al	PROPN
admet-337	1084	15	.	.	PUNCT
admet-337	1085	1	lancet	lancet	PROPN
admet-337	1085	2	387	387	NUM
admet-337	1085	3	(	(	PUNCT
admet-337	1085	4	2016	2016	NUM
admet-337	1085	5	)	)	PUNCT
admet-337	1085	6	1540	1540	NUM
admet-337	1085	7	-	-	SYM
admet-337	1085	8	50	50	NUM
admet-337	1085	9	.	.	PUNCT
admet-337	1086	1	[	[	X
admet-337	1086	2	174	174	NUM
admet-337	1086	3	]	]	PUNCT
admet-337	1086	4	s.	s.	PROPN
admet-337	1086	5	gettinger	gettinger	PROPN
admet-337	1086	6	,	,	PUNCT
admet-337	1086	7	n.	n.	NOUN
admet-337	1086	8	rizvi	rizvi	PROPN
admet-337	1086	9	,	,	PUNCT
admet-337	1086	10	l.	l.	PROPN
admet-337	1086	11	chow	chow	PROPN
admet-337	1086	12	,	,	PUNCT
admet-337	1086	13	et	et	PROPN
admet-337	1086	14	al	al	PROPN
admet-337	1086	15	.	.	PUNCT
admet-337	1087	1	j.	j.	PROPN
admet-337	1087	2	clin	clin	PROPN
admet-337	1087	3	.	.	PUNCT
admet-337	1088	1	oncol	oncol	ADJ
admet-337	1088	2	.	.	PUNCT
admet-337	1089	1	34	34	NUM
admet-337	1089	2	(	(	PUNCT
admet-337	1089	3	2016	2016	NUM
admet-337	1089	4	)	)	PUNCT
admet-337	1089	5	2980	2980	NUM
admet-337	1089	6	-	-	SYM
admet-337	1089	7	7	7	NUM
admet-337	1089	8	.	.	PUNCT
admet-337	1090	1	[	[	X
admet-337	1090	2	175	175	NUM
admet-337	1090	3	]	]	X
admet-337	1090	4	n.	n.	NOUN
admet-337	1090	5	rizvi	rizvi	PROPN
admet-337	1090	6	,	,	PUNCT
admet-337	1090	7	m.	m.	PROPN
admet-337	1090	8	hellmann	hellmann	PROPN
admet-337	1090	9	,	,	PUNCT
admet-337	1090	10	j.	j.	PROPN
admet-337	1090	11	brahmer	brahmer	PROPN
admet-337	1090	12	,	,	PUNCT
admet-337	1090	13	et	et	PROPN
admet-337	1090	14	al	al	PROPN
admet-337	1090	15	.	.	PUNCT
admet-337	1091	1	j.	j.	PROPN
admet-337	1091	2	clin	clin	PROPN
admet-337	1091	3	.	.	PUNCT
admet-337	1092	1	oncol	oncol	ADJ
admet-337	1092	2	.	.	PUNCT
admet-337	1093	1	34	34	NUM
admet-337	1093	2	(	(	PUNCT
admet-337	1093	3	2016	2016	NUM
admet-337	1093	4	)	)	PUNCT
admet-337	1093	5	2969	2969	NUM
admet-337	1093	6	-	-	SYM
admet-337	1093	7	79	79	NUM
admet-337	1093	8	.	.	PUNCT
admet-337	1094	1	[	[	X
admet-337	1094	2	176	176	NUM
admet-337	1094	3	]	]	X
admet-337	1094	4	a.	a.	NOUN
admet-337	1094	5	snyder	snyder	PROPN
admet-337	1094	6	,	,	PUNCT
admet-337	1094	7	v.	v.	ADP
admet-337	1094	8	marakov	marakov	PROPN
admet-337	1094	9	,	,	PUNCT
admet-337	1094	10	t.	t.	NOUN
admet-337	1094	11	merghoub	merghoub	NOUN
admet-337	1094	12	,	,	PUNCT
admet-337	1094	13	et	et	PROPN
admet-337	1094	14	al	al	PROPN
admet-337	1094	15	.	.	PUNCT
admet-337	1094	16	n.	n.	PROPN
admet-337	1094	17	engl	engl	PROPN
admet-337	1094	18	.	.	PUNCT
admet-337	1095	1	j.	j.	PROPN
admet-337	1095	2	med	med	PROPN
admet-337	1095	3	.	.	PROPN
admet-337	1096	1	371	371	NUM
admet-337	1096	2	(	(	PUNCT
admet-337	1096	3	2014	2014	NUM
admet-337	1096	4	)	)	PUNCT
admet-337	1096	5	2189	2189	NUM
admet-337	1096	6	-	-	SYM
admet-337	1096	7	99	99	NUM
admet-337	1096	8	.	.	PUNCT
admet-337	1097	1	[	[	X
admet-337	1097	2	177	177	NUM
admet-337	1097	3	]	]	X
admet-337	1097	4	n.	n.	NOUN
admet-337	1097	5	rizvi	rizvi	PROPN
admet-337	1097	6	,	,	PUNCT
admet-337	1097	7	m.	m.	PROPN
admet-337	1097	8	hellmann	hellmann	PROPN
admet-337	1097	9	,	,	PUNCT
admet-337	1097	10	a.	a.	NOUN
admet-337	1097	11	snyder	snyder	PROPN
admet-337	1097	12	,	,	PUNCT
admet-337	1097	13	et	et	PROPN
admet-337	1097	14	al	al	PROPN
admet-337	1097	15	.	.	PROPN
admet-337	1097	16	science	science	PROPN
admet-337	1097	17	348	348	NUM
admet-337	1097	18	(	(	PUNCT
admet-337	1097	19	2015	2015	NUM
admet-337	1097	20	)	)	PUNCT
admet-337	1097	21	124	124	NUM
admet-337	1097	22	-	-	SYM
admet-337	1097	23	8	8	NUM
admet-337	1097	24	.	.	PUNCT
admet-337	1098	1	[	[	X
admet-337	1098	2	178	178	NUM
admet-337	1098	3	]	]	PUNCT
admet-337	1098	4	e.	e.	PROPN
admet-337	1098	5	akbay	akbay	PROPN
admet-337	1098	6	,	,	PUNCT
admet-337	1098	7	s.	s.	PROPN
admet-337	1098	8	koyama	koyama	PROPN
admet-337	1098	9	,	,	PUNCT
admet-337	1098	10	j.	j.	PROPN
admet-337	1098	11	carretero	carretero	PROPN
admet-337	1098	12	,	,	PUNCT
admet-337	1098	13	et	et	PROPN
admet-337	1098	14	al	al	PROPN
admet-337	1098	15	.	.	PUNCT
admet-337	1098	16	cancer	cancer	NOUN
admet-337	1098	17	discov	discov	NOUN
admet-337	1098	18	.	.	PUNCT
admet-337	1099	1	3	3	NUM
admet-337	1099	2	(	(	PUNCT
admet-337	1099	3	2013	2013	NUM
admet-337	1099	4	)	)	PUNCT
admet-337	1099	5	1355	1355	NUM
admet-337	1099	6	-	-	SYM
admet-337	1099	7	63	63	NUM
admet-337	1099	8	.	.	PUNCT
admet-337	1100	1	[	[	X
admet-337	1100	2	179	179	NUM
admet-337	1100	3	]	]	X
admet-337	1100	4	n.	n.	PROPN
admet-337	1100	5	chen	chen	PROPN
admet-337	1100	6	,	,	PUNCT
admet-337	1100	7	w.	w.	PROPN
admet-337	1100	8	fang	fang	PROPN
admet-337	1100	9	,	,	PUNCT
admet-337	1100	10	j.	j.	PROPN
admet-337	1100	11	zhan	zhan	PROPN
admet-337	1100	12	,	,	PUNCT
admet-337	1100	13	et	et	PROPN
admet-337	1100	14	al	al	PROPN
admet-337	1100	15	.	.	PUNCT
admet-337	1101	1	j.	j.	PROPN
admet-337	1101	2	thorac	thorac	PROPN
admet-337	1101	3	.	.	PUNCT
admet-337	1102	1	oncol	oncol	ADJ
admet-337	1102	2	.	.	PUNCT
admet-337	1103	1	10	10	NUM
admet-337	1103	2	(	(	PUNCT
admet-337	1103	3	2015	2015	NUM
admet-337	1103	4	)	)	PUNCT
admet-337	1103	5	910	910	NUM
admet-337	1103	6	-	-	SYM
admet-337	1103	7	23	23	NUM
admet-337	1103	8	.	.	PUNCT
admet-337	1104	1	[	[	X
admet-337	1104	2	180	180	NUM
admet-337	1104	3	]	]	PUNCT
admet-337	1104	4	k.	k.	PROPN
admet-337	1104	5	ota	ota	PROPN
admet-337	1104	6	,	,	PUNCT
admet-337	1104	7	k.	k.	PROPN
admet-337	1104	8	azuma	azuma	PROPN
admet-337	1104	9	,	,	PUNCT
admet-337	1104	10	a.	a.	PROPN
admet-337	1104	11	kawahara	kawahara	PROPN
admet-337	1104	12	,	,	PUNCT
admet-337	1104	13	et	et	PROPN
admet-337	1104	14	al	al	PROPN
admet-337	1104	15	.	.	PUNCT
admet-337	1105	1	clin	clin	PROPN
admet-337	1105	2	.	.	PUNCT
admet-337	1106	1	cancer	cancer	NOUN
admet-337	1106	2	res	re	NOUN
admet-337	1106	3	.	.	PROPN
admet-337	1107	1	21	21	NUM
admet-337	1107	2	(	(	PUNCT
admet-337	1107	3	2015	2015	NUM
admet-337	1107	4	)	)	PUNCT
admet-337	1107	5	4014	4014	NUM
admet-337	1107	6	-	-	SYM
admet-337	1107	7	21	21	NUM
admet-337	1107	8	.	.	PUNCT
admet-337	1108	1	[	[	X
admet-337	1108	2	181	181	X
admet-337	1108	3	]	]	X
admet-337	1108	4	s.	s.	PROPN
admet-337	1108	5	hong	hong	PROPN
admet-337	1108	6	,	,	PUNCT
admet-337	1108	7	n.	n.	PROPN
admet-337	1108	8	chen	chen	PROPN
admet-337	1108	9	,	,	PUNCT
admet-337	1108	10	w.	w.	PROPN
admet-337	1108	11	fang	fang	PROPN
admet-337	1108	12	,	,	PUNCT
admet-337	1108	13	et	et	PROPN
admet-337	1108	14	al	al	PROPN
admet-337	1108	15	.	.	PUNCT
admet-337	1108	16	oncoimmunology	oncoimmunology	NOUN
admet-337	1108	17	5	5	NUM
admet-337	1108	18	(	(	PUNCT
admet-337	1108	19	2015	2015	NUM
admet-337	1108	20	)	)	PUNCT
admet-337	1108	21	e1094598	e1094598	NOUN
admet-337	1108	22	.	.	PUNCT
admet-337	1109	1	[	[	X
admet-337	1109	2	182	182	NUM
admet-337	1109	3	]	]	PUNCT
admet-337	1109	4	m.	m.	PROPN
admet-337	1109	5	ahn	ahn	PROPN
admet-337	1109	6	,	,	PUNCT
admet-337	1109	7	j.	j.	PROPN
admet-337	1109	8	yang	yang	PROPN
admet-337	1109	9	,	,	PUNCT
admet-337	1109	10	h.	h.	PROPN
admet-337	1109	11	yu	yu	PROPN
admet-337	1109	12	,	,	PUNCT
admet-337	1109	13	et	et	PROPN
admet-337	1109	14	al	al	PROPN
admet-337	1109	15	.	.	PROPN
admet-337	1109	16	osimertinib	osimertinib	NOUN
admet-337	1109	17	combined	combine	VERB
admet-337	1109	18	with	with	ADP
admet-337	1109	19	durvalumab	durvalumab	NOUN
admet-337	1109	20	in	in	ADP
admet-337	1109	21	egfr	egfr	ADJ
admet-337	1109	22	-	-	PUNCT
admet-337	1109	23	mutant	mutant	ADJ
admet-337	1109	24	non	non	ADJ
admet-337	1109	25	-	-	ADJ
admet-337	1109	26	small	small	ADJ
admet-337	1109	27	cell	cell	NOUN
admet-337	1109	28	lung	lung	NOUN
admet-337	1109	29	cancer	cancer	NOUN
admet-337	1109	30	:	:	PUNCT
admet-337	1109	31	results	result	NOUN
admet-337	1109	32	from	from	ADP
admet-337	1109	33	the	the	DET
admet-337	1109	34	tatton	tatton	PROPN
admet-337	1109	35	phase	phase	NOUN
admet-337	1109	36	ib	ib	NOUN
admet-337	1109	37	trial	trial	NOUN
admet-337	1109	38	.	.	PUNCT
admet-337	1110	1	european	european	ADJ
admet-337	1110	2	lung	lung	PROPN
admet-337	1110	3	cancer	cancer	NOUN
admet-337	1110	4	conference	conference	PROPN
admet-337	1110	5	2016	2016	NUM
admet-337	1110	6	.	.	PUNCT
admet-337	1111	1	©	©	PROPN
admet-337	1111	2	2016	2016	NUM
admet-337	1111	3	by	by	ADP
admet-337	1111	4	the	the	DET
admet-337	1111	5	authors	author	NOUN
admet-337	1111	6	;	;	PUNCT
admet-337	1111	7	licensee	licensee	PROPN
admet-337	1111	8	iapc	iapc	PROPN
admet-337	1111	9	,	,	PUNCT
admet-337	1111	10	zagreb	zagreb	PROPN
admet-337	1111	11	,	,	PUNCT
admet-337	1111	12	croatia	croatia	PROPN
admet-337	1111	13	.	.	PUNCT
admet-337	1112	1	this	this	DET
admet-337	1112	2	article	article	NOUN
admet-337	1112	3	is	be	AUX
admet-337	1112	4	an	an	DET
admet-337	1112	5	open	open	ADJ
admet-337	1112	6	-	-	PUNCT
admet-337	1112	7	access	access	NOUN
admet-337	1112	8	article	article	NOUN
admet-337	1112	9	distributed	distribute	VERB
admet-337	1112	10	under	under	ADP
admet-337	1112	11	the	the	DET
admet-337	1112	12	terms	term	NOUN
admet-337	1112	13	and	and	CCONJ
admet-337	1112	14	conditions	condition	NOUN
admet-337	1112	15	of	of	ADP
admet-337	1112	16	the	the	DET
admet-337	1112	17	creative	creative	ADJ
admet-337	1112	18	commons	common	NOUN
admet-337	1112	19	attribution	attribution	NOUN
admet-337	1112	20	license	license	NOUN
admet-337	1112	21	(	(	PUNCT
admet-337	1112	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-337	1112	23	)	)	PUNCT
admet-337	1112	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN